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G01. Mutation Identification for Autosomal Recessive Disorders through 
Whole Exome Sequencing of a Single Affected Member Following Homozygosity 
Mapping vs Whole Exome Sequencing of Multiple Family Members 
M. Kambouris, Y. Al-Sarraj, H. El-Shanti 
Shafallah Medical Genetics Center, Doha, Qatar. 
Introduction: A consanguineous Arab family affected by an undelineated autosomal 
recessive disorder characterized by severe mental retardation, failure to thrive, 
nystagmus, telecanthus & epicanthus was studied by homozygosity mapping followed 
by whole exome sequencing for a single affected member [HMSAE] and by whole 
exome sequencing for two affected siblings and their parents [QUADE]. Methods: SNP 
genotyping on Illumina OmniExpress 700K for five family members. Linkage analyses 
by Homozygositymapper software. "HMSAE" whole exome target enrichment 
sequencing on ABI SOLiD4. "QUADE" whole exome target enrichment sequencing on 
Illumina HiSEQ. In-silico protein modeling by PolyPhen & SIFT software. Variant 
validation & ethnic population frequency determination by Sanger sequencing on ABI 
3730xl DNA Analyzer. Results: "HMSAE" resulted in four major linkage intervals, as 
the number of investigated family members was insufficient for significant LOD scores. 
Four non-synonymous variants were positioned within two homozygous intervals all 
representing missense mutations. One,-a zink finger protein, appears to be the disease 
causing mutation. “QUADE” resulted in twelve non-synonymous variants [10 exonic 
missense and two splice site] homozygous in both affected individuals and 
heterozygous in the parents. Seven of the exonic variants were speculated as 
damaging. Nine total variants warrant further validation for possible pathogenicity 
[seven exonic possibly damaging and two potential splice sites]. Conclusions: 
Comparing the two approaches, "QUADE" resulted in twelve variants with seven 
requiring further validation vs four variants with one for validation for "HMSAE." Only six 
of the 12 variants for "QUADE" mapped within the various linkage intervals (including all 
that "HMSAE" identified). From those, two affect highly conserved amino acids with 
damaging effects and are absent in 200 chromosomes for the ethnic population. One is 
the Zink Finger Protein. "HMSAE" missed two variants probably due to the different 
sequencing platforms, read depth and bead number coverage [although comparable on 
the average] –an issue of significant concern since one missed variant could have been 
the disease causing mutation but is not significantly expressed in tissues of interest. 
The "HMSAE" approach is significantly less labor intensive and considerably more 
economical. Lack of significant LOD scores harbors the danger of ignoring variants in 
limited homozygosity regions. Multiple exome comparative analyses requires significant 
& specialized bioinformatic expertise, is labor demanding, requires validation of a larger 
number of variants and is overall considerably more expensive. The quality of the whole 
exome/genome sequencing for single samples is of utmost importance since the 
offending mutation can easily be missed. 
 
G02. Impact of Pathway Focused Next Generation Sequencing Gene Panels on 
Patient's Quality of Care 
E. Chin, V.W. Zhang, H. Cui, E. Schmitt, J. Wang , L. Wong 
Baylor College of Medicine, Houston, TX. 
Introduction: Next Generation Sequencing (NGS) has helped revolutionize molecular 
genetics testing by enabling large gene panel testing while reducing cost and time. For 
years, Sanger dideoxy sequencing has been the "gold" standard and due to the cost of 
Sanger sequencing, many tests are performed on a gene-by-gene basis and takes a 
long time to obtain a molecular diagnosis. The use of pathway-focused panels such as 
the Glycogen Storage Disorder (GSD) panel helps to illustrate the positive impact that 
panel testing has in improving the diagnostic yield while reducing cost and time needed 
to reach a molecular diagnosis. Methods: Sixteen genes implicated in GSD were 
captured using a custom designed Nimblegen's SeqCap capture and sequenced on an 
Illumina HiSeq2000 instrument. Batches of eight individual samples were barcoded and 
pooled onto a single lane during a 75 cycle, single end sequencing run. Concurrently, 
Sanger sequencing tests were developed for all 16 genes in the GSD panel to assist in 
confirmation and family studies. Results: Average coverage of approximately 500X 
reads were obtained for each coding region in our genes of interest with 100% of bases 
at >20X reads. This test underwent three phases of validation. Phase I involved the 
optimization of test specific operating procedures and the development of the 
corresponding Sanger sequencing assay. Phase II involved testing previously tested 
samples that was sent to laboratory for singles gene testing. Samples were selected to 
ensure that the mutations covering the entire mutation spectrum were represented. All 
expected mutations were detected. Phase III involved testing 17 samples, which had 
clinical indication of GSD and where no mutations have been detected. Our panel was 
able to detect mutations in 12/17 Phase III samples. The pathway focused NGS panel 
greatly improves the yield of molecular diagnosis in GSD. The remainder five samples, 
which were either negative or had unclassified variant in an autosomal recessive gene, 
may be candidates for further genomic analysis including clinical exome sequencing 
and deletion/duplication analysis. The use of pathway-focused panels such as the GSD 
panel will enable payers to save >$13,730 by ordering the panel instead of performing 
traditional, gene-by-gene sequential Sanger sequencing approach. Correspondingly, 
time to molecular diagnosis was reduced by 79.9% when compared with the gene-by-
gene testing approach. Conclusions: We have demonstrated that the use of pathway 
focused NGS panels will not only improve the patient’s quality of care at a greatly 
reduced cost and provides reduced time to a molecular diagnosis. 
 
G03. Analysis of RNAStable Treated Samples by the Illumina DASL Assay and 
Illumina RNA Sequencing 
K. Ardlie1, R. Muller2, S. Ohgi2, K. Kanki1, S. Gupta1, A. Crenshaw1, J. Levin1, D. 
Deluca1, W. Winckler1 
1Broad Institute, Cambridge, MA; 2Biomatrica, San Diego, CA. 
Introduction: The Biological Samples Platform at the Broad Institute is a platform 
dedicated to the receipt, processing, QC, tracking and storage of all biological materials 
that enter the Broad for research. The platform currently stores over 770,000 samples 
from around 623,000 participants and receives approximately 12,000 new samples 
each month. One of the challenges for the platform is that RNA samples are received or 
isolated at very low concentrations, and this is typically the case for RNA processed 
from FFPE material. These low concentration samples typically require concentration 
prior to many downstream applications. Methods: Here we describe our investigation of 
RNAStable as a means to safely concentrate and store samples prior to downstream 
analysis. We treated 3 samples (2 FFPE cancer derived RNA samples and a Universal 
human reference control) with RNA stable and analyzed all three both pre- and post-
RNAStable treatment in duplicate on the Illumina DASL assay. Results: We observed 
no effect of treatment bias on the samples and demonstrated that our Whole Genome-
DASL results were comparable for treated and non-treated FFPE samples. In addition, 
we have been testing the use of RNAStable to concentrate RNA samples for RNA 
Sequencing applications. We present the results of these analyses using a K562 cell 
line control for which we showed that RNA stored in RNAStable was of the same quality 
to un-treated samples when subjected to RNA Sequencing using the Illumina TruSeq 
protocol. Conclusions: RNAStable is an effective and efficient method for 
concentration and storage of RNA samples prior to downstream genetic analyses. 
Further, the ability to safely concentrate RNA samples without yield or quality loss will 
enable the inclusion of many rare samples with limited material that could not previously 
have been run on many of our analytical platforms.  
 
G04. Development and Validation of Next Generation Sequencing for Clinical 
Molecular Diagnosis of Mitochondrial Disorders  
W. Zhang, H. Cui, L. Wong 
Medical Genetics Laboratories, Baylor College of Medicine, Houston, TX. 
Introduction: The next generation sequencing (NGS) technology is being gradually 
adapted as the primary sequencing platform for the molecular diagnosis in clinical 
laboratories. The ability to sequence a group of target genes by NGS is particularly 
useful for molecular diagnosis of genetically heterogeneous clinical syndromes. 
Comprehensive molecular diagnosis of mitochondrial disorders requires the evaluation 
of both nuclear and mitochondrial genomes at high accuracy for clinical diagnosis. The 
next generation sequencing based panel testing becomes the major driving force for 
such application. Methods: For mitochondrial genomes analysis, a comprehensive 
one-step approach has been validated for the detection and quantification of point 
mutations and large deletions by using long range PCR. For nuclear genes, a captured 
based target enrichment followed by deep sequencing was developed. Results: An 
average coverage of >10,000X for each of the 16,569 bases of the mitochondrial 
genome was achieved. Our results demonstrate near 100% sensitivity and specificity of 
base calls compared to Sanger sequencing, with quantitative information at each 
nucleotide position of the 16,569 bp mitochondrial genome. This NGS-based approach 
is able to simultaneously detect large deletions, map breakpoints, and accurately 
quantify low % heteroplasmy of point mutations without the interference of NUMT. In 
addition, capture of 50 nuclear genes known to encode protein subunits and assembly 
factors of complexes of mitochondrial oxidative phosphorylation, followed by NGS-
based sequencing was also developed. Nearly every base in all targeted coding exons 
has been enriched with sufficient coverage for molecular diagnosis. Results of this 
approach provide 100% concordance in base calls compared to Sanger results. In 
addition, the disease causing mutations of positive control cases have been correctly 
identified. Conclusions: The NGS-based assays allow efficient analysis of a set of 
nuclear genes targeted to mitochondria and the comprehensive analyses of the entire 
mitochondrial genome for point mutations and deletions with quantitative information. 
This target gene enrichment deep sequencing approach provides a one-step 
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comprehensive molecular analysis for patients with suspicion of mitochondrial diseases 
in a timely, accurate, and cost-effective fashion suitable for clinical application.  
G05. Next-Generation Sequencing Diagnostic Assays for Genetic Diagnosis of 
Inherited Disorders 
B. Thyagarajan1, M. Bower1, G. Onsongo1, K. Silverstein1, S. Yohe1, A. Hauge1, M. 
Schomaker2, K. Bunjer2, T. Kemmer2, J. Erdmann2, J. Peterson2, R. Peterson2, K. 
Beckman2 
1University of Minnesota, Minneapolis, MN; 2University of Minnesota Medical Center-
Fairview, Minneapolis, MN. 
Introduction: Next-generation sequencing (NGS) methods provide highly accurate and 
timely sequence information for large amounts of genomic data. The ability to multiplex 
several assays on a single platform allows for cost-effective and simultaneous 
implementation of several hundred clinical tests. Methods: We developed and 
validated an NGS panel for use in the clinical diagnosis of over 150 diverse inherited 
disease conditions. These conditions include inborn errors of metabolism, pediatric 
developmental disorders, congenital vision loss, congenital hearing loss, neuromuscular 
disease, neurodegenerative disease, familial cancers, coagulopathies, and non-
malignant conditions requiring hematopoietic cell transplantation. Diagnostic gene 
panels ranged in size from 1-54 genes with the majority of panels containing  10 
genes. We used target enrichment strategy (SureSelect platform, Agilent,Inc.) to 
selectively enrich the target region of 10,067 exons in 568 genes followed by NGS 
using the Hi-Seq 2000 (Illumina Inc.) to obtain a minimum coverage of at least 30X at 
all bases evaluated in these genes. We minimized inter-lane variability by pooling 
sequence data across 3 lanes for all samples. To reduce cost and minimize turn-around 
time we multiplexed 12 bar coded patient samples in each lane of the flow cell. 
Results: We were successfully able to sequence 98% of the targeted exons to the 
required coverage depth of 30X. On average, we detected 848 variants across all 568 
genes. We demonstrated high accuracy of this platform to detect the pathogenic 
mutations by demonstrating 100% concordance in detecting 19 pathogenic single 
nucleotide variations and 11 pathogenic insertion-deletion mutations ranging in size 
from 1-18 base pairs across 20 samples that were previously characterized by Sanger 
sequencing. Using 4 pairs of blinded duplicate samples, we demonstrated a high 
degree of concordance (97% - 98%) among the blinded duplicate pairs. The most 
common cause for the discrepant calls among the blinded duplicates was an insertion 
of an adenine base suggesting that incomplete adenylation of the PCR product may 
affect the performance of the target enrichment-NGS strategy. We have developed 
Sanger sequencing assays for exons that could not be sequenced using the NGS 
platform. Conclusions: We have successfully demonstrated the feasibility of combining 
the NGS platform with Sanger sequencing for accurate, cost effective and timely 
genetic diagnosis of a wide variety of inherited disorders. 
 
G06. Detecting Prenatal Microdeletions Non-Invasively: Case of a 22q11.2 
Deletion
W. Gu, H. Fan, Y. Blumenfeld, Y. El-Sayed, S. Quake 
Stanford University, Stanford, CA. 
Introduction: The emergence of non-invasive detection of Down syndrome and other 
aneuploidies allows pregnant women to obtain highly confident fetal genetic information 
without the hazards of invasive sampling. Here we show that the same non-invasive 
technique using molecular counting can verify a de novo 22q11.2 deletion related to 
Digeorge syndrome. Although past cases of microdeletions have been reported in the 
literature, one was 25 Mbp, another was inherited, whereas Digeorge syndrome is ~3 
Mbp and occurs 90% de novo. Digeorge syndrome affects one of ~4000 newborns, 
represents ~18% of conotruncal anomalies found on prenatal ultrasound, and is 
typically verified using FISH on amniocentesis tissue. Methods: An experiment sample 
suspected for the deletion and another reference sample were extracted, processed, 
sequenced, and analyzed completely in parallel. The experiment sample was taken at 
34 weeks gestation from a pregnant woman with twins and the reference from a second 
trimester gestation pregnant woman. After preparations with typical methods, 
sequencing was over 2 lanes of a 1x50bp Illumina HiSeq 2000 run yielding 47M and 
52M aligned reads each for sample and reference. Raw reads were aligned to the 
human genome and counted by region of the genome. Several computational filters 
were applied to reduce noise and Z-scores were calculated by dividing the difference 
between the each region’s count and the average value across the background regions 
by the standard deviation in background regions. Confirmation of deletion was made 
possible in part by extracting pure DNA from the cell portion of maternal blood and fetal 
cord blood at birth. Results: The Z-scores over the Digeorge region was consistently 
over 8-12 covering a ~3 Mbp deletion that includes the Tbx1 gene. No other 1 Mbp 
regions genome-wide (excluding regions next to centromeres or edges) continuously 
exceeded a Z-score of 3 for a deletion. The deletions were confirmed by: (1) FISH was 
done on amniocentesis samples, (2) qPCR of 3 target regions, including 2 from Tbx1 
was performed on the pure fetal and maternal DNA of the sample as well as reference. 
Conclusions: We believe this test will be best initially used in distinguishing between 
trisomies and DiGeorge syndrome after finding conotruncal anomalies on prenatal 
ultrasound. With decreasing sequencing costs and hence greater sequencing depth, 
there is the potential for microdeletion/duplication diagnostics to be incorporated into 
current non-invasive prenatal aneuploidy screens.  
 
G07. Association of TNF-Į Gene Polymorphisms in Korean Patients with 
Ankylosing Spondylitis and Undifferentiated Spondyloarthritis 
W. Lee1, K. Park2, M. Kim1, S. Kang3 
1Kyung Hee University School of Medicine, Republic of Seoul, Korea; 2Samsung 
Medical Center, Republic of Seoul, Korea; 3Kangdong University Hospital, Republic of 
Seoul, Korea. 
Introduction: Recently, single nucleotide polymorphisms (SNPs) within promoter 
region of the tumor necrosis factor-alpha (TNF-Į) gene have been suggested to play a 
role in the pathogenesis of ankylosing spondylitis (AS), because the TNF-Į level in the 
sacroiliac joints of patients with active AS is increased and TNF- Į blockers improve the 
symptomatic and functional status of patients with AS. The purpose of present study 
was to investigate TNF-Į promoter polymorphisms in Korean patients with AS and 
undifferentiated spondyloarthritis. We also planned association analyses adjusting HLA-
B27 subtypes, sex, and age between case and control subjects. Methods: Eighty 
Korean patients with 58 AS and 22 undifferentiated spodyloarthropathy were studied. 
We selected case subjects without any history of uveitis, prior therapy with anti-TNF-Į 
agents, disease-modifying antirheumatic drugs (DMARDs), or steroids. Thirty nine 
unrelated control subjects were enrolled. Genomic DNA was extracted from EDTA 
chelated peripheral whole blood by standard methods using QIAamp DNA Blood Mini 
Kit (Qiagen, Hilden, Germany). All patients and control subjects were analyzed by 
polymerase chain reaction using sequence-specific primers (PCR-SSP) method. Pel-
Freez SSP Unitray HLA-B*27 kit (Dynal Biotech, USA) including 16 primers were used 
to define HLA-B27 subtypes from B*2701 to B*2735, following the manufacturer’s 
protocol. TNF-Į polymorphisms [-1,031T>C (rs1799964), -863 C>A (rs1800630), -
857C>T (rs1799724), -308 G>A (rs1800629), and -238 G>A (rs361525)] were 
determined using amplification refractory mutation system-polymorphism chain reaction 
(ARMS-PCR). Association analyses were performed with SNPStats (available at 
http://bioinfo.iconcologia.net/). Results: All 58 AS patients were positive HLA-B27 
which subtype is HLA-B2705. Among 22 undifferentiated spondyloarthropathy patients 
and 39 unrelated control subjects, positivity of HLA-B27 was 50% (11/22) and 41% 
(16/39), respectively. In TNF-Į polymorphism study, all genotype frequencies in the 
case and control populations conformed to Hardy-Weinberg equilibrium. No significant 
differences in the frequencies of genotype and allele were identified between case and 
control subjects in TNF-1,031, 863, 857, 308, and 238 (P > 0.05). In addition, there 
were no significant differences in the frequencies of haplotypes between two groups in 
haplotype-based association study. Conclusions: This study has shown that there is a 
lack of association of the TNF- Į -1,031, 863, 857, 308, and 238 polymorphisms with 
ankylosing spondylitis and undifferentiated spondyloarthritis in Koreans. However, 
further studies including larger cohorts will be required.  
 
G08. Exome Sequencing Reveals Novel Compound Heterozygous POMT1
Mutations in a Non-consanguineous Lebanese Family with Intellectual Disability 
and Microcephaly 
S. Kantarci1, H. Lee1, N. Bissar-Tadmouri2, A. Megarbane3, S.F. Nelson1 
1David Geffen School of Medicine at University of California, Los Angeles, CA; 
2University of Sharjah College of Medicine, Sharjah, United Arab Emirates; 3University 
Saint-Joseph, College of Medicine, Beirut, Lebanon. 
Introduction: Intellectual disability (ID) is a clinically and genetically heterogeneous 
group of conditions affecting 1-3% of the general population. ID is characterized by an 
intelligence quotient (IQ) below 70 and significant deficiency in at least two adaptive 
skills that are present from childhood. ID can range from mild to profound and can be 
subdivided into syndromic and nonsyndromic (isolated ID without any additional major 
physical abnormalities, dysmorphism, or neurological abnormalities) forms. 
Environmental and/or genetic factors (i.e., cytogenetic aberrations, pathogenic copy 
number variants, point mutations and small insertions or deletions) can cause ID. 
Currently, the genetic etiology of ~60% of ID remains unknown. Methods: In this study, 
we enrolled a large Lebanese family with two unaffected parents, four affected siblings 
and three unaffected siblings, consistent with an autosomal recessive inheritance 
model. The intellectually disabled siblings (two males and two females) with prior 
normal standard karyotype and fragile-X molecular testing presented with microcephaly 
but no facial dysmorphism or seizures. All affected siblings started walking without any 
help around age 4. Homozygosity mapping of the family members using SNP-based 
array excluded the possibility of unreported consanguinity. We used whole exome 
sequencing approach to identify the mutated gene responsible for ID in this family. 
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Results: Sequencing of father and three affected and one unaffected siblings 
uncovered >19,000 protein coding DNA variants in each individual, of which ~700 were 
novel. About 85% of the coding bases in the genome were covered at >=10X covearge. 
Variant segregation among the sequenced family members revealed novel compound 
heterozygous mutations (maternally inherited p.Ala74Val and paternally inherited 
p.(Arg620*)) in POMT1 (protein-o-mannosyl transferase 1), a glycosyltransferase 
involved in Į-dystroglycan (Į-DG) glycosylation. Clinical phenotype in POMT1-mutated 
patients ranges from a severe congenital form muscular dystrophy-dystroglycanopathy 
(MDDG) with brain and eye anomalies (type A1; MDDGA1, 236670, formerly 
designated Walker-Warburg syndrome), to limb-girdle muscular dystrophy (LGMD) with 
microcephaly and intellectual disability (type B1; MDDGB1; 613155) and mild LGMD 
(type C1; MDDGC1; 609308). Conclusions: We are in the process of genotyping of the 
two variants detected in POMT1 in the remaining family members as well as in 75 
ethnically-matched normal control individuals. Re-evaluation of the affected siblings for 
muscular dystrophy, as well as eye and brain abnormalities in light of the data obtained 
through exome sequencing is also in process. Our study highlights the importance of 
whole exome sequencing to identify causative mutations for clinically heterogeneous 
known single-gene disorders.  
 
G09. Analysis of Copy Number Variation Using Whole Genome Exon-Focused 
Array CGH in Korean Patients with Amyotrophic Lateral Sclerosis (ALS) 
M. Kwon 
Kangbuk Samsung Hospital, Republic of Seoul, Korea. 
Introduction: Amyotrophic lateral sclerosis (ALS) is one of the most common adult-
onset neurodegenerative diseases. As copy number variations (CNVs) are account for 
a substantial part of the genetic variation between individuals; they can directly affect 
gene expression, independent of SNPs, and are associated with several complex 
diseases, the study of CNVs is essential to decipher genetic susceptibility to complex 
disease traits, such as ALS. Our major objectives in this study were to identify CNVs 
that could distinguish sporadic ALS (sALS) patients from control individuals. Methods: 
To find highly susceptible CNVs in SALS patients, we performed array comparative 
genomic hybridization (aCGH) analysis of 78 SALS patients and 72 controls. A total of 
150 samples were labeled and co-hybridized to determine DNA copy number changes 
because of deletions/duplications using the NimbleGen Human CGH 3x720K Whole-
Genome Exon-Focused Array (Roche Diagnostics, Mannheim, Germany). The 
normalized data with quality controls were then processed using Nexus Software using 
the recommended default settings. Results: The aCGH analysis resulted in 13,723 
CNV calls after quality control filters using the application of thresholds defined by 
algorithms; over 9,408 in SALS patients and 4,315 in controls. Using region-based 
association analyses, we identified seven heterozygous deleted loci that showed a 
significant association with SALS after Bonfferoni correction (p<7.38×10-5). We 
coordinated the seven CNVs present only in ALS patients. These CNVs encompassed 
six genes and do not include known ALS candidate genes. Conclusions: Our 
conservative and unbiased approach to detect CNVs in SALS patients revealed that 
significantly more deleted genes were specific to ALS patients than were specific to 
controls. Therefore, our data suggest that, for the regions surveyed and sample size 
used, common CNVs are associated with ALS susceptibility. Further studies involving 
replication of independent genome-wide datasets and screening of large cohorts of 
patients and controls with targeted assays are required to determine the role of these 
deletions in ALS pathology. 
 
G10. Mutational Characterization of the RB1 Gene Mutations in Korean 
Patients with Bilateral Retinoblastoma 
S. Seo1, H. Ahn2, Y. Yu1, H. Kang2, K. Park2, S. Cho1, J. Park1, Y. Hyun1, J. Kim1, M. 
Seong1, S. Park1 
1Seoul National University Hospital, Republic of Seoul, Korea; 2Seoul National 
University College of Medicine, Republic of Seoul, Korea. 
Introduction: Retinoblastoma is a malignant neoplasm that affects the retina, which is 
the most common form of childhood intraocular tumor. Tumor initiation is known to be 
associated with a double (two-hit) mutation in the RB1 gene, requiring mutations in both 
alleles. RB1 mutation detection has greatly improved the clinical management of 
retinoblastoma patients and has provided critical information for predicting the risk of 
disease inheritance. Methods: Twenty one Korean patients were screened for the RB1 
gene; 16 were diagnosed with bilateral retinoblastoma, and 5 with unilateral 
retinoblastoma. None of the patients had a family history of retinoblastoma. DNA was 
extracted from peripheral blood leukocytes, and RB1 gene mutations were screened via 
direct sequencing of all 27 exons and MLPA. RNA analysis was performed to identify 
aberrant splicing products associated with a novel splicing mutation. Results: Germline 
RB1 mutations were detected in 15 of 16 bilateral retinoblastoma patients; however, no 
RB1 mutations were observed in unilateral retinoblastoma patients. Ten known 
mutations (c.265-2A>G, c.380+1G>A, c.409G>T, c.751C>T, c.763C>T, c.1005delA, 
c.1333C>T, c.1494T>G, c.1666C>T, and c.1735C>T) and 4 novel mutations 
(c.1448delA, c.1814+3A>C, c.1969_1981delinsT, and c.2191delC) were identified. 
Subsequent RT-PCR and sequence analysis revealed that the splicing mutation, 
c.1814+3A>C, led to an abnormal transcript by skipping of exon 18. Any large deletion 
or duplication mutation was not found in this series, but we identified one false positive 
MLPA deletion case resulting from a point mutation (c.1448delA) positioned in the 
probe binding site. The detection rate of RB1 mutations in sporadic bilateral 
retinoblastoma patients was 93.8% (15 of 16 patients), similar to that of other recent 
studies using direct sequencing and MLPA for RB1 mutation screening. Conclusions: 
Genetic screening sensitivity in retinoblastoma patients is important for diagnosis, 
genetic counseling, and preimplantation genetic diagnosis in family members. Risk 
prediction and the management of retinoblastoma can benefit from the characterization 
of mutations in the RB1 gene. 
 
G11. Germline Mutations of RET and SDHB in Korean Patients with 
Pheochromocytoma 
W. Lee, M. Bae, S. Kim, S. Chun, J. Ko, W. Min 
University of Ulsan College of Medicine and Asan Medical Center, Republic of Seoul, 
Korea. 
Introduction: Pheochromocytoma is a rare neoplasm, probably occurring in less than 
0.2 percent of patients with hypertension. Most catecholamine-secreting tumors are 
sporadic. However, some patients have the disease as part of a familial disorder. There 
are several familial disorders associated with pheochromocytoma, all of which have 
autosomal dominant inheritance: hereditary paraganglioma-pheochromocytoma 
(PGL/PCC) syndrome, von Hippel-Lindau syndrome, multiple endocrine neoplasia type 
2 (MEN2), and less commonly, neurofibromatosis type 1. We analyzed the mutation 
status of RET, SDHB and SDHD in Korean patients with pheochromocytoma. 
Methods: Thirty-five patients with pheochromocytoma or adrenal paraganglioma were 
enrolled. They were tested for germline mutations in the three genes, RET, SDHB, and 
SDHD, by PCR-direct sequencing. We tested selected exons 8, 10, 11, 13, 14, 15, 16 
of RET, exons 1 to 8 of SDHB, and exons 1 to 4 of SDHD. Results: A mutation was 
identified in 7 (20%) — 4 in RET (11.4%) and 3 in SDHB (8.6%). All mutations of RET 
were missense point mutations involving exon 11. Three patients presented with 
c.1891G>T (p.Asp631Tyr) and the other patient had a c.1901G>T (p.Cys634Phe) 
mutation. In SDHB analysis, two cases were frameshift mutation and one case was 
missense point mutation. One of frameshift mutation was c.392delC (p.Pro131Hisfs*5), 
and the other was c.757delT (p.Cys253Valfs*5). One case of missense mutation was 
c.137G>A (p.Arg46Glu). There were no SDHD mutations in the analyzed subjects. 
Conclusions: The frequency of a mutation in RET or SDHB in Korean patients with 
pheochromocytoma estimates 20 percent. Surveillance of pheochromocytoma patients 
can help detecting multiple synchronous or metachronous tumors from affected patients 
or preventing manifestations of medullary thyroid cancer by prophylactic thyroidectomy 
for probands and their family members. Thus, it is thought to be clinically useful to test 
germline mutation status of RET and SDHB genes in the patients with 
pheochromocytoma or adrenal paraganglioma. 
 
G12. Identification of the CFTR p.Phe508Del Founder Mutation in the Absence 
of a Polythymidine 9T Allele in a Hispanic Patient 
N. Dharajiya1, K. Chisholm2, L. Dietz3, C. Richards4, M. Kharrazi5, I. Schrijver2 
1University of California San Diego, San Diego, CA; 2Stanford University School of 
Medicine, Stanford, CA; 3Stanford Hospital and Clinics, Stanford, CA; 4Oregon Health & 
Science University, Portland, OR; 5California Department of Public Health, Richmond, 
CA. 
Introduction: Cystic fibrosis is a common autosomal recessive disease caused by 
mutations in the CFTR gene.  The most common mutation, p.Phe508del, accounts for 
approximately 66% of CF alleles worldwide, and is thought to have arisen from a single 
mutational event during the Paleolithic period. Intron 8 (IVS8) of the CFTR gene 
harbors two adjacent polymorphic sequences, a poly TG tract and a poly T tract, which, 
depending on the allele, can adversely affect the splicing of exon 9. The p.Phe508del 
mutation, located in exon 10 of the CFTR gene, is in linkage disequilibrium with the 
(TG)10-9T allele in IVS8. Methods: We followed the State of California’s CF newborn 
screening algorithm that includes the following steps: 1) newborn blood spots are used 
to determine immunoreactive trypsinogen (IRT) levels; 2) newborns with an IRT of >62 
ng/mL have DNA extracted from their blood spots to test for 40 locally prevalent CFTR 
mutations; 3) newborns in whom one mutation is identified proceed to DNA sequencing 
from the same blood spot. Results: We identified a child compound heterozygous for 
mutations p.Phe508del (c.1521_1523delCTT) within legacy exon 10 (exon 11 by 
sequential numbering), and p.Phe1074Leu (c.3222T>A) in legacy exon number 17b 
(exon 20). Additionally, homozygous p.Met470 alleles were identified, together with 
(TG)11-5T and (TG)11-7.T. Conclusions: This patient has three significant CFTR 
alleles: the severe p.Phe508del mutation, the disease-modifying 5T allele, and the mild 
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p.Phe1074Leu mutation. The patient is at risk for developing CF-related symptoms and 
will be clinically followed. p.Phe508del has always been reported with (TG)10-9T, 
except in Lebanese Maronites and one North Iranian individual. In the absence of a 9T 
allele, the cis/trans status of the p.Phe508del mutation with the (TG)11-5T/(TG)11-7T 
alleles could not be determined without parental studies. The unusual haplotype in this 
child may have been created by a recombination event, causing the p.Phe508del 
mutation to be present either with the (TG)11-5T or (TG)11-7T allele. This patient is the 
first individual in the United States, as well as in the Hispanic population, to have 
p.Phe508del on a background of 5T and 7T alleles instead of the expected 9T allele. As 
a rule that is routinely used in clinical diagnostic interpretations, founder mutation 
p.Phe508del is always present together with the 9T allele. Our case illustrates that the 
9T assumption should not always be followed and raises the question whether other 
patients with a non-9T configuration may have been overlooked. 
 
G13. Germline Mutations of RET in Korean Patients with Medullary Thyroid 
Cancer 
S. Chun, W. Lee, M. Bae, S. Kim, T. Kim, W. Kim, Y. Shong, S. Hong, W. Min 
University of Ulsan College of Medicine and Asan Medical Center, Republic of Seoul, 
Korea. 
Introduction: Medullary thyroid cancer (MTC) is a neuroendocrine tumor originating 
from the parafollicular or C cells of the thyroid gland. MTC accounts for approximately 
5-10% of all thyroid carcinomas. Most medullary thyroid carcinomas are sporadic. 
However, some are familial as part of the multiple endocrine neoplasia (MEN) type 2. 
We analyzed the mutation status of RET gene, the only gene known to be associated 
with MEN type 2, in Korean MTC patients. Methods: A total of 19 patients diagnosed 
with medullary thyroid cancer were tested for RET mutation status from March 2009 to 
April 2012. They were individuals with no family history of other endocrine tumors. 
PCR-direct sequencing were performed on selected exons of RET gene (8, 10, 11, 13, 
14, 15, and 16). Results: Six out of 19 patients (31.6%) with MTC had known 
pathogenic mutations of RET gene and all of them were missense point mutaions. 
Three cases involved codon 634 on exon 11, two of which were c.1900T>C 
(p.Cys634Arg) and the other was c.1901G>A (p.Cys634Tyr). In exons other than 11, 
we observed mutation of c.2410G>A (p.Val804Met) in two patients and c.2304G>C 
(p.Glu768Asp) in one case. We also detected c.2752A>G, a missense variation 
substituting valine for methionine at codon 918 (p.Met918Val), but the pathogenic 
significance is uncertain. Conclusions: The mutation frequency of RET gene in Korean 
MTC patients was 31.6 percent. Through surveillance of MTC patients, we can prevent 
patients from secondary surgical complications such as intraoperative catecholamine 
crisis, and can allow family members to prevent primary manifestations of MTC or other 
phenotypes of MEN type 2. Thus molecular testing for RET germline mutation can 
confer significant clinical benefit to the patients with MTC and their family members.  
 
G14. Mutations in the HBB Gene: the Experience of a University Center in 
Korea and Report of Two Novel Whole Gene Deletions 
E. Ra, S. Cho, S. Park, S. Seo, M. Seong, S. Park 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: Thalassemia is uncommon in the Korean population; however it needs to 
be included in the differential diagnosis of hypochromic anemia or unexpalined 
hemolytic anemia. The molecular characterization of ȕ-thalassemia is absolutely 
necessary for molecular diagnosis as well as any genetic epidemiological study in this 
region. Methods: We analyzed 94 Korean families with ȕ-thalassemia. Direct 
sequencing of all exons and gene dosage analysis for ȕ-globin genes were performed 
in all patients. Results: Ninty-four ȕ-thalassemia patients were characterized, all of 
which were heterozygous and twenty-nine different mutations were identified. The 
common mutations noted included the initiation codon (CD) ATG>AGG (22.3%), CD 17 
A>T (16.0%), and CD 121 G>T (11.7%). The mutations causing dominantly inherited ȕ-
thalassemia were relatively common (18.2%) including CD 121 G>T, CD 33/34-GGT 
(Hb Korea), and etc. Two large deletions involving the HBB gene were identified in this 
study. Subsequent gap PCR and sequence analysis revealed that the deletion range in 
one case was NG_0000007.3: g.67935_80929del12986. Conclusions: This mutation 
spectrum in this region is characteristic of the low prevalent area of ȕ-thalassemia; 
however it is quite different even from the adjacent countries, Japan or China as well as 
high prevalent area. 
 
G15. Case Report: Two Individuals of Vietnamese Descent with a CF Variant 
Identified Using the Abbott/Celera Oligonucleotide Ligation Assay (OLA) 
V. Pratt, L.L. Pike-Buchanan, A. Buller-Burckle, M. Jarvis, M.G. Cura, K. Muralidharan 
Quest Diagnostics-Nichols Institute, Chantilly, VA. 
Introduction: Since ACMG and ACOG recommended routine cystic fibrosis carrier 
screening for women who are pregnant or considering pregnancy, testing volume 
increased. Here we report 2 cases with an anomalous electropherogram for R553 in 
CFTR, determined using the Abbott/Celera oligonucleotide ligation assay (OLA). 
Methods: Genomic DNA was isolated from whole blood samples from 2 unrelated 
individuals of Vietnamese descent. The DNA was then amplified in a 15-plex 
polymerase chain reaction. Each mutation and its corresponding normal allele were 
interrogated by 3 oligonucleotide probes. The common probe hybridized to both the 
mutant and normal alleles, whereas the remaining 2 probes compete for binding to the 
respective amplicon. Only the probe with perfect complementation to the amplicon 
sequence will hybridize and ligate to the common probe in an allele-specific manner, 
forming an OLA product. The ligation reaction is catalyzed by rTth DNA ligase (OLA 
enzyme). The OLA products were detected on a CEGA-16TM instrument and 
interpreted using the ABI GeneMapper software. DNA sequence analysis of exon 12 
was performed. Results: We observed an abnormally low peak for R553. DNA 
sequencing of exon 12 identified homozygosity for p.I556V (c.1666A>G) in both 
unrelated individuals. Conclusions: This mutation has not been previously described in 
the Vietnamese population. This same mutation, I556L, has been reported in an adult 
French male with chronic bronchitis who was fertile. As a child, he had received a 
diagnosis of pancreatic sufficiency with moderate pulmonary symptoms and positive 
sweat chloride test results. The mutation was also found in another individual who had 
CBAVD (http://www.genet.sickkids.on.ca/MutationDetailPage.external?sp=275, 
accessed 05/21/2012). The occurrence of a single, low peak height for R533 is 
relatively rare, and a large reference laboratory has the advantage of observing such 
rare anomalies at a higher frequency. Although the Abbott/Celera OLA assay is a 
robust screening method for the ACOG/ACMG CF mutations, it may also uncover other 
variants that show up as OLA anomalies. In these cases, we recommend following up 
with sequencing to identify the specific mutation.  
 
G16. Comprehensive Molecular Characterization of the NF1 Gene in Korean 
Patients with NF Type 1 
S. Seo, S. Park, S. Cho, J. Lee, S. Kim, E. Ra, J. Chae, M. Seong, S. Park 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic 
disorder caused by mutations of the NF1 gene. The disease is characterized by multiple 
café-au-lait spots, axillary and inguinal freckling, multiple discrete cutaneous 
neurofibromas, and iris Lisch nodules. Molecular diagnosis of NF1 is generally difficult 
due to its large size of the gene, presence of several pseudogenes and a high 
incidence of sporadic mutations across the entire exons ranging from single nucleotide 
substitutions to complex rearrangements. Methods: A total of 25 unrelated NF1 
patients and 11 family members of 6 patients were tested included in the study. NF1 
gene mutations were screened via DNA sequence analysis of all 58 exons and gene 
dosage analysis by using multiplex ligation-dependent probe amplification (MLPA) kit. 
Also, RNA analysis was performed performed to identify a hidden mutation in patients 
who were mutation-negative in DNA sequence analysis and MLPAaberrant splicing 
associated with a novel mutation. Results: Among 25 patients, 23 (92%) were had 
genetic abnormalities in the NF1 gene including one complex rearrangement confirmed 
as NF1 with sequence analysis and 1 (4%) with MLPA. No mutations were detected in 
RNA analysis for the other two patients who were mutation-negative in DNA sequence 
analysis and MLPA. Twenty two different mutations comprising of various types were 
identified in our patients; 11 were novel and the other 11 were previously defined. Most 
of the mutations were nonsense or frameshift, which provoked premature terminations 
of the protein. Interestingly, a missense mutation of c.1466A>G was found to result in 
an alternative splicing and produce a truncated protein of p.Tyr189X. In 2 families with 
histories of NF1, same mutations were detected among their family members. 
Conclusions: In our study, detection rate of the NF1 mutations was about 92% using a 
combination of direct DNA sequencing, MLPA, and mRNA analysis. This testing 
strategy can be recommended to define the genetic defects in Korean patients with 
NF1. 
 
G17. Using Next-Generation Sequencing Based Exome Analyses for 
identifying Novel Genetic Defects in Rare Immunodeficiency Disorders  
A. Husami, D. Kissell, R. Marsh , K. Zhang 
Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. 
Introduction: Next-generation sequencing (NGS), an ultra-high-throughput sequencing 
technology, has facilitated the discoveries of many genetic causes of human disease. 
Direct sequencing of the exome may provide a fast and cost effective way of finding 
genetic causes of rare immunodeficiency disorders. Methods: Genetic materials were 
collected from a patient with a unique primary immune deficiency and her sibling and 
parents. DNA enrichment was performed using the NimbleGen SeqCap EZ Exome v2.0 
and sequencing was done by Illumina HiSeq2000 using the TruSeq technology. The 
sequence FASTQ files were aligned with the GRCh37.2 human genome reference and 
the variants reports were generated by the NextGENe software. Gene names were 
extracted from the Human Gene Nomenclature Committee (HGNC) database via bulk 
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download and added to the variant reports. A comparison algorithm was used to mine 
108,668 known diseases associated substitutions and micro lesions from data collected 
in the HGMD (Human Gene Mutation Database) Professional 2011.4. Sanger 
sequencing was performed to confirm the sequencing changes as needed. Western 
blot analysis was used to measure the level of protein expression. Results: An 
autosomal recessive inheritance model was used for analyses. We identified two 
truncation mutations in the proband in one novel protein. It belongs to a large, highly 
conservative protein family that is believed to play critical roles in many essential 
biological functions including signal transduction and transcription regulation. Both 
parents are carriers for these mutations and the healthy sibling also carries a single 
mutant allele. Western blot analysis revealed an absence of the protein in T cell blast 
lysates from the proband. Conclusions: Direct exome sequencing provides a useful 
tool for the discovery of genetic causes of rare immunodeficiency disorders. With a 
robust analysis pipeline and affordable sequencing cost, direct exome sequencing 
could provide a clinically useful tool for clinical genetic diagnoses in families with rare 
genetic disorders. 
 
G18. Development of a Comprehensive High-resolution PCR-SBT Method for 
HLA-G Polymorphism 
S. Jeong1, Y. Park1, C. Yoon2, O. Kwon2, H. Kim1 
1Yonsei University College of Medicine, Republic of Seoul, Korea; 2Biowithus Life 
Science Institute, Republic of Seoul, Korea. 
Introduction: Sequence-based typing (SBT) is gold standard method for highly 
polymorphic human leukocyte antigen (HLA) class I loci. SBT for HLA-A, -B, and -C loci 
has been well established so far. HLA-G is a nonclassical HLA class I gene with 
relatively less alleles than classical HLA class I genes. Recently, SBT method for HLA-
G reported, but the method was inconvenient because of 3 PCRs. We have developed 
a comprehensive HLA-G PCR-SBT. Methods: PCR primers were designed on 5’UTR 
and junction of exon 5 and intron 5 that generates about 1.9 kb fragment useful for 
direct sequencing. Twenty-two genomic DNAs from whole blood, 2 homozygotes and 
20 heterozygotes, were amplified by PCR and direct sequenced by automated DNA 
analyzer using G2F, G3R, and G4F sequencing primers with BigDye Terminator v3.1 
(Applied Biosystems, Inc., USA). The data analyzed by BIOWITHUS SBT Analyzer 
software (Biowithus, Inc., Korea). Results: Twenty-two gDNAs’ results showed 100% 
agreement with known genotypes that means the method established in this study is 
reliable and to be a superior genotyping method for HLA-G in clinical samples. 
Conclusions: The approach described in this study offers a precise and efficient 
strategy for high-resolution HLA-G genotyping and at the same time can differentiate 
new alleles.  
 
G19. Metrology for Huntington’s Disease PCR Assays: Repeat Regions to 
Avoid 
M.C. Kline, D.L. Duewer 
National Institute of Standards and Technology, Gaithersburg, MD. 
Introduction: Huntington’s disease (HD) is an inherited neurodegenerative disease 
with clinical manifestations associated with expansion of a polymorphic CAG repeat. 
There are two repeat regions just 12 base pairs (bp) downstream of this clinically 
significant repeat that complicate accurate assessment of the CAG repeat number: a 
[CCG]7-12 and a [CCT]1-2. There are also two repeat regions more than 200 bp 
upstream of the CAG region that must be taken into account in assay design: 
[GGGGGC]1-2 and [GGCCCCGCCTCCGCCGGCGC]1-3. Although none of the 
additional repeat regions are used for diagnostic purposes, knowledge of the existence, 
positions, and variability of these repeat regions remain important to avoid inadvertent 
inclusion of these regions in assay development. There are published PCR primer sets 
that limit amplification to the CAG repeat only; however, other published sets include 
the CCG/CCT repeats. There are also publically available primer design software 
systems that suggest placement of an upstream primer that includes the 20 bp repeat. 
Methods: Sanger sequencing primers were developed to sequence an approximately 
446 bp segment starting 68 bp upstream of the CAG repeat region to confirm the 
upstream repeat regions. After sequence confirmation, genotyping primers were 
developed to type 203 samples, cell lines, and normal population samples for a 282 bp 
segment of this upstream region using capillary electrophoresis. Typing of the CAG 
repeat region for these samples was accomplished using a published primer set and 
capillary electrophoresis bp sizing calibrated to Standard Reference Material 2393: 
CAG Repeat Length Mutation in Huntington’s Disease (SRM 2393). A subset of the 203 
samples used was genotyped using published primer sets for the CCG/CCT repeat 
region. Included in this subset were “apparent” homozygous samples from the CAG 
typing. Results: 203 samples were characterized for the variability of the upstream 
repeat regions. Although 85% of the 406 observed alleles were [6 bp]1 / [20 bp]2, 6% 
were at least 20 bp larger or smaller. Preliminary data of the CCG/CCT repeat region, 
primarily for samples appearing to be homozygous for the CAG repeat, suggest repeat 
variability of 7 to 11 repeat units. Additional data from Sanger sequencing confirms the 
CCG/CCT configuration. Conclusions: Inclusion of the upstream repeat regions in the 
CAG repeat count may have clinical significance and should be avoided in primer 
design. Use of well characterized reference material can also aid in assay development. 
 
G20. Next Generation Sequencing For Cystic Fibrosis 
D. Streck, R. Kurvathi, S. Husain, J. Dermody, M. Schwalb, G. Toruner 
University of Medicine and Dentistry of New Jersey/New Jersey Medical School, 
Newark, NJ. 
Introduction: Cystic fibrosis (CF) is the most common life-threatening autosomal 
recessive condition.It is a progressive, multisystem disease that primarily affects the 
pulmonary, pancreatic, and gastrointestinal systems but does not affect intelligence, 
which is caused by the mutations in the CFTR gene. Carrier screening for CF was 
introduced into routine obstetric practice in 2001. CF screening assays are genotyping 
assays focusing on most common mutations that is responsible for the disease. 
However the frequency of most common mutations are not the same across different 
populations. Therefore the sensitivity of the CFTR screening test varies considerably 
among different ethnic groups. Genotyping screening is most effective in non-Hispanic 
white and Ashkenazi Jewish populations, but not much useful in other populations. The 
way to solve that effectiveness problem is sequencing the entire coding region and 
splice junctions of the CFTR gene. In the past the cost of the CFTR gene testing for 
screening purposes were prohibitively expensive, but the technological revolution (i.e., 
advent of next generation sequencing technologies) in the field of DNA sequencing 
changed the landscape and significantly decreased associated costs. However, 
analytical validity of the next generation sequencing assays needs to be establised. 
That is the aim of the CFTR sequencing experiments using Personalized Genome 
Machine from Ion Torrent Technologies. Methods: Thirty-eight DNA samples, which 
were previously characterized for Cystic Fibrosis mutations using the Luminex Tag-IT 
Cystic Fibrosis panel, were sequenced. PCR reactions were set up to amplify the CFTR 
exons and essential exon/intron boundaries using a panel of 36 individual amplicons. 
The libraries were prepared and barcoded using Ion PGM 200 bp chemistry according 
to the manufacturer's instructions. The barcoded libraries were pooled, equimolarly, and 
placed onto the One Touch for emulsion PCR, which was followed by enrichment of the 
template positive Ion Sphere Particles on the One Touch ES. The ISP enrichment was 
confirmed using the Qubit 2.0 fluorometer. The sample library was prepared for 
sequencing on an Ion 316 chip and sequenced on the PGM for 520 flows using 200 bp 
chemistry. The data from the PGM runs were processed using the SoftGenetics 
NextGENe V2.14. Results: All previously identified CFTR mutations on all tested DNA 
samples were detected. The concordance rate was 100%. Conclusions: Analytical 
validity for Ion Torrent based CFTR sequencing was established. 
 
G21. Association Between the Common p.A986S Polymorphism in CASR Gene 
and a Hypercalcemic Phenotype: Enrichment in a Patient Cohort Undergoing 
Molecular Diagnostic Testing for Inactivating CASR Mutations 
B.Y. Wong1, G.N. Hendy2, D.E. Cole1 
1Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; 2McGill University, 
Montreal, Quebec, Canada. 
Introduction: Private mutations that inactivate the CASR gene may result in 
hypercalcemic disorders, particularly familial hypocalciuric hypercalcemia (FHH), 
familial isolated hyperparathyroidism (FIHP), and allied conditions. The common CASR 
polymorphism, p.A986S, has been associated with increased serum calcium 
concentrations in the general population. However, it is not known whether the p.A986S 
variant shows an increased frequency among patients referred for CASR mutation 
testing due to clinical suspicion of an underlying CASR-based etiology. Methods: We 
assessed p.A986S minor allele frequencies (MAF) in 120 samples obtained from 
samples referred for mutational analysis because of a clinical suspicion of disordered 
calcium metabolism due to an inactivating CASR mutation, and we compared this to the 
population frequency for this mutation (223/1352 chromosomes, MAF = 0.165), using 
the Fisher exact test. Results: In the referred patient group as a whole, there were 55 
variant alleles, which was a significantly greater proportion (MAF = 0.23, p = 0.02) than 
in our background population. In the sub-group found to have a private potentially 
causative mutation, the difference was smaller (15/78, MAF = 0.19) and not significant. 
Mutations in these patients could be classified as follows: missense (32, with 14 known 
mutations, 13 probably deleterious, 5 of unknown significance); nonsense (3); 
regulatory (1); splice- ite (1); in-frame deletion (1) and frameshift (1). In contrast, the 
proportion of 986S minor alleles in the mutation-negative group was found to be about 
40% higher (40/162, MAF = 0.25) than in population controls, a significant difference (p 
= 0.01). Conclusions: The 986S variant, previously found to be associated with 
increased serum calcium, is significantly more frequent in mutation-negative patients 
referred for CASR screening than in controls. Thus, if patients are being appropriately 
referred for screening on the basis of a not-yet-diagnosed hypercalcemic phenotype, 
AMP Abstracts  641
JMD November 2012, Vol. 14, No. 6
the enrichment we see in patients without causative CASR mutations may well be 
areflection of the relatively greater abundance of 986S in a sub-group selected in part 
on the basis of increased extracellular calcium concentrations. 
 
G22. A Retrospective Study of 200 Fragile X Samples Using AmplideX mPCR: 
Improved Workflow, Data Quality and Concordant Results Relative to Southern 
Blot Analysis 
M. Jama, S. Gibson, E. Lyon 
ARUP LABS, Salt Lake City, UT. 
Introduction: Fragile X (FX) syndrome is caused by an expansion of a CGG 
trinucleotide repeat at the 5' untranslated region of the fragile X mental retardation 1 
gene (FMR1). Expansion of CGG repeats beyond 200 (full mutation) become 
abnormally hypermethylated at CpG islands in the 5’- untranslated region of the gene, 
leading to FMR1 gene silencing, the absence of the FMRP protein and consequent 
phenotype. The gold standard for the detection and determination of methylation status 
of such expanded alleles is Southern blot (SB) analysis. Southern analysis is 
expensive, time and labor intensive and requires a high quality and quantity of DNA. A 
novel methylation PCR (mPCR) assay (Asuragen) based on methylation-sensitive 
restriction digest of DNA and comparative PCR of digested products has been 
described to assess methylation as well as (CGG)n sizing of such samples. This high 
throughput approach has the potential to reduce or replace the need for Southern 
analysis for the determination of methylation status of such samples. The assay may 
give a more informative assessment of FXS mosaic samples in determining the percent 
methylation of subpopulations of expanded alleles. Methods: We evaluated 200 FX 
samples that consisted of 112 females and 88 males and comprised of 36 normal, 36 
intermediate, 65 premutation and 63 full mutation alleles. All AmplideX mPCR runs 
were performed at ARUP Laboratories using 10 μL of 20 ng/uL of DNA. Repeat length 
and methylation status were calculated using peak heights of digested and undigested 
DNA. All results were compared directly to in-house PCR and Southern analysis 
whenever possible. Results: The methylation status of the 63 full mutation samples 
revealed by mPCR was concordant with Southern blot analysis for unmethylated, 
partially methylated and fully methylated alleles, and included expansions as large as 
~1000 CGG. In addition, the resolution of mPCR products after capillary electrophoresis 
revealed molecular features of expansion and methylation that could not be discerned 
by Southern blot analysis alone. Premutation and normal samples showed normal 
methylation patterns as expected. Conclusions: We find that mPCR methodology is a 
potential alternative to Southern blot that offers a high throughput, low DNA input, PCR-
only workflow and may clarify the interpretation of complex mosaic samples associated 
with FXS phenotype. 
 
G23. The Analysis of CGG Repeat and AGG Interruption Pattern of the FMR1
Gene Among Korean Women 
E. Cho, J. Jang, E. lee 
Green Cross Reference Laboratory, Yongin, Kyunggi-do, Republic of Korea. 
Introduction: Current methods for Fragile X syndrome rely on Southern blot analysis to 
detect expanded allels too large to be PCR-amplified and to cofirm female homozygous 
alleles with capillary electrophoresis. Recently the introduction of CGG repeat primed 
FMR1 PCR method provide the additional molecular information about length of 
uninterrupted CGG repeat as well as total length of repeat. The presence of AGG 
interruptions within the CGG repeat tract is thought to decrease the likelihood of 
expansion to a full mutation during transmission. In this study, we analyzed the 
frequencies of premutation and gray zone repeat with length of uninterrupted CGG for 
assessment screening strategies in Korea. Methods: We analyzed blood samples of 
4,106 pregnant women (age: 20-45 yrs) for length of total repeat and pure CGG repeat 
using AmplideX (Asuragen, Inc., Austin, TX) PCR kit. Results: We found 7 premutation 
alleles (1 in 588) and 32 gray zone (45-54) repeats (1 in 128). The repeat sizes of 
premutation were 55-74 repeats. Among 7 premutation and 32 gray zone repeat, 5 had 
no interruption of AGG and 22 had more than 25 AGG uninterrupted CGG repeat (1 in 
187). The most common CGG repeats were 29 (45.4%) and 30 (29.2%) repeat and 
30.4% had homozyogous CGG repeat allele. Conclusions: Our data provide the 
distribution of total length of repeat and uninterrupted CGG repeat to assess the 
feasibility and acceptability of population screening in Korean women. 
 
G24. High Resolution Microarray Studies Using the Affymetrix SNP 6.0 Array 
Identified Duplications of Chromosome 17p13.3 in Individuals with Split Hand 
Foot Malformation with Long Bone Deficiency (SHFLD3) 
A. Chaubey1, F.O. Bartel1, C.M. Armour2, R.C. Rogers1, D.B. Everman1, R.C. Rogers1, 
K.R. Holden1, C.E. Schwartz1, B.R. DuPont1 
1Greenwood Genetic Center, Greenwood, SC; 2Kingston General Hospital & Queen's 
University, Kingston, Ontario, Canada. 
Introduction: Congenital limb malformations characterized by median clefts of the 
hands and/or feet comprise the primary clinical findings in Split-Hand/Foot Malformation 
(SHFM). SHFM presents with underdevelopment or absence of central digital rays and 
metacarpal/metatarsal bones and syndactyly of the remaining digits. Significant genetic 
heterogeneity has been reported with different syndromic and isolated forms of SHFM. 
Most forms of SHFM are autosomal dominant disorders with incomplete penetrance 
and variable expressivity. Early literature reports identified chromosomal aberrations in 
individuals with these disorders; however, reports have found single gene mutations as 
being causative of these malformations. Multiple families with SHFM1 and SHFM3 have 
been followed and studied at the Greenwood Genetic Center. Chromosome analysis 
and different molecular methods (including pulse-field gel analysis, FISH, oligo-arrays, 
etc) were employed by researchers at the GGC to identify deletions, and inversions 
involving 7q21q22, and duplications involving 10q24 for the SHFM loci. Methods: High 
resolution microarray using the Affymetrix genome-wide SNP 6.0 array was performed 
on individuals with clinical presentation of SHFLD3. Quantitative PCR using the relative 
threshold cycle (ǻǻCT) method was used to determine the genomic dosage of 17p13.3 
in parents and additional family members. Results: We recently published the 
identification of duplications of 17p13.3 in 3 families presenting with Split-Hand/Foot 
Malformation with Long Bone Deficiency (SHFLD3) using the high resolution SNP 
(Affymetrix SNP 6.0) array (Armour et al,, 2011). An extended molecular analysis of 21 
family members from 4 generations of one of the familial cases revealed 8 affected 
family members harboring the 17p13.3 duplication (including 2 with SHFLD and 6 with 
only hand/foot involvement). However, 5 individuals found to be carrying the duplication 
did not have a significant clinical phenotype associated with SHFM or SHFLD3. 
Conclusions: These findings highlight the incomplete penetrance and variable 
expressivity associated with these disorders. The precise molecular mechanisms 
causing the SHFM/SHFLD phenotype at this locus have not yet been determined. 
However, the role and contribution of possible gene modifiers at either a nearby locus 
or a different region of the genome may help in elucidating the molecular mechanism in 
these disorders.  
 
G25. Performance Evaluation of a Test Kit for the Detection of Methylated 
Septin9 DNA in Plasma 
T. deVos1, R. Tetzner2, A. Fassbender2, S. Rausch2, T. Koenig2, G. Weiss2 
1Epigenomics Inc., Seattle, WA; 2Epigenomics AG, Berlin, Germany. 
Introduction: The presence of methylated Septin9 DNA (Septin9) in plasma has been 
validated as a colorectal cancer (CRC) biomarker in numerous publications. Laboratory-
developed tests are available in the US and Canada and a blood test, Epi proColon 2.0, 
is available as a CE-marked kit in Europe, but is not available for sale in the US. This 
study reports on the analytical and technical evaluation of the Epi proColon test kit. 
Methods: Test kits were developed under design control and manufactured under 
cGMP. Assays were performed and validated both internally and at external sites. 
Bisulfite-converted DNA was prepared from 3.5 mL sample volume and analyzed in 
triplicate for Septin9 and beta-actin (ACTB) DNA by duplex real-time PCR using the 
AB7500 Fast Dx instrument (Life Technologies, Inc.). For analytical validation samples 
were prepared in a protein solution by spiking DNA from a cell line methylated at the 
Septin9 locus (0-50 pg/mL) into DNA from a cell line not methylated at Septin9 (9 
ng/mL) in a concentration series. Samples were also prepared by stage-specific pooling 
of plasma from subjects diagnosed with stage I-III CRC, and from subjects having no 
evidence of disease (NED). Results: The LoD was estimated to be 10pg or ~2 genome 
equivalents per mL based on analysis by multiple site operators using the concentration 
series. Test reproducibility, based on analysis of plasma pools by multiple operators, 
showed a small variation in ACTB CT (standard deviation (SD) <0.2 CTs) and variation 
in Septin9 CT <1.1 SD with 100% agreement in positivity for cancer pools and 89% 
agreement for NEDs. At external sites, the observed agreement was 98% for cancer 
pools and 78% for NEDs. The test demonstrated good robustness based on analysis of 
20 processing failure modes for which erroneous test results were averted by 
application of the internal control (ACTB) results or the results of the required external 
batch controls. Conclusions: Epi proColon is a qualitative assay for the real-time PCR 
detection of methylated Septin9 DNA in EDTA plasma. Studies performed both 
internally and at external sites indicate the test has high analytical sensitivity, 
reproducibility, robustness and repeatability under variable situations such as different 
operators, instruments and kit lots. This blood test was developed as an aid in 
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screening patients at average risk for CRC, and should encourage participation in 
screening programs. 
 
G26. Inter-laboratory Verification of the xTAG Cystic Fibrosis 60 v2 Assay 
S.F. Allen1, K.A. Lebel2, L.J. Tafe1, G.J. Tsongalis1, J.A. Lefferts1 
1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2Baystate Health Center, 
Springfield, MA. 
Introduction: Cystic fibrosis (CF) is an autosomal recessive disease affecting as many 
as 1 in 2500 live births in the Caucasian population. The disease is caused by 
mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), a gene 
approximately 230 kb in size containing 27 coding exons. The ǻF508 mutation is the 
most common CFTR mutation, representing ~30%-70% of mutations depending on the 
population; however, more than 1000 other mutations have been identified. Carrier 
screening is available for individuals considering reproduction to assess risk of CF. 
Here we report our laboratories’ verification study on the performance of the xTAG 
Cystic Fibrosis 60 kit v2 for clinical testing. Methods: DNA from 35 peripheral blood 
specimens previously submitted for CFTR testing (InPLEX, Hologic, Inc.) were de-
identified and blinded to technologists with respect to genotypes. The xTAG assay was 
performed on each sample according to the manufacturer’s protocol in separate 
laboratories as part of two different assay verifications. After test results were obtained, 
each laboratory was unblinded to the results of the original InPLEX assay as well as the 
other laboratory’s xTAG testing. INTROL CF Panel III Control material (MMQCI) was 
used as controls and to verify assay performance with mutations not present in patient 
samples. Results: Identical results were obtained by both laboratories for the 35 patient 
samples analyzed using the xTAG assay. The samples tested were found to include 
four individuals harboring CFTR mutations on both alleles, 29 carriers with single CFTR 
mutations and two individuals with no mutations detected. Among the 33 samples found 
to have mutations, 28 different mutations were detected including 22 ACMG/ACOG-
recommended mutations. Results obtained by the xTAG assay were also found to 
match the InPLEX results. All 60 mutations detected by the xTAG assay were detected 
as expected in at least one of the four members of the INTROL panel. Conclusions: 
Although the ACMG/ACOG only recommends testing 23 of the most common mutations 
for carrier screening, expanded panels offer increased mutation detection rates that 
vary depending on ethnicity/race of the individual being tested. The xTAG panel offers 
accurate detection of 60 CFTR mutations including the 23 ACMG/ACOG-recommended 
mutations.  
 
G27. An Unlabeled Probe Assay for Detection of the GT Deletion in NCF1 
Associated with Autosomal Recessive Chronic Granulomatous Disease  
M. Erali1, D.C. Pattison1, N.H. Augustine2, H.R. Hill3, C.T. Wittwer3 
1ARUP Institute for Clinical & Experimental Pathology, Salt Lake City, UT; 2University of 
Utah, Salt Lake City, UT; 3ARUP Laboratories, Salt Lake City, UT. 
Introduction: Chronic granulomatous disease (CGD) is a disorder resulting from 
mutations in multiple genes, 65% of cases are due to mutations in CYBB, 25% are due 
to mutations in NCF1, commonly a GT deletion (ǻGT) in exon 2, and the remaining 
10% of cases are associated with mutations in CYBA and NCF2. The ǻGT in NCF1 is 
likely due to recombination events between NCF1 and 2 pseudogenes that are highly 
homologous to NCF1. The high homology among the functional gene and pseudogenes 
confounds standard molecular methods of detection. The ratios of ǻGT/GTGT in patient 
samples can be used to determine the NCF1 genotype. The most common ratios are 
6/0 for homozygous mutants, 5/1 for heterozygous carriers, and 4/2 or 3/3 for wild type, 
with less common ratios also possible. This report describes an unlabeled probe assay 
that was developed to detect ǻGT and evaluate the ǻGT/GTGT ratio in NCF1. 
Methods: PCR amplification and melting analysis were performed on the LS32 
instrument using asymmetric PCR and an unlabeled probe complementary to wild type 
sequence. The fluorescence peaks generated as the unlabeled probe melted from the 
sample amplicon were analyzed to assess the ratio of NCF1 and pseudogenes present 
in the samples. Results: The peak heights for melting peaks associated with unlabeled 
probe binding to ǻGT sequence and GTGT sequence were determined for 104 
samples. The mean peak heights ratios were: homozygous 6.96 +/-1.51, heterozygous 
1.43 +/-0.11, and wild type 0.70 +/-0.07 (4/2) and 0.42 +/-0.03 (3/3). The data were well 
separated and allowed differentiation of samples with the four major ǻGT/GTGT ratios. 
Conclusions: This unlabeled probe assay provides a rapid and easy to interpret 
method for identifying affected homozygous individuals with ǻGT/GTGT of 6/0, 
heterozygous carriers with 5/1 ratios, and unaffected individuals with 3/3 ratios. 
Individuals with 4/2 ratios can be identified but unaffected and carrier states cannot be 
differentiated. 
 
G28. Identification of BCL9L as a Novel Heterotaxy Gene by Whole Genome 
Sequencing of a Quartet 
C. Saunders1, N. Miller1, S. Soden1, D. Dinwiddie1, A. Noll1, S. Humphray 2, p. Saffrey 2, 
Z. Kingsbury2, J. Betley 2, R. Grocock2, N. Safina1, J. Petrikin1, K. Hall2, S.F. 
Kingsmore1 
1Children's Mercy Hospitals and Clinics, Kansas City, MO; 2Illumina Inc., Little 
Chesterford, Essex, UK. 
Introduction: Heterotaxy (HTX) is a developmental disorder characterized by abnormal 
left-right asymmetry of the heart, lungs, liver, spleen, and stomach. HTX is frequently 
accompanied by complex congenital abnormalities of the heart (CHD) and great 
vessels. HTX is clinically and genetically heterogeneous, with 75% of X-linked cases 
attributed to mutations in ZIC3. A number of other known genes are sequenced 
clinically, including NODAL, CFC1, and ACVR2B, although other loci have yet to be 
discovered. Methods: We used the HiSeq2500 to perform rapid whole genome 
analysis of two brothers with HTX and CHD and their healthy parents. ZIC3 sequencing 
was done clinically and was normal. Results: Genome sequencing yielded 113 - 137 
GB and 3.9 million variants per individual. Of these, 833-901 variants were classified as 
possibly damaging and had allele frequencies <1%. Among these, there were no likely 
pathogenic mutations in known HTX or CHD genes. A genome-wide search of 
homozygous or compound heterozygous, likely pathogenic variants that were common 
to the affected brothers and heterozygous in their parents yielded two missense 
variants, c.2102G>A, (p.Gly701Asp) and c.554C>T, (p.Ala185Val) in the B-cell 
CLL/lymphoma 9-like gene (BCL9L). BCL9L is one of two human homologs of 
Drosophila legless (lgs), a segment polarity gene required for wingless (Wnt) signaling 
during development. Recently, the Wnt pathway was implicated in the left-right 
asymmetric development of vertebrate embryos with a role in regulation of ciliated 
organ formation and function. Conclusions: BCL9L is a novel disease gene associated 
with HTX and CHD, supported by animal models that display various phenotypes 
related to defective Wnt signaling, as well as genetic studies demonstrating the role of 
BCL9L in the pathway. The key effector of the canonical Wnt pathway is ȕ-catenin, 
which activates Wnt-specific gene expression by binding to BCL9L, which serves a 
docking protein for other transcription coactivators. The p.Gly701Asp mutation found in 
our patient lies within the BCL9L nuclear localization signal (NLS). The failure to bind ȕ-
catenin in the nucleus would lead to decreased Wnt-mediated gene expression, which 
was recently shown in zeBRAFish to result in disruption of left/right patterning, 
shorter/fewer cilia, loss of cilia motility, and decreased foxj1a expression. Foxj1a is a 
member of the forkhead gene family and is a master regulator of transcription 
controlling production of motile cilia.  
 
G29. Genotype Frequencies and Ordering Patterns of Pharmacogenetic Marker 
IL28B rs12979860 in a Clinical Reference Laboratory 
H. Faruki, J. Sebastian, M. Edwards, K. Friedman 
Laboratory Corporation of America, Research Triangle Park, NC. 
Introduction: Multiple studies have identified a single nucleotide polymorphism (SNP) 
on chromosome 19, rs12979860, located 3Kb upstream of the Interleukin28B (IL28B) 
gene encoding interferon-Ȝ3, as being strongly associated with HCV pegylated 
interferon plus ribavirin treatment induced viral clearance. IL28B rs12979860 CC 
carriers have been shown to successfully clear HCV infection more frequently than 
either the CT or TT genotype carriers both during treatment for chronic infection and 
spontaneously following acute infection. IL28B pharmacogenetic testing has rapidly 
been incorporated into the standard management of HCV infection. Methods: A clinical 
reference laboratory database of de-identified IL28B genotype test results, dating from 
July 2010 through December 2011, was queried. Demographic information including, 
gender, age, and ordering account type, was retrieved for analysis of frequencies and 
distributions. Demographic and account information patterns of pharmacogenetic IL28B 
test ordering was compared to other observed HCV test ordering patterns (HCV 
genotype & quantitative RNA). Statistical significance of subgroup comparison was 
assessed using a Chi-square test and the associated p-values are reported. Results: 
IL28B rs12979860 genotype test orders and results from 27,451 samples, dating from 
July 2010 through December 2011, were analyzed. The favorable rs12979860 CC 
genotype was identified in 7,612 (28%) samples. The CT heterozygote and TT 
homozygote genotypes were identified in 13,984 (51%) and 5855 (21%) samples 
respectively. Analysis of demographic information revealed that IL28B tests were more 
likely to be ordered on older individuals (>50 yrs) 63% to 49%, (p<0.001) as compared 
to other HCV related testing such as genotype and/or quantitative RNA. Analysis of 
account information and comparison with other HCV related testing revealed that IL28B 
test orders were more likely to be submitted from a gastroenterologist clinic 27% to 
22%, (p<0.001) or from an infectious disease practice, 13% to 4% (p<0.001), and less 
likely to be ordered from a general practitioner clinic, 12% to 29% (p<0.001). 
Conclusions: Pharmacogenetic testing for the HCV treatment response related IL28B 
rs12979860 genotype revealed a favorable CC genotype in 28% of samples submitted 
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for testing. When compared to HCV genotype or HCV quantitative RNA testing, IL28B 
testing was more likely to have been ordered on older individuals and was more likely to 
have been ordered by a gastroenterologist or infectious disease specialist rather than a 
general practitioner.  
 
G30. The Impact of Expanded Next Generation Sequencing Panel Testing for 
Inherited Cardiomyopathies on Disease Diagnosis: Lessons from the First 500 
Cases 
B.H. Funke1, T.J. Pugh2, S. Gowrisankar2, M.A. Kelly2, K.A. Lafferty2, D.L. Lee2, E. 
Duffy-Hynes2, E.T. White2, L.M. Farwell2, H.L. Rehm2 
1Laboratory for Molecular Medicine, Cambridge, MA; 2PCPGM, Cambridge, MA. 
Introduction: Inherited cardiomyopathies are a group of genetically heterogeneous 
diseases with a relatively high population frequency, association with sudden cardiac 
death, and a substantial genetic component. Although the incentive for identifying 
heritable causes is high, genetic testing has long been a lengthy and costly process and 
gene panels were typically limited to small numbers of genes that could be tested 
simultaneously. Next-generation sequencing (NGS) technologies have removed many 
limitations enabling truly comprehensive testing as well as simultaneous analysis of 
genes for conditions with clinical overlap. These advancements have shortened 
diagnostic odysseys for clinically complex cases but come with novel challenges 
necessitating a critical assessment of when expanded NGS testing is justified. 
Methods: We report our clinical testing experience using data from >500 
cardiomyopathy patients tested using either a “Pan Cardiomyopathy” NGS gene panel 
including 46 genes for HCM, DCM, ARVC, RCM, and LVNC or disease specific sub-
panels. These results were compared to prior diagnostic testing for >2,000 HCM 
probands (11 genes) as well as > 400 DCM probands (19 genes). Results: For patients 
with HCM, the expanded content only marginally improved the prior detection rate of 
~50%, but drastically increased the number of inconclusive reports when the multi-
cardiomyopathy panel was used (64%, n=77 vs. 22%, n=187 sub-panel) . In contrast, 
the detection rate for DCM (prior detection rate =26-29%) increased significantly, with 
titin (TTN) contributing ~10% whereas essentially no difference between the multi-
disease panel and the DCM sub-panel was observed. We report clinically complex 
cases where multi-cardiomyopathy NGS testing helped establish a diagnosis, as well as 
cases illustrating interpretive challenges that can accompany NGS testing. 
Conclusions: Our results illustrate that the clinical utility of NGS panels is greatest for 
disorders with a high degree of genetic heterogeneity and clinical uncertainty (e.g., 
DCM), whereas for other diseases the benefit of testing more genes can be outweighed 
by the steep increase in inconclusive findings (e.g., HCM). These early results from 
targeted gene panels highlight benefits and drawbacks associated with the rapidly 
expanding scope of molecular diagnostic testing.  
 
G31. Fragile X Syndrome Phenotype Assessments Using Methylation PCR and 
X-Chromosome Activation Analysis 
G.J. Latham1, S. Filipovic-Sadic1, A.G. Hadd1, A. Williams2, V. Kaytser2, L. Zhou2, E. 
Berry-Kravis2 
1Asuragen, Inc., Austin, TX; 2Rush University Medical Center, Chicago, IL. 
Introduction: Fragile X syndrome (FXS) cognitive and behavioral phenotypes are 
associated with the methylation and silencing of the fragile X mental retardation (FMR1) 
gene and subsequent loss of protein production. X-activation in females and size and 
methylation mosaicism in males and females have been correlated with higher cognitive 
function in FXS patients. However, some published reports have indicated weak to no 
association with phenotype from these molecular parameters. Some of the discrepant 
findings may be explained by technical and detection variability of Southern blot (SB) 
analysis. Recently, differences in levels of FMR1 methylation and transcription have 
been linked to response to FXS targeted therapies, such as mGluR5 antagonists. Thus, 
it is imperative to simplify and standardize methods for quantifying FMR1 methylation 
status. The purpose of our study was to establish the feasibility of a methylation PCR 
(mPCR) method to quantify methylation in normal and expanded alleles and then link 
these results to fragile X phenotypes. Methods: We assessed the FMR1 gene 
methylation status in 15 full mutation alleles and the activation ratio in 19 female 
premutation samples using AmplideX mPCR, a two-color PCR and capillary 
electrophoresis method, and compared these results with SB analysis. Results: 
Duplicate testing of 19 samples using mPCR yielded X-activation ratios spanning 0-
100% with a CV of 6.1% between replicates. The Pearson correlation between mPCR 
and SB was 0.975, and values for 4 independent samples assessed at 50% activation 
by SB were 47, 50, 52 and 57% by mPCR. In addition, all full mutation and mosaic 
alleles were detected using mPCR. Preliminary examples of differing FMR1 methylation 
fraction in 3 male samples were consistent with the cognitive phenotype. Use of mPCR 
improved the resolution and simplified detection of unmethylated pre- and full mutation 
alleles relative to SB. Conclusions: This preliminary genotype-phenotype study 
establishes the value of mPCR in identifying subtle differences in activation ratios in the 
FMR1 allele of female premutation carriers, and methylation mosaicism in males and 
females. mPCR allowed assessment of methylation status without the DNA quantity, 
labor and interpretation ambiguity associated with SB analysis. These results are a 
foundation for larger correlation studies of mPCR that may also include interrogation of 
protein levels, RNA quantity, and other molecular features linked to phenotype with the 
promise of improving the diagnosis and treatment of FXS.  
 
G32. A Modular Process for the Validation of a Clinical Next Generation 
Sequencing Pipeline Using HapMap Samples 
M.P. Powers 
Locus Development, San Francisco, CA. 
Introduction: With next generation sequencing the whole genome or a large fraction of 
it can be sequenced rapidly. However, clinical validation is difficult given the sheer 
number of possible results (theoretically > 12 billion for whole genome sequencing). 
Therefore, a streamlined evaluation of protocols is needed to ensure that accurate 
clinical results are possible without sequencing samples from every clinical condition 
with every possible variant. Methods: A modular validation pipeline was developed to 
individually evaluate each step of a clinical next generation sequencing protocol 
designed to detect both point mutations and small insertions/deletions: 1) blood to DNA, 
2) DNA to sequence, 3) sequence to variants, and 4) DNA to report. For sequence to 
variants, four HapMap samples (with variants representing SNVs and small 
insertion/deletions) with their corresponding HapMap and 1,000 Genomes results, and 
four HapMap samples with both HapMap, 1,000 Genome and whole genome 
sequencing results were compared to our targeted sequence region of ~2 million bps to 
challenge our pipeline. Then, 29 Coriell samples representing different alleles from 7 
clinical conditions were subjected to our pipeline to confirm our ability to identify 
clinically relevant variants. Results: Based on the eight samples with HapMap/1,000 
Genomes SNP data, our pipeline was able to call the correct variants with 98.7% 
sensitivity and 99.97% specificity. For the four samples with whole genome sequencing, 
our sequence results matched with 98.7% sensitivity and 99.99% specificity. All 29 
clinical samples were called with 100% accuracy. Conclusions: A modular approach 
with samples representing the types of variants a clinical assay is designed to identify 
without covering every possible base is a useful method to validate a next generation 
sequencing pipeline. This process has now been expanded to 145 clinical conditions. 
The variation seen between the HapMap and whole genome data vs. our data may be 
due to minimal analytical error, but we hypothesize that it is due to us, HapMap, and the 
whole genome sequencing having been done on different Coriell sample aliquots from 
different times. We will test these hypotheses by testing a new aliquot of the “same” 
Coriell sample with our process every 3-6 months.  
 
G33. Correlation of FMR1 Southern Blot Analysis and AmplideX mPCR for 
Detection of Size and Methylation Mosaicism in Fragile X Full Mutation Alleles 
A.G. Hadd1, J. Fang2, P. Snyder2, S. Filipovic-Sadic1, T. Prior2 
1Asuragen, Inc., Austin, TX; 2The Ohio State University Medical Center, Columbus, OH. 
Introduction: Current practice guidelines for the diagnosis of Fragile X syndrome 
(FXS) require a combination of CGG repeat length and methylation assessment of the 
fragile X mental retardation-1 (FMR1) gene. Fully expanded alleles are associated with 
>200 CGG and are typically silenced by hypermethylation, leading to the FXS 
phenotype. Although Southern blot (SB) analysis is the de facto gold standard for 
assessing expanded alleles, the procedure is time consuming, laborious, and requires 
large inputs of DNA. In addition, differences in methodology between laboratories can 
impact detection of FMR1 molecular features, such as mosaicism, that may impact the 
patient phenotype. Methylation PCR (mPCR) is a novel assay that has been reported to 
detect size and methylation mosaicism with improved resolution and sensitivity 
compared to SB analysis. Methods: Archived residual DNA samples from 14 full 
mutation males and 4 full mutation females were analyzed using AmplideX mPCR, a 
method for determining the CGG repeat length and methylation status using restriction 
digestion, dye-labeled PCR primers, and two-color capillary electrophoresis. The PCR 
included digestion and DNA reference controls to facilitate analysis. The results were 
correlated to SB analysis for detection of full mutation alleles and size and methylation 
mosaicism. Results: All full mutation and size mosaic alleles were detected in all 
samples with 100% agreement to SB analysis. Two samples had interpretable but low 
signals using mPCR that were resolved on repeat testing. In the 7 size mosaic male 
samples, the peak height and area of the premutation allele were proportional to the SB 
band intensity. In addition, a partially methylated full mutation allele was resolved using 
mPCR and the methylation status in the female samples was concordant with SB. 
Conclusions: These preliminary results indicate that AmplideX mPCR reagents can 
detect and identify the methylation status in a range of allele sizes and epitypes in male 
and female samples consistent with SB analysis. Additional retrospective and 
prospective studies are planned. The use of mPCR has the potential to standardize the 
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detection of low abundance mosaic alleles that are important to the diagnosis and 
treatment of FXS.  
 
G34. Genetic Testing of Autosomal Dominant Polycystic Kidney Disease 
(ADPKD) Using Long-Range PCR and Next Generation Sequencing  
Y. Tan1, A. Michaeel1, G. Liu1, J. Blumenfeld1, S. Donahue2, D. Levine2, T. Parker2, H. 
Rennert1 
1Weill Cornell Medical College, New York, NY; 2The Rogosin Institute , New York, NY. 
Introduction: Genetic testing of PKD1 and PKD2 is useful for diagnosis and prognosis 
of autosomal dominant polycystic kidney disease (ADPKD), particularly in those without 
a family history. However, PKD gene mutation analysis is complicated by duplication of 
PKD1 exons 1 to 33 (six pseudogenes on chromosome 16 with >98% sequence 
homology to PKD1), a high level of allelic heterogeneity (genetic variations), and the 
high cost of Sanger sequencing. We have developed and validated a clinical assay to 
analyze both PKD genes, using next-generation sequencing (NGS), by multiplexing 
barcoded libraries from long-range PCR (LR-PCR) on the Illumina system. We used 
this approach to characterize a cohort of patients with PKD gene mutations previously 
defined by Sanger sequencing. Methods: PKD1 and PKD2 genes were amplified in a 
total of ten LR-PCR reactions (1.4 to 10.9 kb), using locus-specific primers for PKD1 
duplicated regions. LR-PCR amplicons from the same patient were combined and 
indexed with a unique DNA barcode. Indexed libraries from 25 patients were pooled 
together and analyzed using either a flow-cell of MiSeq or a single flow-cell lane of 
HiSeq system (Illumina, Inc., San Diego, CA). Sequencing results were then sorted 
according to the barcodes with FASTX toolkit and aligned against the reference 
sequence with BWA program (http://bio-bwa.sourceforge.net/). Sequence variants were 
called and filtered with GATK software (The Genome Analysis Toolkit, Broad Institute) 
using Best Practice Guidelines recommended by GATK. The raw variant calls were 
then annotated with ANNOVAR software. The whole data analysis pipelines were 
automated with Unix shell scripts. Results: A total of 241 genetic variants were 
identified within exonic and adjunct intronic regions of PKD1 and PKD2 in 25 patients 
with the ADPKD phenotype. Of these, 16 variants were classified as definite pathogenic 
mutations, including two small deletions (a 4-bp and a 10-bp), as well as a 24-bp 
insertion. When compared with conventional Sanger sequencing, this NGS based 
approach achieved a sensitivity and specificity of 100% in detecting pathogenic 
mutations. By using the MiSeq platform, 25 patients were genotyped within one week 
for less than $100 per patient (including all reagents and sequencing costs). 
Conclusions: NGS-based ADPKD genetic analysis is a highly accurate and reliable 
approach for mutation analysis, achieving high sensitivity and improved intronic 
coverage with faster turnaround time and lower cost. Furthermore, this strategy has the 
potential to dramatically improve molecular diagnosis of ADPKD and aid with the 
genetic characterization of large ADPKD populations.  
 
G35. An A to C Mutation Creates an MspI Restriction Site in the S (short) Allele 
of the 5-HTT (SLC6A4) Promoter Region  
B. Ramey-Hartung, D.L. Pierce, M.P. Borgman, K.K. Reynolds, M.W. Linder 
PGXL Laboratories, Louisville, KY. 
Introduction: The promoter region of the 5-HTT (SLC6A4) gene has a 43-bp 
insertion/deletion (rs63749047) yielding two alleles, defined by their length as long (L) 
allele and short (S). The S allele reduces expression of the active transporter protein by 
50% in comparison to the L allele. The long allele also contains an A>G polymorphism 
(rs25531). Presence of the L(G) allele is thought to result in a phenotype similar to that 
of the short (S) allele. The A>G polymorphism generates an MspI restriction site, which 
can be detected by RFLP analysis. Our CLIA laboratory observed an aberrant 
restriction digest pattern in a minority of samples. The samples were clearly S/S or S/L 
according to the PCR product, but when digested with MspI, additional shorter bands 
showed up. We hypothesized that there was an extra MspI site present in the short 
allele, which resulted in the short allele PCR product being cut into two smaller pieces 
We confirmed the presence of an A>G polymorphism in five samples by sequencing. 
Methods: Sample types included buccal swabs and saliva. DNA was isolated using the 
Qiagen EZ1 and EZ1-XL robots and Qiagen tissue kits. PCR generated a 419-bp 
product (for the long allele, or 376 bp for the short allele). Half of the PCR product was 
digested with MspI (New England Biolabs). The PCR product and digested PCR 
product were analyzed by agarose gel electrophoresis. Sequence analysis was 
performed at the DNA Core at the University of Louisville. Results: We found five 
samples that contain the extra MspI site. Three of the samples are S/S, in which one of 
the S alleles has the MspI site, and one does not. Two samples are L(A)/S, with the S 
having the MspI site. The MspI site occurs 195 bp into the 376 bp S allele PCR product, 
resulting in 195-bp and 181-bp fragments. The same A>G mutation in each sample was 
confirmed by sequencing. Conclusions: The clinical implications of the A>G mutation 
causing the MspI site in the short (S) allele of the 5-HTT promoter allele are unknown. 
However, since the short allele already confers reduced expression of the 5-
hydroxytryptamine transporter protein, it is likely that the A>G mutation would not have 
an appreciable effect. More study will be required to determine the effects of the A>G 
mutation on 5-HTT expression.  
 
G36. Validation of X-inactivation Ratio Analysis Using the AR and SLITRK4
Loci 
K. Crooks, K.E. Weck, J. Booker 
University of North Carolina at Chapel Hill, Chapel Hill, NC. 
Introduction: Inactivation of the X chromosome in female cells is generally a random 
process, such that the ratio of inactivation of the maternally- versus paternally-derived 
chromosome does not significantly differ from 50:50. However, X-inactivation (XI) ratio 
is often significantly skewed in female carriers of mutations for X-linked disease. The 
androgen receptor (AR) trinucleotide repeat is the locus most commonly used to 
quantify XI ratio. Highly polymorphic, this locus has been found to be heterozygous in 
approximately 90% of females. For the remaining 10%, examination of XI status 
requires a second locus. Methods: Genomic DNA extracted from peripheral blood of 23 
adult females was subjected to restriction enzyme digestion by (1) HpaII + RsaI, and (2) 
RsaI alone (control). PCR amplification of restricted DNA was performed using 
fluorescently labeled primers for 3 loci: AR, SLITRK4, and CD99. The CD99 locus 
served as a control for digestion completion. PCR products were analyzed by fragment 
analysis using GeneMapper software on an ABI 3130XL capillary analyzer. For AR and 
SLITRK4, the area under each allele peak was used to calculate XI ratios. For 
SLITRK4, regression analysis of stutter peak area was performed to calculate 
background subtraction. Concordance between the AR and SLITRK4 loci was 
examined over multiple runs. Samples with XI ratios  90:10 were considered highly 
skewed, ratios between 80:20 and 89:11 moderately skewed, and ratios <80:20 
unskewed (random X-inactivation). Results: For both AR and SLITRK4, 21 of the 23 
samples (91%) were heterozygous. No sample was homozygous at both loci. Nineteen 
samples were informative at both loci, and concordance was generally high. Of 15 
samples that exhibited random X-inactivation by AR analysis, 14 were also random by 
SLITRK4 analysis. The 15th sample had XI ratios of 21:89 by AR analysis (random) 
and 20:80 by SLITRK4 analysis (moderately skewed). AR analysis identified one 
moderately skewed sample that was randomly skewed by SLITRK4 analysis. The 
remaining 3 samples were considered highly skewed by AR analysis. By SLITRK4 
analysis, one of these was highly skewed and the other two were moderately skewed. 
Conclusions: The dinucleotide repeat at the SLITRK4 locus is a viable alternative to 
the AR trinucleotide repeat for quantification of XI ratio. SLITRK4 may be less sensitive 
to skewing than AR, particularly when stutter peaks interfere with quantification of the 
smaller allele. Thus, analysis of XI by SLITRK4 is best suited for samples that are 
uninformative at the AR locus. 
 
G37. Evaluation of the GenMark Diagnostics eSensor Thrombophilia Risk Test 
to Detect and Genotype MTHFR Polymorphisms C677T and A1298C 
R.S. Liao 
PeaceHealth Laboratories, Springfield, OR. 
Introduction: The methylenetetrahydrofolate reductase (MTHFR) enzyme is involved 
in folate metabolism by catalyzing the reduction of 5,10-ethylenetetrahydrofolate to 5-
methyltetrahydroflate. The C677T and A1298C MTHFR mutations produce enzymes 
with reduced activity from altered catalytic activity and thermolability. The MTHFR 
enzyme is a cofactor in the remethylation of homocysteine and a reduction in function 
causes an increase in plasma homocysteine. MTHFR mutation testing is primarily 
indicated to identify individuals that may experience antifolate medication intolerance, 
particularly when a family history of intolerance exists and to determine the genetic 
contribution for early-onset arteriosclerotic vascular disease or venous thrombosis. 
Methods: A total of 100 frozen archived whole blood specimens previously 
characterized as either: negative, heterozygous or homozygous for each of the C677T 
and A1298C MTHFR mutations, were evaluated. Discrepant results were resolved by 
sequencing. Isolated genomic DNA was extracted from whole blood using the Roche 
MagnaPure LC and amplified using an ABI 9700 with the GenMark Diagnostics 
eSensor Thrombophilia Risk Test. Amplified product was tested using the GenMark 
eSensor XT-8. The eSensor Thrombophilia Risk Test is an in vitro diagnostic for the 
simultaneous detection and genotyping of Factor II G20210A, Factor V G1691A and 
MTHFR C677T and A1298C mutations. All extracted specimens were assessed for 
genomic DNA quantity and purity. Results: The eSensor Thrombophilia Risk Test had 
2 miscalls when compared to the results previously obtained by PCR testing, with an 
A1298C wild type being incorrectly called a heterozygous mutation. These 2 false 
positive results did resolve on repeat testing and were confirmed to be wild type by 
sequencing. Conclusions: The overall percent agreement for the eSensor 
Thrombophilia Risk Test to detect the C677T and A1298C MTHFR mutations was 98%. 
The eSensor Thrombophilia Risk Test performs with a similar accuracy when compared 
to lab developed PCR testing.  
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G38. Retrospective Review and Discussion of Full-Gene CFTR Sequence 
Ordering Patterns with Clinicians is Useful in Promoting Improved Test Utilization 
J.M. Hummel, J.A. Kant 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: For the large majority of patients suspected of having ‘classic’ cystic 
fibrosis (CF), a combination of clinical symptoms and sweat chloride test results confirm 
a diagnosis. Genotypic information from the CFTR gene on such patients can be useful 
for counseling family members or relatives or in reproductive planning, prenatal testing, 
and even therapeutic management. When symptoms are suggestive of CF or 
ambiguous; or when sweat chloride results are unclear, molecular analysis may help to 
confirm a diagnosis. We noticed a tendency from our pediatricians to directly order full 
gene CFTR sequence analysis in patients who had varying degrees of ‘atypical’ 
symptoms for CF, presumably based on the assumption such patients might have a 
predominance of mild mutations less likely to be detected by the recommended 
ACMG/ACOG screening panel. We undertook a review of our experience with CFTR 
full gene ordering over 28 months. Methods: CFTR full gene sequence tests ordered 
from January 2010 through April 2012 were tabulated from our laboratory information 
systems. All but two requests were on patients <20 years of age. The results of this 
review were discussed in a follow-up meeting with physicians, nurse coordinators, and 
administrative staff from the primary clinical group evaluating and caring for patients 
with CF and CFTR-related disorders. Results: 82 specimens from the Pediatric 
Pulmonology Group were referred for full gene CFTR sequence analysis. Nine patients 
had prior ACMG/ACOG screening assays; none of these screening assays revealed a 
CFTR mutation; one of these patients was heterozygous for a p.R170H variant. Thirty-
six cases (44%) yielded a pathogenic mutation; the remaining 46 cases were negative. 
This included 18 heterozygotes, 17 compound heterozygotes and 1 ǻF508 
homozygote. Thirty-two were at least heterozygous for a mutation covered by the 
ACMG/ACOG screening panel. Following data compilation we held an interdisciplinary 
meeting with the major pediatric user group (Pulmonology). This resulted in a decision 
to order the ACMG/ACOG screening panel first for cases and then consider whether to 
pursue full gene CFTR sequence analysis. The major challenge identified was how to 
structure the order set for physician order entry to discourage ordering full gene 
sequencing instead of the panel by non-CF clinicians. Ordering of full gene analysis has 
significantly decreased over 4 months. Conclusions: Review of ordering patterns with 
clinicians is useful to facilitate cost-effective use of screening assays followed, if 
necessary, by more comprehensive analysis. 
 
G39. A Clinical Test for ABO Non-O Genotype to Facilitate Diagnosis of 
Venous Thromboembolism 
J.C. Guenther, J.A. Heit 
Mayo Clinic, Rochester, MN. 
Introduction: Venous thromboembolism (VTE) is a major health problem that results in 
a significant burden on hospitals and patients. Annual incidence of VTE is 1 in 1000 in 
the general population. It is a complex disease exhibiting genetic heterogeneity with 
variable expressivity as well as gene/gene and gene/environmental interactions. Risk 
factors for VTE include: immobilization, prolonged air travel, recent surgery, 
malignancy, major trauma, pregnancy, oral contraceptives, central venous catheters, 
obesity, inherited thrombophilia (i.e., Factor V Leiden, prothrombin gene mutations, 
protein C, protein S and antithrombin deficiencies). ABO non-O genotype has long been 
recognized to increase the risk of VTE, but have only recently been confirmed in 
multiple genome wide association studies and (in subsequent replication studies) in a 
recent candidate gene, case-control association study. The relative risks associated 
with the ABO non-O genotype are lower than that associated with the FV Leiden, but its 
population attributable fraction (PAF) is much higher. Despite the high PAF, ABO non-O 
determination is not included yet in the routine thrombophilia testing. People with non-O 
blood type have a 1.6 to 2.6 fold higher risk of VTE than those with type O genotype. 
People with non-O genotypes have two-fold increased risk of developing thrombosis 
when coupled with another identified risk factor such as Factor V Leiden. Methods: A 
custom singleplex PCR assay was developed by Hologic for the Invader Plus platform 
to detect blood groups of patients being referred to Special Coagulation DNA 
Diagnostic Laboratory for thrombosis testing. The Invader assay uses a structure-
specific flap endonuclease (FEN) to cleave a three-dimensional complex formed by 
hybridization of allele-specific overlapping oligonucleotides to target DNA containing a 
single nucleotide polymorphism (SNP) site. The cleavage product triggers a secondary 
cleavage reaction on a fluorescence resonance energy transfer (FRET) cassette to 
release a fluorescent signal. The reaction is read on a fluorescence detector at 485/530 
and 560/612 wavelengths. This assay will accompany our current Thrombosis Invader 
Plus IVD panel. Sequencing was used as the “gold standard” to confirm ABO 
genotypes. Results: Specimens referred to the Special Coagulation DNA Diagnostics 
Laboratory for thrombosis were genotyped for blood group. The genotyping results 
were confirmed by sequencing exon 6 of the ABO gene. All Invader Plus genotypes 
were 100% concordant with sequencing results. Conclusions: This assay will be 
offered in our lab as an additional assay to determine risk of thrombosis. Information on 
blood group genotype should play a role in the management of thrombophilia patients. 
 
G40. The First 2000 Samples Tested by CFnxt, a 147 Mutation Cystic Fibrosis 
Screening Assay Built on the Illumina BeadXpress Platform 
J.A. Sugalski, T.G. Goodman, K.E. DuRoss, C. Holland, J. Stoerker 
aMDx Laboratory Sciences, Farmington Hills, MI. 
Introduction: In March 2011, the American College of Obstetricians and Gynecologists 
(ACOG) updated its screening recommendations for cystic fibrosis to include offering 
CF screening to all women of reproductive age. The current ACOG mutation panel 
offers a comparatively limited risk-reduction for racial minority patients. We developed a 
CF screening assay that interrogates 147 mutations and 5 variants and provides 
greater risk reduction across all ethnicities. Clinical validation of this assay was 
presented at ISPD 2012. Methods: Through 30 May 2012, aMDx has completed 
testing on 2182 patients. The assay consists of 12 multiplex PCR reactions, treatment 
of the product with a SAP/Exo I mixture, 12 multiplex allele-specific primer extension 
(ASPE) reactions with biotinlyated CTPs, consolidation of ASPE reactions, hybridization 
onto the VeraCode Bead set (Illumina), binding of the streptavidin-Alexa Fluor 
(Invitrogen) conjugate, and scanning of the beads by the BeadXpress. 96 samples and 
controls are run per batch in 384-well plates. Sample transfer is assisted by automated 
liquid handling. All putative positive samples are repeated for confirmation. The run-time 
for CFnxt is approximately 12 hours. Results: A total of 74 were confirmed, resulting in 
an overall confirmed positive rate of 3.39%. Of 74 mutations detected, 66 were part of 
the ACOG panel (89.2%), and 8 were non-ACOG panel (10.8%). A total of 8 out of 23 
ACOG mutations were identified, along with 8 non-ACOG mutations. This includes one 
positive patient of reported Hispanic ethnicity (positive for S549N) and one patient of 
reported mixed ethnicity (positive for ǻF311) who would not have been identified by the 
ACOG panel alone. This also includes two mutations that would not have been 
identified by any other available panel (D110H and G622D), and one available in only 
one other commercial panel (G1244D). All putative ǻF508 mutations confirmed at 
repeat, with total of 45 ǻF508 mutations, representing 60.8% of all mutations. A total of 
2 samples resulted in failed analysis (0.09%). Conclusions: The CFnxt assay provides 
robust screening across a broad range of CF mutations, thereby delivering significantly 
increased carrier detection for all ethnicities, compared to the ACOG panel, and an 
improvement in identification over other expanded panels. 
 
G41. Targeted Resequencing of a Large Panel of Genes Associated with Drug 
Absorption, Distribution, Metabolism and Excretion 
F. Kaper, B. Klotzle, C. April, M. Bibikova, J. Fan 
Illumina, Inc., San Diego, CA. 
Introduction: Individual response to environmental factors, chemicals, and drugs can 
vary significantly and is frequently associated with polymorphisms in genes involved in 
absorption, distribution, metabolism and excretion (ADME). To predict drug response 
and drug toxicity in an individual, it is important to determine the genotype of these 
genes. To allow for the determination of the genotypes of known polymorphisms, while 
simultaneously enabling de novo discovery of previously unknown or rare variants, a 
sequencing approach was adopted. Methods: We selected a panel of 329 ADME 
genes from the PharmaADME.org database, including (but not limited to) ATP-binding 
cassette transporter, cytochrome P450, solute carrier family, and HLA genes, and 
designed probes to capture all exons in a targeted pull-down assay, followed by 
sequencing on an Illumina Genome Analyzer IIx. The targeted region encompasses 1 
Mb, allowing for multiplexing of 12 samples within one assay, whereas achieving 200X 
coverage on one of the 8 lanes of the Genome Analyzer IIx. Additionally, we developed 
a method to obtain the haplotypes of each exon. This information is clinically relevant, 
as the phenotype may vary depending on whether multiple polymorphisms are located 
on the same chromosomal copy or on different copies. Genomic DNA was distributed 
into multiple aliquots, each receiving less than a haploid copy number. The DNA was 
subsequently amplified using a multiple displacement amplification (MDA) protocol 
followed by next generation sequencing library preparation with targeted pull-down of 
the ADME genes. Results: Optimizations to the pull-down assay and probe design 
resulted in coverage of 99.7% of the 329 genes. Coverage was quite uniform, with 70% 
of the genes within 2-fold of average coverage, and 96% within 5-fold of average 
coverage. Of the 329 target genes, 95 have pseudogenes elsewhere in the human 
genome. However, only 6.5% of total aligned reads aligned to pseudogenes. 
Inheritance analysis of 575 loci of a father/mother/daughter trio showed 100% 
concordance, and comparison to genotype calls of 135 SNPs made with the VeraCode 
ADME Core Panel showed only one discordance. Conclusions: We have developed a 
targeted resequencing panel of 329 ADME genes that shows high specificity and 
coverage uniformity and enables economical ADME resequencing studies. 
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G42. Reducing Residual Risk in CF Carrier Screening - Using the Illumina 
MiSeqDx for Cystic Fibrosis Carrier Screening 
M. Chelliserry, R.E. Lenta, J.C. San, W.M. Goldstein, E.J. Peters 
Illumina, San Diego, CA. 
Introduction: Cystic Fibrosis (CF) is one of the most common genetic diseases in the 
US, with approximately 1 in 29 Caucasian individuals being a carrier for CF mutations. 
Although CF is most common in individuals of Caucasian descent, ACOG/ACMG has 
recommended that carrier screening be offered to all couples who are considering 
having a child. To increase the detection rate of cystic fibrosis carriers and reduce the 
residual risk among other demographic groups, genotyping-based tests have been 
developed with larger mutation panels beyond the 23 ACOG/ACMG-recommended 
mutations. Despite this effort, non-Caucasian groups still have risk that current 
genotyping panels will not detect. The CFTR2 project (cftr2.com) has systematically 
examined reported CF-causing mutations and their functional effects. Here we describe 
the development of a new next generation sequencing assay, the Illumina MiSeqDx 
Cystic Fibrosis Carrier Screening Assay, for the detection of CFTR mutations on the 
MiSeqDx instrument. Methods: The test is designed to detect the 157 CFTR mutations 
listed in the CFTR2 database, and is intended to identify an individual's CFTR carrier 
status in genomic DNA extracted from whole blood. The assay technology involves 
targeted amplification of the CFTR gene followed by automated sequencing by 
synthesis on the MiSeqDx instrument. Results: The Illumina assay allows simultaneous 
sequencing of up to 48 samples per run. The assay had a call rate of >99.9% when 
tested on over 200 unrelated blood samples and >1500 HapMap and human variation 
samples of multiple ethnicities. Test results for a set of 48 genomic DNA samples 
representing all 23 ACMG CFTR mutations indicated 100% reproducibility and 100% 
accuracy when compared to results obtained using bi-directional Sanger sequencing. 
Studies show 100% concordance of sequencing results when samples were tagged 
with two unique identifying barcodes, allowing samples to be pooled and sequenced 
together vs. sequencing individually. The assay is able to accurately identify all of the 
targeted mutations within homopolymeric stretches - including insertion/deletions (i.e., 
2184delA), insertion-cum-deletions (i.e., 2183AA>G), and the Poly TG/Poly T region. 
The assay also accurately identifies 2 large deletions within the CFTR gene (CFTR 
dele2,3 and CFTR dele22,23). Conclusions: Using a broad panel of clinically relevant 
mutations based upon the CFTR2 database will reduce the residual risk associated with 
current panels. The design of the instrument and the preliminary performance of the 
Illumina assay make this system appropriate for clinical use following regulatory 
submission and approval. The test is For Investigational Use Only. 
 
G43. High-Throughput Human Leukocyte Antigen Typing on the MiSeq  
F. Kaper, C. April, J. Fisher, T. Royce, J. Fan 
Illumina, Inc., San Diego, CA. 
Introduction: The Human Leukocyte Antigen (HLA) region, located on chromosome 6, 
is one of the most polymorphic regions in the human genome. Polymorphisms in HLA 
genes have been associated with autoimmune disease, cancer, infectious disease, and 
adverse drug reactions. Furthermore, HLA-A, -B, -C, -DQB1, and -DRB1, are important 
donor and recipients matching in bone marrow transplantation. Donor-recipient 
matching generally focuses on exons 2 and 3 for HLA class I genes and exon 2 for HLA 
class II genes, as these exons encode the antigen binding domain. Matching of more 
similar alleles reduces the risk of rejection and graft-versus-host disease. In addition to 
genotype information, determination of the haplotypes for each gene improves the risk 
assessment. Methods: We have developed a strategy for typing exons 2 and 3 of HLA-
A, -B, -C, -DQB1, and -DRB1 using long amplicon PCR amplification followed by 
sequencing on a MiSeq sequencer. Exons 2 and 3 of each gene are amplified in a 
single amplicon. For HLA-A, -B, and -C, exons 2 and 3 are sufficiently close in 
chromosomal location that the amplicons can be used for cluster generation on the 
MiSeq flow cell directly. Combining the clonal nature of sequencing-by-synthesis with 
improved read length chemistry, the detected polymorphisms can automatically be 
phased to derive the haplotypes. For HLA class II genes, exons 2 and 3 are separated 
by a ~2 kb intron. Therefore, direct cluster generation of these amplicons is currently 
not very efficient. Instead, an allele-distribution bias-introducing PCR is used. The 
amplicons are subsequently fragmented and converted into sequencing libraries using 
Nextera transposition, followed by sequencing on a MiSeq. The bias introduced during 
the PCR results in differential sequencing depth, allowing for phasing of the detected 
polymorphisms. In both approaches, each sample receives a unique barcode, allowing 
for pooling and sequencing of several samples simultaneously. Results: Exons 2 and 3 
of each HLA locus were successfully amplified in single amplicons. We have been able 
to generate clusters with library fragments up to ~1kb, allowing for single clusters to 
contain both exons 2 and 3 of the class I genes. Furthermore, TaqMan assays have 
confirmed the introduction of allelic bias during the PCR. Sequencing data analysis is 
currently ongoing and suggests that the bias is maintained in the sequencing libraries, 
allowing for phasing based on read depth. Conclusions: Using this approach to 
perform sequence-based HLA typing on a MiSeq sequencer is efficient, fast, and 
amenable to high-throughput HLA typing. 
 
G44. Validation of PAM50 Breast Cancer Intrinsic Subtypes Using Nanostring 
nCounter Gene Expression Assay 
Z. Hu, Y. Li, C. Fan, K. Weck, C.M. Perou, M.L. Gulley 
University of North Carolina at Chapel HIll, Chapel Hill, NC. 
Introduction: Five classical breast cancer intrinsic subtypes including Basal-like, 
HER2-enriched, Luminal A, Luminal B, and Normal-like can be identified by 
transcriptome profiling of 50 genes and 5 housekeeper genes in the PAM50 algorithm. 
The goal of this study was to determine concordance of a Agilent human gene 
expression microarray on fresh frozen tissue and a Nanostring nCounter gene 
expression assay in FFPE tissue. Methods: 75 pairs of fresh frozen and FFPE breast 
cancer tissues were examined. For fresh frozen tissue, RNA was extracted from 
homogenized tissue using Qiagen RNeasy and was evaluated for RNA integrity number 
(RIN) using an Agilent Bioanalyzer 2100. An Agilent Quick-Amp Labeling kit was used 
to amplify and label the RNA prior to hybridization on an Agilent human gene 
expression microarray either 22K or 44K version. Tumors were classified into intrinsic 
subtypes using PAM50 classification software based on a centroid predictor model 
(Parker et al,., JCO 2009) . For FFPE tissues, RNA was extracted using the Roche 
High Pure RNA Paraffin Kit, and 100ng of purified total RNA was used for Nanostring 
nCounter gene expression profiling. Results were log2 transformed, normalized to the 
housekeepers, and then input into the same PAM50 classification software for intrinsic 
subtype classification. PAM50 classification software uses the centroid predictor 
algorithm in which a new sample's gene expression data is compared by Spearman 
correlation with each of 5 centroids representing 5 intrinsic subtypes in the training 
dataset. Results: Of 75 pairs of fresh frozen tissues tested by gene expression 
microarray and FFPE counterparts tested by Nanostring nCounter, 62 pairs' intrinsic 
subtypes were matched using PAM50 classification software. Between fresh frozen and 
FFPE, PAM50 intrinsic subtype classification had high accuracy of 95% and 93% within 
Basal-like and HER2-enriched subtype respectively, and overall accuracy of 83% with 
correlations of 1) the risk of recurrence (ROR) score at 0.88, 2) proliferation score at 
0.88, and 3) ER status at 0.92. Conclusions: Our results demonstrate a high level of 
concordance using PAM50 classification software between Agilent microarray and 
Nanostring nCounter gene expression assays on fresh frozen versus FFPE breast 
cancer tissue, respectively. The Nanostring nCounter gene expression assay is a 
simple, accurate gene expression profiling technology that suitable for use in clinical 
trials given its ease of use and high concordance with a gene expression microarray 
platform. 
 
G45. Performance Evaluation of a Rapid Methylation Specific PCR (MSPCR) 
Method for the Diagnosis of Prader Willi/Angelman Syndrome (PW/AS)  
P.D. Anderson, J. Juusola, M.F. Sabato, C.I. Dumur, M. Lu, D.S. Wilkinson, A. Pandya, 
A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA 
Introduction: Prader Willi and Agelman syndrome (PW/AS) are distinct 
neurodevelopmental disorders that are associated with deletion of the chromosomal 
15q11-13 region or uniparental disomy of chromosome 15. Our laboratory uses a 
standard MSPCR to target differentially methylated SNRP gene that is extremely 
manually intensive and time-consuming. To streamline the testing process we 
evaluated a commercial product for bisulfite modification and capillary electrophoresis 
using Lab on the Chip for a more rapid clinical assay. Methods: DNA samples from 9 
Corriell DNA samples (4 AS and 5 PWS) as well DNA from 43 anonimized DNA 
samples previously characterized in our laboratory (10 AS, 7 PWS and 26 unaffected 
individual) were subjected to bisulfite conversion using Epitec Bisulfite kit (Qiagen, 
Valencia, CA) according to manufacturer’s recommendations. The MSPCR is a 
multiplex PCR that uses primers specific for methylated and unmethylated promoter 
region of the SNRP gene. PCR products were resolved by capillary electrophoresis 
using Lab-on-a-Chip (Agilent BioAnalyzer). Expected PCR products were 131 bp for 
maternal allele and 164 bp for paternal allele. For ease of interpretation we developed a 
ratio between the PCR product area for the maternal allele over the area of the paternal 
allele PCR product. Unaffected individuals gave a ratio of 0.7 +/- 0.2, AS samples gave 
a ratio of >10 and for PW samples <0.166. Results: Using the ratio, the nine Corriell 
DNA and the patient DNA samples gave 100% concordant results with expected 
values. Interestingly in a number of AS DNA samples, the new assay showed residual 
PCR product amplification for the maternal allele that could be mistaken with mosaic 
AS. To resolve this issue we developed mock mosaic AS samples by making serial 
dilutions of DNA from an AS cell line with DNA from an unaffected cell line. The assay 
was able to detect the presence of mosaic AS samples down to 10% with a mean ratio 
of 1.8. Ratios between 1.8 to 10 were considered mosaic and ratios between 0.9 and 
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1.3 were considered grey zone that required further investigation. Hands on time for the 
new assay were significantly reduced to 30 minutes from 3 hours for our previous 
version. Conclusions: The modified MS-PCR assay for the diagnosis of PW/AS 
showed very good performance, easy to perform and suitable for clinical testing.  
 
G46. Redesign of Cystic Fibrosis Multi-analyte Controls for Compatibility with 
Version 2 Luminex xTAG Kits: Complete Verification of Mutation Detection at All 
Assayed Loci 
C. Huang1, T. Christensen2, R. Meixell1, W. Harwood1, B. Anekella1 
1SeraCare Life Sciences, Inc., Gaithersburg, MD; 2Providence Sacred Heart Medical 
Center and Children's Hospital, Spokane, WA. 
Introduction: Cystic Fibrosis is a common recessive genetic disorder, with over 1300 
mutations discovered in the CFTR gene. Finding controls or reference materials for rare 
mutations is difficult. SeraCare provides synthetic multiplex controls for Luminex xTAG 
assays. Recently Luminex updated the kits and analysis software to screen for an 
altered complement of mutations; the Luminex software now has an inbuilt assumption 
of two alleles for each locus, making design of highly multiplexed controls challenging. 
SeraCare has designed improved controls to meet these challenges. Methods: 
SeraCare developed ACCURUN 639 [A639] for the Luminex xTAG Cystic Fibrosis 
(CFTR) 39 kit v2 [CF39], and ACCURUN 660 [A660] to be used in conjunction with 
A639 for mutation detection on Luminex xTAG Cystic Fibrosis 60 kit v2 (IVD) [CF60] 
and Luminex xTAG Cystic Fibrosis 71 kit v2 (CE) [CF71]. Results: A639 and A660 
provide complete controls for three Luminex xTag kits. A639, for use with CF39, 
contains 2 vials: A639-01, with synthetic reference nucleic acids, controls for mutant 
detection of all loci examined in CF39 except the G551D locus, which gives a wild type 
(WT) call. A639-02, with genomic and synthetic DNA, fulfills the manufacturer’s 
recommendation for a genomic DNA control. A639-02 yields a WT call for all loci except 
G551D, which gives a HET call. When both vials are used with the CF39 kit, mutant or 
heterozygous (MuD or HET) results are observed for the 23 CFTR mutations and 4 
variants recommended by ACMG/ACOG and for 16 additional common mutations. 
A660 contains synthetic reference nucleic acids comprising additional mutations tested 
with Panel B of the CF60 and CF71 kits. A660 produces HET or MuD calls for 20 or 31 
additional mutations and a wild type call for del e2,e3 when tested on CF60 or CF71 
assays respectively. A639-02 yields a HET call for del e2,e3 when assayed with the 
CF60 and CF71 kits. Using both A639 and A660 verifies all mutations and variations 
listed in the CF60 and CF71 package inserts. Conclusions: SeraCare’s controls 
deliver reproducible results and decisively monitor Luminex xTag CF39 v2, CF60 v2, 
and CF71 v2 kit reliability. Depending on the diagnostic assay performed, ACCURUN 
639 or ACCURUN 639 and 660 can be selected for comprehensive quality control. 
These controls positively verify mutation detection at each locus assayed in each test 
without “No Call” results and provide users with the genomic DNA control 
recommended by the kit manufacturer. 
 
G47. Method Comparison Study of the Illumina InfiniumDx CytoSNPǦ12 Assay 
for the Detection of Chromosomal Abnormalities in DNA Extracted from 
Peripheral Blood 
M. Porter, R. Golshani, J. Fabian, M. Harris 
Illumina, Inc., San Diego, CA. 
Introduction: The InfiniumDx CytoSNPǦ12 Assay is intended for use as an aid in post-
natal diagnosis of autism spectrum disorders, developmental delay and/or intellectual 
disability, congenital anomalies, and dysmorphic features in conjunction with other 
currently used information. To demonstrate the utility of this assay, 402 samples with 
reported chromosomal abnormalities were analyzed using the InfiniumDx CytoSNPǦ12 
Assay and at least one other method, including karyotype, FISH, PCR, Multiplex 
Ligation-dependent Probe Amplification (MLPA), qPCR, or an in-house confirmatory 
method for loss of heterozygosity (LOH). Methods: The InfiniumDx CytoSNPǦ12 Assay, 
based on Illumina BeadArray technology and run on the iScanDx System, consists of 
CytoSNPǦ12 assay kits and KaryoStudioDx analysis/reporting software. The 402 
samples were run in singlet. Karyotype, MLPA, FISH, and PCR were performed 
externally with commercially available assays. qPCR and LOH were performed using 
methods validated in-house. Sample success rate (percent of samples passing defined 
QC metrics/total samples run), positive percent agreement (percent of regions reported 
by a comparator method and the assay/total regions expected) and false positive rate 
(percent of regions detected by the assay but not by a comparator method/total regions 
detected by the assay) were calculated to measure the performance of the InfiniumDx 
assay against the comparator methods. Results: Sample success rate upon first 
attempt was 98% (393/402). The 95% lower bound for positive percent agreement for 
all chromosomal abnormality types was 93% (1034/1098). For gains, losses, and copy-
neutral LOH (CNLOH), the 95% lower bound for positive percent agreement for each 
type was 87% (22/224), 91% (25/365), and 95%(17/445), respectively. False positive 
rate across all regions detected by the assay was 12% (144/1170). For gains, losses, 
and CNLOH, the false positive rate for each type was 10% (25/248), 9% (37/392), and 
15% (82/530), respectively. Conclusions: Our study demonstrates comparable 
performance of the InfiniumDx CytoSNPǦ12 Assay to many of the standard clinical 
methods used to determine copy number variation. This assay reports all chromosomal 
abnormalities within the entire genome of a sample, making it more comprehensive 
than FISH, PCR, MLPA, and qPCR. In addition, this assay reports CNLOH regions, 
unlike karyotyping or FISH. This test is For Investigational Use Only. 
 
G48. Noninvasive Fetal RhD Genotyping Using Circulating Cell-free Fetal DNA 
from Maternal Plasma in RhD-negative Pregnant Women 
S. Han1, J. Ryu2, S. Bae3, Y. Kim2, Y. Yang2, K. Lee2 
1Seoul Clinical Laboratories, Republic of Seoul, Korea; 2Seoul Medical Science 
Institute, Seoul Clinical Laboratories, Republic of Seoul, Korea; 3Dongnam Institute of 
Radiological & Medical Sciences, Republic of Busan, Korea. 
Introduction: The prenatal diagnosis of fetal rhesus D (RhD) status is useful for the 
management of RhD-negative pregnant women. Conventional methods for prenatal 
fetal RhD status determination involve invasive procedures such as fetal blood 
sampling and amniocentesis. The demonstration of the existence of cell-free fetal DNA 
(cffDNA) in maternal plasma opens up the possibility of determining fetal RhD status by 
analysis of maternal plasma DNA. Therefore, we assessed the feasibility and accuracy 
of the fetal RhD genotyping from cffDNA in maternal plasma in RhD-negative pregnant 
women. Methods: We analyzed a total of 64 maternal plasma samples from 32 
pregnant women (14-40 week’s gestation) with RhD-negative in serologic testing. The 
RhD real-time quantitative PCR assay can be achieved by including an amplification of 
RhD exon 7. We have concurrently incorporated the use of the RASSF1A (sex-
independent fetal epigenetic marker) and the SRY as internal positive controls for fetal 
RhD genotyping. The fetal RhD genotyping results were compared with the serologic 
analysis of cord blood. Results: Among the 32 fetuses, 24 were RhD-positive and 8 
were RhD-negative on serologic analysis of cord blood. There was complete 
concordance between results of the fetal RhD genotyping and the results obtained from 
serologic testing of cord blood. Among the 8 RhD-negative results, 4 cases were SRY-
negative and RASSF1A-detected. The positive detection of the RASSF1A gene 
confirmed existence of the fetal DNA. Incorporation of RASSF1A gene to verify the fetal 
DNA in RhD-negative fetuses can reduce the possibility of a false-negative result. 
Conclusions: Noninvasive fetal RhD genotyping provides a robust method of 
assessing of fetal RhD status and is an alternative to amniocentesis for the 
management of RhD-negative women and it alleviates the need for unnecessary 
prophylactic Rhogam administration. 
 
G49. Demonstration of Accurate, Precise, and Tunable Cytogenetics Using 
Next-Generation Sequencing Platforms 
T. Royce, F. Kaper, B. Klotzle, J. Fan, M. Eberle 
Illumina, Inc., San Diego, CA. 
Introduction: Technological advances in whole-genome shotgun sequencing have led 
to the successful diagnoses of once-enigmatic illnesses resulting from rare, de novo 
point mutations. Application of the same technology to the discovery of cytogenetic 
abnormalities holds similar promise, with a full range of capabilities yet to be completely 
described and quantified. Methods: Cytogenetically interesting samples were 
sequenced along with a cytogenetically normal cell line in a single flow cell lane on an 
Illumina Genome Analyzer IIx. The two samples in each lane were distinguished by 
short DNA barcodes. Copy number abnormalities were identified as changes in relative 
depth between the sample of interest and its inline control. Informatic downsampling 
was used to simulate different levels of sequencing depth. The data was used to 
simulate copy number gains and losses of varying size. Sensitivity to detect such 
variants was computed and used to establish the technique’s limit of resolution at 
different sequencing depths. Specificity was assessed by conducting two independent 
sample preparations of the same sample, using one as the inline control for the other. 
In addition to “typical” copy number gains and losses, we simulated gains and losses in 
a genetically mosaic background and assessed the technique in these more 
challenging cases. Finally, we investigated the approach’s ability to correctly identify 
cases of uniparental disomies in shotgun sequenced samples. Results: After sampling 
the Genome Analyzer IIx data down to the throughput of the Illumina MiSeqDx platform, 
we find that the technique has the ability to detect 95% of copy number losses of 200 kb 
and 95% of copy number gains of 400 kb. At these limits of resolution, we find virtually 
no false positive calls. The technique is extendable to genetically mosaic events, albeit 
at a higher limit of resolution. Uniparental disomies are readily detectable at the scale of 
whole chromosomes. Increasing read depth improved all capabilities. Conclusions: 
With appropriate study design, the same shotgun sequencing technologies routinely 
used to identify simple point mutations can be employed for sensitive and precise 
detection of cytogenetic abnormalities. At current sequencing throughputs, measures of 
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sensitivity and specificity are on par with array technologies. As shotgun sequencing 
throughputs improve, sequencing will become an increasingly compelling alternative to 
existing cytogenetics technologies. 
 
G50. High Throughput Germline Mutation Screening for Hereditary Breast 
Cancer Using Fluidigm Access Array & 454 GS Junior 
C. Au1, F.B. Law1, B. Ip1, A.T. Wong1, C.L. Wong1, A. Kwong2, E.S. Ma1 
1Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong; 2The University of Hong 
Kong, Pokfulam, Hong Kong. 
Introduction: Breast cancer is prevalent world-wide and has become the leading cause 
of cancer among the female population in Hong Kong. The Hong Kong Hereditary 
Breast Cancer Family Registry was established in 2007 and thus far 1194 patients with 
breast cancer were recruited from hospitals and clinics in Hong Kong. Mutational 
screening of susceptibility genes, BRCA1 and BRCA2, using Sanger full gene 
sequencing was performed and until now 706 cases have been analyzed. We sought to 
apply next-generation DNA sequencing to analyze the remaining samples at higher 
throughput. Methods: We analyzed BRCA1, BRCA2 and also TP53 genes of 192 
cases using 454 GS Junior System. Generation of barcoded amplicon libraries was 
streamlined by microfluidic PCR using Fluidigm Access Array System. Two Fluidigm 
runs can generate 41 BRAC1 and TP53 amplicons and 45 BRCA2 amplicons from 
each of 48 unique cases, and a total of 8 runs were performed. Each Fluidigm run was 
subject to one GS Junior run. Sequencing data (total length 213 Mbp) were 
automatically analyzed by an in-house developed bioinformatics pipeline, which mainly 
consists of GS Amplicon Variant Analyzer, SAMtools and Ensembl Variant Effect 
Predictor. To confirm the detected mutations, full BRCA1 and BRCA2 genes of 10 
cases and individual deleterious mutations of remaining cases were subject to Sanger 
sequencing. Results: On-going analysis revealed 3 novel deleterious mutations (1 
BRCA1 frameshift insertion and 2 BRCA2 non-sense SNPs) among BRCA1, BRCA2 
and TP53 mutations identified from 192 cases. Sensitivity of 454 sequencing approach 
was found to be comparable to Sanger sequencing, although detection of insertion-
deletion polymorphisms around long homopolymers is challenging. Bioinformatics-
based filters were optimized based on Sanger sequencing data and were applied to 
minimize false positives. Signal intensity and the sequence of cyclic nucleotide flows 
were used in mutation prioritization to account for Carry Forward and Incomplete 
Extension errors around homopolymer sequences. Conclusions: Mutational screening 
of BRCA1, BRCA2, and TP53 genes from 192 cases were streamlined and performed 
at much higher throughput. The bioinformatics pipeline developed is expected to 
facilitate data analysis of similar diagnostic settings. In Hong Kong, our laboratory 
pioneered the application of both microfluidic PCR and next-generation sequencing 
systems for molecular diagnostics. 
 
G51. Mutational Characterization of the Dystrophin Gene by Direct Sequencing 
in a Cohort of Patients without Exonic Deletions or Duplications 
K. Hong, S. Park, J. Lee, S. Cho, E. Ra, J. Chae, M. Seong, S. Park 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: The dystrophinopathy is a spectrum of muscle disease caused by 
mutations in the DMD gene. Exonic deletions or duplications account for approximately 
65-80% of patients with Duchene and Becker muscular dystrophy (DMD/BMD). We 
performed sequence analysis of the entire gene in a cohort of patients without exonic 
deletions or duplications. Methods: A total of 58 unrelated DMD/BMD patients were 
participated in the study. Either multiplex ligation-dependent probe amplification or 
multiplex PCR were performed to exclude exonic deletion or duplication of DMD gene. 
Direct sequence analysis was performed for all 79 exons and their flanking regions of 
DMD gene. Results: Among 58 patients, forty-eight patients (82.8%) had 46 different 
pathogenic mutations, five patients (8.6%) had only novel unclassified sequence 
variants, and the other five patients (8.6%) had neither mutations nor sequence 
variants. The pathogenic mutations consisted of five small insertion/deletion mutations, 
25 nonsense mutations, and 16 splice-site mutations. Twenty-three mutations were 
previously known and the others were novel. One patient had a novel nonsense 
mutation, c.2609T>G (p.Leu870X) and a known nucleotide variation, c.2381-3T>C in 
intron 19. This intronic variation was suggested as a splice-site mutation originally, but 
rather it is thought to be a benign variant because it is also detected in normal controls 
(2/153, 1.3%). Conclusions: The molecular characterization revealed in this study can 
extend the mutation spectrum of the DMD gene and will be helpful to establish the 
diagnostic strategy for dystrophinopathy. 
 
G52. Small Clinically Significant CTNND2 Intragenic Deletions and 
Duplications in the Cri-du-Chat Region Identified in Individuals with 
Developmental Delay 
L.D. McDaniel1, P. Bader2, J.H. Miles3, C. Stevens4, J. Reynolds5, R.L. Ladda6, S. Sell6, 
A. Kaddurah7, X. Li8, J.A. Rosenfeld1, J.B. Ravnan1, R.A. Schultz1, P. Mowery-
Rushton1, B.S. Torchia1, B.P. Coe9, E.E. Eichler9, L.G. Shaffer1 
1Signature Genomics Laboratories, PerkinElmer, Inc, Spokane, WA; 2Northeast Indiana 
Genetic Counseling Center, Fort Wayne, IN; 3University of Missouri, Columbia, MO; 
4University of Tennessee College of Medicine, Chattanooga, TN; 5Shodair Children's 
Hospital, Helena, MT; 6Milton S. Hershey Medical Center, Hershey, PA; 7Hurley Medical 
Center, Flint, MI; 8AmeriPath Northeast, Shelton, CT; 9University of Washington School 
of Medicine, Seattle, WA. 
Introduction: Microarray is an important first-tier testing method for individuals with 
developmental delay. The ability to utilize this testing methodology to identify and 
validate new loci with relevance to cognitive impairment through genotype-first 
approach is dependent on (i) adequate array coverage within loci of relevance, (ii) an 
available database of results for large numbers of affected individuals, and (iii) results 
from control populations for assessment of the clinical relevance of copy number 
variation identified. CTNND2 encodes a brain-specific member of the adherens junction 
complex that localizes to synapses. In mice, expression begins early in embryonic 
development and continues into the postnatal period. Null mice display specific severe 
cognitive impairments, with changes and reductions in dendritic spines. CTNND2 
haploinsufficiency has been implicated as a candidate for the severe intellectual 
disability of Cri-du-Chat syndrome with larger deletions of chromosome 5p, but to date 
no study has provided gene-specific evidence of a role for this protein in cognitive 
delay. Methods: We analyzed the results of screening over 23,471 patients by 
oligonucleotide-based microarrays employing comparative genomic hybridization 
(aCGH), stored and displayed within the Genoglyphix database. Fluorescence in situ 
hybridization (FISH) studies confirmed the alterations identified. Patients’ results were 
compared to microarray data compiled from a large, apparently normal control 
population. Results: We identified eleven patients with deletions and one with 
duplication within CTNND2. These alterations were relatively small (75 to 811 kb). The 
deletions all FISH confirmed and, based on the UCSC Genome Browser, result in 
frameshifts and/or a truncated protein. For the single patient with an intragenic 
duplication, FISH results were consistent with a tandem duplication and potential 
disruption of gene function. All of these patients have developmental delay in their 
indication for study. Database analysis also revealed three cases with relatively large 
duplications overlapping one end of the gene. None of these duplication cases had 
developmental delay or intellectual disability as an indication for study, and two were 
found incidentally as a result of parental studies. Analysis of microarray results for a 
large, apparently normal control population (n=8329) identified no similar deletions or 
duplications within CTNND2. Conclusions: Results show that deletions and 
duplications within CTNND2 that interrupt reading frame and result in a truncated 
protein yield a phenotype that includes developmental delay in all patients ascertained. 
These results highlight the importance of appropriately designed microarray coverage 
and access to databases of results for both affected and control populations. 
 
G53. A Comparison Study of Commercial Cystic Fibrosis Controls Tested with 
the xTAG Cystic Fibrosis 60 Kit v2 
S.A. Marconi, K.A. Lebel, S.M. Pflueger 
Baystate Health, Springfield, MA. 
Introduction: The xTAG Cystic Fibrosis 60 kit v2 (Luminex, Austin, TX) detects and 
identifies a panel of 60 mutations and variants in the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) gene in human blood specimens. Stringent quality 
control regulations require proof of the ability to detect the 60 mutations identifiable in 
the assay. Here we report on three commercially available control panels. Methods: 
The Introl CF Panel III (MMQC Inc., Scarborough, Maine), Accurun 644 and 676 CF 
controls (SeraCare Life Sciences, Milford, MA) and Coriell Cell Lines (Coriell Cell 
Repository, Camden, New Jersey) were assessed for ease of use, accuracy and 
efficiency. The Introl CF Panel III contains four separate controls covering 60 mutations. 
The Accurun 644 and 676 controls consist of 2 vials covering 58 mutations. Coriell cell 
lines each identify one to two mutations per control. All controls were tested using the 
xTAG Cystic Fibrosis 60 kit v2xTag according to the manufacturer’s protocol and 
analyzed on the Luminex 100. All control sets were run concurrently with each other 
and across multiple runs to assess accuracy and precision. Results: The individual 
vials of each control set were analyzed for mutation identification. All three control sets 
produced accurate results across multiple runs. The Accurun controls properly identified 
intended mutations and showed “No Call” results for mutations not expected to be 
analyzed. The Coriell cell lines, run individually, identified intended mutations. However, 
when the cell lines were combined in an attempt to create a multi target control, some 
intended mutations failed to be detected. The Introl CF Panel III properly identified all 
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intended mutations and identified wild type calls when appropriate. Conclusions: 
Commercially available control panels for multiplex assays have improved the quality 
control process for clinical testing. In our study, all three panels performed as reported 
by the manufacturers. Of the three tested, only the Introl CF panel identified all 60 
mutations included in the assay. The Accurun set provides detection of 58 mutations, 
not identifying the del e2e3 and G551D mutations, and offers “no call” results in lieu of 
wild type results. The Coriell cell lines are consistent; however, do not easily lend 
themselves to a multi target control. This single mutation identification will result in 
multiple controls needed per run and an extensive control rotation pattern to cover all 
60 mutations within a reasonable amount of time. As more multiplex assays become 
routine testing, the need for extensive control panels will increase. 
 
G54. Validation of IDUA Gene Sequencing Using KAPA2G Robust DNA 
Polymerase as a Tool for Confirmation of Mucopolysaccharidosis Type I (MPS-I) 
via a "Single Protocol PCR" 
R. Majumdar, A. McDonald, D. Matern, D. Gavrilov, D. Oglesbee 
Mayo Clinic Foundation, Rochester, MN. 
Introduction: Mucopolysaccharidosis type I (MPS-I) is an autosomal recessive 
disorder due to deficiency of alpha-L-iduronidase, a lysosomal enzyme encoded by the 
IDUA gene. IDUA gene sequencing, as a supplement to diagnostic testing or population 
screening for alpha-iduronidase deficiency, can aid in obtaining a definitive diagnosis of 
MPS-I, and assist with carrier screening. In our experience, the presence of high GC-
rich sequences (>80%) in nearby exonic regions of the IDUA gene leads to inefficient 
PCR amplification and allele drop out when amplifying template DNA for Sanger 
sequencing using classical methods. Thus, we validated a new method for automated 
universal primer sequencing (UPS) of the IDUA gene with the KAPA2G DNA 
Polymerase (KAPA Biosystems) that overcomes these issues. Methods: 14 exons and 
intron/exon boundaries of the IDUA gene were amplified using FailSafe DNA 
polymerases (FailSafe PCR enzyme mix & PCR 2x Pre mixes, Epicentre) and KAPA2G 
DNA Polymerase systems from normal control DNA with a "Single Protocol PCR." In 
addition, validation of the KAPA2G-based assay included 4 MPS-1 patients with known 
IDUA gene mutations, 6 biochemically-positive patient samples, and 27 normal control 
specimens (2 amniotic fluid, 2 chorionic villi, 2 fibroblast, 5 dried-blood spot, and 16 
EDTA blood samples). Mutation Surveyor V3.24 (Soft Genetics, Inc) was used to 
analyze ABI3730 DNA sequencing results. Results: KAPA2G DNA polymerase is 
capable of amplifying all exons containing high GC-rich regions of the IDUA gene with a 
"Single Protocol PCR." Our method correctly identified mutations in the 4 MPS-1 
patients with known alterations. Of the 6 patients with an MPS-1 biochemical diagnosis, 
3 contained two different mutations and 3 contained a single mutation without another 
mutation detected. Two new IDUA gene mutations (c.367G>T, p.E123X; and 
c.1757C>T, p.S586F) were identified. All negative controls were without IDUA gene 
mutations and allele drop-out was not observed. Conclusions: Using KAPA2G DNA 
polymerase improved our UPS method for sequencing the IDUA gene. It is 
reproducible, robust, and can establish a diagnosis of MPS-I. In IDUA-deficient patients 
lacking a second alteration, deletion analysis is warranted. 
 
G55. Full Gene Sequencing of the RET Proto-Oncogene Enables Expanded 
Diagnostic Utility (Multiple Endocrine Neoplasia Type 2, Hirschsprung’s Disease 
and Congenital Central Hypoventilation Syndrome) 
H. Reddi, W. Highsmith, B. Kipp 
Mayo Clinic, Rochester, MN. 
Introduction: The RET (rearranged during transfection) proto-concogene encodes a 
receptor tyrosine kinase. Loss of function mutations in RET are associated with the 
development of Hirschsprung's disease (HSCR), whereas gain of function mutations 
are associated with the development of various types of human cancer, including 
medullary thyroid carcinoma, multiple endocrine neoplasias type 2A and 2B, 
phaeochromocytoma and parathyroid hyperplasia. A small percentage of cases (5%) 
have both MEN2 and HSCR. Recent evidence has also indicated the presence of RET 
mutations in congenital central hypoventilation syndrome (CCHS), 16-20% of which 
have Hirschsprungs disease. Although the HSCR cases that have MEN2 are observed 
to have MEN2 specific mutations, CCHS cases that have HSCR have mutations spread 
across the gene. Here we report the development of a full gene sequencing assay for 
the RET proto-oncogene in an academic reference laboratory setting for expanded 
diagnostic utility. Methods: A sequencing assay was developed to evaluate additional 
exons 1-9, 12 and 17-21 of the RET proto-oncogene using the universal primer 
sequencing protocol, to be run using an automated laboratory developed fluorescent 
Sanger sequencing workflow. Results: Testing for mutations in the RET gene is 
currently restricted to specific exons (10, 11, 13-16), specifically for MEN2 cases, with a 
potential to miss 5% of mutations that could be involved in HSCR. We designed and 
tested primers for the remaining 14 exons of the RET gene using three laboratory 
normals and three HSCR positive samples. Validations were done using a 3 by 3 inter- 
and intra-assay matrix. A single point mutation was detected in exon 8 of the three 
HSCR samples. We propose to evaluate all our MEN-2 positive samples to determine 
the presence of mutations in the exons 1-9, 12 and 17-21 that may have been missed 
due to restricted exon sequencing. Conclusions: The presence of RET mutations that 
are observed to co-segregate across different diseases, emphasize the importance of 
full gene sequencing versus targeted sequencing. Targeted profiling of genes may have 
a cost-benefit ratio of the test but it needs to be evaluated in terms of the end benefit to 
the patient. The move towards full gene sequencing for genes such as RET with a 
known involvement in multiple diseases, may be a beneficial approach, particularly to 
rule out disease susceptibility. 
 
G56. Development and Validation of a Comprehensive Assay for Detection of 
PMS2 Gene Variants 
M.L. Butz, L.M. Peterson, S.C. Howe, P.A. Lundquist, L.K. Courteau, B.C. Thomas, 
B.R. Kipp 
Mayo Clinic, Rochester, MN. 
Introduction: Germline mutations in the PMS2 gene are associated with Lynch 
syndrome, a condition that predisposes individuals to colorectal, endometrial and other 
solid tumors. Mutation detection of variants within the PMS2 gene is complicated by the 
presence of multiple pseudogenes, including numerous pseudogenes that share 
homology with the 5 prime region of PMS2 and PMS2CL, which has strong homology to 
PMS2 exons 9 and 11-15. Here we describe a long-range PCR and MLPA assay that 
evaluates PMS2 while limiting pseudogene interference. Methods: Long-range PCR 
was performed on 20 specimens to preferentially amplify three PMS2 gene products 
without pseudogene contamination. For the long-range PCR that amplifies exons 10 to 
15 of PMS2, we designed a reverse PCR primer anchored downstream of PMS2 exon 
15 that was not specific to PMS2 to insure that gene conversion events in that region 
did not cause allele drop out. Nested primers were then developed to assess the long-
range products for all 15 exons and splice junctions within the PMS2 gene. We also 
assessed 52 specimens for PMS2 deletions using the MRC-Holland (Amsterdam, 
Netherlands) PMS2 MLPA kit. Lastly, we developed a follow-up PMS2CL long-range 
PCR and sequencing method to resolve the origin of large deletions due to gene 
conversion events between exons 11 and 15 of PMS2 and homologous PMS2CL 
exons. Results: Among the 20 specimens that were sequenced, we correctly identified 
9 PMS2 variants by DNA sequencing in 5 previously tested patient DNA samples 
extracted from peripheral blood. In addition, 25 different polymorphisms were observed 
in 15 anonymous normal samples without IHC data. All specimens with a previously 
identified deletion (n=3) were detected by MLPA. Lastly, we found that gene conversion 
events were frequent (69%) in patients not suspected of having Lynch syndrome. 
Conclusions: Our results showed accurate and reproducible detection of PMS2 
variants using long-range PCR and MLPA. In addition, balanced and imbalanced gene 
conversion events between PMS2 and PMS2CL, especially in exons 13 to 15 of PMS2, 
were frequently observed in patients without known mismatch repair defects. 
 
G57. WITHDRAWN 
 
G58. Identification of Partial Trisomy 8 and ATRX Syndrome in an Infant with 
Overlapping Phenotypic Abnormalities 
K. Houtchens, J.R. ten Bosch, K. Graham, S. Morin, M. Vinson, P.D. Cotter, C. Hoppe 
Children's Hosptial and Research Center Oakland, Oakland, CA. 
Introduction: A term male infant was transferred at birth to Children’s Hospital & 
Research Center Oakland (CHRCO) for persistent respiratory distress and mild anemia. 
Newborn screening (NBS) results revealed elevated Hb Barts, consistent with alpha 
thalassemia (Hb H disease). Clinical examination was notable for facial and digital 
abnormalities, cryptorchid testicle and hypotonia. Alpha globin genotyping at CHRCO 
was negative for alpha thalassemia deletions and point mutations. Most cases of Hb H 
disease are phenotypically normal, but rare cases of HbH disease associated with 
syndromic features, e.g., X-linked alpha thalassemia intellectual disability (ATRX) 
syndrome and ATR16 syndrome exist. Because the constellation of laboratory and 
clinical findings was suggestive of ATRX syndrome, the infant was tested for ATRX and 
evaluated for chromosomal abnormalities. Methods: Primary NBS (quantification of Hb 
Barts by HPLC) was performed at the Genetic Disease Laboratory (CDPH). 
Confirmatory testing for Hb H disease was performed at the CHRCO 
Hemoglobinopathy Reference Laboratory. Blood samples from the infant and mother 
were sent to the MRC Molecular Haematology Unit, Weatherall Institute, Oxford UK for 
comprehensive mutation analysis of the ATRX gene and to the CHRCO Molecular 
Genetics/Cytogenetics Laboratories for evaluation of chromosomal abnormalities using 
arrayCGH and karyotyping. Results: A novel mutation in the ATRX gene was identified 
in infant and mother. ArrayCGH results revealed a 76.2 MB duplication of the long arm 
of chromosome 8 (8q13.2 ĺ qter). The 8q duplication found by arrayCGH was not 
detected by routine karyotyping of PHA-stimulated peripheral blood lymphocytes. 
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Retesting by arrayCGH with the specimen found negative by karyotype confirmed the 
presence of the duplication. Discrepancies between array and karyotyping could be due 
to low level mosaicism or poor growth of abnormal cells in culture. Mosaicism of trisomy 
8 is a frequent finding. There was no indication of mosacism by array. Conclusions: 
Substantial overlap between phenotypes for ATRX and partial trisomy of 8q exists. The 
clinical findings of developmental delay, undescended testicles, abnormal shaped 
pinna, telocanthus, broad nasal bridge, anteverted nares, and arched palate are 
common to both syndromes. Mild to moderate anemia secondary to alpha-thalassemia 
is not associated with 8q duplications. The multi-pronged approach used in this case 
uncovered chromosomal abnormalities in addition to the suspected ATRX mutation. 
Microarrays provide complementary information by identifying a 76.2 Mb duplication of 
8q that likely contributes to the complex phenotype of the patient. 
 
G59. Can Next Generation Sequencing Replace Sanger Sequencing? – A 
Review of the Illumina Cystic Fibrosis Diagnostic Test on the MiSeqDx 
Instrument  
M. Chelliserry, R.E. Lenta, J.C. San, W.M. Goldstein, E.J. Peters 
Illumina, San Diego, CA. 
Introduction: Cystic Fibrosis is a considered to be a common genetic disease, 
especially among the European Union (EU) and United States (US). The WHO 
currently states that the incidence rate in newborns is between 1 in 2000-3000 in the 
EU and 1 in 3500 in the US. Current practice for confirmatory diagnostic testing of 
individuals suspected of having Cystic Fibrosis typically involves the use of single-plex 
PCR and subsequent Sanger sequencing of numerous amplicons spanning the protein 
coding region of the CFTR gene. This process is both time and labor intensive. Here we 
describe the development of a new next generation sequencing assay, the Illumina 
MiSeqDx Cystic Fibrosis Diagnostic Assay, for the detection of all known and novel 
CFTR variants on the MiSeqDx instrument. Methods: The assay is designed to 
sequence the full protein coding region of CFTR and intron-exon boundaries to detect 
variations within the CFTR gene as an aid in diagnosis of Cystic Fibrosis in genomic 
DNA extracted from whole blood samples. The assay is designed to also detect two 
deep intronic mutations (3849+10kbC>T and 1811+1.6kbA>G), and two large deletions 
(CFTR dele2,3, and CFTR dele22,23). The assay technology involves targeted 
amplification of the CFTR gene followed by sequencing by synthesis on the MiSeqDx. 
Results: The Illumina MiSeqDx Cystic Fibrosis Diagnostic assay has been designed to 
fit the needs of the clinical user and will allow up to 8 samples in a single run to be 
sequenced within 2 days with 2.5 hours of hands-on time from extracted DNA to 
sequence data. The assay had a call rate of >99.9% when tested on over 200 unrelated 
blood samples and >1500 HAPMAP and human variation samples of multiple 
ethnicities. The assay had 100% detection for the two deep intronic mutations and for 
the large CFTR dele2,3 deletion. Data is pending for the CFTRdele22,23 deletion. 
Assay performance results against the current 23 ACMG CFTR mutations yielded 
excellent reproducibility (100%) and accuracy (100%) when compared to bi-directional 
Sanger sequencing. Homopolymeric regions known to be challenging to other methods 
(i.e, 2184delA, 2183AA>G, Poly TG/Poly T) were tested. The assay is able to 
accurately sequence the full CFTR gene, including homopolymeric regions. 
Conclusions: The Illumina MiSeqDx Cystic Fibrosis Diagnostic Assay can accurately 
sequence the entire CFTR gene in a single run. This will provide significant workflow 
benefits vs. current Sanger Sequencing methods. This test is for Investigational Use 
Only.  
 
G60. Exome Sequencing of Two Korean Families with Primary Congenital 
Glaucoma 
C. Ki, H. Kim, J. Kim, C. Kee 
Samsung Medical Center, Republic of Seoul, Korea 
Introduction: Primary congenital glaucoma (PCG) is an autosomal recessive form of 
glaucoma that manifests within the first year of life and if left untreated, leads to 
blindness. We have previously reported only 26% of Korean patients with PCG carried 
either one or two mutant alleles of the CYP1B1 gene. We hypothesized another 
causative gene may be involved in the pathogenesis of PCG. Methods: Eight 
individuals from two Korean families with PCG in whom CYP1B1 mutations were not 
identified by Sanger sequencing were subjected to exome capture followed by 
massively parallel sequencing. In one family, both parents without PCG, a healthy 
sibling and a patient with PCG were included. Another family consisted of both parents 
without PCG and monozygotic twins with PCG. Results: After filtering against existing 
SNP databases, all the patients showed no possible mutations located in known 
chromosomal loci for PCG, namely GLC3A, GLC3B or GLC3C, and did not carry 
mutations in target genes associated with PCG or other type of early onset glaucoma. 
And there was no compelling candidate genes containing previously unknown variants 
in all affected individuals. Conclusions: Although this is not a large scale study, exome 
sequencing of two Korean families with PCG could not identify any significant variations 
that were possibly associated with PCG. Therefore, a different approach might be 
needed to identify additional genetic causes underlying the PCG such as further exome 
sequencing of a large number of patients to overcome a genetic heterogeneity or a 
whole genome sequencing to identify any variants in non-coding sequences. 
 
G61. WITHDRAWN 
 
G62. Evaluation of Genomic DNA Purification from Human Whole Blood Using 
the Maxwell CSC Automated Nucleic Acid Extraction System and Maxwell CSC 
Blood Reagents 
G.D. Cameron1, C. Cowan1, C. Newton1, D. Horejsh1, J. Franz1, T. Ellis2, W.M. 
Rehrauer3, P. Brown4, J. Palmer4 
1Promega Corporation, Madison, WI; 2University of Wisconsin Hospital & Clinics, 
Madison, WI; 3University of Wisconsin School of Medicine, Madison, WI; 4University of 
Wisconsin Hospital and Clinics, Madison, WI. 
Introduction: The United States FDA (Food and Drug Administration) has issued draft 
guidance stating that extraction systems for molecular diagnostic use must be designed 
and manufactured under cGMP, and labeled as Clinical Sample Concentrators (CSC). 
Promega Corporation is introducing the Maxwell CSC instrument and the Maxwell CSC 
Blood kit that have been designed and manufactured in compliance with this directive. 
In developing this instrument and chemistry, Promega has performed extensive 
evaluation of purification performance and consistency. The evaluation included 
analysis of genomic DNA yield and purity, consistency of instrument performance 
(multiple instrument, multiple day, multiple user), linearity of purification with input blood 
volume, concentration of eluate across elution volumes, and performance of eluted 
DNA in downstream assays. Methods: Genomic DNA from Human whole blood 
samples collected in EDTA, citrate and heparin tubes was purified using the Maxwell 
CSC instrument and Maxwell CSC Blood kit. Resulting eluates were evaluated for DNA 
concentration, yield, and purity by spectrophotometry. Genomic DNA size was analyzed 
by agarose gel electrophoresis and downstream endpoint and real-time PCR assays. 
Results: Samples processed on the Maxwell CSC met or exceeded specifications for 
concentration and purity: concentrations > 80ng/ul from 300ul whole blood, A260/A280 
> 1.7 and A260/A230 > 1.5. Assay of the gDNA by agarose gel electrophoresis 
demonstrated that the purified DNA is of high molecular weight. Eluates did not inhibit 
amplification of an exogenous internal positive control sensitive to the presence of 
inhibitors and showed amplification performance comparable to control gDNA in both 
endpoint and real-time PCR assays. For all four consistency measurements, the 
percent CV was < 15%. Conclusions: The Maxwell CSC and Maxwell CSC Blood kit 
show excellent consistency and performance in extracting genomic DNA from human 
whole blood. The Maxwell CSC is manufactured in compliance with the FDA directives 
regarding Clinical Sample Concentrators and thus gives laboratories a compliant choice 
for genomic DNA purification from human whole blood samples. 
 
G63. WITHDRAWN 
 
G64. Association of DAB2IP (Disabled Homolog 2-Interacting Protein) Variant 
rs7025486 G/A with Coronary Artery Disease Risk in Indian Population  
B. Das, G. Pradhan, A. Bhanushali 
Super Religare Laboratories Ltd, Mumbai, Maharashtra, India. 
Introduction: The genetic contribution to the risk of coronary artery disease is 
substantial. Several genome-wide association studies (GWAS) have identified markers 
that are associated with increased risk of coronary artery disease (CAD). One such 
sequence variant has been identified within the DAB2IP (Disabled homolog 2-
interacting protein) gene on chromosome 9q33. DAB2IP is a novel member of the Ras-
GTPase activating protein family. The minor allele (A) of rs7025486 present within 
intron-1 of DAB2IP gene has been reported to be associated with 1.08-1.34 higher risk 
of CAD in the Caucasian population. Till date no information exists regarding the 
frequency or the association of this variant with CAD in the Indian population. Hence in 
the current study we have determined the frequency of the rs7025486 SNP and its 
association with CAD in Indians (Indo-Europeans) that are a high-risk group. Methods: 
The study was performed on 214 patients with CAD confirmed by coronary angiography 
and 125 controls: examined clinically and investigated by electrocardiography and 
stress test to exclude CAD. Lipid parameters were investigated on Dade Dimension AR 
analyzer. DAB2IP rs7025486 genotypes were determined for all study participants 
using an allele-specific real-time PCR Taqman genotyping assay. The DNA was 
standardized to 10ng/mL. Chi-square tests were used for comparison of binary 
variables across groups. To determine risk for CAD, odds ratio (OR) with 95% 
Confidence Interval (CI) were determined. Results: The reported minor allele frequency 
rs7025486 A is 0.28 that is almost the same as in other ethnic groups. A higher 
frequency of the rs7025486 A allele was seen in cases as compared to the controls 
(0.31 vs 0.28), resulting in a trend towards increased risk for CAD (OR: 1.157; 95% CI 
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0.820-1.633), although not significantly (P=0.433). Interestingly however when the 
subjects were analyzed in an age-wise manner with respect to this SNP the AA 
genotype was associated with an increased risk in the CAD age group <50 yrs as 
compared to CAD age group >50 yrs (OR 3.149; 95%CI 1.181-8.389; P 0.034) and 
controls >50 yrs (OR 3.430; 95%CI 0.922-12.526;P 0.080) Conclusions: A trend 
towards increased risk of CAD was seen with the DAB2IP rs7025486 A allele by both 
univariate and multivariate analysis. The risk allele (A) was significantly associated with 
greater risk in premature CAD sub-group (<50 yrs) in our study. Hence this marker can 
be further explored in a larger group of individuals premature CAD. 
 
G65. A Novel High-Throughput Method to Identify Absorption, Distribution, 
Metabolism, and Excretion (ADME) Variants in Patients Following Hematopoietic 
Stem Cell Transplantation for Hematologic Malignancy 
S. Khaled, J. Herzog, D. Senitzer, S. Thomas, S. Forman, R. Nakamura 
City of Hope, Duarte, CA. 
Introduction: Allelic variants implicated in drug absorption, distribution, metabolism, 
and excretion (ADME) can determine the pharmacokinetic variability of some 
medications and have been increasingly recognized as important factors in determining 
the success or failure of medical treatments. Acute graft-versus-host disease (aGVHD) 
prophylaxis with tacrolimus and sirolimus is associated with improved aGVHD 
outcomes and reduced transplant-related mortality following allogeneic hematopoietic 
stem cell transplantation (HSCT). Both tacrolimus and sirolimus are characterized by 
narrow therapeutic indices and an increased risk of toxic side effects at higher doses, 
but poor efficacy at lower doses. The overall goal of this project is to determine whether 
ADME variants can affect the blood levels of these drugs and predict adjusted dosages 
to improve their safety and efficacy. In this abstract we demonstrate the feasibility of 
stratifying ADME variants based on genotype, using the iPLEX ADME PGx Panel 
(Sequenom), with the intent to further analyze and correlate this dataset with clinical 
outcomes. Methods: Under a City of Hope IRB-approved protocol, we obtained 
samples from archived DNA materials of 179 patients who underwent HSCT from 
January 2005 to August 2007. These samples were analyzed using the iPLEX ADME 
PGx panel and the MassARRAY Compact Analyzer (Sequenom). The iPLEX ADME 
PGx panel is based on the PharmADME Working Group list and covers >99% of the 
Pharma ADME Core list. The panel interrogates 188 mutations and 12 copy number 
variation assays (in 36 pharmacogenetically relevant genes) through 8 multiplex 
reactions. The panel is a PCR-based amplification method using 80 ng of input genomic 
DNA followed by single-nucleotide primer extension. This high-throughput system is 
capable of analyzing 96 patient samples, for 200 independent assays per sample, in 
approximately 10 hours. Results: Using the iPLEX ADME PGx panel, 179 samples 
were genotyped, of which 178 showed high quality data. The average call rate for these 
samples was 98.85% over 200 assays, with a median call rate of 100%. Of these 
assays, 76 were homozygous for all genotyped samples, 34 were nearly homozygous, 
leaving 78 mutations and 12 copy number variant assays that may be of relevance to 
tacrolimus/sirolimus metabolism. Conclusions: The iPLEX ADME PGx panel is a 
comprehensive high-throughput tool to screen a wide variety of ADME variants. We are 
currently in the process of using this panel to identify the ADME variants associated 
with sub-therapeutic or supra-therapeutic tacrolimus/sirolimus serum drug levels in this 
cohort of patients. 
 
HEMATOPATHOLOGY 
 
H01. Aberrant DNA Methylation in Promoter-Associated CpG Islands in Indian 
Acute Myeloid Leukemia (AML) Patients: First Report of NES1, BMP7, DFNA and 
RIZ1 Gene Methylation 
B. Das, F. Ahmad 
Super Religare Laboratories Ltd, Mumbai, Maharashtra, India. 
Introduction: CpG island hypermethylation in the promoter region of the key regulatory 
genes have been recognized as an alternative mechanism for gene inactivation. These 
epigenetic modifications have been shown to initiate or augment malignant 
transformation. In the current study, we evaluated the promoter methylation status of 
ten selected cancer related genes in de novo acute myeloid leukemia (AML) patients 
from Indian patients. Methods: The promoter hypermethylation was analyzed by 
performing methylation specific PCR MSP in a cohort of 90 de novo AML patients, and 
the results were correlated with clinical, cytogenetic and other molecular markers. 
Results: Overall, approximately 83.3% of the AML subjects presented with methylation 
of at least one of the ten investigated genes, whereas 50% (45/90) harbored concurrent 
hypermethylation of 2-5 genes. The frequency of aberrant methylation in the patient 
samples was 76.6% for p15, 28.8% for ER, 26.6% for BMP7, 20% for NES1, 11.1% for 
DFNA5, 6.6% for RARA, 4.4% for CEBPA, 1.1% for RIZ1 and FHIT each, and no 
methylation was observed for NPM1 gene. Aberrant promoter hypermethylation was 
found in across all FAB subtypes, and there appeared to be a trend towards a higher 
methylation frequency in AML patients with an unfavorable karyotype, but this 
difference was not significant. Conclusions: To the best of our knowledge, this is the 
first study to explore the methylation status of NES1, BMP7, DFNA, and RIZ1 gene in 
AML. Our data indicate that hypermethylation of multiple genes involving fundamental 
cellular pathways is a common event in AML, which varies greatly in frequency among 
the genes examined.  
 
H02. Evaluation of the RUNX1/RUNX1T1 Quantitation Results According to the 
c-KIT Mutation Status in t(8;21) Positive Acute Myeloid Leukemia  
S. Park1, H. Chi2, Y. Cho1, S. Jang1, C. Park1 
1University of Ulsan College of Medicine and Asan Medical Center, Republic of Seoul, 
Korea; 2Asan Medical Center, Republic of Seoul, Korea. 
Introduction: The c-KIT mutations are found in 30% of the core binding factor AML and 
associated with poor prognosis. Given that c-KIT mutations show poor prognosis in 
patients with t(8;21), we can hypothesize that the quantity of RUNX1/RUNX1T1 fusion 
transcript may be initially higher, more persistent, and more easily relapsed in mutated 
t(8;21) patients. To confirm this hypothesis, we evaluated the RUNX1/RUNX1T1 
quantitation results according to the c-KIT mutation status in patients with t(8;21) AML. 
Methods: A total of 50 patients diagnosed as t(8;21) AML in Asan Medical Center from 
July 2001 to September 2010 and were enrolled. We performed direct sequencing to 
confirm c-KIT mutation in exon 8 and 17. We applied real-time quantitative PCR for 
quantitation of RUNX1/RUNX1T1. We compared the proportion of the patients who 
achieved >3 log reduction of the quantitation, molecular relapse free survival, and the 
proportion of the patients who experienced molecular relapse within follow-up for 2 
years according to mutation status. Results: c-KIT mutations were found in 22/50 
(44.0%) patients and among them, exon 17 and 8 mutations were found in 18 and 4 
cases, respectively. There were no significant differences of the quantitation ratio at any 
designated time according to the mutation status. However, patients with c-KIT 
mutations showed trends of lower achievement rates of >3 log reduction of the 
quantitation than those without mutations from at 6 months to 12 months of follow-up 
and especially at six months, the difference was statistically significant (68.8% vs. 
100%, P=0.015). The patients with c-KIT mutations showed significantly shorter 
molecular relapse free survival (320.0 vs. 667.8 days, P=0.043) and significantly higher 
proportion of the patients who experienced molecular relapse within 2 years of follow up 
(95.4% vs. 75.0%, P=0.050) than those without mutations. Conclusions: c-KIT 
mutated patients with t(8;21) showed trends of more persistent RUNX1/RUNX1T1 
fusion transcript from 6 to 12 months of follow up than those without mutations, 
especially significantly at 6 months. They experienced molecular relapse more 
frequently and rapidly than those without mutations within 2 years of follow up. These 
results may be an another clue to guarantee the poor prognostic impact of c-KIT 
mutations in patients with t(8;21) AML, especially for molecular aspects.  
 
H03. Multiplex PCR Assay for Sequence analysis of an Extended V(D)J-J-
intron Region: Enhanced Assessment of IGH Mutation Status in Chronic 
Lymphocytic Leukemia (CLL)  
J.M. Spence1, E.J. Spence2, W. Burack3 
1University of Rochester, Rochester, NY; 2Rochester Institute of Technology, 
Rochester, NY; 3University of Rochester Medical Center, Rochester, NY. 
Introduction: The IGH loci requires chromosomal rearrangement to juxtapose Vh, D 
and Jh segments to make a functional immunoglobulin gene. Additional immunoglobulin 
diversification may be generated by somatic hypermutation (SHM). CLL is a clonal 
proliferation of B-cells with 2 clinical patterns that differ in aggressiveness, best 
predicted by Vh mutation status. Non-mutated Vh status is defined as 98% identity to 
reference sequence to accommodate polymorphisms; however there are recognized 
weaknesses around this 98% mark. We speculate that the intronic-J region immediately 
downstream of the encoding V(D)J, which undergoes the same SHM process as the Vh 
region, might be a less-biased measure of mutation status since it is not constrained to 
encode a functional protein. Methods: We developed a multiplexed set of primers for 
use on genomic DNA from peripheral whole blood of CLL patients to specifically amplify 
the rearranged IGH loci from the leader region of Vh through ~800 bases downstream 
of Jh6. These primers were divided into 3 master mixes, designed to support direct 
Sanger sequencing of IGH amplicons by separating Vh family-specific consensus 
primers based on Vh usage to reduce the probability of co-amplifying two re-arranged 
IGH alleles within one primer mix. Following sequencing, the Vh %ID was determined 
using IgBLAST (http://www.ncbi.nlm.nih.gov/igblast/) whereas the intronic Jh region 
was aligned with a BLAST-like algorithm using CloneMaster (www.scied.com/) and 
scored using published Vh criteria. Results: We determined Vh mutation status on 
55/55 unique CLL specimens: 27 had Vh 98% ID to reference whereas 28 had Vh< 
98% ID, implying SHM had occurred. Additionally, 7 specimens had both IGH alleles 
rearranged: 5/7 had amplicons in separate reactions whereas 2/7 had both amplicons 
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within one reaction, both of which were resolved using standard techniques. In all cases 
only one functional allele was found. Intronic-J sequence analysis found %ID to 
reference was highly correlated to Vh %ID (Pearson correlation =0.86). Indels 6 bases 
in the J-intronic region were common in mutated (22/28=79%) and never observed in 
non-mutated specimens (0/27) (p<.001). Conclusions: We have developed a robust 
PCR based assay for the simultaneous determination of both Vh and intronic-J 
sequence analyses. The %ID to reference was very highly correlated in Vh and J-
intronic sequences whereas only specimens with mutated IGH had J-region indels6 
bases. Results were discordant in 2 cases, both with 99%> Vh 98%ID whereas 
Intronic-J <98%ID, as predicted, suggesting that evaluating both regions can clarify CLL 
mutation status.  
 
H04. DNA Methylation as a Prognostic Marker of Survival In Patients With 
Cytogenetically Normal Acute Myeloid Leukemia 
X. Qu, J. Davison, M. Othus, L. Du, F. Appelbaum, E. Estey, M. Fang 
Fred Hutchinson Cancer Research Center, Seattle, WA. 
Introduction: Despite great progress in identifying molecular markers in cytogenetically 
normal acute myeloid leukemia (CN-AML), little is known about the epigenetic 
characteristics that may differ among these patients regarding prognosis. Most 
methylation studies have focused on CpG islands (CGI) in the promoter region of 
known genes. The current study adopted the comprehensive high-throughput array-
based relative methylation analysis (CHARM) with the aim to identify DNA methylation 
markers prognostic for survival in AML, focusing on CN patients. CHARM analyses 
target CpG enriched regions of the entire genome, including genomic sequences up to 
2kb outside of promoter CGIs, termed “CpG island shores,” in addition to promoter 
CGIs. The shores have been recently demonstrated to harbor more methylation 
alterations than the islands in tissue differentiation and cancer development. Methods: 
For each sample subjected to CHARM analysis, DNA was randomly fractionated and 
divided into two equal portions with and without McrBC treatment, which cleaves 
methylated DNA, then size-fractionated, purified and subjected to whole-genome 
amplification prior to hybridization with the CHARM array. Data analysis was performed 
with R and Bioconductor. CHARM was first applied to a technical validation cohort of 15 
age-matched patients divided into high-, intermediate-, and low-risk groups as defined 
by cytogenetic features following SWOG’s criteria (n=5 in each), as well as 5 normal 
controls. Paired comparisons between every two risk groups were performed to identify 
methylation changes associated with cytogenetic risk groups. To test the technical 
reliability of CHARM, methylation levels of the identified regions were further validated 
using quantitative pyrosequencing. CHARM was then applied to a cohort of 72 CN-AML 
samples from SWOG with known clinical outcome; the Cox proportional hazard model 
was used within CHARM to identify survival-associated methylation regions (SAMRs). 
Results: Analysis using the technical validation cohort demonstrated 87.5% 
concordance between CHARM and quantitative pyrosequencing. When applied to the 
CN-AML cohort, CHARM/Cox identified 527 SAMRs containing at least 10 contiguous 
probes with Z scores above 95% cutoff. These SAMRs are enriched at the CGI shores 
rather than the islands Interestingly, as shown by Ingenuity Pathway Analysis, multiple 
SAMRs related genes are key factors in the development of hematological 
malignancies known to regulate cell cycle and apoptosis, such as BCL6, BRAF, 
DUSP6, FAS, FGFR1 and TP53. Conclusions: CHARM/Cox identified prognostically 
significant novel methylation changes in CN-AML patients. SAMRs with the highest 
hazard ratios will be selected for quantitative pyrosequencing validation, prognostic 
model development, and further clinical validation with independent cohort(s). 
 
H05. Deep Sequencing of BCR-ABL1 in Tyrosine Kinase Inhibitor-Resistant 
CML by Next Generation Sequencing on the Ion Torrent Platform  
P. Szankasi1, T.W. Kelley2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: Tyrosine kinase inhibitor (TKI) therapy has revolutionized the clinical 
management of chronic myelogenous leukemia (CML). However, a subset of patients 
will eventually develop TKI resistance due to the presence of mutations in the BCR-
ABL1 kinase domain (KD) and will require a change in therapy. Importantly, the 
selection of second line TKI is based on the BCR-ABL1 mutation status. Sanger 
sequencing of a BCR-ABL1 cDNA fragment has traditionally been the method of choice 
for detecting resistance mutations. However, this method suffers from poor sensitivity. 
Recent studies have shown that the presence of multiple low-level BCR-ABL1 kinase 
domain mutations at the time of switch to second line TKI correlates with poorer 
outcome. Such low level mutations may be below the detection limit for Sanger 
sequencing. In addition, mutations outside the kinase domain have also been reported 
to cause TKI resistance. With these factors in mind, we developed a BCR-ABL1 
mutation test by next generation sequencing (NGS) on the Ion Torrent platform to 
address the shortcomings inherent in traditional methods. Methods: RNA from patient 
whole blood was converted to cDNA. A large BCR-ABL1 fragment including the SH2, 
SH3, and kinase domains was PCR amplified from the cDNA, fragmented, and 
converted into a NGS library. Sequencing was performed on the Ion Torrent platform 
(Life Technologies). NGS libraries from different samples were generated with 
barcoded adapters and multiplexed in a single run. Results: We show the detection of 
several kinase domain mutations by NGS and their confirmation by Sanger sequencing. 
Mutations could be detected down to single digit percent levels. We also demonstrate 
the detection of additional mutations outside the kinase domain. Mutation detection, 
including allele frequencies, was reproducible in multiple experiments and different 
combinations of multiplexed samples. Conclusions: NGS approaches to the detection 
of BCR-ABL1 mutations in TKI resistant CML yield wider and deeper coverage. This 
allows the detection of clinically significant low-level mutations and novel mutations 
outside the area covered by standard Sanger sequencing. Multiplexing of barcoded 
patient samples make this approach feasible and cost effective for the clinical 
laboratory. 
 
H06. Molecular Diagnosis of Acute Promyelocytic Leukemia in 30 Minutes by 
Single-Step Retro Transcription Loop Mediated Amplification Reaction (RT-
LAMP) 
F. Rigo1, G. Minnucci1, G. Amicarelli1, G. Rizzo1, R. Mesturini1, P. Zanghì2, O. Spinelli2, 
F. Colotta1, A. Rambaldi2 
1DiaSorin SpA, Gerenzano, Italy; 2Ospedali Riuniti di Bergamo, Bergamo, Italy. 
Introduction: A rapid detection of PML-RARĮ translocation is crucial for effective 
management of patients affected by acute promyelocytic leukemia (APL). This life-
threatening disease, if diagnosed promptly, benefits from treatment with retinoids and 
arsenic trioxide that have revolutionized therapy over the last decade. The molecular 
detection of the three PML-RARĮ transcripts (bcr1, bcr2, bcr3) is actually based on 
conventional RT-PCR, a long and laborious multi-step method often not suitable for 
clinical needs. Methods: we have developed a novel non-PCR method based on LAMP 
that, starting directly from patient’s RNA, retrotranscribes, amplifies and detects the 
PML-RARĮ translocation in a single, ultra-rapid step. The reaction, being in a multiplex 
fluorescent format, detects and distinguishes in real time the most frequent transcripts 
(bcr1 and bcr3) and the GUSȕ housekeeping RNA that acts as internal control. In case 
of negative results, a second duplex reaction for detection of the less frequent bcr2 and 
the internal control gene can be performed. Results: the triplex (bcr1-bcr3-GUSE) and 
duplex (bcr2-GUSE) RT-LAMP assays performed on 170 replicates of wild type cell 
lines (HL-60, REH, RS4-11, kasumi, MV-4, 697, K-562, TOM-1) amplified exclusively 
the GUSȕ internal control gene, demonstrating 100% specificity. On serial dilutions of 
mutated sequences (bcr1, bcr2 and bcr3 respectively) into wild type RNA (from HL-60 
cell line) the two assays showed a sensitivity level of 10-3 on 30 replicates within the 
reaction time (30 minutes). Interestingly, a perfect relationship between the 
amplification time and the amount of mutation has been observed. Finally, RT-LAMP 
showed fully concordance with the conventional RT-PCR in detection of 30 clinical 
samples from patients affected by APL. Conclusions: The one-step, fluorescent RT-
LAMP assays for the detection of bcr1, bcr2, bcr3 and GUSȕ internal control RNA 
represents an ultra-rapid, specific, sensitive and cheap method for molecular 
confirmation of APL. The single-step format monitored in real-time simplifies the entire 
reaction set-up and ensure reliability. The 30 minutes RT-LAMP reaction can 
significantly improve the outcome of APL patients allowing to start the therapy timely.  
 
H07. Detection of Clonal T-Cell Gamma Gene Rearrangements on the Ion 
Torrent NGS Platform 
J.A. Schumacher1, P. Szankasi1, D. Crockett1, T.W. Kelley2 
1ARUP Laboratories, Salt Lake CIty, UT; 2University of Utah, Salt Lake CIty, UT. 
Introduction: Rearrangement of the T-cell receptor (TCR) gamma gene provides a 
molecular marker of clonality in T-cell neoplasms. Traditionally, testing is performed by 
capillary electrophoresis (CE) and amplicons are resolved by size. Criteria for 
identifying clonality generally rely on measuring the height of a clonal peak above the 
background. This approach has limited sensitivity and is inappropriate for detection of 
minimal residual disease. False positives also occur. To address these issues, we 
developed a method for sequencing the entire TCR gamma repertoire by next 
generation sequencing (NGS). Methods: Genomic DNA was isolated from whole blood. 
TCR gamma gene rearrangements were amplified in one multiplexed PCR reaction 
using 5 forward V-gamma primers and 3 reverse J-gamma primers (Greiner T.C. and 
Rubocki R.J.. 2002. J Mol Diagn; 4:137-143.). Amplicons were converted into a NGS 
library and sequenced on the Ion Torrent platform. Analysis was performed with open 
source software to sort NGS reads 150 nucleotides into groups of identical sequences 
and to identify the V-gamma segment used in the rearrangements. Grouped identical 
reads were expressed as percent of total reads. Results: In our initial experiments, 
analysis of a polyclonal sample yielded 11,825 total reads demonstrating 7,167 unique 
sequences. The largest group of identical reads constituted 0.4% of total reads. 
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Analysis of a clonal sample, demonstrating a biallelic rearrangement by CE, yielded 
67,946 total reads, with 7,848 unique sequences. Consistent with the CE findings, two 
clonal rearrangements were identified by NGS. One represented 48.8% of total reads 
and the other represented 29.5% of total reads. The next largest group of identical 
reads, the so-called sample background, represented 0.4% of total reads. For 
comparison of sensitivity, CE analysis demonstrated that the clone was approximately 
5X the height of the Gaussian distribution of rearrangements representing the 
background. In contrast, sequence analysis by NGS demonstrated that the same clone 
was approximately 100X more prevalent than the largest group of identical sequences 
representing the most common background rearrangement. Conclusions: Our initial 
findings indicate that NGS is an extremely sensitive tool for detecting clonal 
rearrangements of the TCR gamma gene. Experiments are ongoing to better define the 
spectrum of TCR gamma rearrangements by NGS in normal individuals, in those with 
reactive conditions and in those with T cell malignancies. We expect that NGS will 
eventually replace CE as the method of choice for assessing T cell clonality in the 
clinical laboratory.  
 
H08. Optimal Strategy for Obtaining Chromosome (CA) and FISH Results for 
Plasma Cell Dyscrasias (PCD) by Using Both Positive and Negative Fractions of 
CD138 Enriched Plasma Cells (EPC) 
V. Ortega, C. Mendiola, W. Ehman, G. Mohammad, G.V. Velagaleti 
University of Texas Health Science Center, San Antonio, TX. 
Introduction: Plasma cell dyscrasias comprise a genetically diverse group of diseases 
such as monoclonal gammopathy of undetermined significance, plasmacytoma, 
smoldering myeloma, indolent myeloma, and plasma cell myeloma. FISH is superior to 
CA in detecting important prognostic genetic abnormalities in PCD; however, its 
sensitivity is hampered due to paucity of PCs in whole BM and often shows false-
negative results when frequency of abnormal cells is below the cut-off values. Studies 
have shown that the abnormality detection rate in EPCs is greater than unselected 
plasma cells (UPC), but purification techniques are limiting to only FISH when bone 
marrow volumes are inadequate. The inability to perform CA may compromise patient 
care since CA is equally important for detecting non-PC related abnormalities, such as 
secondary myelodysplastic syndrome, when diagnosis is undefined. Methods: To 
resolve this critical issue and optimize limited quantity received, we designed a pilot 
study where an immnunomagnetic CD138 enriched positive selection was used for 
FISH whereas the negative selection was used to retrieve other myeloid elements for 
CA. Parallel FISH studies were performed using UPCs and CD138 EPCs, whereas 
karyotyping was achieved using whole BM and discarded myeloid elements. Results: 
Purity of EPC was confirmed by flow-cytometry (47.3% to 96.9%). Results showed that 
the abnormality rate of EPC (74%) was doubled compared to UPC (34%) for FISH, and 
CA displayed 100% (37/37) success rate using the discarded myeloid elements. PCD 
related chromosome abnormalities were confined to whole BM whereas non-PCD 
related abnormalities were found in both whole BM and discarded myeloid elements 
confirming effective removal of PCs by isolation and efficient utility of the supernatant 
for CA. Significantly higher frequency of IGH rearrangements (36%) and hyperdiploidy 
(24%) was observed in the EPC group compared to the UPC group (11% for both). 
Conclusions: Our results confirm the superior diagnostic potential of selecting PCs 
and demonstrate the feasibility of using the remaining myeloid elements for CA. 
 
H09. Conversion of a BCR-ABL1 Laboratory Developed Test (LDT) to the 
Standardized International Scale (IS) 
C.I. Dumur, F. Sabato, P. Morris, D.S. Wilkinson, A. Ferreira-Gonzalez 
Virginia Commonwealth University, Richmond, VA. 
Introduction: The International Randomized Study of Interferon vs STI571 (IRIS) trial 
for treatment of chronic myeloid leukemia (CML) and monitoring of residual disease 
determined that the achievement of major molecular response (MMR) corresponded to 
a 3-log decrease in BCR-ABL1 expression from a standard baseline level. Recently, an 
international scale (IS) linked to the standard baseline level (which corresponds to 
100% IS) from the IRIS trial was established. Accordingly, MMR corresponds to 0.1% 
IS. However, a wide variety of pre-analytical, analytical and reporting methods have 
been historically used among different laboratories for the quantitation of the expression 
levels of BCR-ABL1 fusion transcripts. Recently, a reference panel was developed by 
the WHO with the purpose of calibrating secondary reference materials, which are 
manufactured in large scale and are commercially available to laboratories worldwide. 
The purpose of this study was to convert our existing assay to reporting in the IS. 
Methods: Two standards (high and low levels of BCR-ABL1 transcript) used in our LDT 
were run in quadruplicate on 3 independent runs using the BCR-ABL Mbcr IS-MMR kit 
from IPSOGEN, which provides one IS calibrator calibrated to the international 
reference panel at the MMR level. Also, 25 CML patient RNA samples, previously 
analyzed on our LDT were re-run using the BCR-ABL Mbcr IS-MMR kit. The results 
obtained for these patient samples were compared to re-calculated previous titers, 
using IS-converted LDT standard values. The IS being a non-linear scale, the IS-Log10 
values were used for all the analyses. Results: The LDT high standard was calculated 
as 12.92 ± 0.69 %IS and the LDT low standard was calculated as 0.14 ± 0.02 %IS. The 
inter-run coefficients of variation for the high and low standards were 5.38% and 
11.06%, respectively. An excellent correlation (Pearson’s r = 0.979) was observed for 
the results obtained for the 25 patient samples compared to re-calculated previous 
titers, using IS-converted LDT standard values. Also, a Bland-Altman analysis showed 
a mean bias of -0.35, with 95% limit of agreement of ± 4.9-fold. Conclusions: Our 
results strongly support the use of a secondary reference material traceable to the 
WHO reference panel to calibrate LDTs to the IS to enable the standardization of 
quantitative BCR-ABL1 testing results for the determination of MMR. The use of such 
reference material allows for semi-annual monitoring of an LDT performance, including 
calibration verification. 
 
H10. COLD-PCR Re-Analysis of Myleodysplastic Syndrome Samples Reveals 
Previously Undocumented Low-Level Point Mutations in the NRAS Oncogene  
D.M. Murphy, R. Bejar, B.L. Ebert, G.M. Makrigiorgos 
Dana-Farber Cancer Institute, Boston, MA. 
Introduction: Myelodysplastic syndromes (MDS) are a group of hematopoietic 
disorders characterized by inefficient hematopoiesis, cytopenias, and an increased risk 
of progression to acute myeloid leukemia (AML). Current prognostic scoring methods 
for MDS use clinical features and karyotypic abnormalities to stratify patients into risk 
groups according to the International Prognostic Scoring System (IPSS). However, 
samples with identical chromosomal abnormalities often have varied clinical outcomes 
indicating additional heterogeneity among patients with same IPSS score. Somatic 
mutations have also been implicated as drivers of clinical phenotypes. A recent analysis 
(Bejar et al, N Engl J Med 364, 2496-2506, 2011) revealed that somatic point mutations 
in a cluster of genes are associated with poor outcome and are strong prognostic 
factors. It is still not clear, however, whether rare sub-clones containing these point 
mutations at levels below the mutation detection limit can influence clinical phenotype. 
Although NGS and MALDI are powerful technologies for high-throughput mutation 
analysis, MDS samples are often genetically heterogeneous. This can result in low-
abundance somatic mutations falling below the current NGS/MALDI detection limit. To 
increase the sensitivity of the MDS mutation analysis, we employed COLD-PCR (co-
amplification at a lower denaturation temperature) a form of PCR that preferentially 
amplifies mutation containing sequences over wild-type alleles. Methods: We focused 
on detecting low-level mutations within NRAS, an oncogene associated with a shorter 
survival period and increased risk of progression to AML in MDS patients. After 
selecting a group of 295 MDS patients that had a Low/Intermediate-1 risk according to 
IPSS, we examined samples from 87 patients with the shortest overall survival. We 
then used highly sensitive COLD-PCR combined with High-Resolution-Melting analysis 
followed by Sanger sequencing to screen for NRAS mutations in DNA from these 87 
samples. This approach allowed for the detection of low-level mutations down to an 
abundance of 0.5%. Results: Our analysis revealed additional point mutations in exon 
2 of the NRAS oncogene in 11 of the 87 samples analyzed. Six of these mutations were 
lower level mutations (0.5-5% abundance) that had been missed by the previously 
employed techniques. Conclusions: COLD-PCR-based analysis of MDS patient 
samples increases the sensitivity of regular screening approaches and allows for the 
detection of clinically significant low-level mutations that are potential biomarkers with 
prognostic significance. Future experiments will determine the prevalence of other 
specific mutations that are below detection by other technologies, and will try to 
determine whether any identified mutations alter the clinical phenotype of the disease. 
 
H11. A Novel Method for BRAF V600E Allele Quantitation by Allele-specific 
PCR using a Single-Concentration Heterozygous Control Plasmid and No 
Standard Curve 
P. Szankasi1, N.S. Reading1, J.T. Prchal2, T.W. Kelley2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: Activating oncogenic mutations occur in many genes and often cluster in 
small numbers of affected codons. In several instances predominant mutations affect a 
single codon with a recurring DNA change. With such scenarios, alternatives to 
classical DNA sequence analysis, such as allele-specific PCR (AS-PCR), are faster, 
cheaper, and more sensitive for routine analysis in the clinical laboratory. AS-PCR has 
the additional ability to accurately quantify mutant alleles over a wide range of 
concentrations for monitoring response to therapy and for detecting minimal residual 
disease. Here we describe a TaqMan-based AS-PCR test for the BRAF V600E 
mutation that does not require the generation of standard curves for accurate and 
reproducible allele quantitation. Methods: A standard AS-PCR design with a TaqMan 
probe was run on the Roche LC480 real time PCR instrument. A heterozygous control 
plasmid containing one wild type and one mutant sequence was run at a single 
concentration as a reference standard with each run. This plasmid is representative of a 
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sample with exactly 50% mutant allele and the crossing points obtained by AS-PCR, 
together with the PCR efficiency, are used to calculate the percentage mutant allele in 
patient samples. Results: We used this test to evaluate the BRAF V600E mutant allele 
burden in hairy cell leukemia samples. We found that the test has a linear range 
between 100% and 0.1% mutant allele. The concentration of the heterozygous control 
plasmid used for calibration is not critical for accurate allele quantitation. Thus, this 
method is not subject to pipetting errors that can negatively affect controls used for the 
generation of standard curves. The results obtained by this method were in good 
agreement with those from classical allele quantitation using standard curves. 
Conclusions: We describe a quantitative AS-PCR test for the BRAF V600E mutation 
that uses a heterozygous control plasmid for data calibration thereby eliminating the 
need for generating standard curves with known plasmid copy number.  
 
H12. Prognostic Significance of Co-Expression of ERG, MN1 and BAALC
Genes by RT-qPCR in Cytogenetically Normal Acute Myeloid Leukemia 
Specimens 
K. Deeb, N. Risch, K. Attwood, M. Wetzler, E. Wang, P. Starostik 
Roswell Park Cancer Institute, Buffalo, NY. 
Introduction: The prognostic impact of cytogenetic abnormalities, gene mutations and 
gene expression has been established in acute myeloid leukemia (AML), and such 
distinct abnormalities may define individual AML entities. Recently, specific gene 
expression signatures allowed for identification of prognostically important subgroups of 
AML, particularly in cytogenetically normal AML (CN-AML). Aberrant expression of 
genes important for proliferation, survival and differentiation has been shown to affect 
outcome in CN-AML. High expression level of BAALC (brain and acute leukemia, 
cytoplasmic), ERG (v-ets erythroblastosis virus E26 oncogene homolog, avian), MN1 
(meningioma [disrupted in balanced translocation] 1), WT1 (Wilm’s tumor gene) and 
EVI1 (ecotropic virus integration 1) genes in CN-AML is associated with poor prognosis 
for each gene. In this study, we developed a multiplex RT-qPCR quantitative assay to 
determine expression levels of the BAALC, ERG, MN1, WT1 and EVI1 genes in a 
cohort of CN-AML patients, and to evaluate whether co-expression of these genes, in 
comparison to individual genes, could have relative importance in CN-AML patient 
outcome. Methods: Total RNA was isolated from cytogenetically normal AML bone 
marrow specimens (n=96), normal controls consisting of peripheral blood (n=15) and 
bone marrow aspirates (n=15), and cell lines (n=15). RNA was reverse transcribed into 
cDNA that was amplified in Taqman-based real-time qPCR. BAALC, ERG, EVI1, MN1, 
and WT1 transcripts levels were quantified relative to the TBP transcript control, which 
also served as a control for RNA quality. Gene expression results were correlated with 
patient survival data in univariate and multivariate analyses. Results: Univariate 
analysis of BAALC, ERG, EVI1, MN1 and WT1 transcript levels in CN-AML 
demonstrated a significant correlation between higher BAALC, ERG and MN1 
expression and poorer overall survival (p=0.006, p=0.004, p=0.017, respectively; 
unadjusted Log-rank test). EVI1 and WT1 levels were not significantly associated with 
patient survival in this study. A multivariate analysis of the co-expression of three gene 
transcripts (BAALC, ERG, and MN1 but not WT1 and EVI1) showed a significant 
correlation between higher gene expression and inferior overall survival. Conclusions: 
We established a multiplex RT-qPCR assay to determine the expression of several 
genes shown to impact prognosis in CN-AML. High co-expression levels of BAALC, 
ERG and MN1 genes can be used as a negative prognostic factor in this patient cohort. 
In conjunction with analysis of specific mutations, eg, FLT3, NPM1 and CEBPA, they 
may impact future clinical management in CN-AML.  
 
H13. Cereblon Expression is Heterogeneous in Follicular Lymphoma and 
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 
A.P. Matynia1, J. Schumacher2, P. Szankasi2, E.D. Hsi 3, T.W. Kelley1 
1University of Utah, Salt Lake City, UT; 2ARUP Laboratories, Salt Lake City, UT; 
3Cleveland Clinic, Cleveland, OH. 
Introduction: A subset of patients with follicular lymphoma (FL) and chronic 
lymphocytic leukemia/small lymphocytic lymphoma (CLL) respond to treatment with 
thalidomide and related immunomodulatory drugs (IMiDs) such as lenalidomide. 
However, a marker to predict and monitor response to IMiD therapy remains elusive. 
Recently, the E3 ubiquitin ligase cereblon (CRBN) was identified as the putative binding 
target for IMiDs in plasma cell myeloma and the level of CRBN expression appears to 
correlate with response to therapy. Known targets of cereblon activity important for B-
cell differentiation and function include interferon regulatory factor-4 (IRF4/MUM1). 
Given the established activity of IMiDs in B-cell lymphoproliferative disorders, we 
investigated CRBN expression in 58 cases of FL and 46 cases of CLL/SLL, to establish 
baseline expression levels in an effort to determine the suitability of CRBN as a 
treatment response marker. Methods: We performed a search of our in-house 
database for FL (2007-2012) and CLL/SLL (2002-2012) cases, and identified 58 FL and 
46 CLL/SLL cases with available formalin-fixed-paraffin-embedded tissue blocks. Total 
RNA was extracted using RNeasy FFPE kit (Qiagen) and reverse transcribed using 
SuperScrip III First-Strand Synthesis System for RT-PCR (Invitrogen). Quantitative 
PCR (qPCR) was performed using TaqMan Universal PCR Master Mix with 
predesigned primers and hydrolysis probes (Applied Biosystems) on a LightCycler 480 
Real-Time PCR System (Roche). All qPCR reactions were performed in duplicate. 
CRBN expression was normalized to mean expression of the reference genes GAPDH 
and TBP. Furthermore, a subset of cases of FL and CLL were stained by 
immunohistochemistry for MUM1/IRF4 to assess potential correlations with CRBN 
expression. Results: Expression data was analyzed for 50 cases of FL and 39 cases of 
CLL. The remaining samples failed for technical reasons. There was a spectrum of 
CRBN expression across all samples with marked differences between cases with ‘low’ 
and ‘high’ expression of up to 18-fold in FL and up to 30-fold in CLL. There was no 
correlation between the grade of FL and CRBN expression. Semi-quantitative analysis 
of MUM1/IRF4 expression by immunohistochemistry was heterogeneous in both FL and 
CLL/SLL and did not correlate with CRBN expression by qPCR. Conclusions: The 
heterogeneity of CRBN expression in FL and CLL/SLL supports the selection of CRBN 
as a candidate marker of treatment response to thalidomide and related 
immunomodulatory drugs. Initial studies indicate no correlation between CRBN 
expression and other tumor features such as grade, in FL, or expression of the 
downstream target IRF4/MUM1. More detailed analyses are ongoing. 
 
H14. Metabolomic Analysis of NPM-ALK Lymphoma Cell Lines 
S.R. McDonnell, A. Raskind, C. Ruan, C.F. Burant, K.S. Elenitoba-Johnson, M.S. Lim 
University of Michigan, Ann Arbor, MI 
Introduction: Anaplastic large cell lymphoma (ALCL) is an aggressive form of non-
Hodgkin lymphoma often characterized by the expression of the fusion protein 
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The constitutive activation of 
the ALK kinase induces multiple downstream growth regulatory proteins such as the 
PI3K/AKT, JAK/STAT, and PLCȖ that results in enhanced proliferation and resistance to 
apoptosis. Recent studies have shown that tyrosine kinase signaling pathways can 
regulate cellular metabolism to promote cell growth (Warburg effect). Therefore, we 
hypothesized that NPM-ALK elicits global metabolic regulation to promote the Warburg 
effect. Methods: To determine the role of NPM-ALK in regulating cellular metabolism, 
we evaluated the metabolomic changes that occurred as a result of ALK inhibition using 
gas chromatography-mass spectrometry (GC-MS) and positive and negative mode 
liquid chromatography-mass spectrometry (LC-MS). Metabolite data were gathered 
after six hours of chemical inhibition of ALK from cell lysates of four ALCL derived cell 
lines, all analyzed in biological quintuplicate. Results: The analysis resulted in 
quantification of >7000 mass spectral features with >500 of these as identifiable 
metabolites. Cluster analysis revealed that ALK inhibition results in a statistically distinct 
metabolic status. Metabolic pathway analysis tools identified that glucose, nucleotide 
and lipid metabolism were significantly altered upon ALK inhibition. Many metabolites 
were significantly altered by ALK inhibition, including fructose-bisphosphate, guanosine 
and glycerophosphocholine. Furthermore, 13C-glucose flux analysis revealed that 
NPM-ALK signaling increased glycolysis, pentose phosphate pathway, and lactate 
production while decreasing ATP production. Conclusions: These data show that 
NPM-ALK signaling is associated with a distinct metabolic profile and may induce a 
metabolic switch toward a Warburg effect in which biomass production is upregulated 
while energy production is downregulated. Future studies to understand the mechanism 
of how NPM-ALK drives the Warburg effect and subsequent cell growth will lead to 
identification of novel therapeutic targets for ALK-driven neoplasms. 
 
H15. Optimization of a Q-RTPCR Assay for Identification of Multiple BCR-Abl1
Transcripts from Degraded RNA Specimens 
S. Verma, P.D. Cotter, M.W. Moore 
Custom Diagnostics, Irvine, CA. 
Introduction: Q- RTPCR is the method of choice for monitoring BCR-Abl1 transcripts 
in CML and ALL. The majority of transcripts are comprised of the three typical variants 
(e1a2, e13a2 and e14a2). However, a number of atypical BCR-Abl transcripts (e1a3, 
e13a3, e14a3, e19a3, e19a2, e6a2, etc.) were also reported. Most current q-RT-PCR 
kits for detecting BCR-Abl1 are designed and optimized for detecting the three typical 
breakpoint variants. Other transcripts may also be detected by these methods but very 
large PCR products are involved and therefore mostly escape detection. Moreover, the 
sensitivity and accuracy of detecting typical transcripts is dependent on the quality of 
sample RNA that is variable depending on when the patient sample was received. In 
typical clinical settings, in the time from blood draw to receipt in the laboratory, a 
significant percentage of RNA has been degraded, significantly decreasing the 
sensitivity of current qRT-PCR assays. Methods: A Taqman probe-based multiplex q-
RTPCR assay was designed to detect all currently known BCR-Abl1 fusion transcripts 
and to monitor them with high sensitivity in clinical settings. The following design criteria 
were used, a) for increased sensitivity, primers were designed to yield an amplicon 
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between 70-80 bp size. b) for increased specificity, primers are designed at the junction 
of BCR and Abl1 for different fusion transcripts. c) Abl1 was used for normalization to 
reduce variation resulting from the differential rate of transcript degradation. Results: 
54 samples were analyzed for accuracy and showed 100% concordance between the 
test and a reference assay. 20 samples were analyzed for repeatability and 
reproducibility and showed 100% concordance. 24 positive sample results were 
compared to the reference assay and correlation of the two assays showed a linear 
relationship. The CT values of the Abl1 gene were compared between the reference 
and test assays and the average increase in assay sensitivity was 272-fold, or 
approximately 8 cycles, for the new assay. The quantitation limit for all the fusions was 
100 copies or less and detection limit for all the fusions was 10 copies or less. This new 
assay was challenged with 14 QNS samples. 12/14 samples obtained quantifiable 
results, whereas no results were obtained by reference assay. Conclusions: This new 
BCR-Abl1 assay is highly sensitive and specific and able to detect all known BCR-Abl1 
fusion transcripts in clinical samples. 
 
H16. Analytic and Diagnostic Performance of Two Allele-specific PCR Assays 
for the Clinical Detection of BRAF V600E in Hairy Cell Leukemia 
N.A. Brown1, H.C. Weigelin1, N.G. Bailey1, J. Laliberte2, K.S. Elenitoba-Johnson1, M.S. 
Lim1 
1University of Michigan, Ann Arbor, MI; 2Swift Biosciences, Ann Arbor, MI. 
Introduction: Hairy cell leukemia (HCL) is a mature B-cell neoplasm with characteristic 
clinical and immunophenotypic features. Detection of high frequency BRAF V600E 
mutations in classic HCL has important diagnostic and therapeutic implications. Thus, 
the development and assessment of sensitive and specific assays for the detection of 
BRAF V600E from routine clinical material in a molecular diagnostic laboratory setting 
are clearly warranted. In this study, we sought to determine the analytic and diagnostic 
performance of two allele-specific polymerase chain reaction (PCR) assays for the 
detection of BRAF V600E in HCL and its variants in formalin-fixed paraffin embedded 
(FFPE) bone marrow (BM) aspirate clots and frozen cell pellets. Methods: 29 cases of 
classic HCL were retrospectively identified, including 22 FFPE BM aspirate clots and 7 
frozen cell pellets from blood or BM. Also included were 6 HCL-variant cases and 40 
non-hairy cell mature B-cell lymphomas. Each specimen was evaluated using a 
laboratory developed allele-specific PCR assay for the BRAF V600E and V600K 
mutations and a commercially available allele-specific quantitative PCR assay –myT 
BRAF Ultra (Swift Biosciences). Results: The BRAF V600E mutation was detected in 
27 of 29 HCL cases (93.1%). The diagnostic sensitivity of the laboratory developed 
assay and the commercial assay was 92.6% (18/20 FFPE; 7/7 frozen) and 85.2% 
(16/20 FFPE; 7/7 frozen) respectively. Both assays showed a specificity of 100% (0/46 
non-HCL) and an analytic sensitivity of 0.3% by flow cytometry (0.1% by quantitative 
PCR) in frozen specimens and less than 5% by immunohistochemistry (0.3% by 
quantitative PCR) in FFPE. A diagnostic specimen from a HCL case harbored the 
V600E mutation at low level (0.7% mutant allele).The V600K mutation was absent in all 
cases. Two cases (6.9%) were negative for V600E by both assays in spite of high level 
leukemic involvement and excellent amplification of wild-type BRAF. Of these, one was 
CD5+ whereas the other was CD5-. Conclusions: Allele-specific PCR-based assays 
offer a sensitive and specific avenue for detection of the BRAF V600E mutation in 
routine clinical samples including BM clot sections. myT BRAF Ultra offers the 
advantage of being a single tube assay able to quantify the percentage of mutant BRAF 
relative to wild-type. Although both assays offer the ability to detect BRAF V600K 
mutations, such mutations were not identified in HCL or in other B-cell non-Hodgkin 
lymphomas. In this cohort, two cases were negative for V600E, one of which showed 
expression of CD5. 
 
H17. Clonality Analysis By Ig/TCR Rearrangements Using BIOMED-2 
Fluorescent Multiplex PCR Assays for Detecting Minimal Diseases of Lymphoid 
Malignancies in 585 Bone Marrow Aspiration Specimens 
G. Lee, J. Kim, S. Lee, J. Kim, Y. Shim, J. Park, M. Kim, Y. Kim, K. Han, J. Lim 
The Catholic University of Korea College of Medicine, Republic of Seoul, Korea. 
Introduction: Multiplex PCR assays with BIOMED-2 primers have been used as 
reliable tools for clonality assessment in a suspected lymphoproliferation. The detection 
of minimal diseases in bone marrow (BM) of lymphoid malignancies is important to 
determine stage of disease and choose more effective treatment options. This study 
was performed to evaluate the usefulness of clonality assay for detecting BM minimal 
diseases of lymphoid malignancies in molecular level. Methods: The clonality analysis 
using fluorescent multiplex PCR assays (InVivoScribe Technologies, San Diego, CA) 
was performed in 585 BM aspiration specimens of patients with 491 B-lymphoid 
malignancies (B-LM) and 94 T-lymphoid malignancies (T-LM). The assay targets were 
IGH, IGK, IGL, TCRG, TCRB, and TCRD genes. The results obtained from GeneScan 
fragment analysis with GeneMapper Software v4.1 (Applied Biosystems, Foster City, 
CA). The morphologic examinations of BM smear under the microscope were done in 
all cases for assessing BM invasion. Results: Ig rearrangement was detected in 78.8% 
in 104 B-LM with BM invasion including 59.6% IGH, 74.0% IGK, and 20.2% IGL 
whereas 16.3% in 387 B-LM without BM invasion including 9.8% IGH, 12.9% IGK, and 
2.8% IGL. IGK is the most common locus of Ig rearrangement in B-LM. TCR 
rearrangement was detected in 60.0% in 25 T-LM with BM invasion including 48.0% 
TCRG, 24.0% TCRB and 16.0% TCRD whereas 52.2% in 69 T-LM without BM invasion 
including 44.9% TCRG, 21.7% TCRB and 14.5% TCRD. TCRG is the most common 
locus of TCR rearrangement in T-LM. The cases of T-LM without BM invasion were 
higher detection rate than in B-LM without BM invasion. The distribution of Ig/TCR 
rearrangements was diverse in different disease entities including 16.1% IGH, 20.1% 
IGK, and 4.3% IGL in 279 DLBCL, 7.4% IGH, 13.9% IGK and 0.9% IGL in 108 MALT 
lymphoma, 63.6% IGH, 72.7% IGK and 27.3% IGL in 22 CLL/SLL, 26.7% IGH, 46.7% 
IGK and 6.7% IGL in 15 follicular lymphoma, 43.3% TCRG, 30.0% TCRB and 26.7% 
TCRD in 30 PTCL, 52.0% TCRG, 24.0% TCRB and 12.0% TCRD in 25 extranodal 
NK/T-cell lymphoma, nasal type, 56.5% TCRG, 17.4% TCRB and 0% TCRD in 23 T 
lymphoblastic leukemia/lymphoma. Conclusions: Ig/TCR rearrangements are diverse 
in the status of morphologic BM invasion and different disease entities. The detection 
rate of BM invasion is enhanced with combination of BIOMED-2 multiplex PCR assays 
and it may provide a powerful strategy in the assessment BM minimal disease in 
patients with lymphoid malignancies. 
 
H18. Prevalence of MPL Gene Mutations in Myeloproliferative Neoplasms and 
Acute Myeloid Leukemias Using Pyrosequencing 
G. Insuasti-Beltran1, J.M. Gale2, M.A. Vasef1 
1University of New Mexico, Albuquerque, NM; 2Tricore Reference Laboratories, 
Albuquerque, NM. 
Introduction: Mutations in the thrombopoetin receptor gene (myeloproliferative 
leukemia gene/MPL) have been identified in a low percentage of patients with JAK2 
V617F-negative myeloproliferative neoplasms (MPN) and some cases of acute myeloid 
leukemias (AML), in particular acute megakaryoblastic leukemia (AMKL) subtype. We 
evaluated the prevalence of MPL gene mutations in our population of MPN and AML 
using pyrosequencing technology as a more sensitive alternative to traditional Sanger 
sequencing. Methods: A total of 143 cases were retrieved from our archived pathology 
files and were analyzed for the presence of MPL exon 10 mutations using 
pyrosequencing. The cases included 63 cases of previously characterized AML and 80 
MPNs. The MPN cases included: 28 essential thrombocythemia (ET), 30 primary 
myelofibrosis (PMF), 21 myeloproliferative neoplasm, unclassifiable, and one case of 
polycythemia vera. Results: MPL mutations were identified in 5 out of 80 (6%) of MPN 
cases including 3 ET and 2 PMF. All the mutated cases (5/5) demonstrated the 
TGG>TTG resulting in substitution of tryptophan for leucine in codon 515 (W515L) of 
the MPL gene. All five cases were negative for the JAK2 V617F mutation. No MPL 
mutations were identified in any of AML cases including 7 cases of AMKL subtype. 
Conclusions: Our results indicate that the overall prevalence of MPL gene mutations, 
using pyrosequencing, in myeloproliferative neoplasms (MPN) is low (6%). In addition, 
MPL mutations appear to be restricted to only JAK2 V617F-negative cases with 
essentially similar prevalence in both essential thrombocythemia and primary 
myelofibrosis. MPL mutations were not detected in our AML cases indicating that these 
mutations are rare in acute myeloid leukemias. Our results confirm and further expand 
the prior observations by other investigators. Based on our results, the MPL gene 
mutation analysis should be performed in all JAK2 V617F-negative suspected MPN 
cases.  
 
H19. A Comparison of Two p210 BCR/ABL1 gRT-PCR Methods, One 
Commercial and One Laboratory Developed, Reporting on the International Scale 
(IS) 
A.E. Shrimpton, C. Lamberson 
SUNY Upstate Medical University, Syracuse, NY 
Introduction: In the US, quantitative p210 BCR/ABL1 testing is performed by a variety 
of laboratory-developed (LD) tests or commercially available assay systems. 
Quantitative results generated by different testing laboratories are generally not directly 
comparable. In an effort to standardize quantitative BCR/ABL1 results across testing 
laboratories, reporting of results on an International Scale (IS) has been proposed. 
Briefly, using reference materials with known %IS values, a conversion factor is 
determined that converts the “local” assay’s quantitative results to a percent on the IS 
(%IS). The CAP 2011 MRD-B survey was the first survey to include reporting on the IS. 
For sample MRD-06, the mean %IS + 1SD based on 23 reporting labs was 0.038% + 
0.049%. The large standard deviation that was observed with %IS results for sample 
MRD-06 prompted us to question the overall success of current efforts to achieve 
standardized reporting on the IS. Methods: Our laboratory-developed assay is based, 
with slight modification, on the published EAC protocol. We use ABL1 as the control 
gene and derived our IS conversion factor using the e14a2 ARQ IS Calibrator Panel 
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(Assuragen Inc., Austin, TX). The BCR-ABL Mbcr IS-MMR kit (Ipsogen, Inc., Marseille, 
France) is a commercially available test system; it also employs ABL1 as the control 
gene and includes a single point calibrator for reporting results on the IS. Using 11 
archived RNA samples with normalized BCR-ABL1 to ABL1 ratios of less than 10%, we 
compared the %IS results obtained with our laboratory developed assay to those 
obtained using the Ipsogen IS-MMR kit. Results: Data from 9 samples met the 
acceptance criteria for both assays. The %IS results obtained with our LD assay and 
laboratory-specific conversion factor were consistently higher than the %IS results 
obtained using the Ipsogen IS-MMR kit. Fold differences ranged from 2.12 to 9.03 fold. 
Conclusions: One purpose of IS reporting is to minimize the effect of qRT-PCR 
method variables on BCR/ABL1 quantitative results. In that respect, the range of fold 
difference seems high. When determining an IS scale conversion factor, it is desirable 
for all %IS results to fall within + 2.5 fold of the “true” value. Even assuming that the two 
assays represent the upper and lower fold differences from the true %IS value, the fold 
difference between individual results should not exceed 5. With our limited data set, this 
was true for 6/9 samples. 
 
H20. Detection of Complete and Incomplete IGH Gene Rearrangements in Non-
Hodgkin Lymphomas by BIOMED-2 PCR Primers 
A. Nazarullah, Y. Wang, K. Vadlamudi, M.C. Kinney, W. Furmaga, H. Fan 
The University of Texas Health Science Center at San Antonio, San Antonio, TX. 
Introduction: BIOMED-2 immunoglobulin heavy chain (IGH) gene rearrangement 
assays are widely used in the diagnosis of lymphoproliferative disorders, and include 
reactions for complete VH-JH (Tubes A,B,C for FR 1,2,3) and incomplete DH-JH 
(Tubes D,E) rearrangements. Most clinical molecular diagnostic laboratories only report 
VH-JH rearrangement results due to difficulty in interpretation of DH-JH assay results. 
DH-JH rearrangements are useful for clonality detection in mature B-cell lymphomas 
with higher rates of somatic hypermutation, in B-cell lymphoblastic leukemia/lymphoma 
(ALL), as well as immature T-cell malignancies. We evaluated the BIOMED-2 IGH 
assays in fresh/frozen and formalin-fixed paraffin-embedded (FFPE) tissue of patients 
with non-Hodgkin lymphomas (NHL). Methods: During the period 01/2009 - 04/2012, 
IGH gene rearrangement assays were performed on 236 samples that included 68 
fresh/frozen (15 blood, 47 bone marrow, and 6 other), and 168 FFPE (102 skin, 31 
lymph node and 35 other). DNA was extracted using the BioRobot EZ1 workstation with 
EZ1 DNA Tissue Kit (Qiagen) for FFPE, and the PUREGENE DNA Purification Kit 
(Gentra Systems) for fresh/frozen samples. IGH gene rearrangement detection was 
performed by IGH Gene Clonality Assay Kit (InVivoScribe Technologies) and capillary 
gel electrophoresis (Applied Biosystems 3130xl Genetic Analyzer). Results were 
analyzed by GeneMapper software. VH-JH assays were performed in all 236 cases, 
whereas DH-JH assays were performed in 67 cases. Results: Clonal VH-JH 
rearrangements were detected in 49% (117/236) of total samples and 0/15 of reactive 
cases. Among 65 cases with conclusive diagnosis of a specific NHL, clonal VH-JH 
rearrangements were detected in 83% (54/65) cases (25/27 fresh/frozen and 29/38 
FFPE); and clonal DH-JH rearrangements were detected in 57% (37/65) cases (17/27 
fresh/frozen and 20/38 FFPE). 5 cases were DH-JH positive only (VH-JH negative) 
including marginal zone lymphoma (2/5), chronic lymphocytic leukemia/small 
lymphocytic lymphoma (2/5) and follicular lymphoma (1/5). Among the 30 skin FFPE 
samples with NHL, clonal VH-JH were detected in 73% (22/30) and DH-JH in 53% 
(16/30) samples. For all IGH positive samples, duplicate assays exhibited identical 
clonal peak patterns. Conclusions: Using BIOMED-2 IGH primers, clonal IGH 
rearrangements were detected in 91% (59/65) NHL cases, with 93% (25/27) using 
fresh/frozen samples, and 89% (34/38) using FFPE samples, including 87% (26/30) 
detection rate in skin FFPE samples with NHL that are technically more difficult. 
Combined use of DH-JH rearrangement is useful and increases IgH clonality detection 
in NHL by approximately 8%. 
 
H21. Clinical Evaluation of a Commercially Available Assay for Quantification 
of BCR/ABL1 Fusion Transcripts 
J.A. Woolworth1, K.G. Church1, M.L. Cremona2, V.S. Aggarwal2, D.J. Wolff1, F.S. Nolte1 
1Medical University of South Carolina, Charleston, SC; 2Columbia University Medical 
Center, New York, NY. 
Introduction: The monitoring of the BCR/ABL1 fusion transcripts is useful in patients 
with chronic myelogenous leukemia to assess response to tyrosine kinase inhibitor 
(TKI) therapies. Here, we report the clinical evaluation of a multiplex, reverse-
transcription, real-time PCR assay designed to detect and quantify three BCR/ABL1 
fusion transcripts (BCR/ABL1 Quant (RUO), Asuragen, Austin, TX). Methods: Blood 
samples from 48 patients were collected and compared to results from national 
reference laboratories. Twenty-three specimens had detectable levels of a BCR/ABL1 
fusion transcript, whereas 25 specimens had no fusions transcripts detected. The assay 
was designed to amplify and detect the two major BCR/ABL1 fusion genes b2a2 and 
b3a2, and the minor fusion gene e1a2, the ABL1 gene (endogenous control) and a 
fusion transcript exogenous control (BCR/ABL1 Quant Norm). In addition to positive 
and negative percent agreement, we also evaluated precision, dynamic range, 
international scale (IS) conversion using the Asuragen armored RNA IS calibrator 
panel, and exchanged 12 specimens (5 positive and 7 negative) with two other test 
sites using the Asuragen assay. Results: Compared to the reference laboratory results, 
our local results had a positive and negative percent agreement for detection of a fusion 
transcript of 100% and 86.2%, respectively. The inter-assay coefficient of variation (CV) 
was 23.55% for the ratio of BCR/ABL1 to ABL1. The local international scale 
percentage (IS%) conversion factor was determined and the local IS% were compared 
to the reference laboratory IS% with a log10 difference 0.53 for all samples and a 
mean log10 difference of 0.21. Comparison of BCR/ABL1 to ABL1 ratios between three 
sites using the Asuragen assay revealed a 30.80% CV for the 5 positive samples. 
Conclusions: The Asuragen assay was found to be accurate and reproducible in 
determining the presence of BCR/ABL1 fusion transcript and the ratio of BCR/ABL1 
fusion transcript to ABL1 endogenous control transcript. The comparison of 
international scale percentage values was also found to be similar between the local 
site and reference laboratories.  
 
H22. “Calling Cards,” a Novel Approach for Identifying Transcription Factor-
DNA Interactions, Uncovers AML-Related HOXA9-NUP98 Fusion Product Targets 
G.A. Bien-Willner, A. Takeda, D. Mayhew, R. Mitra, N.R. Yaseen 
Washington University, St. Louis, MO. 
Introduction: The NUP98-HOXA9 fusion product is an aberrant transcription factor that 
has been described in a subset of acute myeloid leukemia patients. It is leukemogenic 
in mice, and has been shown to induce cell proliferation and prevent differentiation in 
human and mouse hematopoietic precursors. The identification of the targets of such 
oncogenic fusion proteins is critical to the progress of personalized medicine as it may 
help aid therapy in a tumor genotype-specific manner. However, few targets of this 
aberrant transcription factor have been fully elucidated. This is in part because current 
methods of large-scale identification of DNA-protein interactions rely heavily on quality 
antibodies that may not be available or easy to produce, and because timing of 
experiments may miss such interactions depending on the activity of the onco-protein in 
the cell cycle. Methods: “Calling Cards” is a novel approach to identify transcription 
factor binding sites genome-wide with the aid of cellular machinery that is native to the 
cell: transposable elements and transposases. Briefly, the eukaryotic PiggyBac (PB) 
transposase is fused to the transcription factor of interest, and introduced into a relevant 
cell along with a bar-coded transposon. When the transcription factor binds its target, 
the fused PB induces the insertion of the barcoded transposon into the DNA nearby, 
thus leaving a permanent “calling card” of where it has bound in the genome. The 
NUP98-HOX9A fusion gene was linked to the PB transposase (helper plasmid) and 
transfected into mouse embryonic stem cells (RW4) along with the selectable and 
barcoded transposon (donor plasmid). Transfected cells were then selected, and 
unique sites of integration of the barcoded transposons (i.e., sites of NUP98-HOX9A 
binding) were identified via next-generation sequencing (Illumina HiSeq) and 
subsequent sequence alignment. Results: Over 2300 unique insertion events were 
identified, a vast majority forming clusters in the 5’UTR of known genes. Many of these 
target genes were already known to be associated with leukemia, such as Bag3 and 
Mll3. Two biological replicates, including adding the PB and both the N and C terminus 
of NUP98-HOX9A, yielded similar results. Conclusions: "Calling Cards" is a novel 
technique that can readily identify the targets of transcription factors associated with 
oncogenic translocations. As such, it may be a useful tool for the advancement of 
personalized medicine as it may aid in the identification of unique genes and pathways 
associated with specific cancer genotypes. 
 
H23. Quantitative Detection of BCR-ABL1 Fusion Transcripts by Droplet Digital 
RT-PCR 
L. Jennings, D. George, J. Czech, M. Yu, F. Smith 
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL. 
Introduction: Quantitative detection of BCR-ABL1 fusion transcripts by real-time RT-
PCR (qRT-PCR) is the method of choice for monitoring minimal residual disease in 
patients with CML as well as Ph+ ALL. However, absolute quantification by qRT-PCR is 
difficult because it is not possible to control for variations between the sample and the 
reference material regarding target degradation and reverse transcription or 
amplification efficiency. Most laboratories therefore opt for relative quantification based 
on internal reference genes. This approach has its own problems because the target 
and control gene can vary with regards to expression, degradation, and amplification 
efficiency. On the other hand, digital PCR uses end point detection and avoids 
problems with efficiency, thus allowing absolute quantification. Therefore, we developed 
a digital RT-PCR method (ddRT-PCR) to detect and accurately quantify BCR-ABL1. 
Methods: Primers and probes were designed to identify the BCR-ABL1 p210 fusion 
transcript and a housekeeping gene transcript, GUSB. Serial dilutions were made using 
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total RNA from a BCR-ABL1 positive cell line and a BCR-ABL1 negative cell line. Four 
replicates were made of the following concentrations: 100%, 10%, 1%, 0.1%, 0.01%, 
and 0.001%. Eight replicates of negative cell line RNA were also made for a total of 32 
wells. These samples were tested by 2 technologists using the droplet Digital PCR 
system (Bio-Rad). Results: Absolute quantification of BCR-ABL1 fusion transcripts by 
ddRT-PCR showed linearity (R2=1) with an analytical measurement range spanning 4-
logs and reportable range spanning 5-logs. The coefficient of variation ranged from 4% 
to 22% at the lowest dilution (0.001%). Absolute quantification of GUSB transcripts 
showed a large variation between the positive and negative cell lines (101 and 36 
copies/ ng total RNA, respectively). This large variation highlights one of the challenges 
with relative quantification based on internal reference genes. Conclusions: ddRT-
PCR offers several advantages over qRT-PCR for the detection of fusion transcripts. 
ddRT-PCR uses endpoint detection so efficiency of reverse transcription and 
amplification is not a concern. Thus, standard curve and calculated efficiencies are not 
necessary and the result is given as an absolute copy number for a given volume or 
total RNA. Also, even with a single well the limit of detection is comparable to qRT-PCR 
and the limit of quantification is far better. At the lowest dilution, the coefficient of 
variation was 22% whereas qRT-PCR can vary by up to 300%. In addition, by 
combining wells, the limit of detection and quantification can be improved even more.  
 
H24. In CML Patients Treated with Tyrosine Kinase Inhibitors, BCR-ABL PCR 
Negativity after 18 Months of Therapy, Compared to Major Molecular Response, 
Portends a Superior Progression-Free Survival  
M.H. Luu1, R.D. Press1, C.B. Rempfer2 
1Oregon Health & Science University, Portland, OR; 2Knight Diagnostic Laboratories, 
Portland, OR. 
Introduction: In CML patients treated with TKI’s, the use of quantitative reverse-
transcriptase polymerase chain reaction (RQ-PCR) to measure BCR-ABL transcripts in 
peripheral blood or bone marrow is the consensus method for monitoring therapeutic 
efficacy. Although achieving a major molecular response (MMR; IS < 0.1%) at 18 
months post-TKI is the consensus threshold defining an “optimal” treatment response, 
the additional prognostic value of achieving BCR-ABL PCR-negativity, has not been 
adequately evaluated. In this study, we compared the long-term outcome of patients 
who achieved a major molecular response to those who achieved PCR negativity at 18 
months post-TKI. Methods: The BCR-ABL PCR results of all patients referred for serial 
testing at our medical center from 2001 to 2012 were reviewed. Patients who had an 18 
month post-TKI PCR result at or below 0.1% IS were included in the study, and were 
stratified as either having had a major molecular response (IS < 0.10%) or PCR 
negativity. Long-term follow-up was monitored with serial PCR’s with disease 
progression defined by a loss of MMR (BCR-ABL RNA > 0.1% IS). The statistical test 
for the time-to-event analysis was the Kaplan-Meier method. A Cox proportional hazard 
regression model was used to determine the relative hazard ratio for disease 
progression for the two groups. Results: Of the 100 patients eligible for this analysis, all 
(100%) received imatinib as initial leukemia treatment. There were 52 males to 48 
females. At 18 months post-TKI, 49 patients had an MMR compared to 51 patients with 
PCR negativity. The mean interval PCR monitoring was 3.6 months in the MMR group 
compared to 3.8 months in the PCR negative group (p = 0.14). The mean post-TKI 
follow up for the MMR group was 92.2 months compared to 87.4 months for the PCR 
negative group (p = 0.52). 23 patients (47.1%) in the MMR group experienced disease 
progression compared to 8 patients (15.7%) in the PCR negative group. The 
progression free survival for the PCR-negative patients was significantly prolonged 
(median not reached) compared to that of the MMR patients (median post-TKI survival 
= 64 months; log-rank P < 0.001). The hazard ratio for disease progression for patients 
in the MMR group was 4.6 (95% confidence interval: 2.1 to 10.3) relative to the PCR 
negative group (Cox p = 0.002). Conclusions: The achievement BCR-ABL PCR 
negativity at 18 months post-TKI predicts a significantly better long-term clinical 
outcome than does the achievement of MMR alone.  
 
H25. Genomic Analysis by Array Comparative Genomic Hybridization of 
Primary Myelofibrosis with Isolated del(13q) 
G. Lu1, K.P. Patel1, R.N. Miranda1, L. Medeiros1, T. Chen2, B.M. Mishra1, R. Abraham1, 
R. Muddasani1, R. Luthra1 
1UT MD Anderson Cancer Center, Houston, TX; 2Tulane University School of Medicine, 
New Orleans, LA. 
Introduction: The genetic features of primary myelofibrosis (PMF) are poorly 
understood. We identified a subset of patients with PMF who harbored isolated 
del(13q), suggesting this chromosomal region as a potential site of genes that may be 
involved in pathogenesis of PMF. We therefore analyzed these cases by using array-
based comparative genomic hybridization (aCGH) to identify deletion boundaries and 
the minimal deleted region. The results were correlated with clinicopathologic features 
and outcome. Methods: The cytogenetic database at MD Anderson Cancer Center was 
searched for cases of PMF diagnosed between 1/1997 and 6/2010. Cases with clonal 
cytogenetic abnormalities were identified and those with isolated del(13q) as primary 
abnormality were selected for analysis by aCGH using a 4X44 K array (Agilent 
Technologies, Santa Clara, CA). The results were correlated with clinicopathologic data 
and outcome. Results: We identified 17 patients with PMF who had isolated del(13q). 
Patient age ranged from 53-85 years (median, 67 years) and there were 11 men and 6 
women. Splenomegaly was present in 16/17 patients. A complete blood count showed: 
white blood cells 2.6-73.7 x 109/L (median 12.6); hemoglobin 8.6-14.3 g/dL (median, 
9.8); and platelets 78-479 x 109/L (median, 229). Bone marrow cellularity was 10-95% 
(median, 55%), blasts ranged from 2-10% (median, 2.0), osteosclerosis was present in 
12/17, and fibrosis was graded as: MF-0 (n=1), MF-1 (n=1), MF-2 (n=3), and MF-3 
(n=12). Molecular analysis showed JAK2 V617F mutation in 6/16 cases assessed. In 
14 cases with available DNA, aCGH showed a minimum deletion of 15.323 Mb within 
genomic region from 13q13.3 to 13q14.3, which contains 3 genes (RB1, FOXO1, and 
SUCLA2). At last follow-up, 5 of 16 patients were alive at 18-232 months (median, 49 
months) whereas 11 patients died with overall survival of 77 months. Two patients who 
died had transformed to acute myeloid leukemia (n=1), or accelerated phase with 14% 
blasts (n=1), at 36, and 48 months, respectively. Conclusions: PMF with isolated 
del(13q) is associated with male predominance, high rate of advanced bone marrow 
fibrosis with osteosclerosis, splenomegaly, and an intermediate prognosis. JAK2 V617F 
mutation was observed at a relative lower frequency. By using aCGH, we show for the 
first time a minimal deleted genome of 15.323 Mb at 13(q13.3-q14.3). This region 
contains the genes RB1, FOXO1, and SUCLA2, suggesting a role for these genes in 
the pathogenesis of PMF. 
 
H26. High Sensitive Molecular Detection of the BCR-ABL Major and Minor 
Fusion Transcripts in a Multiplex, Close-Tube Format by the Isothermal Loop 
Mediated Amplification Reaction (RT-LAMP) 
C. Pultrone1, M. Giulia1, G. Amicarelli1, E. D'Agostini1, V. Tettamanzi1, C. Boroni2, O. 
Spinelli2, F. Colotta1, A. Rambaldi2 
1DiaSorin SpA, Gerenzano, Italy; 2Ospedali Riuniti di Bergamo, Bergamo, Italy. 
Introduction: The molecular techniques employed for genetic confirmation of Chronic 
Myeloid Leukemia (CML) and risk classification of Acute Lymphoblastic Leukemia (ALL) 
are currently based on conventional RT-PCR. The main limitations are time-consuming 
and multi-step procedures that slow down the diagnostic labs routine and require highly 
specialized personnel. Methods: We developed a novel non-PCR assay based on 
LAMP to obtain a simpler, faster and more reliable molecular detection of BCR-ABL 
translocation. RT-LAMP rapidly retro-transcribes, amplifies and detects both the Minor 
(p190) and Major (p210) transcripts in a single-step procedure performed at constant 
temperature. Simultaneously, RT-LAMP amplifies also the endogenous Gusȕ RNA, as 
internal control, for validation of negative results. The presence of an intercalating dye 
(Yo-Pro 1, Invitrogen) allows a real-time reaction monitoring and the amplified products 
can be distinguished by annealing analysis for different melting temperatures. Results: 
The RT-LAMP sensitivity is 10-4 and 10-5 for p190 and p210 transcripts respectively in 
a 50 minutes reaction. The sensitivity was determined in serial dilutions of positive into 
wild type cell line RNA (i.e., TOM-1 or K-562 into HL-60 RNA). The specificity, 
established on 121 replicates from 7 wild type cell lines, is 100%. The assay was 
validated on RNA from patients affected by CML (n=30, p210) and B-ALL (n=3 p210, 
n=29 p190) at the onset, previously tested by RT-PCR. The two methods showed 100% 
concordance. Thanks to the high level of sensitivity, RT-LAMP was also validated on 
RNA from CML patients under treatment (n=18 p210) whose Minimal Residual Disease 
(MRD) is monitored by Quantitative-PCR, obtaining fully concordant results. Finally, the 
specificity was validated on 26 RNA samples from Philadelphia negative patients (13 B-
CLL; 5 AML; 1 ALL; 3 PV; 2 HES; 2 TE) and on 28 RNA samples obtained from healthy 
donors. In this cases RT-LAMP amplified exclusively the GUSȕ housekeeping gene 
transcript. Conclusions: the triplex p190-p210-GUSȕ RT-LAMP assay detects the 
major and minor BCRABL transcripts in a single step procedure reducing time-to-
results, risk of contaminations and errors, costs, assay set-up and risk of false negative 
results. RT-LAMP overcomes the main limitations of the conventional RT-PCR 
techniques and can also be considered for long term monitoring of CML patients in 
molecular remission. 
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H27. Design and Validation of a Restriction Fragment Length Polymorphism 
Assay for the Detection of DNMT3A Mutations in Patients with Acute Myeloid 
Leukemia 
E.I. Schindler1, C.M. Lockwood2, J.E. Payton2 
1Barnes Jewish Hosptial, St. Louis, MO; 2Washington University School of Medicine, St. 
Louis, MO. 
Introduction: Aberrant DNA methylation is believed to contribute to the pathogenesis 
of cancer. Mutations in DNMT3A, which encodes a DNA methyltransferase, have been 
identified in 10 to 30% of acute myeloid leukemia (AML) patients with intermediate risk 
or normal karyotype (NK). DNMT3A mutations are the most powerful predictor of 
decreased survival in AML after age, making the development of a rapid, cost-effective 
screening assay for these mutations a priority. Across several studies, the majority of 
DNMT3A mutations identified affected the arginine residue at position 882. Methods: A 
differential restriction enzyme digest (RE assay) using the enzyme AciI was designed to 
detect mutations at position 882. All of the reported mutations at position 882 abolish an 
AciI recognition site occurring in the normal DNMT3A. Two additional AciI recognition 
sites within the PCR product serve as internal controls for complete digestion of the 
product in both wild type and R882 mutant DNMT3A. The wild type PCR product is 
digested into four fragments sized 127 bp, 51 bp, 16 bp, and 179 bp. The R882 mutant 
product is digested into three fragments sized 178 bp, 16 bp, and 179 bp. A 5’-FAM 
labeled primer is used in the PCR step of the assay. The wild type product yields a 127 
bp 5’-FAM labeled fragment and the R882 mutant product yields a 178 bp 5’-FAM 
labeled product. These fragments are differentiated using capillary electrophoresis 
sizing discrimination. DNA from the OCI-AML3 cell line served as the positive control 
and pooled genomic DNA from individuals without AML served as the negative control. 
Fifty DNA samples obtained from diagnostic NK AML bone marrow specimens collected 
in 2010 or 2011 were assayed to validate this assay. Sanger sequencing was 
performed to confirm the results. Results: The RE assay correctly differentiated the 
positive and negative controls and detected mutations in 9/50 patient specimens (18%). 
Sequencing confirmed mutations in all 9 specimens. R882 mutations were identified by 
sequencing as the R882H mutation (NM 175629.1:c.2983G>A) in seven specimens 
(14%) and the R882C mutation (NM 175629.1:c.2982C>T) in two specimens (4%). 
Sequencing confirmed negative RE assay results in 10/10 specimens tested. 
Conclusions: This RE assay rapidly and cost-effectively identifies DNMT3A mutations 
involving the R882 residue. Given the paramount prognostic value of DNMT3A 
mutations, such an assay could provide important information for induction treatment 
choices (eg clinical trials) and early planning for bone marrow transplantation.  
 
H28. Evaluation of a Multiplexed qPCR Assay for the Detection of BCR-ABL 
Fusion Transcripts on the ICEPlex System 
M.C. Schwab, G.J. Tsongalis, J.A. Lefferts 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Identification and monitoring of the BCR-ABL fusion oncogene has 
become standard of care in managing patients with CML. The majority of CML and a 
subset of ALL patients are shown to harbor the p210 BCR-ABL fusion transcript (b3a2 
or b2a2). Other fusion transcripts such as e1a2 (p190) and e19a2 (p230) can occur in 
CML and ALL patients. To date, commercially available diagnostic assays primarily 
identify p210 transcripts. Here we evaluate an assay designed to identify multiple 
known transcripts of the BCR-ABL fusion gene using an automated highly multiplexed 
qPCR platform. Methods: Samples from patients received in the lab for the quantitative 
assessment of the BCR-ABL translocation using the Cepheid BCR-ABL assay on the 
GeneXpert, were concurrently assessed on the ICEPlex. Two different RNA extractions 
were performed using a silica column and an automated magnetic bead based 
technique. The total number of white cells and elution volumes were normalized. RNA 
was reverse transcribed and cDNA used in the subsequent multiplexed qPCR reaction 
on the ICEPlex. Invivoscribe BCR/ABL RNA Dilution Sets for b2a2, b3a2 and e1a2 
transcripts were run to evaluate the linearity of the assay. Results: The BCR-ABL 
translocation was detected in a number of patients, some of which were characterized 
as low level positive, using the GeneXpert assay. Retesting using the ICEPlex system 
identified patients with the b3a2 and/or b2a2 transcripts in both extractions, and 
additional patients showed this translocation in one of the extractions only. Also, a 
number of patients were shown to harbor a transcript (e1a2) in at least one of the 
extractions used on the ICEPlex that is not detected using the Cepheid assay. 
BCR/ABL RNA Dilution sets run on the ICEPlex system for b2a2, b3a3 and e1a2 
showed a linear regression R2 value for calculated BCR-ABL copy number versus 
concentration of 0.9959, 0.9824 and 0.9747, respectively. Conclusions: Using an 
automated, highly multiplexed qPCR platform, the ICEPlex system, to identify known 
transcripts of the BCR-ABL fusion gene allowed us to identify translocations detected 
using the Cepheid assay. The multiplexed assay also identified patients harboring a 
transcript not detected using commercially available assays. With further investigation 
into the extraction and specimen processing techniques, this method will allow the 
reliable detection and quantification of known BCR-ABL transcripts in patients with 
leukemia. 
 
H29. FISH Analysis of MLL Gene Rearrangement: Frequent Detection of 
Concurrent 3’ Signal Gain or Loss 
J. Lim, E. Seo, Y. Cho, S. jang, C. Park, H. Chi 
Asan Medical Center, Republic of Seoul, Korea. 
Introduction: The rearrangement of MLL at 11q23 occurs through translocations and 
insertions involving a variety of genes on a partner chromosome. Few studies of 
aberrant MLL signal patterns, such as concurrent 3` MLL deletion, have been 
performed. For the present study, we analyzed MLL signal patterns for patients at Asan 
Medical Center with positive MLL rearrangement detected by fluorescence in in situ 
hybridization (FISH) analysis. Methods: Patients who had a positive result with regard 
to MLL rearrangement on MLL FISH analysis were enrolled in the study. We compared 
the results of FISH analysis and conventional chromosome analysis, and analyzed the 
pattern of aberrant MLL signals. Influences on the prognosis of aberrant MLL signals 
were also analyzed. Results: In total, 33 cases showed positive MLL rearrangement 
results. Twenty-eight cases involved known MLL partner genes and loci: 10 cases of 
9p22, 6 cases of 4q21, 5 cases of 6q27, 4 cases of 10p12, 2 cases of 19p13.1 and 1 
case of 17q25. Three cases showed balanced translocation on conventional 
karyotypes, but partner genes were not known: 2q21, 10q22 and 13q32, respectively. 
Two cases had unknown partner loci or genes. Six cases (18.2%) had aberrant MLL 
signals: 2 cases of 3` MLL signal loss and 4 cases of 3` MLL signal gain. Two cases of 
3` MLL signal loss had balance translocation between 9p22 and 11q23. In cases of 3` 
MLL signal gain, we performed metaphase FISH to find the location of additional 
signals. Additional signals were found at der(4)t(4;11), der(6)t(6;11), and Xp22.1. All 
patients who showed 3` MLL signal gain were diagnosed as AML and showed poor 
prognoses. Conclusions: Five unknown genes or loci were found in our study. We 
found that aberrant MLL signals were frequently detected through FISH analysis. 
Interestingly, concurrent 3’ MLL gains were more common in AML and might be likely to 
influence prognoses. We recommend that aberrant FISH signal patterns be further 
investigated, so as to determine their impact on prognosis and disease status. 
 
H30. NOTCH1 Mutations in Chronic Lymphocytic Leukemia: A Correlative 
Study with Trisomy 12 and Immunoglobulin Heavy Chain Variable Region Gene 
Status 
G. Insuasti-Beltran1, J.A. Halfacre1, J.M. Gale2, M.A. Vasef1 
1University of New Mexico, Albuquerque, NM; 2TriCore Reference Laboratories, 
Albuquerque, NM. 
Introduction: Recent studies using whole genome sequencing have identified 
NOTCH1 gene mutations in chronic lymphocytic leukemia/small lymphocytic lymphoma 
(CLL/SLL). In addition, these studies report an association between mutated NOTCH1 
gene and trisomy 12 as well as unmutated IgH variable region genes (IGHV), conferring 
a distinctive transcriptional profiling and overall unfavorable prognosis. The purpose of 
our study was to analyze the NOTCH1 mutational status in our cohort of CLL/SLL 
patients to further analyze these potential associations. Methods: From our archived 
files, we retrieved 192 purified DNA samples extracted from previously diagnosed 
cases of CLL/SLL. Using High Resolution Melting (HRM), the PCR amplified products 
were screened for the presence of NOTCH1 mutations. Cases with abnormal melting 
curves were re-run in duplicate and then sequenced using Sanger sequencing. FISH 
analysis using probes to detect recurrent CLL/SLL-associated abnormalities including 
11q22.3, 13q14.3, 13q34 and 17p13 deletions, and/or trisomy 12 had been previously 
performed in all cases. Results: NOTCH1 mutations were identified in 14 out of 192 
(7%) of cases analyzed. All mutated cases displayed a recurrent 2 base-pair frameshift 
deletion (ǻCT7544-7545, P2515fs). The NOTCH1 mutated cases included 3 out of 24 
(12%) cases of CLL with trisomy 12, 7 out of 78 (9%) cases of CLL/SLL with unmutated 
IGHV status, and only one NOTCH1 mutated CLL case with both IGHV unmutated 
status and trisomy 12. Conclusions: Based on our evaluation of 192 
unselected/unbiased cohort of CLL/SLL cases, we do not identify any significant 
correlation between NOTCH1 mutations and the presence of trisomy 12 and/or 
unmutated IGHV status in CLL/SLL cases. These results contradict previously 
published data. In addition, our results do not support the clinical utility of NOTCH1 
mutation assay as a prognostic biomarker in CLL/SLL at this time.  
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H31. Fluorescent In Situ Hybridization Assay and Single Nucleotide 
Polymorphism Array: Complementary Tools for Detection of Clinically Significant 
Copy Number Variation in Hematologic Malignancies 
A. Oultache, C.V. Hedvat 
Memorial Sloan Kettering Cancer Center, New York, NY. 
Introduction: Hematologic malignancies are characterized by numerous chromosomal 
aberrations that have diagnostic, therapeutic and prognostic impact. So far, 
conventional cytogenetics remains the gold standard for the detection of these 
abnormalities as SNP array technology emerges as a valuable tool for the analysis of 
copy number variation across the whole genome. Our goal was to evaluate the 
performance of the Illumina HumanOmni1-Quad Beadchip microarray, which contains 
1,134,514 markers with a 2.63 kb mean spacing, on the detection of specific copy 
number alterations in hematologic malignancies. Methods: Genomic DNA was 
extracted from 11 BM aspirates and 5 peripheral blood samples of patients with a 
confirmed histologic diagnosis of CLL (6), MDS (4) or multiple myeloma (6). The B-
Allele Frequency and Log2R ratio were analyzed using both Illumina GenomeStudio 
analysis software and Nexus Copy Number software. Results: All samples passed 
DNA quality QC and the mean call rate was 98%. SNP array analysis allowed for the 
identification of 81% of the abnormalities detected by FISH assays, and additional 
significant copy number alterations were identified in all the cases. As expected, 
balanced translocations were not detected and 25% (4/16) of the cases showed 
significant gains or deletions that were not captured by the SNP array, highlighting the 
importance of coupling the two technologies for a comprehensive genomic assessment. 
Conclusions: HumanOmni1-Quad Beadchip microarray is a powerful tool for cost 
effective, high throughput analysis of genetic alterations in hematologic malignancies 
and a valuable addition to locus specific FISH assays for genomic profiling. 
 
H32. Analysis of BRAF V600E Mutation in Langerhans Cell Histiocytosis Using 
Pyrosequencing Technology  
J. Halfacre1, J.M. Gale2, M.A. Vasef3 
1University of New Mexico, Albuquerque, NM; 2TriCore Ref Laboratories, Albuquerque, 
NM; 3University of New Mexico Health Science, Albuquerque, NM. 
Introduction: Langerhans cell histiocytosis (LCH) is a disease with heterogeneous 
clinical presentations ranging from localized to systemic and from self-limited to fatal. 
Prior studies using X-linked polymorphic DNA probes (HUMARA) have shown that the 
majority of the non-pulmonary LCHs are clonal proliferations. However, the molecular 
pathogenesis of LCH remains uncertain at present time. One recent study reports 
BRAF V600E mutation in greater than 50% of the LCH. In this study, we analyzed the 
status of BRAF V600E mutation on DNA extracted from diagnostic samples from 
localized, systemic and pulmonary LCH. Methods: From archived files in the 
department of Pathology at the University of New Mexico, we retrieved 11 samples from 
previously characterized cases of LCH. H&E slides from all 11 cases were reviewed to 
assure the presence of adequate amount of tumor for an accurate and reliable 
molecular analysis. Briefly, after reviewing and marking the concentrated diagnostic 
tumor areas on H&E slides, the corresponding foci on unstained slides were scrapped 
for DNA extraction using the DNeasy blood and tissue kit. DNA concentration and purity 
were determined using a Nanodrop 8000. The extracted DNA was subjected to PCR 
amplification. The reverse strand of PCR amplified product was used for final sequence 
analysis using pyrosequencing. Results: The BRAF V600E mutations were identified in 
3/11 (27%) of samples analyzed including 1 out of 3 (33%) cases with localized 
pulmonary LCH. The BRAF V600E mutated cases included a 15 month old female with 
systemic disease and diffuse lymphadenopathy, a 33-year-old male smoker with 
pulmonary LCH, and a 30-year-old male with a localized skull lesion. Conclusions: 
The results of our study indicate that approximately 27% of LCHs harbor BRAF V600E 
mutation. Our results confirm and further expand the prior sparse reports of detectable 
BRAF V600E in LCH cases although the incidence of this mutation appears lower in our 
study. Detection of BRAF V600E mutations in a subset of localized smoking-associated 
pulmonary LCH may argue against an entirely reactive LCH proliferation in this setting 
as reported in literature. At present time, it is uncertain if a subset of LCH with BRAF 
V600E mutation may benefit from BRAF kinase inhibitors.  
 
H33. Clinical Implementation of Efficient and Cost-effective Pediatric Leukemia 
MRD Assays 
C. Webb, C.A. Vega, V.S. Hernandez, J.M. Jakacky, A.D. Rector, D.H. Lopez-Terrada 
Texas Children's Hospital, Houston, TX. 
Introduction: Treatment protocols for pediatric leukemias are based on clinical and 
laboratory prognostic factors that are used for patient stratification. These prognostic 
factors include phenotype, chromosomal abnormalities, aberrant fusion genes, specific 
gene mutations, and clinical parameters (i.e., response to initial therapy). The advent of 
molecular testing for specific genetic alterations has enabled the detection of leukemic 
cells at a sensitivity exceeding that of traditional cytogenetics and flow cytometry 
testing, making molecular testing preferred for minimal residual disease (MRD) in many 
cases. However, implementation of cost-effective molecular assays for the numerous 
leukemia targets can be challenging for clinical laboratories. To implement time-efficient 
and cost-effective assays for MRD, the Qiagen BCR-ABL and PML-RARA FusionQuant 
assays were clinically validated in our laboratory using a modified protocol that 
improved overall test efficiency and significantly reduced the cost/test. Methods: 
Primers and probes from the Qiagen FusionQuant BCR-ABL mbcr & Mbcr and PML-
RARA bcr1 & bcr3 kits were utilized in individual one-step, real-time, RT-PCR assays 
with the QuantiTect Probe RT-PCR Kit, instead of following the two-step procedure(s) 
with reagents recommended by the FusionQuant manufacturer. Testing was performed 
on the Roche LightCycler480. Identical mastermix reagents and cycling conditions were 
used for all fusion and control gene targets. Archived standard curves (retested 
quarterly or with reagent lot changes) were used for quantitation of targets. Results: 
Utilizing primers and probes optimized with the same reagents and cycling conditions 
enabled batching of all targets onto one test plate tested by one technologist, thus 
reducing technologist hands-on time by ~50%. Modifying reaction components and 
volumes resulted in a reduction in the number of reagents, time required for setup, and 
total reaction volume from 25μL to 11μL; the reagent cost savings appreciated was 
$10.07/reaction. Utilizing archived standard curves for quantitation resulted in 
decreased batch sizes by 15 reactions/batch, further reducing the cost by $35.11/batch. 
The combined savings appreciated over 1 year was an 89% decrease in reagent costs. 
Conclusions: Use of commercial primers/probes reduces development and 
optimization time for clinical validation. However, by modifying the suggested protocols 
to meet the workflow and resource requirements of the laboratory, significant time and 
cost-savings can be realized. Batching multiple test targets under identical conditions 
allows for optimal laboratory efficiency and productivity. Additional modifications in 
progress include multiplexing each fusion gene with the control gene and including 
TEL-AML1 detection. Other targets planned for future implementation include E2A-
PBX1, AML1-ETO, CBFB-MYH11, and MLL-AF4. 
 
H34. Comparison of Next Generation Sequencing Platforms for Multi-Gene 
Mutational Profiling of Hematologic Malignancies in a Clinical Diagnostics 
Laboratory 
K.P. Patel, R. Singh, N. Reddy, M. Routbort, K. Aldape, L. Medeiros, R. Sargent, S.S. 
Chen, C. Yin, J. Zuo, B.A. Barkoh, B. Handal, A. Paladugu, R. Patel, H. Rahimi, F. 
Grant, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Recent availability of affordable bench-top next generation sequencing 
(NGS) instruments has opened up the possibility of NGS-based molecular testing in 
routine clinical diagnostics. The Ion personal genome machine (PGM; Life 
Technologies, Carlsbad, CA) and MiSeq (Illumina Inc, San Diego, CA) represent two of 
the most popular choices among the bench-top NGS instruments. We compared the 
performance characteristics of the Ion Torrent and MiSeq platforms using comparable 
multi-gene panels for routine clinical testing of hematologic malignancies. Methods: 
Archival DNA from 35 bone marrow aspirates from patients with various hematologic 
malignancies was tested in parallel on the two NGS platforms. For semiconductor 
sequencing on the Ion PGM, 10 ng DNA per sample was utilized for mutational hot-spot 
profiling of 46 genes (Ion AmpliSeq panel, Life Technologies) on a 316 (up to 200 Mb) 
or 318 (up to 1 Gb) chip. For reversible terminator-based sequencing by synthesis on 
MiSeq, 250 ng DNA per sample was utilized for mutational hot spot profiling of 48 
genes (TruSeq amplicon cancer panel, Illumina) on a single lane flow cell (up to 2 Gb). 
46 genes are the same in both the panels. AmpliSeq panel plus 2 additional genes. The 
results were compared to or confirmed by an independent conventional test method. 
Results: The total analysis time (library preparation, sequencing, alignment, variant 
calling) was approximately 20 hours for PGM for a unidirectional sequencing (average 
read length: 100 bases) of 4 (316 chip) to 8 (318 chip) samples and 32 hours for MiSeq 
for paired-end sequencing (read length: 2x150 bases) of 20 samples per flow cell. All 
samples were successfully sequenced at a high depth of coverage, which was inversely 
proportional to the number of samples multiplexed per chip or flow cell. Both PGM and 
MiSeq platforms successfully detected previously known mutations in the samples 
tested including point mutations in FLT3, IDH1, JAK2, NRAS and KRAS and, insertions 
in NPM1 at a comparable quantitative levels. Additional mutations in novel genes were 
detected by both the platforms. Conclusions: Both Ion PGM and MiSeq provide useful 
platforms for multi-gene mutational analysis of hematologic malignancies. Differences in 
the length and complexity of sample preparation steps, turn around time, single versus 
paired end reads, sample throughput and ease of data analysis identified in our study 
provide useful decision making matrices for the selection of a test platform for a specific 
clinical diagnostics workflow.  
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H35. Evaluation of Multiplex Quantitative Measurement of BCR–ABL1 Using 
Asuragen BCR/ABL1 Quant (RUO) Assay Calibrated to the International 
Reporting Scale 
D. Ma, G.C. Caponetti, J.R. Hackman, J.W. Heusel, A.D. Bossler 
University of Iowa Hospitals and Clinics, Iowa City, IA. 
Introduction: The presence of the Philadelphia chromosome (Ph+), t(9;22)(q34;q11) 
translocation that fuses the ABL1 and BCR genes, is the hallmark of chronic 
myelogenous leukemia (CML). This gain-of-function translocation is present in >95% of 
CML, 20-40% of adult acute lymphocytic leukemia (ALL) and a subset of pediatric ALL. 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) assessment 
for the BCR-ABL transcript has become the standard for monitoring CML patients 
undergoing tyrosine kinase inhibitor therapy and the Ph+ ALL. Variation in reporting 
BCR-ABL values among different laboratories has been problematic. The establishment 
of an international reporting scale in 2003 and the development of the WHO 
international standard (IS) should aid in standardizing results. We evaluated the 
BCR/ABL1Quant (RUO) assay (Asuragen, Austin, TX) for simultaneous and 
quantitative detection of the three BCR-ABL fusion transcripts and compared results 
with a commercial reference laboratory after obtaining the laboratory specific 
conversion factor based upon the WHO international reporting scale. Methods: 
Peripheral blood or bone marrow was collected in duplicate for testing between the two 
laboratories. Total RNA was extracted using QIAamp RNA blood mini kit (Qiagen, 
Valencia, CA) and reverse-transcribed. Quantitative PCR was performed according to 
manufacturer’s instructions. BCR-ABL copy number was calculated based on the 
BCR/ABL QuantTM Calibrators (Asuragen) using ABL1 as the normalizer. Analytical 
sensitivity was assessed by diluting positive cells or cell line RNAs (K562 carrying 
e14a2, Meg01 carrying e13a2 or a plasmid containing e1a2) into BCR-ABL negative 
cells or cell line RNA (HL60). Breakpoint discrimination was assessed by capillary 
electrophoresis sizing of the fusion products. Results: The BCR/ABL1Quant (RUO) 
assay demonstrated an analytic sensitivity of 0.001% (~ 30 copies/reaction) with a 
linear detection range of at least 4 logs. A laboratory specific conversion factor of 0.38 
was obtained. Results from the paired patient specimens demonstrated 100% positive 
agreement (9/9) and 87.5% negative agreement (14/16) with the commercial laboratory. 
Our results showed a higher ABL copy number in most specimens, which could be 
explained by better RNA quality due to shorter time lapse between blood/bone marrow 
drawing and processing. Conclusions: The BCR/ABL1Quant (RUO) assay, a multiplex 
RT-qPCR assay that simultaneously detects three variants of BCR-ABL transcripts, was 
validated and a laboratory specific conversion factor was identified. Reporting by IS 
scale allows for a direct comparison of results from different laboratories and a 
consistent interpretation of patient response to therapy.  
 
H36. Towards Clinical Use of Next Generation Sequencing to Screen for 
Mutations in Liquid and Solid Tumors 
R.D. Daber, J. Zhao, A.J. Fox, M. Martinez-Lage, D. Roth, K. Nathanson, M. Carroll, 
J.J. Morrissette 
University of Pennsylvania, Philadelphia, PA. 
Introduction: Rapid advances in massively parallel sequencing allow for the 
simultaneous analysis of mutation status across a large number of cancer related 
genes. Despite advances in sequencing technologies, major barriers in clinical 
implementation are building clinical grade analytic pipelines and pathogenic mutation 
databases. Here we discuss our experience in developing both solid and hematologic 
malignancy gene sequencing assays. Methods: Genomic DNA was extracted from 50 
AML samples previously characterized using Sanger sequencing for 16 different loci 
(Levine et al, 2012). After designing a larger gene panel covering 42kb and 20 
additional genes, two custom library preparation platforms were compared. Libraries 
were produced using Truseq Custom Amplicon (Illumina) and Haloplex (Agilent) and 
sequenced on the Illumina Mi-Seq to an average depth of coverage over 1000x. In 
addition, sequencing libraries were also generated with DNA from 192 formalin-fixed 
paraffin-embedded (FFPE) tissue samples using the Illumina TruSeq Amplicon-Cancer 
Panel (TSACP). Bio-informatic pipelines were created using a combination of open 
source and custom algorithms designed to pull out essential performance statistics and 
to determine copy number status over each loci. Results: After testing a variety of 
sequence alignment tools, the greatest sensitivity and specificity was achieved using 
Novoalign (Novocraft). Following alignment and quality filtering, variant calling resulted 
in an average of 20-30 variants in each FFPE specimen, corresponding to between 0 
and 5 somatic changes. Allele frequencies as low as 9% were detected in the samples 
tested. Although the data was generated using an amplicon approach, we were able to 
detect genomic amplifications of EGFR in roughly 33% of the glioblastoma samples by 
writing a bioinformatics program designed to detect copy number alterations. With the 
hematologic malignancy gene panel, we were able to detect both point mutations as 
well as insertions with the most clinically relevant occurring within FLT3. Comparison of 
libraries generated with both Illumina and Agilent capture technologies demonstrated 
strengths and weaknesses of each approach. Conclusions: The mutation status of 
many clinically relevant genes can be reliably detected in both FFPE and non-FFPE 
samples using a single molecular assay followed by high throughput sequencing. 
Despite the availability of many open source programs for next generation sequencing, 
the development of a true clinical grade analysis pipeline requires many additional 
informatic tools to verify the performance of a given run, with the most critical need still 
being a clinical grade database of pathogenic variants.  
 
H37. Molecular Profiling of Diffuse Large B-Cell Lymphoma Subtypes on the 
ICEPlex System 
J. Nolling1, A.M. Collie2, J.J. Lin2, B.T. Hill2, T. Radivoyevitch3, E.D. Hsi2, L. Kong1 
1PrimeraDx, Mansfield, MA; 2Cleveland Clinic, Cleveland, OH; 3Case Western Reserve 
University, Cleveland, OH. 
Introduction: Molecular profiling of diffuse large B-cell lymphoma (DLBCL) has 
emerged as an important prognostic tool for affected patients. Current molecular 
profiling technologies are not capable of providing quantitative, specific, and sensitive 
assays that are also able to examine large numbers of analytes simultaneously, in 
particular when using material extracted from formalin-fixed paraffin-embedded (FFPE) 
specimens. To overcome these limitations, we developed a novel high-multiplex gene 
expression profiling assay on the automated ICEPlex System that allows differentiation 
between germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes of 
DLBCL from FFPE specimens. Methods: Primer design followed a proprietary 
approach, extension tag amplification (ETA), that allows amplification and detection of 
low quality RNA targets with template size less than 100 nucleotides from FFPE 
specimens. Primers were designed across exon junctions and were screened in silico 
for potential sequence interaction using our software. Multiplexed reactions were 
optimized for target identification and amplification performance on the ICEPlex 
instrument using RNA from ABC and GCB DLBCL cell lines. Relative quantification of 
target gene expression was achieved by normalization to reference genes. The assay 
was further tested for analytical performance, amplification efficiency, dynamic range 
and precision, using FFPE-extracted cell line RNA. Results: A real-time 19-plex 
expression profiling assay for DLBCL tumor subtyping was developed on the ICEPlex 
System. The single-reaction assay comprised of a 17-gene panel, established as 
biomarkers for DLBCL subtyping (Wright classifier and Lossos outcome predictor), and 
two reference genes. Multiplex assay performance showed similar PCR efficiencies for 
all targets. The high assay precision allowed discrimination of two-fold changes in 
expression levels. As little as 1 ng of FFPE-extracted material was sufficient to enable 
classification of DLBCL cell lines into GCB or ABC subtypes. Conclusions: We have 
developed a novel 19-plex quantitative expression profiling assay designed for DLBCL 
tumor classification into GCB or ABC subtypes from FFPE specimens. This enabling 
work will be applied to a clinical validation set of DLBCL patients treated with 
immunochemotherapy. This assay has the potential to provide rapid and accurate 
subclassification and prognostic information in DLBCL. 
 
H38. Ultra-Deep Sequencing to Identify Rare Variants within Mutational 
Hotspots: Application to IGH Diversification in Follicular Lymphoma 
J.M. Spence1, J.P. Spence2, W. Burack3 
1University of Rochester, Rochester, NY; 2Consultant, Rochester, NY; 3University of 
Rochester Medical Center, Rochester, NY. 
Introduction: Genomic instability is the hallmark of all cancers, generating intra-
tumoral heterogeneity that influences both tumor progression and treatment failure. 
Massively parallel sequencing approaches have been used to measure tumor 
heterogeneity that work well in regions with low divergence from reference sequence. 
We have designed an analytical pipeline that reliably detects rare variants in genomic 
regions with high mutation levels. We demonstrate this approach using clone-specific 
IGH from follicular lymphoma (FL) specimens, a target known both for high mutation 
rates and intra-clonal diversity within this B-cell tumor. Methods: We used SOLiD for 
targeted resequencing of clone-specific IGH and promoter regions of several proto-
oncogenes associated with lymphoma from 12 FL specimens, 3 hyperplastic lymph 
nodes and 1 cell line, at levels to achieve ~10,000-fold coverage. These genomic 
regions were amplified with a high-fidelity polymerase (pfu) using template 
concentrations equivalent to ~40,000 cells to limit the effect of even first round PCR 
errors. BFAST software was used to map reads to reference sequences. Each 
reference sequence was broken into overlapping regions of interest (ROIs) for analysis 
of independent read subsets. Sequence variations within subsets were identified and 
counted to form an ROI dictionary (ROID) of observed subsequences and count data. 
Filtering performed on this data includes bi-directionality, minimum frequency 
thresholding, and verification using overlapping independent ROIDs. The resulting 
collection of verified subsequences were partially assembled to form additional 
reference alleles for remapping and reanalysis. Results: Reiterative ROID-based 
analysis identified significant sequence diversity of IGH, relative to clone specific IGH 
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Sanger sequencing results, detecting 1917 additional mutations over 21520 bases 
(8.9%, range 0.6-20.7%) in the 12 FL specimens. Most of these additional mutations 
(median =97%) occurred at frequencies <20%, well below Sanger detection limits. Rare 
variants in IGH and some proto-oncogene promoter regions were detected down to 
0.3% frequency, with some variants detected down to 0.1%, whereas many proto-
oncogene promoter regions showed no variation beyond patient germline SNPs. Low 
frequency variants were detected in regions with mutation densities up to 25%. 
Conclusions: Iterative mapping and analysis converged in 1 to 4 iterations, improving 
mapping and mutation frequency analysis. This process identified significant intra-clonal 
variation in the IGH of FL tumors, up to 20%, without generating significant false calls 
as demonstrated by many proto-oncogene promoter regions with no called mutations. 
Additionally, the word-based algorithm allows for local cladistic analysis of IGH 
mutation, providing insight into relative rates of clonal diversification versus proliferation. 
 
H39. Comparison of the Performance Characteristics of Two Commercially 
Available Real-time RT-qPCR Assays for the Quantification of BCR/ABL1 
Transcripts on the WHO International Scale 
R.T. Ramjit, S.R. Stowell, C.E. Hill, S. Nabila, L. Zhang, K.P. Mann 
Emory University School of Medicine, Atlanta, GA. 
Introduction: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm 
characterized by the reciprocal translocation t(9;22)(q41;q11)[BCR-ABL1]. Use of real-
time quantitative RT-PCR (RT-qPCR) testing for disease monitoring is standard of care 
to evaluate response to therapy with kinase inhibitors (with a target of > 3 log10 
reduction of transcript levels). The WHO has recently developed an international 
standard (IS) to aid in this assessment.This study was designed to evaluate the 
performance characteristics of 2 kits that are calibrated to the IS, the BCR-ABL Mbcr 
IS-MMR Dx kit (Iposgen SA,)(kit A) and the BCR/ABL1 Quant (Asuragen, Inc.)(kit B) to 
determine clinical utility and to compare to our prior method (Roche LightCycler t(9;22) 
quantification kit). Methods: Previously tested, archived RNA extracts (-80°C) were 
selected (16 positive, 15 negative). Dilutions of the K562 cell line (extracted RNA in 
normal spleen RNA) were used to determine linearity, limit of detection (LOD) and 
reproducibility of kit A and kit B on ABI 7500 TaqMan. Dilutions tested were 1:2, 
1:1,000, 1:10,000, 1:50,000, 1:100,000, and 1:1,000,000. The 95% LOD for each test 
was determined by Probit analysis (BioStat 2009). Results were compared to the prior 
method and correlation was assessed between methods. Results: All previous positive 
results were positive in kits A and B. Seven prior negatives were positive in kits A and 
five prior negatives were positive in kit B. LOD for kit A was 0.0016 copies/ml 
(Mbcr/ABL) and and 0.0051 copies/ml (BCR/ABL1:ABL)(kit B). The reproducibility of kit 
A varied through all concentrations tested (SD: 0.01 to 2.02), with the lowest precision 
at high and low concentrations of Mbcr and the greatest precision in the mid range. Kit 
B showed little variability throughout the concentrations tested (SD: 0.0 to 0.19). The 
linear range for both tests was at least 6 log10. Comparison of the IS% between tests 
showed close correlation. Conclusions: Both kits have good performance 
characteristics and are comparable. They have improved sensitivity as compared to our 
standard method. The use of the %IS calibration gives excellent correlation between 
kits. In our hands, Kit B showed lower run to run variability. It is important to note that 
Kit A is not designed to detect e1a2 breakpoints, whereas, Kit B detects this as well as 
the characteristic CML translocations. 
 
H40. The Role of Quantitation of PML-RARa Fusion Transcript in the Risk 
Stratification in Patients with Acute Promyelocytic Leukemia 
Y. Cho, H. Chi, S. Park, S. Jang, C. Park, E. Seo, K. Lee 
University of Ulsan, College of Medicine and Asan Medical Center, Republic of Seoul, 
Korea. 
Introduction: Although acute promyelocytic leukemia (APL) is a highly curable 
disease, early death and relapse remain major impediments for the management of 
APL. We investigated the clinical significance of quantitative analysis of PML-RARa 
fusion transcript in patients with APL. Methods: We analyzed the prognostic 
significances of quantitative results of PML-RARa transcript, as well as other predictive 
factors, in 192 consecutive patients with APL, from January 1991 to March 2012 at a 
single institution. Real-time quantitative polymerase chain reaction assays were used to 
detect PML-RARa fusion transcript. Results: Overall death rate was 31.8%, and early 
death explained the majority (65.6%) of these cases. Overall relapse rate was 11.5%, 
with a median interval from first remission of 25.3 months. Microgranular morphology, 
high-risk group based on the PETHEMA risk stratification, high lactate dehydrogenase 
level, and high level of PML-RARa transcript at diagnosis were associated with inferior 
overall survival (OS) (P = 0.008, 0.001, 0.007 and 0.004, respectively), but none of 
them remained significant in a multivariate analysis. Shorter disease-free survival was 
associated with microgranular morphology, presence of additional chromosomal 
abnormalities, normal levels of fibrinogen, and a failure to achieve negative conversion 
of PML-RARa transcript after induction therapy (P = 0.022, 0.029, 0.002 and 0.011, 
respectively). However, in a multivariate analysis, only the residual PML-RARa 
transcript after induction remained significant (hazard ratio 6.076, P = 0.014). 
Conclusions: High level of PML-RARa transcript at diagnosis was associated with 
shorter OS, and residual chimeric transcript after induction chemotherapy was an 
independent adverse prognostic factor for the relapse in patients with APL. Therefore, 
PML-RARa transcript quantitation could contribute to the improvement of the risk 
stratification, and programmed monitoring is necessary for the risk-adapted therapeutic 
strategies in APL. 
 
H41. Targeted Sequencing of Exons Commonly Mutated in Juvenile 
Myelomonocytic Leukemia Using 454 Next-Generation Deep-Sequencing 
Technology Facilitates Rapid Molecular Diagnosis 
J.A. Van Ziffle, J. Weng, M.P. Powers, M.L. Loh, L.J. Jeng 
University of California, San Francisco, San Francisco, CA. 
Introduction: Juvenile myelomonocytic leukemia (JMML) is a rare 
myeloproliferative/myelodysplastic malignancy of early childhood. JMML is a lethal 
disease without therapy, and even with allogeneic hematopoietic stem cell 
transplantation, relapse rates remain relatively high. Establishing a diagnosis of JMML 
can be difficult, as many of the clinical and laboratory findings overlap with viral-
infection-associated diseases. The most common genetic abnormalities associated with 
JMML are activating point mutations in the RAS/mitogen activated protein kinase 
(MAPK) signaling pathway, occurring in approximately 75% of cases. Mutations in 
KRAS, NRAS, and PTPN11 are known to be associated with JMML. In addition, 10-
15% of patients have clinical neurofibromatosis with loss of heterozygosity of the 
wildtype NF1 allele in their affected bone marrow. These mutations are associated with 
hypersensitivity to granulocyte-macrophage colony stimulating factor (GM-CSF) in 
malignant myeloid progenitor cells. More recently, mutations in CBL, an E3 ubiquitin 
ligase, have also been discovered in association with this leukemia. Currently, 
comprehensive molecular testing on a clinical basis is not routinely available due to the 
rarity of this disorder. Methods: Using the Roche 454 GS Junior platform, we 
developed a rapid assay to interrogate the exons of the genes commonly mutated in 
JMML, including CBL exons 8 and 9, KRAS exons 2 and 3, NRAS exons 2 and 3, and 
PTPN11 exons 3, 4 and 13. Following amplicon preparation of the targeted exons, 
standard 454Jr emulsion PCR and sequencing chemistry was used for sequence 
ascertainment. Results: After optimization, an independent cohort of 38 JMML patients 
was analyzed. For each patient, a median of 718 reads was generated (coverage 
range, 320 to 1968-fold), allowing for a robust detection of mutations. All mutations 
were also detected using Sanger sequencing. This assay showed 100% accuracy for 
samples detected by Sanger sequencing. Dilution studies were performed to a level 
below that detectable by Sanger sequencing (15-20%), setting the sensitivity limit of the 
454Jr to approximately 1%. Conclusions: Next-generation amplicon sequencing 
provides an exceedingly accurate and sensitive detection method for mutations in CBL, 
KRAS, NRAS, and PTPN11, facilitating the routine diagnosis of JMML. 
 
H42. DNA-qPCR vs RT-qPCR for Monitoring MRD in Chronic Myeloid Leukemia 
A. Morley1, P. Bartley1, S. Latham1, B. Budgen1, D. Ross1, E. Hughes1, D. White2, S. 
Branford2, T. Hughes2 
1Flinders University, Bedford Park, Australia; 2SA Pathology, Adelaide, Australia. 
Introduction: RT-qPCR is a valuable technique for quantification of MRD in CML but it 
does have some disadvantages. Recent work has shown that quantification of MRD by 
DNA-qPCR is feasible and is more sensitive than quantification by RT-qPCR. If DNA-
qPCR is to become a practical alternative to RT-qPCR then it needs to provide a simple 
method for obtaining the BCR-ABL sequence, an alternative to patient-specific primers, 
similar results to RT-qPCR and a simple technique of measurement. Methods: Rapid 
isolation and sequencing of the BCR-ABL breakpoint was performed as previously 
described (Brit J. Haem v149, pp231-236, 2010). The need for patient-specific PCR 
primers was obviated by developing a library of presynthesised primers and selecting 
the appropriate pair "off-the-shelf" when a sample presented for analysis. Primers were 
tested for amplification efficiency and absence of nonspecificity both during 
development of the library and again prior to use for assay of a sample. MRD was 
determined i) initially by PCR quantification in 10 μg DNA the test BCR-ABL sequence 
against a standard curve prepared from dilutions of diagnosis DNA, and ii) 
subsequently by quantifying in 1.5 μg DNA the BCR-ABL sequence relative to a BCR-
BCR sequence of approximately the same length, using the same forward BCR primer 
and using the ǻǻCt method. MRD results were also measured by RT-qPCR. Results: 
The BCR-ABL sequence was determined in 158/162 patients. The primer library 
consisted of 19 BCR and 568 ABL primers. Using standard curve quantification, MRD 
was measured in 156 samples from 44 patients over a 6 log range. There were 124 
samples quantified by both RT-qPCR and DNA-qPCR, with correlation r = 0.93, p<< 
0.0001 and 23 samples with MRD 10-4 to 10-6 only quantifiable by DNA-qPCR. 
Quantifying BCR-ABL relative to BCR-BCR, MRD was measured in 68 samples from 45 
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patients. MRD was not detected by either RT-qPCR and DNA-qPCR in 2 samples, only 
quantified by DNA-qPCR in 2 samples, only quantified by RT-qPCR in 1 sample and 
quantified by both techniques in 63 samples, over a 5 log range and with r = 0.86, p << 
0.0001. Conclusions: DNA-qPCR by relative quantification is simple and cheap. The 
upfront costs are modest and can be amortised over multiple MRD assays. The results 
are comparable to those of RT-qPCR except that DNA-qPCR is more sensitive. DNA-
qPCR does not have the disadvantages of RT-qPCR. DNA-qPCR merits consideration 
as an alternative to RT-qPCR for monitoring MRD in CML. 
 
H43. Genome-Wide DNA Methylation Analysis of High-Risk, Untreated Chronic 
Lymphocytic Leukemia (CLL) Reveals Distinct Epigenetic Profiles in Patients with 
Aberrations on Chromosome 17p and Chromosome 11q  
A. Stone1, W.C. Carter1, L. Frederick2, C.S. Zent2, D.S. Viswanatha2, S.A. Schichman1 
1Central Arkansas Veterans Healthcare System, Little Rock, AR; 2Mayo Clinic, 
Rochester, MN. 
Introduction: Promoter CpG island hypermethylation and global hypomethylation are 
two key events implicated in CLL tumorigenesis. Genome-wide methylation profiling 
was performed on 22 patients with early-intermediate stage, untreated CLL who have 
high risk disease based on molecular and immunophenotypic markers. Differential 
methylation and pathway analyses were focused on two unfavorable prognostic 
subgroups of CLL defined by defects in ATM (11q22) or TP53 (17p13). Methods: Eight 
patients had 11q deletion and 2 additional patients had mutant ATM with uniparental 
disomy of 11q (ATM defective group). Five patients had 17p deletion (TP53 defective 
group). CLL and non-malignant cells were separated from patient peripheral blood 
samples by immunomagnetic beads. Purified genomic DNA from CLL and non-
malignant cells for each patient was bisulfite-modified, whole-genome amplified and 
hybridized to Illumina Infinium HumanMethylation 450 microarrays containing 482,421 
CpG sites. Epigenetic data was analyzed using the Differential Methylation Module in 
Illumina GenomeStudio V2010.3 Software. Further bioinformatic analysis of 
differentially methylated targets was performed using ArrayTrack (National Center for 
Toxicological Research, US FDA). Results: We identified 6,343 differentially 
methylated targets with significant Diff Scores (p-values  1.0 x 10-5) between groups 
with ATM and TP53 defects. After removal of loci that represented unknown genes or 
hypothetical proteins, we found 4,572 probes for interaction pathway and functional 
analysis. ArrayTrack detected 3,453 unique genes divided into 9 significant functional 
networks, the majority found in signaling and cell cycle regulation pathways (p<6 x 10-
5). GOFFA (Gene Ontology for Functional Analysis) determined that the most 
significant molecular function of these genes is sequence-specific DNA binding 
transcription factor activity (p<5 x 10-27; n=254 genes). Of the 3,453 unique genes 
identified by ArrayTrack, approximately 55% were hypomethylated in the TP53 
defective group as compared to the ATM defective group. The remaining 45% of 
differentially methylated genes were hypermethylated in the TP53 defective group with 
respect to the ATM defective group. Aberrant hypermethylation was found in clusters of 
FOX, HOX, and SOX genes. Conclusions: Whole genome methylation analysis by 
high-resolution microarrays greatly expands our ability to detect aberrant epigenetic 
events in CLL. Applying this new genomic technology to CLL patients with defects in 
ATM (11q22) or TP53 (17p13) reveals significant differences in methylation patterns 
among these prognostic subgroups. This finding suggests that methylation patterns 
may provide additional prognostic information in CLL. Further studies are necessary to 
define critical methylation targets that modulate CLL proliferation and apoptosis.  
 
H44. Activation of c-MYC in Acute Leukemia 
S. Bhagavathi, H. Aviv 
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson University 
Hospital, New Brunswick, NJ 
Introduction: Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) 
are some of the most common malignancies in children and adults. The genetic events 
involved in their pathogenesis lead to either constitutive activation of oncogenes or 
down regulation of tumor suppressor genes. Pathogenesis due to activation of the c-
MYC oncogene is rare in acute leukemia. Our objective was to determine the incidence 
of c-MYC activation in acute leukemia and to identify genes of c-MYC. Methods: 
Pathology files of UMDNJ-RWJUH were searched using words: “acute leukemia” and 
“c-MYC” from 2005 to 2012. Abnormalities of c-MYC activation due to a translocation or 
amplification were found by karyotype and FISH analyses. In cases of translocation, the 
partner chromosome and gene was identified. Karyotypes were defined as simple or 
complex by having fewer or more than 6 genetic abnormalities respectively. Results: A 
total of 720 cases of acute leukemia (ALL, 300; AML, 420) were diagnosed over 7-
years period and 8 of them (ALL, 4; AML, 4) showed c-MYC activation. The overall 
prevalence of c-MYC activation in acute leukemia was 1% (for ALL, 1.3%; AML, 1%). 
C-MYC was activated by translocation or amplification in 4 cases of AML or ALL each. 
The c-MYC was activated by reciprocal translocation in all cases of ALL and the partner 
gene was either immunoglobulin heavy chain (IgH) or T cell receptor (TCR) (2 cases 
each). However, in case of AML, the c-MYC was activated by amplification all cases (4 
out of 4 cases). The age of patients ranged from 10 to 76 years with an average of 41 
years. The male to female ratio was 1:3. Conclusions: C-MYC abnormalities are rare 
in acute leukemias. The age of patients with T and B-cell ALL was younger (10 to 33 
years, average 17 years). The c-MYC activation was accomplished by translocation 
with the TCR (2 cases of T-ALL), or with IgH (2 cases of B-ALL) and the karyotype was 
simple in two cases and complex in the other two cases. The age of patients with AML 
ranged from 49 to 76 years (average 65). C-MYC activation was accomplished by 
amplification in the form of double minutes or ring or marker chromosomes in all AML 
cases, and the karyotype was complex in 3 patients and simple in one. 
 
H45. Array Comparative Genomic Hybridization (aCGH) post Plasma Cell 
Enrichment Increases Detection of Genomic Aberrations in Plasma Cell 
Neoplasia 
L. Hartmann1, L. Lim2, K. Johnson1, C. Stephenson1, D. Chapman1, M. de Baca1, D. 
Wells1, M. Loken1, B. Tirtorahardjo2, S. Gunn2, B. Zehentner1 
1HematoLogics Inc, Seattle, WA; 2Combimatrix, Irvine , WA. 
Introduction: As a result of genetic heterogeneity, numerous genomic aberrations are 
associated with plasma cell neoplasms (PCNs), including trisomies of odd-numbered 
chromosomes, translocations involving the IGH gene locus and deletions of TP53 or 
13q. The detection of aberrations present in monoclonal plasma cells has implications 
for diagnosis, prognosis and disease monitoring. However, cytogenetic (metaphase) 
analysis is often hampered by the inherently low proliferation rate of abnormal plasma 
cells (PCs) in vitro and interphase fluorescence in situ hybridization (FISH) analysis is 
limited to the number of genomic loci chosen by a laboratory to assay. Array CGH 
(aCGH) provides a powerful analysis tool in PCNs as it circumvents the major 
disadvantages of cytogenomic analysis and FISH. Array CGH is independent of the 
mitotic activity of malignant PCs and also enables evaluation of the entire genome at a 
submicroscopic level. Methods: We tested 33 bone marrow specimens with known 
PCN for the presence of genomic aberrations using microarray analysis in combination 
with PC enrichment and results were compared to FISH and cytogenetics findings. The 
percentage of monoclonal PC in the unpurified samples varied between 1.2- 67% 
(median 12%) and PC enrichment was performed by magnetic activated cell sorting 
(MACS). Several microarray platforms were evaluated to assess the genomic copy 
number status: bacterial artificial chromosome (BAC), oligonucleotide as well as single 
nucleotide polymorphism (SNP) array. Results: Cytogenetic analysis revealed PCN 
related genomic aberrations in 15% of tested specimen. In contrast, FISH and aCGH 
results were positive in 83.7% and 90.9% of cases, respectively. On average, 2.6 
abnormalities per case were detected by FISH, compared to 6.6 by aCGH. In addition 
to increased detection rate, aCGH results were also superior for disease risk 
stratification. Risk stratification was not possible for 17/33 patients (51%) using FISH 
findings alone. However, aCGH analysis was able to assign this patient subset to 10 
standard, 4 intermediate and 3 high risk categories. Conclusions: This study 
demonstrates the superiority of aCGH following plasma cell enrichment as compared to 
FISH and conventional cytogenetics. The implementation of array CGH into the 
diagnostic work-up of patients with PCNs allows full characterization of chromosome 
gains and losses and is consequently a powerful tool for prognostic assessment and 
risk stratification in this disease. 
 
H46. T Cell Receptor Gamma Gene Rearrangement Clonality studies: A Pilot 
Study Using “Percent Area” for Interpretation 
D.M. Itani1, S.M. Itani2, K.R. Roache1, C.L. Vnencak-Jones1 
1Vanderbilt University Medical Center, Nashville , TN; 2UC Berkeley, Berkeley, CA. 
Introduction: T cell receptor gamma gene (TRGȖ) rearrangement testing is used to 
detect clonality. The results can support a morphologic or clinical diagnosis and can 
provide a molecular marker for monitoring of disease. Common interpretation methods 
include calculation of peak height ratio (RN) or normalized X2 error (ND). We evaluated 
a series of specimens by identifying a significant population(s) (SP) of cells and 
determining the percent burden of the SP within the polyclonal background. SP is any 
population above background and could be explained by clinical-immunologic-
histopathologic (CIH) findings. Methods: Nineteen peripheral blood (PB) and 10 bone 
marrow (BM) samples with no expected clonal rearrangement of TRGȖ based on CIH, 
were used as controls and compared to 87 sequential test cases that included primarily 
BM, PB, skin and lymph nodes. Multiplex PCR was performed using reported primers (J 
Mol Diag 2003; 5:82–87) that were modified with fluorescent labeled V region primers of 
different colors. Amplicons were detected using capillary electrophoresis. Tabular data 
was extracted in a .csv format and results calculated using Matlab. The percent area 
(PA) of the prominent peak(s) representing one or two SP was calculated and equated 
to the area generated from all peaks. The CIH-based PA results were compared to RN 
(cut-off 3) and X2 ND (cut-off1) values. Results: Controls showed insignificant 
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prominent peak(s) with average PA=9.7 ±4.9%; average RN =1.6; and average X2 
ND=0.06. 46/87 test cases showed insignificant prominent peak(s) with average PA= 
9.0±4.1%; average RN= 2.2; average X2 ND= 0.29. 21/87 samples had a malignant 
population. 14/21 had one SP; average PA =86.1±14.7%. 7/21 had two SP; average 
PA=53±11.5% in primary SP; average PA=26.2 ±7.01 in second SP. 8/87 showed 
treatment related SP (TRSP); 1/8 had two TRSP; PA=43.0 &13.2% and 7/8 showed 
one TRSP; average PA= 46±18%. 5/87 cases with SP were referral cases with no CIH 
available for correlations. 7/87 cases had a SP; average PA=47.5±24.6% however CIH 
was not definitive in determining the nature of the SP (Malignant vs TRSP). Traditional 
RN and X2 ND calculations did not correlate with PA in all cases and in some instances 
may have led to erroneous reporting. Conclusions: Percent area of a prominent peak 
(s) may be an alternative way of analyzing and reporting TRGȖ results. This method 
identifies a significant population(s), determines the percent burden within the specimen 
and clarifies the relevance of the significant population in the context of clinical and 
morphologic findings. 
 
H47. SNP Microarray Analysis to Further Characterize Genomic Abnormalities 
in 30 Pediatric Oncology Cases 
T.A. Smolarek, S.L. Zimmerman 
Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 
Introduction: SNP microarray analysis is valuable in the characterization of previously 
identified chromosomal abnormalities and is essential in the identification of novel 
genomic changes that previously have been unappreciated. This technology can be 
applied to oncology cases to identify novel DNA copy number changes, clarify identified 
chromosome abnormalities, as well as identify regions of loss of heterozygosity (LOH) 
that will more fully characterize the genome. Methods: Conventional chromosome 
analysis, fluorescence in situ hybridization (FISH) and SNP array analyses were 
performed on samples from 30 patients (15 pre-B or B-cell ALL, 2 T-cell ALL, 2 T-
myeloid leukemia, one MDS, eight AML and two with other diagnoses). The Illumina 
610-Quad chip was used for the analysis in 10 cases, whereas the remaining 20 cases 
were analyzed using the Omni1-Quad chip. Results: Abnormal array results were 
identified in 28 cases. Novel abnormalities were identified in 22 cases, whereas 5 
showed the expected abnormalities. One had an abnormality that was of unknown 
significance. LOH was identified in 5 of the cases. Three patients (AML, MDS, HLH 
immunodeficiency) (30%) had monosomy 7 that was identified by FISH, chromosome, 
and SNP array. For the 2 remaining cases with no array abnormalities, 1 showed 
normal histology, whereas the other showed a clinically significant balanced 
translocation. Conclusions: These studies suggest that the integration of conventional 
chromosome analysis, FISH, and SNP array results will be essential in the identification 
of potential novel abnormalities that may be important in staging, prognosis, and 
treatment.  
 
H48. Validation of BCR-ABL Mbcr Quantification with International Scale Using 
the Qiagen Rotor-Gene Q Platform 
W. Xu, Q. Sun, S. Schmitt, Z.Y. Pessetto, L. Tilzer, A.K. Godwin 
The University of Kansas Medical Ceneter, Kansas City, KS. 
Introduction: The quantification of BCR-ABL Mbcr b3a2 & b2a2 fusion gene transcript 
levels is critical for assessing therapeutic response in patients with CML and some 
patients with AML. Substantial variations occurring in real-time quantitative PCR 
performed across different laboratories poses challenges for clinical practice. The 
introduction and use of the BCR-ABL international scale (IS) helps to improve the 
comparability of results between laboratories. Methods: Samples were obtained from 
both internal and reference laboratories. RNA was extracted from bone marrow or blood 
samples using the QIAamp RNA blood mini kit. Strand cDNA was synthesized from 
total RNA, and then used as a template to quantify BCR-ABL copy numbers using the 
Ipsogen BCR-ABL Mbcr IS-MMR kit on a Qiagen Rotor-Gene Q platform. BCR-ABL 
copy numbers were then transformed to the IS using obtained IS-CAL values. Results: 
A total of 63 samples were tested blinded in the validation study. The reportable range 
observed was 0.002% - 79.84% (corresponding to 3 to 107,088 copies of BCR-ABL). 
0.1% of IS-NCN was used as a cutoff for MMR. Analytic sensitivity and specificity of 
100% were achieved, though there were some variations in the low end of detection 
limits. Conclusions: BCR-ABL Mbcr quantification with the IS using the Ipsogen BCR-
ABL Mbcr IS-MMR kit and the Qiagen Rotor-Gene Q platform is readily applicable to 
clinical testing and demonstrates excellent performance and reproducibility. The 
quantification of BCR-ABL with the IS will facilitate the planning and management of 
personalized treatment for CML and Ph+ AML patients. 
 
H49. SNP/CGH Array Can Identify Clonal Evolution in Acute Myelogenous 
Leukemia 
L. Hartmann, C. Stephenson, K. Johnson, D. Chapman, S. Smading, T. Burnworth, M. 
de Baca, D. Wells, M. Loken, B. Zehentner 
HematoLogics Inc, Seattle, WA 
Introduction: Single nucleotide polymorphism (SNP) arrays were originally used for 
genome wide association studies. Of recent interest is SNP array analysis in the 
context of hematopoietic malignancies. SNP arrays have several advantages over more 
routine tests (metaphase analysis and fluorescence in situ hybridization [FISH]) as the 
genome can be evaluated at the submicroscopic level in its entirety with a single assay. 
SNP arrays detect copy number gains and losses, provide genotype information and 
allow identification of allelic imbalances such as copy number neutral loss of 
heterozygosity (cnLOH). SNP arrays are of limited use, however, in the identification of 
low-level mosaicism. In two AML case studies presented here, we demonstrate how 
manual re-analysis of initial microarray data can achieve improved resolution of the 
clonal composition, confirming the presence of clonal sub-populations as well as clonal 
evolution. Methods: DNA from two bone marrow aspirates with acute myelogenous 
leukemia (AML) were investigated for the presence of genomic aberrations using the 
Agilent SurePrint G3 180K Cancer CGH+SNP microarray. Data was analyzed with the 
Agilent CytoGenomics software. After initial characterization of the major clone 
abnormalities, manual ‘peak re-assignment’ analysis was performed to reveal 
aberrations harbored by a minor clone. Findings were compared with results from FISH 
studies and metaphase analysis. Results: Patient 1: the major clone demonstrated a 
complex set of genomic lesions, including deletion of chromosome 17, 7q-, 7p+, 16q- 
and a 48Mb long interstitial deletion on 5q. Manual peak re-assignment further identified 
a minor clone with additional genomic abnormalities, including a homozygous deletion 
of 7q. With the exception of ploidy status, all SNP/CGH findings, were concordant with 
FISH results. Patient 2: a major clone was detected with +8 and 20p+. Manual peak 
reassignment further characterized a clonal sub-population with additional gains of 
chromosomes 19, 20 and 21. Cytogenetic metaphase and FISH analysis revealed 
clonal evolution, confirming SNP/CGH findings. Conclusions: SNP/CGH array analysis 
allows for additional characterization of clonal sub-populations and, therefore, 
demonstration of clonal evolution. This is a valuable asset for the clinical work-up of 
hematopoietic neoplasms since clonal evolution is associated with disease progression 
and adverse clinical outcome.  
 
H50. Molecular Analysis of IDH2, DNMT3A, EZH2, WT1 and CBL Mutations in 
Acute Myeloid Leukemia Patients with t(8;21)(q22;q22) 
H. Shin1, I. Kim2, E. Lee2, H. Kim3, J. Won4, H. Kim5 
1Pusan National University, Republic of Busan, Korea; 2Pusan National University 
Hospital, Republic of Busan, Korea,; 3Chonnam National University Hwasun Hospital, 
Republic of Hwasun, Korea; 4Soonchunhyang University Hospital, Republic of Seoul, 
Korea; 5Ulsan University Hospital, Republic of Ulsan, Korea. 
Introduction: The development of acute myeloid leukemia (AML) is a multistep 
process that requires at least two genetic abnormalities including epigenetic 
modification for the development of the disease. Although the t(8;21)(q22;q22) is the 
most common translocation in AML with favorable prognosis, 40% to 50% of patients 
relapse, emphasizing the need for risk-adapted treatment approaches. According to 
current findings for the identification of these gene mutations (DNMT3A, TET2, IDH1/2, 
ASXL1, EZH2, etc.), most of which are frequently found in cytogenetically normal AML; 
however, so far little is known about the incidence and distribution patterns of genetic 
and epigenetic mutation in the t(8;21)(q22;q22) AML group. Therefore, the aim of this 
study is to investigate the frequencies and distributions of epigenetic mutations (IDH2, 
DNMT3A, and EZH2) and genetic mutations (WT1 and CBL) in the t(8;21)(q22;q22) 
AML group. Methods: We searched for mutational hot spots of IDH2, DNMT3A, EZH2, 
WT1 and CBL in 94 AML patients with t(8;21)(q22;q22) using the direct DNA 
sequencing of exon-coding sequences. Results: In this study, the incidences of 
mutational hot spots were observed for IDH2 R140Q (2.1%), DNMT3A (5.4%; R882C 
1.1%, M880V 4.2%), EZH2 (3.2%), WT1 (10.7%), and CBL (1.1%) genes, respectively 
(Table 1). Compared to the reported frequencies of IDH2(3.0-8.7%), DNMT3A (22.1%), 
ASXL1 (10.8%), WT1 (6.8%), and CBL (0.6%) in cytogenetically normal AML, the 
mutations of WT1 and CBL gene are more frequently noted; however, the frequencies 
of IDH2 and DNMT3A mutations are relatively lower than other studies. Conclusions: 
It is reported that WT1 mutations are correlated with poor prognosis in cytogenetically 
normal AML patients, the prognostic significance of the WT1 mutated t(8;21) AML 
should be validated prior to clinical implementation. In addition, the low prevalence of 
epigenetic regulatory genes (IDH2, DNMT3A, and EZH2) associated mutations in our 
study highlights the differences in the pathogenesis of t(8;21) versus cytogenetically 
normal AML, at the genetic as well as potentially at the epigenetic level. Relatively, the 
t(8;21) specific characteristics of AML underscore the importance of studying the other 
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genetic and epigenetic molecular biology, as the development of novel therapeutics 
should account for these biologic differences.  
 
H51. A Novel BCR-ABL1 Fusion Identified by Targeted Next Generation 
Sequencing in a Patient with an Atypical Myeloproliferative Neoplasm 
L.A. Frederick1, D.S. Viswanatha1, F. Beardell2 
1Mayo Clinic, Rochester, MN; 2Delaware Clinical and Laboratory Physicians, P.A, 
Newport, DE. 
Introduction: Chronic myeloid leukemia (CML) is characterized by the BCR-ABL1 
fusion mRNA resulting from fusions between BCR exon e14 (or e13) and ABL1 exon 
a2. Uncommon BCR-ABL1 fusion types involving BCR exons e6, e19 and ABL1 a3 
have been described, as well as rarer transcript types. We describe the case of a 60-
year-old male with an atypical myeloproliferative neoplasm (MPN) characterized by 
marked megakaryocytic hyperplasia, bone marrow fibrosis and cytogenetic/FISH 
positivity for the t(9;22)/BCR-ABL1 abnormality. Standard qualitative and quantitative 
RT-PCR investigations revealed only very low level e1-a2 type BCR-ABL1 mRNA, 
incompatible with the cytogenetic analysis. Targeted next generation sequencing (NGS) 
of PCR amplicons revealed a novel BCR-ABL1 fusion with a breakpoint in BCR intron 
8. The patient had suboptimal therapeutic responses to imatinib and nilotinib, and 
achieved only partial cytogenetic response with dasatinib. Methods: Diagnostic RT-
PCR analysis for BCR-ABL1 mRNA was performed with multiplex primers for fusions 
involving BCR e1, e6, e13, 14, e19, e20 and ABL1 a2 and a3 exons. Quantitative RT-
PCR for the e13/e14-a2 and e1-a2 fusion types was performed using the Cepheid 
GeneXpert and an in house developed assay respectively. Rapid Amplification of cDNA 
Ends (RACE) was performed and products analyzed by Sanger sequencing, and NGS 
(Ion Torrent PGM). The novel fusion was confirmed by RT-PCR and sequencing. 
Results: Diagnostic RT-PCR was weakly positive only for e1-a2 BCR-ABL mRNA 
(quantitative level <0.01%). Standard Sanger sequencing of RACE products was 
uninformative, but NGS detected a novel fusion sequence: BCR exon 8-CABIN1 exon 
34-ABL1 exon 2. This mRNA product is predicted to be in-frame and to generate a 208 
KDa protein. Conclusions: We report the identification of a novel BCR-ABL1 fusion 
product in a t(9;22) positive MPN with atypical clinicopathologic features. Very rare 
reports of alternate BCR breaks involving exon 8 have been described, but these were 
intraexonic and associated with insertions of nucleotides to maintain an open reading 
frame; our case is unique because of the retention of exon 8 and interposition of a 
single complete exon from the downstream CABIN1 gene. These findings resolve the 
molecular nature of an unusual case presentation and suggest an explanation for the 
suboptimal responses to kinase inhibitor therapy. This case also demonstrates the 
utility of targeted NGS to resolve an initially ambiguous BCR-ABL1 abnormality and 
indicates application of this technology for molecular diagnosis of difficult variant gene 
fusion events.  
 
H52. SNP Array Genome-wide Analysis of Plasma Cell Myeloma Detected New 
Genetic Aberrations with Potential Clinical Significance 
L. Zhang, I. Znoyko, J.A. Woolworth, D. Wolff 
Medical University of South Carolina, Charleston, SC. 
Introduction: Routine detection of recurrent genetic changes of plasma cell myeloma 
(PCM) by conventional karyotyping and/or fluorescent in situ hybridization (FISH) 
suffers from low resolution or incomplete coverage. Several studies have confirmed the 
clinical value of single nucleotide polymorphism (SNP) array whole genome profiling as 
a powerful tool in genetic evaluation of PCM. This study investigates the potential 
advantages of high resolution SNP array to detect genetic aberrations with potential 
clinical significance in addition to conventional karyotyping and FISH studies. Methods: 
Bone marrow morphology, flow cytometry, FISH and/or G-band karyotyping were 
performed routinely. Residual bone marrow cells were used for SNP array analysis with 
the approval of the Medical University of South Carolina’s institutional review board. 
Samples containing less than 50% plasma cells were enriched with CD138 antibody 
using immunomagnetic beads. SNP array based analysis was performed using the 
CytoSNP-12 chips (Illumina, Inc.) that covers a majority of cancer related genes. 
Results: Twenty six of the 39 specimens yielded enough DNA for SNP array analysis. 
In the first series of 12 specimens analyzed with the CytoSNP-12 chip. SNP array 
revealed a total of 123 copy number changes (CNAs) and 8 loss of heterozygosity 
(LOH) in 10 cases. The number of abnormalities in each case ranged from 4 to 32 and 
involved each chromosome except chromosome 10. Numerous genes were affected by 
these CNAs and LOHs, including genes associated with cell proliferation, survival, 
apoptosis, cell signaling and DNA damage response. SNP array failed to recognize any 
abnormalities in one case with an extra copy of CCND1 and TP53 deletion at 25% 
mosaicism as identified by FISH, and in another case with only an 11;14 balanced 
translocation. SNP array results correlated well with results of FISH and conventional 
karyotyping when the abnormalities involved gene dosage changes. However, FISH 
detected only 19 well defined abnormalities in 12 cases. In addition, in cases with 
complicated karyotyping, SNP findings helped to clarify the karyotype, such as 
identifying unknown marker chromosomes or chromosomes with additional unknown 
material, so that they could be better defined. Interestingly, possible clonal diversity was 
only identified in one case based on the difference of mosaic percentage. 
Conclusions: SNP microarray analysis provides a useful tool to detect genomic 
aberrations in PCM. The use of this technology not only assists in the identification of 
genetic aberrations of known clinical significance, but can also be used to identify new 
aberrations that may have potential significance. 
 
H53. Characterization of FLT3 ITD Mutations in 1,711 Clinical Samples 
A.R. Cubbon, T.Y. Fodrie, A. Henthorne, C. Salazar, R. Khoshabeh, W.B. Paxton 
LabPMM, San Diego, CA. 
Introduction: The FLT3 internal tandem duplication (ITD) is common mutation in acute 
myeloid leukemia (AML) occurring in approximately 20% of all AML patients. The FLT3 
gene encodes a receptor tyrosine kinase that is important for hematopoietic cell growth 
and differentiation. The ITD mutation occurs in exon 14 or 15 of the FLT3 gene and is 
believed to lead to the constitutive activation of FLT3 through a conformational change 
of the protein. Many studies have found that AML patients with a FLT3 ITD have a 
significantly lower event free survival and overall survival with traditional chemotherapy 
but are good candidates for hematopoietic stem cell transplant. In this study we have 
looked at 1,711 FLT3 ITD positive patients and have characterized the patients by ITD 
insertion size, number of insertions and the presence of a concurrent FLT3 TKD or 
NPM1 exon 12 mutation. Methods: FLT3 ITD, FLT3 TKD, and NPM1 PCR were 
performed on DNA isolated from AML patients undergoing routine clinical testing at 
LabPMM. The PCR reactions contained fluorescently labeled primers for the regions 
surrounding the mutation being detected. All PCR products were analyzed on either an 
ABI 3130xl or an ABI 3500xl capillary electrophoresis. The LabPMM ITD assay has a 
sensitivity of approximately 1% of alleles. All patients with an ITD result were included 
in the study. All data from the clinical samples were completely de-identified. Results: 
ITD insertions varied from 3 bp to 303 bp with over 50% of insertions between 18 bp 
and 48 bp. Approximately 7% harbor the FLT3 TKD mutation and 33% contained more 
than one FLT3 ITD insertion. Of patients that were also tested for NPM1 (N=213) over 
49% had a detectable exon 12 mutation. Conclusions: The majority of AML patients 
harboring ITD mutations have a single mutation and an ITD that is 48 bp. However 
>7% of patients had ITD mutations that are >100 bp, and over 33% of patients had 
more than a single ITD. Interestingly almost 50% of FLT3 ITD positive patients also had 
an NPM1 mutation, which suggests that NPM1 testing is important in FLT3 ITD positive 
patients because of its moderating effect on the poor outcome in patients with FLT3 
ITD. 
 
H54. Detection of Clonal TCRG Gene Rearrangements Using Targeted Deep 
Sequencing 
H. You, Y. Huang, R.L. Ringler, J.H. Shaw, J.E. Miller 
Invivoscribe Technologies, Inc., San Diego, CA 
Introduction: During T cell development, somatic rearrangements of T cell receptor 
gamma (TCRG) genes generate V-J rearrangements that are unique in length and 
sequence within each cell. Since T cell malignancies arise from transformation of a 
single cell, over-represented TCRG rearrangements that have a shared clonal origin 
can be identified in the majority of T cell and some B cell malignancies. Clonal 
rearrangements are generally not seen in benign reactive processes. Rearrangements 
of TCRG appear first and are retained, making TCRG a preferred target for clonality 
assays. PCR-based capillary electrophoresis (PCR-CE) assays are the current gold 
standard for detecting clonal rearrangements. These assays are sensitive, but provide 
limited information. In this study, we developed a TCRG clonality assay using the 
Roche 454 Genome Sequencer FLX and Illumina MiSeq to investigate whether 
Targeted Deep Sequencing (TDS) can be used to detect clonal T cell populations and 
to evaluate if TDS can validate performance of a PCR-CE assay. Methods: DNA from 
12 clonal cell lines and 20 clinical samples (17 FFPE, 2 PB and 1 BM) were used for 
PCR-CE and amplicon sequencing. Ten normal peripheral blood (PB) and 4 tonsil 
DNAs were used as polyclonal controls. Our primers were adapted to enable the PCR 
products to be sequenced on each platform. Data was analyzed by in-house developed 
bioinformatics. Results: Sequencing results generated using both platforms 
demonstrated that CDR3 sequence lengths were consistent with PCR-CE sizing data. V 
and J usage, as well as patient- and clone-specific sequence information required for 
minimal residual disease detection, were identified in all samples tested. TCRG gene 
rearrangements were diverse in tonsil and normal PB samples. The highest percentage 
of unique reads was 1.57% in tonsil and 4.41% in normal PB. The sequencing results 
were reproducible with an R-square for linear fit of 0.96 and 0.95, respectively, in top 
frequency reads of clinical samples between MiSeq repeats and between 454 runs, as 
well as linearity for the frequency of sequences generated from 1% to 20% clonal cell 
lines mixed with tonsil DNA. Conclusions: T cell clonality can be detected using both 
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Roche 454 Genome Sequencer FLX and Illumina MiSeq. Data from both platforms 
correlated strongly with and support the results from the PCR-CE assay. We conclude 
that targeted deep sequencing can effectively detect clonal TCRG gene 
rearrangements and offers a number of potential advantages, which include sequence 
information critical for subsequent monitoring of minimal residual disease.  
 
H55. Diagnostic Role of a SNP Microarray in the Evaluation of Patients with 
Myelodysplastic Syndrome (MDS) 
S. Schwartz, R. Thomason, J. Tepperberg, P. Papenhausen, S.M. Anderson 
Laboratory Corporation of America, Research Triangle Park, NC. 
Introduction: The diagnosis of myelodysplastic syndromes (MDS) is many times 
complex and often requires correlation of morphologic findings with the results of 
ancillary tests such flow cytometry and cytogenetics. It is not uncommon for cases to 
remain equivocal based on the results of these tests. In this study, the utility of 
microarray analysis to augment the diagnosis of myelodysplasia is investigated. 
Methods: To determine the efficacy of this technology in MDS patients, a two phase 
study was undertaken, involving over 160 clinical specimens. In both parts of the study 
samples were evaluated initially with cytogenetics and/or FISH, and then with the 
Affymetrix SNP microarray analysis. Two different Affymetrix SNP platforms were 
utilized; the 6.0 version in the initial evaluations, and the Cytoscan HD platform in the 
latter part of the study. The initial study involved samples from patients diagnosed with 
MDS, both with and without chromosomal findings. The second phase of the study 
involved a group of low risk MDS patients who were evaluated by pathology and 
molecular technologies. In this group, neither morphology or flow cytometry could be 
utilized by a hematopathologist to make a definitive diagnosis. Results: In the initial 
study, our evaluation revealed that 30% of patients with a normal karyotype had a 
detectable abnormality by the array analysis. It also showed that in cytogenetically 
abnormal patients, numerous additional abnormalities could be detected by the array 
analysis. In the second phase of the study, cytogenetic/FISH analysis established a 
clonal diagnosis in 38% of the patients, whereas the array analysis detected a clonal 
abnormality (either dosage related or copy neutral aUPD) in 62% of the patients. 
Conclusions: The results from these studies show the importance and efficacy of 
utilizing microarrays in the study of MDS. Findings of particular significance include: (1) 
The microarray detection of abnormalities in 30% of cases that were initially considered 
normal by cytogenetics and/or FISH; (2) In cases determined to be abnormal by 
cytogenetics and/or FISH, additional abnormalities were detected by the microarray 
analysis in 51% of patients; (3) Prognostic/diagnostic information was obtained in over 
37% of the patients studied; (4) Acquired Uniparental disomy (aUPD) was detected in 
23% of the patients with abnormal cytogenetic findings; (5) Utilization of the SNP array 
was instrumental in allowing an independent diagnosis in patients without other testing; 
and (6) These studies provide a new paradigm for the diagnosis of patients with 
suspected MDS. 
 
H56. A Comprehensive T Cell Receptor Gamma Gene Rearrangement Assay 
and Interpretive Algorithm For Data Analysis 
R. Ringler, J.E. Miller, J. Shaw 
Invivoscribe, San Diego, CA. 
Introduction: Clonality testing of the T cell receptor gamma (TCRG) gene is often 
included in the routine diagnostic evaluation of lymphoproliferative disorders, as clonal 
TCRG rearrangements are present in >90% of T-ALL and a majority of T cell and some 
B cell malignancies, but they are generally not present in reactive lesions. However, 
most TCRG assays rely on subjective interpretation of testing data, which can result in 
over-interpretation of minor peaks that can lead to false-positive calls. Here we present 
an improved TCRG Gene Rearrangement Assay 2.0 (TCRG V2) and an objective 
algorithm developed for TCRG data analysis. TCRG V2 uses a single master mix and 
targets all known TCRG variable regions and joining regions that are rearranged in 
lymphoid malignancies. The algorithm analyzes TCRG V2 output data, which includes 
calculating relative peak height ratio (RPR) and D(x) values for each peak. The RPR is 
calculated by dividing the height of each peak by the smaller of its neighboring peaks. 
The D(x) value is based on a variation of the Kolmogorov-Smirnov test, which 
compares two empirical distributions and determines whether they are statistically 
different. Methods: All samples were amplified with TCRG V2, and the resulting PCR 
products were run on an ABI 3130xl capillary electrophoresis instrument. The size and 
peak height data were analyzed with the TCRG Algorithm worksheet. Twenty samples, 
which included blood, bone marrow, and FFPE samples, were sequenced using the 
Roche 454 platform and assayed with TCRG V2. Six DNA samples from cell lines 
known to be positive for TCRG rearrangements were diluted into tonsil DNA at 5% and 
also tested. Results: All seven samples determined to be positive for clonality on the 
basis sequencing were also identified as positive for clonality using the algorithm and 
data generated by the TCRG assay. Nine of twelve samples identified as negative for 
the presence of clonality by sequencing were concordant. All six of the 5% control cell 
lines were identified as clonal. Conclusions: The TCRG V2 assay and interpretive 
algorithm presented here yield a more objective and comprehensive analysis of TCRG 
gene rearrangements than existing approaches - even assays that use multiple master 
mixes to target all VȖ and JȖ gene segments. When clonality is present, this improved 
assay generally detects biallelic clonal rearrangements, which are expected and 
present in most T cell malignancies. The algorithm introduced here also offers an 
objective alternative to traditional, subjective interpretation. 
 
H57. Assessment of Post-RNA Extraction Variability in BCR/ABL1 Transcript 
Levels Using Three Commercial Kits 
S. Bhagavathi, T. Kirn, D. Galkowski, A. Sahota 
University of Medicine and Dentistry of New Jersey–Robert Wood Johnson University 
Hospital, New Brunswick, NJ. 
Introduction: The molecular monitoring of BCR/ABL1 transcript levels by real time 
quantitative PCR has been performed using a variety of internal control genes, 
including ABL1 and G6PDH. To control for method variability among laboratories, 
efforts are underway to adopt a standardized international scale (IS) for reporting 
BCR/ABL1 quantitative data. As part of the process of transitioning to an IS-compliant 
protocol, we compared the performance of two kits with IS calibrator (BCR/ABL1 Quant 
from Asuragen and FusionQuant from Ipsogen) with the currently used Roche kit. 
Herein, we report our observations on the wide variability in BCR/ABL1 transcript levels 
using these three kits. Methods: RNA was extracted from blood or bone marrow using 
Qiagen kits and 21 RNA samples (including six for proficiency testing) were analyzed. 
The fusion transcript status of these samples has been previously verified. In addition, 
11 samples (8 positive and 3 negative for m-mbr) were procured from another hospital 
for inter-laboratory comparison of IS-normalized m-mbr transcript levels using Ipsogen 
reagents. Samples were processed and data analyzed in accordance with kit 
instructions. The Roche kit uses G6PDH as a control gene and hybridization probes for 
transcript detection; the Asuragen and Ipsogen kits use ABL1 as a control and 
hydrolysis probes for detection. In the Asuragen and Roche kits, the BCR/ABL1 major 
(b2a2, b3a2) and minor (e1a2) transcripts are amplified in a multiplex reaction. In the 
Ipsogen kit, separate PCR reactions are performed for the major and minor transcripts. 
Standard statistical procedures were used for method comparison and data analysis. 
Results: Although categorical agreement (positive or negative) was good, there was no 
direct quantitative correlation between the values generated using the three kits; 
nevertheless, there was better agreement between the Asuragen and Ipsogen kits. Six 
of the 21 samples contained the minor transcript in addition to one of the major 
transcripts but, contrary to expectations, BCR/ABL1 transcript levels in these samples 
were not consistently elevated in the Roche or Asuragen protocols relative to the 
Ipsogen protocol. A 1/40,000 dilution of 500 ng of K562 mRNA could be readily 
detected using all three kits. There was no significant difference in the IS-normalized 
values for the eight m-mbr positive samples used for inter-laboratory assessment of the 
Ipsogen kit. Conclusions: Quantitative analysis of BCR/ABL1 transcripts is a multistep 
process subject to many variables, and our findings demonstrate that analytical 
procedures post-RNA extraction are a major source of this variation. 
 
H58. Charaterization of 6q Deletions in Chronic Lymphocytic Leukemia (CLL) 
Using Array-Based Comparative Genomic Hybridization 
K.P. Patel, M.G. Luthra, E.J. Schlette, W. Wierda, M.J. Keating, L.J. Medeiros, L.V. 
Abruzzo, B.M. Mishra, R. Luthra, R.L. Sargent 
University of Texas-MD Anderson Cancer Center, Houston, TX. 
Introduction: Routine clinical testing for specific alterations of chromosomes (chr) 11, 
12, 13 and 17 is used for prognostication in CLL. Although deletions in the long arm of 
chromosome 6 (6q) are associated with distinct hematologic features and an 
intermediate prognosis, they are not routinely evaluated in the clinical setting by FISH 
or aCGH assays. Using aCGH we studied a series of CLL cases to accurately define 
the deleted region(s) of chr 6q and to identify unique protein-coding/microRNA (miRNA) 
genes potentially involved in the pathogenesis of CLL secondary to this genomic 
aberration. Methods: A 60-mer, 44K probe oligonucleotide array with a 50-75kb 
average spatial resolution was augmented with high-density probe tiling at loci 
frequently aberrant in CLL (Agilent Technologies, Santa Clara, CA). Labeled genomic 
DNA from CLL patients was hybridized against reference DNA. We analyzed the aCGH 
data using CGH Analytics (Agilent) and Nexus software (Biodiscovery; El Segundo, 
CA), and compared the results with G-banded karyotypes and aberration percentages 
from 200-cell FISH studies using probes for ATM (11q22.3), CEP12, 13q14.3/D13S319, 
LAMP1 (13q34) and TP53 (17p13.1) (Abbott, Downers Grove, IL). We also reviewed 
clinicopathologic data. Results: Out of 120 CLL cases with 6q aberrations identified by 
conventional karyotyping, 29 had DNA available for study. 21/29 (72%) showed 
complete aCGH/cytogenetic concordance. 8/29 (28%) showed 6q aberrations in a 
limited number of metaphases and were below the aCGH level of detection. Chr 6q 
deletions varied from partial (44 Mb) to complete (109 Mb). The telomeric end of the 
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deleted region frequently involved 6q14.1 (10/21, 48%). All cases showed a minimally 
deleted region of 5.5 Mb, corresponding to cytobands 6q21-q22.1, which includes 44 
genes affecting diverse cellular processes but no known miRNAs. FISH results 
available in 21 cases with chr 6q deletions showed additional aberrations in chr 11 
(6/21, 29%), chr 12 (2/21, 10%), chr 13 (6/21, 29%), and chr 17 (10/21, 48%). Overall, 
18/21 (86%) cases with 6q deletions showed an additional cytogenetic abnormality by 
either Conclusions: Our data show that although chr 6q deletions varied, all cases 
shared a minimally deleted region of 5.5 Mb. Concurrent aberrations in chr 11, 13, and 
17 were common. Further studies are required to determine the alterations in gene 
expression that result from 6q deletions and their relationship to CLL pathogenesis. In 
the interim, aCGH permits accurate delineation of chr 6q aberrations for use in routine 
clinical testing of CLL. 
 
H59. Cytogenetic Analysis Helps Identification of Prognostic Groups in 
Multiple Myeloma: The Experience from India  
P. Kadam Amare, H. Jain, S. Nikhalje, M. Sengar, H. Menon, N. Inamdar, M. 
Subramanian, Y. Badri, R. Nair 
Tata Memorial Hospital, Mumbai, India. 
Introduction: The genetic picture of multiple myeloma (MM) is heterogeneous. Specific 
genetic aberrations have disclosed their prognostic significance that has become an 
integral part of disease management. The genetic heterogeneity enabled the 
categorization of disease in to several subclasses, hyperdiploid group, IgH translocation 
group and chromosome 13 aberration group. In comparison with conventional 
karyotyping, FISH could efficiently detect various genetic changes in non-cycling 
plasma cells in 50% to 90% of MM cases.The present studies were undertaken to 
evaluate the prevalence, clinical relevance of cytogenetic abnormalities with an 
approach to implement the information in the diagnosis and disease management of de 
novo MM in our group of patients. Methods: A total of 412 patients were studied by 
interphase- and metaphase-FISH. Results: Of 412, 255 cases (62%) showed recurrent 
cytogenetic changes. The incidence of chromosome 13 aberrations, TP53 deletion, IgH 
translocations and hyperdiploidy was 42%, 10%, 45% and 57% respectively. Low 
prevalence of t(11;14):IgH-CCND1 XT (9%) and higher frequency of t(4;14): IgH-
FGFR3 (17%) in our series was an interesting observation probably due to ethnic 
diversity. Clustering of chromosome 13 aberrations and IgH translocations in non-
hyperdiploidy with poor risk clinical and laboratory features confirmed prognostic 
significance of ploidy in MM. Non-hyperdiploid chromosome 13 aberration group and 
non-hyperdiploid variant IgH translocation specifically t(4;14):IgH-FGFR3 group was 
found to be high risk group due to its significant correlation with high serum ȕ2 
microglobulin, increase in plasma cells and advanced stage of disease. The sole 
hyperdiploid group was found to be a low risk group. These findings also confirmed 
prognostic significance of ploidy, chromosome 13 aberrations and IgH translocations in 
MM. A small clone size of sole del(13q)/-13 than that of del(13q)/-13 associated with 
IgH translocations indicated that chromosome 13 aberration is probably an initiating 
event in sole 13 aberration group and progressive event in IgH plus 13 aberration 
group. Conclusions: In conclusion, identification of high risk cytogenetic groups 
alongwith selective gene expression profile should be explored for prognostic 
classification and development of risk adapted treatment strategies for better 
management of disease. 
 
H60. Detection of Chromosomal Rearrangement and Gene Mutation by 
Expression Profiling on a Chip for Acute Myeloid Leukemia 
C. Arana Yi1, P. Yadav1, M. Musick1, K. Scott1, N. Flomenberg1, M. Weiss1, M. Kasner1, 
W. Hoos2, R. Schaller3, P. Fortina1 
1Thomas Jefferson University, Philadelphia, PA; 2Skyline Diagnostics, Rotterdam, 
Netherlands; 3Affymetrix, Inc, Santa Clara, CA. 
Introduction: The diagnosis of Acute Myeloid Leukemia (AML) requires a bone marrow 
examination. 50% of AML has cytogenetic abnormalities or mutations in FLT3, 
nucleophosmin (NMP1), KIT or CEBPA genes. The analysis of these abnormalities can 
take two weeks. The AMLprofilerTM test RUO is a qualitative custom assay developed 
by Skyline Diagnostics and built on the Affymetrix GeneChip expression analysis 
platform using Affymetrix in-vitro diagnostics (IVD) reagents. It has the potential to 
simplify recognition of AML subtypes, give faster results, improving AML classification 
and therapy. Methods: Total RNA (5 ȝg) from twelve de-identified, bone marrow 
samples and two positive controls that passed QC parameters were processed using 
the Affymetrix’s FDA cleared/CE IVD Gene Profiling Reagent Kit. The cRNA was 
generated, purified, fragmented and biotinylated after quality check. cRNA with several 
quality spike-in controls was loaded on the custom chips for hybridization in the 
GeneChip oven 645. It was followed by staining and washing in the Gene chip FS450 
Dx system They were then processed on an Affymetrix Dx2 system using Affymetrix’ 
Console genotyping software with the AML Profiler RUO 2.0 Assay Software Module 
(ASM) on a secure server. The report and QC results were generated automatically. 
Results: Fourteen samples (eleven with newly diagnosed AML, one normal and two 
positive controls) were analyzed with the AMLprofilerTM assay. The AML samples were 
previously assessed for cytogenetics and gene mutations as: one with normal 
cytogenetics, two with normal cytogenetics and FLT 3-ITD positive, three with inv[16], 
one with t[8;21], two with t[15;17], one with NPM1 WT and one with complex 
cytogenetics. Ten of the AML samples matched the cytogenetics. Discrepancy was 
observed in the t[8;21] sample despite repeated analysis, the cause of which is under 
investigation. The two positive controls confirmed t[8;21] and inv 16 abnormalities. EVl1 
was high in one FLT3 ITD sample and one with complex cytogenetics, low BAALC was 
detected in one normal cytogenetic AML sample and the normal subject. CEBPA 
double mutation was negative in all samples. NPM 1 was detected in one sample with 
normal cytogenetics only and in one with FLT3 ITD mutation. Conclusions: The 
AMLprofilerTM RUO assay detects t[8;21], t[15;17] and inv[16], NPM1 mutation types 
A, B and D, CEBPA double mutation, EVI1 high expression and BAALC low expression. 
In 3 days one test provided a reliable and feasible assessment of the most common 
chromosomal and gene mutations in AML. 
 
H61. Integrated Transcriptional and Functional Screening Identifies Novel 
Regulators of Lymphoid Lineage Determination 
E. Laurenti1, S. Doulatov2, S. Zandi 1, I. Plumb1, M. Doedens1, C. April2, J. Fan2, J. Dick1 
1Ontario Cancer Instutite, Toronto, Canada; 2Illumina, San Diego, CA. 
Introduction: The hematopoietic system is a highly regulated cellular hierarchy, 
responsible for the day-to-day production of mature blood cells that can be divided in 
two major lineages, myeloid and lymphoid. In contrast to mice, very few transcription 
factors (TFs) regulating early lineage decisions have been identified in human 
hematopoiesis. Methods: We previously demonstrated that single Multi-Lymphoid 
Progenitors (MLPs) retain the capacity to differentiate into all lymphoid cell types, as 
well as monocytes and dendritic cells, indicating that molecularly, the choice between 
any of these fates must be determined at this stage. To identify TFs responsible for 
lymphoid vs. myeloid commitment, we interrogated MLP gene expression in the context 
of a high-resolution transcriptome analysis of 10 human hematopoietic stem and 
progenitor populations. Consistent with their multipotentiality, MLPs displayed balanced 
stem, lymphoid and myeloid transcriptional programs. We then used a combination of 
computational approaches to extract 10 lineage-modulating TFs, the function of which 
we tested in a knock-down screen based on a novel clonal assay for simultaneous 
read-out of B, NK, and myeloid cell. Results: Altered cell fate decisions from single 
MLPs, in particular decreased commitment towards the B cell lineage, were observed 
upon knock-down of half of our candidates. Interestingly, 4 of these (BCL11A, BCL6, 
EBF1, SOX4) have been so far implicated in later stages of murine B cell development, 
suggesting that these TFs not only contribute to maturation of B cells, but also favor 
initial commitment. Preliminary data also provides the first report for a function of 
TEAD1, a transcriptional mediator of the Hippo pathway, in a hematopoietic context. 
Conclusions: In summary, we have developed a genome-wide strategy that 
successfully identified novel regulators of adoption of human lymphoid fate in primary 
human cells.  
 
INFECTIOUS DISEASES 
 
ID01. A Comparative Evaluation of the Siemens VERSANT HCV Genotype 2.0 
(LiPA) and GenMark eSensor HCV Genotyping Tests 
T.E. Schutzbank, J.C. Romack, M.E. Tibbs, C.H. Tutt, A.D. Light, V. Michel-Treil 
Covance Central Laboratory Services, Indianapolis, IN. 
Introduction: Infections caused by Hepatitis C virus (HCV) genotypes, 1a and 1b, are 
more refractory to antiviral therapy than those caused by other genotypes. HCV 
genotyping is a critical component of the standard of care of HCV-infected patients. 
HCV genotyping tests available to the clinical laboratory include the Siemens 
VERSANT HCV Genotype 2.0 (LiPA) and GenMark eSensor HCV Genotyping assays. 
The latter was recently introduced to the market. This study was designed to compare 
the performance and accuracy of both methods for genotyping HCV. Methods: Ninety-
six HCV positive plasma samples, comprising all six HCV genotypes were tested by 
both methods, including the SeraCare HCV RNA Genotype Performance Panel. The 
GenMark eSensor and Siemens LiPA HCV genotyping assays were performed 
according to the manufacturers’ instructions. The LiPA method has an upfront PCR 
amplification resulting in the production of biotinylated amplicons, followed by 
hybridization of the amplicons to probes captured on a nylon membrane and 
colorimetric detection using streptavidin-alkaline phosphatase. The capture probes 
target both HCV 5’UTR and core gene sequences. The eSensor test employs amplified 
DNA products generated by the Roche Cobas TaqMan HCV version 2 viral load assay. 
After enzymatic conversion to single-stranded DNA, the amplicons are injected into the 
eSensor cartridge, and placed into the eSensor XT-8 instrument for analysis. Results: 
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The Siemens LiPA method successfully genotyped 92 of the 96 patient plasma 
specimens (95.8%). Three of the failed genotypes were due to non-interpretable 
banding patterns, and one was due to inconclusive results in the core region. 
Genotypes were determined for all 96 samples (100%) using the GenMark eSensor 
method. The LiPA method called 57 type 1 samples subtype 1a, 8 of which subtyped 1b 
by GenMark. GenMark called five type 1 samples 1a/1b mixed infections. Nineteen (19) 
samples were called 1b by LiPA, one of which was resulted as a 1a by GenMark. Of the 
remaining samples there were 5 type 2b, 5 type 3, 3 type 4, one type 5, and one type 6, 
which were all in agreement by both methods. The LiPA method was able to subtype 
types 3 and 5; this is not available with the eSensor assay. Conclusions: The 
performance of the GenMark HCV Genotyping assay compared very well against the 
LiPA methodology. The differences between 5’UTR and Core region subtyping among 
type 1 samples needs to be addressed by further research. The GenMark assay offers 
significant processing time and labor savings over the LiPA assay. 
 
ID02. Design, Development, and Performance of the IMDx Flu A/B and RSV for 
Abbott m2000 Assay 
S. Bradley, D. Slater, C. Leslin, A. Jacobs, R. Del Mastro 
IntelligentMDx, Cambridge, MA. 
Introduction: An influx of symptomatic patients during peak flu seasons can impose a 
substantial strain on clinical laboratories that may lack the resources necessary for 
screening large numbers of patients. Fast and reliable diagnostic solutions with high 
volume capacity are necessary to help improve patient care. An automated assay on 
the Abbott m2000 system was developed that provides a high throughput testing option 
for the detection of Flu A/B and RSV. Methods: IMDx has employed its proprietary 
bioinformatics platform, NGENix, to design an in silico screened, qualitative, 
multiplexed, real-time PCR-based assay for the detection and differentiation of 
conserved gene regions in Flu A, Flu B, and RSV A/B viruses. The IMDx Flu A/B and 
RSV for Abbott m2000 assay is validated for use with nasal swabs and nasopharyngeal 
swabs from symptomatic patients. Sample extraction is performed on the Abbott 
m2000sp and amplification and detection is performed on the Abbott m2000rt. Results: 
The IMDx Flu A/B and RSV for Abbott m2000 assay is highly specific, detecting 4 
strains of Flu A, 10 strains of Flu B, and 2 strains of RSV A/B tested. No cross-reactivity 
was detected when the assay was tested against 30 viruses and microorganisms 
commonly found in respiratory specimens. No interference from 20 endogenous and 
exogenous compounds was observed. The limit of detection of the IMDx Flu A/B and 
RSV for Abbott m2000 assay was determined for 4 strains of influenza A, 2 strains of 
Influenza B, and 2 strains of RSV and ranged from 4.3 to 43 TCID50/mL. Compared to 
standard viral culture methods, the IMDx Flu A/B and RSV for Abbott m2000 assay 
exhibits 100% sensitivity and 100% specificity for Flu A (n=117), 100% sensitivity and 
100% specificity for Flu B (n=116), and 97.0% sensitivity and 100% specificity for RSV 
A/B (n=115). Conclusions: The multiplexing capability and flexible throughput capacity 
of the IMDx Flu A/B and RSV for Abbott m2000 make it a desirable option for testing 
large numbers of symptomatic patients. The fully automated assay design eliminates 
hands-on time needed for viral sample preparation and provides same-day results for 
up to 94 patients. The IMDx Flu A/B and RSV for Abbott m2000 assay is targeted to be 
CE-marked in 2012. The IMDx Flu A/B and RSV for Abbott m2000 assay is not 
available for sale in US or Canada. 
 
ID03. Impact of Mutation Type and Context on DNA Melting Peak Width in a 
High Resolution Melting (HRM) Diversity Assay 
M.M. Cousins1, D.A. Swan2, C.A. Magaret2, D. Donnell2, S.H. Eshleman1 
1Johns Hopkins University School of Medicine, Baltimore, MD; 2Fred Hutchinson 
Cancer Research Center, Seattle, WA. 
Introduction: Most high resolution melting (HRM) applications are based on 
measurement of the peak melting temperature (Tm) of DNA samples. In contrast, the 
HRM diversity assay uses DNA melting peak width (HRM score) to quantify the 
diversity of a DNA sample. The HRM diversity assay has been used to study the 
diversity of human immunodeficiency virus (HIV) in samples from infected individuals. In 
this study, we analyzed the impact of mutation type and context on HRM score. 
Methods: DNA from three regions of the HIV genome was cloned (HXB2; gag, pol, and 
env, ~1000 base pairs [bp] each). Site-directed mutagenesis was used to generate 
plasmids with single base changes and defined insertions and deletions. Mutant and 
wild type plasmids were mixed in varying concentrations to generate mixed DNA 
populations. The plasmids (pure or mixed) were used as templates for amplification in 
the HRM diversity assay. Varied primer sets were used for amplification to vary the 
mutation position in the amplicons and to vary amplicon length. Plasmids and plasmid 
mixtures were analyzed to evaluate the effects of mutation type, the concentration of 
the mutant variant, and mutation location on HRM score. HRM scores were also 
compared for plasmid-derived amplicons from 12 different regions of the HIV genome to 
evaluate the impact of G/C content on HRM scores. Results: The relative impact of 
mutations on HRM scores (difference in peak width compared to wild type) was as 
follows: 1bp deletion < single base change < 3bp insertion < 9bp insertion. Amplicon 
length and the position of the mutation within the amplicon impacted HRM score. 
Mutations present at concentrations of 5%-95% impacted HRM score. The greatest 
impact was observed when the concentration of the mutation was 50%. G/C content of 
amplicons influenced the temperature at which melting began (T1) and ended (T2), but 
had no impact on HRM score (T2-T1). Conclusions: Many factors can influence the 
width of melting peaks in HRM analysis, including the type of mutation, mutation 
concentration, and the position of the mutation in the amplicon. These data provide new 
insights into the impact of these factors on DNA duplex melting and are therefore 
relevant to the design of assays that measure genetic diversity with HRM technology. 
Similar approaches could be used to examine the impact of these factors on other 
melting peak characteristics. 
 
ID04. Sensitivity of Respiratory Virus Multiplex RT-PCR and Nasopharyngeal 
Viral Loads 
J. Deng1, Z. Ma1, W. Huang2, C. Li1, R. Zhou2, Y. Zheng1, Y. Tang3 
1Shenzhen Children’s Hospital, Shenzhen, China; 2Guangzhou Medical University, 
Guangzhou, China; 3Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Multiplex RT-PCR assays have provided cost-effective tools for detection 
and differentiation of a panel of respiratory viral pathogens. In this study, we evaluated 
the ResPlex V2.0 kit (Qiagen, Germany) that uses a target enriched multiplex RT-PCR 
amplification coupled with a suspension array detection. We also correlated the 
ResPlex assay sensitivity with viral loads in nasopharyngeal swab (NPS) specimens 
determined by quantitative, monoplex real-time TaqMan RT-PCR. Methods: NPS 
specimens were collected from pediatric inpatients with lower respiratory tract infections 
at the time of admission in the Shenzhen Children’s Hospital from May 2009 to April 
2010. Total nucleic acids were extracted by using a EZ1 system (Qiagen, Germany), 
and the ResPlex kit was used to detect and differentiate 17 respiratory viruses and 
genotypes including influenza A virus (IFA), IFB, parainfluenza virus 1 (PIV1), PIV2, 
PIV3, PIV4, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), 
rhinoviruses (RhV), enteroviruses (EnV), bocaviruses (BoV), adenoviruses, four 
coronaviruses (229E, OC43, NL63 and HKU1), and IFA 2009 pandemic H1N1. In 
parallel, 16 real-time TaqMan quantitative RT-PCR assays were used to detect these 
viruses except for RhV. Influenza and parainfluenza viral cultures were also performed. 
Results: Among the total 438 NPS specimens collected during the study period, one or 
more viral pathogens were detected in 274 (62.6%) and 201(45.9%) specimens by 
monoplex TaqMan RT-PCR and multiplex ResPlex RT-PCR, respectively. When results 
from monoplex PCR or cell culture were used as the reference standard, the multiplex 
PCR possessed good specificities ranging from 92.9% to 100.0%. The sensitivity of 
multiplex PCR for PIV3, hMPV, PIV1 and BoV were 73.1%, 70%, 66.7% and 55.6%, 
respectively, whereas low sensitivities (11.1-40.0%) were observed for IFA, EnV, OC43, 
RSV and H1N1. Among the nine viruses/genotypes detected with higher frequencies, 
multiplex PCR sensitivities were correlated significantly with viral loads determined by 
the TaqMan RT-PCR in RSV, OC43, EnV, IFA and H1N1 (p=0.012-0.000). 
Conclusions: The Qiagen ResPlex multiplex RT-PCR kit possesses excellent 
specificity for simultaneous detection of 17 viral pathogens in NPS specimens in 
pediatric inpatients at the time of admission. The sensitivity, in contrast, awaits 
improvement especially for IFA, EnV, OC43, RSV and H1N1. For viruses and 
genotypes including RSV, OC43, EnV, IFA and H1N1, the multiplex PCR sensitivity 
correlated significantly with viral load levels. 
 
ID05. Molecular Typing Links Probiotic Supplement Use as the Source of 
Bacteremia and Endocarditis 
J. Schwartz1, M. Sims1, K. Movva1, K. Sawarynski1, J. Makin1, K. Powell1, S. Singh2, B. 
Robinson-Dunn1, B.L. Boyanton1 
1Beaumont Health System, Royal Oak, MI; 2Metro Infectious Diseases Consultants, 
Rochester Hills, MI. 
Introduction: Lactobacillus species are components of normal human flora and 
probiotic supplements. Some evidence has linked probiotic use to clinical infection, 
especially in immunocompromised hosts; however, molecular data confirming a 
probiotic as the definitive source of an infection in an immunocompetent host is sparse. 
We report a case of invasive disease due to Lactobacillus in a 51-year-old male with a 
history of colon cancer in remission. He developed post-operative sepsis and 
endocarditis following surgical repair of a colovesicular fistula. Several Lactobacillus 
species were cultivated from the patient’s blood and a surgically removed mitral valve. 
Upon further investigation, it was discovered that the patient was consuming several 
probiotic supplements. Methods: Probiotic supplements used by the patient were 
obtained and cultured. All patient and probiotic isolates were identified by phenotypic 
methods and bidirectional 16S rRNA sequencing. Repetitive element PCR (rep-PCR; 
Diversilab, BioMerieux) was performed on all isolates from the probiotic supplements 
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and the patient’s blood and valve cultures. Results: Recovered probiotic isolates 
(n=14) included various Lactobacillus species (rhamnosus [n=3], delbrueckii [n=2], kefiri 
[n=1], plantarum [n=1], salivarius [n=1]), Lactococcus lactis subsp. cremoris (n=1), and 
Streptococcus thermophilus (n=5). Three isolates of Lactobacillus rhamnosus were 
recovered from the patient’s blood and mitral valve. Two patient and two probiotic 
isolates of L. rhamnosus were deemed identical by rep-PCR and linked to a single 
probiotic supplement. The remaining patient and probiotic isolates were unrelated. 
Conclusions: Microorganisms used in probiotic supplements may also cause invasive 
infection in select immunocompetent patients. To our knowledge, this is the first report 
confirming the source of this type of infection using rep-PCR. Molecular typing methods, 
including rep-PCR, are valuable tools for identifying the source of infection among many 
possible potential pathogens. A most intriguing facet of this case is that only 
Lactobacillus rhamnosus caused invasive disease, despite confirmed exposure to 
approximately 30 different types and strains of bacteria and yeast within the probiotic 
supplements used by the patient. Additional research is warranted to elucidate the 
growth, pathogenicity, and virulence factors of Lactobacillus rhamnosus that lead to 
invasive disease in select patient populations. 
 
ID06. Detection and Identification of Bacterial Pathogens in CSF and Sera from 
Meningitis Patients Using PCR-Electrospray Ionization/Mass Spectrometry  
H. Carolan1, M. Salgado2, D. Toleno1, L.B. Blyn1, L.H. Harrison3, D.J. Ecker1, R. 
Sampath1, C. Sacchi2 
1Ibis Biosciences, Inc., Carlsbad, CA; 2Instituto Adolfo Lutz, Sao Paolo, Brazil; 
3University of Pittsburgh, Pittsburgh, PA. 
Introduction: Bacterial meningitis is a serious and often fatal infection. In many 
developing countries, surveillance for bacterial meningitis is hampered by limited use of 
bacterial culture and a high frequency of negative cultures. This problem leads to an 
underestimation of disease burden and assessments of the potential impact of 
vaccination. Non-culture methods, such as real-time PCR, can increase the diagnostic 
yield for bacterial meningitis in both developed and developing countries. Here we 
present a broad PCR approach coupled to electrospray ionization mass spectrometry 
(PCR/ESI-MS) that is capable of detecting both common and atypical bacteria directly 
from clinical specimens. Methods: CSF and sera specimens submitted for meningitis 
diagnosis to Instituto Adolfo Lutz (IAL), which serves as the Brazilian National 
Reference Laboratory for Bacterial Meningitis, were included in the study. Culture and 
real-time PCR analysis was performed on these as described earlier. An aliquot of the 
original sample was analyzed using the PLEX-ID System running the BAC Detection 
(05N13-61) assay. Results: A total of 77 CSF and 94 sera specimens from suspected 
meningitis patients with sufficient leftover volume for PLEX-ID testing were included in 
the study. Of the 77 CSF specimens, 43 were positive by real time PCR and only 19 
were culture positive. In comparison, PLEX-ID identified bacteria in 61 specimens, 
which included all 43 found by real-time PCR. The breakdown of the detections were as 
follows (real-time PCR, PLEX-ID): N. meningitidis (NM) (25, 28), S. pneumoniae (SP) 
(18, 20), Others (0,16). Of the 94 plasma specimens, 33 were real-time PCR positive 
and 5 were culture positive. In contrast, 45 specimens were PLEX-ID positive, including 
29 of the 33 the samples that were real-time PCR positive. The breakdown of the 
detections were as follows: NM (17, 22), SP (12,15), Others (0, 12). Conclusions: 
PLEX-ID using a broad bacterial detection assay is a potentially attractive solution to 
screening for bacterial pathogens in meningitis patients. Preliminary investigations 
using archived CSF and sera showed 100% and 96% concordance, compared to real-
time PCR. In addition, PLEX-ID detected one or more pathogens in 18/34 negative 
CSF, which is a 53% reduction of the negative CSF samples number compared to real-
time PCR. For sera, we were able to detect pathogens in 12/61 negative sera by real-
time PCR, which represents a 20% reduction of the negative sera samples. The clinical 
relevance of the significantly increased pathogen detection rates by PLEX-ID merits 
further investigation.  
 
ID07. Detection of Bacterial, Viral, and Protozoan Pathogens Using the 
FilmArray Gastrointestinal (GI) System  
M. Rogatcheva1, M. Vaughn1, R. Wallace1, R. Crisp1, G. Alger1, J. Gardner1, B. Harrel1, 
T. Barney2, A. Pavia3, J. Daly3, T. Barney2 
1Idaho Technology, Inc, Salt Lake City, UT; 2Primary Children’s Medical Center, Salt 
Lake City, UT; 3University of Utah, Salt Lake City, UT. 
Introduction: The number and diversity of diarrhea causing pathogens together with 
the overlapping clinical presentation pose major challenges in the diagnosis of 
infectious diarrhea. Current diagnostic practice involves multiple tests, often laborious 
and slow, resulting in low positive yield. Idaho Technology, Inc. is developing a fully 
automated sample to result FilmArray test for simultaneous detection of 25 
gastrointestinal (GI) pathogens: diarrheagenic E. coli (STEC and serotype O157:H7, 
EAEC, EPEC, EIEC, and ETEC), Aeromonas, Vibrio, V. cholerae, Shigella, S. 
dysenteriae, Salmonella, Campylobacter, Yersinia enterocolitica, Clostridium difficile 
and C. difficile NAP1, Plesiomonas shigelloides, Norovirus, Rotavirus, Human 
Astrovirus, Adenovirus 40/41, Cryptosporidium, Giardia lamblia, Cyclospora 
cayetanensis, and Entamoeba histolytica. The FilmArray GI pathogens detection (FA 
GI) system processes diluted fecal specimen and provides a fully automated report in 
one hour. Methods: The Limit of Detection (LOD) of the FA GI System was estimated 
using (i) fecal specimens spiked with well-characterized strains and (ii) viral RNAs from 
clinical specimens. The performance of the FA GI System was assessed on 138 
residual stool specimens from children with diarrhea comprised of 84 ‘positive’ stools 
with at least one identified pathogen and 54 stools negative for all conducted tests. The 
initial clinical testing included only laboratory tests requested by physicians; each 
specimen was tested for 1 to 7 pathogens, whereas the FA GI system assessed each 
specimen for 25 pathogens with a single test. The FA GI reports were compared with 
lab detections for concordance. The discrepancies were resolved by secondary tests 
and sequencing. Results: Preliminary LOD of the FA GI system was established. The 
comparative testing of clinical specimens demonstrated the advantage of multi-target 
approach: 151 pathogens were detected by the multi-target FA GI test whereas only 87 
were identified by conventional methods. Among 66 pathogens detected by the FA GI 
only, 22 could have been detected using available lab tests if they had been ordered by 
physicians, but 44 were pathogens for which testing was unavailable. Detection was 
highly concordant with the exception of Adenovirus. The FA GI system detected 
pathogens in 44% of ‘negative’ specimens. Co-infections were observed in about 25% 
of patients; suggesting that use of the FA GI system could have contributed to more 
accurate diagnosis in about 30% of ‘positive’ specimens. Conclusions: These results 
demonstrate that the FA GI System provides rapid and accurate detection of 25 
pathogens, which when used in diagnosis may improve the management and treatment 
of patients with infectious gastroenteritis. 
 
ID08. Comparison of Direct Sequencing Assay with Restriction Fragment Mass 
Polymorphism Method for Detecting Drug Resistance Mutations in Chronic 
Hepatitis B Virus Infections 
S. Jeong, S. Yoo, Y. Park, H. Kim 
Yonsei University College of Medicine, Republic of Seoul, Korea. 
Introduction: Resistance of hepatitis B virus (HBV) to nucleos(t)ide reverse 
transcriptase inhibitors (NRTIs) is a serious problem in treatment of chronic hepatitis B 
(CHB). Genetic testing for identifying drug resistances is recommended in patients who 
experience virological breakthrough during treatment. We compared between the 
results of direct sequencing and restriction fragment mass polymorphism (RFMP) 
method for detecting known mutations causing drug resistance. Methods: A total of 43 
plasma samples from CHB patients were collected, and mutations in HBV reverse-
transcriptase gene were detected by using direct sequencing by two kinds of DNA 
sequencer, i.e., ABI 3130 and 3500 DNA analyzers (Applied Biosystems, Foster City, 
CA, USA) and additionally performed RFMP method at the same time. Direct 
sequencing can be able to detect mutations in whole reverse-transcriptase gene region 
by the two DNA sequencers, whereas RFMP in our study identifies mutations in 7 
positions including rt180, rt181, rt184, rt202, rt204, rt236 and rt250. Detected changes 
in gene sequences were analyzed by resistance prediction rules. Results: Mutations 
detected by both direct sequencing machines and RFMP were the same in 18 samples, 
whereas the other results of remaining 25 specimens were different with each other. 
Direct sequencing by ABI 3130 and 3500 sequencer identified more types of mutations 
than RFMP in 8 samples, whereas RFMP detected drug resistance-related mutations in 
18 samples, which could not be detected by sequencing. Drug resistance analysis for 
the detected mutations showed that RFMP found more resistances to NRTIs in 6 
samples than direct sequencings. Conclusions: Direct sequencing by ABI 3130 and 
3500 sequencer showed an advantage of wider detection coverage on the HBV 
reverse-transcriptase gene, whereas RFMP demonstrated better detection sensitivity 
than direct sequencing in detecting drug resistance mutations in the same specimens 
from CHB patients.  
 
ID09. Chlamydia trachomatis (CT) and Neisseria gonorroheae (NG) Infections 
Reveal Variation in Outcomes as per Anatomic Site  
S. Lee, Y. Elshimali, A. Scarsella 
Consolidated Laboratory Services, Van Nuys, CA. 
Introduction: Evidence of salivary mucosal immune responses in controlling bacterial 
infection has been well documented. CLS has verified and validated urine and swab 
specimens (throat and rectal) using of FDA approved Abbott RealTime (ART) PCR for 
Chlamydia trachomatis (CT) and Neisseria gonorroheae (NG). The semi-quantitative 
bacterial count is best represented as the numerical result (Delta Cycle or DC) 
corresponding to the difference in cycle number (CN) between the assay cut off and the 
sample. To explore the effects of the host immune response on CT/NG infections, this 
study was aimed to compare the DC values of CT/NG among three different anatomic 
sites, urine, throat and rectal. Methods: From January 2009 to March 2012, a total of 
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16442 samples, 7591 urine, 5967 throat swabs and 2884 rectal swabs from male 
patients were routinely screened for CT/NG infections by Abbott’s m2000 system 
following the manufacturer procedure. The DC values for all positive specimens were 
recorded and analyzed. A one-way ANOVA (analysis of variance) statistical analysis in 
the statistical package Statplus was used to test differences of DC values for each 
CT/NG of each sample type. Significantly different means is defined as p < 0.05. For 
optimal data analysis, data points from “after treatment” were excluded from analysis. 
Results: A total of 293 patients were determined to be CT (+) (urine 88, throat 60, 
rectal 145). The mean and (SD) for CT were 9.38 (3.46), 7.42 (3.96), and 10.17 (4.89) 
for urine, throat and rectal samples respectively. A total of 357 patients were 
determined to be NG (+) (urine 95, throat 190, rectal 72). The mean and (SD) for NG 
were 13.29 (3.04), 7.08 (3.94), and 10.26 (5.18) for urine, throat and rectal samples 
respectively. Both CT and NG levels were significantly different (p < 0.05) among all the 
sample sites except the CT amount between rectal and urine samples (p = 0.17). 
However, comparison of the NG (+) and CT (+) of specific site showed significant 
similar loads at rectal (p = 0.8374) and throat (p = 0.5425) whereas urine comparison 
trended oppositely (p = 0.00). Urine samples contained the highest CT and NG burden. 
However, the throat specimens had the lowest CT and NG loads. Conclusions: Our 
study results reveal significantly different CT/NG infection levels as per anatomic site. 
The current data supports the role of salivary mucosal immunity for the variation in 
outcomes.  
 
ID10. Comparative Study between Three Different Methodologies for HCV 
Genotyping 
M. Shah1, L.J. Glaser1, A. Thornberg2, K. Rusterholz2, C.D. Watt1, V.M. Van Deerlin1 
1Hospital of University of Pennsylvania, Philadelphia, PA; 2GenMark Dx, Carlsbad, CA. 
Introduction: Persistent infection with the hepatitis C virus (HCV) is a common cause 
of chronic liver disease and is a leading indication for liver transplantation. Treatment 
for chronically infected patients varies depending upon the viral genotype. Phylogenetic 
analysis classifies HCV into 6 distinct genotypes and over 50 viral subtypes that vary in 
prevalence as a function of geography. Although the HCV genome is highly variable, 
the 5’UTR and core region tend to be highly conserved and genotype specific. Given 
the clinical significance of an accurate genotype, we compared the performance and 
workflow of three HCV genotyping methods that interrogate either the 5’UTR or both the 
5’UTR and the core region. Methods: HCV positive samples (n=78, viral load 2.9 to 7.6 
log IU/mL) previously genotyped at a reference laboratory by direct sequencing of the 
5’UTR and samples from a commercial genotyping panel (n=9, SeraCare) were 
genotyped by a line probe assay (LiPA, Siemens) and a solid phase electrochemical 
method (eSensor, GenMark Dx). The performance of each method, in terms of 
genotyping and subtyping HCV, was analyzed. A workflow comparison of the LiPA and 
eSensor assays was also performed. Results: Our study shows excellent concordance 
of HCV genotyping among the three methods with 85/87 samples matching at the 
genotype level. In one sample with a low viral load, a mixed infection was detected by 
the LiPA and sequencing assay and only one genotype was identified by the eSensor 
assay. In a genotype 6 sample, the eSensor assay called an indeterminate genotype, a 
result that the eSensor assay will show when it cannot identify the proper genotype; 
preventing a miscall. In contrast to genotyping, HCV subtyping proved to be much more 
variable, specifically for subtyping type 1 viruses as 1a or 1b. Workflow comparisons 
will also be presented. Conclusions: We conclude that all three methods accurately 
provide HCV genotyping for genotypes 1-5. The performance of the three methods with 
mixed infections and genotype 6 samples warrants further investigation. There is also 
discordance between LiPA and eSensor assays for subtyping genotype 1 to the 5’ UTR 
calls were concordant however LiPA ultimately assigns the subtype with core region 
sequence. Currently, subtype information is rarely used for clinical decision making, but 
there is evidence that genotype 1b may portend a worst prognosis. Although both 
methods are feasible in the clinical setting, the eSensor offers less hands-on time and a 
more straightforward analysis process as compared to LiPA. 
 
ID11. Comparison of MagNA Pure 96, Chemagic MSM1, and QIAamp MinElute 
for Hepatitis B Virus Nucleic Acid Extraction 
S. Kang, G. Park, S. Jang, D. Moon 
Chosun University Medical School, Republic of Gwangju, Korea. 
Introduction: This study was designed to compare two automated systems and one 
manual system for hepatitis B virus (HBV) nucleic acid extraction. One of the two 
automated systems was the MagNA Pure 96 DNA and Viral NA small volume kit 
(Roche Applied Science, Manheim, Germany) with MagNA pure 96 (Roche Applied 
Science). The second automated system was the Chemagic Viral DNA/RNA kit 
(Chemagen, Baesweiler, Germany) with Chemagic MSM1 (Chemagen). The manual 
system was the QIAamp MinElute Virus spin kit (Qiagen, Hilden, Germany). Methods: 
Sixty-eight samples that were within the detection range of the Cobas Ampliprep/Cobas 
TaqMan (CAP/CTM) platform (Roche Molecular Systems, Manheim, Germany) were 
selected. Extracted viral nucleic acids from the three systems were quantified using an 
AccuPower HBV Quantitative PCR kit (Bioneer, Daejon, Korea). Results: The MagNA 
Pure 96 system and QIAamp system did not detect viral loads in one sample. The 
Chemagic system did not detect low viral loads in nine samples (range, 26–290 IU/mL 
by the CAP/CTM platform). Comparisons of the viral loads of the samples from the 
MagNA Pure 96 system, the Chemagic system, and the QIAamp system with those 
from the CAP/CTM platform provided correlation coefficients of 0.977, 0.914, and 
0.967, respectively. Comparisons of the MagNA Pure 96 system and the Chemagic 
system with the QIAamp system provided correlation coefficients of 0.987 and 0.939, 
respectively. Conclusions: The MagNA Pure 96 system demonstrated better 
performance than the Chemagic system for HBV nucleic acid extraction. The MagNA 
Pure 96 system demonstrated comparable performance with the QIAamp system. 
 
ID12. Asymmetric PCR Increases Robustness of Abacavir Hypersensitivity 
Assay on the LightCycler 2.0 
S. Chowdhury1, M. Aakre1, N. Gomes1, M. Hoffmann2, D. Xu2 
1Pathology Associates Medical Laboratories, Spokane, WA; 2Providence Sacred Heart 
Medical Center and Children's Hospital, Spokane, WA. 
Introduction: Abacavir sulfate (Ziagen) is a nucleoside reverse transcriptase inhibitor 
used in the treatment of HIV infection. Abacavir hypersensitivity reactions occur in 
approximately 2-8% of the population, dependent on ethnicity. Hypersensitivity to 
abacavir has been strongly linked to HLA-B*5701 allele status. Multiple large clinical 
studies have shown the rs2395029 single nucleotide polymorphism (SNP) to be a 
strong surrogate marker of HLA-B*5701 status. Interrogation of the rs2395029 SNP via 
semi-quantitative PCR is faster and cheaper than HLA typing and sequencing 
technologies. The purpose of our study was to develop a fast, reliable, assay on the 
LightCycler 2.0 to interrogate the rs2395029 SNP. Methods: The assay utilizes PCR 
with fluorescence monitoring and melting curve analysis. Primers were designed to 
amplify a 185 bp amplicon flanking the rs2395029 SNP. Fluorescence resonance 
energy transfer (FRET) probes were designed such that the mutant allele peak melting 
temperature (Tm) was higher than the wild-type allele. Initial validation studies revealed 
a low and broad mutant peak, especially for heterozygous patients. Similar results have 
been observed in other laboratories. Thus, asymmetric PCR was employed to 
determine if this protocol alteration could aid in generating more robust curves for 
easier interpretation and increased confidence in genotype calls. Ten control samples 
were obtained from a reference laboratory and 107 randomly selected Magna Pure 
(Roche Diagnostics, Indianapolis, IN) isolated DNA samples were used in the validation 
studies. Results: Through the use of asymmetric PCR, our laboratory was able to 
generate mutant allele curves far more robust than using equal amounts of forward and 
reverse primer. Raw fluorescence values for heterozygous samples increased by up to 
70% using asymmetric PCR compared to traditional PCR. The increased fluorescence 
resulted in high quality, reproducible peaks for wild-type, heterozygous, and mutant 
genotypes. Validation studies for the 117 selected samples revealed small standard 
deviations for both wild-type (0.18) and mutant melting peaks (0.10). Positive 
heterozygous patient sample were confirmed via Sanger Sequencing. Conclusions: 
Previous studies have validated the rs2395029 SNP as a surrogate marker for HLA-
B*5701 status. Although other laboratories have developed and used the LightCycler 
2.0 for the prediction of abacavir hypersensitivity in clinical practice, we present our 
findings to provide an additional example of how asymmetric PCR can enhance a 
clinical genetics assay performance, and allow easier interpretation of results. This 
improvement in assay performance may be especially valuable in DNA samples in 
which DNA quality and quantity are compromised. 
ID13. Comparison of Ventana Benchmark ULTRA HPV-16 L1 Antibody and 
Cervista HPV HR Sequencing for Identification of HPV-16 in Puerto Rican Female 
Population: A Preliminary Study 
A. Rosado, M.A. Noy, J.R. Paz 
Laboratorio de Patologia, San Juan, PR. 
Introduction: The rise of high-risk HPV cases in Puerto Rico has made high-risk HPV 
screening a critical part of the Puerto Rican woman’s evaluation in OB/GYN clinics. 
Liquid-based preparations for sample collection demonstrate better quality for cytology 
reading, and are key in viral DNA presence detection of high-risk HPV serotypes 
showing more precise and accurate readings. The health reform medical insurance of 
Puerto Rico (“Mi Salud”), given to those who cannot afford private medical insurance, 
does not cover the expenses of liquid-based preparations or molecular testing, leaving 
this population at disadvantage for HPV testing. For this reason and the danger of HPV 
as a precursor of cervical cancer, the focus of this investigation is to study the 
sensitivity, specificity and clinical use of Immunicytochemistry (ICC) by Ventana 
Benchmark ULTRA for detection of HPV-16 serotype, therefore verifying if this is an 
assertive alternate route for the Puerto Rican health reform patients. Methods: Ventana 
Benchmark ULTRA is an individual slide processing solution that permits an easy 
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management of STAT requests with no interruption to the in-process slides system, and 
provides a special stain for slide detection of HPV-16 L1 protein. The Cervista HPV HR 
is a 14-type High Risk screening test that uses Proprietary Invader Chemistry to detect 
individual base pair changes associated with high-risk HPV strains. These two 
screening tests are HPV high-risk serotypes for detection and determination of patient 
management. A total of 55 cervical specimens, in liquid-based preparations, were 
randomly obtained from OB/GYN clinics around Puerto Rico and were previously tested 
for HPV-HR in Cervista and Immunocytochemistry (control). Acquired results from 
Cervista were submitted for slide preparation with BD PrepStain Slide Processor and 
Ventana Benchmark ULTRA Immunocytochemistry HPV-16 antibody for comparison of 
sensitivity and specificity. Each sample was analyzed following specific criteria: a 
minimum of three cells with intact brown nuclei staining of three different forms 
(complete, granulated and halo- forming). Results: From 55 samples: 17 were negative 
and 22 positive to HPV-16 on both assays. The remaining 16: 8 were HPV-16 positive 
by Cervista and negative by ICC, and 8 were HPV-16 positive by ICC and negative by 
Cervista. Conclusions: Results show that Immunocytochemistry, compared to 
Cervista, has a sensitivity of 85% and a specificity of 72%. An annual study will be 
continued. 
 
ID14. Sensitivity of High-Throughput Sequencing for Viral Detection in Blood 
E. Samayoa1, S. Naccache1, A. Rein-Weston1, K. Luk2, J. John Hackett2, S. Miller1, C. 
Chiu1 
1University of California, San Francisco, CA; 2Abbott Diagnostics, Abbott Park , IL. 
Introduction: Unbiased high-throughput sequencing is a promising method for viral 
detection in clinical and public health settings. However, optimal library preparation 
techniques and limits of detection are largely unexplored with this technology. We 
analyzed the effect of various library preparation protocols on the ability of the Illumina 
MiSeq instrument to detect viral sequence reads, and performed sensitivity analysis for 
detection of HIV in human plasma. Methods: Plasma containing HIV at various titers 
was used to prepare multiplexed libraries for sequencing on the MiSeq instrument using 
a 300 cycle Miseq reagent kit for a 150-cycle paired-end run. We assessed two different 
library preparation methods (Illumina ScriptSeq and TruSeq-modified) as well as 
nuclease treatment prior to extraction (“pre-nuclease” / “pre-DNAse”) or immediately 
after extraction (“post-DNAse”) to reduce host background contributions to the 
sequencing reads. Sensitivity was determined using a dilution series containing 10^2 to 
10^6 HIV particles spiked into negative matrix sera. Sequences were identified as viral 
by nucleotide BLAST (BLASTn) alignments to HIV (e-value cutoff of 10^-10), and the 
number of HIV sequence reads generated for each sample as a percentage of total 
reads was compared. Results: Approximately 1.3 to 4.3 million sequence reads were 
obtained for each sample. At 10^6 viral copies/mL, pre-nuclease treatment increased 
viral reads from 0.03% of total reads (445 reads) with no treatment to 3.1% (45,517 
reads). ScriptSeq and TruSeq-modified post-DNase protocols generated comparable 
percentages of 0.07% (2,928 reads) and 0.08% (1,410 reads) HIV reads, respectively. 
At viral loads of 10^4, 10^3 and 10^2 copies/mL pre-nuclease treatment yielded 1.68% 
(27,173 reads), 0.28% (3,762 reads) and 0.002% (39 reads), whereas pre-DNase 
treatment yielded 1.75% (28,300 reads), 0.14% (2,020 reads) and 0.004% (50 reads) 
HIV sequence reads. Log-log regression plots of the read percentage against the 
spiked HIV titer were linear with an R2 of approximately 0.998. Conclusions: Pre-
nuclease / pre-DNAse treatment of samples significantly increased the number and 
proportion of viral sequence reads in plasma samples. Two different Illumina library 
preparation protocols achieved similar yields of viral sequence reads. Our protocol was 
able to detect viral sequence reads down to at least 100 copies/mL, and is thus a 
sensitive method to perform unbiased detection of viruses present in clinical samples. 
Sample analysis for viral detection and discovery using these methods is available as a 
core laboratory service through the UCSF Viral Diagnostics and Discovery Center 
(vddc.ucsf.edu). 
 
ID15. A Comparison of Real-Time PCR and Broth Enrichment Methods for the 
Detection of Group B Streptococcus
R.L. DesPlas, R. Rich, A. Willis, K. Youens, K. Murphy 
ProPath Services, LLP, Dallas, TX. 
Introduction: Group B Streptococcus (GBS) is the leading infectious cause of neonatal 
morbidity and mortality in the United States. Intrapartum maternal genitourinary or 
gastrointestinal GBS colonization is the primary risk factor for disease, and the Centers 
for Disease Control and Prevention currently recommends that all pregnant women be 
screened for colonization using a broth enrichment method. The sensitivity of GBS 
culture is greatest when a specimen is processed within 24 hours of collection, a 
requirement that can present difficulties in a reference laboratory setting. We compared 
the performance of two broth enrichment GBS detection methods and a lab-developed 
real-time PCR GBS assay. Methods: 255 vaginal/rectal swab specimens were 
inoculated to Lim broth and tested using 1) traditional culture 2) a broth-enriched DNA 
probe method (AccuProbe, Gen-Probe) and 3) a real-time PCR assay targeting the cfb 
gene. Traditional culture was performed by subculturing the Lim broth, after incubation, 
to selective agar. The AccuProbe method was performed according to the 
manufacturer’s instructions. For the PCR method, a 1 mL aliquot was removed 
immediately following Lim broth inoculation, spiked with an inhibition control, and 
subjected to DNA isolation using a Maxwell 16 instrument and reagents (Promega). 
Multiplexed PCR amplification of GBS target and the control was performed using a 
single primer set and differentially labeled TaqMan probes using the ABI 7500 FAST 
DX (Applied Biosystems). Results: Of the 255 specimens tested, 239 (94%) yielded 
concordant results using all three methods. The positivity rates for traditional culture, 
AccuProbe, and real-time PCR were 19%, 18%, and 23% respectively. Using traditional 
culture as the gold standard, the sensitivity and specificity of the AccuProbe test were 
93% and 100% respectively. For the real-time PCR assay, the sensitivity and specificity 
were 98% and 96% respectively. Conclusions: The performance of the lab-developed 
real-time PCR assay suggests that it is acceptable for clinical use. Real-time PCR 
allows for adequate GBS detection without broth enrichment, a potentially useful 
characteristic in a reference laboratory setting in which specimen shipping requirements 
may affect microbial viability. Because the PCR assay is performed after Lim broth 
inoculation, the specimen can still be tested for antimicrobial sensitivity if necessary. 
 
ID16. Comparison of the BD Affirm VP III Assay to Microbiologic Methods for 
the Diagnosis of Infectious Vaginitis 
S. Hong, H. Shin, E. Ra, S. Joo, E. Kim, K. Han, S. Kang, S. Park, M. Seong 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: Infectious vaginitis is a common disorder in women. There are three 
main categories of vaginitis, bacterial vaginitis (BV), yeast vaginitis and Trichomonas 
vaginalis vaginitis. The laboratory diagnosis of vaginitis is still very time-consuming and 
labor-intensive. The BD Affirm VP III (Becton Dickinson, Sparks, MD) is a DNA probe-
based diagnostic test that quickly identifies Candida, Gardnerella and Trichomonas. 
The aim of this study is to compare the performance of the BD Affirm VP III with 
traditional microbiologic methods. Methods: Total 65 pairs of initial vaginal specimens 
of patients with symptom were used for Affirm assay, Gram stain and culture. Vaginal 
specimens of 20 healthy women without symptom were tested for control group by 
Affirm assay. In-house PCR test was used for the confirmatory test for T. vaginalis. 
Results: The positive rates of Gardnerella, Candida and Trichomonas by Affirm assay 
were 33.8 % (22/65), 13.8 % (9/65) and 0% (0/65) in the patients group and 15.0 % 
(3/20), 10.0 % (2/20) and 0% (0/20) in the control group, respectively. Using a Nugent 
Gram stain score indicative of BV (>6), the sensitivity and specificity of Affrim assay for 
BV were 77.8 % and 83.0 %. The sensitivity and specificity of Affirm assay for Candida 
spp. were 77.8 % (7/9) and 98.2 % (55/56) based on Gram stain and culture. T. 
vaginalis was negative in the all of the samples of patients but one sample was positive 
in PCR test. Conclusions: The BD Affirm VP III assay is fast and useful test for 
bacterial and yeast vaginitis but showed lower sensitivity than qualitative PCR for 
detection for the T. vaginalis. 
 
ID17. Comparison of the GenMark eSensor Respiratory Viral Panel to Routine 
Respiratory Culture on R-Mix Cells 
J. Shieh, M. Stanley, J. Schapiro, T. Lorey 
TPMG Kaiser Regional Laboratory, Berkeley, CA. 
Introduction: Respiratory viruses are responsible for a wide range of acute respiratory 
tract infections. Disease severity can be especially high in the young, the 
immunocompromised, and the elderly patients. Rapid diagnosis of respiratory viral 
infection is an important part of patient care and management, facilitation the timely 
initiation of antiviral therapy and implementation of infection control practices. The 
objective of this study was to evaluate test sensitivity and performance of the eSensor 
RVP Test (GenMarkDx, Carlsbad, CA) in comparison with viral culture (R-Mix cells) 
currently used in TPMG Regional Laboratory. Methods: Total of 227 samples 
submitted for respiratory viral culture were also tested by the eSensor RVP. R-Mix viral 
culture detects Flu A/B, RSV, adenovirus (ADV) and parainfluenza 1,2,3 (P1, P2, P3). 
The eSensor RVP detects all eight viruses plus paraflu 4 (P4), rhinovirus (HRV), human 
metapneumovirus (hMPV) and coronaviruses (COR). It also detects subtypes of FluA, 
RSV, and ADV. Discrepant results were tested using an alternate molecular assay: 1). 
With Flu A/B, RSV were run on Proflu+, 2). With ADV, P1, P2, P3, HRV and hMPV 
were sent for Luminex RVP testing, 3). With P4, COR were sent to reference lab for 
real-time PCR. Results: Of the 227 samples, 109 (48%) were positive for at least one 
virus by eSensor RVP; 89 (39.2%) detected one virus whereas R-Mix identified 24/227 
(10.6%). Positive results for the eSensor RVP were as follows: 19 (8.4%) Flu A, 1 
(0.44%) Flu B, 24 (10.6%) RSV, 9 (4%) ADV, 1 (0.44%) P1, 2 (0.88%) P4, 29 (12.8%) 
HRV, 27 (11.9%) hMPV and 16 (7%) COR. R-Mix had 4 ADV, 7 Flu A, 1 Flu B and 8 
RSV. The discrepant samples with Proflu+ resolution added on 10 Flu A and 9 RSV. 
Conclusions: As expected the GenMark eSensor RVP detected significantly more 
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viruses than R-Mix viral culture. The eSensor RVP detected viruses that were not 
tested for in our lab, and it also detected co-infections that are important in cohorting of 
patients. The eSensor RVP has a 6.5 hour turnaround time for results. We found that 
the GenMark eSensor RVP assay offers increased sensitivity, reduced turnaround time 
and was less-labor intensive than the R-Mix viral culture. The GenMark eSensor RVP 
assay is a viable alternative to R-Mix viral culture. 
 
ID18. Effectiveness Molecular Analysis of BCG-Derived Complications 
M. Han, Y.J. Hong, S.M. Hwang, T.S. Kim, K.U. Park 
Seoul National University Bundang Hospital, Republic of Seongnam-si, Korea. 
Introduction: In Korea, the BCG Pasteur 1173 P2 strain has been used for vaccination 
for more than 40 years. Since the end of 2007, this strain has been replaced by the 
Danish strain. The BCG Tokyo 172 strain has also been used for the past 15 years. 
Currently, BCG coverage rate exceeds 95%, and almost 90% of the individuals are 
vaccinated with the Tokyo strain by using multipuncture methods. Increased BCG 
utilization has increased the incidence of BCG-related complications. Quick and 
accurate methods are required to rapidly identify the exact origin of these 
complications. Herein, we introduce molecular methods to identify BCG substrains and 
report cases of BCG-related complications that were confirmed by various molecular 
methods. Methods: DNA was extracted from formalin-fixed paraffin-embedded (FFPE) 
tissues or surgical specimens, as well as from mycobacterial colonies. To differentiate 
between BCG Mycobacterium bovis and non-BCG M. tuberculosis complex (MTBC), 
we performed 2 independent real-time PCRs that targeted the IS6110 region and the 
53-bp mycobacterial interspersed repetitive units (MIRUs) of the senX3-regX3 
intergenic region (IR). In addition, we performed multiplex PCR that targeted senX3-
regX3 IR and the region of difference 1 (RD1). Finally, to differentiate among the BCG 
substrains, we performed multiplex PCR that targeted RD1, RD8, and RD14. Results: 
The real-time PCR results were positive for the IS6110 region and negative for the 53-
bp MIRUs of senX3-regX3 IR; these findings suggested that the mycobacteria belonged 
to the BCG strain and not to the M. tuberculosis strains. In multiplex PCR that targeted 
the senX3-regX3 IR and RD1, all BCG strains gave a 362-bp product, whereas non-
BCG MTBC strains gave a 208-bp product. In the multiplex PCR that targeted the RDs 
(i.e., the presence or absence of RD1, RD8, and RD 14) the BCG Tokyo strain gave the 
196-bp, 252-bp, and 472-bp amplicons; the BCG Pasteur strain gave the 196-bp and 
472-bp amplicons; M. tuberculosis gave the 146-bp, 252-bp, and 472-bp; and the 
nontuberculous mycobacteria gave no products. Since beginning the use of these 
molecular assays in 2007, we have confirmed 10 cases of BCG-related complications. 
Out of these cases, 8 were of BCG Tokyo strain and 1 of BCG Pasteur strain; however, 
in 1 case, the specific BCG substrain could not be identified. Conclusions: Molecular 
analysis of RD and senX3-regX3 IR is suitable for identifying the specific BCG isolates 
in a variety of patients, including both immunosuppressed children and adults 
undergoing therapy for bladder cancer. 
 
ID19. ProGastro SSCS vs Luminex GPP: A First Experience in Comparing Two 
Multiplex Assays for Gastrointestinal Pathogens 
P. Kahlau, M. Malecki, V. Schildgen, F. Mattner, O. Schildgen 
Kliniken der Stadt Köln gGmbH, Cologne, Germany. 
Introduction: Gastroenteritis remains a medical and economic problem worldwide. The 
range of pathogens causing gastroenteritis is broad, and in industrialized countries the 
majority of gastrointestinal infections are caused by bacteria and viruses. Especially in 
nosocomial settings, it is crucial to rapidly identify the causitive pathogen to avoid 
pathogen spreading and to direct appropriate therapies when most beneficial. 
Methods: Recently, two novel multiplex assays have been developed that may help 
rapidly identify the causitive pathogen, namely the ProGastro SSCS assay (Gen-Probe 
Inc., San Diego, CA, USA) and the Luminex GPP (Luminex, Austin, TX USA). We 
compared both assays with a set of 30 prospectively collected pathogen positive stool 
samples from patients suffering from severe hospitalized diarrhea. Sample preparation 
and extraction of nucleic acids was performed as recommended by Gen-Probe and by 
Luminex and multiplex assays were performed for both extraction methods with each 
assay. ProGastro SSCS utilized Investigational Use Only (IUO) reagents and were run 
on the (off-label) Rotorgene platform. Results: In total, 42 matches were obtained 
between the results of the ProGastro SSCS and the xTAG GPP assays. Different 
results were obtained in 18 cases and were mainly associated with the pretreatment 
method. It appears that pretreatment according to the Luminex protocol is more 
sensitive than pretreatment for the ParaPak C&S System (Meridian) as recommended 
by GenProbe. Surprisingly, the Luminex GPP assay more frequently detected 
Salmonella that were neither detected by the Gen-Probe assay nor could be confirmed 
by culture. Conclusions: Both assays have advantages and disadvantages. The turn-
around-time is similar for both assays as results can be obtained in less than 8 hours 
upon specimen arrival. The ProGastro assay appears to be more specific for the 
detection of bacterial pathogens, mainly for Salmonella. ProGastro SSCS does not 
include detection of viral pathogens and parasites that the Luminex GPP assay includes 
so each has utility dependant on the patient’s clinical presentation. In summary, both 
assays are able to reduce the time from sample collection to clinical decision making 
and bear the potential to save indirect costs due to reduction of nosocomial infections, 
and reduction of hospital length-of-stay. 
 
ID20. Validation and Clinical Utility of Biohelix Isoamp Assay for the Detection 
of HSV 1 & 2 from Vesicles in a Pediatric Hospital 
L. Chandramohan1, W. Greaves2, P. Revell1 
1Baylor College of Medicine, Houston, TX; 2Texas Childrens Hospital, Houston, TX. 
Introduction: Human Herpes Simplex Virus 1&2 (HSV 1&2) infections are significant 
human pathogens, with substantial morbidity, mortality and transmission potential. HSV 
is a member of the Herpesviridae family and is one of the most commonly transmitted 
diseases in the US HSV 1&2 are implicated in a variety of diseases, including viral 
meningitis, skin infection, genital herpes, and neonatal herpes. HSV transmission can 
result from direct contact with infectious secretions from either symptomatic or 
asymptomatic individuals. Accurate identification of HSV infection is necessary for 
optimal patient management and prevention of transmission. Culture-based virus 
isolation and typing of HSV is currently considered the “gold standard” for diagnosis of 
acute genital herpes infections. However, viral culture has limited sensitivity, longer 
turnaround times and is labor intensive. Although numerous molecular assays for HSV 
1&2 detection are available, they require specimen extraction and expensive 
instrumentation. The aim of this study was to evaluate the performance characteristics 
of the IsoAmp HSV assay (BioHelix Corporation, Beverly, MA) for the detection of HSV 
infection in vesicular lesions. This assay detects HSV 1&2 by the Helicase-Dependent 
Amplification (HDA) method without DNA extraction. Methods: A total of 37 clinical 
specimens consisting of vesicular lesion swabs from various anatomic sites were 
collected from patients presenting to the Texas Children’s Hospital with clinical features 
suggestive of HSV infection. These samples consisted of 24 positives and 13 negatives 
as determined by the HSV culture method at the Diagnostic Virology laboratory. HDA 
reactions were performed using an IsoAmp HSV assay according to the manufacturer’s 
instructions. Briefly, the specimens were diluted in the dilution buffer and isothermal 
amplification of the diluted specimens was performed by heating at 64ƕC for 60 min. 
The colorimetric detection of amplicon was performed in a Type II BEStTM Cassette 
(BioHelix Corporation, Beverly, MA). Results: All of the 24 HSV culture positive 
specimens tested positive and 12 of the 13 HSV culture negative specimens tested 
negative by the IsoAmp HSV assay. The assay has 100% clinical sensitivity and 92.3% 
specificity for the detection of HSV 1&2 from vesicles when compared to the reference 
culture method. Conclusions: The IsoAmp HSV assay is a powerful tool in the 
detection of HSV 1&2 from vesicles and showed excellent sensitivity and specificity 
when measured against conventional virologic testing. The total assay turn-around time 
is less than 1.5 h from specimen processing to result reporting. 
 
ID21. Prospective Comparison of ProFlu+TM with Simplexa Flu A/B & RSV, 
Eragen ASR and LightCycler PCR for the Detection of Influenza A/B and RSV in 
Respiratory Specimens 
M. Espy, L.M. Sloan, S.K. Schneider, B.S. Pritt 
Mayo Clinic, Rochester, MN. 
Introduction: Influenza and respiratory syncytial virus (RSV) infection cause significant 
annual morbidity and mortality. Real-time PCR methods allow for rapid and sensitive 
detection of these viruses in respiratory specimens. Our laboratory uses a modified 
version of the GenProbe ProFlu+TM assay for influenza A and B and RSV detection 
and has previously demonstrated comparable sensitivity between modified and FDA-
approved versions of this test. In this study we compared the detection of influenza A 
and B in respiratory specimens by the modified ProFlu+ assay with two commercial 
assays, the FDA-approved Simplexa FLU A/B & RSV assay, Eragen ASR assay, and a 
previously described Mayo Clinic laboratory developed test (Mayo LDT) targeting the 
matrix protein gene. ProFlu+ and Simplexa FLU A/B & RSV were also compared for the 
detection of RSV in respiratory specimens. Methods: Materials and Methods: 
Respiratory specimens (n=215) sent to the clinical virology laboratory for routine 
influenza A/B and/or RSV testing were concurrently tested by all 4 assays. Nucleic acid 
was extracted from 200 μL of raw specimen using the Roche MagNA Pure instrument 
(total nucleic acid kit) into a 100 μL elution volume. Five microliters of extract were 
tested by the Eragen and Mayo assays using the LightCycler (LC) 2.0 instrument, 
ProFlu+TM using the LC480 instrument, and Simplexa using the 3M integrated cycler. 
Forty-one specimens were also extracted by the MagNA Pure using the FDA approved 
process for the Focus Simplexa assay (RNA kit; 200 μL input, 50 μL eluate). Five μL of 
extract was then tested as above by all 4 assays. Results: Of 215 specimens, the 
ProFlu+, Simplexa, Eragen, and Mayo LDT methods detected 42, 42, 43, and 46 
positive influenza A specimens respectively. All 4 methods detected 2 positive influenza 
B specimens. The 2 assays that were capable of detecting RSV, the ProFlu+ and 
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Simplex assays, also detected 14 and 17 positive RSV specimens respectively. Of the 
41 specimens that underwent RNA extraction using 2 methods followed by testing with 
the Simplexa FLU A/B & RSV test, the 100 μL and 50 μL eluate methods detected 35 
and 38 total positive specimens respectively. Conclusions: Conclusion: Comparable 
results were obtained by ProFLU+, Eragen, Mayo, and Simplexa for the detection of 
influenza A and B and RSV respectively. Limited data suggests that the two extraction 
methods (Mayo SOP and FDA approved method) are comparable for the detection of 
influenza A and B and RSV in respiratory specimens. 
 
ID22. Validation of an HCV Genotyping Assay to Predict Antiviral Therapy 
Response 
S.S. Sam1, H.B. Steinmetz2, G.J. Tsongalis1, L.J. Tafe1, J.A. Lefferts1 
1Geisel School of Medicine at Dartmouth, Lebanon, NH; 2Dartmouth-Hitchcock Medical 
Center, Lebanon, NH. 
Introduction: Chronic hepatitis C virus (HCV) infection is one of the most common 
chronic liver diseases infecting 130-170 millions of people around the world placing 
them at high risk for developing cirrhosis, end-stage liver disease, and hepatocellular 
carcinoma. Currently, decisions for HCV treatment are based on genotype, which is the 
most significant baseline predictor of response to therapy. HCV is a genetically 
heterogeneous RNA virus, with a genome consisting of a single-stranded 9.4-kb RNA. 
Variation within the genome sequence has led to classification of 6 distinct genotypes. 
The objective of this study was to validate HCV genotyping to detect major subtypes 
using the eSensor HCV genotyping assay (GenMark eSensor XT-8 system). Methods: 
Fourty eight plasma specimens representing the major subtypes of HCV (1a, 1b, 2b, 
2ac, 3, 4, 5, and 6ab) were subjected to quantitative RT-PCR using the Roche COBAS 
Ampliprep Taqman HCV assay. The HCV amplicon obtained from the Roche assay 
served as a template for the nested PCR followed by a direct analysis on the 
electrochemical eSensor XT-8 detection system for 8 HCV sub-types. Dilutions of 8 
plasma specimens were made to establish the limit of detection (LOD). These samples 
were tested in duplicate for 10 non-consecutive days by two different operators to 
determine the precision of the GenMark assay. Accuracy was assessed by comparing 
GenMark results with VERSANT HCV (LiPA) genotyping assay. Control plasma 
samples harboring human immunodeficiency virus, hepatitis B virus (Acrometrix), and 
west nile virus (Zeptometrix) were used to assess specificity of the assay. Results: The 
LOD determined was below 175 IU/ml for all the subtypes except 6ab. The genotypes 
detected using the GenMark eSensor XT-8 system were in concordance with the 
VERSANT HCV (LiPA) genotype assay results with the exception of several samples 
identified as 1a by LiPA and 1b by the GenMark assay. This minor and clinically 
insignificant discrepancy in subtype can be expected due to differences in regions of 
the HCV genome analyzed by the two assays. Conclusions: The rate of progression to 
chronic hepatitis as well as the response to HCV antiviral drugs is influenced by HCV 
genotype. In the United States, genotypes 1a and 1b are most common, followed by 
genotypes 2 and 3, which show better therapeutic response rates. The high sensitivity, 
good intra- and inter-assay precision, and agreement with a validated method, make 
this assay particularly well suited for clinical HCV genotyping to guide antiviral therapy.  
 
ID23. Evaluation of the Nanosphere Verigene Respiratory Virus + with Xpert Flu 
for the Detection of Influenza A with Subtyping and Influenza B from 
Nasopharyngeal Swabs 
P. Pancholi, A. Johnson, C. Kelly 
The Ohio State University Wexner Medical Center, Columbus, OH. 
Introduction: Influenza A (FluA), Influenza B (FluB) and Respiratory Syncytial Virus 
(RSV) cause a majority of respiratory illnesses with significant morbidity and mortality. 
PCR testing offers greater sensitivity and methodologies for rapid and flexible 
automated testing have recently become available. The study’s purpose was to 
evaluate two rapid moderately complex FDA-cleared assays – the Verigene Respiratory 
Virus Plus (RV+, Nanosphere, Northbrook, IL) and the Xpert Flu (Xpert, Cepheid, 
Sunnyvale, CA) – in comparison with the Prodesse ProFlu+ (ProFlu+, Gen-Probe 
Prodesse, Waukesha, WI) for the detection of influenza A/B and RSV. Methods: 
Specimens evaluated included 176 nasopharyngeal (NP) swabs tested during routine 
clinical care from November 2011 to May 2012 (including 6 FluA 2009 H1N1 specimens 
from Jan-March 2011). Samples were evaluated for FluA, FluB, and RSV by ProFlu+ 
and compared to RV+ results for FluA, FluA subtypes (H1, H3, and 2009 H1N1), FluB, 
and RSV subtypes (A and B); and Xpert results for FluA, FluB, and FluA subtype 2009 
H1N1. Assays were performed following package instructions. Sensitivity and specificity 
of these assays was established by comparing the Xpert and RV+ results to the 
ProFlu+ assay with CDC's FDA-approved Human Influenza Virus Real-Time RT-PCR 
(CDC RT-PCR) diagnostic panel for discordant analysis. Results: Of the 176 
specimens, 51 were positive for FluA (43 Seasonal H3, 7 H1N1, 1 non-typable), 28 for 
FluB and 50 were negative by all three assays. RV+ and ProFlu+ additionally detected 
2 FluA’s (one H3 and one 2009 H1N1) and 5 FluB’s that were not detected by Xpert. 
Two FluA H3 and 1 FluB were unresolved by Xpert. One FluA H3 was mis-identified as 
2009 H1N1 by Xpert. Four FluB specimens were positive and one was inconclusive by 
ProFlu+. CDC RT-PCR revealed these to be false positives. In comparison to ProFlu+ 
and CDC RT-PCR, the sensitivity of RV+ was 100% (FluA), 100% (FluB) and Xpert was 
96.2% (FluA) and 84.8% (FluB), respectively. The specificity was 100% for FluA and 
FluB with both assays. The RV+ and ProFlu+ both detected 30 RSV (20 RSVA and 10 
RSVB). Two RSV specimens were positive only by ProFlu+. One of two was false 
positive by CDC RT-PCR. Conclusions: The Verigene RV+ performs well for detection 
of Influenza A with subtyping, Influenza B, and RSV with subtyping. The RV+ was more 
sensitive for the detection of Flu A and Flu B and provided a broader virus detection 
range as compared to the Xpert. 
 
ID24. Cycle Threshold Value Distribution and the Evaluation of HSV CNS 
Infections  
C. Scott, C. Paquette 
Fletcher Allen Health Care, Burlington, VT. 
Introduction: Molecular virology testing is becoming standard of care in detecting 
herpes simplex virus (HSV). Most notably in the evaluation of patients with mental 
status changes, PCR assays on cerebrospinal fluid (CSF) identify HSV central nervous 
system (CNS) infections with early diagnosis decreasing morbidity and mortality. Viral 
load variability presents an analytical barrier to definitive diagnosis; assays are checked 
against controls to assure reliability at low viral loads. We noted that our CSF HSV Ct 
(cycle threshold) values were higher compared to non-CNS body sites, and 
hypothesized that different sample types may have different Ct value distributions. In 
this study we aim to assess the performance of our laboratory’s assay and evaluate this 
hypothesis. Methods: A retrospective analysis of samples from 5/1/09-12/31/11 
performed at one institution using an HSV assay (Cepheid, Sunnyvale CA). Results 
were interpreted as follows: Ct < 35 positive, 35  Ct < 40 borderline, Ct=0 or Ct  40 
negative. The results were separated into CNS and non-CNS origin, and the Ct values 
were analyzed using descriptive statistics. We focused on HSV-2, the most common 
CNS positive subtype at our institution. Results: We reviewed 6101 HSV specimens: 
4127 (68%) were negative, 1126 (18%) HSV-1 positive, and 848 (14%) HSV-2 positive. 
Of the HSV-2 positives, 23 (2.7%) were from the CNS, of which 15 (65%) had a 
borderline Ct, compared to 68 (8.2%) of non-CSF samples. The average Ct for HSV-2 
positive non-CNS samples was 25.6 cycles (SD=5.2) whereas the average for CNS 
samples was 35.1 (SD=2.7). Conclusions: In our experience, HSV positive CNS 
samples are more likely to have a borderline Ct value compared with non-CNS sites, 
possibly due to lower viral loads and/or reduced interfering substances. The Ct 
standard deviation was almost double in non-CNS compared to CNS sites, which may 
reflect heterogeneity of sites. In practice, we evaluate all borderline positives from CNS 
specimens and often re-run the specimen and/or use an alternate PCR platform, at 
pathologist’s discretion. As standard anti-viral therapy has low morbidity, we usually 
report CSF results conservatively (positive if borderline). Our present study is limited by 
a small number of positive CNS samples precluding formal statistical analysis; further 
studies are needed, including cases with ‘gold standard’ viral culture or PCR of CNS 
tissue. 
 
ID25. Clinical Evaluation of the Quidel Sofia Influenza A+B FIA Compared to the 
Binax NOW Influenza A&B Assay and Real Time Multiplex RT-PCR for Detection 
of Pediatric Influenza Virus Infections 
J. Dunn, J. Obuekwe, T. Baun, P. Abell, J. Rogers, R. Loonam, T. Patel, D. Holsten, L. 
Snow 
Cook Children's Medical Center, Fort Worth, TX. 
Introduction: The Quidel Sofia Influenza A+B fluorescence immunoassay (FIA) 
employs immunofluorescence technology that is used with the Sofia analyzer to detect 
and differentiate influenza A and B virus nucleoproteins in 15 minutes. This study 
evaluated the performance characteristics of the Sofia FIA for detection of influenza 
virus infections in pediatric patients. Methods: A total of 135 prospective and 
retrospective nasal wash specimens were evaluated using the Sofia FIA, Binax NOW, 
and real-time multiplex RT-PCR. The RT-PCR assay was able to detect and identify 
three targets: influenza A, B, and the novel H1N1 subtype. The average age of patients 
was 3.8 years and the median age was 3.0 years. Results: Compared to RT-PCR, the 
Sofia FIA was positive for influenza A virus for 50 of 52 samples (sensitivity = 96.2%) 
and positive for influenza B virus for 29 of 29 samples (sensitivity = 100%) with an 
overall accuracy of 97.0% and 97.8% for influenza A and influenza B detection, 
respectively. The Binax NOW was positive for 44 of 52 samples with influenza A 
(sensitivity = 84.6%) and 26 of 29 samples with influenza B (sensitivity = 89.7%) with an 
overall accuracy of 89.6% and 94.8% for influenza A and influenza B detection, 
respectively. The average RT-PCR crossing threshold (Ct) (±SD) for Sofia influenza A-
positive specimens was Ct = 21.3 (±3.7) whereas that for Binax influenza A-positive 
specimens was Ct = 20.5 (±3.4). For the seven samples that were Sofia FIA influenza 
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A-positive and Binax influenza A-negative, the average Ct = 25.4 (±3.4). For the three 
samples that were Sofia FIA influenza B-positive and Binax influenza B-negative, the 
average Ct = 26.5 (±1.8). Conclusions: These data demonstrate that the Sofia 
Influenza A+B FIA is a sensitive, specific, accurate, and rapid method for detection and 
differentiation of influenza A and B viruses in pediatric nasal wash specimens. 
 
ID26. Evaluation of Custom Liquid Bead Arrays for the Molecular Detection of 
Gastrointestinal Pathogens in a Pediatric Population  
L. Millecker, C.R. Webb, P.A. Revell 
Texas Children's Hospital, Houston, TX. 
Introduction: Gastrointestinal (GI) infections due to viruses and bacteria are common 
among the pediatric population worldwide. Conventional culture and electron 
microscopy (EM) techniques can be complex and time consuming, leading to 
misidentification and lengthy turnaround times. The ability to detect GI pathogens using 
molecular methods from stool samples may significantly increase the accuracy and 
timeliness of results. Analyte specific reagents (ASR) from Luminex Molecular 
Diagnostics were used to create 3 custom multiplex assays for the qualitative detection 
of 17 GI pathogens. Each panel was designed to meet the clinical needs and ordering 
patterns of physicians at Texas Children’s Hospital. The panels were: Acute Bacterial 
Panel for Y. enterolitica, Salmonella, Shigella, Campylobacter, Vibrio, E. coli O157, 
Enterotoxins LT&ST and Shiga Toxins 1&2; Toxigenic Clostridium difficile Panel for C. 
difficile toxins A&B; and a Viral Panel for Rotavirus, Adenovirus, Enterovirus and 
Norovirus GI&GII. Methods: A total of 175 samples (89 stool specimens and 86 
archived nucleic acid samples previously isolated from stool specimens) were obtained. 
Of the 175, 132 were previously positive for at least 1 target included in the panels. The 
remaining 43 were either previously negative for or not tested for these specific targets. 
Stool specimens were homogenized in Roche STAR buffer, spiked with an MS2 internal 
control and extracted on the Roche MagNA Pure using a TNAi Isolation Kit. Samples 
were amplified with identical cycling conditions, a primer mix specific for each panel and 
the Qiagen Multiplex PCR kit or One-Step RT-PCR kit. Amplicons were hybridized to 
panel-specific MagPlex microspheres and detected on a Luminex 200 instrument. 
Median bead counts and Mean Fluorescence Intensity values for all targets were 
analyzed using previously established threshold values. Results: Seventy samples 
were tested with the Acute Bacterial Panel, 77 with the C. difficile panel and 99 with the 
Viral Panel yielding target agreements of 696/700(99.4%), 151/154(98.1%) and 
467/495(94.3%), respectively. Combined specificity and sensitivity for the panels was 
117/132(89%) and 102/102(100%), respectively. Discrepancies among the Luminex 
panels were due to misidentifications, previous weak positive samples or failure to 
detect co-infections. Further investigations for these samples are ongoing. 
Conclusions: The Luminex assays allowed for detection of additional targets as well 
as current targets with equivalent or better sensitivity than our current practice. In 
addition, turnaround time for the Luminex assays was 6 hours compared to days and 
weeks for culture and EM, significantly enhancing our current test menu with minimal 
changes to personnel/resource requirements. 
 
ID27. Adaptation of a Qualitative PCR Assay to Detect the Presence of 
Acanthamoeba Infection in Ophthalmological Samples 
M.A. Melan1, G.J. Oakley2, R.P. Kowalski1, L. Karenchak1, J.A. Kant1 
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Marshall University, 
Huntington, WV. 
Introduction: The assessment of clinical and environmental samples for the presence 
of Acanthamoeba is useful in diagnosing corneal keratitis. Often this condition is 
acquired from contaminated eye care products or from aquatic sources such as lakes or 
swimming pools. Our laboratory was asked to provide testing for Acanthamoeba 
detection by modifying an existing protocol developed for the SmartCycler platform 
(Thompson et al, 2008. J. Clin. Microbiol. 46: 3232.) for use on the LightCycler 
instrument. This procedure detects a portion of the 18S rRNA gene specific to 
Acanthamoeba. Methods: Initial attempts for adaptation consisted of using the same 
primers, locked nucleic acids probe and cycling conditions from the cited procedure on 
the LightCycler 2.0. Distinguishing signal from background was problematic under these 
conditions. The probe was then modified to a simple TaqMan hydrolysis probe and 
amplification performed on a LightCycler 1.2 with improved performance but non-
specific amplification at higher cycle numbers was detected. BLAST analysis of the 
amplicon showed a 25bp identical match to a portion of human chromosome 2 
suggesting interference from human genomic DNA in the patient samples. Further 
modifications of the forward primer, the TaqMan probe and annealing temperature 
showed reduced non-specific amplification. This current primer-probe set gives results 
that have a high correlation with culture results. Results: Our final assay protocol 
demonstrates 100% (9/9) sensitivity, 97% (87/90) specificity and a limit of detection to 
10 plasmid copies of Acanthamoeba DNA. Samples showing amplification below 10 
plasmid copies are reported as “not detected” due to possible non-specific amplification 
in this range. Conclusions: PCR analysis of ophthalmological samples for the 
detection of Acanthamoeba provides a rapid alternative to detection by growth in 
culture. It should, however, be used in combination with other clinical findings to provide 
a definitive diagnosis. 
 
ID28. Using Post-Cytology ThinPrep T2000 Specimens for Roche COBAS 4800 
HPV Test: Validation and Comparison to Digene HR-HPV HC2 Assay 
K. Bourgeois, A. Baker, D. Ewing, R. Peters, G. Coshatt, W. Benjamin, S. Harada 
University of Alabama at Birmingham, Birmingham, AL 
Introduction: Our laboratory has used the Digene HR-HPV HC2 assay for gynecologic 
HPV testing; however, with FDA approval of the Roche COBAS 4800 HPV test, we saw 
an opportunity for savings by decreasing the technologist’s time running HPV tests and 
genotyping (HPV 16 and 18). Due to workflow issues, specimens need to be processed 
first by cytology using ThinPrep T2000, before arrival in molecular diagnostics. As not 
FDA approved for post-cytology specimens, we validated them using the COBAS 4800 
as a laboratory developed test. Methods: A carryover study was first performed by 
pooling known positives and negatives by the Digene HR-HPV HC2 assay to provide 
sufficient volume to be run by cytology’s ThinPrep T2000 and testing by the Digene 
assay. 10 positives and 10 negative pooled specimens were alternated when 
processed by cytology; then tested again by the Digene assay. 40 consecutive patient 
specimens were then tested pre- and post-cytology testing using the Roche COBAS 
4800 HPV test. Following carryover testing, comparison testing was performed on post-
cytology specimens using the Digene HR-HPV HC2 and Roche COBAS 4800 HPV 
assays for 212 tests, 174 different patients and 4 Acrometrix controls totaling 38 tests. 
Send out, linear array testing was performed on 10 specimens, aiding in discrepant 
results. Results: The Digene carryover study revealed all 10 positives and negatives 
were in agreement, 100%. The 40 patients run pre- and post- cytology showed 39 
(97.5%) agreement and 1 discrepant result, pre- high risk positive and post- negative. 
Of the total 212 post cytology comparison tests, 199 (93.9%) agreed. Of the 212, 174 
were separate patients that had 161 (92.5%) agreement. All 4 of the Acrometrix 
controls, 3 positive and 1 negative, agreed in all 38 tests run. 7 discrepancies were 
resolved by linear array: 2 false negatives, both by Digene; and 5 false positives, 2 by 
Digene and 3 by Roche. Of the Roche false positives, 2 of the 3 correctly resulted on 
repeat testing. There were 6 unresolved discrepancies not sent out for linear array, all 
were positive by Digene and negative by Roche. Conclusions: The Roche COBAS 
4800 HPV assay validated as a laboratory developed test is accurate, reliable, and 
decreases the amount of technologist time. There was no observed carryover from the 
ThinPrep T2000 by either the Digene or Roche assays. Unresolved discrepancies are 
most likely due to crossover by Digene.  
 
ID29. Comparison of Rapid Antigen Test and Real-Time RT-PCR for Diagnosing 
Influenza B 
H. Kim, Y. Lee 
Hallym University Medical Center, Anyang, Republic of Gyeonggi-do, Korea. 
Introduction: Rapid antigen test and real-time RT-PCR (rRT-PCR) are widely used for 
the detection of influenza A. Here we evaluated the usefulness of a rapid antigen test 
currently in use, compared to rRT-PCR as a screening test for detection of influenza B. 
Methods: A total of 85 patients were tested with Rapid antigen test (SD BIOLINE 
Influenza Ag, SD, Korea) and rRT-PCR (Anyplex FluA/B Real-time Detection, Seegene, 
Korea) during outbreak of influenza B. Results: Sensitivity and specificity of the rapid 
antigen test in the detection of influenza B were 68.3% and 100% compared to rRT-
PCR, respectively. Twenty-eight patients (32.9%) were positive for both rapid antigen 
test and rRTPCR, and 42 (49.5%) were negative for both rapid antigen test and rRT-
PCR. A total of 13 (15.3%) patients were only positive for rRT-PCR. Two patients 
showed invalid results in rRT-PCR. There were significant difference in detection rates 
of the rapid antigen test between different H1 Ct (threshold cycle) interval groups. 
Conclusions: The rapid antigen test showed relatively high sensitivity and specificity 
and the good correlation woth rRT-PCR. The rapid antigen test will be useful in early 
detection of influenza B and in treatment decisions. 
 
ID30. Consolidation of Five Transplant Associated Viral Targets into a Single 
Real-Time PCR Thermo-Cycling Program 
N. Tisdel1, D. Walton1, H. Hendrickson2, C. Lewing3, T. Lasco1, A. Chen1 
1St. Luke's Hospital, Houston, TX; 2The Methodist Hospital, Houston, TX; 3MD 
Anderson Cancer Center, Houston, TX. 
Introduction: Over the last few decades, St. Luke’s Episcopal Hospital and the Texas 
Heart Institute within the Texas Medical Center have become leaders in transplant 
medicine. The ongoing care for patients in current programs, along with the expansion 
of transplant services, has increased demand for effective testing and efficient 
turnaround time for critical transplant related viral targets. Accordingly, this study sought 
to streamline our current test methods by consolidating quantitative real-time PCR 
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protocols for Epstein-Barr virus (EBV), cytomegalovirus virus (CMV), BK virus, and 
qualitative real-time PCR for herpes virus 1 and 2 (HSV) into a single thermo-cycling 
program on the Rotor-Gene Q platform (Qiagen, Hilden, Germany). Methods: Precision 
of the unified Rotor-Gene Q protocol and BK, CMV and EBV RG ASR kits (Qiagen) was 
assessed by first evaluating lower limit of detection, and subsequently creating standard 
curves based on the linearity panel for each respective target (Zeptometrix, Buffalo, 
NY). HSV was validated using clinical patient samples and serially-diluted control viral 
cultures. Standards were extracted on the QIAsymphony SP (Qiagen), using the 
Bacteria Virus DSP Mini Kit (CMV, BK) and Bacteria Virus MIDI Kit (HSV, EBV) with the 
Cellfree_200_DSP and Virus_500_DSP extraction protocols respectively. Lastly, clinical 
samples were extracted with the above protocols and then amplified in duplicate to 
assess accuracy of the consolidated PCR program against validated laboratory-
developed tests currently in use. Results: There was 95.7% concordance observed 
between current laboratory-developed assays and the unified thermo-cycling PCR 
program. Positive predictive value (PPV) was calculated to be 95.8%, 97.6%, 95.6%, 
95.4% for CMV, BKV, EBV and HSV respectively. Negative predictive value was 
calculated to be 97.6%, 95.7%, 95.5% and 97.5% for CMV, BKV, EBV and HSV 
respectively. Quantitative standard variance between runs remained within 0.5 log 
(range: -0.2 to 0.24 log) for CMV, BKV, and EBV. Conclusions: The consolidation of 
five analytes onto one real-time PCR thermo-cycling program significantly reduces 
turnaround time of batched tests, potentiating earlier treatment interventions and 
improved patient care. 
 
ID31. Evaluation of the Performance of the cobas 4800 Ct/NG Test for Female 
Urines, Cytology Specimens and Endocervical Swabs 
J. Wisotzkey, M. Severns 
Central Pennsylvania Alliance Laboratory, York, PA. 
Introduction: The cobas 4800 CT/NG Test on the cobas 4800 system is an in vitro 
nucleic acid amplification test that utilizes PCR and nucleic acid hybridization for the 
qualitative detection of Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (NG) 
DNA to aid in the diagnosis of chlamydial and gonococcal disease. In this study, the 
performance of the cobas 4800 CT/NG Test was assessed in direct comparison to the 
cobas AMPLICOR CT/NG for the detection of CT/NG in endocervical swabs collected in 
BD ProbeTec medium, cytology specimens in PreservCyt solution and CT in female 
urines. The performance of the cobas 4800 CT/NG Test on NG specimens was 
compared to the BD Probe Tec method for female urines. Methods: Sixty five (65) 
endocervical swab samples collected in BD Probe Tec Media, 202 cytology specimens, 
and 57 CT female urines that were all previously tested by the cobas AMPLICOR 
CT/NG test were run on the cobas 4800 CT/NG assay. In addition, 37 NG specimens, 
previously tested by the BD Probe Tec method, were run on the cobas 4800 CT/NG 
assay. Sensitivity studies were also performed using known CT and NG controls spiked 
into each media type. Results: For endocervical swabs, the overall percent agreement 
for CT and NG was 96.7% and 93.6%, respectively with a positive agreement of 95.1% 
(CT) and 72.7% (NG) and a negative agreement of 100% (CT & NG). Cytology samples 
collected in PreservCyt medium demonstrated an overall percent agreement of 99% 
(CT) and 93.6% (NG); a positive agreement of 93.1% (CT) and 88.9% (NG); a negative 
agreement of 100% (CT) and 93.8% (NG). Comparing the performance between 
assays for the detection of CT and NG in female urines, the overall, positive and 
negative agreement was 100% for CT with an overall agreement, positive agreement 
and negative agreement of 94.7%, 87% and 97% respectively for NG. Conclusions: 
The cobas 4800 CT/NG Test is a very sensitive and specific assay for the real time 
PCR detection of Chlamydia trachomatis and Neisseria gonorrhoeae in endocervical 
swabs, urine and PreservCyt media. Due to the improved target design with the cobas 
4800 CT/NG Test and the increased specificity of the NG detection, it is evident that the 
cobas 4800 CT/NG Test performs in a manner superior to the cobas AMPLICOR 
CT/NG test currently employed in many laboratories. 
 
ID32. Comparison of Automated and Manual PCR Set Up for a Laboratory 
Developed Novel 2009 Influenza A/H1N1 Real-Time rtPCR Assay 
N. Tisdel, D. Walton, A. Chen 
St. Luke's Hospital, Houston, TX. 
Introduction: In response to the Novel Influenza A/H1N1 Pandemic of 2009, St. Luke's 
(SLEH) Molecular Pathology laboratory developed a qualitative real-time rtPCR assay 
to confirm Influenza A/H1N1 in hospitalized patients with symptoms of Influenza-Like-
Illness. As the influx of specimens grew workflow shifted to a more automated platform 
utilizing the QIAsymphony SP (Qiagen, Hilden, Germany) for RNA extraction, coupled 
with manual set up of the PCR reaction. With the recent acquisition of the 
QIAsymphony AS Module (AS), we sought to further decrease technologist hands on 
time (HoT) by automating the PCR set up process. This study aims to compare our 
current manual PCR set up method with that of the AS automated method, and 
subsequently validate the AS module for clinical laboratory use at SLEH. Methods: An 
Influenza A/H1N1 stock virus culture was serially diluted and a low concentration 
positive dilution was selected. Ten replicates of the chosen dilution were first extracted 
then set up manually for PCR, and subsequently set up using AS module automation. 
AS automation was performed using the LC_PCR_15+5 protocol, with the 
corresponding cooling hardware and capillaries. Both manual and automated sample 
sets were amplified on either the LightCycler 1.2 or Light Cycler 2.0 (Roche 
Diagnostics, Indianapolis, IN). Once the accuracy and precision of the AS were 
assessed and compared to the manual set up method, a blinded set of respiratory swab 
samples from our normal patient population were extracted then amplified in duplicate 
to assess relative clinical performance. Results: There was 100% concordance of the 
manual set up versus the automated set up. Technologist hands on time was reduced 
by a minimum of fifteen minutes when greater than seven samples were set up per 
target, totaling to fourteen reactions per test. Variance in relative crossing threshold 
(CT) values was negligible amongst patient samples and controls. Comparable 
sigmoidal amplification curves were observed between both methods. Conclusions: 
The QIAsymphony AS module provides a significant reduction of Hands on Time for the 
technologists performing this assay at SLEH. The automated method performs as 
accurately and precise as our current manual PCR set up method, and is a viable 
option for increasing efficiency of workflow within this testing model. 
 
ID33. Evaluation of Quidel Influenza A+B Test Run on The Applied Biosystems 
7500 Fast Dx and Cepheid SmartCycler Compared to the Cepheid Flu A/B Test for 
Detection of Influenza A/B in Clinical Specimens 
B.W. Buchan1, M. Rifelj2, N.A. Ledeboer1 
1Medical College of Wisconsin, Milwaukee, WI; 2Dynacare Laboratories, Milwaukee, WI. 
Introduction: Several FDA-cleared tests for the detection of influenza virus are 
available for use in the clinical laboratory. Some of these tests can be performed on 
multiple platforms including the SmartCycler (SC) (Cepheid, Sunnyvale, CA) and ABI 
7500 Fast Dx (ABI) (ABI, Foster City, CA), which are tailored to random access or batch 
testing. We compared performance of the Quidel Influenza A+B test (Quidel, San 
Diego, CA) on both the SC and ABI platforms to the Cepheid Flu A/B test. Methods: A 
collection of 75 prospective and retrospective specimens (nasal swab, throat swab, 
BAL) in M4 or M6 viral transport medium were extracted using the NucliSENS EasyMag 
system. Nucleic acid extracts were tested using the Quidel Flu A+B test on ABI and SC. 
The same set of specimens was also tested using the Cepheid Flu A/B test on SC. 
Results were compared between samples run using each test and on each platform. To 
establish detection thresholds (LoD), serial dilutions of Flu A and B controls were 
prepared and tested using each of the 3 methods described. Results: Clinical 
specimens were positive for influenza A (SOIV: 11, H3: 9), influenza B (7), or both A 
and B (1). All specimens containing influenza A and or B were detected by both the 
Quidel and Cepheid Flu A/B tests on the SC. All clinical specimens containing influenza 
A or B were also positive by Quidel Flu A/B test on the ABI. A single specimen was 
resulted as positive for both influenza A and B using Quidel Flu A+B on SC and ABI, 
but was only positive for influenza B using the Cepheid Flu A/B test. A third molecular 
test (RV+, Nanosphere, Northbrook, IL) detected both influenza A and B in this 
specimen. Serial dilutions of spiked influenza A or B samples demonstrated a LoD of 
8.9 and 22.2 TCID50/mL for influenza A and B, respectively, using the Quidel Flu A+B 
test on both SC and ABI. LoD using the Cepheid Flu A/B test on the SC was 889.1 and 
2.2 TCID50/mL, respectively, for influenza A and B. Conclusions: Quidel Flu A+B test 
demonstrated 100% sensitivity (28/28) and specificity for detection of influenza A/B 
when run on the SC or ABI. Cepheid Flu A/B was 96.4% sensitive (27/28) when run on 
the SC. Quidel Flu A/B test was two log10 more sensitive for influenza A as compared 
to the Cepheid FluA/B test. 
 
ID34. Molecular Characterization of Hepatitis B Virus: A Six Year Follow Up of 
Genotypes and Subgenotypes Distribution  
R. Sitnik, R.A. Santana, L. Oyakawa, C.L. Mangueira, J.R. Pinho 
Hospital Israelita Albert Einstein, São Paulo, Brazil. 
Introduction: Hepatitis B virus (HBV) is classified into nine genotypes (A-I), further 
classified in subgenotypes, that show distinct geographic distribution worldwide. In 
Brazil, genotype A is the most frequent (particularly subgenotype A1), followed by 
genotypes D and F. Few data are available from the subgenotypes circulating in 
different populations groups from São Paulo, Brazil, which is the largest city in the 
country and receive immigrants from all other Brazilian regions as well as from other 
countries. Methods: We analyzed retrospectively 671 patients tested in a Private 
Hospital from March/2006 to April/2012. HBV subgenotypes were determined by 
sequencing the overlapping region coding both for HBsAg and DNA polymerase genes. 
Sequences were compared to a database that allows distinction of HBV subgenotypes 
and determination of relevant mutations for drug resistance in polymerase gene and 
resistance to HBIg, anti-HBs monoclonal antibody, or vaccination in HBsAg. Analysis 
was performed by selecting found mutations on an Excel macro that generates the 
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report containing subgenotype and resistance pattern to each antiviral drug. Results: 
Subgenotypes A1 (46.3%), D3 (17.4%), C2 (10.0%), F2 (6.3%) and A2 (5.0%) were the 
most frequent. D2, D4, D1, G, E, F4, B2, F1, C1 and B1 were also found. Comparing 
samples obtained from private laboratories to those from the public system, 
subgenotype A1 and D3 were the most frequent in both of them, but overall distribution 
were statistically different (p<0.003). Analyzing each year separately, genotype A1 
frequency is increasing, especially among patients from the public health system. 
Conclusions: Genotypes A, D, C and F are the most frequent in our casuistics. This 
result reflects the origins of the population living in São Paulo city, as there are many 
European, African, and Asian descendants. Several HBV subgenotypes are found and 
some new cases of rare genotypes, such as genotype E, start to be detected. HBV 
genotyping is considered relevant to indicate treatment as genotype A (A2) and B 
patients might benefit from interferon treatment whereas those with genotypes C and D 
might receive nucleoside/tide analogs. There are few data indicating the use of 
interferon for subgenotype A1 patients reinforcing the need of subgenotyping in our 
population. 
 
ID35. USP - A Simple, Equipment-Free Method for Nucleic Acids Purification 
Applicable to Various Clinical Specimens 
A. Kodvawala, M. Wessendarp, C. Hauck, A. Hindupur, V.I. Slepnev, K. Kozak, V. 
Elagin 
Meridian Bioscience, Cincinnati, OH. 
Introduction: We describe a simple, fast and cost effective method that has universal 
applicability for nucleic acid purification from diverse biological specimens. The 
Universal Sample Preparation (USP) device utilizes concepts of size exclusion 
chromatography to process sample volumes of 200 Pl to 350 Pl. The purification 
process is performed by gravity flow and does not require any laboratory equipment (no 
centrifuge). Purified nucleic acids are suitable for various molecular applications. The 
USP method can support molecular testing in near- patient or resource-limited settings. 
Methods: Clinical samples were subjected to an alkaline lysis and were directly applied 
to USP devices. USP analytical performance was compared to blood kit (Qiagen) using 
Mycoplasma pneumoniae FH strain spiked into M4 transport medium and detected by 
illumigene Mycoplasma assay (Meridian)*. Culture-enriched GBS clinical samples were 
puirifed with DNeasy blood kit and USP and detected by illumigene GBS (Meridian) and 
in-house PCR. Urine samples, positive for Chlamydia trachomatis were processed with 
USP and tested by PCR and LAMP assays*. USP clinical performance was compared 
to Xpert C. difficile (Cepheid) assay using frozen stool specimens previously tested by 
Xpert. Samples were purified with USP and tested by illumigene C. difficile (Meridian) 
assay. Discrepant samples were retested by Cepheid and in-house PCR. (*not cleared 
by FDA) Results: The USP yield and quality of DNA from Mycoplasma pneumoniae 
specimens was similar to DNeasy extraction kit, when used for LAMP amplification. 
Similar performance was observed for detection of GBS in enriched cultures using 
standard silica-based DNA purification and USP. Preliminary results demonstrated 
applicability of USP for detection of Chlamydia trachomatis in urine. The clinical 
performance of illumigene C. difficile test with USP was concordant to Cepheid test (19 
of 20 positives, 28/30 negatives). Two illumigene-USP positive/ Cepheid negative 
samples had Cepheid Ct values above assay cut-off and were positive by in-house 
PCR. One illumigene-USP negative was negative when re-tested by Xpert that may 
suggest DNA degradation during freeze storage. Conclusions: We demonstrated 
versatility of USP method for nucleic acids purification from a variety of clinical 
specimen types. The prepared DNA is suitable for PCR or isothermal amplifications. It 
enables similar analytical and clinical sensitivity as commonly used silica-based 
purification methods without using any laboratory equipment. Fast (less than 5 minutes) 
sample processing time from specimen to purified DNA can enable broader use of 
molecular tests in near patient settings. 
 
ID36. The Pulmonary Microbiome in Patients with Cystic Fibrosis: Next 
Generation Sequencing and Conventional Pathogen Detection 
R. Luna, E.B. Hollister, M. Pitashny, J.K. Runge, Y. Shang, P.A. Revell, C.M. Oermann, 
P.W. Hiatt, J. Versalovic 
Texas Children's Hospital/Baylor College of Medicine, Houston, TX. 
Introduction: Although the 16S rRNA gene has been a common target for single 
pathogen identification, next generation sequencing targeting the same gene now 
allows for the characterization of the complete bacterial community within a given 
specimen. Microbiome characterization of specimens submitted to the clinical 
microbiology laboratory will aid in initial correlations of bacterial identification by both 
sequencing and conventional microbiology. For this study, respiratory specimens 
collected from patients with cystic fibrosis (CF) were analyzed via routine culture and 
next generation sequencing. Methods: Following microbial culture, remaining sputum 
specimens collected from patients with CF were obtained for microbiome analysis. 
Bacterial DNA was extracted from 34 archived sputum specimens, and the V3V5 
variable regions of the 16S rRNA gene were amplified with barcoded primers. The 
resulting libraries were purified and prepared for 454 sequencing. An average of 7,000 
reads were obtained per sample with an average read length of 525 bases. Resulting 
sequence libraries were analyzed via the Genboree Microbiome Workbench. Results 
from routine respiratory culture were compared as well as basic clinical demographics. 
Results: A total of 35 different genera were detected among the respiratory specimens 
with a range of 4 to 15 genera detected in each specimen. Streptococcus spp. were 
found in all 34 subjects and was the most abundant genus in 14 subjects. Prevotella 
and Veillonella were also highly prevalent and were detected in 33 of 34 subjects. 
Individual pathogens isolated by culture were not always identified in the bacterial 
community by next generation sequencing. However, identification of Pseudomonas 
spp. (8 subjects) and Staphylococcus spp. (12 subjects) via sequencing were 
accompanied by a corresponding culture result in every instance, with varying levels of 
relative abundance of these genera in individual sequence libraries (averages of 12% 
for Staphylococcus and 44% for Pseudomonas). Conclusions: Chronic and acute 
respiratory infections are highly common in patients with CF, and the characterization of 
the microbiomes present in this population will provide a greater understanding of the 
fluctuations in disease-associated bacterial communities of the respiratory tract. With 
routine respiratory cultures recommended for all patients with CF, ongoing comparisons 
of conventional culture results to next generation sequencing results will provide further 
insights into the impact of individual pathogens and “pathogenic microbiomes” in CF. 
These studies will also help guide implementation of direct DNA sequencing for 
molecular diagnostics in the context of CF and respiratory tract infections. 
 
ID37. Verification of the COBAS AmpliPrep / COBAS TaqMan HBV Test ver. 2.0  
K.A. Lebel1, C.L. Bissaillon1, H.B. Steinmetz2, G.J. Tsongalis2, F. Moore1 
1Baystate Health, Springfield, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: Verification of quantitative test systems in the clinical laboratory is 
essential in providing quality patient care. Recently, our laboratory instituted the 
COBAS AmpliPrep / COBAS TaqMan HBV Test Version 2.0 test for clinical use. Here 
we present data for verification of this new assay. Methods: Verification studies were 
performed in the laboratory following the Roche Assay Verification Activities Plan. The 
Valiquant HBV DNA quantitative panel (Acrometrix, Benicia, CA) was used to assess 
accuracy, linearity, precision and limit of detection. This panel consists of six samples 
spanning the range of 0-5x106 HBV IU/ml. Accuracy and precision were assessed 
using a high and low control run in triplicate over a 5 day span. Linearity was assessed 
by testing the Valiquant panel in triplicate within a single run. Limit of detection was 
assessed using a panel member at the lower limit of detection for the assay (20 IU/ml) 
within a single run in 20 replicates. In addition, 20 de-identified, frozen clinical samples 
were tested to assess method correlation. Results were compared to previously 
obtained results using the COBAS AmpliPrep / COBAS TaqMan HBV Test ver. 2.0. 
Results: The interlaboratory results of the clinical samples were nearly identical. 
Precision was assessed at 3% and 1% Total (log 10) %CV for low and high controls, 
respectively. Accuracy measured at two levels over 5 days yielded a mean log 10 
difference (expected to observed) at 0.10. Linearity studies resulted in a regression of 
y=0.9934x-0.0818, with a correlation coefficient (r2) of 0.998. The limit of detection was 
demonstrated to be accurate within 95% confidence. Conclusions: Analysis of data 
obtained with the COBAS Ampliprep/COBAS Taqman HBV Test ver. 2.0 verified 
manufacturers’ claims stated in the package insert. Furthermore, correlation of results 
ensures accurate assessment of HBV viral load in patients is consistent across 
platforms. The lower limit of detection and detection of several genotypes will enable 
laboratories to better assist in the care of HBV infected patients. The verification 
process, although time consuming, provides a precise mechanism to establish the 
parameters necessary to deliver high quality of care. 
 
ID38. Molecular Characterization of Adenoviruses from Four Outbreaks of 
Keratoconjunctivitis in New York State in Early 2012 
K. St. George1, D. Lamson1, R. Ramani1, M. Quinn2, A. Newman2, J. Whitehouse2, J. 
Greenko2, E. Adams2, A. Kajon3 
1Wadsworth Center, Albany, NY; 2New York State Department of Health, Albany, NY; 
3Lovelace Respiratory Research Institute, Albuquerque, NM. 
Introduction: Ocular infections caused by adenovirus (ADV) are highly contagious and 
the most severe, caused by ADV group D (ADV 8, 19 and 37) are classified as 
epidemic keratoconjunctivitis (EKC). During the early months of 2012, EKC outbreaks 
occurred in neonatal intensive care units in three hospitals in New York and Suffolk 
County in NYS. A total of 30 neonates were affected, 14 of whom were laboratory 
confirmed as ADV-infected. Twelve health care workers were also affected, 2 of whom 
were confirmed as ADV-positive by laboratory testing. A fourth outbreak of EKC among 
patients attending a private ophthalmology practice in Ulster County involved a total of 
46 cases. The objective of this study was to perform molecular characterization of the 
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ADV strains on available samples from all four outbreaks, to assess the relatedness of 
the viruses and likelihood of linkage between the outbreaks. Methods: Available patient 
samples were cultured, and harvested samples used as template in a nested PCR that 
targets the hypervariable region of the hexon gene of ADV. PCR products were 
sequenced, compared to reference strains, and phylogenetic analysis was performed. 
Isolates were cultured to large quantity, and restriction fragment length polymorphism 
(RFLP) performed on the ADV DNA. Additionally, further sequence characterization 
was performed on the fiber knob gene. Results: A total of 12 eye swab samples, 
collected from cases in all four outbreaks, were received for testing. All 12 samples 
tested positive for ADV by real-time PCR and were determined to be ADV 8 by 
sequence analysis of a partial hexon gene region. Phylogenetic analysis of the 
sequence found that the samples from the three NICU outbreaks were 
indistinguishable, whereas those from the private practice outbreak had a single 
nucleotide change. Sequence analysis of the fiber knob region also demonstrated 
minimal differences. Isolates are being further assessed by whole genome RFLP 
pattern. Conclusions: The highly contagious nature of ADV keratoconjunctivitis, and 
the potential for more serious disease manifestations in a NICU setting, warranted a 
prompt and thorough investigation. The occurrence of multiple outbreaks in rapid 
succession, including cases among health care workers and patients, encouraged the 
analysis of infecting strains for molecular evidence of relatedness. Despite the highly 
similar molecular patterns and sequences observed, ADV 8 is documented as having a 
relatively stable genome, and extensive epidemiological investigations could find no link 
between the outbreaks.  
 
ID39. Evaluation of the Roche COBAS HPV Test 
M. Pieretti, L. Medling, A. Harrison 
BayCare Health System, Tampa, FL. 
Introduction: The Roche COBAS HPV detects 14 high risk Human Papilloma Virus 
(HR HPV) types, including HPV 16 and 18. Our laboratory currently uses the Qiagen 
HC2 assay that detects 13 HR HPVs. The HC2 test is labor intensive, with several 
hands-on steps. Additionally, this test has a reported low specificity. The Roche assay 
utilizes real time PCR and is currently FDA approved for PreservCyt aliquots taken prior 
to cytology testing. The purpose of this study was to compare the performance of the 
Roche and Qiagen assays, and review the performance of the Roche test on matched 
aliquots taken prior and after cytology testing. Methods: For the method to method 
comparison, residual samples were tested with the COBAS test after HC2 testing was 
completed. One-hundred-twenty-nine (129) non-consecutive samples were tested. 
Samples with discrepant HPV results were further tested off-site either with the Hologic 
Cervista or the Roche HPV Linear Array assays. For the pre- and post-aliquot study on 
the COBAS, two 1.0 mL aliquots from 50 consecutive samples were transferred to 
empty tubes before and after cytology testing. Results: Of the 129 samples in the 
method to method comparison, 71 were positive for HR HPV with both methods, and 41 
were negative for both methods. The remaining 17 samples had a discrepant result, 
with 15 samples positive for HC2 only, and 2 samples positive for COBAS only. Of the 
15 HC2 positive/COBAS negative samples: 12 were negative and 3 were positive by a 
third method. Of the 2 HC2 negative/COBAS positive samples: 1 was positive by Linear 
Array and 1 had insufficient volume to be retested. For the pre- and post-aliquot study, 
45 aliquots were negative prior and after cytology testing, 3 were HPV positive prior and 
after cytology, whereas two samples has mismatched results. No further testing was 
conducted on these discrepant aliquots. Conclusions: There was good agreement 
(87%) between the COBAS and the HC2 HPV assays. For the majority (76%) of the 
discrepant samples the third assay confirmed the COBAS HPV result. There were two 
false negative COBAS HPV results and one false negative HC2 result; for all these 
samples, a Ct close to the cutoff was detected in the COBAS assay. These 
discrepancies may be due to variations in weakly positive samples. For the pre- and 
post aliquot study, the majority of aliquots had matching results (96%). No trend was 
observed pointing to contamination of samples after cytology processing. 
 
ID40. Comprehensive Assessment of Merkel Cell Polyomavirus in Merkel Cell 
Carcinomas: Fluorescence in situ Hybridization Versus qPCR? 
E.M. Speel1, A. Haugg1, D. Rennspiess1, A. zur Hausen1, G. Cathomas2, J. Becker3, D. 
Schrama3 
1Maastricht UMC, Maastricht, Limburg, Netherlands; 2Kantonsspital, Liestal, 
Switzerland; 3Medical University of Graz, Graz, Austria. 
Introduction: Merkel cell polyoma virus (MCPyV) is detected in 80% of Merkel cell 
carcinomas (MCC). The clonal integration and tumor specific mutations in the large T 
Antigen (LTAg) gene identify MCPyV as a novel human tumor virus. To date the 
relationship between the viral presence and cancer induction, development or clinical 
prognosis is discussed controversially. Yet almost all studies are based on quantitative 
virus detection, i.e., PCR or qPCR. Here we aimed to gain information about the quality 
of the viral presence on the single cell level in the histomorphological context. 
Methods: We performed MCPyV-FISH of formalin fixed and paraffin embedded (FFPE) 
MCCs (n=62) on tissue microarrays (TMAs), determined the hybridization patterns and 
correlated these with qPCR data on the basis of a determined cut-off. MCPyV-FISH 
was established using the MKL-1 cell line that harbors integrated copies of MCPyV 
DNA. For MCPyV-qPCR a LT primer pair (Becker et al, 2009) was used on whole tissue 
sections. Results: MCPyV-FISH on FFPE MKL-1 cells revealed punctate signals 
compatible with viral integration. The MCPyV-FISH positive MCC cores (76%) mainly 
revealed two different signal patterns: a punctate pattern (85%) that correlated with a 
moderate relative viral abundance and in some areas the punctate pattern was 
combined with a diffuse pattern (15%) indicating the episomal presence of the virus that 
is linked to viral replication. A mixed hybridization pattern was associated with very high 
qPCR values. Comparing MCPyV-FISH and qPCR data the results highly correlated 
(83%) with the MCPyV positive evaluated group, whereas the negative group showed a 
concordance of 93%. The mean of the qPCR values of all MCPyV positive cores 
differed significantly from the negative cores (p=0.0076). In some tumor areas of one 
and the same patients the FISH signals were heterogeneous in intensity, pattern and 
nuclear localization. Conclusions: A strong correlation between MCPyV FISH and the 
relative MCPyV abundance by qPCR was detected. Thus, although presence of 
MCPyV can be verified by qPCR, the quality of the presence can be visualized by 
MCPyV specific FISH analysis. In this regard, MCPyV qPCR and MCPyV FISH are 
important complementary tools to gain maximum biological information of the presence 
of MCPyV in MCC and thus to further elucidate MCPyV related carcinogenesis. 
 
ID41. Discordance in HBV Viral Load with the COBAS TaqMan HBV Test and 
the VERSANT HBV DNA 3.0 Assay (bDNA) 
J.J. Germer1, K. Brown2, J. Harris2, S. Kumar2, C. Ngo2, N. Schoenbrunner2, N. 
Newton2, M. Lin2, C.E. Bommersbach1, J.D. Yao1 
1Mayo Clinic, Rochester, MN; 2Roche Molecular Systems, Inc., Pleasanton, CA. 
Introduction: HBV viral load (VL) is an important prognostic and therapeutic response 
indicator among HBV-infected patients. The COBAS TaqMan HBV Test for use with the 
High Pure System (HPS/CTM) and COBAS AmpliPrep/COBAS TaqMan HBV Test, v2.0 
(CAP/CTM) are FDA-approved, real-time PCR assays for quantification of HBV DNA in 
human serum or plasma. This study evaluated potential causes of discordance between 
VL results obtained by HPS/CTM and the VERSANT HBV DNA 3.0 Assay (bDNA), 
among clinical specimens. Methods: Correlation and agreement between HPS/CTM 
and bDNA were studied among 80 unique clinical specimens containing HBV levels 
ranging from 378 to 16,105,400 IU/mL, as determined by bDNA. Direct sequencing of 
the HBV PreCore/Core region was performed with all specimens yielding VL differences 
of 1.0 log10 IU/mL and an equal number of specimens with VL differences of 0.5 
log10 IU/mL (ie, controls). HBV genotype (GT) determination and interrogation of 
primer/probe binding regions for HPS/CTM and CAP/CTM were performed with these 
sequences. Plasmids containing HBV DNA were generated from 3 of the specimens 
yielding discordant results. Along with additional plasmids containing incremental 
sequence modifications (ie, corrections), these plasmids were tested by HPS/CTM and 
CAP/CTM. For each assay, the impact of individual mutations was assessed directly by 
calculating relative change in VL for individual plasmids containing various mutations 
versus plasmids containing the corresponding original, uncorrected sequence. Results: 
Despite generally good overall correlation and agreement between HPS/CTM and 
bDNA, 12 specimens yielded VL differences of 1.0 log10 IU/mL with 2 of them (C130 
and C159) yielding differences of 2.0 log10 IU/mL. No association between VL 
discordance and HBV GT was identified, but potentially critical mismatches were found 
in specimens C130 and C159. Testing of plasmid constructs containing sequences 
derived from these 2 specimens confirmed that unexpected mismatches in PCR 
primers were primarily responsible for VL discordance. The atypical HBV sequences 
found in C130 and C159 had less impact on CAP/CTM than HPS/CTM results, with VL 
differences between assays of 1.31 and 0.83 log10 IU/mL, respectively. Conclusions: 
HPS/CTM yielded substantially lower HBV DNA VL than bDNA in a subset of clinical 
serum specimens. When compared to HPS/CTM, CAP/CTM showed better tolerance 
for critical primer/probe mismatches found in HBV sequences originating from clinical 
specimens. Despite use of standardized units, significant HBV VL discordance among 
assays highlights the continued importance of using the same assay for monitoring 
HBV VL over time in individual patients. 
ID42. Comparison of Whole-Blood IGRA, TST, PCR, and HRCT for Rapid 
Diagnosis of Smear-Negative Pulmonary Tuberculosis in Korea 
S. Suh1, O. Lee1, S. Kee1, M. Shin1, J. Shin1, D. Ryang1, B. Park2 
1Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic 
of; 2Mokpo National University, Muan-gun, Chonnam, Republic of Korea. 
Introduction: It is challenging to early detect pulmonary tuberculosis (PTB), especially 
in smear-negative PTB cases. There are several assays for rapid diagnosis of PTB, 
including whole-blood interferon-Ȗ release assay (IGRA), tuberculin skin test (TST), 
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polymerase chain reaction (PCR), and high-resolution computed tomography (HRCT). 
However, little is known about the diagnostic performance of such methods. The 
purpose of this study is to compare whole-blood IGRA, TST, sputum PCR, and HRCT 
in the diagnosis of smear-negative PTB. Methods: Retrospective comparison of the 
performance of whole-blood IGRA (QuantiFERON-TB Gold-In Tube; Cellestis, 
Australia), TST, sputum PCR using Amplicor kit (Roche Diagnostics, Switzerland), and 
HRCT in the rapid diagnosis of PTB was conducted from April 2009 to March 2010 at a 
university hospital in Korea. Results: Of 319 patients available for all the rapid assay 
results in the study, 237 were smear-negative, including 78 patients with PTB and 159 
with non-TB. The sensitivities of IGRA, TST, PCR, and HRCT were 79.5%, 60.3%, 
39.7%, and 71.8%, respectively, and the specificities were 59.9%, 77.4%, 96.9%, and 
90.6%, respectively. The positive predictive values of IGRA, TST, PCR, and HRCT 
were 50.9%, 56.6%, 86.1%, and 78.9%, respectively, and the negative predictive 
values were 84.5%, 79.9%, 76.6%, and 86.8%, respectively. Among 71 patients 
suspected of having PTB based on HRCT, 25 patients showed positive PCR results, 
and 24 (96%) of those were diagnosed with active PTB. Among 166 patients suspected 
not to have PTB based on HRCT, 155 patients showed negative PCR results, and 140 
(90.3%) of those were diagnosed as non-TB. Among 62 patients suspected of having 
PTB based on HRCT, 42 patients showed positive IGRA results, and 41 (97.6%) of 
those were diagnosed with active PTB. Among 149 patients suspected not to have PTB 
based on HRCT, 77 patients showed negative IGRA results, and 72 (93.5%) of those 
were diagnosed as non-TB. Conclusions: The combined results of HRCT and IGRA 
could help finding more PTB cases in smear-negative patients than those of HRCT and 
PCR. However, the combination of HRCT and PCR could be helpful to rule out more 
non-TB cases in smear-negative patients than that of HRCT and IGRA. 
 
ID43. Prevalence of Co-Infection of HPV Subtypes in Women Treated at A.C. 
Camargo Hospital in Sao Paulo, Brazil  
L.D. Andrade, B. Pellegrini, M.P. Macedo, G. Baiocchi Neto, D.M. Carraro, I.W. Cunha, 
V.P. Andrade 
A.C.Camargo Hospital, Sao Paulo, Brazil. 
Introduction: Human papillomavirus (HPV) is a large group of epitheliotropic viruses 
with variable risk to development of cervical cancer. Patients with persistent HPV 
infections with specific subtypes are at higher risk of cancer development and the role 
of co-infection remains unclear. Studies linking HPV-subtypes with and without co-
infection to morphology are few in the literature. We aimed to analyze the prevalence of 
type specific HPV infection and co-infections in women with cervical carcinomas and 
intra-epithelial neoplasia. Methods: 256 women underwent gynecologic examination 
with liquid-based cytology and biopsy sampling between June 2009 and October 2011 
at AC Camargo Cancer Hospital, Brazil. None of the woman received HPV vaccine in 
the past. Cytology was classified according to 2001 Bethesda System into 
normal/inflammatory (NL; n=52), atypia of undeterminate significance (AUS, n=74), 
intraepithelial neoplasia (low-grade=LSIL, n=84; high-grade=HSIL, n=40) or carcinoma 
(CA, n=6). DNA was successfully extracted and amplified from cytologic specimen in 
248 cases and HPV detection was performed using Linear Array HPV Genotyping HPV 
(6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 
66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, IS39 and CP6108 subtypes). Results: 
HPV was detected in 63% of the samples including 36 different virus subtypes. 
Detection of a single HPV subtype occurred in 21% of NL samples, 17% of AUS, 18% 
of LSIL, 23% of HSIL and 50% of CA. HPV-16 was the most prevalent subtype in all 
abnormal groups followed by HPV-61 in AUS/LSIL and HPV-66 in HSIL and HPV-31/53 
in CA. Co-infection was detected in all groups [NL=8%, AUS=43%, LSIL=61%, 
HSIL=64%, CA=33%]. At least one high-risk subtype was present in 139 samples 
(56%) including all groups [NL=8 (15%); AUS=39 (57%), LSIL=55 (67%), HSIL=37 
(82%), CA=5 (83%)]. No high-risk subtype was detected in 12% of LSIL, 2,5% of HSIL 
and 0% of CA, and co-infection with low-risk subtypes only was seen in 6%, 2,5% and 
0%, respectively. Conclusions: In Sao Paulo, Brazil, high-risk HPV subtype is common 
across the spectrum of cervical lesions with a stepwise increase until carcinoma, 
supporting the high-risk concept. Co-infection was more common than single subtype 
infection in LSIL/HSIL/CA. A proportion of HSIL/CA developed without a high-risk 
subtype, suggesting that persistent infection/low-risk co-infection also carries a relevant 
risk to cancer development. 
 
ID44. Development of a Software Tool for Calculation of Diversity Measures 
from High Resolution Melting (HRM) Data 
M.M. Cousins1, D.A. Swan2, C.A. Magaret2, S.H. Eshleman1 
1Johns Hopkins University School of Medicine, Baltimore, MD; 2Fred Hutchinson 
Cancer Research Center, Seattle, WA. 
Introduction: High resolution melting (HRM) assays usually rely on software tools to 
identify changes in the peak melting temperature (Tm) of DNA samples that reflect the 
presence of specific mutations. Additional melting characteristics may provide 
information for other applications of HRM technology, but these characteristics may be 
difficult to measure due to a lack of specialized software tools. The HRM diversity assay 
is a rapid method for quantifying nucleic acid diversity by measuring the width of melting 
peaks. This assay has been used to measure the genetic diversity of human 
immunodeficiency virus (HIV) in samples from infected individuals. Results from the 
HRM diversity assay are significantly associated with diversity measures derived from 
sequence data, including data from next generation sequencing. We explored whether 
a software tool could be used to characterize features of melting peaks other than Tm. 
Methods: More than 700 plasma/serum samples from HIV-infected individuals were 
analyzed in duplicate with the HRM diversity assay (2-8 genomic regions/sample, 
LightScanner Instrument, Idaho Technology). The resulting data were used to develop 
an R package capable of generating DNA melting peaks from the raw data output 
(plotted as -dFluorescence/dTemperature vs. Temperature) and determining the Tm 
and width of melting peaks. Seventeen user-controlled analysis parameter settings 
were included in the software package, allowing the user to customize the analyses. 
Duplicate melting curves from 1,164 sample/regions were used as a test dataset for the 
software tool using 64 different software tool settings. Melting peaks were evaluated for: 
(1) correct calling of the Tm, (2) reproducibility (deviation less than 0.5 degrees) of peak 
width measurements between duplicate runs, and (3) accuracy of start melt and end 
melt temperature measurements. Results: In the test set of 1,164 sample/regions, the 
Tm was correctly identified 100% of the time using all software tool settings. The 
reproducibility and accuracy of peak width calculations varied with different software 
settings. The best settings resulted in reproducible peak width determination 99% of the 
time. Correct start and end melt temperatures were identified 99% of the time. The 
program processes data from a 96-well plate in approximately 1 minute as opposed to 1 
hour required for a less-objective manual method. Conclusions: This versatile software 
tool provides reproducible and accurate measurements of melting peak width, 
decreases analysis time, runs on most computer platforms, and can be easily adapted 
to characterize other features of DNA melting curves for other applications. 
 
ID45. Validation of a Molecular Identification Assay for Pathogenic Fungi in a 
CLIA Certified Molecular Diagnostics Laboratory 
L.W. Razai, K. Vadlamudi, B.L. Wickes, J. Fu, D.I. McCarthy, A.W. Fothergill, D.A. 
Sutton, W. Furmaga, H. Fan 
University of Texas Health Science Center at San Antonio, San Antonio, TX. 
Introduction: Fungal identification via molecular techniques is evolving into an 
important tool for clinical diagnosis. Despite the need for rapid diagnosis, few 
laboratories offer molecular testing. To fill this gap, we report a validation study of a 
molecular assay by Sanger sequencing using primers targeting the internal transcribed 
spacer (ITS) and domains 1 and 2 of the large ribosomal subunit (D1/D2) regions. This 
assay was developed using the Clinical and Laboratory Standards Institute (CLSI) 
Guidelines (MM18-A, MM03-A2). Methods: DNA was extracted from 22 mold and 14 
yeast species. The ITS and D1/D2 regions were amplified using the panfungal 
ITS1/NL4 primer pair. PCR products were purified and sequenced bi-directionally using 
ITS1/ITS4 and NL1/NL4 primers using BigDye sequencing reagents and an ABI3130xl 
Genetic Analyzer (Applied Biosystems). Resulting sequences were analyzed by 
Lasergene software (DNASTAR, Inc) and used to query GenBank by BLASTn search. 
Assay conditions for DNA extraction, PCR, and sequencing were optimized. Accuracy, 
specificity, sensitivity and reproducibility were assessed. Results: DNA extraction by 
CTAB (cetyl trimethyl-ammonium bromide) combined with a cell breakage by bead 
beating showed better DNA yields than EZ1 DNA Tissue kit (Qiagen), averaging a yield 
of 66 and 509 ng/Pl for mold or yeast respectively. For PCR, Takara Ex Taq (Takara 
Biotechnology Co., LTD) with 4% DMSO produced consistent results over four other 
polymerases. During the product purification step, Performa DTR Ultra (EdgeBIO) 
produced better sequence results than BigDye Xterminator (ABI). Clean sequence on 
ITS and D1/D2 regions with average read length of 1000-1200 base pairs were 
obtained for all isolates. Assay accuracy was confirmed by morphologic and physiologic 
identification. Identical sequence results were obtained for these isolates using the 
UTHSCSA Nucleic Acid Core Facility. The specificity was tested on selected viral, 
bacterial, and human DNA samples with no cross reaction being observed. The assay 
was sensitive enough to produce sequence data on 1 ng of fungal DNA. Assay 
precision and reproducibility were assessed by analyzing 2 mold and 2 yeast isolates in 
4 runs, with results in agreement among all replicates. Conclusions: The result of this 
validation process for fungal molecular identification by Sanger sequencing for ITS and 
D1/D2 regions was satisfactory by diagnostic standards. This assay can be performed 
routinely on cultured clinical isolates. Primers targeting other fungal loci are under 
validation to increase the molecular discrimination power, especially for Asperillgus and 
Fusarium species.  
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ID46. Development of an Amplicon Enrichment and Barcoding Strategy for 
Cytomegalovirus (CMV) Genotypic Drug Resistance Testing by Next-Generation 
Sequencing 
M. Lefterova, M.K. Sahoo, F. Yamamoto, H. Farina, M.W. Anderson, B.A. Pinsky 
Stanford University School of Medicine, Stanford, CA. 
Introduction: Cytomegalovirus (CMV) is a major cause of morbidity following solid 
organ transplantation and hematopoietic stem cell transplantation. Even with antiviral 
treatment, mortality from CMV remains high. A significant complication of CMV therapy 
is the development of resistance. All currently available CMV antivirals, including 
ganciclovir, its oral prodrug valganciclovir, foscarnet, and cidofovir, ultimately target the 
CMV DNA polymerase UL54. Therefore, mutations in this gene confer resistance. 
Importantly, ganciclovir and valganciclovir require phosphorylation by the CMV 
phosphotransferase UL97 for antiviral activity and mutations in this gene also result in 
resistance to these specific drugs. CMV resistance testing is typically performed using 
standard sequencing techniques that have limited sensitivity to detect rare viral 
variants. To take advantage of the rare variant detection and multiplexing capabilities of 
next-generation sequencing, we developed an amplicon enrichment and barcoding 
strategy for detecting CMV genotypic resistance using the Fluidigm Access Array and 
454 sequencing. Methods: Overlapping primers spanning the UL97 and UL54 genes 
were designed using NCBI Primer-BLAST. Variant sequences were avoided by 
evaluating all primers using multiple sequence alignment of CMV UL97 and UL54 
sequences. Target-specific forward and reverse primers were tagged with consensus 
sequences 1 and 2 (CS1 and CS2), respectively, for target enrichment and barcoding 
using the Access Array. Primer pairs were initially validated using standard taq PCR 
(Fermentas) and agarose gel electrophoresis. Subsequently, primers underwent 2-
primer reactions using Access Array PCR conditions. Primer pairs that successfully 
generated amplicons of the expected size, as determined by rapid capillary 
electrophoresis (eGene), were subjected to 4-primer reactions that resulted in the 
addition of barcode sequences. The amplicon sizes and relative concentrations of 
successful 4-primer reactions were determined using the Agilent Bioanalyzer. Nucleic 
acids from the AD169 reference CMV strain were used as template in all experiments. 
Results: A total of 15 primer pairs (4 UL97 and 11 UL54) were designed that cover all 
known mutations conferring reduced susceptibility to anti-CMV drugs. These primer 
pairs generated amplicons covering 303-412 bases on the CMV target with a minimum 
of 66 overlapping bases. Successful amplification was achieved using the Fluidigm 4-
primer strategy for multiplexed amplicon generation. Conclusions: We confirmed the 
feasibility of an amplicon enrichment and barcoding strategy for the detection of CMV 
drug resistance mutations. Future experiments will determine the analytical and clinical 
performance characteristics of this approach using reference viruses and clinical 
specimens. 
ID47. Rapid Automated Multiplex PCR Identification of Blood Pathogens; 
Microorganism Reactivity Testing  
A. Hemmert, E. Amiott, B. Baarda, M. Buccambuso, V. McCarthy, O. Cham, E. Barker, 
I. Ota, R. Crisp 
Idaho Technologies, Inc., Salt Lake City, UT. 
Introduction: The ITI FilmArray (FA) Blood Culture Identification (BCID) system 
provides rapid identification of a broad range of microorganism pathogens direct from 
blood culture. The BCID panel was developed to detect ~90% of the most common 
bacteria and yeast isolated from positive aerobic blood cultures (PABC), as well as 
select antibiotic resistance genes. Here we report the testing of multiple 
microorganisms to demonstrate that the 27 PCR-assay based interpretations included 
in the FA BCID panel react with the targets they were designed to detect, and are 
exclusive against non-desired targets. This current investigational use only (IUO) 
multiplex PCR technology could improve patient outcomes by greatly reducing the time 
required to achieve blood culture pathogen identification; from several days to 
approximately 1 hour. Methods: Various gram-positive and gram-negative bacteria, as 
well as Candida yeast isolates were tested for assay reactivity. Each species was 
selected for testing based on BCID assay designs. Mock PABC samples were prepared 
by spiking microorganism into a mixture of human whole blood and BD BACTEC 
Aerobic Plus/F blood culture medium. For assay reactivity testing, microorganisms were 
spiked at concentrations consistent with that observed for blood culture bottles that had 
recently been indicated ‘positive’ for growth by the BD BACTEC 9050 system (103 to 
108 CFU/mL). Exclusivity samples were prepared at microorganism concentrations 
expected for blood culture bottles that may have remained overnight (~8 hours after the 
initial positive signal) in a blood culture machine (108 CFU/mL yeast and 1010 CFU/mL 
for bacteria). Samples were loaded into an FA BCID pouch and processed in an FA 
instrument. Nucleic acid extraction, purification, amplification, and results analysis are 
automated by the FA BCID system, with a total processing time of approximately one 
hour. Results: The FA BCID system exhibited 100% reactivity (111/111) with the panel 
of inclusivity microorganisms (including those harboring antimicrobial resistance genes). 
For example, the FA BCID panel detected 17/17 Staphylococcus isolates, 19/19 
Enterococcus isolates, and 30/30 Enterobacteriaceae isolates. Similarly, the FA BCID 
system did not detect 62/62 (100%) microorganisms for which the assays were not 
expected to react. The average specificity per interpretation [True Negative/(True 
Negative + False Positive)] in the BCID system was 100% (155/155; 95% CI 98.1-
100.0%). Conclusions: The ITI FA BCID system demonstrates suitable reactivity for 
blood culture microorganism detection with no unexpected cross-reactivity. The rapid 
identification of a large number of pathogens with this technology could greatly improve 
medical management of bloodstream infections.  
 
ID48. Evaluation of a Qualitative Fluorescent Loop Mediated Isothermal 
Amplification (LAMP) Assay for Varicella Zoster Virus (VZV) 
G. Cannon, A. Corcoran, G. Keating, D. Adlerstein 
Biotrin International Ltd., Co. Dublin, Ireland. 
Introduction: Varicella Zoster Virus (VZV) is a herpes virus that can cause chickenpox 
or herpes zoster, and occasionally give rise to CNS complications such as encephalitis 
and myelitis. Loop-mediated isothermal amplification (LAMP) is an isothermal method 
for rapid and highly specific amplification of nucleic acid through the recognition of 
multiple DNA/RNA target regions. This study evaluated a new qualitative LAMP assay 
that detects a target region highly conserved among all genotypes of the VZV genome 
and is multiplexed with an internal control for the validation of negative results. The 
analytical performance of multiple batches of LAMP VZV assay was evaluated and 
performance on a number of External Quality Assessment (EQA) panels was assessed 
relative to commercial PCR. Methods: Three pilot batches of LAMP VZV were 
prepared, consisting of freeze-dried reaction mix, reconstitution buffer, and positive, 
negative and internal controls. Testing was performed using prototype LAMP Analysers 
(Biotrin, Ireland), for temperature control and multi-channel fluorescent detection. Assay 
sensitivity was determined by testing replicates of extracted viral DNA at a number of 
concentrations across multiple instrument runs. 42 positive EQA panel members 
(QCMD, UK) and 31 negative samples were extracted using Qiagen columns and 
tested with all 3 LAMP assay lots and PCR (Affigene). 5μL of Internal Control was 
added to each sample prior to extraction, and 25μL of extract added to 25μL of 
reconstituted LAMP reagents before incubating on the LAMP Analyser at 67°C. 
Results: 100% of viral DNA replicates at 0.5 cps/μL were detected with all lots of 
LAMP VZV. Affigene PCR detected 38/42 positive QCMD panel members (90%). Lots 1 
& 3 of LAMP VZV detected 39/42 samples (93%), and Lot 2 detected 40/42 (92%). All 
31 negative samples gave concordant negative results for all LAMP lots and PCR. 
LAMP Internal Control was correctly amplified in all negatives. Conclusions: LAMP 
VZV demonstrates excellent analytical sensitivity and lot-lot reproducibility. Sensitivity 
for QCMD panels is superior to commercial PCR. With a time to result of 45 minutes, 
LAMP VZV is also faster than PCR. The assay includes a control for both extraction 
and inhibition that generates a fluorescent signal in an independent channel to validate 
negative specimen results. The use of a stable lyophilised reagent preparation removes 
any requirement for frozen storage, and the isothermal nature of LAMP reduces 
instrument costs. 
 
ID49. HPV Testing of Anal Specimens: Prevalence and Correlation with 
Cytology and Histology 
D.I. Quigley, J.E. McDonald, M.A. Elbaz, J.T. Hill, R.J. Krum 
Kaiser Permanente Northwest, Portland, OR. 
Introduction: High risk human papilloma virus (HPV) subtypes have been implicated 
as the causative agent in anal cancer, particularly in immunosuppressed individuals. 
Cytological evaluation of anal “pap smears” is starting to become a more routine part of 
standard care for these at risk individuals. However, HPV screening of these samples 
has not been generally adopted as a practice standard. Combined anal pap analysis 
and high risk HPV screening of immunosuppressed individuals should identify 
individuals at higher risk for anal cancer and allow for early intervention. Methods: HIV 
positivity was the only criterion for selecting patients for anal pap analysis (or possibly 
other conditions causing immunosuppression). Anal pap analysis was offered as an 
annual test to these individuals. High risk HPV analysis was generally offered following 
an abnormal pap result. Cellular anal samples for pap or HPV testing were collected 
using a water-moistened Dacron swab with 30-seconds of swabbing the anal area. 
Swabs are then swirled in Preserve-Cyt fixative vials to disperse the cells. Cytology 
samples were processed using standard liquid based methods. High risk HPV testing 
was performed using the CervistaTM HR HPV method. Results: To date, of the 105 
samples tested for HPV, seventy-five (71.4%) were HPV positive. Five samples (4.8%) 
yielded no HPV result due to hypocellularity. The remaining samples were HPV 
negative. Concurrent cytology and/or histology was abnormal in 64/74 (86.5%) of HPV 
positive samples. When available, histology was abnormal in all samples (n=64) that 
were HPV positive. About half of samples (52%) that were HPV negative had abnormal 
concurrent cytology and/or histology. Conclusions: There is a high incidence of high 
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risk HPV in anal specimens from immunosuppressed (HIV positive) individuals. The 
sample collection method is adequate as HPV failure due to hypocellularity is low. HPV 
testing correlates well with abnormal cytology and histology in our data set. However, 
the negative predictive value of HPV testing is likely to be low in this at risk population. 
Histology appears to be the most sensitive predictor of risk, but less invasive cytology 
and HPV testing may be good screening tools.  
 
ID50. Comparison of Two Methods for IL28B Genotyping 
M. Patel1, B. Baltadjieva1, L. Mazur1, M. Mihalov2 
1ACL Central Laboratory, Rosemont, IL; 2Lutheran General Hospital/ACL Laboratories, 
Park Ridge, IL. 
Introduction: Hepatitis C virus (HCV) infects 170 million people worldwide, including 
2.7 million in the United States. Current standard-of-care therapy for chronic HCV 
infection consists of a 24-48 week course of intravenous pegylated interferon alpha 
(PEG-IFN) with oral ribavirin (RBV). Treatment, however, is expensive, difficult to 
tolerate and may precipitate serious side effects. Therefore, mechanisms to predict 
potential responders are desirable. A strong association with sustained virological 
response has been demonstrated with two single nucleotide polymorphisms (SNP) – 
rs12979860 (C/T) and rs8099917 (T/G) variants – of the Interleukin 28B (IL 28B) gene 
on chromosome 19. This study evaluates two laboratory-developed assays for routine 
analysis of these ILB28 B variants. Methods: Two different technologies were utilized 
for testing on a panel of 60 purchased clinical samples of known genotypes: 1) Roche 
LC480 Probe Master reagent kit and custom designed primers and FRET probes, real 
time PCR followed by meting curve analysis for both SNPs on Light Cycler 2.0; and, 2) 
Life Technologies TaqMan real time PCR primers and MGB probes, combined with 
allelic discrimination analysis using SDS software on the ABI 7500 Fast instrument. 
Sixty EDTA whole blood samples were extracted using BioMerieux NucliSENS easy 
MAG. The testing panel was composed of a representative distribution of genotypes for 
each mutation with mostly white ethnic background. For rs12979860 SNP, there were 
represented by 27 C/T, 11 C/C, and 22 T/T genotypes. For rs8099917 SNP, there were 
19 T/G, 11 G/G, and 30 T/T genotypes. Results: Results from the study were 100% 
correct when compared with the expected external results. There was also 100% 
agreement in the expected genotype calls for both SNP’s. Based on the result study we 
find that for rs12979860 polymorphism 11/60 samples had the favorable CC genotype 
and 22/60 unfavorable TTgentype; for rs8099917 polymorphism, 30/60 had favorable 
TT genotype and 11/60 GG unfavorable genotype. Since our validation panel was not 
randomly selected we have not correlated allele frequencies with published data. 
Conclusions: The study demonstrates that both the real time PCR Light Cycler 2.0 and 
Life Technologies TaqMan assays are equally sensitive and specific for genotyping of 
IL28B polymorphisms. Simultaneous genotyping of two SNP’s will provide more 
accurate pretreatment prediction for sustained viral response in HCV 1-infected 
patients. Based on above study, ACL Laboratories chose to implement the Life 
Technologies TaqMan assay due to lower reagent cost and better workflow. 
 
ID51. Molecular Proficiency Testing for Infectious Diseases, Statistical Analysis 
Across 10 Years of Quality Assessment Programmes and Establishment of Key 
Performance Criteria 
C. Di Lorenzo, C. Scott, S. West, P. Wallace 
Quality Control for Molecular Genetics, Glasgow, UK. 
Introduction: Quality Control for Molecular Diagnostics (QCMD) is responsible for the 
coordination of International proficiency testing programmes focused on molecular 
infectious disease detection and determination. The proficiency testing programmes 
cover a comprehensive range of viral, bacterial, fungal, and parasitic pathogens. These 
include the blood borne viruses (BBV) such as HIV, HBV, HCV, and B19. Respiratory 
pathogens such as para-influenza, rhinovirus, Mycoplasma pneumonia and Legionella 
pneumophila, and STD’s such as Chlamydia trachomatis and Neisseria gonorrhoeae. 
Each year over 1500 participants from 100 countries take part in the annual quality 
assessments using a wide range of molecular diagnostic technologies. The data and 
laboratory information obtained through these studies over the last 10 years provides 
valuable insight into the development of molecular diagnostics in the routine clinical 
diagnostic setting and in identifying new performance criteria for ensuring quality of the 
molecular service provided. Methods: Data from over 1500 laboratories in 100 
countries using a wide range of molecular diagnostics methods for the detection and 
determination of infectious diseases was collected and collated. The data was 
statistically analysed to determine key performance over time in relation to qualitative 
and quantitative scoring of results within the annual proficiency testing schemes. 
Results: Analysis of the data over 10 years of molecular proficiency testing reveals 
improvements in pathogen detection rates, an overall reduction in false positive and 
negative results, although false positive results in respiratory pathogen detection 
remain. Reproducibility of results within the laboratory has improved based on paired 
sample analysis. Inter-laboratory and inter-technology comparability remains difficult for 
many pathogens, particularly where no International standard or recognised reference 
materials are available. Laboratory developed tests remained an important part of the 
diagnostics in many countries particularly were there were limited availability of 
commercial assays for specific pathogens. In countries where laboratories are 
regulated and proficiency testing is mandatory, the percentage of laboratories using 
commercial assays as opposed to laboratory developed assays was higher. Factors 
that influenced this were regulatory clearance of the commercial assay, availability and 
cost. Conclusions: This study helps identify focus areas within the proficiency testing 
assessment process that can then be used to help assist laboratories in establishing 
additional performance criteria specific to their individual laboratories requirements.  
 
ID52. Association of Mupirocin Resistance (mupA) Gene and Presence of 
Antibiotic Resistance in Methicillin-Resistant Staphylococcus aureus (MRSA) 
S. Das, C. Anderson, B. Miller, R.B. Thomson, L. Peterson, A. Robicsek 
NorthShore University Health System, Evanston, IL. 
Introduction: Eradication of nasal MRSA colonization for prevention of clinical infection 
is typically done using topical mupirocin (Mup). The presence of mupA gene is a marker 
of mup resistance and detection is often the first “antimicrobial resistance screening” of 
MRSA isolates in these programs. This study investigates the association of mupA 
gene with other antimicrobial resistance in unique clones of MRSA. Methods: 
Surveillance and clinical MRSA isolates (n=466) were collected from admitted patients 
between July 2005 and November 2011. All isolates were tested for the presence of 
mupA and mecA gene using in-house real-time PCR. Antimicrobial susceptibility testing 
was performed on all mupA positive and a selection of clinical and surveillance mupA 
negative MRSA isolates (n=111) using the Clinical and Laboratory Standards Institute 
(CLSI) methods. Molecular typing of all isolates was performed by sequencing the 
Staphylococcal protein A (spa) region and analyzed using the Biomumerics software 
v.4.6 (Applied Maths Inc. USA) and PFGE (n=361). Fisher Exact test was used for 
statistical comparison of different groups. Results: The mupA gene was identified in 36 
out of 466 (7.5%) isolates. Although 72% of mup resistant isolates were spa types 
belonging to clonal cluster (CC8), only 31% of mup resistant isolates were spa types in 
CC5 (HA-MRSA) (p<0.0002) . Reduced susceptibility to TMP/SMX, gentamicin; and 
minocycline (52%, 63%, 47% respectively) was significantly more common in isolates 
harboring the mupA gene than in mupA negative strains (2.8%, 4.2%, 7.4%; p<0.0001). 
Spa type t064 constituted 89% of mupA positive strains. Clindamycin resistance was 
not associated with the presence of mupA gene (p=0.5). Major spa type clusters 
included those in CC5 and CC8 representing 50% and 25% of all isolates, respectively. 
Conclusions: High level mup resistance can predict resistance to commonly used 
antibiotics (TMP/SMX) and appears common in certain MRSA isolates (CC8), which 
could pose a challenge to treatment. 
 
ID53. The Memorial Healthcare System Experience and Evaluation of Two 
Respiratory Virus Panel Assays (RVP): Luminex xTag and GenMark eSensor 
R.C. Arcenas, F.L. Kiechle 
Pathology Consultants of South Broward/Memorial Healthcare System, Hollywood, FL. 
Introduction: The purpose of this study is to compare the GenMark RVP (GM-RVP) to 
the Luminex xTag RVP (LX-RVP). Methods: Two-hundred eleven samples were run in 
both assays. The GM-RVP assay was performed in parallel with clinical samples run on 
the Luminex and results compared and evaluated. Nucleic acid extraction was 
performed on the EasyMag from BioMerieux. Time studies were performed, comparing 
the hands-off/hands-on time involved for the 2 assays. A commercial respiratory virus 
panel (Zeptometrix) was run in both assays that consisted of known positive and 
negative samples for the respective assays. Environmental testing was performed to 
examine the potential of contamination since there is post-PCR handling of the samples 
with the potential for amplicon spread. Results: The Zeptometrix panel gave results as 
expected. Environmental samples were negative for both assays as expected. Out of 
165 total patient samples, 38 samples were concordantly negative and 98 samples 
were concordantly positive. Amongst those 98 samples, 88 showed single virus 
correlations; an additional 10 showed at least 1 viral target concordance, with additional 
virus(es) detected in the GM-RVP. Amongst 38 Influenza A positive results, LX-RVP 
subtyping showed 2 FluA-H3, 1 FluA-H1, and 35 Non-Subtypeable FluA (NS-FluA). 
Those same samples, run in the GM-RVP showed 12 FluA-H3, 1 FluA-H1, and 25 
FluA-2009 H1N1. Four samples were detected as Rhinovirus/Enterovirus in the LX-
RVP that were GM-RVP(-). These 4 samples were confirmed to be Enterovirus by 
another in-house assay specifically for Enterovirus. There were a total of 25 viruses that 
were LX (-) and GM(+); 10 of those viruses are in the LX panel. Time studies show GM 
to be an overall shorter assay by 1.27 hrs with a lesser hands-on-time of 0.71 hrs. 
Conclusions: The GM-RVP showed a better ability in subtyping NS-FluA samples that 
were also tested in the LX-RVP. Issues with Rhinovirus-Enterovirus cross reactivity 
were not observed for the GM-RVP that can be an important distinction in pediatric 
patients. The GM-RVP also showed an overall increased detection for viruses that the 
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LX-RVP should have detected. An additional advantage is the lesser hands-on-time 
that streamlines the workflow in the laboratory, but more importantly decreases the 
amount of manipulation by the Medical Technologist that ultimately lowers the chances 
of contamination and introduction of PCR inhibitors. The improved detection capabilities 
will benefit patient care as the morbidity/mortality and epidemiology of respiratory 
viruses are becoming better understood. 
 
ID54. Multiplex Assay Evaluation of Luminex xTAG Analyte-Specific Reagents 
for Diagnosis of Gastrointestinal Pathogens 
K.C. Chapin, R.A. Dickenson, S.B. Andrea, R. Huang 
Rhode Island Hospital, Providence, RI. 
Introduction: Diagnosis of acute infectious GI illness is often unrewarding secondary to 
multiple factors that limit the ability to detect the pathogen, including but not limited to, 
the need to use multiple methods, high level technical expertise, reliability of patient 
specimen collection and transport , sensitivity of current methodologies and inability of 
current methods to detect common GI pathogens. Having a multiplex panel for common 
GI pathogens might offer a streamlined and more effective approach to prompt and 
reliable diagnosis. Methods: An evaluation of the Luminex xTAG GI ASR reagents was 
performed for a panel of stool pathogens consisting of 18 individual primer sets, 
including shiga toxin and norovirus, not routinely available in most labs. Stool extraction 
and primers were optimized with an initial evaluation of 100 selected specimens. 164 
consecutive specimens were subsequently evaluated with a lab developed protocol 
using approximately 100 Pl of stool. Results obtained from the xTAG molecular panel 
were compared with routine culture for bacterial pathogens, EIA, DFA and Ova and 
Parasite exam for Giardia, Cryptosporidium sp. and E. histolytica/dispar, and PCR for 
norovirus. Discrepant analysis by sequencing is pending in cases where pathogens 
were detected by xTAG and not by routine methods. Presentation and past medical 
history of all patients was reviewed to identify the symptoms of acute GI illness. 
Results: Of 164 specimens analyzed to date, routine methods detected 8 pathogens 
(5%). xTAG detected all of these organisms as well as an additional 21 pathogens. 
Diarrhea, hypoalbuminemia, and history of travel outside of the US were all statistically 
associated with infectious colitis (P<0.05 for all). Conclusions: The xTAG ASR GI 
primers used in a multiplex assay had both 100% accuracy for detection of pathogens 
identified by currently used routine laboratory methods as well as detecting more GI 
pathogens, including norovirus and shiga toxins, that may not be routinely available. 
Additional benefits of the multiplex assay included detection of multiple pathogens of a 
variety of species from a single container and assay results available in a single shift, 
streamlining laboratory workload and minimizing patient collection issues.  
 
ID55. Comparison of Four Molecular Assays for the Qualitative Detection of 
High Risk Human Papillomavirus (HR HPV) in Cervicovaginal Specimens 
B.C. Sutton, K.M. Jacobs, W.J. Kaliney, D. Sun, Q. Li, K. Maggert, M. Cross, T. Ray, G. 
Kestermeier, E. Hamilton 
South Bend Medical Foundation, South Bend, IN. 
Introduction: HPV infection is associated with cancer of the cervix. Of sexually 
transmitted HPV types, 14 genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59, 66, and 68) are considered HR due to a strong association with cervical cancer. 
Persistent cervical infection by HR HPV is associated with an increased risk for 
developing squamous carcinoma or its precursor lesion, High Grade Cervical 
Intraepithelial Neoplasia (CIN2-3). When cytologic and HR HPV screening are 
combined to detect pre-cancerous lesions, cervical cancer has been shown to be highly 
preventable. In this report we compare the performance of four molecular platforms that 
detect HR HPV in cervicovaginal specimens with confirmed cytologic diagnoses. 
Methods: 308 cervicovaginal specimens were processed using the ThinPrep system 
(Hologic, Bedford, MA). Smears were evaluated using Bethesda system guidelines. The 
cases were grouped by cytologic diagnoses as negative (NEG); atypical squamous 
cells of undetermined significance (ASC-US); atypical squamous cells cannot exclude 
high grade squamous intraepithelial lesion (ASC-H); Low Grade Squamous 
Intraepithelial Lesion (LSIL); high grade squamous intraepithelial lesion (HSIL), and 
other. Post-processing aliquots from the ThinPrep vials were assayed for HR HPV 
using four molecular platforms: hc2 HPV DNA test (Digene, Gaithersburg, MD); cobas 
4800 HPV Test (Roche Diagnostics, Indianapolis, IN); APTIMA HPV Assay (Gen-Probe 
Incorporated, San Diego CA); and the Cervista HPV HR test (Hologic). Selected cases 
were assessed for HR HPV genotypes 16 and/or 18. Results: There were 98 NEG, 80 
HSIL, 25 LSIL, 81 ASC-US, 16 ASC-H, 5 Other, and 3 unsatisfactory (UNS) cases. 
HSIL cases showed a high percent positive rate of 96-100% for all 4 platforms, with hc2 
HPV DNA test and APTIMA HPV Assay detecting 100% of positive samples. ASC-H 
cases showed consistent results for all platforms, ranging from 81% positive specimens 
for the APTIMA HPV Assay to 88% for the other tests. ASC-US samples were 51%-
61% positive in the four assays, and LSIL cases were 68-80% positive. One of 5 Other 
cases was positive in all 4 tests . One of 3 UNS cases was positive in all 4 tests. A low 
level positive rate of 6-9% was detected in the NEG specimens in three of the four 
tests, with the Cervista HPV HR test showing a slightly higher positive rate of 14%. 
Conclusions: 1. These assays detected HR HPV in HSIL, ASC-H and ASC-US cases 
and performed similarly. 2. A low level false positive rate was noted in all four assays. 
 
ID56. Evaluation of the GenMark Hepatitis C Genotyping Assay 
A. Best, K. Walker, L. Watson, J. Sullivan, R. Fader, A. Rao 
Scott and White Hospital, Temple, TX. 
Introduction: Hepatitis C Virus, a major world wide agent of acute and chronic hepatitis 
has been classified into 6 genotypes and numerous sub-types. In the US, genotypes 1a 
and 1b are the most common and until the recent introduction of two new direct acting 
antiviral agents, telaprevir and boceprevir, genotype 1 infections were difficult to 
eradicate. This improved response has resulted in an increased demand for accurate 
genotyping, for which there are currently no FDA approved tests. In this study we 
compare the results from the Siemens Versant HCV Genotype 2.0 assay (LiPA) and the 
GenMark Hepatitis C Genotyping assay. Methods: Serum samples were extracted and 
amplified using the Roche Ampliprep/Taqman Hepatitis C Quantitative assay and 
resultant amplicons were used as the starting specimen for the GenMark Hepatitis C 
Genotyping assay. The GenMark results were compared results obtained from the 
Siemens Versant HCV Genotype 2.0 Assay (LiPA). Percent concordance, sensitivity 
and specificity of the GenMark assay were evaluated against the Siemens assay. 
Results: Of the 139 samples tested, 69 were type 1a, 26 were type 1b, 9 were type 1 
but unable to be further classified, 22 were type 2, and 12 were type 3 according to the 
Siemens assay. When tested with the GenMark HCV genotype assay 62 were type 1a, 
39 were type 1b, 3 were type 1 but unable to be further classified, 22 were type 2, and 
10 were type 3. 11 samples were called type 1a using the Siemens assay but were 
typed as 1b on the GenMark assay whereas 3 were called type 1b with the Siemens 
assay but type 1a with the GenMark assay. 2 samples were type 3 according to the 
Siemens assay but called a type 1 using the GenMark assay. Hands on time using the 
GenMark assay was approximately 30 minutes with a total assay time of approximately 
2 ½ hours. Conclusions: Overall concordance, sensitivity and specificity for type 1 
were 97.9%, 98%, and 97% respectively. The GenMark HCV Genotyping assay, 
compared to the Siemens Versant assay, had an overall specificity of 91.5% and a 
sensitivity of 94%. Thus, the good performance, ease of use and limited hands on time 
makes the GenMark Hepatitis C Genotyping assay an attractive option for routine 
clinical use. 
 
ID57. Evaluation of the Cobas 4800 High Risk HPV Assay 
H.B. Steinmetz, V. Padmanabhan, G.J. Tsongalis 
Geisel School of Medicine at Dartmouth, Lebanon, NH. 
Introduction: The Roche Cobas Human Papilloma Virus (HPV) test is a qualitative in 
vitro test for the detection of HPV in liquid cytology specimens. This test specifically 
identifies 14 high risk (HR) types, including 16 and 18. The FDA approval of the Cobas 
4800 HPV assay was based on a pre-aliquot of the Thin Prep cervical sample, meaning 
that HPV would be analyzed using a sample that has not been previously processed in 
the cytology laboratory. In this study, we verified the performance of this newly FDA-
approved assay on post-aliquot liquid cytology specimens. Methods: We used 226 
convenience samples that were previously tested using the Hologic HPV ASR. 
Precision was assessed using 50 previously positive samples that were run in 
duplicate, by different operators, over multiple days. HPV High Risk control material 
was purchased from Acrometrix, Inc. and run on the Cobas 4800 in 10 replicates within 
the same run with previously tested negative samples between each positive control. 
Since our laboratory will be using a sample that has been previously processed in the 
cytology laboratory for HPV analysis, we needed to validate post-aliquot specimens for 
performance and to rule out cross contamination. 10 normal HPV samples were spiked 
with three volumes of Acrometrix HPV High Risk Positive control, 2 samples each with 
4mL, 2mL, and 1mL of the control material. Each of these 6 samples was passed 
through the Cytyc T-3000 with a previously normal HPV samples interspersed to check 
for cross contamination. After processing on the Cytyc T-3000, each sample was 
analyzed for HPV using the Cobas 4800. Results: 92 samples were analyzed on the 
Cobas 4800 that were previously positive for HPV by the Hologic assay. 58 (63%) of 
those previously positive samples were also positive using the Cobas 4800, whereas 34 
(37%) had a negative result from the Cobas 4800. For precision, there was 100% 
concordance of results between runs and operators. In cross contamination 
experiments, all 10 samples had a positive result with a mean Ct of 33.33 whereas the 
interspersed negative samples all had a negative result. 134 previously negative 
samples by the Cervista HPV assay were analyzed using the Cobas 4800 HPV assay. 
Of the 134 samples previously tested, 128 were also negative by the Cobas 4800 
(96%). Conclusions: The Cobas 4800 HPV assay showed good performance and 
allows for a more streamlined workflow due to its automation and batch sizes. 
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ID58. Evaluation of a Novel Real-Time Multiplexed Molecular Assay for the 
Detection of Respiratory Syncytial Virus and Human Metapneumovirus in Clinical 
Specimens  
P.A. Granato1, B. Alkins1, P. Pancholi2, T. Curtiss3, J. Pappas3, L. Grippa3, R. Kelly3 
1Laboratory Alliance of Central New York, Liverpool, NY; 2Ohio State University Wexner 
Medical Center, Columbus, OH; 3Quidel Corporation, Athens, OH. 
Introduction: Respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) 
are significant respiratory pathogens of the very young and the elderly in both 
developed and developing countries. Further, these viruses present with the same 
symptoms, thereby confounding unaided clinical diagnosis. Molecular testing provides a 
sensitive and specific method for the detection and differentiation of these two important 
respiratory pathogens. We evaluated the Quidel Molecular RSV + hMPV (QM RSV + 
hMPV) multiplex real-time PCR (RT-PCR) assay for the detection of RSV and hMPV in 
respiratory specimens. Methods: Evaluation of the QM RSV + hMPV assay was 
conducted as a prospective study during the 2012 respiratory virus season. Samples 
analyzed included fresh (N=414) and frozen (N=600) nasopharyngeal swab specimens 
in viral transport media that were collected for routine respiratory virus testing. RNA was 
extracted using the bioMérieux NucliSENS easyMag and 5 ȝL of the sample was added 
to 15 ȝL of the reconstituted QM RSV + hMPV master mix provided as lyophilized, 4°C 
stable reagents. Real-time PCR was performed using the Applied Biosystems 7500 
Fast Dx and Cepheid SmartCycler II platforms. Each sample contained an integrated 
process control that monitors the extraction and amplification. Results were compared 
to direct specimen DFA (DSFA) and culture with DFA for RSV and with the Prodesse 
ProhMPV+ test for hMPV. Discrepants were resolved by nucleotide sequencing and by 
comparison of results to the Prodesse ProFlu+ test for RSV. Results: Combined site 
data results from the 7500 Fast Dx showed 98.6% sensitivity and 96.8% specificity for 
detection of RSV compared to DSFA and culture with DFA. Discordant resolution 
showed 27/28 and 25/28 to be positive for RSV by sequencing and the Prodesse 
ProFlu+ test, respectively. Results from the SmartCycler showed 97.9% sensitivity and 
97.6% specificity for detection of RSV compared to DSFA and culture with DFA. All 
(21/21) discordants were positive for RSV by sequencing. hMPV had 98% PPA and 
99.3% NPA (7500 Fast Dx) and 96.7% PPA and 99.6% NPA (SmartCycler) when 
compared with the Prodesse hMPV test. All putative “false positive” hMPV samples 
were resolved in favor of the QM RSV + hMPV assay by sequencing. Conclusions: 
Results from these studies indicate that the QM RSV + hMPV multiplex RT-PCR assay 
is highly sensitive and specific for the detection of RSV and hMPV. This assay utilizes a 
greatly simplified workflow and convenient lyophilized reagents and thermocycling times 
of about one hour. 
 
ID59. Clinical Validation of the COBAS Ampliprep/TaqMan CMV RT-PCR Test 
on Human Plasma 
A. Patel, J. Davis 
LeBonheur Children's Hospital, Memphis, TN. 
Introduction: Cytomegalovirus (CMV) infections are typically asymptomatic among 
healthy individuals, but can cause illness in patients who are immunocompromised, 
such as HIV-infected individuals, organ transplant recipients, and new-born infants. 
Once infected with CMV, the virus will remain in a person’s body for life and potentially 
cause life-threatening illness in those with weakened immune systems. Among organ 
transplant recipients, since 50% to 80% of individuals will be infected with CMV by the 
age of 40, viral-load monitoring is important to detect the reactivation of latent infections 
that can cause life threatening illness. The COBAS Ampliprep/TaqMan (CAP/CTM) 
CMV Test is a nucleic acid amplification test for the quantification of CMV DNA in EDTA 
human plasma that can be used to monitor the viral-load within infected patients with 
excellent accuracy and sensitivity. Methods: We validated a quantitative real-time PCR 
assay on the COBAS Ampliprep/COBAS Taqman 48 (CAP/CTM) CMV test (Roche 
Diagnostics) to detect CMV DNA in plasma. This test combines automated extraction of 
nucleic acids on the Ampliprep instrument with real-time PCR on the Taqman Analyzer. 
Results: The CAP/CTM CMV test demonstrated a dynamic range from 500 to 500,000 
copies/mL measured by quantification panel of Acrometrix calibrated standards. The 
limit of detection for the CMV assay was established down to 200 copies/mL using 
dilutions of the Acrometrix standards. Excellent agreement between observed and 
expected values was seen with linearity between 500 and 5.0 x 105 copies/mL and a 
coefficient of determination of R2 = 0.99 % using the calibrated standards. 42 CMV 
positive plasma specimens were run comparing the CAP/CTM CMV assay to the in-
house reference PCR. Compared to the reference method, the CAP/CTM CMV assay 
identified 23 of 23 CMV positive plasma specimens (sensitivity = 100%). The CAP/CTM 
CMV assay also detected 12 additional weak positive (<150 copies/mL) samples that 
were negative by the reference method. Conclusions: The CAP/CTM CMV assay is 
useful in the molecular laboratory setting for its improved accuracy and sensitivity for 
the detection and quantification of CMV infections within immunocompromised 
populations such as organ transplant recipients. The assay is an important 
improvement to the testing that our laboratory offers for better therapy treatment and 
monitoring of patients at risk for illness caused by CMV infections.  
 
ID60. Validation of the BD MAX GBS Assay on the Automated BD MAX Platform 
Used for Detection of Group B Streptococcus in Pregnant Women  
S. Beqaj, D. Simmons, N. Banta 
Pathology, Inc, Torrance, CA. 
Introduction: Group B Streptococcus (GBS) is a leading cause of illness and death in 
newborns in the US. The new 2010 CDC guidelines for prevention of prenatal GBS 
disease recommend that all specimens should undergo 18 to 24 hour incubation at 
35°C to 37°C in an appropriate enrichment broth medium to enhance the recovery of 
GBS before testing by any detection method. The BD MAX GBS Assay performed on 
the fully automated BD MAX System (BD Diagnostics, Sparks, MD) detects GBS DNA 
in LIM Broth cultures after incubation for  18 hours, obtained from vaginal and rectal 
swab specimens from antepartum pregnant women. The purpose of this validation 
study was to evaluate the clinical performance of the BD MAX GBS assay. Methods: A 
total of 125 vaginal/rectal swab specimens collected from pregnant women at 35-37 
weeks of gestation were tested using the BD MAX GBS assay in parallel with the LIM 
broth culture method and the BD GeneOhm StrepB assay (BD Diagnostics, Sparks, 
MD). Stability studies were performed from LIM broth enriched specimens stored at 
room temperature and 4-8°C at days 1, 2, 3 and 7 followed by testing with the MAX 
GBS assay. The results were monitored by comparing PCR amplification cycle 
threshold (Ct) values. Results: Of the 125 specimens tested after 18 hours LIM broth 
incubation, 33 were positive by the MAX GBS assay whereas 29 were positive by the 
StrepB assay yielding a positive and negative percent agreement of 81.8% and 97.8% 
respectively, and an overall agreement of 93.6%. The prevalence of GBS colonization 
was 25.6%. Of 117 specimens that were compared to culture, 29 were positive by both 
the MAX GBS assay and culture. One sample was negative by the MAX GBS assay but 
positive by culture, giving an assay sensitivity of 96.7%. The remaining 87 specimens 
that were negative by the BD MAX GBS assay were also negative by culture, yielding 
an assay specificity of 100% and an overall correlation agreement of 99.1%. In the 
stability studies, all specimens resulted in consistent Ct values for the positives and 
negatives and internal control Ct values for all the time points evaluated. Conclusions: 
In conclusion, this validation study demonstrated that the BD MAX GBS assay 
performed on the BD MAX automated system used for the detection of GBS DNA in 
vaginal/rectal swabs from enriched media meets and exceeds new CDC 2010 
guidelines.  
 
ID61. Evaluation of the Aptima HPV Assay on the Fully Automated Panther 
System
N. Sikhamsay, B. Eaton, J. Quinto, M. Telebrico, J. Dockter 
Gen-Probe, San Diego, CA. 
Introduction: The APTIMA HPV (AHPV) assay is a multiplex assay that detects HPV 
E6/E7 mRNA from 14 high-risk (HR) types. The AHPV assay is approved for use in the 
United States with the high-throughput fully-automated TIGRIS DTS System with 
ThinPrep liquid cytology (TP) specimens. The fully-automated PANTHER System was 
developed for low- to moderate-volume laboratories. This study evaluated the analytical 
and clinical performance of the AHPV assay on the PANTHER System as compared to 
the TIGRIS DTS System. Methods: Analytical sensitivity was evaluated by testing 
serial dilutions of HR HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 
68 in vitro transcripts (IVT) spiked into HPV-negative TP specimens. Probit analysis 
was performed to determine the 95% detection limit of each HPV type. Reproducibility 
was evaluated by testing a 20-member panel (comprised of HPV IVT or HPV-positive 
cell lines at varying concentrations) by 2 operators, with 2 reagent lots on 3 instruments 
over multiple days. Agreement with the expected result was determined. Clinical 
performance was evaluated by testing residual TP specimens (n=601) from women 
referred to colposcopy due to an abnormal Pap, a positive HPV result, or other reason. 
The positive and negative agreement between instrument systems were determined, as 
well as the sensitivity and specificity versus a histological disease endpoint. Results: 
Predicted 95% detection limits for both instrument systems were <50 copies/reaction for 
HPV types 16, 31, 35, 39, 45, and 68, <150 copies/reaction for HPV types 18, 33, 56, 
58, and 59, and <450 copies/reaction for HPV types 51, 52, and 66. There was no 
difference in agreement between reagent lots, operators or instruments for either the 
PANTHER or TIGRIS DTS System for any of the panels for the reproducibility study. 
The positive and negative agreement between the PANTHER and TIGRIS DTS 
Systems for the clinical specimens were 98.8% and 95.9%, respectively. Sensitivity for 
detection of CIN2 and CIN3 was  92% and > 97%, respectively, for both instrument 
systems. The specificity for <CIN2 was > 51% for both instrument systems. 
Conclusions: The AHPV assay demonstrated sensitive detection of HR HPV mRNA 
on the PANTHER System. Reproducibility was high for both the PANTHER and TIGRIS 
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DTS Systems. Clinically, the PANTHER and TIGRIS DTS Systems had comparable 
performance and demonstrated strong agreement for detection of disease in ThinPrep 
liquid cytology specimens. 
 
ID62. Model for Production of Nucleic Acid-Based Standard Reference 
Materials by NIST for Clinical Diagnostics 
R.J. Haynes, M.J. Holden, M.C. Kline, J.M. Butler 
National Institute of Standards and Technology, Gaithersburg, MD. 
Introduction: Certified reference materials are critical for standardization of assays for 
the detection and quantification of nucleic acids involved in infectious disease, genetic 
disease and cancer. The first viral DNA Standard Reference Material (SRM) produced 
at the National Institute of Standards and Technology (NIST) “SRM 2366 
Cytomegalovirus for DNA Measurements” was released in 2011. The work preceding 
the release helped develop the model for future viral DNA SRMs; particularly, material 
production, packaging, and certification. Methods: The material that later became SRM 
2366 was acquired as the Towne strain of CMV in a bacterial artificial chromosome 
(Towne ǻ147 BAC). At NIST the BAC was propagated in Escherichia coli and the DNA 
was isolated and purified. CMV DNA in buffer was packaged in perfluoroalkoxy 
fluoropolymer (PFA) tubes to minimize absorption of DNA onto tube walls. An 
innovation for the certification of the concentration of the viral DNA was the use of 
digital PCR (dPCR). The use of dPCR allows the direct counting of molecules, so 
quantification can be achieved without the use of calibrants. In the past the number of 
replicate PCR reactions needed limited the accuracy and precision of digital PCR. 
However, new microfluidic technology makes the technique viable for measuring the 
concentration of DNA with reasonable measurement uncertainty. In addition to 
quantification, the DNA sequence of relevant regions of the CMV genome was verified 
by Sanger sequencing. Results: SRM 2366 has three components A, B, and C; by 
digital PCR the concentrations of each are 420, 1702 and 19641 copies per microliter, 
with standard uncertainties of 56, 130, and 365 copies per microliter, respectively. 
Sequence information is given for 14555 base pairs across nine regions of interest – 
UL34, UL54, UL55 to 56, UL80, UL83, UL97, UL122 to 127, UL132 and US17. All the 
regions of interest match the Towne sequence as deposited in GenBank accession 
number AY315197.2 with one exception at position number 78651 (UL54) is described 
as a Y at NIST and a C in GenBank. Conclusions: SRM 2366; Cytomegalovirus for 
DNA Measurements is the model by which NIST will produce additional Standard 
Reference Materials. The second viral DNA SRM is currently in development for BK 
virus. This SRM will also be DNA in buffer, packaged in PFA, sequenced, and certified 
for concentration with digital PCR. 
 
ID63. Protocol for Direct Detection of Mycoplasma pneumoniae from Sputum 
without Inhibition of the Focus Diagnostics M. pneumoniae Analyte Specific 
Reagent (ASR) PCR Chemistry 
J.T. Hill, S.E. Sharp 
Kaiser Permanente, Portland, OR. 
Introduction: Mycoplasma pneumoniae is a bacterium known to cause community 
associated respiratory tract infections (CA)-RTI. Timely detection of M. pneumoniae 
supports the decision to treat a case of (CA)-RTI with a macrolide, fluoroquinalone or 
doxycycline therapie in lieu of a ȕ-lactam. The fastidious nature of the bacterium makes 
routine culture from respiratory specimens impractical. Additionally, serological testing 
using complement fixation or DNA Probe hybridization methods lack sensitivity, leaving 
a molecular method as the preferred choice for detection. Comparison studies of 
sampling sites for the detection of M. pneumoniae have shown sputum to have superior 
diagnostic sensitivity. However PCR inhibitors found in sputum such as heme, 
polysaccharides and mucolytic agents can contribute to increasing the rate of chemistry 
inhibition. Methods: Ten replicates each of 25, 12.5, 6.25, 3.125 mM Dithiothreitol 
solution in Tris-EDTA buffer (DTT/TE) titrations as well as a pure TE-buffer control were 
spiked with 10,000 copies/mL of M. pneumoniae standard DNA and then evaluated for 
performance. Samples were processed by swabbing and transferring approximately 1 
cm3 of respiratory culture sputum into 1 mL of each titration of DTT/TE, heated to 95°C 
for 10 minutes at 1400 rpm of constant mixing and then spun for 3-5 seconds at 
approximately 22,000 RCF. Liquefied sputa were then aspirated using a Rainin 2-20ȝL 
pipette to evaluate viscosity. An evaluation of mastermix enhancements was performed 
where the addition of 1mg Bovine Serum Albumin (BSA)/2% glycerol, .5mg BSA/2% 
glycerol and unaltered Focus Dx chemistry were compared for differences in PCR Ct 
values. Results: Digestions using 6.25 DTT/TE balanced a lack of inhibition with the 
ability to liquefy sputa. PCR Ct values of spiked 6.25 mM DTT/TE and TE controls were 
statistically equivalent by student T test (p = .897) showing no inhibition. 98.3% (95/96) 
of patient specimens digested in 6.25mM DTT/TE were successfully pipetted to a 
complete 20 μL. PCR Ct values from 10 replicates each of 1 mg BSA/2% glycerol, 
.5mg BSA/2% glycerol compared to unenhanced mastermix formulations run in patient 
sputum background showed no significant enhancement to performance (Student T 
test; p = .119 and .146 respectively). Conclusions: Patient specimens liquefied by 6.25 
mM DTT/TE added directly to the Focus Diagnostics M. pneumoniae PCR chemistry 
show no significant inhibition. Addition of BSA and glycerol to the mastermix showed no 
enhancement of sensitivity.  
 
ID64. Evaluation of the Abbott Realtime HCV Genotype II RUO Assay with 
Reference to 5’UTR, Core and NS5B Sequencing 
M.A. Mallory1, M.T. Sears1, D.X. Lucic2, G.A. Cloherty2, D.R. Hillyard1 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 2Abbott 
Molecular Inc, Des Plaines, IL. 
Introduction: HCV genotype testing has had an important and evolving role in the 
management of HCV infected patients. Genotyping is currently used as an acceptance 
qualifier for treatment with the protease inhibitors (PI) boceprevir and telaprevir, which 
are approved for treatment of genotype 1 infections. Although not part of current 
treatment algorithms, studies have demonstrated different risks for virologic 
breakthrough with new PIs for viral subtypes 1a versus 1b. The objective of this study 
was to evaluate the level of concordance between the Abbott RealTime HCV Genotype 
II RUO assay and two sequencing-based, laboratory-developed tests (LDT) for 
genotyping and subtyping HCV in clinical specimens. Methods: Forty-four de-identified 
patient specimens with known titers and previous genotype results based on two 
sequencing-based LDTs, one targeting the 5’UTR and another targeting the core and 
NS5B genes, were analyzed using the Abbott HCV RealTime GT II RUO assay 
according to the manufacturer’s recommendation. For the LDTs, genotypes were 
assigned using a laboratory-developed reference sequence library, the NCBI nr 
database and the online HCV genotyping tool COMET (http://comet.retrovirology.lu/). 
Results: Based on the core/NS5b LDT assay, a total of 29 genotype 1s, four genotype 
2s, seven genotype 3s, two genotype 4s, and two genotype 6s were identified in the 
study. No amplification failures were observed using the Abbott assay. Genotype calls 
by the Abbott, 5’UTR LDT, and core/NS5B LDT assays were concordant for 42/44 
samples. Two discrepant samples identified by the Abbott and 5’UTR LDT assays as 
genotype 1 were identified by the core/NS5B assay as unusual genotype 6 samples 
(subtypes 6l and 6u). Among the 29 samples identified as genotype 1, 27 were 
subtyped as 1a and two were subtyped as 1b by the core/NS5B LDT assay. The Abbott 
assay successfully subtyped 25/27 1a samples and 2/2 1b samples. The remaining two 
samples were identified by the Abbott assay as genotype 1 with no subtype 
designation. Subtype calls were not determined using the 5’UTR LDT assay. 
Conclusions: The Abbott HCV GT II RUO assay is an automated method for HCV 
genotyping with improved accuracy over 5’UTR sequencing. However, unusual 
subtypes may challenge the assay. Based on this study, samples identified by the 
Abbott assay as genotype 1 with no 1a/1b subtype designation may require further 
interrogation by a higher resolution assay. 
 
ID65. HCV and HIV Testing Using a Novel Dried Ambient Sample Collection and 
Transport Device: VIVEST 
A.M. McClernon, J. Waters, D.R. McClernon 
bioMONTR, Research Triangle Park, NC. 
Introduction: Monitoring HIV and HCV infection usually requires plasma to be shipped 
frozen to central laboratories requiring special packaging that is expensive and 
laborious. Here we compared performance of a novel dried ambient sample collection 
and transportation device, ViveST, to frozen plasma with commercial HCV and HIV-1 
genotypic and viral load assays manufactured by Abbott Molecular. Methods: To 
evaluate HIV-1 RNA recovery, comparative analysis was performed using 1 mL  
aliquots of twenty (20) HIV-1 positive plasma samples (frozen vs. processed thru 
ViveST) per Abbott’s FDA approved RealTime HIV-1 assay (0.5 mL protocol). In 
addition, comparative genotypic analysis was performed on seventeen (17) HIV-1 
plasma samples (frozen vs. processed thru ViveST) per FDA approved ViroSeq HIV-1 
Genotyping System v2.0 Kit. As part of the HIV-1 study, we evaluated ViveST recovery 
using molecular grade water or mLysis buffer provided in mSample System. To 
evaluate HCV recovery, comparative analysis was performed using 1 mL aliquots of 
nineteen HCV positive plasma samples (frozen vs. processed thru ViveST) per FDA 
approved RealTime HCV and Research Use Only HCV Genotyping II assays. Results: 
HIV-1 VL showed average reduction of 0.26 log recovered from ViveST using mLysis 
buffer and 0.59 log reduction using water. HCV VL showed average reduction of 0.32 
log for ViveST eluates vs. frozen plasma. HCV genotyping demonstrated 100% 
concordance between ViveST and frozen plasma with genotypes 1, 1a, 1b, 2 and 3. 
HIV-1 Drug Resistance Mutations were identified in 10/17 pairs and demonstrated 
100% concordance between ViveST compared to frozen plasma. A mixture T215Y/C 
was identified in 1/17 ViveST whereas corresponding plasma reported a mutation 
T215Y. A mutation at V75I was identified for 1/17 plasma sample whereas the paired 
ViveST sample was wild type. 1/17 pair demonstrated deletion at T69 preventing 
generation of ViroSeq report. 1/17 plasma sample had M184V but results were not 
AMP Abstracts  683
JMD November 2012, Vol. 14, No. 6
generated for corresponding ViveST sample due to low viral load. No genotypic results 
were generated for 3/17 paired samples due to low viral loads. Conclusions: This 
study confirms the ViveST sample transportation and storage device demonstrates 
utility for transporting plasma obtained from HCV and HIV-1 positive samples for viral 
load and resistance testing. The use of ViveST can enhance access to healthcare in 
resource-limited countries and significantly reduce the burden associated with shipping 
frozen samples. 
 
ID66. Development of a Fully Automated, CE-Marked Molecular Assay for the 
Detection of Toxigenic and Hypervirulent Strains of C. difficile 
S. Bradley, D. Slater, H. Reiske, C. Leslin, A. Jacobs, R. Del Mastro 
IntelligentMDx, Cambridge, MA. 
Introduction: Infection with Clostridium difficile reached historical heights in 2012, 
causing an annual 14,000 deaths and over 300,000 hospitalizations in the US alone. 
Because it is easily transmitted via contact, early detection of C. difficile is critical to 
reducing unnecessarily prolonged patient hospital stays and associated costs. 
Methods: IMDx has employed its proprietary bioinformatics platform, NGENix, to 
design an in silico screened, qualitative, multiplexed, real-time PCR-based assay for the 
detection of toxigenic C. difficile, including the NAP1/B1/027 strain. The NGENix-
designed assay has built-in redundancy, containing separate oligonucleotide sets for 
the detection of tcdA and tcdB genes. A third set extends coverage to A-B+ strains of C. 
difficile, such as the 1470 strain. The IMDx C. difficile for Abbott m2000 assay is 
validated for use with human liquid or soft stool specimens from symptomatic patients. 
Sample extraction is performed on the Abbott m2000sp and amplification and detection 
is performed on the Abbott m2000rt. This study evaluated the analytical and clinical 
performance characteristics of this assay. Results: The IMDx C. difficile for Abbott 
m2000 assay is capable of analyzing 94 patient samples in under 4 hours, providing a 
qualitative (positive or negative) diagnosis of C. difficile infection. Direct analysis of 
swabs from 251 stool samples demonstrated 95.7% sensitivity and 99.5% specificity 
compared to a cell culture cytotoxicity neutralization assay. No cross-reactivity was 
observed when tested against a panel of 58 common enteric viruses and 
microorganisms and no interference was seen in the presence common endogenous 
and exogenous substances. The IMDx C. difficile for Abbott m2000 assay is highly 
specific for its intended targets, identifying  95% of tcdA, tcdB, and tcdB-v sequences 
tested. Precision studies demonstrated > 98% concordance across all variables. The 
limits of detection for targets in the NAP1 strain were determined to be 21.2 CFU/mL for 
tcdA and 21.9 CFU/mL for tcdB. The limits of detection for targets in the 1470 tcdB-
variant strain were determined to be 7.7 CFU/mL for tcdA and 7.9 CFU/mL for tcdB. 
Conclusions: The IMDx C. difficile for Abbott m2000 assay addresses the growing 
need for rapid and timely C. difficile detection. The flexible volume capacity and 
automated nature of the assay allow multiple patients to be screened simultaneously, 
allowing physicians to make rapid, informed decisions about patient management. The 
assay was CE-marked in 2011. The IMDx C. difficile for Abbott m2000 assay is not 
available for sale in the US or Canada. 
 
ID67. Sampling Bias Occurs with Dual Sample Collection of Cervical Cytology 
Samples for Molecular Testing 
J. Hall, T. Myers, R. Lahr, D. Geralts, A. Spitz, G. Miller, S.P. Day 
Hologic, Inc., Madison, WI. 
Introduction: Dual sample collection is often used in cervical cancer screening (one 
cytology sample and one HPV testing sample) and in trials investigating the clinical 
performance of molecular tests. This research study examines whether dual-collected 
samples actually provide similar representations of the cervical site sampled. Methods: 
As part of an IRB-approved cervical sample collection study, two liquid-based cytology 
(LBC) samples were collected from each of 401 subject from two recruitment sites, with 
one sample being collected in FDA-approved LBC A (approved for cervical cytology 
and HPV testing) and the second in FDA-approved LBC B (approved for cervical 
cytology only), using FDA-approved collection devices appropriate for each sample 
type. One site collected LBC A first and the second site collected LBC B first. All 
samples were then tested using Cervista HPV HR. The high-risk HPV result and 
average genomic DNA (gDNA) signals from the test’s internal control were recorded. 
Analysis was performed to determine if order of sample collection affected HPV 
positivity rate and statistically affected (paired Student’s t-test) the gDNA signal as a 
surrogate of sample equality. Results: Site 1 and Site 2 populations differed. When 
LBC A was collected first its HPV positivity was 22.9% versus 20.1% for the LBC B 
sample. When LBC B was collected first its HPV positivity rate was 37.3% versus 
34.9% for the LBC A sample. Analysis of whether the sample collected first versus 
second affected average gDNA signal strength showed sample collection order did 
affect the gDNA signal with the second sample having lower gDNA (P< 0.05). Analysis 
of average gDNA signal by collection order revealed that if LBC A was collected first the 
average gDNA signal for LCB A was significantly different than that for its paired LBC B 
sample (P<0.05); however, when LBC B was collected first there was no significant 
difference between the paired LBC A and LBC B gDNA signals. Conclusions: 
Sampling bias does exist when dual sample collection is used with LBC cervical 
sampling. Difference with respect to HPV positivity and significant differences in gDNA 
levels occur between the two samples collected and depending on which LBC sample 
type is collected first versus second. This should raise questions about the 
appropriateness of the use of dual sample collection as part of cervical cancer 
screening or as part of trials comparing the clinical performance of HPV tests when 
comparing results from dual-collected samples. 
 
ID68. Comparison of Two Multiplex Respiratory Virus Panels: The Idaho 
Technology FilmArray and GenMark Dx eSensor System  
T.T. Taylor, K.D. Poselenzny, M. Regner, S. Das, K.A. Mangold, K.L. Kaul, R.B. 
Thomson 
Northshore University Health System , Evanston, IL. 
Introduction: Molecular detection of respiratory viruses has become the diagnostic 
standard, and is rapidly progressing from single target assays to multiplex panels. We 
compared the performance of two multiplex respiratory virus panels (RVP), the fully 
integrated Idaho Technologies FilmArray and the array based-GenMark eSensor, to 
well validated laboratory-developed real-time PCR tests (LDT) for the detection of 
influenza A, influenza B, RSV, and adenovirus. Methods: FilmArray and eSensor 
performances were assessed using serial dilutions of cultured viral standards, blinded 
proficiency samples obtained from the College of American Pathologists (CAP), and 53 
retrospective nasopharyngeal swabs (NP) previously characterized by LDT. FilmArray 
and GenMark assays were further compared for detection of Coronavirus HKU1, hMPV, 
HRV, and parainfluenza I in the 53 clinical specimens. Results: FilmArray and eSensor 
sensitivities in serial dilution testing were comparable for the detection of RSV and 
influenza B. FilmArray was ten-fold less sensitive than eSensor for adenovirus, whereas 
both registered equivocal results with high influenza A dilutions. CAP proficiency 
samples were tested with FilmArray and eSensor resulting in uniform agreement for 
detection of RSV, parainfluenza 1, influenza A H3N2, and adenovirus, and a single 
false-positive result for RSV using FilmArray. Using clinical samples, eSensor detected 
100% of the Adenovirus (2/2), Influenza A (24/24), Influenza B (5/5), and RSV (12/12). 
FilmArray detected 100% of the Adenovirus (2/2) and RSV (12/12) but only 20 of the 24 
influenza A, and 4 of 5 influenza B. Viruses not targeted by the LDT included 
parainfluenza, hMPV, rhino- and human coronaviruses; performance was equivalent 
between eSensor and FilmArray, though the number of positives was small. 
Conclusions: GenMark Dx eSensor RVP demonstrated greater sensitivity than 
FilmArray in dilution tests for Adenovirus, and detected 43/43 viruses in NP samples. 
FilmArray detected 38/43 viruses in NP samples. Both tests trended toward a higher 
sensitivity for the detection of RSV compared to LDT; however, FilmArray trended 
toward a lower sensitivity for Influenza A and B. FilmArray’s integrated design, simple 
workflow, and single sample test capabilities offer advantages in certain clinical 
settings, such as laboratories that require frequent on-demand testing. GenMark offers 
better sensitivity with higher throughput capability but is a two step assay with more 
potential for amplicon contamination. Supported by the Department of Pathology, 
NorthShore University HealthSystem. 
 
ID69. Comparison of Assay Sensitivity in FDA Approved Assays for the 
Detection of High-Risk HPV Genotypes  
R. Vemula, M. Unger, C. Huang, C. Konter, W. Harwood, A. Przybylek, R. Meixell, B. 
Anekella 
SeraCare Life Sciences, Inc., Gaithersburg, MD. 
Introduction: Early, sensitive, specific detection of Human Papilloma Virus (HPV) in 
cervical samples is imperative for diagnosis and treatment of cervical cancers, a leading 
cause of death for women ages 35-55. Several FDA approved test methods for HPV 
DNA detection have been introduced in recent years: digene HC2 HPV DNA Test from 
QIAGEN, Cervista HPV HR from Hologic, and cobas 4800 HPV Test from Roche 
Diagnostics, each with limitations and advantages. Assays are FDA approved for 
samples collected in PreservCyt fixative (Cytyc Corp, MA). We formulated panels in 
PreservCyt using characterized cellular HPV controls with known HPV genotypes to 
evaluate the sensitivity and specificity of these assays. Methods: Linearity panels for 
HPV genotypes 16, 18, and 51 were manufactured from cells containing full-length 
episomal HPV DNA mixed with uninfected human cells formulated in PreservCyt 
fixative to mimic actual patient samples. Each panel consists of 8 members with a 
defined copy number target for HPV (200-20,000 copies/mL of sample) and a constant 
number of human cells. Panel member testing was performed in triplicate on all three 
FDA approved platforms. Results: The FDA approved HPV assays are qualitative. 
Cervista and digene involve hybridization of nucleic acid probes complementary to the 
viral genome, followed by signal amplification for detection. The cobas test utilizes DNA 
amplification by PCR and amplicon hybridization for detection of multiple HPV types in 
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one analysis. The Limit of Detection (LOD) of each test platform was evaluated using 
the linearity panels. LOD is the lowest tested concentration demonstrating a 100% 
positive hit rate. Cervista and digene assays showed an LOD of ~5000 copies/mL of 
sample suspension. The cobas assay has an LOD of ~200 copies/mL. Based on the 
test results, the Roche cobas assay is >10 fold more sensitive than the Cervista and 
digene assays. Similar testing is ongoing using remnant characterized patient samples. 
Conclusions: We formulated HPV linearity panels to determine the sensitivity of three 
FDA approved HPV DNA assays. This study indicates that the cobas 4800 HPV test is 
more sensitive than the Cervista and digene assays. Furthermore, the cobas assay 
requires only 1 mL of the test sample and tests both HPV16 and 18 simultaneously, as 
opposed to the Cervista and digene assays that require 2 and 4 mL respectively. All 
assays test for HPV16, 18, and 51 as high risk genotypes; the cobas assay specifically 
identifies HPV16 and -18 while concurrently detecting other high risk types. 
 
ID70. Molecular Detection of Bordetella pertussis and Bordetella parapertussis
Using the EraGen MultiCode-RTx System and the Roche LightCycler 2.0 
M.J. Bankowski, C. Ying, T. Koyamatsu, W. Kim 
DLS and The Queen's Medical Center, Aiea, HI. 
Introduction: Bordetella pertussis is the etiologic agent of whooping cough and 
Bordetella parapertussis may also cause a pertussis-like illness. B. pertussis is more 
prevalent than B. parapertussis, but both are contagious and contribute to respiratory 
disease. Both are fastidious, gram negative bacilli that require special media for 
isolation and long incubation times (3 - 7 days). The use of molecular amplification with 
high test performance has contributed substantially to improving the laboratory 
diagnosis and patient care. The present study evaluates the test performance of the 
EraGen MultiCode-RTx System and the Roche LightCycler 2.0 in the detection of B. 
pertussis and B. parapertussis in clinical respiratory specimens. Methods: Nucleic acid 
was extracted using the Cobas MagNA Pure - Cobas Amplicor, followed by real-time 
amplification and detection using the EraGen MultiCode-RTx System with the Roche 
LightCycler 2.0. Known specimens containing B. pertussis or B. parapertussis (N=33) or 
negative for both or containing other known pathogens (N=11) were used in the study. 
Test performance was challenged for analytical and clinical sensitivity and specificity, 
reproducibility, specimen stability, and viral transport media suitability. Results: Clinical 
test performance was 100%, 85.7%, 93.3%, and 100% for sensitivity, specificity, PPV, 
and NPV respectively. Analytical sensitivity for B. pertussis and B. parapertussis was 15 
CFU and 1500 CFU respectively. Analytical specificity was challenged at 1.5 x 106/mL 
and revealed some cross reactivity to both B. holmesii and B. bronchiseptica, but not to 
other bacteria tested. Inter-run and intra-run reproducibility was in the 0.1% to 3.9% 
range. Specimens containing blood or mucus did not exhibit any inhibition. Likewise, 
viral transport media (M4, M5, and M6) at various times and temperatures did not show 
any significant effect on test performance. Conclusions: The test performance of the 
EraGen MultiCode-RTx System using the Roche LightCycler 2.0 for the detection of B. 
pertussis and B. parapertussis in clinical respiratory specimens showed a very 
favorable outcome. This real-time PCR test using the EraGen MultiCode-RTx System 
appears suitable in turnaround time and test performance for use in the clinical 
laboratory. 
ID71. Rapid Detection of Herpes Simplex Virus 1 and 2 in Cerebrospinal Fluid 
by the GenturaDx IDBox HSV 1/2 Assay 
M. Wood1, A. McNamara1, A. Zuniga1, K. Mai1, A. Benn1, G. McKinley1, M. Huang2, K.R. 
Jerome2 
1GenturaDx, Hayward, CA; 2University of Washington/Fred Hutchinson Cancer 
Research Center, Seattle, WA. 
Introduction: Rapid and sensitive detection of HSV1 and HSV2 from cerebrospinal 
fluid (CSF) is critical for patients with suspected encephalitis or meningitis since early 
administration of anti-viral therapy has been shown to improve prognosis. The 
GenturaDx IDbox system is an automated platform for nucleic acid detection from 
various sample matrices in under 4 hours. The IDbox assays are performed in single-
use cassettes that contain all the reagents required to analyze a patient sample, i.e., 
viral lysis, DNA purification, PCR amplification and detection. The IDbox HSV 1/2 assay 
is currently being developed for use with ano-genital swab samples in viral transport 
medium (VTM); the purpose of this study was to determine analytical performance of 
this assay when CSF was used in place of VTM and to assess assay performance with 
blinded clinical CSF samples that had previously been tested for HSV1 and HSV2 with 
a laboratory developed, ultra-sensitive quantitative real-time PCR assay. Methods: 
Viral strains were obtained from the ATCC and Zeptometrix. Healthy human CSF was 
from Bioreclamation. Deidentified clinical CSF samples were from the University of 
Washington viral reference laboratory. The IDbox HSV 1/2 assay used PCR primers 
and probe (gD gene) from EliTech; HSV1 and HSV2 subtyping was performed by melt 
analysis after PCR. The real-time PCR assay (gB gene) was based on TaqMan 
chemistry. Results: Equivalence of VTM and CSF for the IDbox HSV 1/2 assay was 
shown after spiking HSV1 (final concentration = 100 TCID50/mL) into each sample 
type. Both matrices yielded equivalent Ct and Tm values (average of 6 replicates): VTM 
– Ct = 37.1 and Tm = 60.9°C; CSF – Ct = 37.7 and Tm = 61.2°C. Preliminary limits of 
detection for HSV1 and HSV2 in CSF were shown to be 100 TCID50/mL and 40 
TCID50/mL for HSV1 and HSV2, respectively. The IDbox results from 19 blinded 
clinical CSF samples were 100% concordant with the results obtained by the 
quantitative PCR assay with 9/19 samples called positive. Of the 9 positives, 4 were 
typed as HSV1 and 5 as HSV2 by the IDbox assay. Conclusions: The IDbox HSV 1/2 
assay cassette processed HSV1-spiked CSF and VTM samples with equal efficiency. 
Testing with blinded clinical CSF samples showed that the IDbox HSV 1/2 assay 
detected both HSV1 and HSV2 and was 100% concordant with the real-time PCR 
comparator method. The IDbox HSV 1/2 assay provides a highly sensitive method for 
detecting low levels of HSV1 and HSV2 in CSF. 
 
ID72. Curetis UnyveroTM - A New Solution for the Rapid Detection of Bacteria 
and Antibiotic Resistances 
S. Barth, M. Klein, H. Motejadded, B. Sandra, G. Luedke 
Curetis AG, Holzgerlingen, Germany. 
Introduction: Pneumonia is a severe, life-threatening, predominantly bacterial infection 
of the lower respiratory tract. It is a fast progressing disease with high mortality rates 
and treatment costs. Here we describe a new solution for the rapid detection of 
pathogens causing pneumonia in hospitalized patients. Methods: The Curetis 
UnyveroTM instrument platform in combination with the pneumonia cartridge detects 16 
bacteria, 22 antibiotic resistance markers and one fungus that are responsible for 
approximately 80 % of severe non-viral pneumonia. Included pathogens are either 
common, need a complicated treatment or are not addressed by current guidelines. The 
resistance markers cover frequent resistance genes highly relevant for antibiotic 
therapy decision. The UnyveroTM solution is fully automated: the whole process is 
software controlled and includes sample preparation of native patient samples, DNA 
isolation and purification, end-point multiplex PCR, detection of amplified DNA 
fragments by hybridization and result interpretation and presentation. The sample 
preparation, used to liquefy patient samples to enable DNA isolation, can handle 
diverse, clinically relevant respiratory samples types like broncho alveolar lavage (BAL), 
tracheal aspirate, protected brush and even mucous sample types like sputum. The 
direct use of native patient samples together with the simultaneous detection of 
pathogens and resistance markers offers significant time savings, resulting in 4 hours 
for the UnyveroTM results compared to 2-3 days for classical clinical microbiology. 
Results: A sample set consisting of 48 fresh or frozen native patient samples of 
different sample types was tested with the UnyveroTM solution compared against 
standard clinical microbiology, showing an excellent concordance with positive 
microbiology results. Microbiology positive pathogen findings can be reproduced by the 
UnyveroTM solution and phenotypic resistance can be predicted by the system's 
genotypic markers. In addition to these correlating results some species like 
Streptococcus pneumoniae or Stenotrophomonas maltophilia showed non-correlating 
results, characterized by a significantly lower than average signal intensity. These 
species are suspected to be part of the respiratory flora. This aside, strains like 
Pseudomonas aeruginosa, which are not part of a normal respiratory flora and 
important for therapy decision were also additionally detected in some cases. All 
bacteria lacking a positive microbiology were independently confirmed by bidirectional 
sequencing. Conclusions: The UnyveroTM system is able to detect pathogens and 
resistance markers in respiratory samples concordant with standard clinical 
microbiology. Additionally detected pathogens are either part of the sample specific 
flora or were confirmed to be present and have been missed by traditional microbiology. 
ID73. Possible Dual or Triple Infection with Dengue Viruses DENV-1, -2, and -4 
in an Early Infection Series 
P. Garrett1, T. Lee2, M. Busch2, P. Patel3, M. Niedrig3, G. Anez4, M. Rios4 
1SeraCare Life Sciences, Inc., Milford, MA; 2Blood Systems Research Institute, San 
Francisco, CA; 3Robert Koch Institute, Berlin, Germany; 4CBER/US FDA, Bethesda, 
MD. 
Introduction: The spread of the four Dengue viruses (DENV-1 to -4) beyond earlier 
endemic areas, and the potential for transmission by blood transfusion, have increased 
efforts to detect DENV RNA in blood. The unavailability of serial samples from early 
DENV primary or secondary infections, when the virus is present in blood prior to 
development of symptoms, has inhibited test development and evaluation. Methods: A 
series of six plasma collections over 15 days from an adult male was found positive for 
DENV RNA and NS1 antigen. To confirm the presence of RNA and determine 
quantitative results, samples were provided to three laboratories with in-house assays 
for detection of DENV-1 through DENV-4 RNA, and were tested by commercially 
available methods for NS1 and anti-Dengue Ab. The in-house assays were all designed 
for quantitative detection of DENV in patient samples and are based on quantitative RT-
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PCR technology (TaqMan), using universal DENV-complex or type-specific primers and 
probes in standard and/or multiplex formats. Results: Qualitative tests for NS1 antigen 
and anti-Dengue Ab were positive for all samples. All three RNA assays found DENV-2 
in all six samples in variable but generally diminishing concentrations. Two assays also 
detected DENV-1 and -4 at lower concentrations, and the third found ambiguity 
between DENV-1 and DENV-2. Attempts to culture virus from the plasma samples are 
underway. Conclusions: Simultaneous infections with multiple Dengue viruses are 
uncommon, although previously reported. This series may represent a dual or triple 
infection with DENV serotypes. Naturally-occurring serial samples representing early 
primary or secondary infections, in sufficient volume to be made commercially available, 
fill an unmet need in the development and evaluation of Dengue RNA assays. 
 
ID74. Performance Evaluation of a HHV-6 Real-Time PCR Assay for Monitoring 
HHV-6 in Transplant Patients 
M. Sabato, P. Morris, D. Wilkinson, A. Ferreira-Gonzalez 
Virginia Commonwealth University Health System, Richmond, VA. 
Introduction: HHV-6 is a common infection after bone marrow and solid organ 
transplantation. This is an immunomodulatory and immunosuppressive virus that has 
been associated with a higher rate of CMV disease after transplantation. HHV-6 
infections occur earlier than CMV with a reported median time to onset of 22 days. 
Although the reactivation rate is high, HHV-6 monitoring is not routinely performed. We 
report here the performance characteristics of an LDT for the detection and 
quantification of HHV-6 in plasma using the QIAsymphony RGQ system. Methods: 
Assay calibration was performed using a tenfold dilution from 7.20E+06 to 7.2E+01 
copies/ml of commercial HHV-6A and HHV-6B DNA (Advanced Biotechnologies Inc, 
Columbia, MD). Linearity and lower limit of quantification (LoQ) were determined by 
analyzing a dilution series of HHV-6 virus from 1.00E+07 to 1.25E+02 copies/ml 
plasma, run in duplicate over 3 different days. Analytical precision was tested with the 
same panel. Specificity of QPCR assay was tested using a multi-analyte reference 
material containing CMV, EBV, VZV, BKV, Adenovirus and HSV-1/2. DNA purification 
was done using the QIAsymphony DSP Virus/Pathogen Mini kit with the Cellfree200 
protocol (plasma input/elution volume of 300 Pl/95 Pl, respectively). Thirty anonymized 
patient samples previously tested in a reference laboratory were used for correlation 
study (15 samples with <500 copies/ml and 15 positive samples). Serial plasma 
specimens from 85 patients tested in our laboratory for CMV after transplantation were 
included in this study. Results: The calibration curve showed an average slope of -
3.529 (R2=0.99). The assay was linear from 1.00E+07 to 5.00E+02 copies/ml 
(slope=1.00 and R2=0.99). The LOQ of the assay was 5.00E+02 copies/ml. High level 
of precision was obtained along the analytical measurable range of the assay with 
coefficient of variation of less than 5% log copies/ml at 3.0 and 7.0 log copies/ml. No 
cross-reactivities were detected. Fourteen of the 15 undetectable samples by the 
reference laboratory, were undetectable by our assay. One sample with a low viral load 
was detectable with our assay but undetectable by the reference laboratory. All positive 
samples were detected except for all samples from one patient. In addition, serial 
samples from 85 patients were tested for HHV-6. Reactivation was detected earlier than 
CMV reactivation for the patients that were positive for HHV-6. Conclusions: The 
QPCR assay presented in this study using the QIAsymphony RGQ system showed 
excellent analytical performance and can be used for monitoring reactivation of HHV-6 
in transplant patients. 
ID75. The Tm Profile, a Rapid Real-Time PCR Method Generating Signatures to 
Detect and Identify Mycobacterium Species in Clinical Samples 
C. Courtemanche1, L. Deschênes1, L. Bélanger2 
1Centre Hospitalier Universitaire de Québec, Quebec City, Canada; 2Centre de 
Recherche du CHUQ, Quebec City, Canada. 
Introduction: To detect Mycobacterium tuberculosis in clinical samples, our laboratory 
has been using a real-time PCR method with consensus primers for the mycobacterial 
16S rRNA gene and hybridization probes that are specific for tuberculosis. On a melting 
curve analysis, M. tuberculosis have a high melting temperature (Tm) whereas other 
mycobacteria have a lower Tm. Although specific and sensitive for M. tuberculosis, this 
method is not precise enough to identify other mycobacteria. In fact, many share the 
same Tm therefore species identification require sequencing. Our objective was to 
develop an assay to detect and identify common mycobacterium species in a single 
experiment. Methods: We designed probe pairs specific for three mycobacteria: M. 
avium, M. intracellulare, and M. gordonae (M. gordonae being a frequent contaminant 
of culture). Each pair of probes, in addition to unambiguously identify its specie by the 
high Tm, displays a lower Tm for other mycobacteria. The combination of the four Tm 
generates a unique signature for each mycobacterium called a Tm profile. Results: 
Using this method, we analyzed 500 clinical samples (respiratory samples, cultures, 
frozen and FFPE tissues), and were able to identify 20 frequent mycobacterium species 
having unique Tm profiles, including kansasii, marinum, scrofulaceum, haemophilum, 
and leprae. Species were confirmed by sequencing. Conclusions: The Tm profile 
method allows rapid identification of mycobacteria in various clinical samples and helps 
the diagnostic of mycobacterial infections. 
 
ID76. Development of an Improved Real-Time PCR Assay for the Detection of 
Varicella Zoster Virus DNA: Increased Performance and Efficiency 
R. Martinez, L. Cook, S. Wendt, E. Atienza, K.R. Jerome 
University of Washington Medicine, Seattle, WA. 
Introduction: Because Varicella Zoster Virus (VZV) can be life-threatening in a variety 
of patient settings, especially in immunocompromised populations; rapid, sensitive 
methods of detection are of particular importance. Our current diagnostic assay, 
developed more than a decade ago, utilizes LightCycler technology as a means to 
rapidly quantify VZV viral DNA. The goal of this study was to reevaluate our current 
assay, as well as identify potential improvements based on increased genomic 
sequence data currently available. Methods: A literature survey was performed to 
assess previously established real-time PCR assays for the detection of VZV DNA. 
Sequence data were analyzed to identify the regions of the VZV genome with the least 
variability to identify candidate target genes. Primer and probe sequences obtained 
from the literature (3 sets), newly designed primers and probes (2 sets), along with a 
TaqMan probe designed for the current LightCycler primers were evaluated in this 
study; resulting in a total of 6 different primer and probe sets. The ABI StepOnePlus 
and Fast reagents were used. Results: In silico analyses revealed approximately 325 
VZV DNA sequences, including 46 complete genomes in GenBank. Literature findings 
in conjunction with alignment data revealed 4 candidate target genes. Two of the six 
primer sets displayed optimal amplification; both targeted different regions within 
ORF62. Both of the new assays had better sensitivity than the current assay. Overall 
good agreement was observed with 71 positive and 59 negative patient samples when 
results for our current assay and the two new assays were compared for 104 plasma or 
CSF samples and 26 swabs. When compared to each other, the 2 new primer sets 
displayed similar specificity and sensitivity with the exception of 4 samples. Three 
samples from two patients were approximately 1-log higher in one assay, and 1 sample 
was a high positive quantity with one assay and negative with the other (a PCR 
amplication failure). Conclusions: Bioinformatic developments have increased the 
quantity and quality of publically available data and thus facilitated the initial phase of 
this study by reducing the amount of time and costs associated with assay 
development. The 2 primer sets that displayed optimal amplification targeted different 
regions of ORF62, suggesting that ORF 62 is a good gene target for the detection of 
VZV. In conclusion, we have developed a TaqMan assay that performs with better 
sensitivity and reproducibility than our current assay; thus maximizing laboratory 
efficiency.  
ID77. Rapid Identification of Pathogens in Positive Aerobic Blood Cultures  
N. Garrone, M. Buccambuso, E. Amiott, E. Dastrup, S. McNeil, V. McCarthy, C. Carter, 
G. Alger, K. Nilsson, S. Thatcher 
Idaho Technology Inc., Salt Lake City, UT 
Introduction: The FilmArray is a user friendly, multiplex PCR system developed by 
Idaho Technology Inc. that performs sample-to-result pathogen identification in one 
hour. The FilmArray system consists of a bench-top instrument and a single use 
reagent pouch that employs automated, magnetic-bead-based sample preparation. A 
blood culture identification (BCID) pouch is being developed for the FilmArray system to 
identify a diverse panel of targets that account for ~90% of pathogens in positive blood 
cultures, including gram negative and positive bacteria, Candida. spp. yeast, and select 
antibiotic resistance genes. This study sought to characterize the performance of the 
FilmArray BCID system with simulated clinical, positive aerobic blood culture samples. 
Methods: Each pathogen on the BCID panel was grown in a liquid culture that was 
enumerated on agar plates. The enumerated liquid cultures were used to spike low 
levels (eg, 100 CFU) of pathogens into 10 mL of human whole blood. The spiked blood 
was inoculated into BD BACTEC or BioMerieux BacT/Alert blood culture media bottles 
that contain the PCR inhibitor sodium polyanetholsulfonate (SPS) and were grown to 
positivity, in BD BACTEC or BioMerieux BacT/Alert instruments. Positive blood cultures 
were tested on the FilmArray system in the developmental BCID pouch and were 
enumerated on agar plates. Results: The developmental FilmArray BCID pouch 
exhibited 100% sensitivity for 29/31 organisms and 4/4 antibiotic resistance targets that 
were tested in this study. Subsequent modifications to the FilmArray BCID system, that 
included redesigned PCR primers, improved sensitivity to 100% for 31/31 organisms. 
These organisms include high prevalence pathogens such as Staphylococcus, 
Streptococcus, Enterococcus spp. and E. coli, low prevalence pathogens such as 
Neisseria meningitidis and Listeria monocytogenes, and five species of Candida yeast. 
Pathogen titers in positive aerobic blood cultures were typically lower for Candida spp. 
(median ~10e6 CFU/mL) than bacteria (median ~10e10 CFU/mL). The range of times 
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to positivity was 10-150 hours for all organisms, with Candida spp. typically requiring 
longer amounts of time to reach positivity than bacteria. Conclusions: The FilmArray 
BCID system is capable of rapidly identifying a panel of diverse pathogens that are 
prevalent in positive aerobic blood cultures. Automated sample preparation in the 
FilmArray BCID system effectively removes PCR inhibitors from positive blood cultures 
whereas purifying DNA from gram negative and positive bacteria, and Candida spp. 
yeast. Acknowledgements: This work was supported by grant number U01 AI082184 
from the NIAID, NIH. This abstract contains information on the FilmArray BCID pouch 
that has not been approved by the FDA.  
 
ID78. Performance of the Cobas4800 and Cervista HPV Tests on SurePath 
Cytology Specimens 
A.D. Bossler1, G.S. Cynthia1, J.A. Jordan2 
1Carver College of Medicine, University of Iowa, Iowa City, IA; 2George Washington 
University, Washington, DC. 
Introduction: Testing for high risk (HR) human papillomavirus (HPV) types is important 
in the triage of atypical squamous cells of undetermined significance (ASC-US) cytology 
results and in co-testing women 30-65 years in evaluating for cervical cancer or high 
grade dysplasia. Though SurePath liquid based preservative (Becton, Dickinson Co) is 
commonly used in cytologic specimen collection, no assay using SurePath has been 
FDA approved for HPV detection. We compared the performance of the cobas 4800 
HPV Test (Roche Diagnostics, Inc.) using real-time PCR and the Cervista HPV Assay 
(Hologic, Inc.) using Invader/cleavase signal amplification for the detection of HR HPV 
types on SurePath cytology specimens. Methods: Testing was performed on residual 
SurePath cytology specimens from the molecular pathology laboratory (University of 
Iowa IRB #200808713). The performance of the cobas 4800 for detection of HR HPV 
types 16 and 18 was compared with genotyping results generated using the Linear 
Array (LA; Roche Diagnostics, Inc) HPV genotyping probe hybridization assay. 
Results: Results from the cobas 4800 HPV Test and the Cervista HPV Assay 
demonstrated 88.2% (711 of 806 specimens) agreement. The percent of specimens 
identified as ASC-US demonstrating presence of HR HPV DNA by the cobas 4800 
assay was 51% (225 of 440 specimens) compared to 44% (195 of 440) by the Cervista 
HPV Assay. The cobas 4800 demonstrated sensitive detection of HPV types 16 (92 
specimens) and 18 (47 specimens) in comparison with LA genotyping (73 and 34 
specimens, respectively). Of the cobas HPV 16 positive discrepant results, the LA 
results were positive for other HR HPV type(s) (in 8), negative (in 5), and invalid (in 2). 
Of the cobas HPV 18 positive discrepant results, after removing those not able to be LA 
tested, the LA results were positive for other HR HPV type(s) (in 6) and negative (in 4). 
The nine LA negatives had cobas HPV16 or 18 CT’s >37. Conclusions: The cobas 
4800 HPV Test demonstrated reliable HPV detection from cytologic specimens 
collected in SurePath with a greater percent positivity than the Cervista HPV assay, had 
automation that reduced hands on time, and was able to provide reliable HPV 16 and 
18 genotyping.  
ID79. Broad-Range Microbial DNA Isolation from Clinical Specimens for 
Universal PCR Diagnosis 
C. Disque1, M. Linow1, N. Murphy2 
1Molzym Gmbh, Bremen, Germany; 2CaerusBio Inc., Downingtown, PA. 
Introduction: Molecular analysis has proven to be a valuable tool in the timely 
diagnosis of the etiological agents of infectious diseases such as sepsis, endocarditis 
and meningitis. DNA extraction of a broad range of microorganisms is a key issue for 
sensitive detection and precise sequence-based identification. The aim was to test the 
broad-range microbial DNA extraction capability of the molecular analytic kit, Universal 
Microbe Detection, using a variety of clinical material coming in for routine molecular 
analysis. Methods: Specimens originated from patients under suspect of an infection. 
Samples were processed as advised (Molzym, Bremen, Germany). Microbial DNA was 
detected using universal rRNA gene PCR assays. Amplicons were sequenced and 
BLAST-analyzed to identify the organisms. Results: In total, 430 clinical specimens 
were analyzed, including blood, synovia, swabs (wounds, prostheses, pus, bones), 
CSF, and heart valve/aortal tissues. Among 186 positive samples, 95 showed typical 
pathogens (eg, S. aureus, E. faecalis/faecium, E. coli, C. albicans) and 91 opportunistic 
strains (eg, CoNS, viridans streptococci, Moraxella osloensis). Rare etiologies 
comprised bacterial pathogens, among them Bacteroides fragilis, Bartonella quintana, 
Borrelia graninii, Coxiella burnetii, Listeria monocytogenes, Providencia stuartii, and 
Tropheryma whippleii, and fungal pathogens (non-albicans Candida, black yeast). One 
blood sample from a malaria patient was positive in a specific assay for the etiological 
agent, Plasmodium falciparum. Conclusions: The pre-analytical processing comprises 
the removal of human DNA, concentration and enzymatic lysis of microbes, and DNA 
extraction. The data from randomly collected, diverse clinical material indicated that a 
broad range of microorganisms were lysed, including Gram-positive and Gram-negative 
bacteria, yeasts and other fungi, as well as a protist. The supply of DNA from diverse 
microbial taxons to the PCR analysis greatly supports the detection and precise 
molecular identification of common and rare etiologies. 
 
ID80. Comparison of the Cobas HPV Test and Hybrid Capture 2 High-Risk HPV 
DNA Test 
M.T. Pyne, C. Law, D.R. Hillyard, R. Schlaberg 
ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 
Introduction: Testing for high risk (HR) HPV and cytology are recommended for 
cervical cancer screening in women over 30. There currently are 4 US FDA-cleared 
assays for HR-HPV testing. The Hybrid Capture 2 assay (hc2, Qiagen) targets 13 HR-
HPV types, the cobas HPV test (cobas, Roche) detects 14 HR-HPV types with optional 
genotyping for HPV 16 and 18. We compared both assays using consecutive clinical 
specimens and performed discrepant analysis by repeat testing and Linear Array HPV 
genotyping. Methods: Consecutive residual cervical samples in ThinPrep preservative 
(n=696) from women over 30 with 8 ml residual volume after hc2 testing were 
analyzed by cobas. Agreement of hc2 and cobas was calculated. Samples with 
discordant results were retested with both assays. Linear Array HPV genotyping (LA, 
Roche) was performed on all samples positive in one or both assays using residual 
DNA after cobas testing. The LA detects 37 HPV genotypes including all high-risk types 
targeted by both assays and is not FDA-cleared for cervical cancer screening. Results: 
The overall positivity rates were 10.6% (hc2) and 12.2% (cobas) and agreement was 
94.4% (kappa=0.72). Of the 39 samples with discordant results, 25 (64.1%) were hc2-
/cobas+ and 14 (35.9%) were hc2+/cobas-. Repeat-testing results differed for hc2 in 4 
cases (positive to negative, mean RLU/CO ratio=3.9), for cobas in 11 cases (positive to 
negative) and for both assays in 1 case (hc2: positive to negative, cobas: negative to 
positive). Results remained discordant for the remaining 23 of 39 (59%) samples (14 
hc2-/cobas+, 9 hc2+/cobas-). HR-HPV types were detected by LA in 13 of the 14 hc2-
/cobas+ with available LA results and in 2 of the 9 hc2+/cobas- samples. Of 85 cobas 
HR-HPV positive samples, 22 (25.9%) were positive for HPV 16 of which 20 (90.9%) 
were confirmed by LA; 6 (7.1%) were positive for HPV 18 of which 5 (83.3%) were 
confirmed by LA. No additional samples were LA-positive for HPV16 and/or 18. 
Conclusions: Performance of both assays was comparable with similar positivity rates 
(p=0.35) and overall agreement of 94.4%. Of the initially discordant results, 41% were 
not reproducible. This may be due to low HPV loads as suggested by low hc2 RLU/CO 
ratios, sampling error, sample contamination, or other reasons. For 87% of repeatedly 
discordant results LA and cobas results agreed, although possibly biased since DNA 
from the cobas extraction was used for LA. HPV 16 and/or 18 was detected by LA in 
89.3% of samples positive by cobas. 
ID81. Prevalence of HPV 16 & 18 Subtypes in HIV Positive and Negative Women 
from an Inner City Hospital Clinic 
A. Seth, C. Dixey, M. Keane-Tarchichi, Y. Kasama, H. Fernandes 
University of Medicine and Dentistry of New Jersey, Newark, NJ. 
Introduction: Several studies have demonstrated that women with HIV infection are 
much more likely to have persistent HPV infection with oncogenic subtypes compared 
to HIV-negative women. Furthermore, the rate of oncogenic HPV was almost three 
times higher among HIV-positive women and these women had a higher risk of CIN 
than HPV positive, HIV-negative women. This study is aimed at investigating the 
prevalence of HPV 16 and 18 in an inner city population of HPV positive women with 
and without HIV infection. We have also attempted to correlate the data with cervical 
cytology status. Methods: Over a period of three years, total of 191 women with 
ASCUS cytology were positive for high-risk HPV when tested in either the Digene 
Hybrid Capture assay or the Cervista HR assay at University Hospital in Newark, NJ. 
These patients were subsequently subtyped for the detection of HPV 16 and/or HPV 18 
using a laboratory developed assay. The assay was validated using subtype specific 
primers and Taqman probes, on the ABI 7500 realtime PCR platform. The PCR results 
were correlated with HIV status and cytology classification. Results: Of the 191 
women, 74 (39%) were HIV positive and 117 (61%) were HIV negative. The average 
age of HIV positive and negative subjects was 47 and 38 respectively. The majority 
(92%) of the HIV positive women were African American whereas 37% of the HIV 
negative women were of the African American ethnicity and 44% were found to be of 
Hispanic origin. Cytology results showed that more than 38% of the HIV positive women 
had ASC-US and 46% had low to high grade squamous intraepithelial lesions, whereas 
almost 90% of the HIV negative patients had ASC-US. Overall 17% of the HIV+ 
patients had either HPV16/18 compared to 12% in the HIV negative group. The 
percentages of HPV 16 positive patients in both groups was comparable; however there 
was a significant difference in HPV 18 positive patients between the two groups; 16% in 
HIV positive versus 3% in HIV negative. Conclusions: In summary HIV positive 
women, predominantly of African American ethnicity had an increased risk of HPV 
infection associated with neoplastic lesions and were infected predominantly with the 
oncogenic HPV 18 subtype. 
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ID82. Performance Evaluation of the Cytomegalovirus DNA qPCR artus System 
on the QIAsymphony RGQ System Using Small Plasma Sample 
M. Sabato, P. Anderson, W. Payne, D. Wilkinson, A. Ferreira-Gonzalez 
Virginia Commonwealth University Health System, Richmond, VA. 
Introduction: Cytomegalovirus (CMV) DNA quantification in plasma has become the 
standard of care for disease diagnosis in post-transplant patients. Data addressing the 
performance characteristics of the QIAsymphony RGQ system for CMV quantification in 
plasma using Qiagen artus CMV reagents have been reported using a large input 
volume of plasma (1.2 ml). It would be desirable to have a method that provides a 
clinically useful quantification range with smaller input sample. A large volume of 
plasma is not always available from a patient sample, especially when several other 
tests are ordered on the same sample. In this study, the performance of the 
QIAsymphony RGQ system for CMV DNA quantification in plasma using artus CMV 
reagents (Qiagen) was evaluated using a small input volume of plasma. Results were 
compared to our Laboratory-Developed Test (LDT) for correlation and agreement. 
Methods: The Acrometrix OptiQuant CMVtc quantification panel with additional 
dilutions (5.5, 4.5, 3.5, 2.5, 2.0 and 1.7 log copies/ml) was used to determine linearity, 
precision and lower limit of quantification (LoQ). The studies were performed in 
duplicates on 3 different days using the QIAsymphony DSP Virus/Pathogen Mini kit in 
combination with the Cellfree200 protocol (input/elution volume of 300 Pl and 95 Pl, 
respectively). Each of the samples was analyzed using the artus CMV reagents 
(Qiagen, Valencia, CA). A multi-analyte transplant control with a low (3.7 log copies/ml) 
and a high (5.0 log copies/ml) was included in each run for control evaluation. In 
addition, anonymized patient samples, previously tested with our LDT were used for 
clinical correlation. Results: Measurable range spanned from 2.5 to 5.5 log10 CMV 
copies/ml (R2=0.99). The LoQ was 300 copies/ml that is well below the clinical 
significant values. The method showed high precision with a total CV of 0.2-11.5% log 
copies/ml. All undetectable samples by the LDT were below the LoQ established for the 
RGQ system. Positive samples analyzed by both methods were comparable but not 
identical. The difference in quantification between samples by both methods was on 
average higher for the Qiagen method than for the LDT (from 0.0 to 0.82 log copies/ml). 
A Pearson’s correlation coefficient of 0.78 was obtained between methods. 
Conclusions: The qPCR method presented in this study with sample preparation and 
assay setup using the QIAsymphony RGQ system showed excellent analytical 
performance with the advantage of having a clinically useful quantification range using 
only 300 Pl of plasma. 
 
ID83. Evaluation of a Qualitative Fluorescent Loop Mediated Isothermal 
Amplification (LAMP) Assay for Toxoplasma gondii
A. Dolan, G. Keating, D. Adlerstein 
Biotrin International Ltd., Co. Dublin, Ireland. 
Introduction: Toxoplasmosis infection is caused by the parasite Toxoplasma gondii. 
Infection in healthy individuals is generally mild or asymptomatic, but may have severe 
consequences in immunocompromised or pregnant patients. Loop-mediated isothermal 
amplification (LAMP) is an isothermal method for rapid and highly specific amplification 
of nucleic acid through the recognition of multiple DNA/RNA target regions. This study 
evaluated a new qualitative LAMP assay that detects a target region on the T. gondii 
genome and is multiplexed with an internal control for the validation of negative results. 
The analytical performance of multiple batches of LAMP Toxo assay was evaluated and 
performance on a number of External Quality Assessment (EQA) panels was assessed 
relative to commercial PCR. Methods: Three pilot batches of LAMP Toxo were 
prepared, consisting of freeze-dried reaction mix, reconstitution buffer, and positive, 
negative and internal controls. Testing was performed using prototype LAMP Analysers 
(Biotrin, Ireland), for temperature control and multi-channel fluorescent detection. Assay 
sensitivity was determined by testing replicates of plasmid at a number of 
concentrations across multiple instrument runs. 31 positive EQA panel members 
(QCMD, UK) and 24 negative plasmas and QCMD samples were extracted using 
Qiagen columns and tested with all 3 LAMP assay lots and PCR (Nanogen). 5μL of 
Internal Control was added to each sample prior to extraction, and 20μL of extract 
added to 30μL of reconstituted LAMP reagents before incubating on the LAMP 
Analyser at 67°C. Results: 100% of plasmid replicates at 0.4 cps/μL were detected 
with all lots of LAMP Toxo. All 3 lots of LAMP Toxo detected 30 out of 31 positive 
QCMD panel members (97%), compared to 26/31 (84%) detected with Nanogen PCR. 
The sample not detected by LAMP contained 1.15 cells/mL according to QCMD data, 
and was detected by only 18% of labs in 2009. All 24 negative samples gave 
concordant negative results for all LAMP lots and PCR. LAMP Internal Control was 
correctly amplified in all negatives. Conclusions: LAMP Toxo demonstrates excellent 
analytical sensitivity and lot-lot reproducibility. Sensitivity for QCMD panels is superior 
to commercial PCR. With a time to result of 45 minutes, LAMP Toxo is also faster than 
PCR. The assay includes a control for both extraction and inhibition that generates a 
fluorescent signal in an independent channel to validate negative specimen results. The 
use of a stable lyophilised reagent preparation removes any requirement for frozen 
storage, and the isothermal nature of LAMP reduces instrument costs. 
 
ID84. Characterization of Candidate Host Susceptibility Genes for Chlamydia 
trachomatis Infection  
K.M. Bennett, P. Grubb, M. Littlejohn, R. Mize, J. Moreno, C. Weissenburger, E.C. 
Hendrix 
Texas Tech University Health Sciences Center, Lubbock, TX. 
Introduction: Chlamydia trachomatis infection is a significant health concern worldwide 
and is the most common sexually transmitted infection in the United States. There are 
many differences between patients in the persistence and progression of infection, 
which are believed to be strongly influenced by the genetics of the host. The objective 
of this study is to identify genetic differences that may confer susceptibility to genital 
Chlamydia trachomatis infection. Single nucleotide polymorphisms (SNPs) were 
examined in several genes that play a role in the attachment and entry of C. 
trachomatis bacteria, bacteria nutrient acquisition, and the host immune response. The 
initial goals were to identify the genotype frequencies of these potential susceptibility 
genes in the study population. Methods: This study was a retrospective, hypothesis-
driven case-control research design. The initial genotyping studies were performed with 
a sample size of 60 subjects, which was 75% female with a median age of 22 years 
(18-33 years). The C. trachomatis infection status was determined by the Roche 
Amplicor CT/NG assay. The initial subjects were determined to be “not detected” for C. 
trachomatis DNA and thus served as the controls for the study. DNA was isolated from 
de-identified urethral or endocervical swab specimens, using the Qiagen QIAmp DNA 
isolation kit, and genotyping was performed using TaqMan allelic discrimination assays 
(Applied Biosystems) on the ABI 7500 real-time PCR instrument. The host genes 
examined included protein disulfide isomerase (PDIA2, rs400037), interferon gamma 
receptor (IFNGR1, rs2234711), hemochromatosis (HFE, H63D, rs1799945), immunity-
related GTPase (IRGM, rs13361189), and lipocalin-2 (LCN2, rs11794980). Results: 
High quality DNA was isolated from the swab specimens, with the exception of six 
specimens that had insufficient DNA or produced inconclusive results. The genotype 
frequencies for each of the candidate susceptibility gene polymorphisms were 
calculated and compared to the expected Hardy-Weinberg equilibrium frequencies, 
using Chi-square analysis. Genotype frequencies were as follows: PDIA2 (AA 0%, AG 
32%, GG 68%), IFNGR1 (AA 34%, AG 45%, GG 21%), HFE H63D (CC 75%, CG 23%, 
GG 2%), IRGM (CC 6%, CT 22%, TT 72%), and LCN2 (CC 20%, CG 37%, and GG 
43%). Conclusions: Initial results provided a control baseline for the further study of 
these SNPs, and statistical analysis demonstrated that the genotype frequencies were 
all in Hardy-Weinberg equilibrium. Future studies include the genotyping of C. 
trachomatis positive specimens, followed by statistical analysis of the association 
between these candidate susceptibility genes and C. trachomatis infection. 
 
ID85. Comparison of Antigen and PCR Tests for Respiratory Viruses in 
Emergency Department Patients 
S.G. Spitzer, S. VanScoy, E.D. Spitzer 
SUNY at Stony Brook, Stony Brook, NY. 
Introduction: Nucleic acid amplification tests, e.g., RT-PCR, are now routinely used for 
diagnosis of respiratory virus infections, particularly Influenza A and B and respiratory 
syncytial virus (RSV). Many clinical laboratories also utilize rapid immunodiagnostic 
tests (RIDTs) to detect these viruses. Although RIDTs can yield results in 20 minutes 
they have limited sensitivity that is kit specific. Nucleic acid amplification based tests are 
considered to be a gold standard for diagnosis; however, they are labor intensive and 
most have a 4-8 hour turn-around time. The Stony Brook Emergency Department (ED) 
sees a large number of patients with respiratory virus symptoms. We conducted a 
retrospective review to determine the performance characteristics of RIDTs vs. PCR 
based tests in ED patients. We also investigated whether the performance of these 
tests differed between patients who were admitted compared to those who were not 
admitted. Methods: We reviewed laboratory data for ED patients who were tested for 
Influenza (Flu A and Flu B) and/or RSV by both RIDT and PCR from 9/1/10 to 10/31/11. 
Specimens were tested with the Remel Xpect FLU A/B and Binax NOW RSV RIDTs 
and the Prodesse ProFlu+ reverse transcription real-time PCR (Gen-Probe Inc). For 
each virus, data were stratified into two groups, admitted patients and non-admitted 
patients. Sensitivity and specificity of the antigen tests were calculated using PCR as 
the reference method. Results: There were 40 cases of RSV, 103 cases of Flu A and 
27 cases of Flu B. The overall sensitivities of the RIDTs for Flu A, Flu B and RSV were 
22%, 33% and 48 % respectively. The specificities ranged from 94% to >99%. 
Comparison of admitted vs non-admitted patients revealed the following sensitivities: 
15% vs 27% for Flu A, 33% vs 33% for Flu B and 50% vs 44% for RSV. The prevalence 
in admitted/non-admitted patients was 21%/21% for Flu A, 3%/7% for Flu B, and 
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32%/32% for RSV. Conclusions: This study confirms that rapid antigen tests have 
poor sensitivity (with Flu being worse than RSV). There was virtually no difference in 
the prevalence of infection in admitted patients vs non-admitted patients for all three 
viruses. This may be due to presence of other risk factors or co-morbidities that 
determine whether a patient is admitted. Our results point out the limitations of rapid 
testing compared to real time PCR and may aid in the development of better testing 
algorithms. 
 
ID86. Validations of Two Novel Real-Time Multiplexed Molecular Assays for the 
Detection of Influenza A+B and Human Metapneumovirus 
T.A. Ranalli, R. Lollar, H. Liang, R. Kelly, J. Stockwell, R. Przybyla, L. Grippa, T. 
Curtiss, V. Armendarez, A. Wright, T.R. Ott, C. Lewis, T. Pack, T. Stenzel 
Quidel, San Diego, CA. 
Introduction: Respiratory infections are the most common acute infection in both 
adults and children. Significant causative agents include both influenza (flu A/B) and 
human metapneumovirus (hMPV). We recently developed two assays based upon 
novel, lyophilized, 4oC stable reagents for use in multiplexed RT-PCR for the detection 
and differentiation of flu A/B and hMPV, respectively. These assays both utilize a 
simplified workflow that significantly reduces the number of steps required for testing, 
have thermocycling times of about one hour and can be run on the same plate. 
Methods: RNA from either clinical specimens or spiked matrix samples was extracted. 
Five (5) ȝL of the sample was added to 15 ȝL of the reconstituted Quidel Molecular 
Influenza A+B (QM flu) or Quidel Molecular hMPV (QM hMPV) master mix. Real-time 
PCR was performed using the Applied Biosystems7500 Fast Dx. An integrated process 
control was added to each sample for monitoring both extraction and amplification. 668 
fresh specimens were tested for flu A/B and compared to Prodesse ProFlu+. Seven 
hundred twelve (712) fresh clinical specimens were tested for hMPV and compared to 
Prodesse Pro hMPV+. Results: The ProFlu+ assay detected 139 flu A-positive 
specimens and all 139 tested positive in the QM flu assay. There were 8 additional flu 
A-positive specimens in the QM flu assay and 7 of these were confirmed positive by bi-
directional sequencing. Of the 110 flu B-positive specimens in the ProFlu+ assay, 105 
tested positive in the QM flu assay. There were an additional 12 flu B-positive samples 
by QM flu and all 12 were confirmed positive by bi-directional sequencing. The assay 
was found to be highly reproducible and had a limit of detection (LOD) of between 5.7 
and 92 TCID50/mL, depending upon the strain. In addition, this assay has been 
validated on the Cepheid SmartCycler (data not shown). Fourty-four (44) of 45 Pro 
hMPV+ positive specimens tested positive with the QM hMPV assay. Six hundred sixty-
six (666) of 667 Pro hMPV+ negative specimens tested negative with the QM hMPV 
assay. The assay was found to be highly reproducible and had a limit of detection 
(LOD) of between 3.2 and 53 TCID50/mL, depending upon the strain. Conclusions: 
Results from these studies indicate that these two novel real-time assays are sensitive 
and specific for the detection of influenza A, influenza B, and hMPV, respectively. 
ID87. Comparison of Analytical and Clinical Performance of Abbott RealTime 
High Risk HPV, Hybrid Capture 2 and HPV DNA Chip Assays in Gynecology 
Patients 
S. Park, H. Shin, Y. Kang, D. Kim, E. Kim, M. Seong, S. Park 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: Cervical cancer, as the sixth common cancer in Korean women, is mainly 
caused by persistent Human papillomavirus (HPV) infection in uterine cervix. The high-
risk HPV test in cervical cancer screening is important for early diagnosis of cervical 
cancer or pre-cancerous lesion, which indicates a higher probability of cervical cancer. 
We evaluated analytical and clinical performances of three high-risk HPV assays in 
gynecology patients. Methods: A total of 991 specimens were included in this study: 
787 specimens requested for a Hybrid Capture II (HC2; Qiagen, MD, USA) and 204 
specimens requested for a HPV DNA chip (Biomedlab, Seoul, Korea). For each 
specimen, we performed Abbott RealTime High-risk HPV (Abbott HR; Abbott, 
Wiesbaden, Germany) and sequence analysis using PGMY primers as well as the test 
requested. Medical records for cervical cytologic and histologic examinations were 
reviewed. Results: Clinical sensitivities for all abnormal cytology were 72.9% for HC2, 
68.2% for HPV DNA Chip and 62.9% for Abbott HR, and clinical sensitivities for severe 
abnormal cytology, HSIL+ group were 81.8% for Abbott HR, 77.3% for HC2 and 66.7% 
for HPV DNA Chip in order. Clinical sensitivities for all abnormal histology were 81.8% 
for HC2, 75.0% for Abbott HR and 61.5% for HPV DNA Chip, and clinical sensitivities 
for severe abnormal histology with CIN2 or above were 91.7% for HC2, 87.5% for 
Abbott HR and 73.3% for HPV DNA Chip. Compared to sequence analysis, HC2, HPV 
DNA Chip, and Abbott HR showed concordance rates of 94.3% (115/122), 61.5% 
(16/26), and 90.0% (117/130), respectively. Conclusions: The HC2 assay and Abbott 
HR assay showed comparable results to each other in clinical and analytical 
performances, otherwise the HPV DNA Chip assay showed poor clinical and analytical 
performances. The real-time PCR-based Abbott HR assay can be a good alternative 
option for high-risk HPV testing with an advantage to allow simultaneous differentiation 
of high-risk types of 16 and 18. 
 
ID88. Comparative Analysis of a Novel Real-Time Multiplex Influenza A and B 
Assay with Cell Culture/DFA on 929 Human Clinical Specimens from the 2011 
Respiratory Season 
T.A. Ranalli, R. Lollar, H. Liang, L. Grippa, T. Curtiss, V. Armendarez, T.R. Ott, T. Pack, 
T. Stenzel 
Quidel, San Diego, CA. 
Introduction: Influenza A and B (Flu A/B), RNA viruses of the family Orthomyxoviridae, 
spread in regular epidemics resulting in the deaths of more than 250,000 people 
worldwide annually. Cell culture and direct fluorescent antibody (DFA) assays have 
been used traditionally to diagnose influenza infections. We have recently developed an 
assay based upon novel, lyophilized, 4 degree centigrade stable reagents for use in 
multiplexed RT-PCR for the detection and differentiation of Flu A/B. This assay utilizes 
a simplified workflow that significantly reduces the number of steps required for testing, 
with thermocycling times of about one hour. Methods: RNA from either clinical 
specimens or spiked matrix samples was extracted. 5 ȝL of the sample was added to 
15 ȝL of the reconstituted Quidel Molecular (QM) Influenza A+B master mix. Real-time 
PCR was performed using the Applied Biosystems7500 Fast Dx. Each sample also 
contained an integrated process control that controls for the extraction and amplification 
of the sample. 929 clinical specimens were tested and compared to Cell culture and 
DFA with discrepant analysis performed using Prodesse ProFlu+ or bi-directional 
sequencing. Results: For Influenza A, cell culture/DFA had 77.9% sensitivity to QM 
PCR (190/244) and 100% specificity (685/685). All Flu A discrepant samples were 
positive by either ProFlu+ or bi-directional sequencing. For Influenza B, cell culture/DFA 
had a 91.8% sensitivity (178/194) and 99.6% specificity (732/735). All Flu B discrepant 
samples were resolved in favor of the QM assay by either ProFlu+ or bi-directional 
sequencing. Analysis of a panel of 51 microorganisms at high titers indicated no cross-
reactivity in the assay. Inclusivity of the assay was analyzed with 20 Flu A and 13 Flu B 
strains as well as 17 non-clinical Flu A strains and all were detected. Testing with a 
panel of 11 potential interfering substances showed no interference. Negative samples 
in carryover and cross-contamination testing studies were all negative.Conclusions: 
These data demonstrate that the assay is a highly sensitive and specific method for 
detecting these viruses and provides superior performance to cell culture and DFA. 
 
ID89. Development of a Custom TaqMan Array Card for the Simultaneous 
Detection of 16 Pathogens Causing Gastroenteritis 
A. Ferlinz1, E. van Hannen2, C. Cummings1 
1Life Technologies, Darmstadt, Germany; 2St Antonius Hospital, Nieuwegein, Germany. 
Introduction: Gastroenteritis is a very common infectious disease syndrome of 
humans. Yearly, around 5 billion cases of diarrhea occur worldwide. Many microbial 
pathogens cause acute gastroenteritis making identification a laborious task. In recent 
years molecular tools like multiplex PCR have been developed that significantly aid in 
the detection of pathogens causing gastroenteritis. Although multiplex PCR reduces the 
number of PCR reactions needed, still many tests have to be performed to cover all 
pathogens. Here, we describe the development and technical validation of a microfluidic 
molecular device for the simultaneous detection and discrimination of the nucleic acid of 
16 pathogens involved in gastroenteritis. Methods: We developed quantitative real-time 
PCR assays for the detection of 3 viral pathogens (adenovirus, norovirus and rotavirus), 
8 bacterial pathogens (STEC, Shigella, Salmonella, Campylobacter coli, C. lari, C. 
jejuni, Yersinia entericolitica, Clostridium difficile) and 5 parasitic pathogens (Giardia 
lamblia, Entamoeba histolytica, Cryptosporidium parvum, Dientamoeba fragilis and 
Blastocytis hominis) using a proprietary bioinformatics pipeline from Life Technologies. 
To control for PCR inhibition and inefficient nucleic acid isolation, 3 different internal 
controls (Synechococcus, PDV and PhHV) are included. We first tested all assays for 
their sensitivity and specificity on clinical isolates using 96well plates. In a next step 
these TaqMan Assays were spotted on 384 well, microfluidic cards that allow the 
simultaneous detection of 24 assays in duplicate reactions within 1 hr. A set of several 
hundred stool samples was analyzed with the new system and compared to 
conventional methods like culture and microscopy. All targets were tested against an 
inclusion and exclusion panel and PCR efficiencies were determined by serial dilution 
experiments. Results: The results of the in- and exclusions panels showed that all 
PCRs were specific for the targets they were designed for and all PCR efficiencies were 
>90%. Testing stool samples showed that the Custom TaqMan Array Cards were much 
more sensitive than conventional techniques like culture and microscopy. The results 
obtained with the Custom TaqMan Array Cards were in concordance with in-house 
developed qPCR assays. Conclusions: We successfully technically validated real-time 
PCR assays to detect & discriminate 16 different pathogens involved in gastroenteritis. 
The Custom TaqMan Array Cards described here provide us with a fast, sensitive and 
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cost-effective way for the simultaneous detection of nucleic acid from gastro-intestinal 
pathogens in stool samples.  
ID90. Comparison of Two Real-Time PCR Assays for the Qualitative Detection 
of Varicella Zoster Virus in Lesion and CSF Specimens 
S.M. Wenceslao1, B. Rodic-Polic2, R. Martinez2, K. Culbreath2, S. Young2 
1University of New Mexico, Albuquerque, Albuquerque, NM; 2TriCore Reference 
Laboratories, Albuquerque, NM. 
Introduction: Direct fluorescent-antibody (DFA) and/or culture-based assays are 
traditional detection methods for Varicella Zoster Virus (VZV), human herpes virus type 
3, the etiologic agent of chicken pox and shingles. Molecular based assays have been 
shown to be effective tools for detection of VZV in a range of clinical samples. We 
evaluated the performance characteristics of the MultiCode RTx VZV ASR and FOCUS 
Diagnostics VZV ASR in the qualitative detection of VZV DNA from swab and CSF 
specimens. Methods: Forty-four prospective and retrospective swab specimens and 
thirty retrospective CSF specimens were tested. DNA samples were extracted in 
duplicate for amplification and detection on the LightCycler 480 II using MultiCode RTx 
VZV ASR assay (Roche Applied Science). Samples extracted for testing with the 
FOCUS Diagnostics VZV ASR were analyzed on a 3M Integrated Cycler. Determination 
of analytical specificity was performed on a panel of viral and bacterial pathogens, 
whereas analytical sensitivity was determined by measurement of VZV serial dilutions 
with M5 viral transport media. Precision studies performed for the Positive and Negative 
Control material assessed intra- and inter-run variations. Results were compared to the 
DFA (current in-house test) and a home-brewed qualitative PCR assay (ABS 7900 
platform) from a Reference Laboratory. Results: Both assays detected VZV DNA in 14 
swab and 10 CSF samples, in concordance with the DFA and reference laboratory 
tests. Limit of detection (LOD) for the MultiCode-RTx VZV PCR and FOCUS 
Diagnostics VZV PCR assay are six and five copies/reaction, respectively. Both assays 
demonstrated equivalent performance characteristics: analytic sensitivity, specificity, 
precision, and accuracy. Conclusions: The MultiCode- RTx ASR and FOCUS 
Diagnostics ASR assays exhibited satisfactory performance characteristics with 
excellent concordance with both the DFA and outside reference method for the 
qualitative detection of VZV DNA. Although, the FOCUS Diagnostics VZV assay 
exhibited a better LOD, future testing with a higher number of clinical samples is 
necessary to further delineate any discrepancies between the two assays. Despite this 
study limitation, both assays proved to be robust with a straightforward workflow 
suitable for most clinical laboratories looking to implement a qualitative PCR method for 
the detection of Varicella zoster in CSF and swab specimens.  
ID91. Detection of Nasal Carriage of Methicillin-Resistant Staphylococcus 
aureus by Healthcare Workers Using Real Time Polymerase Chain Reaction 
M. Kim, W. Lee, S. Kang 
Kyung Hee University Hospital at Gangdong, Republic of Seoul, Korea. 
Introduction: Healthcare-associated infections (HAIs) caused by methicillin-resistant 
Staphylococcus aureus (MRSA) have recently become an important issue for 
healthcare facilities due to high rates of infection, mortality, and high treatment costs. In 
this study, we aimed to investigate the frequency of nasal carriage of Staphylococcus 
by healthcare workers (HCW) and to assess the performance of the LightCycler MRSA 
Advanced test. Methods: Nasal swabs from the anterior nares of participating 
healthcare workers at an intensive care unit were cultured and identified as S. aureus, 
methicillin-sensitive or methicillin-resistant coagulase-negative staphylococci (MSCoNS 
or MRCoNS), or MRSA by using conventional culture and the LightCycler MRSA 
Advanced test (Roche Diagnostics GmbH, Mannheim, Germany) that involves 
amplification of the mecA gene. The limit of detection was evaluated with S. aureus 
ATCC 33591, methicillin-resistant strain. Isolate was prepared in saline suspensions at 
a concentration of 106 CFU/ml and absorbed onto double headed swabs and diluted 
with 10-fold from 10 to 106 CFU/mL and absorbed onto double headed swabs like the 
preceding. Specificity of the the LightCycler MRSA Advanced test was performed in 
duplicate, using reference strains and clinical isokates. Results: Of the 142 healthcare 
workers that participated in this study, 51 were residents, 51 were nurses, 19 were 
nursing auxiliaries, and 21 were physicians. Although only 11 participants (7.8%) were 
MRSA-positive by conventional culture and MRSA ID, 24 (16.9%) were positive for 
mecA by real time PCR. Among the 13 discordant specimens, 6 were MRCoNS, 4 were 
methicillin susceptible S. aureus (MSSA), and 3 were MSCoNS. In terms of diagnostic 
performance, the LightCycler MRSA Advanced test had a sensitivity of 100%, a 
specificity of 90.1%, a positive predictive value of 45.8%, and a negative predictive 
value of 100% compared with conventional culture method. The detection limit of the 
LightCycler MRSA Advanced test is 103colony/mL. All tested species were found 
negative for MRSA with the LightCycler MRSA Advanced test for analytical specificity 
test. Conclusions: Qualitative PCR amplification of mecA was able to rapidly and 
sensitively detect MRSA in healthcare workers. However, it must be confirmed by 
culture method due to false positivity. 
 
ID92. HPV Status Predicts Outcome after Chemoradiation in Head and Neck 
Cancer 
E.M. Speel1, J. Pranama2, J. Mooren1, M. van den Brekel2, L. van Velthuysen2, B. 
Kremer1, A. Begg2 
1Maastricht UMC, Maastricht, Netherlands; 2Netherlands Cancer Institute, Amsterdam, 
Netherlands. 
Introduction: Head and Neck squamous cell carcinoma is the sixth most common 
cancer in the world. Half of these patients have advanced disease. In these cases 
chemoradiation can achieve locoregional control rates of around 65%. Besides smoking 
and alcohol use, infection by human papillomavirus (HPV) is an additional etiological 
factor promoting the development of oropharyngeal squamous cell carcinomas (OSCC). 
HPV can be detected by p16INK4A immunostaining, followed by HPV-specific DNA 
PCR and/or fluorescence in situ hybridization (FISH). In this study we wanted to assess 
the incidence and predictive value of HPV in a series of OSCC treated with 
chemoradiation. Methods: Patients were treated within Phase II and randomized 
Phase III trials at the Netherlands Cancer Institute with concurrent radiotherapy and 
chemotherapy (cisplatin). Tissue microarrays were conducted for 
immunohistochemistry and FISH and gene expression microarrays were used to 
produce gene expression profiles with RNAs derived from pre-treatment material. 
Pretreatment material was also used for DNA isolation and subsequent HPV-specific 
PCR. Endpoints included local and locoregional control, distant metastasis and disease 
free survival. Results: Out of 111 OSCC, 37 were p16INK4A and HPV positive (33%; 
35x HPV 16 and 2x HPV 33). HPV positive tumors had no significant locoregional 
control rate in comparison with HPV negative tumors. HPV positive tumours, however, 
predicted the absence of distant metastases and a more favourable disease free 
survival (p=0.023 and p=0.05, respectively). Within the HPV positive group, EGFR 
immunopositive tumors had a worse survival than EGFR negative cases (p= 0.046). 
Conclusions: P16INK4A is a good surrogate marker for a HPV positive OSCC. HPV 
status did not predict a more favourable locoregional control, but did predict the 
absence of a distant metastasis and a favourable disease free survival. HPV positive 
tumors with EGFR immunopositivity are a distinct subtype with a significantly worse 
survival. 
 
ID93. Hepatitis C Virus Genotyping by PNA Probe Based Real-Time PCR  
J. Park1, J. Kim1, Y. Choi2, H. Jang1, G. Joe1, S. Ha1, H. Park1 
1Panagene, Republic of Daejeon, Korea; 2Soonchunhyang University Cheonan 
Hospital, Republic of Cheonan, Korea. 
Introduction: HCV genotype affects the progression of chronic liver diseases and 
response to antiviral therapy. HCV genotype 1 is the most difficult to treat, whereas 
genotypes 2 are the most susceptible to antiviral therapy. Accordingly, rapid and 
accurate genotyping of the hepatitis C virus (HCV) is essential for prognosis and 
prediction of treatment duration. We developed PNA probe based real-time PCR assay 
(PNAqPCR) to genotype HCV. PNA are artificially synthesized DNA analogues with a 
neutral peptide backbone. PNA probes have chemical, thermal and biological stability 
compared with DNA probe. The aim of this study was to develop and evaluate a novel 
PNA probe based real-time PCR assay (PNAqPCR) for detection of HCV genotyping 
and discrimination of HCV genotype 1 and 2. Methods: We optimized probes to 
discriminate genotype 1, genotype 2 and others in a single tube. The sensitivity of the 
real-time PCR assay was determined by serial dilution of the HCV RNA Genotype 
Performance panel. PNAqPCR was compared with sequencing method on 130 clinical 
samples. Results: The sensitivity of PNAqPCR is 102 IU/ml. 86 positive samples and 
44 negative samples were tested for this study. Genotype 1(54/86), genotype 2(17/86), 
genotype 1&2 mixed form (12/86) and other type (3/86) were detected. The result of 
PNAqPCR revealed a 98.5% concordance with sequencing in 130 clinical samples. 
Conclusions: We developed rapid and accurate method for detection of HCV genotype 
using PNA probe based real-time PCR. The PNA probe based real-time PCR assay 
(PNAqPCR) will be a useful and efficient method for detection and discrimination of 
genotype 1 and 2 in clinical diagnosis.  
ID94. Standardization of Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), BK 
Virus (BKV), and Adenovirus Values by Digital PCR and Comparison to Higher 
Order Standards 
M.D. Shahbazian, F. Le, J. Boonyaratanakornkit, E.R. Schoenbrunner 
Life Technologies, Benicia, CA. 
Introduction: Viral load testing by nucleic acid test methods such as real-time PCR, 
despite becoming a standard part of clinical diagnostics, shows a high level of variability 
and a wide range in results between laboratories. The use of common calibrators does 
improve the comparability of results, but different calibrators often vary in methods used 
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for value assignment. Digital PCR (dPCR) is a method that allows for copy number 
establishment in a manner that is independent of an external calibrator. We used this 
method to establish copy numbers for four viral calibrators (CMV, EBV, BKV, and 
adenovirus). Additionally, for CMV and EBV, we determined values based on calibration 
to the WHO International Standards and CMV values were also ascertained according 
to calibration to NIST Standardized Reference Material. Methods: AcroMetrix 
standards and panels were established by diluting cultured virus (CMV, EBV, BKV, and 
adenovirus) into normal human plasma. DNA was extracted using the QIAGEN 
MinElute Virus Kit. For the dPCR experiments, the DNA was diluted in TE buffer to an 
expected concentration of 0.5 copy/reaction and amplification was performed using 
TaqMan-based primers and probes with the OpenArray Real-Time PCR platform and 
reagents. For comparison to the WHO standards, samples were diluted in plasma, 
extracted, and amplified using the QIAGEN artus kits for CMV and EBV with an Applied 
Biosystems 7300 Real-Time PCR System. Results: The value of the AcroMetrix CMV 
standard was determined to be 2.69E6 copies/mL by dPCR, 3.27E6 copies/mL by 
comparison to NIST SRM 2366, and 5.69E6 IU/mL by comparison to the WHO 
standard. The value of the AcroMetrix EBV standard was determined to be 3.69E6 
copies/mL by dPCR and 4.30E6 IU/mL by comparison to the WHO standard. The BKV 
standard concentration was determined as 5.53E7 copies/mL by dPCR and the 
Adenovirus standard value was 7.13E5 copies/mL by dPCR. Conclusions: We 
observed that for CMV, all three values were in close agreement, with a maximum 
difference of 2.1-fold. The two values for EBV were also close, with a difference of 1.17-
fold. Due to the traceability of other AcroMetrix materials for CMV, EBV, BKV, and 
adenovirus to the AcroMetrix standards according to ISO 17511, new values based on 
dPCR and comparison to the WHO and NIST standards have been assigned. 
 
ID95. VanA Real-Time PCR Surveillance for Vancomycin-Resistant 
Enterococcus faecium
T. Kim1, Y. Hong2, M. Han1, S. Hwang2, H. Kim1, K. Park1 
1Seoul National University Bundang Hospital, Republic of Seongnam, Korea; 2Seoul 
National University Hospital, Republic of Seoul, Korea. 
Introduction: Enterococci have been recognized as an important cause of nosocomial 
infection in the past few decades. Moreover, vancomycin-resistant isolates of E. 
faecium and E. faecalis have been described. The CDC published recommendations for 
preventing the spread of vancomycin resistance in 1995. It included a policy for 
deciding the time of removal of patients from isolation; VRE-negative results on at least 
three consecutive occasions (1 week apart) in cultures. This recommendation has 
generally been accepted, but the rationale seems to stem from an empirical basis. In 
Korea, most VRE infections were caused by E. faecium. A previous work on E. faecium 
isolates from 10 teaching hospitals showed that all VRE harboured the vanA gene. The 
aim is to determine the clinical usefulness of real-time PCR for detection of the vanA 
gene over the conventional culture method in VRE-colonized patients, and to re-
evaluate the optimal number of negativity before isolation release. Methods: In the 
evaluation stage, 100 consecutive clinical specimens were analyzed for the vanA gene 
via real-time PCR with four different specimen preparations (direct specimen, isolate 
cultured in BAP for 24 h, isolate cultured in broth for 24 h, and isolate cultured in BAP 
for 24 h and in broth for the previous 24 h). In the application stage, 1115 clinical 
consecutive specimens from 82 patients were kept under surveillance for 20 months by 
vanA real-time PCR via broth incubation preparation. Results: In evaluation stage, for 
isolates prepared via broth incubation for 24 h, the PCR results were all concordant with 
those of the conventional method. The vanA real-time PCR results of the other three 
methods showed relatively low sensitivity. In application stage, three consecutive 
negative results on vanA real-time PCR were shown in 23 patients. In these patients, 
the median value of the time spent in isolation and the number of test repeats to 
isolation release was 71 days and 5.5 times. Conclusions: Real-time PCR shows more 
rapid, sensitive, and reproducible results than conventional PCR and minimize 
carryover contamination rate. Because broth medium is more convenient and less time-
consuming to use than agar medium, real-time PCR with 24-h broth incubation might be 
more appropriate and easier to perform. The optimal negative test number for the 
isolation release was three or more. We believe that our study proves the usefulness of 
real-time PCR for surveillance purposes. Considering the geographical difference, real-
time PCR might replace the conventional culture method in VRE surveillance. 
 
 
 
 
 
 
 
ID96. A Novel, Rapid and Extraction-Free Molecular Assay for the Detection 
and Differentiation of Herpes Simplex Virus 1 and 2 and Varicella Zoster Virus in 
Lesion Specimens 
C.J. Lewis, M. Hata, N. Mohamed, V. Armendarez, R. Lollar, T.A. Ranalli, T.T. Stenzel, 
R. Kelly 
Quidel Corporation, Athens, OH. 
Introduction: Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are DNA viruses of the 
family Herpesviridae that cause lesions at a variety of sites on the body. The lesions 
result from either primary infection by the virus or from reactivation of latent virus, 
causing recurrent episodes of the disease. HSV-1 and HSV-2 are genetically and 
antigenically distinct forms of HSV. Varicella-zoster virus (VZV) is also a DNA virus of 
the family Herpesviridae that presents clinically as a lesion. Because all three viruses 
present with symptoms that can be phenotypically difficult to differentiate, it is 
advantageous to have a sensitive and specific molecular assay to distinguish them. We 
have developed an assay based upon novel, lyophilized, 4oC stable reagents for use in 
the Quidel Molecular (QM) Direct HSV 1+2/VZV assay. This assay utilizes a simplified, 
extraction free workflow that reduces turnaround time to approximately 60 minutes for 8 
specimens. An assay with the aforementioned characteristics would provide an 
advantage to clinical labs that currently perform culture/DFA methods for HSV-1, HSV-2 
and VZV detection. Methods: A rapid, extraction-free, multiplexed real-time TaqMan 
assay was developed to detect and differentiate HSV-1, HSV-2 and VZV from lesion 
specimens. Further improvements include the use of novel, 4oC stable lyophilized 
reagents. Virus strains and cultured clinical isolates were used to establish the initial 
performance characteristics on the Applied Biosystems 7500 Fast Dx and Cepheid 
SmartCycler II. Remnant direct lesion specimens (93) were tested in the QM HSV 
1+2/VZV assay and results compared to culture/DFA. Results: Preliminary studies 
showed detection limits of 3.55e4, 9.02e3, and 7.43e1 TCID50/mL for HSV-1, HSV-2, 
and VZV, respectively. The HSV 1+2/VZV assay was tested against a panel of 105 
virus strains and clinical isolates and was found to be inclusive for the respective 
targets. Analysis of 93 previously characterized and frozen lesion specimens using both 
thermocyclers showed that 23 tested HSV-1 positive, 22 tested HSV-2 positive, 28 
tested VZV positive and 20 tested negative for all three viruses. Analysis of the PCR 
positive and culture negative discrepant specimens (3 VZV) in another molecular assay 
showed that these were resolved in favor of the Quidel Molecular Direct HSV 1+2/VZV 
Assay. Conclusions: Our data show that the rapid Quidel Molecular Direct HSV 
1+2/VZV Assay has greater sensitivity compared with culture methods and provides a 
simple to perform molecular assay for the detection and differentiation of HSV-1, HSV-2 
and VZV in lesions. 
 
ID97. A Comprehensive Respiratory Virus Panel Assay Performed Using a 
Multiplex Bead Array in Hospitalized Patients Suspected of Having Viral 
Respiratory Tract Infections 
S. Hwang1, Y. Hong2, M. Han2, T. Kim2, K. Park2 
1Seoul National University College of Medicine, Republic of Seoul, Korea; 2Seoul 
National University Bundang Hospital, Republic of Seongnam, Korea. 
Introduction: Acute viral respiratory tract infections are a significant cause of morbidity 
and mortality in patients with a compromised immune system. Nucleic acid amplification 
tests have shown their superiority over classical diagnostic methods in identifying 
broader range of viruses with higher sensitivity and specificity. We evaluated the results 
of the Luminex xTAG RVP (respiratory virus panel) assay by using the in-house 
multiplex real-time PCR and the rapid immunochromatographic assay. In addition, we 
analyzed the characteristics of respiratory viral infections in hospitalized patients during 
the study. Methods: We included 158 specimens submitted for respiratory virus testing. 
The xTAG RVP assay was performed to detect the following viruses and subtypes: 
influenza A (nonspecific influenza A, subtype H1, subtype H3, and subtype H5), 
influenza B, RSV (subtype A and subtype B), coronavirus (corona 229E, corona OC43, 
corona SARS, corona NL63, and corona HKU1), parainfluenza virus (para 1, para 2, 
para 3, and para 4), enterovirus/rhinovirus, metapneumovirus, and adenovirus. Positive 
results from xTAG RVP assay were confirmed with in-house multiplex real-time PCR. 
The immunochromatographic assay for influenza virus and RSV was performed in 
cases with available specimen. The respiratory virus detection results were compared 
with those reported in the National Surveillance Statistics in Korea. Results: The xTAG 
RVP assay revealed positive results in 91 specimens (57.6%). In total, 103 viruses 
were detected, and 7.6% of the specimens showed co-infection of respiratory viruses. 
The concordance rate of the results of the xTAG RVP assay with those of the in-house 
multiplex real-time PCR was 100%. The immunochromatographic assay showed 
positive results for only 52.9% of the confirmed RSV specimens and did not show 
positive results for the 3 influenza specimens. In fact, 7.1% of the 
immunochromatographic assay results for the influenza virus were false-positive. 
During the period, RSV subtype B was more prevalent (88.9%) than RSV subtype A. 
corona OC43, para 1 and para 3 were detected in few specimens. Human 
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metapneumovirus was positive in 11.6% of the specimen. We compared our virus 
detection rates with those reported in the Surveillance Statistics and found similar 
positive detection rates, except for a significantly higher detection rate for RSV in the 
specimens from the Seoul National University Bundang Hospital. Conclusions: The 
xTAG RVP assay performed with a multiplex bead array and the in-house multiplex 
real-time PCR are useful and sensitive methods, and can be reliably used in a clinical 
setting for detecting various respiratory viruses in hospitalized patients.  
 
ID98. Rapid Detection of Streptococcus pyogenes Using the Simplexa Group A 
Strep Direct Assay 
C. Cheng, Y. Chen, M.T. Dang, R. Hazelo, Y. Parocua, M. Aye, M. Tabb, M. Exner 
Focus Diagnostics, Cypress, CA. 
Introduction: Group A streptococcus infection can result in serious sequelae if not 
treated, so a rapid and accurate diagnosis is important. Currently, rapid antigen 
detection tests are available. However, the sensitivity of these tests is limited in such 
that they require additional tests by culture to rule out false negative results; 
consequently, needed treatment may not be immediately initiated. In an effort to provide 
an alternative to the rapid test, we developed a real-time PCR assay that detects group 
A Streptococcus directly from throat swabs in just over an hour. Methods: The 
Simplexa Group A Strep (GAS) Direct assay, which targets the conserved exotoxin B 
gene, was performed using the Direct Amplification Disc (DAD). For each assay, 50 PL 
of E-swab patient throat swab sample and 50 uL of GAS Direct Mix were added to their 
respective wells on the disc. The disc was then placed in the 3M Integrated Cycler. The 
system automatically meters the correct amounts of patient specimen and Direct Mix 
into the real time PCR reaction chamber. Assay results were compared with culture 
(n=205). Analytical limit of detection (LoD), specificity, interference and reproducibility 
studies were also performed. Discrepant results were resolved by sequencing a region 
of the exotoxin B gene different from the one targeted by the Simplexa assay. Results: 
The limit of detection (LoD) of the Simplexa GAS Direct assay was 18 CFU/reaction. In 
comparison to culture, assay sensitivity and specificity of Simplexa Group A Strep 
Direct were 100% and 81.4%, respectively. With the incorporation of results from 
discrepant resolution via sequencing, the assay sensitivity and specificity were 100% 
and 98%, respectively. The assay did not cross react with 30 common pathogens. No 
interference from any of the 20 potential interfering substances including blood, 
antibiotics and over the counter throat remedies was observed. Inter- and intra-assay 
reproducibility assays yielded <2.3% coefficient of variation. Conclusions: The 
Simplexa GAS Direct assay detected positive patients that culture missed, in 
agreement with sequencing results. With no requirement for nucleic acid extraction, the 
GAS Direct assay provides quick turnaround time without compromising detection 
sensitivity. 
 
ID99. Comparison of Two Multiplex Real-Time PCR Assays for Detection of 
Respiratory Viral Infections 
H. Kim, M. Hur, H. Moon, C. Park, Y. Yun 
Konkuk University School of Medicine, Republic of Seoul, Korea. 
Introduction: Respiratory viruses are main causes of upper and lower respiratory tract 
diseases, especially in infants, young children, the elderly and immunocompromised 
patients. The multiplex assay has the advantage of prompt screening of many possible 
viral pathogens in a short time. In this study, two multiplex real-time polymerase chain 
reaction (PCR) assays for detection of respiratory viral pathogens were compared. 
Methods: A total of 245 respiratory samples (229 sputum samples, 14 bronchoalveolar 
lavage samples, 6 nasal swabs, 3 throat swabs, unknown 7) were analyzed using two 
multiplex assays: One-step RV real-time PCR (BioSewoom, Seoul, Korea) and Seeplex 
RV 12 Detection kit (Seegene, Seoul, Korea). The results were further confirmed using 
sequencing as a reference method. Results: Among 245 samples (265 identifications 
including co-infections), the identification of respiratory viruses was 44.9% (119/265), 
44.2% (117/265), 45.3% (120/265) by One-step RV assay, Seeplex RV assay, and 
sequencing, respectively. The concordance rate between One-step RV assay and 
sequencing was 95.5% (253/265), and that between Seeplex RV assay and sequencing 
was 89.8% (238/265). The sensitivities of One-step RV and Seeplex RV assays were 
93.3% (95% confidential interval [CI], 87.3% to 97.1%) and 83.3% (95% CI, 75.4% to 
89.5%), respectively. The specificities of One-step RV and Seeplex RV assays were 
97.2% (95% CI, 93.1% to 99.2%) and 95.2% (95% CI, 90.3% to 98.0%), respectively. 
Conclusions: The performances of One-step RV and Seeplex RV assays were 
comparable. Both multiplex real-time assays can be used for the rapid diagnosis and 
management of patients with respiratory infections. 
 
 
 
ID100. Evaluation of s Novel, Rapid, Real Time PCR Assay for the Detection of 
Clostridium difficile from Stool Specimens Targeting Both TCDA and TCDB 
J. Rivera1, K. Mitchell1, T. Curtiss2, J. Pappas2, R. Lollar2, T. Stenzel2 
1Clinical Pathology Laboratories, Austin, TX; 2Quidel, San Diego, CA. 
Introduction: Cytotoxic Clostridium difficile is a gram-positive, anaerobic, spore 
forming bacillus capable of producing Clostridium difficile associated diarrhea (CDAD), 
or pseudomembranous colitis. These symptoms are the result of the presence of either 
one or both of two related cytotoxins – toxin A and toxin B. The genes for toxin A and 
toxin B (tcdA and tcdB, respectively) are located together within the Pathogen Locus, or 
PaLoc. Within those strains that contain a pathogen locus, there are significant genetic 
differences including point mutations, frame shifts, insertions and several hundred base 
pair deletions. An assay targeting both genes may therefore provide additional levels of 
assurance for the detection of C. difficile. Methods: This evaluation was performed with 
Quidel Molecular processing reagents and the Quidel Molecular Direct (QM) C. difficile 
Tox A/B assay on the Applied Biosystems 7500 FastDx. Primers and probes were 
designed to detect both the tcdA and tcdB regions with the same fluorophore to allow 
for redundant detection. The overall time from sample to result is about an hour for 
small batch sizes. 137 fresh clinical samples were tested with both the QM C. difficile 
Tox A/B and enzyme immunoassays (EIA). Results: The EIA method detected 42 C. 
difficile-positive specimens and 40/42 tested positive in the QM assay. There were 10 
additional C. difficile-positive specimens with the QM assay. 85 specimens were 
negative in both assays. Discordant resolution favored the QM C. difficile Tox A/B 
assay in all cases. Of the 10 QM+/EIA- cases, nine were positive by a commercially 
available IVD PCR test and the tenth was positive by cell culture cytotoxin. Of the two 
QM-/EIA+ cases, both were negative by both cell culture cytotoxin and a commercially 
available IVD PCR test. Conclusions: These preliminary results indicate this novel, 
easy-to-use, rapid molecular C. difficile assay is very specific and is significantly more 
sensitive than EIA.  
 
ID101. Accurate Identification of Coagulase-Negative Staphylococci and 
Nonhemolytic Streptococci to the Species Level: Sequencing of Various Genes 
Versus MALDI-TOF MS Analysis 
Y. Hong, M. Han, S. Hwang, T. Kim, K. Park 
Seoul National University College of Medicine, Republic of Seoul, Korea. 
Introduction: Coagulase-negative Staphylococci (CNS) and nonhemolytic streptococci, 
which belong to the most frequently isolated group of bacteria in clinical microbiology 
laboratories, are responsible for a broad spectrum of clinical manifestations ranging 
from contamination to serious infection. Thus, accurate species-level identification of 
these bacteria is necessary for decisions on further treatment. Currently, molecular 
diagnostic methods such as sequencing are used to identify bacteria even though they 
are time- and labor-consuming and expensive. Matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), which 
analyzes proteins from bacteria, has recently been introduced in clinical laboratories. 
We compared the performance of MALDI-TOF MS analysis with that of DNA 
sequencing in the species-level identification of CNS and nonhemolytic Streptococci. 
Methods: We analyzed 93 CNS isolates and 50 nonhemolytic streptococcal isolates 
from clinical specimens by using Microflex MALDI-TOF MS (Bruker Daltonics, Bremen, 
Germany). The mass spectra were analyzed using MALDI BioTyper 3.0 software 
(Bruker Daltonics, Bremen, Germany), and the results were compared with those of 
DNA sequencing. We performed sequencing of the tuf gene and 16S rDNA for CNS 
and that of the recA gene and 16S rDNA for nonhemolytic Streptococci. Results: The 
MALDI results of 90 out of the 93 isolates of 10 species of CNS showed an agreement 
with the results of sequencing, the exceptions being 2 cases of S. epidermidis and 1 
case of S. hominis. Further, MALDI analysis identified 4 isolates into S. pettenkoferi, 
whereas DNA sequencing did not discriminate between S. pettenkoferi and S. 
pseudolugdunensis. Among the 50 nonhemolytic streptococcal isolates of 12 species, 7 
(2 S. constellatus, 2 S. mitis, 1 S. intermedius, 1 S. anginosus, and 1 S. cristatus) 
showed “unreliable identification” as a result of low MALDI scores, and 3 isolates (1 S. 
anginosus, 1 S. mitis, and 1 S. thermophilus) could not be assessed using MALDI 
analysis. Although 10 of the other 40 isolates were incorrectly identified to the species 
level, the results for 8 of these 10 showed the results belonging to the same 
streptococcal groups to DNA sequencing. Conclusions: In comparison with molecular 
identification, MALDI-TOF MS analysis showed superior species-identification ability in 
CNS isolates. In cases of nonhemolytic Streptococci, although it frequently failed to 
identify isolates to the species level and often yielded inaccurate results, MALDI-TOF 
MS analysis showed good concordance up to the group level. It is expected to be a 
promising method in clinical microbiology laboratories after further evaluation using 
diverse bacteria and development of updated databases. 
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ID102. Characterization of the Performance of a Novel, Easily Automated Total 
Nucleic Acid Isolation Method for Respiratory Specimens 
M. Jost, L. Nelson, S. Mytton, T. Tuggle, P. Douglass, S. Visuri, D. Kolk 
Gen-Probe, San Diego, CA. 
Introduction: We present a novel, rapid, total nucleic acid isolation method and its 
integration onto a user-friendly, fully automated prototype instrument. The new total 
nucleic acid isolation method is based on hybridization chemistry with a unique capture 
oligonucleotide that binds to nucleic acids in a sample and is subsequently purified with 
magnetic beads. FDA approved Prodesse respiratory molecular diagnostic assays were 
used to compare the fully automated, novel isolation method to a semi-automated 
purification method with several different spiked respiratory viruses and nasopharyngeal 
swab specimens. Methods: Concentrated viral stocks of influenza A, influenza B, RSV 
A, adenovirus, hMPV and parainfluenza 3 were spiked into pooled negative 
nasopharyngeal swab specimens and processed (n=20 replicates) with the new method 
on a fully automated instrument. Viruses were spiked to concentrations at the limit-of-
detection (LoD) for Prodesse ProFlu+, ProFast+, ProAdeno+, ProhMPV+ and 
ProParaflu+ assays as described in the manufacturer’s package insert. As a 
comparison, Boom silica based chemistry was run on a semi-automated instrument 
according to the manufacturer’s instructions. For clinical matrix studies, viral stocks 
were spiked at their respective LoD into 24 individual negative nasopharyngeal swab 
specimens. Interference studies were done in the presence of mucin, gram negative 
and positive bacteria, eukaryotic cells and whole blood at clinically relevant 
concentrations. Competition studies were run for multiplexed viral targets, one virus at 
the LoD and others above the LoD. Clinical sensitivity of our novel isolation method was 
compared to the predicate method in nasopharyngeal swab specimens (n= 148 
positive, n=51 negative). Results: Common interfering substances did not produce an 
effect on Prodesse assay sensitivity. Moreover, we did not observe target competition 
and matrix effects. Using RNA and DNA viral targets, we observed equal or better 
sensitivity with the novel isolation method compared to Boom silica based chemistry. 
Additionally, we tested 148 clinical nasopharyngeal swab samples that were known to 
be positive for Influenza or RSV. For both extraction methods, 147/148 of the samples 
were correctly identified as positive (99.3% positivity), with a single sample testing 
negative using both methods. Conclusions: The new method equals or exceeds the 
performance of a standard extraction method based on Boom chemistry. We 
demonstrated full automation of the new method on a Gen-Probe prototype instrument, 
allowing high throughput of samples with minimal hands-on time. 
ID103. Development and Evaluation of a Multiplex Real-Time PCR Assay to 
Identify Mycobacterium tuberculosis Complex DNA and Mycobacterium avium
Complex DNA Directly in Clinical Specimens 
A.C. Tran, T.A. Halse, V.E. Escuyer, K.A. Musser 
Wadsworth Center, New York State Department of Health, Albany, NY. 
Introduction: Infections from Mycobacterium tuberculosis complex (MTBC) remain a 
major health problem today. The rise in infections caused by Mycobacterium avium 
complex (MAC), particularly in areas with low incidence of tuberculosis disease and 
among immunocompromised patients, has demanded more rapid and direct diagnostic 
tools. Culture, a reliable gold standard, is time consuming and commercially available 
tests for identification require culture growth and have been found to lack specificity. 
Our laboratory has developed a rapid, sensitive and specific multiplex real-time PCR 
assay, with an internal inhibition assessment, for the detection of MTBC and MAC DNA 
in clinical specimens. Methods: A real-time PCR assay for the identification of MAC 
was developed and multiplexed with a previously developed singleplex real-time PCR 
assay for MTBC. The new multiplex real-time PCR assay targets the insertion 
sequence 6110 (IS6110) and the 16S-23S rRNA internal transcribed spacer (ITS) 
region for the identification of MTBC and MAC, respectively. Validation included the 
assessment of specificity, sensitivity and reproducibility, followed by retrospective and 
prospective studies of clinical specimens tested by real-time PCR for MTBC and 
AccuProbe for MAC. Results: This multiplex assay correctly identified all available type 
strains with a sensitivity of 0.90 and 14.0 colony-forming units for MTBC and MAC, 
respectively. To evaluate the performance of this assay, 165 clinical samples were 
tested prospectively. Of these, 63 samples were MTBC positive in both the singleplex 
and multiplex assays, resulting in 100% correlation. Additionally, among the 165 clinical 
specimens, 46 samples were tested by AccuProbe following culture with 16 samples 
positive for MAC by both AccuProbe and this assay, resulting in 100% correlation. 
Interestingly, two samples were found to be positive for both MTBC and MAC using the 
new assay. In a retrospective study that included 90 clinical specimens, 61 samples 
were MAC positive with Accuprobe and 72 samples were MAC positive with the 
multiplex assay. The 11 samples that were discordant were determined to be MAC 
positive by sequence analysis. Conclusions: This new multiplex real-time PCR assay 
for MTBC and MAC has been shown to be sensitive and specific for the identification of 
both MTBC and MAC directly in clinical samples. The assay provides results prior to the 
availability of results for cultured material, within 24 h of receipt. This evaluation 
suggests that the multiplex assay can be used directly on clinical specimens and will 
provide rapid, sensitive and specific results compared to culture methodologies. 
 
ID104. Performance of the Sofia Fluorescent Immunoassay for Influenza A and B 
Versus Culture and PCR and Detection of 2009 H1N1 and Seasonal H3N2 
L. Mimms 
Quidel Corporation, San Diego, CA. 
Introduction: The 2009 influenza pandemic underscored the need for rapid diagnostic 
tests with improved clinical performance and raised concerns about the ability of rapid 
influenza detection tests (RIDT) to accurately detect the novel 2009 H1N1 strain. 
Variants of this strain are still circulating today and comprise approximately 19% of 
typed influenza A viruses in 2011-2012. The Sofia Influenza A+B FIA was recently 
release for the detection of influenza A and B virus. This test uses novel detection 
chemistries and automated fluorescent reader capabilities that are superior to the rapid 
tests available during the 2009 pandemic. This study reports on the performance of the 
Sofia Influenza A+B FIA versus culture and RT-PCR and demonstrates its ability to 
detect not only the 2009 H1N1, but seasonal H3N2 during the 2010-2011 respiratory 
season. Methods: Materials and Methods: The Sofia Analyzer, Sofia Influenza A+B FIA 
was supplied by Quidel. The culture method used R-Mix-2TM shell vials supplied by 
Diagnostic Hybrids, Inc. RT-PCR was performed using the Prodesse ProFLU+, and 
Prodesse ProFAST+. This study was conducted in early 2011. Specimens were 
collected from 959 consented patients with influenza-like illness (ILI) within 48 hours of 
onset of symptoms. Two nasal swabs (NS) or nasopharyngeal swabs (NPS) were 
collected per patient. One swab was tested according to the Sofia Influenza A+B FIA 
package insert. The second swab was inserted into 1.5 ml of UTM for testing with RT-
PCR assays. All specimens were tested within 24 hours of collection. Specimens were 
transported on wet or blue ice and were not frozen before testing. Results: Compared 
to culture, the Sofia test yielded 96.3% sensitivity and 97.4% specificity for influenza A 
and 92.3% and 97.9%, respectively for influenza B. Compared to PCR, the Sofia test 
yielded 80.7% sensitivity and 99.3% specificity for influenza A and 86.1% and 97.8%, 
respectively for influenza B. For PCR-specimens with Ct counts  30, Sofia detected 
96% that were PCR positive for A and 98% that were PCR positive for B. The Sofia 
detected 92.1% (117/127) of the seasonal specimens subtyped as H3N2, and 92.7% 
(51/55) of the specimens subtyped as 2009H1N1. Conclusions: Sofia Influenza A+B 
FIA demonstrates high clinical accuracy versus the culture and RT-PCR and also 
demonstrates excellent sensitivity and specificity for circulating variants of the H3N2 
and 2009 H1N1 influenza A viruses. This level of performance combined with its rapid 
turn-around time supports the use of Sofia Influenza A+B FIA. 
 
ID105. Design, Development, and Performance Characteristics of the CE-Marked 
IMDx VanR for Abbott m2000 Assay 
S. Bradley, H. Reiske, C. Leslin, A. Jacobs, R. Del Mastro 
IntelligentMDx, Cambridge, MA. 
Introduction: Vancomycin-resistant Enterococci (VRE) infections are a major cause of 
health care-associated infections, leading to increased treatment costs and longer 
hospital stays. We have addressed the need for rapid and sensitive tests for the 
detection and differentiation of the vanA and vanB genes most commonly found in VRE 
through development of the IMDx VanR for Abbott m2000 assay. Methods: IMDx has 
employed its proprietary bioinformatics platform, NGENix, to design an in silico 
screened, qualitative, multiplexed, real-time PCR-based assay for VRE detection. The 
assay was designed to qualitatively detect and differentiate the vanA and vanB genes in 
VRE strains from E. faecium MMC4 and E. faecalis V583. The IMDx VanR for Abbott 
m2000 assay is validated for use with human peri-rectal or rectal swabs or stool 
samples from patients at risk for VRE colonization. Sample extraction is performed on 
the Abbott m2000sp and amplification and detection is performed on the Abbott 
m2000rt. This study evaluated the analytical and clinical performance characteristics of 
the IMDx VanR for Abbott m2000 assay. Results: The IMDx VanR for Abbott m2000 
assay is highly specific for its intended targets, reacting with 2 strains of E. faecium and 
3 strains of E. faecalis. No cross reactivity was observed when tested against 60 
viruses and microorganisms. No interference was observed in the presence of 
commonly used substances, such as over the counter medications frequently used at or 
around the sampling site. The limit of detection was determined to be 95.0 CFU/mL for 
vanA in E. faecium strain MMC4 and 170.3 CFU/mL for vanB in E. faecalis strain V583. 
Direct analysis of 158 rectal or peri-rectal swab samples demonstrated 96.3% 
sensitivity and 93.9% specificity as compared to standard culture. A total of 576 tests 
were performed in precision studies and demonstrated <4% CV of FCN for all variables. 
Conclusions: With minimal hands-on time, the IMDx VanR for Abbott m2000 assay 
can process up to 94 patient samples in less than 4 hours. The flexible throughput 
capacity and the performance of the IMDx VanR for Abbott m2000 make it a useful tool 
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for the control of VRE infections. The assay was CE-marked in 2011. The IMDx VanR 
for Abbott m2000 assay is not available for sale in the US or Canada. 
 
ID106. Molecular Detection of Chlamydia trachomatis and Neisseria 
gonorrhoeae Using SurePath Liquid-Based Pap Specimen Media with the COBAS 
4800 SYSTEM 
M.J. Bankowski, S. Ono, C. Ying, T. Koyamatsu, W. Kim 
DLS and The Queen's Medical Center, Aiea, HI. 
Introduction: C. trachomatis (Ct) is the most frequently reported bacterial sexually 
transmitted disease (STD) in the United States and ranks second in the world. N. 
gonorrhoeae (Ng) cases also account for as many as 700,000 new cases/year. A 
spectrum of disease presentations exists for these agents in both sexes, ranging from 
urethritis to pelvic inflammatory disease (PID). Nucleic acid amplification exhibits the 
highest values in test performance compared to other laboratory testing. The present 
study evaluates the test performance of a novel test using a duo target approach on the 
cobas 4800 system using the SurePath Liquid-based Pap Specimen Media. Methods: 
SurePath specimens (n = 96) were tested from patients submitted for Ct and Ng testing. 
Testing for Ng also consisted of N. gonorrhoeae spiked specimens. The 4800 system is 
completely automated and consists of the cobas x 480 for nucleic acid extraction and 
the cobas z 480 for real-time PCR. The 4800 system was compared to the cobas 
MagNA Pure - cobas Amplicor and our in-house LDT LightCycler confirmatory assay. 
Results: In total, 96 SurePath specimens were tested for C. trachomatis and N. 
gonorrhoeae. The results showed a 27.1 % (26/96) positivity rate for C. trachomatis 
with 3/26 positive only with the 4800 with high Ct values. The C. trachomatis Ct values 
for both test systems compared favorably at R² = 0.9096. The positivity rate for varying 
quantities of N. gonorrhoeae was 18.8% (18/96) with 8/11 negative at 10 CFU/ml, which 
is around the LOD for the test. The cobas 4800 system was 100% sensitive and 95.9% 
specific for Ct. In addition, the technologist time spent on the LDT was approximately 
4.6 fold higher for hands-on-time and 7.5 fold higher for hands-off-time compared to the 
cobas 4800 system. Conclusions: The cobas 4800 system is completely automated 
and compared very favorably using SurePath Liquid-based Pap Specimen Media with 
the performance of the Cobas MagNA Pure - Cobas Amplicor and the LDT LightCycler 
assay currently in use in our laboratory. The time savings is very desirable compared to 
the current laborious scheme used to screen and confirm Ct and Ng in our laboratory. 
ID107. Isothermal Amplification and Detection of Group A Streptococci from 
Throat Swabs Using illumigene Group A Strep 
J.E. Mortensen1, D. Mayne2 
1Cincinnati Children's Hospital, Cincinnati, OH; 2Sacred Heart Hospital, Pensacola, FL. 
Introduction:  illumigene Group A Streptococcus (not FDA cleared) is a rapid and 
simple molecular assay (Meridian Bioscience Inc., Cincinnati, OH) that uses loop-
mediated isothermal amplification (LAMP) technology to detect Streptococcus 
pyogenes. It is designed to target a conserved exotoxin gene of the S. pyogenes 
genome. The reaction is performed on the Meridian illumipro-10 incubator/reader under 
isothermal conditions. Following DNA amplification, magnesium-pyrophosphate is 
produced as a by-product resulting in turbidity that is measured by the instrument. 
Methods: Duel throat swab samples were collected and submitted to the laboratory in a 
non-nutritive transport medium. A single throat swab was used first for conventional 
culture on 5% sheep blood agar and then the same swab was directly tested by the 
illumigene Group A Strep assay without any culture enrichment. Discrepant results 
were assessed using real-time PCR assay (ASR) at a reference laboratory. Blood-Agar 
grown and quantified stocks of two S. pyogenes strains were used to determine the 
Limit of detection (LoD). Cross-reactivity and inhibition was assessed using 52 non-
GAS bacteria and human genomic DNA. Results: 462 total specimens were tested by 
illumigene and culture. Culture and illumigene were positive on 53 samples, negative on 
393 samples, there were 12 samples positive by illumigene that were culture negative 
and 2 samples were invalid. Culture did detect 2 Group A Strep that was not detected 
by illumigene. Results with a reference PCR assay confirmed Group A Strep in 11/12 
discrepant samples. The overall resolved sensitivity and specificity performance for 
illumigene was 97.0% and 99.7% respectively. The invalid rate was 0.4%. A LoD of 
approximately 160 cfu/test was determined for S. pyogenes. No inhibition or cross-
reactivity observed with the bacteria and human genomic DNA. Conclusions: The 
illumigene Group A Streptococcus assay is a rapid and sensitive method for the direct 
detection of Streptococcus pyogenes from throat swab samples. 
 
ID108. Clinical Evaluation of the Great Basin Clostridium difficile Assay and the 
BD GeneOhm Cdiff ACP Assay for the Rapid Detection of Clostridium difficile 
Toxin B Gene in Fecal Specimens 
D.D. Fuller, K.L. Newcomer, A.L. June, J.D. Talbott, R.J. Buckner, T.E. Davis 
Wishard Health Services-Indiana University School of Medicine, Indianapolis, IN. 
Introduction: Clostridium difficile (Cdiff) is one of the most common and deadly 
hospital-acquired infections (HAIs) affecting nearly 700,000 people in the US annually 
according to the CDC. With the number of Clostridium difficile infections (CDI) on the 
rise, accurate and rapid diagnosis is imperative to aid in therapy selection, improve 
patient outcome, prevent disease spread and lessen negative impacts on healthcare 
systems. This evaluation compared the performance of the Great Basin Cdiff Assay 
(GBCA) and the BD GeneOhm Cdiff ACP Assay (BDCA) for the rapid detection of Cdiff 
toxin B gene (tcdB) in fecal specimens. Great Basin technology entails an integrated 
disposable cartridge that contains all necessary reagents and an inexpensive bench-top 
analyzer that executes the assay, interprets the results and provides electronic output 
all in about 90 minutes. The BD GeneOhm assay (utilizing the Cepheid SmartCycler) is 
performed directly on the specimen, utilizes polymerase chain reaction (PCR) for the 
amplification of specific targets and fluorogenic target-specific hybridization probes for 
the detection of the amplified DNA. Methods: Surplus, de-identified, liquid to soft stool 
samples from patients suspected of CDI were tested with both Great Basin’s Cdiff 
assay (utilizing their bench top analyzer) and BD GeneOhm’s Cdiff ACP assay. Each 
stool was collected, processed, and tested according to the institution’s standard of 
care and each assay was performed according to manufacturer’s package insert 
instructions. Results: To date, 75 stool samples have been included in this evaluation 
yielding 48 that tested negative with both GBCA and BDCA whereas 27 tested positive 
with both assays yielding 100 percent agreement. Conclusions: The Great Basin 
Clostridium difficile Assay utilizing the benchtop analyzer exhibited excellent sensitivity 
and specificity (100%), was easy to perform with no more than two or three hands-on 
steps, fit easily in to laboratory workflow and provided a rapid turn-around-time. 
 
ID109. Design and Development of a Fully Automated Assay for Detection and 
Differentiation of HSV-1 and HSV-2: The IMDx HSV-1/2 for Abbott m2000 
S. Bradley, H. Reiske, J. Salcius, B. Lauzier, C. Leslin, A. Jacobs, R. Del Mastro 
IntelligentMDx, Cambridge, MA. 
Introduction: Infection with herpes simplex viruses (HSV-1 and HSV-2) is one of the 
most prevalent sexually transmitted infections, affecting an estimated 4 billion people 
worldwide. Because HSV can cause lifelong infection with ramifications for health, 
relationships, and pregnancy, a laboratory diagnosis is essential to provide critical 
prognostic and management information for clinicians and patients. The IMDx HSV-1/2 
for Abbott m2000 assay provides an automated molecular diagnostic option to replace 
current time-consuming culture methods used for detection and differentiation of HSV-1 
and HSV-2. Methods: IMDx has employed its proprietary bioinformatics platform, 
NGENix, to design an in silico screened, qualitative, multiplexed, real-time PCR-based 
assay for the detection and differentiation of conserved gene regions in HSV-1 and 
HSV-2 viruses. The IMDx HSV-1/2 for Abbott m2000 assay is validated for use with 
male and female genital or oral lesions from patients. Sample extraction is performed 
on the Abbott m2000sp and amplification and detection is performed on the Abbott 
m2000rt. This study evaluated the analytical and clinical performance characteristics of 
this newly designed assay. Results: The IMDx HSV-1/2 for Abbott m2000 assay is 
highly specific for HSV-1 and HSV-2, differentiating both viruses in all sample types 
tested. No cross-reactivity or interference was observed in the presence of 43 
potentially interfering organisms or 22 endogenous and exogenous compounds. After 
testing 109 swab samples, the IMDx HSV-1/2 for Abbott m2000 demonstrated 100% 
sensitivity and 98% specificity for HSV-1 compared to standard culture. Likewise, after 
testing 110 swab samples, the assay demonstrated 100% sensitivity and 97% 
specificity for HSV-2, compared to standard culture methods. In initial studies, the limit 
of detection of the IMDx HSV-1/2 for Abbott m2000 assay was calculated as 10.81 
TCID50/mL for HSV-1 and 0.58 TCID50/mL for HSV-2. Conclusions: The IMDx HSV-
1/2 for Abbott m2000 assay provides results for 94 patient samples in under 6 hours 
and eliminates the hands-on time often required for sample extraction. The assay offers 
a highly sensitive and accurate method for detection and differentiation of HSV-1 and 
HSV-2, helping physicians make confident patient management decisions. The IMDx 
HSV-1/2 for Abbott m2000 assay will be CE-marked in 2012. The IMDx HSV-1/2 for 
Abbott m2000 assay is not available for sale in the US or Canada. 
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ID110. Evaluation of the Quidel Amplivue C. difficile Assay for Qualitative 
Detection of Toxigenic Clostridium difficile Compared to Cell Culture Cytotoxicity 
Neutralization and Xpert C. difficile Assays 
P. Pancholi1, P.A. Granato2, N.A. Ledeboer3, J. Dunn4, M. Raczkowski1, L. Swyers1, 
B.R. Alkins2, B.W. Buchan3, T. Biney-Assan3, T. Stenzel5 
1The Ohio State University Wexner Medical Center, Columbus, OH; 2Laboratory 
Alliance of Central New York, Liverpool, NY; 3Medical College of Wisconsin , 
Milwaukee, WI; 4Justin Rogers Cook Children’s Medical Center, Fort Worth, TX; 
5Quidel, San Diego, CA. 
Introduction: Clostridium difficile (CD) is the most important cause of nosocomially- 
acquired diarrhea. Laboratory techniques to identify toxigenic CD in fecal specimens 
include toxigenic culture, cell culture cytotoxicity neutralization assay (CCNA), lateral 
flow, microplate immunoassays and DNA detection. We evaluated the performance of 
the Quidel AmpliVue assay, a novel isothermal, instrument-free molecular assay 
compared to CCNA and the Xpert C. difficile assay for detection of pathogenic CD in 
diarrheal stool samples. Methods: The AmpliVue C. difficile assay combines 
isothermal, helicase-dependent amplification (HDA) with a disposable self-contained 
detection device that allows for the rapid detection of labeled amplicons generated by 
primers and probes specific for a region present in the tcd A gene found in all known 
toxigenic strains of CD. A process control monitors for sample processing, amplification 
and detection. First, a swab from a patient sample is placed into a dilution tube. An 
aliquot from this tube is briefly heated to lyse the cells and transferred to a reaction tube 
containing lyophilized HDA reagents. After incubation at 64 degrees centigrade for 60 
minutes, the HDA tube is placed in the lateral flow cassette where the presence of toxin 
and/or internal control is visualized within 10 minutes. The CCNA (DHI) and Xpert C. 
difficile assays were performed per the manufacturer’s instructions. Discordant results 
were analyzed by sequence analysis or a second commercially available IVD molecular 
assay. Results: A total of 672 evaluable stool samples were enrolled. Of these, 77 of 
79 CCNA positives were also AmpliVue positive (sensitivity 97.5%). Only one of the two 
AmpliVue-negative specimens was positive by an alternate commercially available IVD 
molecular assay. Thirty-four samples were CCNA negative/AmpliVue positive 
(specificity 94.3%). Of these, 29 confirmed positive by an alternate commercially 
available IVD molecular assay. The AmpliVue and Xpert assays were in agreement with 
111 positive and 543 negative stools. Two samples positive by AmpliVue were negative 
by Xpert. Sixteen samples were positive by Xpert and negative by AmpliVue. Upon 
discordant resolution, the positive percent and negative percent agreement was 93.3% 
and 99.8%, respectively. Conclusions: Quidel AmpliVue C. difficile assay is highly 
specific and significantly more sensitive than cytotoxin cell culture. The AmpliVue assay 
showed a slightly reduced sensitivity as compared to the Xpert. The entire assay is 
performed in less than 1.5 hrs and can be performed “on-demand” eliminating the need 
to batch samples. 
ID111. Development and Evaluation of a Novel, Rapid, Extraction-Free, Real 
Time PCR Assay for the Detection of Clostridium difficile from Stool Specimens 
Targeting Both tcdA and tcdB
T.A. Ranalli, T.R. Ott, V. Armendarez, H. Liang, J. Ahle, J. de Leon, T. Curtiss, J. 
Pappas, R. Lollar, T. Pack, T. Stenzel 
Quidel, San Diego, CA. 
Introduction: Cytotoxic Clostridium difficile is a gram-positive, anaerobic, spore 
forming bacillus capable of producing Clostridium difficile associated diarrhea (CDAD), 
or pseudomembranous colitis. These symptoms are the result of the presence of either 
one or both of two related cytotoxins – toxin A and toxin B. The genes for toxin A and 
toxin B (tcdA and tcdB, respectively) are located together within the Pathogen Locus, or 
PaLoc. Within those strains that contain a pathogen locus, there are significant genetic 
differences including point mutations, frame shifts, insertions and several hundred 
base-pair deletions. The development of an assay targeting both genes would therefore 
provide additional levels of assurance of detection of C. difficile. Methods: Initial 
studies were performed with newly developed simple-to-use sample processing 
reagents and the Quidel Molecular (QM) Direct C. difficile Tox A/B Assay on the Applied 
Biosystems 7500 FastDx. Primers and probes were designed to detect both the tcdA 
and tcdB regions with the same fluorophore to allow for redundant detection. Sample 
processing reagents are stable at room temperature and the PCR reagents are 
lyophilized and stable at 4°C. The overall time from sample to result is about an hour 
for small batch sizes. One hundred thirty-one (131) fresh clinical samples were tested 
with both the QM and BD GeneOhm assays. Results: The BD GeneOhm assay 
detected 24 C. difficile-positive specimens and 23/24 tested positive in the QM assay. 
There was 1 additional C. difficile-positive specimen with the QM assay. 106 specimens 
were negative in both assays. Preliminary studies demonstrated assay reproducibility, 
inclusivity and analytical specificity with the chosen primers and probes and a limit of 
detection of  9.50E-01 CFU/assay, depending on the strain. Patient samples were 
shown to be stable in the sample processing buffers at 4 degrees centigrade and/or 
room temperature for up to one month. Conclusions: These preliminary results 
indicate this novel, easy-to-use, rapid assay for C. difficile is both sensitive and specific. 
 
ID112.  Comparison of Two Methods for Detection of Adenovirus from 
Respiratory Samples 
O. Jedry1, B. Baltadjieva1, L. Mazur1, M. Mihalov2 
1ACL Central Laboratory, Rosemont, IL; 2Lutheran General Hospital/ACL Laboratories, 
Park Ridge, IL. 
Introduction: Human adenovirus (HAdV) was the first respiratory virus to be isolated 
and characterized and has been persistent in the global population. To date, 57 HAdV 
genotypes have been identified and are classified according to their immunochemical 
properties, nucleic acid similarities, hexon and fiber protein characteristics, biological 
properties, and phylogenetic analysis. These 57 adenovirus genotypes all infect 
humans are classified into seven species (Human adenovirus A to G) with HAdV B, C 
and E mainly responsible for acute respiratory disease (ARD). Several manufacturers 
offer clinical assays that vary in the specific genotypes and species detected. This study 
evaluates the performance of two comertially available kits. Methods: According to the 
GenProbe product insert, the ProAdeno+ kit is capable of detecting 51 of 54 tested 
HAdV genotypes covering all species (A-G). Based on the Luminex product insert, the 
xTAG RVP kit will detect most of the genotypes and species but sensitivity may be 
compromised if low viral copies are present for genotypes: 7a (species B), 41 (species 
F), 1, 2, 5, and 6 (species C). In this study we tested retrospectively and prospectively 
493 respiratory samples collected by nasal pharyngeal (NS) swabs in UTM media. All 
samples were tested by two FDA IVD kits: (1) GenProbe Prodesse ProAdeno+ kit run 
on ABI 7500 Fast instrument and (2) xTAG RVP (Respiratory Viral Panel) kit from 
Luminex run on Eppendorf MasterCyler and LX200 instrument from Luminex. Samples 
were extracted using Abbott m2000sp. To minimize variability of the extraction the 
same elution was utilized for both assays. Results: Both methods demonstrated 99.8% 
agreement in testing clinical samples: 51/50 positive, 442/443 negative with one 
discrepant sample positive by ProAdeno+ assay. Clinical sensitivity and specificity for 
ProAdeno+ was 100%; clinical sensitivity and specificity for xTAG RVP were 99.8% and 
98% respectively. Conclusions: The study suggests that both FDA IVD assays tested 
by our laboratory have similar performance characteristics despite differences in the 
manufacturers’ claims: ProAdeno+ (100%,100%) vs kit insert data (95.6%, 97.5%) and 
xTAG RVP (98%, 99.8%) vs kit insert data (78.3%, 100%).  
OTHER (EDUCATION, ETC.) 
 
OTH01.   Analytical Validation of a Multi-Analyte Serum Protein Based Test for 
Assessing Coronary Heart Disease Risk 
N. Nolan1, L. Tee1, S. Vijayakumar1, I. Burazor2, E. Hytopoulos1, W.H. Biggs1, M. 
Beggs1, C. French1, D. Harrington1 
1Aviir Inc, Irvine, CA; 2University of Nis, Nis, Serbia. 
Introduction: Coronary Heart Disease (CHD) remains a leading cause of morbidity and 
mortality despite efforts to develop improved methods for CHD risk assessment. Over 
half of the individuals who present with a severe cardiac event, such as Myocardial 
Infarction (MI) or Unstable Angina (UA), have at most one risk factor as included in the 
commonly used Framingham Risk assessment. This underscores the insufficiency of 
relying on typical risk factors to identify subclinical cardiovascular disease. The Aviir 
TruRisk assessment, a clinically validated, multi-analyte immunoassay was developed 
to improve upon the assessment of CHD risk in individuals currently identified as 
intermediate risk. Here we describe the development and analytical validation of the 
novel biomarker assays comprising the TruRisk panel. Methods: Multiplexed 
immunoassay panels (Luminex xMAP and MesoScale Discovery MULTI-SPOT 
technologies) were developed to contain the seven serum protein assays used in the 
TruRisk CHD risk assessment algorithm. Commercial control and donor serum samples 
were used to evaluate the specificity, sensitivity, interfering substances, and 
reproducibility of the TruRisk assessment panel. The effects of pre-analytical specimen 
processing on the protein measurements were also evaluated. Results: Individual 
analytical measurements for all proteins (CTACK, eotaxin, Fas ligand, HGF, IL-16, 
MCP-3 and sFas) included in the TruRisk panel were found to exhibit accuracy (100% 
+/- 30%), cross-reactivity (<1%), interference (<30% at high concentrations of bilirubin, 
lipid, hemoglobin, and HAMA), sensitivity (limits of detection: 2.8, 4.9, 5.5, 3.4, 3.4, 1.4, 
and 0.5 pg/mL, respectively) and reproducibility (<30% CV maintained across 
independent runs, multiple operators, and multiple instruments) within the specifications 
established during the clinical validation studies. Recoveries of all seven analytes when 
subjecting the donor sera to typical clinical laboratory pre-analytical conditions were 
within 100% +/- 30% after 30 min serum clotting time followed by up to 72 hr of 2°C to 
8°C storage before freezing at -20°C. The calculated CHD risk scores for the donors 
were not substantively impacted by the pre-analytical handling variables resulting in the 
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same risk level assessment per donor. Conclusions: The operational performance 
demonstrated during the analytical validation of the TruRisk assessment in a clinical 
laboratory setting meets or exceeds the specifications established during test 
development and the clinical association studies used to validate clinical utility. The 
high reproducibility of the risk score within the same individual across multiple test 
scenarios suggests the assays are not susceptible to pre-analytical and analytical 
sources of variation typically encountered in clinical testing labs. 
 
OTH02.   Innovative Web-Based Educational Resource in Molecular Pathology for 
Undergraduates, Medical Students and Residents 
A.J. Zarbo1, D. Chitale2, M. Cankovic2 
1Wayne State University, Detroit, MI; 2Henry Ford Hospital, Detroit, MI. 
Introduction: The Internet provides ready access to the latest medical information and 
is embraced by the current generation of medical students. Molecular Pathology (MP) is 
a field of exponential growth that defines the future of personalized medicine and 
targeted therapeutics. Due to its constantly evolving nature, individuals desiring 
proficiency in MP may be overwhelmed with multiple resources. In an effort to increase 
competency of undergraduates, medical students, and residents planning to do a 
molecular rotation, our aim was to create an orientation/educational website to be 
viewed in advance to maximize the learning experience in the MP laboratory 
supplementing didactic lectures and compulsory lab rotations. Methods: A website was 
created to make all information available in a user-friendly format providing choice to 
accommodate different interests. Emphasis was placed on molecular tests, techniques, 
and specialties employing molecular diagnostics. Quizzes were included to test 
comprehension in the form of pretest and posttests. Expectations during rotations for 
undergraduates, medical students, and residents were included. Research projects of 
current and past residents were featured to demonstrate potential avenues for further 
research. A search bar specific to the website enabled immediate search capability. 
Local undergraduates, medical students, and residents were surveyed to examine the 
educational impact. Results: Of 26 survey respondents, 38.5% were in medical school; 
38.5% in residency; 19.2% in undergraduate studies; 3.8% in high school. 92.3% would 
feel more prepared in viewing an educational website prior to the visit to the laboratory. 
96.2% satisfaction was evident with the review of MP and techniques; 100% with the 
information about molecular tests; 100% with the specialties with MP diagnostics (of 
92.3% who reviewed); 96.2% with MP clinical significance and interpretation of tests (of 
96.2% who reviewed); all with the quizzes as a learning tool (of 53.8% who reviewed); 
95% with the personalized expectations (of 76.9% who reviewed). Furthermore, 
Pathology residents appreciated the taxonomy of MP abnormalities by clinical specialty 
and quizzes as a means of board review. Conclusions: The 21st Century demands the 
sharing of information through technology. This website offers succinct and frequently 
updated information about MP, all of which can be searched and accessed through a 
computer, tablet device, or smartphone. This innovative web-based approach to 
education was embraced overwhelmingly at all education levels and therefore will be 
provided to rotators in MP to enhance both self-directed learning and subsequent 
hands-on experience during the laboratory rotation. 
 
OTH03.   Utilization Review: Value Added Care That Makes Cents 
J. Laser, S. Deonandan, C. Sreekantaiah, J. Crawford 
North Shore-LIJ Health System, Manhasset, NY. 
Introduction: The United States spends more per capita on healthcare than any other 
nation in the world, without achieving better healthcare outcomes compared to peer 
countries. At the core of the problem is unexplained variation in clinical practices. In the 
realm of laboratory diagnostics, potential over utilization of esoteric tests contributes to 
excessive cost, without necessarily improving the quality of health care. We are actively 
intervening through the use of two processes to reduce: (a) inappropriate inpatient 
reference testing (all tests), and (b) excessive in-house testing, particularly oncologic 
FISH tests. Methods: 1) Inpatient reference testing: We created a simple four question 
algorithm to determine which tests were appropriate for the inpatient setting, based on 
the premise of medically necessary inpatient tests are those that will have direct 
influence on that hospital admission. Tests that did not meet the requirements were 
deferred to the outpatient setting. 2) In-house oncologic FISH testing: A process was 
developed to review and correlate each FISH request to other diagnostic tests (bone 
marrow biopsy / flow cytometry) to determine clinical value. Requests that did not add 
value, given other diagnostic results, were cancelled in consultation with the ordering 
provider. Results: 1) Inpatient reference testing: In 2011 (January-December), the 
approval algorithm identified 61 test requests that did not add value to inpatient 
management. This accounted for 8.3% of all inpatient reference testing requests and 
resulted in $48,000 in direct savings to the hospital. The valuation was a 23.8% 
reduction in costs had this process not been in place. 2) In-house FISH testing: Over a 
9 month period (July 2011- March 2012) review of retrospective and concurrent lab 
results identified 881 FISH probe requests that did not add value to the clinical 
management of the patient. This accounted for 11.4% of all FISH probe requests and 
resulted in $154,000 in cost reduction (reagent and technical costs) over the nine month 
period. Conclusions: Patient-centric utilization review is one of many tools available to 
reduce ordering variation. We successfully employed a rigorous "gatekeeper" 
methodology to reduce unnecessary "low volume / high cost" testing. Although 
significant effort was needed to evaluate each request; the financial outcome was 
favorable given the high costs associated with these tests.  
 
OTH04.   Pyrosequencing: An Educational Module 
M.T. Olson, E. Lin, C. Harrington, J.R. Eshleman 
The Johns Hopkins Hospital, Baltimore, MD. 
Introduction: To provide molecular diagnostics services, clinical molecular labs 
continually train new technologists, residents, and fellows in new techniques and data 
interpretation. Pyrosequencing constitutes a challenge to training because the 
“sequencing-by-synthesis” approach can be difficult to conceptualize for newcomers. 
Additionally, the development of increasingly sophisticated automated interpretation 
techniques raises the difficulty level of pyrograms that require manual review and 
makes the need for trained personnel all the more relevant. Methods: We used 
Pyromaker (http://pyromaker.pathology.jhmi.edu) to generate educational exercises. 
This free and publically available program takes user inputs of pyrosequencing 
parameters (wildtype and mutant sequences, whether the mutation is heterozygous or 
homozygous, and the % tumor cells) and renders a virtual pyrogram that can be used to 
teach the trainee about pyrosequencing fundamentals and the critical function those 
parameters play in the implementation of the method and interpretation of the data. 
Trainees work through a series of 5 exercises designed to demonstrate the core 
concepts involved. The exercises include: generation of a wild-type sequencing 
pyrogram, generation of a pyrogram from a single point mutation, the effect of using a 
cyclic dispensation order versus an optimized one, the use of partitioned pyrograms to 
understand how the pyrosequencing signal is generated, and the identification of a 
pyrogram that is out-of-register. Results: Although its clinical utility has been discussed 
elsewhere, we demonstrate an educational module for training that is now available for 
free through the Pyromaker website. With a computer and internet connection, any user 
can access this training module and learn pyrosequencing fundamentals and analysis. 
The introduction includes background information to explain sequencing basics to new 
users with minimal education in molecular techniques, and the directions are easy to 
use. The exercises come with a thorough description of why the pyrogram looks the 
way it does. Conclusions: The Pyromaker educational module is a valuable tool for 
molecular labs hoping to educate staff and other trainees in the manual interpretation of 
pyrograms. It may also prove valuable to pathologists who are not familiar with 
pyrosequencing. This new feature of Pyromaker is especially timely given both the 
increasing use of pyrosequencing and the growing availability of automated techniques 
that recognize easier pyrograms and spot ones that require knowledgeable laboratory 
personnel. 
 
OTH05.   IMPDH mRNA Expression after Mycophenolic Acid Administration in 
Male Volunteers 
S. Kim1, H. Kang2, W. Lee2, S. Chun2, W. Min2 
1Ilsan Paik Hospital, Inje University College of Medicine, Republic of Goyang, Korea; 
2University of Ulsan College of Medicine and Asan Medical Center, Republic of Seoul, 
Korea. 
Introduction: Mycophenolic acid (MPA) is widely used for preventing acute rejection in 
solid organ transplantation. The immunosuppressive effect of MPA occurs through 
inhibition of inosine monophosphate dehydrogenase (IMPDH) on lymphocytes. It has 
been reported that IMPDH mRNA expression could be a useful pharmacodynamic 
marker for MPA. However, study results are not consistent. The aim of this study was to 
investigate the gene expression of 2 IMPDH isoforms during in vivo exposure to MPA. 
Methods: To reduce other causes of variability, we performed a genotyping assay for 
10 SNPs that are influenced by the drug in a total of 70 healthy male volunteers. Six of 
the volunteers with the same genotypic pattern were given a single dose of 1000 mg 
MPA. Blood was sampled pre-dose and at 1, 2, 3, 4, 6, 8, and 10 h post-dose. The 
experiments were repeated 1 week later using the same 6 volunteers. The expression 
of IMPDH1 and IMPDH2 were quantified in mononuclear cells by previously developed 
real-time RT-PCR. The mononuclear cells were isolated within 1 h of sampling and 
lysed in a guanidine thiocyanate buffer. All gene expression measurements were 
performed in quadruplicate. Target gene expression was normalized to the 
housekeeping gene, ACTB. Total MPA and free MPA concentration were analyzed. 
Results: The assay was linear over 8 logs of cDNA input and demonstrated specific 
quantification of IMPDH1 and IMPDH2 expression in patient samples. The limit of 
detection and quantification were 2 copies of cDNA per reaction. Within-run CVs were 
<15% for normalized expressions. However, changes in IMPDH1 and IMPDH2 
expression were highly variable and even showed different expression patterns in the 
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same individual after the second dose of MPA. There was no correlation between 
expression levels and MPA concentration. Conclusions: Theoretically, IMPDH mRNA 
expression is a proper pharmacodynamic marker because of the mechanism of action 
of MPA. However, it is not yet practical to measure the IMPDH mRNA expression in 
clinical practice, because the results are highly variable, as shown by our study.  
 
SOLID TUMORS 
 
ST01. Mutational Analysis of EGFR, KRAS and BRAF in Advanced 
Cholangiocarcinoma and Association with Clinical Outcomes – An Interim Report 
of a Phase II Trial  
D. Sohal, U. Teitelbaum, T. Uehara, K. Mykulowycz, C.D. Watt, N. Damjanov, B. 
Giantonio, M. Carberry, P. Wissel, M. Jacobs-Small, P. O'Dwyer, W. Sun, A.R. 
Sepulveda, W. Sun 
University of Pennsylvania, Philadelphia, PA. 
Introduction: Cholangiocarcinoma is an aggressive neoplasm. There are scant data on 
the molecular biology of this disease, due to it being an uncommon cancer, and poor 
patient survival, making large, well-controlled prospective studies difficult to conduct. 
Available retrospective data indicate that the epidermal growth factor receptor (EGFR) 
pathway is associated with tumor stage and overall prognosis. Agents targeting the 
EGFR pathway may have clinical utility in this disease, and mutations in signal 
transduction molecules in this pathway, such as EGFR, KRAS and BRAF, may play a 
role in response to therapy to such agents. We performed mutational analysis of 
samples collected during an ongoing phase II trial of gemcitabine, irinotecan, and the 
EGFR antibody, panitumumab, to assess if such mutations were associated with 
response to therapy. Methods: An ongoing phase II trial [NCT00948935] is enrolling 
patients with advanced (unresectable or metastatic) cholangiocarcinoma, to be treated 
with panitumumab on day 1, and gemcitabine and irinotecan on days 1 and 8 of a 21-
day cycle. Tissue specimens for molecular analyses were diagnostic biopsy, fine needle 
aspirates, or resection specimens. Analyses of EGFR (exon 19 deletion; L858R), KRAS 
(codons 12, 13), and BRAF (V600E) were done on samples with adequate material for 
testing. Results: Data on 27 patients are available. A median of 8 (0-30) cycles were 
administered. During the study, 3 patients had complete response (with 2 patients 
undergoing complete surgical resection), 6 had partial response, and 11 had stable 
disease (disease control rate of 74%). Two patients had progressive disease, with 5 
patients going off study prior to first assessment scan (not evaluable). Median overall 
survival is 12.7 months. There were 17 testable tissue samples, including 5 cytology 
samples and 12 biopsy or resection specimens. There were no EGFR or BRAF 
mutations identified. There were 7 KRAS mutations (41% of tested samples); three 
G12D, two G12V, and two G13D. However, KRAS mutation status was not significantly 
associated with overall survival or response; one patient with a G12D mutation had a 
complete response. Conclusions: Molecular analyses of EGFR, KRAS and BRAF are 
feasible from small tissue samples in advanced cholangiocarcinoma. KRAS mutations 
are frequently seen. There appears to be no association of KRAS mutational status with 
response to EGFR antibody therapy. Broader mutational analyses of signaling 
pathways and possibly combinations of targeted therapies may be needed to identify 
the role of EGFR pathway genes and therapies in cholangiocarcinoma. 
 
ST02. Global Profiling of Signaling Networks of Papillary Thyroid Carcinoma: 
Emphasis on the Potential Protein Biomarkers 
K. Huang1, F. Ye2, M. Cui2, A. Han1, D. Zhang2, Y. Li1 
1The First Affiliated Hospital Of Sun Yat-Sen University, Guangzhou, China; 2Mount 
Sinai School Of Medicine, New York, NY. 
Introduction: Thyroid cancer is the most common endocrine malignant tumor 
comprising 91.5% of all endocrine malignancies. Papillary Thyroid Carcinoma is the 
most common thyroid malignancy, representing 80% to 85% of all thyroid malignancies 
in United Stated (Papillary thyroid carcinoma: an update) and the incidence is growing 
fast (Thyroid Cancer Epidemiology and Prognostic Variables). Early accurate diagnosis 
and treatment are significant to reduce the mortality. Despite many genetic markers of 
PTC have been identified, such as RET/RAS/BRAF/MAPK pathway, the rate of these 
mutations is low. The goal of this study was to identify potential protein biomarkers and 
to explore the potential pathways involved in PTC. Methods: We profiled 65 
proteins/phosphoproteins in 27 pairs of PTCs and their normal thyroid tissue 
counterparts using Protein Pathway Array (PPA). The values of the expression and 
phosphorylation were normalized by Z-score. Data were analyzed by SAM to detect 
differentially expressed proteins. The pathways and network constituted by these 
proteins were identified by using Ingenuity Pathway Analysis (IPA). Results: 1. Of 65 
proteins/phosphoproteins screened, 30 were detected in PTCs and among which 11 
were identified as significant proteins as compared between tumor and normal tissue 
(Q-value <0.05). Of these 11 proteins and phosphoproteins, 8 were up-regulated: p-p70 
S6 kinase (Thr389), p-PKCį (Thr505), Stat1, Raf-B, cytokeratin 18, glutamine 
synthetase, HMG-1, HDAC1, whereas 3 proteins were down-regulated: p-ERK 
(Thr202/Tyr204), cytokeratin 5, BECN1. 2. Hierarchical clustering analysis of 30 
differentially expressed proteins/phosphoproteins in 54 PTCs samples (27 pairs of 
PTCs and their normal counterparts). Only 8 samples (15%) are mismatch. 3. Top ten 
major pathways were affected in PTC including IL-8 pathway (-log(p-value)= 3.54), 
ERK/MAPK pathway (-log(p-value)= 3.44), IL-3 pathway (-log(p-value)= 2.85), p70S6K 
pathway (-log(p-value)= 2.4), IL-12 pathway (-log(p-value)= 2.33), mTOR pathway (-
log(p-value)= 2.05), phospholipase C pathway (-log(p-value)= 1.87), IL-22 pathway (-
log(p-value)= 1.72), JAK pathway (-log(p-value)= 1.72), protein kinase A pathway (-
log(p-value)= 1.64). 4. Establish the interactive network model in PTC. STAT 1 and p-
ERK (Thr202/Tyr204) are the most critical ones in regulating the network. 
Conclusions: Our conclusion is that different pathways are affected in PTC. They may 
be responsible for carcinogenesis of PTC, and of which Stat 1 and p-ERK 
(Thr202/Tyr204) may play critical roles and may serve as potential biomarkers. 
Additionally, IL-8 and ERK/MAPK signaling pathway are specifically activated in PTC, 
which may be used for targeted treatment. It is the first time to report that Cytokeratin 5, 
cytokeratin 18, BECN1, glutamine synthetase and p-PKCį (Thr505) are involved in the 
PTC progress.  
 
ST03. ALK Kinase Domain Mutations Detected in Archival Neuroblastoma 
Samples Using Newly Designed Sanger Sequencing and High Resolution Melting 
Assays 
S.F. Sarabia1, P.M. Rodriguez-Waitkus1, C.R. Webb2, D.H. López -Terrada1, A. Roy1 
1Baylor College of Medicine, Houston, TX; 2Texas Children's Hospital, Houston, TX. 
Introduction: Activating point mutations in the tyrosine kinase domain of the anaplastic 
lymphoma kinase (ALK) oncogene occur in approximately 7-8% of all neuroblastoma 
tumors. The identification of known and new ALK mutations in refractory and recurrent 
neuroblastomas is important for selecting therapeutically effective small molecule ALK 
inhibitors that are currently in clinical trials. The purpose of this study is to determine the 
performance of laboratory-developed sequencing and high resolution melting (HRM) 
assays to detect and characterize ALK mutations in neuroblastoma. Methods: 
Universal M13 sequence-tagged primer sets were designed to amplify exons 23, 24 
and 25 including ~50 bases of flanking intronic sequences of the ALK gene. Genomic 
DNA was extracted from 20 micron-thick sections cut from 34 formalin-fixed paraffin-
embedded (FFPE) neuroblastoma specimens from a total of 30 individual patients. 
Following PCR and bi-directional Sanger sequencing, sequence analysis was 
conducted with Mutation Surveyor, version 4.0.4 (Softgenetics LLC, State College, PA). 
HRM analysis of each amplicon was performed using the same primers with 
LightCycler 480 HRM reagents, instrumentation and Gene Scanning Software (Roche 
Diagnostics, Indianapolis, IN). Results: Amplification quality was specific and robust 
with each primer set in all 34 samples. Intra- and inter-run reproducibility of 
amplification and sequencing was 100% with a subset of both wild type and mutant 
amplicons. Point mutations were identified in 3 of 30 (10%) neuroblastoma patients. 
Two of these mutations (c.3522 C>G; p.F1174L of exon 23 and c.3733T>A; p.F1245I of 
exon 24) have been previously reported as activating somatic mutations. The F1174L 
mutation was identified in two separate specimens obtained one year apart from a 
single patient. In another case, a novel variant (c.3804 T>G; p.I1268M of exon 25) of 
undetermined significance was identified that is absent in both the Catalog of Somatic 
Mutations in Cancer (COSMIC) and dbSNP (v.135) databases. Each mutation/variant 
was detected by HRM analysis; however HRM reaction conditions are currently under 
optimization. Conclusions: We present a robust targeted sequencing assay to detect 
the most common and therapeutically relevant kinase domain ALK mutations in patients 
with neuroblastoma. Consistent with the literature, ALK mutations were identified in 
10% of cases, and known or novel variants were identified in each exon targeted. This 
assay may be useful for patients with relapsed/resistant neuroblastoma failing to 
respond to standard chemotherapy, as they may be candidates for ALK genotyping and 
targeted therapeutics.  
 
ST04. Gene Expression Profiling of Clear Cell Papillary Renal Cell Carcinoma 
K.E. Fisher1, Q. Yin-Goen1, D. Alexis1, J.S. Sirintrapun2, W. Harrison2, R.B. Isett1, M.R. 
Rossi1, C.S. Moreno1, A.N. Young1, A.O. Osunkoya1 
1Emory University School of Medicine, Atlanta, GA; 2Wake Forest University School of 
Medicine, Winston-Salem, NC. 
Introduction: Clear cell papillary renal cell carcinoma (CCPRCC) is a recently 
described distinct variant of renal cell carcinoma (RCC) that shares some overlapping 
histologic and immunohistochemical features of clear cell RCC (CCRCC) and papillary 
RCC (PRCC). Our previous work elucidated differential molecular expression 
biomarkers that distinguish CCRCC from PRCC. Although the CCPRCC 
immunohistochemical profile is well described, the CCPRCC mRNA expression is less 
well understood. Using previously identified candidate genes, we investigated the gene 
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expression profile of CCPRCC. Methods: 15 cases of CCRCC, 19 cases of CCPRCC, 
and 13 cases of PRCC with classic histologic and immunohistochemical profile were 
selected for molecular analysis after histologic review. RNA was extracted from 
formalin-fixed paraffin-embedded tissue and cDNA was prepared. Quantitative real-time 
PCR was performed in duplicate targeting alpha-methylacyl coenzyme-A racemase 
(AMACR), BMP and activin membrane-bound inhibitor (BAMBI), carbonic anhydrase IX 
(CA9), ceruloplasmin (CP), nicotinamide N-methyltransferase (NNMT), schwannomin-
interacting protein 1 (SCHIP1), solute carrier family 34 (sodium phosphate) member 2 
(SLC34A2), and vimentin (VIM). 28S ribosomal RNA (RNA28S1) was used as an 
amplification control. Results: CCPRCCs expressed all eight genes at some level. Of 
the three tumor types, CCPRCCs expressed the most CA9 (mean ¨¨Ct 15.7 vs. 12.9 
and 3.4 for CCRCC and PRCC, respectively) and the least SLC34A2 (mean ¨¨Ct 0.6 
vs. 1.3 and 3.4 for CCRCC and PRCC, respectively). Compared to CCRCCs, 
CCPRCCs expressed more BAMBI (mean ¨¨Ct 2.4 vs. 1.7) and SCHIP1 (mean ¨¨Ct 
2.1 vs. 1.8), but less AMACR (mean ¨¨Ct 6.8 vs. 9.7), CP (mean ¨¨Ct 46.0 vs. 63.2), 
NNMT (mean ¨¨Ct 222.1 vs. 376.2), and VIM (mean ¨¨Ct 7.6 vs. 13.0). Compared to 
PRCCs, CCPRCCs expressed more CP (mean ¨¨Ct 46.0 vs. 4.0), NNMT (mean ¨¨Ct 
222.1 vs. 86.6), and VIM (mean ¨¨Ct 7.6 vs. 4.4), but less AMACR (mean ¨¨Ct 6.9 
vs. 23.5), BAMB1 (mean ¨¨Ct 2.4 vs. 12.3), and SCHIP1 (mean ¨¨Ct 2.1 vs. 3.0). 
Conclusions: Although variable mRNA expression was seen in CCPRCCs, most 
CCPRCCs expressed abundant CA9, CP, and NNMT, moderate amounts of VIM and 
AMACR, and little BAMBI, SCHIP1, or SLC34A2 mRNA. CCPRCCs exhibit a unique 
molecular signature that is characterized by abundant CA9 and minimal SLC34A2 
expression. CCPRCCs express CP at comparable levels to CCRCCs and express 
SCHIP1 at comparable levels to PRCCs indicating that CCPRCCs share molecular 
overlap with both CCRCCs and PRCCs. Understanding the molecular basis of 
CCPRCC will assist in future sub-classifications and molecular-targeted treatment of 
patients with this unique tumor. 
ST05. Clinical Utility of Molecular Testing for GNAS Mutations in Pancreatic 
Cyst Fluid Samples 
G.S. Mantha, A. Khalid, M. Miller, M. Durso, M. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: Pancreatic cysts can be present in over 10% of the adult US population. 
Branch duct intraductal papillary mucinous neoplasm (BD-IPMN) is the most common 
premalignant cystic lesion and an accurate diagnosis is key to its management 
including surveillance and resection. Imaging and cyst fluid analysis remain inadequate 
tools for the diagnosis of BD-IPMN. Pancreatic cyst fluid KRAS mutations have been 
shown to be associated with mucinous cysts including IPMN, and recent data on 
surgically acquired tissue suggests that GNAS mutations are specific for IPMN. In this 
study, we evaluated the clinical utility of testing for GNAS and KRAS mutations in 
pancreatic cyst fluid samples. Methods: Patients undergoing Endoscopic Guided 
Ultrasound-Fine Needle Aspiration (EUS-FNA) of pancreatic cysts from 7/2007 to date 
were eligible for the study. Archived DNA from samples in patients that underwent 
resection was analyzed for GNAS and KRAS mutations. DNA was amplified with 
primers flanking GNAS exons 8 (codon 201) and KRAS exons 2 & 3 (codons 12, 13 & 
61) and sequenced on ABI 3730 (Applied Biosystems). Results: Forty-one (41) 
samples from 24 IPMN (2 intraductal papillary mucinous carcinomas IPMC), 7 
mucinous cystic neoplasms (MCN), 1 serous cystic tumor (SCT), 2 pancreatic ductal 
adenocarcinomas (PDA), 3 pancreatic endocrine tumors (PET) and 4 benign cysts were 
analyzed. GNAS p.R201C or p.R201H mutations were identified in 11/24 (46%) IPMN 
(including 1 of 2 IPMC) but were not detected in any other pancreatic cyst (p=0.001). A 
GNAS or KRAS mutation was detected in 22 of 24 (92%) IPMN and both mutations 
were found in 9 (38%) IPMN. Conclusions: GNAS R201 mutations can be identified in 
clinically acquired EUS-FNA samples and are highly specific for IPMN. The combination 
of GNAS and KRAS mutational analysis could accurately diagnose over 90% of IPMN 
in pancreatic cyst fluid samples and could be used clinically for refining diagnosis and 
patient management.  
 
ST06. Comparison of SNP Array Karyotyping, FISH and LOH Analysis for 
Diagnosis of Gliomas 
S. Roy1, J.M. Hagenkord2, M.B. Durso1, S.F. Kash3, R.L. Hamilton1, M.N. Nikiforova1 
1University of Pittsburgh Medical Center, Pittsburgh, PA; 2Complete Genomics Inc, 
Mountain View, CA; 3Creighton University School of Medicine, Omaha, NE. 
Introduction: Glial tumors are typically diagnosed and graded based on 
histomorphologic characteristics. Diagnostic challenges arise due to tumor 
heterogeneity especially when there is limited and/or non-representative tissue 
sampling. Molecular testing is increasingly used to help evaluate these tumors. 
Currently, fluorescence in-situ hybridization (FISH) and loss of heterozygosity (LOH) 
analysis are the most common modalities for molecular testing of gliomas. Although 
these tests are useful for known targets, SNP array karyotyping gives a broader 
evaluation of the tumor genome. In this study, we tested clinical utility of SNP array 
karyotyping in gliomas and compared it with FISH and LOH analysis. Methods: 
Formalin-fixed paraffin-embedded tissue specimens from glial tumors previously tested 
clinically by FISH and LOH for 1p/19q deletion, TP53 (17p) loss, PTEN (10q) loss, and 
CDKN2A/p16 (9p) loss were analyzed by Affymetrix 250K SNP microarray (Affymetrix, 
Santa Clara, CA). The array data analysis was performed with Copy Number Analyzer 
for Affymetrix GeneChip Arrays Software (CNAG) v.3.2.0.0. Results: Fourteen (14) 
gliomas (7 oligodendrogliomas, WHO grade II, 5 anaplastic oligoastrocytomas, WHO 
grade III, and 2 glioblastomas multiforme, WHO grade IV) were analyzed. There was 
100% concordance with SNP array, FISH, and LOH analysis for 1p and 19q deletion 
status. Detection of deletion of the CDKN2A (p16) gene at 9p21 by FISH and LOH 
showed 60% and 100% concordance with SNP array, respectively. Two cases missed 
by FISH were due to uniparental disomy (copy-neutral LOH) at this region. Deletion of 
the PTEN (10q23) and TP53 (17p13) genes showed 100% correlation between SNP 
array and LOH analysis. In addition, SNP array was able to detect other chromosomal 
abnormalities: monosomy of chromosomes 4 (n=3) and 13 (n=1), EGFR amplification 
(n=3), 6p deletion (n=1) and uniparental disomy (n=4). Conclusions: SNP array 
karyotyping using Affymetrix 250K array can be performed on clinical glioma FFPE 
tissue specimens and demonstrated high concordance with FISH and LOH analysis. 
SNP array karyotyping allows high precision testing for chromosomal alterations in the 
whole genome and can be used for evaluation of gliomas in a clinical setting. 
 
ST07. GGT Insertion Between Codons 12 and 13 of Kras Gene in Colorectal 
Carcinoma 
M.P. Macedo, L.C. Lima, F.M. Melo, L.D. Andrade, B.C. Lisboa, F.A. Soares, I.W. 
Cunha, D.M. Carraro 
A.C.Camargo Hospital, Sao Paulo, Brazil. 
Introduction: Kras mutation is seen in 35-40% of colorectal carcinomas (CRC), and it 
is a negative predictor value of anti-EGFR therapy response. Codons 12 (GGT) and 13 
(GGC) are the most frequent codons involved in Kras gene mutations (73% and 22% 
respectively). The most frequent type of mutation in codon 12 is GGT>GAT and in 
codon 13 is GGC>GAC. Mutations involving codons 61, 146, and also multiple mutation 
have also been reported. Most of the reports are of single nucleotide substitutions. 
Insertions in Kras gene is a rare finding, with some cases reported in other tumors, but 
just one involving the codons 12 and 13 in CRC. Here we report a case of GGT 
insertion between codons 12 and 13 of Kras gene in a 65 years old man, with a 7,0 cm 
CRC. The tumor was localized in the right colon and was associated to a villous 
adenoma with high grade dysplasia. Kras mutation was tested in different tumor areas 
and in the precursor lesion. Methods: DNA from three different tumor areas and from 
the adenoma was obtained by scrapping off paraffin embedded 5um tissue from the 
glass. Mutations were tested by pyrosequencing and confirmed by direct sequencing. 
Results: We detected a GGT insertion between codons 12 and 13 of Kras gene in 
three different areas of the invasive tumor and also in the adenoma. Direct sequencing 
was performed in one of the invasive areas to confirm the findings, and showed the 
same result. Conclusions: Here we show a GGT insertion between codons 12 and 13 
of Kras gene present in three different areas of a CRC and in the associated adenoma. 
It is a rare type of mutation, with a single report on the literature in CRC, with no data 
regarding its clinical impact. One author reported an insertion in the Kras gene between 
codons 10 and 11 in a hematologic tumor with assay showing its pathogenicity. It is 
sugested that this insertion is present in the begging of the carcinogenesis process of 
the tumor, as it has been detect in the adenoma, and throughout the tumor in three 
different areas. It is also a diagnosis challenge because of the difficult and unusual 
pyrosequencing findings. 
 
ST08. ALK Gene Rearrangement Testing in Non-small Cell Lung Carcinoma: 
Correlation Between Ultrasensitive IHC and FISH 
E.C. Minca, B.P. Portier, Z. Wang, C. Lanigan, C. Farver, Y. Feng, P.C. Ma, V.A. 
Arrossi, J. Brainard, R.R. Tubbs 
Cleveland Clinic Foundation, Cleveland, OH. 
Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangements in advanced 
non-small cell lung carcinomas (NSCLC) are an indication for targeted therapy with 
ALK-specific inhibitors, including crizotinib. ALK rearrangement status is commonly 
assessed by fluorescence in-situ hybridization (FISH) using the IVD class FISH system 
approved by the US FDA as a companion diagnostic tool for crizotinib-based treatment 
eligibility {Abbott Molecular Vysis (AMV)}. The utility of IHC, a more affordable and 
accessible method, has been challenged by low protein expression levels of ALK fusion 
transcripts in NSCLC. Here we assessed a modified ultrasensitive IHC method as an 
alternative to FISH for detecting ALK rearrangements in a NSCLC case series at our 
institution. Methods: The study included formalin-fixed paraffin-embedded tissue 
samples (FFPET) from 198 patients with advanced NSCLC clinically referred for ALK 
testing. IHC was performed using a recently developed rabbit monoclonal antibody to 
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the ALK protein c-terminus domain preserved in all known pathologic ALK fusions 
(D5F3, a generous gift from Cell Signaling Technology) linked to an ultrasensitive 
multimer-based detection system (OptiView DAB IHC Detection Kit, a generous gift 
from Ventana Medical Systems). To increase reproducibility, IHC staining was 
interpreted as positive or negative rather than scored on a semi-quantitative scale. 
FISH was performed using the AMV ALK Break Apart FISH Probe Kit (Abbott 
Molecular, USA). ThinPrep bronchial wash samples from 2 patients were also used for 
FISH to resolve discordant cases. Results: Of 166 samples negative for ALK 
rearrangements by FFPET FISH, all were also negative for ALK expression by IHC. Of 
32 samples positive by FFPET FISH, 29 were also positive by IHC. All 3 discordant 
cases were close (15, 17, 18%) to the FISH cut-off of 15% positive cells; 2 cases were 
further investigated by ThinPrep FISH and were negative for ALK rearrangements, in 
agreement with the initial IHC result. The third discordant case could not be resolved 
due to unavailability of ThinPrep material. Overall, after discordance resolution, IHC 
demonstrated 96.7% sensitivity, 100% specificity, 100% positive predictive value and 
99.4% negative predictive value in detecting ALK over-expression in FFPET NSCLC 
samples. The overall agreement between FISH and IHC on FFPET samples was 
98.5%. Conclusions: Ultrasensitive IHC can reliably detect ALK-encoded protein over-
expression resulting from ALK gene rearrangements in NSCLC. The high concordance 
between IHC and FISH warrants the routine use of IHC as the initial component of an 
algorithmic approach to clinical ALK molecular testing in NSCLC, followed by reflex 
FISH confirmation of IHC-positive cases. 
ST09. Promoter SEPT9 V3 DNA Methylation in Premalignant and Malignant 
Colon Patients: A Biomarker from Tissue in Plasma  
K. Toth, A. Kalmar, B. Wichmann, Z. Tulassay, B. Molnar 
Semmelweis University, Budapest, Hungary. 
Introduction: Colorectal cancer (CRC) is one of the most frequent causes of cancer-
related death worldwide. Colonoscopy is the gold standard for early detection of CRC, 
but patient compliance in CRC screening programs is low. Blood-based tests are 
thought to increase patient compliance for cancer screening. Epi proColon, a product 
based on detection of SEPT9 DNA methylation (mSEPT9), has shown to be suitably 
sensitive and specific for the detection of CRC in blood. We aimed to show in this study 
that correlation exists between mSEPT9 in matched peripheral blood and biopsy tissue 
samples. Furthermore evaluation of mSEPT9 for adenoma detection in blood. 
Determination the correlation between mSEPT9 positivity and septin9 protein 
expression in tissue. Methods: Plasma samples were collected and analyzed from 
patients with no evidence of disease (NED), adenomas and CRC (n = 20 per class). 
Matching biopsy tissues were available from 13 NED, 10 adenoma and 16 CRC 
patients. Total DNA from tissue was prepared using QIAamp DNA extraction followed 
by custom bisulfite treatment. Plasma samples were processed using the Epi proColon 
kit (Epigenomics AG, Berlin, Germany). Quantitative determination of total DNA and 
mSEPT9 was performed using the Epi proColon real time-PCR assay. Septin9 protein 
expression in biopsy tissue was evaluated by immunhistochemistry using a polyclonal 
antibody for Septin9. Results: mSEPT9 PMR (percent methylation reference) values 
larger than 1% were detected in 7.7% (1/13) NED, 100% (10/10) adenoma and 100% 
(16/16) CRC biopsy tissues. In plasma from the same patients, however, mSEPT9 
PMR values larger than 0.01% were detected in 10% (2/20) NED, 25% (5/20) adenoma 
and 75% (15/20) CRC. Immunhistochemical detection of Septin9 protein decreased 
with increasing disease pathology, with Septin9 expression detected in 100% NED, 50-
60% adenoma and 10-20% CRC tissues. Conclusions: mSEPT9 was confirmed as a 
highly sensitive biomarker for the detection of CRC in blood. Although the high level of 
mSEPT9 in CRC tissue correlated strongly with sensitive detection of these cancers in 
plasma, the strong correlation was not maintained in tissue and plasma from adenoma 
patients. Varying degrees of tissue vascularization might underlie this observation, 
among other explanations. Finally, mSEPT9 in biopsy tissue was inversely correlated 
with expression of the Septin9 protein. 
 
ST10. Targeted Next-Generation Sequencing of Clinical Formalin-Fixed Paraffin-
Embedded (FFPE) Samples Detects Relevant Point Mutations and Copy Number 
Variations in High-Grade Gliomas 
M. Martinez-Lage, C. Gentile, D.B. Roth, J.J. Morrissette, R.D. Daber 
University of Pennsylvania, Philadelphia, PA. 
Introduction: Molecular classification of adult gliomas offers valuable prognostic and 
potentially predictive information. Targeted next-generation sequencing is an ideal 
method to be used in clinical practice, especially if validated in DNA obtained from 
formalin-fixed paraffin-embedded tissue (FFPE). Methods: Genomic DNA was 
extracted using three 10μm or macrodissected 5μm sections from FFPE blocks 
(ranging 1-10 years old) with the QIAamp DNA FFPE Tissue Kit. 27 samples from adult 
gliomas (13 glioblastomas, 6 WHO grades II or II diffuse gliomas, and 8 recurrent high-
grade gliomas) were selected with concentrations 50 ng/μl by fluorometric quantitation 
(Qubit 2.0). The Illumina TruSeq amplicon Cancer Panel kit targeting 48 known cancer 
genes was used to generate multiplexed libraries that were sequenced using the 
Illumina MiSeq. Follow up verification of mutation status was conducted using 
alternative technologies. Results: Mean overall depth of coverage was 2000X for all 
samples analyzed with the lowest mutation allele frequency detected at 9.72%. 22 
known pathogenic mutations were detected in IDH1 (R132H, in 8 WHO grade II and III 
samples), KIT (M541L, in 6), EGFR (R108K in 1, A289V in 2, G598V in 1), MET 
(N375S in 4), RET (R897Q in1), PTEN (R233X in 1), KRAS (G12D in 1), PTPN11 
(Q510H in1), RB1 (Q689X), TP53 (8 mutations in 10 samples), STK11 (F354L in 1), 
and JAK3 (V722I in 1). Using in house algorithms, EGFR amplifications were also 
identified in 7 glioblastoma samples, including all four cases with EGFR point 
mutations. Conclusions: Mutations within relevant genes, such as IDH1 and EGFR, as 
well as copy number variations, can be reliably detected in FFPE samples from primary 
brain tumors using targeted next-generation sequencing with a single molecular assay. 
The sensitivity and specificity of this test across a large panel of genes provides 
clinically useful information to directly impact patient care.  
ST11. Development and Validation of a High Sensitivity SNaPshot Assay for 
Mutation Profiling of Non-Small Cell Lung Cancer (NSCLC) Patients 
L. Farilla, P. Reynolds, J. Marola, A. Marrs, S. Groshong, P. Ramamoorthy 
National Jewish Health, Denver, CO. 
Introduction: Non-small cell lung carcinoma represents the primary cause of cancer-
related death in both men and women in the United States. Molecular profiling of tumor 
mutations is the key to implementation of a personalized therapeutic approach for 
NSCLC patients. Our laboratory has developed a molecular diagnostic test for NSCLC 
based on SNaPshot methodology for resected NSCLC tumor specimens. Our challenge 
was to extend the SNaPshot assay to much smaller specimens, such as transbronchial 
biopsy samples as well as core-needle biopsies. The limiting factor was the purification 
of a sufficient amount (100ng) of genomic DNA from small tumor samples necessary for 
PCR amplification of all targets, within the five panels. To overcome this obstacle, we 
modified the standard protocol conventionally applied to resected NSCLC tumors by 
adding a pre-amplification step before performing multiplex PCR. Methods: The 
SNaPshot test is a multiplexed mutation detection assay involving PCR amplification of 
target genes, followed by single base extension detection of lung cancer associated 
mutations. More specifically, the assay analyzes thirty-eight mutations distributed on 
eight frequently mutated genes (AKT, BRAF, EGFR, KRAS, MEK, NRAS, PIK3CA and 
PTEN), divided into five panels. Briefly, less than 10ng of DNA was pre-amplified during 
a first round of PCR (10 cycles) using a high fidelity proof-reading Taq polymerase. A 
small amount of pre-amplified DNA was subjected to a second round of PCR (40 
cycles), followed by single base extension and finally detection of mutations by capillary 
electrophoresis. The two rounds of PCR amplifications were performed using the same 
primer sets, without the need for designing a second round under nested primers 
amplification conditions. Results: A total of ten 20G needle core punches of resection 
specimens made to approximate the size of a core biopsy were analyzed under the 
above described methods, and the results compared to those obtained from resected 
tumors. Our preliminary data show successful genotyping of these lung cancer 
biopsies, with complete profiling of the thirty-eight mutations, as obtained for resected 
NSCLC tumors. Conclusions: Our laboratory has developed a highly sensitive 
SNaPshot assay to conduct mutation profiling of very small NSCLC tumor specimens 
such as transbronchial biopsies and core needle biopsies. We believe that this modified 
SNaPshot method significantly increases the diagnostic yield despite the relatively low 
genomic DNA starting concentration. 
 
ST12. Differential Strand Separation at Critical Temperature Reveals Low-
Abundance Mutations in Cancer Samples 
M. Guha, M. Makrigiorgos 
Dana Farber Cancer Institute, Boston, MA. 
Introduction: Detection of specific cancer DNA biomarkers is becoming more 
important than ever in the field of personalized medicine. Molecular approaches that 
detect and enrich for low-level mutations in tumor specimens remains a challenge, as 
clinical samples frequently contain far more wild-type than mutant DNA. Most methods 
that detect low-abundance mutations rely on the upstream use of polymerase chain 
reaction (PCR) by which mutations are identified. However, polymerases may introduce 
mis-incorporations that appear as ‘mutations’, thus limiting the ultimate detection limit of 
PCR-based techniques. We propose a novel method that uses Differential Strand 
Separation at Critical Temperature (DISSECT) to enrich for mutations prior to PCR and 
in the absence of an enzyme, enabling downstream detection of low-level DNA variants 
in a wild-type background. Methods: Following a few cycles of multiplex-PCR pre-
amplification from genomic DNA, amplicons are captured on magnetic beads using 
sequence-specific binding to bead-immobilized DNA probes. These short probes 
correspond to the wild-type sequence of regions prone to mutations, and therefore 
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presence of a mutation at any sequence position generally leads to a mismatch that 
lowers the melting temperature (Tm) of the duplex. Mutant DNA is then preferentially 
released from beads by denaturation at a critical temperature determined either 
experimentally or theoretically. The critical denaturation step elutes mutant DNA strands 
into the supernatant whereas wild-type sequences remain bound to the beads that are 
subsequently removed by magnetization. The DISSECT method can be repeated 
several times to enable further enrichment of mutation-containing DNA targets. In the 
final step, the released mutant sequences are PCR-amplified and sequenced. Results: 
Three rounds of DISSECT were sufficient to identify and sequence Kras and Tp53 
mutations of 0.05% abundance in a wild-type background, corresponding to mutation 
enrichments of 100- to 200-fold. Various mutations at different positions along the target 
sequence were successfully enriched. DISSECT was able to simultaneously enrich 
multiple mutations within a single tube and without enzymatic modification of the target 
DNA, demonstrating the simplicity and scalability of the procedure. Conclusions: 
DISSECT is a novel method to enrich DNA samples for low-level unknown mutations 
and is based purely on thermal denaturation, without the need for PCR or other 
enzymatic reactions. The process is also readily amenable to scaling and automation. 
The simplicity of DISSECT makes it a powerful method to screen for multiple mutant 
targets in a single tube without compromising accuracy or sensitivity.  
 
ST13. IDH1 and IDH2 Mutations in Chondrosarcomas 
K. Nafa, N.P. Agaram, L. Borsu, G. Schwartz, J. Healey, M. Ladanyi, M. Hameed 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Chondrosarcoma is the second most common primary malignant tumor 
of bone, characterized by neoplastic cartilage formation. Traditionally these tumors are 
graded based on their histological appearance to low and high grade tumors (Grade I, II 
and III). Recently, somatic mutations in IDH1 and IDH2 have been reported in 56% of 
cartilaginous neoplasms, mostly chondrosarcomas, with 40% of mutations being IDH1 
R132C. Previously, somatic mutations at IDH1 R132 and IDH2 R172 mutations had 
been reported in several types of gliomas and in hematopoietic neoplasms. The IDH2 
R140 mutation is found in hematopoietic neoplasms only. Mutations in IDH1 and IDH2 
result in aberrant enzymatic activity leading to the production of 2-hydroxyglutarate, a 
novel biomarker for these neoplasms Methods: We searched for mutations in exon 4 of 
IDH1 and IDH2 in 33 chondrosarcomas using Sanger DNA sequencing. PCR products 
were purified and sequenced with both forward and reverse directions. The samples 
were also genotyped on the Sequenom MassArray platform. Results: IDH1 and IDH2 
mutations were present in 48.5% of chondrosarcomas (16/33) of which 11 were IDH1 (1 
R132H, 3 R132C, 6 R132G & 1 R132S) and 5 were IDH2 (3 R172S & 2 R172M) 
mutations. In chondrosarcomas, one third of the mutations were in IDH2 and IDH1 
R132G was more frequent than R132H. Conclusions: These results confirm the high 
prevalence of IDH1 and IDH2 exon 4 mutations in chondrosarcomas. These mutations 
constitute the first genetic biomarker for chondrosarcomas. Further molecular study of 
downstream effects of IDH1 and IDH2 mutations in these tumors may lead to the 
identification of potential therapeutic targets in these highly chemoresistant tumors. 
 
ST14. Comparison of Formalin-Free Nucleic Acid Stabilization and Preservation 
in Tissue Samples 
K.J. Sparks Kilbourne1, N.M. Jun2, K.M. Lohnes1, N.R. Mosher1, A.F. Sassoon1, L.S. 
Sender1 
1Children's Hospital of Orange County, Orange, CA; 2GE Healthcare, Clarient, Aliso 
Viejo, CA. 
Introduction: Formalin-fixation with paraffin-embedding is the most common method to 
preserve and archive diagnostic tissue. This process can cause problems for down-
stream molecular assays like sequencing and gene expressing studies because of 
cross-linking and nucleic acid degradation. We compared two formalin-free systems for 
stabilization and preservation to determine which method was preferable for nucleic 
acid isolation and/or histomorphology. Methods: Ten tissue samples were collected 
fresh directly from the operating room or the pathology suite. Tissue samples included 
rhabdomysarcomas, ependymoma, Ewing's sarcoma, bone, thyroid tumor, fibroid, 
muscle, uterus and ovary. Specimens were divided for stabilization in RNAlater and 
PAXgene to allow for the comparison of the two systems. The DNA was isolated from 
the ten pairs of tissue manually using the Qiagen Gentra Puregene Cell Kit. The RNA 
was isolated from the ten pairs of tissue manually using the Qiagen RNeasy Mini Kit. 
DNA was assessed for quality and quantity by spectrophotometry, picgreen, and 
agarose gel electrophoresis. DNA was assessed for quality and quantity by 
spectrophotometry and real-time PCR. All tissue specimens were subsequently 
dehydrated and embedded into paraffin using a formalin-free tissue processor. 
Hematoxylin eosin slides were prepared from each block for histological evaluation. 
Results: Both RNAlater and PAXgene yielded high molecular weight double-stranded 
DNA, although in most cases the DNA extracted from the PAXgene tissue had a higher 
concentration than the corresponding RNAlater sample. The quantity and quality of the 
RNA was comparable between the RNAlater and PAXgene pairs. The morphology was 
better preserved with PAXgene than RNAlater and was more comparable to formalin 
fixation. Conclusions: Both RNAlater and PAXgene are suitable for stabilization and 
preservation in tissue samples. Although it is suggested PAXgene is superior to 
RNAlater concerning DNA yield and histomorphological preservation, additional work 
are required. 
 
ST15. Methods Comparison for Detecting BRAF Codon 600 Mutations  
M.C. Aakre1, N. Gomes1, S. Chowdhury1, M. Hoffmann2, D. Xu2 
1Pathology Associated Medical Laboratories, Spokane, WA; 2Providence Sacred Heart 
Medical Center & Children's Hospital, Spokane, WA. 
Introduction: The activating mutation (V600E) in the serine-threonine protein kinase B-
RAF gene (BRAF) has been used as a screening biomarker for drug response in 
patients with various cancers, mainly metastatic melanoma and colorectal cancer. Less 
common mutations affecting codon 600, including V600K, V600R, V600D, V600M, and 
V600G, have also been reported; however, the sensitivity for mutations other than 
V600E detected by different methodologies is not clear, and their impact on the final 
allele call has not been fully evaluated. In this study, we compared three different 
approaches; Roche Diagnostics’ cobas 4800 BRAF V600 Mutation Test, a laboratory-
developed real-time PCR hybridization probe test (LDT-PCR), and a Sanger 
sequencing assay, for the detection of BRAF V600 mutations in formalin fixed paraffin 
embedded (FFPE) specimens of melanoma and colorectal cancer. Methods: Fifty-
three FFPE samples were collected from our Histology Laboratory at PSHMC and four 
other laboratories. These fifty-three samples were evaluated for V600 mutations using 
the cobas assay and the LDT-PCR assay. All samples positive for a V600 mutation 
determined by either of the two assays, along with an additional 10 negative samples, 
were further evaluated by Sanger sequencing. Results: A total of 19 samples positive 
for the V600E mutation were consistently detected by all three methods. The LDT-PCR 
assay further identified mutant alleles with shifted melting peak profiles in four additional 
samples. Of these, three samples were determined to have the V600K mutation and 
one was determined to have the V600R mutation by Sanger sequencing analysis. Since 
the cobas 4800 BRAF V600 Mutation Test was specifically designed to detect the 
V600E mutation, the high-level V600R mutation was not detected. Nevertheless, the 
cobas assay showed a certain level of cross-reactivity to the V600K mutation as it 
detected 2 out of 3 samples positive for this mutation. The V600K mutation not detected 
by the cobas assay was marginally detected by Sanger sequencing analysis. 
Conclusions: Our study revealed that the cobas 4800 BRAF V600 Mutation Test is 
specific for the V600E mutation with some cross-reactivity to the V600K mutation. The 
LDT-PCR assay reflexed to Sanger sequencing analysis is more sensitive for other 
mutations at codon 600 of the BRAF gene. Currently, the clinical significance of BRAF 
mutations other than V600E has not been fully determined in either melanoma or 
colorectal cancers. Methods with the capability of differentiating the various mutations 
at codon 600 have the potential to identify subpopulations carrying mutations other than 
V600E. 
 
ST16. Detection of BRAF V600K Mutations in Melanoma: A Comparison of 
Cobas 4800 BRAF V600 Mutation Test and Laboratory Developed 
Pyrosequencing Assay 
S.M. Wenceslao1, J. Gale2, M.A. Vasef1 
1University of New Mexico, Albuquerque, Albuquerque, NM; 2TriCore Reference 
Laboratories, Albuquerque, NM. 
Introduction: Recent clinical trials for melanoma have shown clinical efficacy in the use 
of the selective BRAF inhibitor, vemurafenib, in a subset of patients with tumors 
harboring V600E (GTG>GAG) mutation, an activating mutation identified in over half of 
all melanomas. Other reported mutations in the BRAF codon 600 hotspot include 
V600K (GTG>AAG), V600R (GTG>AGG), V600E2 (GTG>GAA). The purpose of this 
study was to compare the FDA-approved cobas 4800 BRAF V600E mutation test with 
the PyroMark Q24 pyrosequencer. Methods: Genomic DNA was obtained from four 5-
micron, unstained sections for each of the 33 samples (where paraffin blocks were 
available) destined for analysis on the cobas 4800 and PyroMark. Isolation was 
performed according to manufacturer’s guidelines – manual extraction for the cobas 
and automated extraction for the PyroMark. Additionally, a single H&E slide was used 
to determine tumor percentage for each sample. Known V600K samples that went 
undetected on the cobas were reanalyzed on the PyroMark to ascertain mutant allele 
percentages. Results: All 15 wild type and 13 BRAF V600E mutated samples were 
accurately identified on both instruments. The BRAF V600K mutations were identified in 
5 out of 5 (100%) previously characterized mutated samples by pyrosequencing. In 
contrast, the cobas failed to detect BRAF V600K mutations in 3 out of 5 samples with 
mutant allele burden less than 27%. However, the mutant allele burden in three failed 
V600K samples were below the manufacturer’s stated detection limit of 31%. 
Conclusions: Our study confirms the manufacturer’s stated analytical sensitivity of 
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BRAF V600E detection and cross-reactivity with V600K mutations containing >30% 
mutant alleles. However, it appears that cobas may potentially miss the BRAF V600K 
mutations in clinical samples with <30% mutant alleles.  
 
ST17. Allele Specific PCR with Competitive Probe Blocking for Sensitive and 
Specific Detection of BRAF V600E in Metastatic Melanoma Fine Needle Aspiration 
Smears 
G. Smith1, B.E. Chadwick2, E.A. Jarboe2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT. 
Introduction: In some cases of metastatic melanoma diagnostic interpretation is based 
on samples from fine needle aspiration (FNA). Roughly 40% of metastatic melanomas 
harbor a V600E mutation in the BRAF gene, and recent clinical trials suggest that such 
cases are responsive to therapy using inhibitors that target RAF and other MEK 
pathway members. We asked whether direct FNA smears or cell blocks made from 
FNA needle rinse specimens, could be used for determination of BRAF status. We 
selectively amplified the V600E mutation using a sensitive PCR assay that has the 
ability to detect the mutation in a cell population of 0.02% tumor cells in a background of 
normal (wild type) cells. Methods: Tumor enriched DNA was extracted from de-stained 
FNA smears or cell blocks collected and prepared in 2000/2001 from 7 de-identified 
patient samples with a cytodiagnostic interpretation of metastatic melanoma. In some 
cases immunohistochemical staining for S-100 and/or HMB-45 and concurrent 
histological sampling had been performed. An allele-specific primer selectively amplified 
the 1799 T>A BRAF mutation whereas an unlabeled probe simultaneously blocked 
amplification of wild type (WT) BRAF during PCR. Mutation analysis was accomplished 
by melting analysis of the probe. Results: The seven FNA samples were collected in 
2000/2001 from two female and five male patients ranging from 54-81 years of age 
(average 65). The FNA samples were from various sites including an arm, axillary 
mass, lung, liver, as well as neck lymph nodes, masses, or nodules. Five of the de-
stained Diff-Quik smears showed clear PCR results after a crude DNA extraction, with 
the V600E mutation present in two of the five samples, including one in which the 
extracted area contained a maximum of 100-200 tumor cells. One smear and the cell 
block slide required further purification of the extracted DNA before amplification, with 
the mutation detected in the cell block sample that had been stained initially with 
hematoxylin and eosin. The BRAF V600E mutation was thus detected in 3 of 7, or 43% 
of the samples. The presence of the BRAF mutation did not correlate with the presence 
or absence of S-100 or HMB-45 expression in the tumor cells. Conclusions: Our 
results show that archived FNA smears and cell block slides represent good sources of 
material once de-stained for determining BRAF status using allele-specific PCR with 
competitive probe blocking, even when the overall numbers or percentages of tumor 
cells are low.  
 
ST18. Comparison of Mutation Detection Rate in EGFR and KRAS Genes 
Between Surgical and Cytology Specimens 
R.S. Shibata, F. Ye, J. Longtine, M. Lee, J. Malaczynska, H.M. Hussein, M. Wu, Q. Si, 
D.Y. Zhang 
Mount Sinai Hospital, New York, NY. 
Introduction: EGFR/KRAS mutations occur in 10-35% lung and adenocarcinoma and 
determine potential response to tyrosine kinase inhibitors (TKI). Previous studies 
showed that cytology specimens (FNA and fluid) are of limited utility for mutation 
analysis due to insufficient tumor cells. Methods: Two hundred and twenty eight 
paraffin embedded blocks with lung adenocarcinoma were analyzed for EGFR and 
KRAS mutations. Among them, 168 samples were surgical specimens (lung wedge 
resection and needle core biopsy) and 60 were cytology specimens (pleural fluid, 
metastatic lymph node FNA and direct lung FNA). Tumor content was evaluated using 
recut H&E slides, and DNA from serial sections was extracted using modified QIAamp 
DNA blood Mini Kit (QIAGEN). Cutoffs for insufficient specimens were established as a 
minimum 20% tumor cells and a 0.1cm tissue diameter. KRAS/EGFR mutations were 
tested by either multiplex PCR and capillary electrophoresis on the ABI 3130 platform 
or ARMS-PCR and subsequent agarose gel electrophoresis. Results: The overall 
insufficient specimen rates were 6.90% for cytology specimens and 2.38% for surgical 
specimens. The KRAS mutation detection rates were similar between the surgical 
(30.95%) and cytology (32.26%) groups. The surgical group had a mutation rate of 
30.95% with the most common one being a GGT to TGT mutation (19.05%). Cytology 
specimens were subdivided into a pleural fluid/lymph node group and a direct lung FNA 
group. The pleural fluid/lymph node group had a mutation rate of 23.10% with GGT to 
TGT mutation being the most common (15.38%). The Direct lung FNA group had a 
mutation rate of 38.89% with GGT to TGT being the second most common mutation 
(11.11%) and GGT to GTT being the most common mutation (16.67%). The surgical 
specimens showed an overall EGFR mutation rate of 12.70%, whereas the combined 
cytology specimens showed a rate of 19.35%. The aforementioned pleural fluid group 
showed a mutation rate of 7.69%, whereas the direct lung FNA group showed a 
markedly higher rate of 27.78%. Conclusions: The insufficient specimen rate was 
slightly higher in cytology specimens compared to surgical biopsy specimens, 
suggesting that cytology specimens are sufficient for mutation analysis in most cases. 
The mutation detection rates for EGFR and KRAS were notably higher in direct lung 
FNA specimens than pleural fluid and surgical specimens, suggesting that direct 
sampling of tumors provide a more representative method of lung lesions.  
 
ST19. PIK3CA Mutation Detection by Three Methods: TrimGen Mutector II, 
Qiagen qBiomarker Somatic Mutation PCR Array, and Sanger Sequencing 
S.S. O'Neill, K.C. Chao, M.L. Gulley, J.K. Booker, K.E. Weck 
University of North Carolina, Chapel Hill, NC. 
Introduction: Phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, is 
mutated in a significant proportion of breast, colorectal, and endometrial cancers. 
Therapies targeting PI3K and downstream signaling molecules are in development, and 
PIK3CA mutation status may also predict responsiveness to EGFR targeted therapy. 
The majority of activating mutations are missense mutations in exons 9 and 20 
corresponding to the helical and kinase domains, respectively. Three hotspots for 
mutation are codons 542 and 545 (exon 9) and codon 1047 (exon 20) that together are 
estimated to represent approximately 80% of activating somatic mutations. Methods: 
Three different methods for PIK3CA mutation detection were compared: Mutector(TM) 
II kit (TrimGen), qBiomarker somatic mutation PCR array (SABiosciences/Qiagen), and 
Sanger sequencing. The Mutector II employs a shifted termination assay to test for five 
nucleotide substitutions in the three hotspots. The qBiomarker array is a real-time PCR 
panel to test for seven nucleotide substitutions including the three hotspots. A Sanger 
sequencing assay was custom designed to sequence the coding regions of exons 9 
and 20. Performance of the three methods was evaluated using DNA extracted from 
formalin-fixed, paraffin-embedded (FFPE) tumors as well as cell lines containing 
specific PIK3CA mutations. Mutation detection accuracy, sensitivity, hands-on time, and 
total run time were compared. Results: Cell line DNA and three of four FFPE tumors 
with different PIK3CA mutations were accurately identified by all three methodologies. 
The fourth FFPE tumor sample contained an exon 9 c.1625A>T [p.E542V] mutation 
that was identified by Sanger sequencing only, as the other two assays do not test for 
this mutation. Dilution studies demonstrate that the qBiomarker assay is at least 2.5 
times more sensitive for mutation detection than Sanger sequencing, and at least 5 
times more sensitive than the Mutector II kit. Hands-on time was equivalent for the 
Mutector II and qBiomarker assays, and half that of Sanger sequencing. Total run time 
was also greatest for Sanger sequencing at 7 hours compared to 3.7 hours for the 
Mutector II kit, and 2 hours for the qBiomarker assay. Conclusions: The TrimGen 
Mutector II(TM), qBiomarker somatic mutation PCR array, and Sanger sequencing are 
all accurate methods for PIK3CA mutation testing. Sanger sequencing has the longest 
hands-on and run times but also has the greatest mutation coverage. The qBiomarker 
assay has the highest analytic sensitivity for mutation detection. Further work is needed 
to demonstrate clinical performance in predicting response to therapy. 
 
ST20. EGFR Mutations in Non Small Cell Lung Cancer Patients: Single Centre 
Experience from India  
A.B. Choughule1, K. Prabhash1, A. Thavamani2, S. Desai1, A. Joshi1, V. Noronha1, S. 
Banavali1, N. Jambhekar1 
1Tata Cancer Hospital, Mumbai, India; 2ACTREC, TMC, Mumbai, India. 
Introduction: The variability of the response of the patients to Gefitinib or Erlotinib 
based upon EGFR mutations, and also the variability of the occurrence of these 
mutations, based upon a range of clinico-pathological parameters such as patient’s 
ethnic origin, sex, tumor histology, smoking status, has kindled a lot of interest, resulting 
in numerous studies performed on different populations worldwide. The tyrosine kinase 
domain (exons 18-21) of the Epidermal Growth Factor Receptor (EGFR) gene is a 
hotspot of mutations or variations that can be used as predictive markers for sensitivity 
or resistance to EGFR Targeted therapy in Non Small cell lung cancer (NSCLC) 
patients. Methods: In this study, we have investigated the mutations in the EGFR gene, 
tyrosine kinase domain exons 18-21 of 368 Non Small Cell Lung Carcinoma patients 
from Indian cohort and correlated it with the response to therapy of each patient. The 
Mutation analysis was done by PCR direct sequencing of exons 18 to 21 in a sample 
size of twenty five and were validated further with Taqman based real time PCR, 
thereafter the remaining 343 samples were detected for 10 most common mutations of 
EGFR by only TaqMan based real time PCR assay (on LC 480 II platform). Results: 
Activating mutations were present in 99 patients out of 368 (27 %). There was almost 
equal occurrence of 45 % in the, in frame deletions in exon 19 and exon 21 L858R point 
mutation, followed by exon 18 G719C mutation ( 8.3 %) of mutant patients. 
Conclusions: In this selected patients the EGFR mutation rate is 27% in our 
population. The prevalence of different type of mutations in our population is similar to 
reported in literature.  
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ST21. Development of a Non-Invasive Genomic Detection Assay for Melanoma 
Using Real-Time Quantitative RT-PCR 
S. Chang1, T. Palmer1, T. Harris1, W. Wachsman2 
1DermTech International, San Diego, CA; 2VA San Diego Helathcare System, San 
Diego, CA. 
Introduction: When detected and diagnosed early, melanoma is highly curable. 
However, studies show that only 3-5% of pigmented lesions biopsied for suspicion of 
melanoma contain the disease. Reader studies also reveal that 20% of melanomas go 
unbiopsied. Thus, visual and optical clues for melanoma detection are inadequate. Our 
goal is to develop a non-invasive assay to facilitate melanoma detection. Previously, we 
used epidermal genetic information retrieval (EGIR) to expression profile stratum 
corneum cells overlying lesions suspicious for melanoma. We discovered a multi-gene 
classifier that discerned in situ and invasive melanoma from nevi. Subsequently, using 
off-the-shelf reagents, we initiated translation of this assay onto a quantitative RT-PCR 
(qPCR) platform. We now report on the next phase of assay development, in which 
custom TaqMan primer/probe sets for top-ranked gene targets were designed and 
validated, and used for class prediction modeling to produce a risk scoring system for 
melanoma detection. Methods: Pigmented skin lesions, suspicious for melanoma, were 
tape-stripped and biopsied as per standard of care. Total RNA isolated from tape by 
EGIR was pre-amplified by 14 cycles of PCR and assayed on a custom OpenArray 
plate, using TaqMan qPCR. The plate contained 100 validated gene targets from 
microarray-based discovery research for a melanoma classifier, as well as 6 internal 
control gene targets. Resultant data were normalized with the internal control genes by 
geometric means. The TreeNet algorithm was used to generate a class prediction 
model on a training dataset, which was then tested using an independent dataset. 
Results: The training dataset was produced from 50 melanomas and 50 nevi. TreeNet 
modeling yielded an 18-gene classifier that distinguished both in situ and invasive 
melanoma from nevi. The test dataset, produced from 74 melanomas and 53 nevi, 
showed this classifier to be 100% sensitive and 68% specific (ROC AUC=0.894). This 
class prediction model was used to produce a risk scoring metric (0=lowest risk, 
5=highest risk) to determine the likelihood that a suspicious pigmented skin lesion 
harbors melanoma. All 124 melanoma lesions with in situ or invasive disease scored 
between 3 and 5. In contrast, 78% of benign lesions exhibited risk scores that ranged 
between 0 and 2. Conclusions: We have produced a non-invasive test for assessing 
the risk that a pigmented skin lesion is melanoma. This EGIR-based qPCR assay has 
the potential to improve clinical evaluation of pigmented skin lesions and melanoma 
care. 
 
ST22. A Rapid Assay to Assess EGFR Mutations Leads to Earlier Diagnosis and 
Treatment of Lung Adenocarcinoma 
N.D. Pecora1, J.L. Bruce1, S. Amr2, T.E. Mullen2, P.A. Janne3, N.I. Lindeman1 
1Brigham and Women's Hospital, Boston, MA; 2Harvard Medical School, Boston, MA; 
3Dana-Farber Cancer Institute, Boston, MA. 
Introduction: Activating somatic mutations in the epidermal growth factor receptor 
(EGFR) gene are present in ~20% of lung adenocarcinoma. Patients with EGFR-mutant 
tumors respond to treatment with ATP-mimetic inhibitors of the EGFR tyrosine kinase 
(TKI’s), such as gefitinib and erlotinib.. EGFR mutations are traditionally diagnosed by 
Sanger sequencing of exons 18-21. The majority of EGFR mutations are either small in-
frame deletions involving codons 746-750 of exon 19 (~65% of mutations) or a 
missense point mutation at codon 858 in exon 21 (~25%). Because of slow turnaround 
time associated with Sanger sequencing of exons 18-21, a rapid assay for the two most 
common mutations was developed and assessed for accuracy and impact on time to 
diagnosis and treatment initiation. Methods: EGFR mutation detection was performed 
on 72 lung adenocarcinoma specimens, by two methods. The reference method was 
bidirectional Sanger sequencing following nested PCR, with and without mutant 
enrichment with peptide nucleic acid (PNA) probes. The rapid method involves capillary 
electrophoresis of exon 19 PCR amplicons to detect deletions and insertions, and real-
time PCR of exon 21 with mutant and wild-type probes targeting codon 858. 
Turnaround time (TAT) for test results and time between test request and initiation of 
therapy were recorded. Results: The rapid EGFR assay performed comparably to 
Sanger sequencing, with overall agreement of 96% (69/72). The three discrepant cases 
included an L858R result detected only by Sanger sequencing and two exon 19 
deletions detected only by the rapid assay. In addition, four more samples gave rapid 
EGFR results but were insufficient for Sanger sequencing; one of these had an EGFR 
mutation. Three mutations were detected by Sanger sequencing that cannot be 
detected by the rapid assay: two exon 20 mutations (insertion, T790M) and a codon 
861 substitution. The mean TAT for the rapid EGFR assay was 2.8 days, versus 21.2 
days for Sanger sequencing. The speed of the rapid EGFR assay had an impact on 
patient care, as therapy was initiated within 9.7 days of the rapid EGFR result, 12 days 
before the Sanger result was even available. Conclusions: Rapid EGFR testing for the 
two most common mutations is an accurate method that enables more rapid diagnosis 
and initiation of therapy. However, the method cannot detect all possible mutations, and 
Sanger sequencing is still indicated for samples that do not show an EGFR mutation in 
the rapid assay. Follow-up studies are underway to assess the value of earlier 
treatment on clinical outcome. 
 
ST23. PIK3CA Mutation Detection in Clinical Samples Using PNA Mediated Real-
Time PCR Clamping Assay 
H. Kim, J. Choi, H. Park 
Panagene, Republic of Daejeon, Korea. 
Introduction: Somatic mutations in the PIK3CA gene have been frequently found in 
various human cancers, and their presence correlates to therapy response. These 
somatic mutations within the PIK3CA gene are localized in exon 9 and 20. Methods: 
We have developed a highly sensitive and simple method to detect 13 mutations in 
exons 9 and 20 of PIK3CA using PNA-mediated real-time PCR clamping, 
PNAClampTM. PNAClampTM is based on unique properties of PNA probes that PNA 
oligomers are not recognized by DNA serving as sequence-selective clamps during 
PCR amplification. This method can also detect 13 mutations through only three tube 
reactions each with 10 ng of the target DNA. PNAClampTM is simple and reliable with a 
detection limit of approximately 3% mutant alleles using 10 to 50 ng of normal DNA as a 
template. The turnaround time for performing this assay was only 2 hours. Furthermore, 
whereas direct sequencing method will detect most of PIK3CA samples as having 
E545A mutation, due to homology in exon 9 in PIK3CA gene, highly specific 
PNAClampTM Method have overcome this perceived problem. Results: In clinical 
studies with breast cancer patients in Korea, PIK3CA mutations were detected utilizing 
PNAClampTM in 60 (35.7 %) of clinical samples, and the results were compared with 
direct sequencing method. Among 168 patients, 6 (3.6 %) had mutations in codon 542, 
23 (13.7 %) had mutations in codon 545 and 31 (18.5 %) had mutations in codon 1047. 
To confirm these results, the same clinical samples were analyzed with a sequencing 
assay. Consistent results were obtained from 137 (81.5 %) of the 168 clinical samples 
between PNAClampTM and the sequencing assay. The results not in agreement with 
the sequencing numbered 21 (12.5 %) samples. Ten samples did not react by direct 
sequencing due to quality problems with the target DNA. The remaining samples were 
initially determined as the wild type by direct sequencing, but they were found to be 
PIK3CA mutant using PNAClampTM. This result was likely due to the high sensitivity of 
PNAClampTM. Conclusions: PNAClampTM is a rapid, sensitive and easy to perform 
tool that can be used for the detection of PIK3CA mutations in the clinical field.  
 
ST24. Comparison of Molecular Assays for Detection of the BRAF V600E 
Mutation in Fine Needle Aspiration Samples of Thyroid Nodules  
K. Park 
Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of 
Seoul, Korea. 
Introduction: Until recently, the B-type Raf kinase (BRAF) V600E mutation has been 
reported one of the most common genetic alternation in papillary thyroid carcinoma 
(PTC). It has been associated with the development and progression of this disease. 
Recently, there have been several molecular assays for detecting the BRAF V600E 
mutation in fine needle aspiration cytology (FNAC) samples. However, despite the 
advances of techniques to detect this mutation, these are rarely evaluated or compared. 
The aim of the present study was to compare the diagnostic performance of BRAF 
V600E mutation between three molecular assays. Methods: In this study, the 297 
consecutive FNAC samples from patients with ultrasonography features that were 
suspicious for increased malignancy risk were used. BRAF V600E mutation analysis 
was performed by dual-priming oligonucleotide (DPO) PCR (Seeplex BRAF ACE 
detection system, Seegene, Korea), mutant enrichment with 3’-modified 
oligonucleotides (MEMO) sequencing, and real-time PCR with a TaqMan minor groove 
binding (MGB) probe (Real-QTM BRAF V600E detection kit. Biosewoom, Korea). We 
evaluated the limit of detection of three methods, using ten-fold serially diluted mutant 
DNA obtained from a BRAF V600E positive cell line (SNU-790). Results: In the 
cytological examination, 122 (41.1%) of the 297 cases were diagnosed as papillary 
thyroid carcinoma (PTC). Among those, the detection rates of DPO PCR, MEMO 
sequencing, and real-time PCR with a TaqMan MGB probe for PTC were 88.5% (108 of 
122), 91.0% (111 of 122), and 90.2% (110 of 122), respectively. In addition, 26 cases 
were diagnosed as suspicious for papillary carcinoma in the FNAC. The detections 
rates of DPO PCR, MEMO sequencing, and real-time PCR with a TaqMan MGB probe 
for those cases were 61.5% (16 of 26), 65.4% (17/26), and 61.5% (61.5%), 
respectively. Between three methods, there were 12 discrepant results. The detection 
limits (percentage of detectable mutant DNA in the admixture of normal DNA) of DPO 
PCR, MEMO sequencing, and real-time PCR with a TaqMan MGB probe were 10%, 
0.1%, and 0.1%, respectively. Conclusions: For detecting the BRAF V600E mutation 
in thyroid FNAC sample, the MEMO sequencing and real-time PCR with a TaqMan 
MGB probe show more comparable performance and are more sensitive than the DPO 
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PCR method. Compare to MEMO sequencing, real-time PCR with a TaqMan MGB 
probe method is advantageous for reducing the hands-on time and cross-contamination 
during the testing procedures, and for cost-effectiveness.  
 
ST25. Characterization of Chromosome Abnormalities in Meningiomas 
Combining Conventional Cytogenetics and Array Comparative Genomic 
Hybridization Techniques 
J. Han1, J. Choi1, B. Kim1, J. Kim1, K. Kim1, C. Jeon2, L.G. Shaffer3 
1Dong-A University College of Medicine, Busan, Korea, Republic of; 2Daegu Catholic 
University School of Medicine, Republic of Daegu, Korea; 3Signature Genomic 
Laboratories, Spokane, WA. 
Introduction: Meningioma is the most frequent tumor of neuroectodermal origin in 
humans. It is usually benign. However, certain histological variants show more 
aggressive biological behavior and are clinically associated with a high risk of local 
recurrence and a less favorable prognosis. Cytogenetic and molecular biological 
studies are important to identify characteristic genetic aberrations associated with 
meningioma tumorigenesis and progression. Methods: We studied 90 meningioma 
tumor samples. Fresh tissues were mashed and finely minced to dissociate the cells in 
a Petri dish containing RPMI 1640 medium with L-glutamine. The cells were in situ 
cultured with Chang medium supplemented with L-glutamine and P-streptomycin at 
37°C in a 5% CO2 atmosphere for 7~10 days. Next, G-banded karyotypes were 
interpreted according to the recommendation of ISCN 2005 and 2009. When needed, 
microarray comparative genomic hybridization (CGH) tests were also performed using 
SignatureChip. Results: On the cytogenetic level, we observed abnormal karyotypes in 
60 (66.7%) patients, whereas 4 cases did not produce enough metaphases and 26 of 
90 (28.9%) patients had normal karyotypes. The most common numerical alterations 
were loss of chromosome 22 (observed in approximately 75.0% of the abnormal 
cytogenetic cases). In 25 cases, monosomy 22 was found as a single primary 
abnormality and in the remaining 20 patients, it was combined with another numerical 
or structural chromosome abnormality. Hyperdiploidy and hypodiploidy were observed 
in 5 and 3 cases, respectively. The remaining 7 abnormal cytogenetic cases included 
balanced or unbalanced translocations and deletions. In cases with complex structural 
rearrangements, the array CGH technique enabled the best identification of 
abnormalities. Conclusions: At present, it is well established that meningiomas are 
genetically heterogeneous tumors. Our results also indicate that meningiomas show 
variable patterns of chromosomal instability. Conventional cytogenetic techniques may 
hamper the identification of all tumor cell clones present in samples because of the 
relatively low percentage of neoplastic metaphases. Instead, array CGH analyses can 
be systematically employed to reveal combinations of aberrations that are not observed 
when only one method is used. 
 
ST26. Discovery of Breast Cancer Morphologic Subtypes and Characterization 
of their Molecular Underpinnings 
Y. Xia, M.M. Hefti, N. Knoblauch, A.H. Beck 
Beth Israel Deaconess Medical Center, Boston, MA. 
Introduction: The Cancer Genome Atlas (TCGA) recently performed comprehensive 
molecular profiling (mRNA expression profiling, DNA copy number alterations, DNA 
methylation profiling, proteomics analysis (RPPA)) on ~500 cases of invasive breast 
carcinoma. Each of these data types was analyzed by the TCGA to define breast 
cancer molecular subtypes. The aim of our project is to: 1) perform quantitative 
morphologic analyses of TCGA breast cancer samples, 2) discover breast cancer 
subtypes based on quantitative morphologic profiling data, and 3) integrate morphologic 
and molecular subtyping data to gain insight into the morphologic phenotypes 
associated with breast cancer molecular subtypes. Methods: We downloaded whole 
slide digital images (svs files) from the TCGA data portal on 495 breast cancer cases 
previously subtyped. We adapted the C-Path platform for use on whole slide images, 
quantitated a total of 19 global stromal and epithelial features per image, and performed 
consensus clustering on the quantitative morphologic data to identify robust 
morphologic subtypes. After estimating the optimal number of morphologic subtypes, 
we performed chi-square analyses to evaluate associations between morphologic 
subtypes (identified in our analysis) and molecular subtypes (previously determined by 
the TCGA Analysis Working Group). Results: We identified 4 robust morphologic 
subtypes. Subtypes 1, 2, 3, and 4, were comprised of 94 (19%), 106 (21%), 89 (18%), 
and 206 (42%) of breast cancer cases, respectively. Morphologic subtypes were 
significantly associated with molecular subtypes defined by mRNA expression (X2 = 37, 
p =0.0002), DNA copy number (X2 = 28.6, p = 0.004), DNA methylation (X2 = 26.8, p = 
0.008), miRNA expression (X2 = 38.3, p = 0.003), and RPPA (X2 = 37, p = 0.001). 
Morphologic Subtype 1 is significantly enriched for the Basal-like and depleted for the 
Luminal A mRNA expression subtypes, whereas Morphologic Subtype 4 shows the 
opposite pattern. Interestingly, Morphologic Subtype 1 is significantly enriched for a 
Basal-like RPPA protein expression pattern (similar to the mRNA data); however, 
Morphologic Subtype 4 shows a strong enrichment for the newly defined “Reactive I” 
pattern, with no significant association with the Luminal A pattern of protein expression 
(unlike the mRNA expression data). This finding provides insight into the set of 
morphologic phenotypes associated with the recently described “Reactive I” RPPA 
signature. Conclusions: Morphologic profiling of comprehensively annotated cancer 
specimens facilitates the discovery of novel morphologic subtypes and characterization 
of their molecular underpinnings.  
ST27. HER2 Testing in Gastric Cancer – An Inter-laboratory IHC and FISH 
Correlation Study 
L.J. Tafe1, J. Cao2, G.J. Tsongalis1 
1Dartmouth-Hitchcock Medical Center, Lebanon, NH; 2Baystate Health System, 
Springfield, MA. 
Introduction: In 2010, trastuzumab was FDA approved for use in combination with 
chemotherapy in patients with metastatic gastric or gastro-esophageal junction cancer 
(GC/GEJ) following the results of the ToGA phase III, international, randomized 
controlled trial that showed increased overall survival in patients receiving trastuzumab 
versus those treated with chemotherapy alone. However, the best HER2 testing 
strategy in these tumor types has not been defined. The goal of this study was to 
perform an inter-laboratory comparison of HER2 IHC and FISH performance in paired 
biopsy and resection specimens and evaluate if the ASCO/CAP scoring criteria 
established for breast cancer was applicable to these tumor types. Methods: Paired 
FFPE biopsy and resection specimens were selected from the archives of two 
institutions. H&E slides were reviewed to document tumor content. FISH analysis was 
performed at two independent laboratories using the PathVysion DNA probe kit. IHC 
was performed at one laboratory on the Ventana Benchmark XT with Ventana’s 
Pathway anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody (~6μg/ml). Scoring 
and interpretation of results were performed independently at both institutions according 
to the ASCO/CAP guidelines for breast carcinoma. Results: The 20 cases used in this 
study consist of 13 gastric and 7 GEJ tumors, 6 diffuse type and 14 intestinal type (11 
moderately differentiated, 3 poorly differentiated). Four of the cases showed HER2 
amplification by FISH (20%); of these three were 3+ and one was 1+ by IHC on the 
biopsy sample. Two cases were equivocal by IHC (2+) of which one was subsequently 
non-amplified by FISH, the other amplified. Tumor heterogeneity was seen in one of the 
paired samples that was IHC 2+ in the biopsy but IHC3+ in the resection; both showed 
amplification by FISH. The IHC and FISH correlation between biopsy and resection 
specimens evaluated by the two sites was 100%. Conclusions: We present data from 
an inter-laboratory collaborative study of the performance of HER2 FISH and IHC within 
GC/GEJ tumors in paired biopsy and resection specimens. Our preliminary data show 
20% HER2 FISH positivity rate in GC/GEJ tumors all of which had intestinal type, 
moderately differentiated histology, similar to prior reports in the literature. The overall 
concordance between IHC and FISH was 95% (19/20) and the inter-laboratory 
concordance was 100%. Continuing studies are needed but the ASCO/CAP guidelines 
developed in breast cancer may be applicable to this tumor type. 
 
ST28. Molecular Characterization of Sporadic Pheochromocytoma and 
Paraganglioma in Korea 
S. Cho, J. In, S. Park, S. Seo, J. Kim, S. Kim, K. Lee, M. Seong, S. Park 
Seoul National University Hospital, Republic of Seoul, Korea. 
Introduction: Pheochromocytoma and paraganglioma (PHEO/PGL) are tumors derived 
from the adrenal medulla or extra-adrenal ganglia, respectively. Up to date, ten 
susceptibility genes have been identified as participating in PHEO or PGL 
tumorigenesis. In nonsyndromic patients with apparently sporadic tumors, genetic 
mutations have been found in 7.5-24% in four major genes (RET, SDHB, SDHD, and 
VHL) and genetic testing is now recommended for all patients with PHEO/PGL. This 
study aimed to understand the genetic background causing of sporadic nonsyndromic 
PHEO/PGL in Korea. Methods: We performed direct sequencing analysis to detect the 
presence of mutations in all coding regions of SDHB, SDHD and VHL, and exons 10, 
11, 13-16 of RET from 33 patients with sporadic nonsyndromic PHEO and/or PGL 
histologically confirmed. Results: Four different germline mutations were identified in 4 
of the 33 (12.1%) patients. The first mutation, SDHD: c.94_95delTC (p.Ala33Ilefs*35) 
was found in patient with both bilateral PHEO and head and neck PGL. The second 
mutation, RET: c.1891G>T (p.Asp631Tyr) was identified in patient with unilateral 
PHEO. The other two mutations were detected in PHEO patients: c.666_678del13 
(p.Arg223Glnfs*21) and c.392delC (p.Pro131Hisfs*5). Notably, in the patients with 
SDHB mutation, no malignant and extra-adrenal PGL phenotype were observed. 
Conclusions: A considerable portion of sporadic PHEO/PGL results from germline 
mutation in one of at least in the major susceptibility genes. Therefore genetic testing 
can be helpful in discovery of genetic background can allow us to understand 
prognostic factors and decide a better management strategy. 
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ST29. A TaqMan Array System For Mutation Profiling of Solid Tumors Using 
Routine Surgical Pathology and Cytology Specimens 
Z. Walther, K. Ronski, M. Wan, J. Sklar 
Yale University School of Medicine, New Haven, CT. 
Introduction: High throughput analysis of tumor DNA for somatic mutations to predict 
response to targeted anti-neoplastic drugs has become a major part of modern 
oncologic practice. A number of technical approaches have been taken for this purpose, 
including one recently adapted by us using parallel real-time PCR assays for multiple 
mutations. Methods: TaqMan SNP Genotyping assays were designed against hotspot 
mutations in BRAF, EGFR, ERBB2, KRAS, NRAS, and PIK3CA. Assays are run in 384-
well plates on an ABI ViiA7 real-time PCR instrument. The sensitivity and specificity of 
each mutation assay were determined using formalin fixed, paraffin embedded archival 
specimens and/or human tumor cell lines, or, in a few cases (for rare mutations), 
plasmid constructs. Pyrosequencing has been employed for independent confirmation 
of the nature and concentration of the mutations found. For clinical specimens 
containing a low percentage of tumor cells, manual or laser capture microdissection of 
paraffin sections is performed prior to DNA extraction. Methods for pre-amplification of 
DNA have been validated to enable routine analysis of minute clinical specimens. 
Results: A total of 79 mutation assays were created and validated, of which 66 are now 
in routine clinical use in the Yale-New Haven Hospital Tumor Profiling Laboratory. Our 
total experience comprises mutation profiling of over 500 specimens. Currently, the 
most commonly analyzed tumor types in our laboratory are non-small cell lung cancer 
(NSCLC) and colorectal cancer (CRC). Over 240 NSCLC clinical cases have been 
profiled to date, including 67 needle biopsies and 49 cell block specimens from fine 
needle aspirates. Among these cases, the prevalence and distribution of EGFR and 
KRAS mutations detected by us are concordant with published data and the COSMIC 
database. The cost of reagents is less than $100 per specimen for a panel of 50 
mutation assays. The estimated turnaround time for the tumor profiling clinical service is 
7 to 10 business days. Conclusions: We have developed an efficient, rapid and cost-
effective system for molecular profiling of solid tumors that provides sensitive detection 
of clinically actionable mutations in routine diagnostic pathology specimens. This 
methodology enables the molecular pathologist to screen for panels of mutations in 
very scant clinical specimens that are inadequate for multi-gene analysis by other, more 
widely used techniques. Furthermore, because the assays are performed and analyzed 
concurrently in sealed wells without transfer of PCR products between wells or tubes at 
various steps, opportunities for cross contamination between assays are minimized. 
 
ST30. Challenges in the Interpretation of Cancer Exome Data: A Tiered Strategy 
to Effectively Report Sequence Variants 
A. Roy1, W. Parsons1, J. Reid1, S. Plon1, D. Wheeler1, M. Bainbridge1, A. Peterson2, M. 
Li1, F.A. Monzon1 
1Baylor College of Medicine, Houston, TX; 2The Methodist Hospital, Houston, TX. 
Introduction: Next-generation sequencing of cancer exomes typically generate large 
datasets consisting of tens to hundreds of sequence variants per specimen. Although 
informatics strategies to deal with read mapping, variant calling, and variant annotation 
are rapidly being improved, effective clinical reporting strategies that communicate the 
relevant information to the clinical team in a user-friendly manner are lacking. Here we 
present a tiered and structured approach to reporting all sequence variants identified in 
any single cancer sample within one integrated report. Methods: We obtained whole 
exome sequencing data from research and validation samples from different human 
tumor types. We assembled a team of molecular pathologists, geneticists and 
oncologists to determine a strategy for sequence variant categorization based on 
established and potential clinical utility as well genes/pathways of interest in cancer 
biology. Results: Single nucleotide variants (SNV) and indel mutations with human 
genome 19 (hg19) coordinates were grouped into four categories as follows: category I 
– mutations with known clinical utility (diagnostic, prognostic or therapeutic) in tumor 
type based on published clinical practice guidelines (NCCN and others) or institutional 
Genomics Tumor Board; 13 genes with over 1200 somatic mutations reported in the 
Catalog of Somatic Mutations in Cancer (COSMIC) were included in this category. 
Category II – variants in genes or pathways that are targeted by existing approved or 
investigational drugs; 63 genes were included in this category. Category III – variants in 
‘cancer genes’ as defined by the Wellcome Trust Sanger Institute cancer gene census 
(487 genes, March 15, 2012 release); and category IV – all other variants. Variant lists 
for cancer genes, excluding structural variants, were downloaded from the latest (v.38) 
release of the COSMIC database, pathway and drug target information was obtained 
from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and other 
online resources. Conclusions: We have established a tiered strategy for the 
interpretation and reporting of cancer exome sequencing data that provides categorized 
genetic variants based on clinical relevance according to available public information. 
There is a need for consensus in the community for categorization of “actionable” 
mutations/variants and for the development of clinical-grade curated databases for 
cancer genes, cancer pathways and availability of targeted agents within clinical trials. 
 
ST31. Standardization and Validation of EWSR1 Test in 31 Tumors, Including 18 
Unconventional Ewing Sarcomas/Primitive Neuroectodermal Tumors (PNETs)– 
An Indian Perspective 
B. Rekhi1, R. Basak2, S.R. Mumbarkar2, R.Y. Mohite2, J. Bodake2, S.B. Desai1,2, N.A. 
Jambhekar1,2 
1Tata Memorial Hospital, Mumbai, Maharashtra, India; 2Advanced Centre for Treatment, 
Research and Education in Cancer, Khargar, India. 
Introduction: EWSR1 rearrangement is present in certain soft tissue sarcomas, most 
commonly in a Ewing sarcoma(ES)/PNET. EWS-FLI1 transcript is specific for 
ESs/PNETs that also express other transcripts, as a result of variant translocations. 
Herein, we present analysis of 31 tumors tested for EWSR1 rearrangement, including 
18 unconventional ESs/PNETs. Methods: Twelve retrospective (confirmed with EWS-
FLI1, by RT-PCR) and 6 prospective ESs/PNETs were tested for EWSR1 
rearrangement using EWSR1 Dual color Break Apart Kit (Abbott Molecular Inc.). 
EWSR1 rearrangement was interpreted as “detected” in cases showing green-orange 
split signals in more than 15% tumor nuclei. Other tumors tested for EWSR1 
rearrangement were alveolar rhabdomyosarcoma (1), soft tissue myoepithelial tumors 
(3), infiltrating duct carcinomas (2), synovial sarcomas (4), extraskeletal myxoid 
chondrosarcoma (1), pleomorphic sarcoma (1) and a prostatic tumor with differential of 
small cell carcinoma versus ES. Immunohistochemistry in ESs/PNETs was performed 
by immunoperxoidase method using MAC H 2 Universal HRP-Polymer detection kit, 
Biocare, CA. Results: Age-range of ES/PNET cases was 1-35 years (mean, 15). 
Tumors occurred in conventional sites, (mostly older patients) like lower extremities (4), 
upper extremities (3), and uncommon sites like kidney (2), parafalcine area (1), ovary 
(1), head and neck (3), chest wall (1), abdomen (1), pelvis (1) and ‘unknown’ site (1). 
IHC of 18 ESs/PNETs included MIC2 positivity, mostly membranous (16/18) (88.8%), 
Fli1, (6/8) (75%), synaptophysin (4/8) (50%), EMA (5/8) (62.5%), cytokeratins (1/7) 
(14.2%), CD56 (2/2) and BCL2 (2/4). Among 12 EWS-FLI1 positive tumors, 6/9 tumors, 
where results were interpretable, showed rearrangement. Five of 6 prospective cases 
showed EWSR1 rearrangement. A single case was uninterpretable on RT-PCR results, 
but showed positive EWSR1 rearrangement. Most tumors with EWSR1 rearrangement 
displayed single or double split signals. However, 3 tumors revealed complex patterns, 
including multiple orange signals (1) and multiple split signals (2). Among 13 other 
tumors, EWSR1 rearrangement was detected in 2 myoepithelial carcinomas. 
Conclusions: This study testifies reasonable sensitivity and specificity of EWSR1 
rearrangement in ES/PNETs. Two techniques (FISH and RT-PCR) are complimentary. 
FISH test in older blocks is a limitation, especially in referral cases within our settings. 
Complex FISH signals could be as a result of section cutting or deletions with possible 
prognostic implications. EWSR1 rearrangement was also noted in other tumors like 
myoepithelial carcinomas. Optimal IHC panel for ES in resource-limited settings 
includes MIC2, Fli1 and synaptophysin. Variable epithelial markers, expressed in 
certain ESs, result in diagnostic overlap, especially with synovial sarcoma, wherein 
molecular and or genetic confirmation is necessary.  
 
ST32. Use of the Affymetrix Cytoscan HD Array for Evaluation of Chromosomal 
Copy Number Changes in Formalin-Fixed Paraffin-Embedded Specimens 
K. Alvarez1, S. Thakur1, R. Shippy2, F.A. Monzon1 
1Baylor College of Medicine, Houston, TX; 2Affymetrix Inc, Santa Clara, CA. 
Introduction: The Affymetrix Cytoscan HD array provides high-resolution (2.6 million 
markers) coverage of the entire genome using both copy-number and single nucleotide 
polymorphism (SNP) probes. Due to the high coverage of RefSeq and cancer genes 
with one array and assay it is desirable to use this array in cancer applications. This 
technology has shown excellent results with blood, bone marrow, cells, fresh and frozen 
tissues; however no data on its performance with Formalin-Fixed Paraffin Embedded 
(FFPE) tissue has been reported. We have previously demonstrated the reliable 
performance and reproducibility of FFPE tissue on the Affymetrix 250K array. In this 
study we evaluate the performance of the Affymetrix Cytoscan HD array using FFPE 
tissue. Methods: DNA from 28 FFPE samples ranging from 2 to 8 years of age were 
extracted and processed following the standard protocol provided by the array 
manufacturer. Data was analyzed using the Chromosome Analysis Suite (ChAS) 
Software (v2.0.225). Results: From 28 FFPE samples processed, 23 samples yielded 
sufficient PCR product for hybridization on to a Cytoscan HD array. Since QC 
parameters were established based on blood-derived samples, the QC metrics for 
FFPE samples including, SNP QC, MAPD and Waviness SD were out of range, yet the 
data showed reliable identification of chromosome copy number changes and loss of 
heterozygosity (LOH) in more than 50% of the samples. When looking only at data for 
samples that were 4 years of age or newer the rate of samples yielding adequate 
results increases to 71%. Results were concordant with previous data for the same 
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samples obtained on 250K Nsp arrays. Bias in the distribution of PCR product sizes 
correlated with lower QC metrics and non-interpretable data. Conclusions: These 
results show that processing FFPE tissue is feasible using the Cytoscan HD array if the 
age of the samples is less than 4 years old. As seen with the 250k Array, age of sample 
greatly impacted the quality of the data and QC metrics established by Affymetrix. 
Using parameters such as the PCR product distribution of each sample via gel 
visualization isan informative quality control step that can be established to determine if 
a sample is likely to perform well on the array. Our results suggest that this array can be 
an option for analysis of FFPE tissue specimens for routine use. 
 
ST33. Multiplexed Real Time PCR Profiling for Cancer Gene Copy Number 
Alterations in Formalin Fixed Paraffin-Embedded Lung Adenocarcinomas 
J. Bruce1, N. Lindeman1, C. Lee1, D. Dillon1, S. Long2, L.M. Sholl1 
1Brigham and Women's Hospital, Boston, MA; 2QIAGEN Center of Excellence in 
Biological Research Content, Frederick, MD. 
Introduction: Gene copy number (CN) alterations are common in lung 
adenocarcinoma and may predict response to targeted therapies. Fluorescence in situ 
hybridization (FISH) is considered the gold standard for assessing CN but is time 
consuming and less amenable to multiplexing. PCR-based analysis of gene copy 
number permits multiplexing and can be run on standard real time instruments. In this 
study we examine the accuracy of a real time PCR assay versus FISH for CN 
assessment of commonly altered genes in lung adenocarcinoma. Methods: Fifteen 
lung adenocarcinomas (resected from 1994-2011) were selected from the pathology 
archives based on known EGFR, MET, and/or ERBB2 copy number. DNA was 
extracted from 1 mm cores taken from formalin fixed, paraffin-embedded tissue blocks 
from areas containing >50% tumor cells. Real time PCR using QIAGEN qBiomarker 
Copy Number PCR Arrays assessed 23 oncogenes and tumor suppressor genes as 
well as a multicopy reference assay using 200-400 ng of starting DNA. Each assay was 
performed in quadruplicate on an ABI 7900 RTPCR machine. Gene copy number was 
calculated based on the ¨¨CT method, utilizing normal lung as a calibrator. Results: 
Of the 15 samples tested, one sample from 1994 failed due to poor amplification in the 
reference assay. Eight of the 14 remaining samples were EGFR amplified by FISH. 
Using an EGFR CN cutoff of 6, PCR was 100% sensitive and 85% specific for the 
presence of amplification by FISH. MET FISH CN was known in 13 cases, none were 
amplified (range 1-5.7). No cases were MET amplified by PCR, but this approach 
tended to underestimate the FISH CN (range 1.2-3.1). ERBB2 FISH CN was known in 6 
cases, and one was amplified (CN 6.7 by FISH). ERBB2 PCR CN correlated well, and 
identified the same case as amplified (CN 7.2). In addition, MYC, HMGA2, VEGFA and 
CSMD1 were commonly amplified (in two or more samples), according to the PCR 
assay. CN loss of CDKN2A/p16INK4A, FGFR1, PIK3CA, PTEN, or REL was identified 
in at least one of the tested samples. Conclusions: Multiplexed real time PCR for 
tumor gene copy number is a sensitive technique for detection of amplification in 
formalin fixed paraffin embedded tumor specimens. Further study is needed to 
determine the utility of this assay in detection of more subtle copy number changes. 
This assay shows promise as a rapid screening tool for tumor copy number alterations 
to complement targeted mutation analysis. 
 
ST34. Application of Next-Generation Sequencing in Using Fine Needle 
Aspiration Smears and Cell Blocks from Solid Tumors 
R. Kanagal-Shamanna, R.R. Singh, M.J. Routbort, K.D. Aldape, B. Handal, H. Rahimi, 
N.G. Reddy, B.A. Barkoh, B. Mishra, A.V. Paladugu, J. Manekia, G.A. Staerkel, L. 
Medeiros, R. Luthra , K.P. Patel 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Increasing use of fine needle aspirations for oncologic diagnosis, 
whereas minimally invasive, poses a challenge for mutational profiling due to high 
sample requirement of traditional sequencing platforms. The advent of affordable 
benchtop next generation sequencing platforms has facilitated multi-gene mutation 
profiling using nanograms of DNA. To our knowledge, no studies have reported 
application of NGS in cytology specimens. Here, we describe successful NGS-based 
testing of cytology specimens (aspirate smears and cell blocks) in a clinical laboratory 
setting. Methods: Fifteen cytology specimens (cell blocks:7, aspirate smears:8) with 
known mutational status for clinically relevant genes was utilized for the study. Tumors 
included papillary (n=2) and medullary (n=1) thyroid carcinomas, primary and 
metastatic adenocarcinomas of the lung (n=3) and colon (n=2), non small cell 
carcinomas of the lung (n=4), metastatic melanomas (n=2) and alveolar soft part 
sarcoma (n=1). Coverslips were removed from the Diff Quik stained smears. DNA was 
extracted following manual microdissection. Paraffin-embedded cell pellets of H2122 
cell line diluted in HL60 cell line was used as a control. Ten nanograms of DNA per 
sample was tested by a 46 gene mutation panel using a 318 chip on Ion personal 
genome machine (PGM) Sequencer (Life Technologies, CA). Results: The median 
tumor percentages in the smears and cell blocks were 70% (range, 60-90, n=5) and 
50% (range, 25-80, n=7) respectively. The median number of slides used to extract 
DNA was 1 for smears (range: 1 to 2) and 4 for cell blocks (range: 2 to 6). DNA yield 
was adequate with a median concentration of 2.5 ng/Pl (range, 0.85 - 21.0). All samples 
underwent successful targeted sequencing of the 46 genes with a median number of 
filtered Q20 alignment reads at 467,812 (range: 167,391 to 610,704). A 100% 
concordance was noted between the NGS and conventional test platforms for all 
previously known point mutations (BRAF, KRAS, KIT, MET, NRAS, PET, PIK3CA, 
PTEN and RET ) including 15 base pair deletion (EGFR) as well as all wild-type calls. 
Additional variants were identified in KDR, TP53, APC, PIK3CA, KIT, FLT3, FGFR2, 
SMAD4, STK11, CTNNB1 and MLH1 in 11/15 (73%) cases increasing the utility of 
mutation analysis. Conclusions: Our results demonstrate successful NGS-based 46-
gene mutational profiling using nanogram amounts of DNA from cytology smears and 
cell blocks enhancing the combined utility of fine needle aspirations as a minimally 
invasive tool and NGS platforms in personalized cancer medicine. 
 
ST35. Detection of USP6 Gene Rearrangement in Nodular Fasciitis. An 
Important Diagnostic Tool 
H. YE1, F. Berisha1, M. Alorjani1, M. Eskandarpour2, T. Diss3, R. Tirabosco1, A.M. 
Flanagan1, M. Amary1 
1Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom (Great 
Britain); 2University College London Cancer Institute, London, United Kingdom (Great 
Britain); 3University College London Hospital, London, United Kingdom (Great Britain). 
Introduction: Nodular fasciitis (NF) is a fast-growing, usually self-limited benign 
mesenchymal lesion, which is diagnostically challenging and can be misdiagnosed as 
sarcoma. There are no specific immunohistochemical markers and the diagnosis, until 
recently, was based purely on histology. A USP6 (17p13) gene rearrangement was 
recently detected in 92% of cases of NF in a series of 48, and a MYH9- USP6 fusion 
transcript has been detected in 75% of these. In this project we tested a new series in 
an attempt to confirm the published finding so that we could introduce the test into our 
service as an ancillary diagnostic tool. Methods: A total of 34 cases previously 
diagnosed as NF were screened for the presence of the USP6 gene rearrangement by 
interphase fluorescence in situ hybridisation (FISH) on formalin-fixed paraffin-
embedded tissue sections using non-commercial break-apart probes. 28 of these 
cases, where tissue was available, were also analysed by RT-PCR assays for MYH9-
USP6 fusion transcripts. Results: 31 of the 34 cases (91%) examined were positive for 
the published USP6 gene rearrangement by interphase FISH. 21 of these gave 
informative results by RT-PCR: 19 positive and 2 negative for USP6 gene 
rearrangement. Of these 19 cases, 14 (74%) showed a MYH9-USP6 fusion transcript 
by RT-PCR. Conclusions: USP6 gene rearrangement is a recurrent genetic event in 
nodular fasciitis and it is a valuable ancillary tool for the diagnosis of these lesions. 
Although in the majority of cases (75%) the balanced translocation involves the MYH9 
gene (22q12.3-q13), in ~26% the fusion partner of the USP6 gene remains unknown. 
 
ST36. Development, Clinical Validation and Initial Experience with a Direct 
Sequencing-Based Assay for Detection of PDGFRA Mutations in Gastrointestinal 
Stromal Tumors  
G. Sharma, H.C. Weigelin, K. Elenitoba-Johnson, B.L. Betz 
University of Michigan Health System, Ann Arbor, MI. 
Introduction: Gastrointestinal stromal tumor (GIST) is the most common (60-85%) 
mesenchymal tumor of the gastrointestinal tract. Approximately 81% of GISTs harbor 
oncogenic mutations in the KIT gene, whereas 7% harbor mutations in PDGFRA, a 
related receptor tyrosine kinase. The PDGFRA mutations associated with GIST involve 
exons 12, 14, and 18 with an approximate frequency of 9%, 1%, and 90%, respectively. 
The most common PDGFRA mutation (D842V) is associated with imatinib resistance. 
Thus, testing for PDGFRA mutation can aid in the diagnosis and molecular 
characterization of GIST, and may help predict response to imatinib therapy. The intent 
of this study was to develop and validate a clinical assay to detect PDGFRA mutations 
in GISTs and to report our initial experiences with the test. Methods: A direct 
sequencing-based assay was designed to interrogate PDGFRA exons 12 and 18 from a 
pathologist-selected tumor specimen (containing at least 40% tumor cells). After assay 
optimization, the analytic performance characteristics were determined in a panel of 
diverse specimens. Finally, a blinded inter-laboratory specimen exchange was 
performed and the test was implemented in January 2012. Test results were reviewed 
from the first five months of clinical testing. Results: The assay exhibited robust 
amplification of the 205 bp (exon 12) and 195 bp (exon 18) fragments from DNA 
extracted from both fresh and FFPE tissues. High quality sequence data was obtained 
in all cases. 9 cases with PDGFRA mutations (all within exon 18) were detected in a set 
of 46 FFPE specimens previously determined to be KIT mutation negative. As 
expected, no mutations were detected in normal reference tissues. By serial dilution 
studies, the analytical sensitivity was determined to be at least 10% mutant allele. Inter-
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laboratory specimen exchange concordance was 100% (10/10) and included 5 positive 
(3 exon 12 and 2 exon 18) and 5 negative cases. In the clinically tested specimens 
(n=16), 6 (38%) tested positive for a mutation. The most common mutation was 
PDGFRA c.2525A>T,p.D842V (n=3) followed by PDGFRA 
c.2526_2537del,p.I843_D846del (n=2) and PDGFRA c.1666_1695dup, 
p.E556_I565dup (n=1). Conclusions: Targeted direct sequencing provides a sensitive 
and specific means to detect PDGFRA mutations associated with GIST. Our assay 
exhibited robust performance characteristics warranting the test to be utilized clinically. 
 
ST37. Protein Expression and Gene Amplification of PDGFRĮ in Gliomas by 
Immunohistochemistry and Fluorescence in situ Hybridization 
T. Ha, C. Chow, N. Jun, P. Choppa, K. Bloom, K. Gutekunst 
Clarient, A GE Healthcare Company, Aliso Viejo, CA. 
Introduction: Glioblastoma multiforme (GBM) have been classified as the most 
common and most malignant primary brain tumor in human adult, accounting for >70%. 
However, the incidence is only 2-3 cases per 100,000 people in Europe and North 
America. Current treatment includes surgical resection, radiation therapy and adjuvant 
chemotherapy. Unfortunately, patient prognosis is still poor with a mean survival of 
approximately one year. Identification of a novel therapeutic target would hopefully lead 
to a positive prognosis. Several receptor tyrosine kinases have been identified that may 
play an important role in a cell’s life-cycle regulation in glioma cells. We tested for 
protein expression of platelet-derived growth factor receptor alpha-type (PDGFRĮ) by 
IHC and compared to genetic amplification testing by FISH. Methods: IHC and FISH 
was performed on 22 brain samples received from August 2011 to May 2012 for 
PDGFRĮ. Several sections were cut from formalin-fixed, paraffin-embedded tissue 
blocks. An adjacent slide was hematoxylin-eosin (H&E) stained and used to select 
tumor. Tissue sections for IHC were deparaffinized and treated with citrate for the 
antigen retrieval method. Afterwards samples were detected with a polyclonal PDGFRĮ 
antibody (Santa Cruz Biotechnolgy, Santa Cruz, CA) and visualized on a bright field 
microscope. Serial sections of the same sample for FISH were deparaffinized, 
pretreated with 8% NaSCN and digested with pepsin. A custom developed PDGFRĮ 
and satellite enumeration 4 (SE4) probe (Kreatech, Amsterdam, Denmark) was applied 
to assess amplification. Visualization was performed on a fluorescence microscope with 
Texas Red and FITC single band-pass filters. Results: A total of 22 GBM samples 
were analyzed for over expression of PDGFRĮ by IHC and was detected in 17 cases 
(77.3%). Of the 17 cases, amplification (PDGFRĮ:SE4 2.00) was detected by FISH in 
only 1 case (5.8%). Additionally, 5 cases (22.7%) with PDGFRĮ over expression, 
exhibited 5 copies of PDGFRĮ and a total of 18 cases had 3 copies of chromosome 
4. Conclusions: PDGFRĮ may be an important marker to identify GBM candidates for 
a gene targeted therapy. However, the lack of correlation of IHC to FISH may need to 
be resolved by a more appropriate scoring system that may not only include 
PDGFRĮ:SE4 ratio, but also take into account gene and chromosome copy number. 
Alternatively, gene expression may be driven by a factor other than PDGFRĮ 
amplification, thereby making FISH an inappropriate test for therapy eligibility and/or 
prognosis. Further study is warranted. 
 
ST38. Performance of the Targeted Next Generation Sequencing Ion Torrent 
Platform for Detection of Clinically Relevant Somatic Mutations 
M. Durso, Y.E. Nikiforov, L.M. Kelly, M.N. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: The availability of next generation sequencing has opened a possibility of 
efficient detection of multiple mutations without significant cost increase. In this study, 
we evaluated the performance of Ion AmpliSeqTM Cancer Panel on Ion Torrent PGM 
(Life Technologies) for clinical testing of solid tumors in a molecular diagnostic 
laboratory. Methods: Total of 53 tumors and 3 normal tissues were tested for mutations 
in 46 genes using the Ion AmpliSeqTM Cancer Panel. The validation set included 31 
tumors previously positive for mutations in the KRAS, NRAS, HRAS, BRAF, RET, KIT, 
EGFR, PDGFR, TP53 genes and 22 tumors negative for mutations. Analysis was 
performed using 316 and 318 chips with up to 10 barcoded samples per chip, AmpliSeq 
v.2.0 chemistry and Ion Sequencing 200 kit. Data were analyzed by Variant Caller 
v2.0.1.0 and NextGene (Softgenetics) softwares. Results: Using 10 ng of DNA we 
were able to successfully analyze all samples (33 frozen, 19 FFPE and 4 FNA) for 
mutations in 46 genes. The average of 536,660 mapped sequence reads per barcoded 
sample (range 189,802 to 1,334,101) was achieved with the 72bp mean read length, 
2,783 mean reads for hot spot coverage, and 92% uniformity of coverage. Ion Torrent 
detected 27/27 (100%) of point mutations and 2/4 (50%) of insertion/deletions and 
overall provided 94% sensitivity of mutation detection. Two complex mutations were 
missed: a complex mutation in BRAF (p.T599_H608delins) and a TKI resistance 
insertion mutation in EGFR exon 20 (p.D770_N771insSVE). These mutations were not 
visible on manual review of the region and not detected by softwares. In addition to 
known sequence variants, Ion Torrent detected novel mutations in the PIK3CA, TP53, 
MET, ATM, and KDR genes that were confirmed by Sanger sequencing. However, 
multiple low-frequency variant calls were detected across all samples and were mostly 
due to errors in homopolymer regions. The filtering algorithm was established with cut 
off of 10% to exclude low-frequency calls. The limit of mutation detection was 5-10% 
and turnaround time was 72 hours. Conclusions: Targeted sequencing using the 
AmpliSeq Cancer panel on Ion Torrent allows testing for a broad spectrum of mutations 
with low input of DNA and rapid turnaround time. The platform detects point mutations 
with 100% sensitivity but has limitations in detecting insertion/deletions. The reduction 
of homopolymer-associated errors would be desirable. Use of Ion Torrent in a clinical 
laboratory should take into consideration the current limitations of this technology in 
detecting indels and after establishing of appropriate detection cut offs. 
 
ST39. Identification of KIT Activating Mutations in Pediatric Solitary 
Mastocytoma 
D. Ma, A.A. Stence, J.R. Hackman, J. Buhay, J.A. Pruessner, S. Forde, M.T. Zubcic, 
A.M. Bellizzi, J.W. Heusel, A.D. Bossler 
University of Iowa Hospitals and Clinics, Iowa City, IA. 
Introduction: Mastocytosis is characterized by abnormal mast cell proliferation 
involving various organs, skin and bone marrow in particular. The cutaneous 
presentation of pediatric mastocytosis includes mastocytoma, urticaria pigmentosa, and 
diffuse cutaneous mastocytosis. Although KIT D816V mutation is frequently found in 
adult mastocytosis, it is rarely seen in childhood onset solitary mastocytoma and the 
frequency and role of KIT mutation in this subgroup is controversial. In this study, we 
analyzed nine cases of pediatric solitary mastocytoma using a laboratory developed 
assay and report the frequent association of KIT activating mutation in pediatric solitary 
mastocytoma. Methods: Cases were reviewed by a surgical pathologist. Areas with 
tumor content >50% were selected for molecular testing. Genomic DNA was isolated 
from microdissected formalin-fixed, paraffin-embedded tissue. Mutational analysis of 
KIT exons 8, 9 and 17 was performed by PCR amplification followed by Sanger cycle 
sequencing using the ABI Prism 3130XL (Applied Biosystems, Carlsbad, CA). The limit 
of detection of this assay is ~10%. Results: The age range of the patient group is 1 
month to 10 years. All had solitary mastocytoma in the skin with no other cutaneous or 
systemic involvement. A majority of the lesions was located in the head and neck region 
(four in the scalp and two in the neck) with the reminder in the extremities or shoulder. 
Sequencing analysis identified c.2447A>T (p.D816V) point mutation (in exon 17) in 
three cases, and internal tandem duplication in exon 9 (c.1504_1509dup, 
p.A502_Y503dup) in another three cases. No exon 8, 9 or 17 mutations were detected 
in the remaining cases. Conclusions: One-third of solitary mastocytomas carries the 
D816V mutation, the same mutation identified in adult systemic mastocytosis. 
Curiously, 3 of the cases (33%) showed internal tandem duplication (p.A502_Y503dup) 
in the transmembrane domain at exon 9, which is frequently seen in gastrointestinal 
stromal tumor. These finding suggests that pediatric solitary mastocytoma is frequently 
associated with KIT activating mutation. Since childhood onset mastocytoma usually 
undergoes spontaneous regression, the significance of a clonal proliferation involving 
KIT activation warrants further investigation. 
 
ST40. MiR-217 as a Diagnostic Marker for Hepatocellular Carcinoma 
A.N. Abou Tayoun1, Y. Xue2, D.A. Axelrod1, R.B. Freeman1, A.A. Suriawinata1, G.J. 
Tsongalis1 
1Geisel School of Medicine at Dartmouth, Lebanon, NH; 2Dartmouth Hitchcock Medical 
Center, Lebanon, NH. 
Introduction: Hepatocellular carcinoma (HCC) is the fifth most common cause of 
cancer worldwide and is reaching epidemic proportions in the US Low survival is 
attributed to late diagnosis, resistance to treatment, tumor recurrence, and metastasis. 
Hence, it is very important to find more appropriate novel diagnostic and surveillance 
tools and to develop more effective therapeutics. The study herein was conducted to 
assess expression of several microRNA levels in HCC resection specimens in an effort 
to identify potential new diagnostic biomarkers. Methods: FFPE resection specimens 
containing conventional hepatocellular carcinoma (n=10) in a non-neoplastic liver 
parenchyma (n=10) were selected from the archives of the Department of Pathology. 
H&E stained tissue sections were reviewed by a pathologist and corresponding 
unstained sections (5 μm) were marked for macrodissection. Total RNA extraction was 
performed using the Qiagen RNeasy FFPE Kit. Reverse transcriptase reactions were 
performed using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) 
with primers specific for the following miRNAs: RNU6B (internal control), miR-21, mir-
122, miR-148a, miR-196a, or miR-217. Real time PCR was peformed on the AB 7500 
FAST instrument (TaqMan MicroRNA Assays, Applied Biosystems) and each PCR was 
run in duplicate. The average cycle threshold (CT) value was calculated and used to 
determine expression levels of each miRNA (log2 (2-ǻCT)). Results: We performed 
separate RNA extractions from macrodissected HCC and its surrounding non-
neoplastic tissue within the same tissue section. This allowed for direct comparison 
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between miRNA levels in the two tissue types. Our data show that miR-217 levels were 
significantly reduced in HCC lesions compared to the surrounding non-neoplastic tissue 
(P<0.05). Furthermore, mir-196a levels were modestly elevated in the tumor tissue 
(P=0.056). Conclusions: Our data demonstrate that miR-217 expression level is down-
regulated in HCC and thus could be useful as a diagnostic marker to distinguish tumor 
lesions from non-neoplastic liver parenchyma.  
 
ST41. Identification of Tumor Loco Ignoto by HR-HPV Genotyping, E6/E7 HR-
HPV Oncogene Expression by RT-PCR and by Immunohistochemical Analysis of 
Metastases in the Lymph Nodes from the Neck.: Case Report 
E. Weismanova1, F. Kurinec 2, P. Vitazka3, J. Benko 2, L. Horváth 4, P. Weismann 5 
1St. Elizabeth Cancer Institute, Bratislava, Slovakia; 2University Hospital and Clinic, 
Nove Zamky, Slovakia; 3OUSA, Bratislava, Slovakia; 4National Reference Laboratory 
for Genetically Modified Organisms, Bratislava, Slovakia; 5Medical Faculty of Comenius 
University, Bratislava, Slovakia. 
Introduction: It has been shown that a subset of oropharyngeal squamous cell 
carcinomas (OSCC) is associated with HR-HPV infection. Although the HPV-positive 
OSCC are able to metastasize to regional lymph nodes, patients have better response 
to therapy, disease-specific survival (DSS) and overall survival (OS) when compared to 
HPV-negative OSCC patients. Our laboratory received two lymph nodes extracted from 
a patient’s neck area that we initially tested for presence of HR-HPV DNA and E6/E7 
HR-HPV oncogene expression by RT-PCR to determine the origin of a primary loco 
ignoto tumor. To confirm histological tumor type we analyzed tissue, subsequently 
extracted from the oropharyngeal region, by morphology and by IHC analysis for 
CDKN2A (p16), TP53 (p53), and MKI67 (Ki67). The HPV-positive OSCC tumors with 
elevated expression of CDKN2A (p16) are associated with good prognosis whereas 
MKI67 (Ki67), and mutated TP53 (p53) overexpression is associated with elevated cell 
proliferation. Methods: The HR-HPV genotyping and E6/E7 HR-HPV oncogene 
expression was performed by RT-PCR using RNAlater preserved tissue from two neck 
lymph nodes. Confirmation of histological tumor type was performed by morphology 
and by IHC analysis of CDKN2A (p16), TP53 (p53), and MKI67 (Ki67) on formalin-fixed, 
paraffin-embedded tissue (FFPE) extracted from oropharynx. Results: We confirmed 
presence of HR-HPV 35 in both analyzed metastases but we failed to detect the E6/E7 
HR-HPV oncogene expression. By IHC we detected p16-positivity, p53-positivity in 51% 
of cells and Ki67-positivity in 52% of cells. Conclusions: Detection of HR-HPV 35 
genotype led us to assume that metastases might have originated from a primary tumor 
localized in the oropharynx, likely HPV-positive OSCC. E6/E7 HR-HPV oncogene 
expression was not detected, therefore, HR-HPV infection is unlikely the reason of cell 
transformation. Detailed analysis of FFPE tissue extracted from the oropharyngeal 
region revealed presence of dysplastic tissue of basaloid morphology in tonsils. By IHC 
we confirmed elevated expression of tumor suppressor p53 (frequently inactivated by 
mutations in OSCC) and Ki67, reflects high proliferation activity of dysplastic cells. 
Contradictory, we also detected p16 up-regulation associated with HR-HPV-positivity, 
considered to be a marker of better prognosis in OSCC. Detection of HR-HPV and 
other molecular markers facilitated in our patient detection of loco ignoto HPV-positive 
tonsillary carcinoma with basaloid histology, generally considered to have better 
prognosis.  
 
ST42. Sequencing with Locked Nucleic Acids (LNA) in Solid Tumor Testing 
J.L. Winters, J.S. Voss, K.M. Rumilla, S.N. Thibodeau, B. Kipp 
Mayo Clinic, Rochester, MN. 
Introduction: Sanger sequencing is known to lack the analytical sensitivity required to 
detect somatic mutations in solid tumors. Locked Nucleic Acids (LNA) are modified 
nucleotides that strongly bind and inhibit PCR amplification of the wild-type sequence, 
thus favoring amplification of the mutant allele. LNA are inexpensive and easy to 
develop for most targets, making them a good option for stand-alone or confirmatory 
testing. We present our experience using LNA in BRAF and KRAS Sanger sequencing 
assays. Methods: For KRAS, we tested 111 FFPE tumor DNA samples for codons 12 
and 13 using LNA sequencing. These samples were previously tested using a 
commercial RT-PCR assay that has a reported sensitivity of 5%. We performed 
experiments to determine analytical sensitivity and DNA requirements. For BRAF, we 
tested 37 FFPE tumor DNA samples for V600 mutations. These samples were 
previously tested using a V600E AS-PCR assay having a sensitivity of 5-10%. For both 
KRAS and BRAF, we sequenced samples in parallel with and without LNA to compare 
mutant signals. In a subsequent study, we used BRAF LNA sequencing to resolve 
discrepant results between multiple BRAF platforms. Results: We observed 100% 
concordance in KRAS results between the two methods. We determined the analytical 
sensitivity of LNA sequencing to be 1-5% and the minimum DNA input requirements to 
be 1 ng of DNA. There was also 100% concordance in BRAF results. The BRAF LNA 
sequencing method identified V600K in 3 samples that were negative by our AS-PCR. 
Using LNA increased the mutant peaks by ~40% (KRAS) and ~45% (BRAF) compared 
to sequencing without LNA. We observed no false positive mutations by LNA 
sequencing compared to reference methods. In the subsequent study, LNA sequencing 
resolved discrepant results between multiple BRAF platforms, identifying V600K and 
V600E (GAA instead of more common GAG) alterations. Conclusions: LNA 
sequencing assays provide the level of sensitivity (1-5%) needed for solid tumor testing, 
rivaling costly commercial kits. This method can often test for multiple mutation targets 
in one PCR and can be achieved with far less DNA over most commercial kits. Design 
and development is straightforward for most targets. LNA sequencing assays can serve 
as an effective stand-alone test, confirmation test, or a means to resolve discrepant 
results. 
 
ST43. Targeted Next Generation Sequencing of 287 Cancer-Related Genes 
Using Individually Synthesized Biotinylated DNA Capture Probes  
Z. Zwirko, M. Jarosz, D. Lipson, J. He, G. Frampton, F. Juhn, K. Brennan, M. Nahas, R. 
Yelensky, A. Parker, P. Stephens, M. Cronin 
Foundation Medicine, Cambridge, MA. 
Introduction: Characterization of the genomic changes that drive an individual patient’s 
disease is now critical to inform rationally targeted therapies and treatment planning for 
patients with cancer. But as the number of therapeutically relevant cancer genes 
increases and biopsy size decreases, individual assay or hotspot panels are becoming 
increasingly inadequate. We have developed a targeted, pan-solid tumor next 
generation sequencing (NGS) strategy using in-solution hybrid selection to examine the 
entire coding regions of 287 cancer-related genes that accurately reports all classes of 
genomic alteration in a single test. Many commercially available hybrid selection kits 
rely on biotinylated DNA or RNA capture probes that are synthesized on arrays and 
PCR amplified as a pool, which inevitably leads to uneven coverage, GC bias and 
coverage gaps. As an alternative, we’ve developed a capture method that relies on 
biotinylated DNA capture probes that are individually synthesized, quality controlled and 
normalized to ensure deep coverage of every targeted base with superior uniformity. 
The individual-synthesis approach has the additional benefit of modularity as new 
content can readily be added to an existing pool without re-synthesizing the entire set. 
Methods: Indexed ligation-based libraries were prepared using 200ng of genomic DNA 
from a variety of formalin-fixed paraffin-embedded tumor specimens (n=12) or high 
quality DNA obtained from commercially available cell lines (n=16). 2Pg of library was 
then captured using a pool of ~24,000 individually synthesized 120-mer biotinylated 
DNA oligonucleotide capture probes (Integrated DNA Technologies) spanning a 1.6 Mb 
target territory. The selected libraries were sequenced on an Illumina HiSeq 2000 
sequencer with 49bp paired-end reads and a 7-base index read at an average of 32 
million clusters/sample. Results: Over 99% of the target territory was covered at 150X 
or greater in 100% of the samples tested (28/28). Median exon coverage depth ranged 
from 249.6X to 899.0X with an average CV per sample of 22.8%. Mean coverage of 
different exons had minimal dependence on GC-content; as an example, in a cell-line 
used as a standard process control exons with 20-40% GC averaged 492.6X, exons 
with 40-60% GC averaged 547.5X, and exons with 60-80% GC averaged 456.7X. 
Conclusions: These results demonstrate that individually synthesized DNA capture 
probes can be used to produce deep and highly uniform sequence coverage across a 
large number of exons ensuring high sensitivity across all targets in a clinical NGS 
assay. 
 
ST44. Validation of Affymetrix 250K Nsp Arrays for Clinical Use in the 
Evaluation of Genomic Copy Number Alteration and Loss of Heterozygosity in 
Cancer 
S. Thakur, K. Alvarez, M. Weindel, M.M. Li, F.A. Monzon 
Baylor College of Medicine, Houston, TX. 
Introduction: Chromosomal aberrations provide important insight for clinical diagnosis 
and management of malignancies such as chronic lymphocytic leukemia (CLL) and 
renal epithelial tumors. Array comparative genomic hybridization and SNP arrays have 
emerged as powerful tools to provide high resolution copy number data. Clinical 
validation of the performance of these technologies is a crucial step before clinical 
implementation. In this study we report the validation of the Affymetrix GeneChip 250K 
Nsp array on 23 commonly tested specimens. Methods: Genomic DNA was obtained 
from a total of 23 specimens including 5 frozen renal cell carcinomas (RCC), 8 formalin-
fixed paraffin embedded (FFPE) RCCs, 5 peripheral blood, and 5 bone marrow 
samples. DNA was processed with the Affymetrix GeneChip human mapping 250k Nsp 
I array according to the manufacturers’ protocol for frozen samples and with previously 
reported modifications for FFPE specimens. CEL files generated from Genotyping 
Console (Affymetrix) were further analyzed by CNAG3.3. Copy number variation and 
SNP genotyping data were obtained. Samples were tested blindly in terms of gender, 
diagnosis and test result. Intra lab reproducibility was also evaluated. Results: All the 
samples performed successfully and passed established internal QC criteria for PCR 
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amplification and hybridization metrics. Interpretation of copy number data for each 
renal tumor sample was in concordance with expected tumor type based on histology 
and with Affymetrix SNP 6.0 (Frozen) and 250K Nsp (FFPE) results from external 
laboratories. 250K Nsp arrays detected all previously reported lesions 300kb or larger in 
FFPE samples, although some deletions down to 10kb were detectable in areas with 
high probe coverage. Interpretation of copy number data for each bone marrow and 
peripheral blood specimens was in concordance with results from conventional 
cytogenetic analysis or array CGH. In the two brain oligodendroglioma FFPE samples, 
1p/19q co-deletion was observed that was in concordance with previously reported 
results from FISH analysis. Conclusions: The Affymetrix GeneChip 250K Nsp array 
showed adequate performance in the detection of copy number abnormalities and LOH 
for a wide variety of samples including FFPE samples. The SNP arrays were able to 
detect expected copy number abnormalities for the specific tumor types and correlated 
with other techniques such as cytogenetics and array CGH. The limit of detection was 
established at 300kb based on comparisons with higher density arrays. 
 
ST45. Microsatellite Instability Discordance in Synchronous Colorectal 
Adenocarcinoma—Evidence for Parallel Oncogenic Pathways Involving Distinct 
Molecular Mechanisms 
J.M. Savage, D. Ma, G.C. Caponetti, A.D. Bossler, J.W. Heusel 
University of Iowa, Iowa City, IA. 
Introduction: Microsatellite instability (MSI) arises from defects in DNA mismatch 
repair (MMR), and is used to screen for germline mutations in MMR loci that underlie 
hereditary non-polyposis colorectal cancer (HNPCC, Lynch syndrome). However, the 
majority of MSI-high colorectal tumors are of sporadic origin, often due to 
hypermethylation of the MLH1 locus. Here we report a case of complete MSI 
discordance between two primary colorectal adenocarcinomas resected in the same 
procedure. We report on additional molecular features of these synchronous tumors 
and discuss the implications for distinct, parallel oncogenic pathways in this patient. 
Methods: DNA was prepared from FFPE tissue containing >75% moderately 
differentiated adenocarcinoma at each site. MSI testing, BRAF exon 15 and KRAS 
codons 12, 13 and 61 mutational analyses were performed by validated UIHC 
Molecular Pathology Laboratory-developed assays, in duplicate. Immunohistochemistry 
(IHC) for MMR proteins MLH1, MSH2, MSH6 and PMS2 was performed by Mayo 
Medical Laboratories (Rochester, MN). MLH1 methylation testing will be performed by 
an in-house assay and confirmed by a reference laboratory. Results: Tumor 1 was 
resected from the transverse colon. It was found to be MSH-high (5/5 microsatellites 
unstable), had a V600E (c.1799 T>A) BRAF mutation and showed loss of MLH1 and 
PMS2 proteins by IHC. Tumor 2 was resected from distal left colon and was 
microsatellite-stable (MSS, 0/5 microsatellites unstable). Tumor 2 had a K601N 
(c.1803A>C) BRAF mutation and showed robust nuclear staining for MMR proteins. 
Results on the presence of somatic KRAS mutations and the MLH1 methylation status 
in each tumor are pending. Conclusions: These results confirm and expand upon 
previous findings that oncogenesis in the gut may arise via distinct molecular pathways. 
Tumor 1 shows high-level MSI, most likely due to MLH1 promoter hypermethylation, 
whereas tumor 2 has no apparent MMR defect. Although relatively rare, MSI 
discordance has been reported recently for synchronous and metachronous tumors 
(Bae et al, 2012), as well as for synchronous adenomas and colorectal carcinomas 
(Ogino et al, 2006). Here, we also report distinct activating BRAF mutations in each 
tumor. Such cases present a rare opportunity to understand the degree of overlap in 
synchronous oncogenic pathways, the relationship between defective MMR and 
associated somatic mutations, and possibly the mutational evolution within each tumor. 
Toward this goal we anticipate the results of more comprehensive mutational analysis 
using massively parallel sequencing technology comparing the patient’s constitutional 
genome to those of the synchronous tumors in this unique case.  
 
ST46. A Dinucleotide Repeat, (GT)24, Located within the 3’-UTR of the 
Microsomal Prostaglandin E Synthase-1 (PTGES) Gene is Frequently Mutated in 
Microsatellite Instability High (MSI-H) Colorectal Cancers 
D. Cherukuri, J. Deignan, K. Das, H. Herschman 
University of California, Los Angeles, CA. 
Introduction: Microsomal prostaglandin E synthase 1 (PTGES, also referred to as 
mPGES-1) lies downstream of COX2 in the COX2-PGE2 pathway and is functionally 
involved in the synthesis of PGE2. Previous studies have shown mPGES-1 
overexpression in some human colorectal tumors. Overexpression of mPGES-1 in 
human colorectal cancer cell lines resulted in increased cell growth and increased 
PGE2 production. Furthermore, genetic deletion of mPGES-1 in animal models 
significantly reduced intestinal tumorigenesis in Apc-mutant mice and also in 
carcinogen-induced colorectal tumor formation. Collectively, these data implicate a role 
for mPGES-1 in colorectal tumorigenesis. DNA mismatch repair deficiency, due to 
genetic and epigenetic inactivation of mismatch repair genes (hMLH1, hMSH2, hMSH6, 
and hMSH3), leads to microsatellite instability in a subset of human colorectal tumors. 
Previous studies have shown that altered expression of several genes in MSI-H 
colorectal tumors was associated with mutations in microsatellites that are located 
either in the coding region or in the regulatory regions of gene(s). We identified a 
dinucleotide repeat, (GT)24, located within the 3’-untranslated region (UTR) of the 
mPGES-1 gene (Genbank accession no: NM_004878.4; nucleotides 1665-1712). In this 
study we investigated whether the (GT)24 repeat in the mPGES-1 gene exhibits 
instability in MSI-H colorectal tumors. We also surveyed levels of mPGES-1 mRNA in 
MSI-H as well as MSS colorectal cancer cell lines. Methods: A total of 27 colorectal 
tumors, categorized either as MSS (n=13) or MSI-H (n=14) based on the Bethesda 
reference marker panel screening, and their matched controls were used in this study. 
The (GT)24 repeat region of mPGES-1 was PCR-amplified with fluorescently labeled 
primers and the products were analyzed by capillary electrophoresis using an ABI 
3130xl genetic analyzer. We scored (GT)24 repeat region as unstable when novel 
allele(s) were detected in tumor DNA in comparison with the corresponding normal 
DNA. Results: The mPGES-1 3’-UTR dinucleotide repeat (GT)24 exhibited MSI in all 
14 MSI-H colorectal tumors analyzed. None of the MSS tumors demonstrated instability 
of the mPGES-1 3’-UTR (GT)24 repeat. Quantitative real time PCR-based analysis of 
mPGES-1 mRNA expression showed relatively higher mPGES-1 mRNA levels in MSI-H 
colorectal cancer cell lines (HCT116 and LoVo) compared to those observed in MSS 
cell lines (Caco2, SW680, and LS174T). Conclusions: In conclusion, we have 
identified a novel mutation in a (GT)24 dinucleotide repeat located within the 3’-UTR of 
the mPGES-1 gene in MSI-H colorectal tumors.  
 
ST47. New Markers for Improved Detection of MSI in Endometrial Cancers 
J. Bacher1, J. Vidugiriene1, D. Kanopiene2 
1Promega Corporation, Madision, WI; 2Vilnius University Institute of Oncology, Vilnius, 
Lithuania. 
Introduction: Mononucleotide repeats consisting of long polyA tracts tend to be 
unstable and exhibit high mutation frequencies in cells lacking DNA mismatch repair. 
Mutations in mononucleotide repeat tracts are biased toward deletions, which are 
belived to get progressively larger during clonal expansion in tumor development. This 
property of long mononucleotides is potentially advantageous for MSI testing of extra-
colonic tumors, which generally exhibit an attenuated MSI phenotype. This study tests 
the hypothesis that long mononucleotide repeat markers are more sensitive than 
commonly used MSI markers for determining the MSI status of endometrial cancers. 
Methods: We have identified microsatellite markers with polyA runs of 40-60bp that are 
considerably longer than repeats in markers commonly used for MSI analysis. To test 
whether long mononucleotide repeats are more sensitive markers for MSI testing, 300 
endometrial tumors and matching normal samples were assayed for MSI using 
mononucleotide markers Bat-25, Bat-26, Mono-27, NR-21 and NR-24 in the MSI 
Analysis System (Promega), as well as new long mononucleotide repeats Bat-52, Bat-
55, Bat-56, Bat-57 and Bat-59. Confirmation of mismatch repair status is determined by 
immunohistochemistry for expression of MLH1, MSH2, MSH6 and PMS2 proteins. 
Results: The percent of endometrial cancers that were MSI-positive was: 2.3% for NR-
24, 2.6% for NR-21, 3.6% for Bat-25, 4.5% for Bat-57, 5.5% for Bat-26, 5.8% for Mono-
27, 8.1% for Bat-56, 9.4% for Bat-55, 9.4% for Bat-52 and 10.4% for Bat-59. A 
combination of lower frequency of MSI and a high number of equivocal calls due to 
small deletions resulted in lower overall MSI detection using markers with shorter polyA 
tracts. This result is consistent with earlier reports that the MSI phenotype is attenuated 
in endometrial cancers compared to colon cancers using standard MSI markers. In 
contrast, with the long mononucleotide repeat markers the size of the deletions were 
significantly larger (p=0.002), with an average change in allele size in MSI-positive 
samples of 12.8bp for the long mononucleotides compared to 4.5bp for the MSI 
Analysis System markers. In addition, the sensitivity of the long mononucleotide repeats 
was significantly higher (p=0.004), with 19.3% of tumors either MSI-Low or MSI-High 
with long mononucleotides versus 8.1% with the MSI Analysis System. Conclusions: 
These data suggest that a panel of long mononucleotides microsatellite markers will be 
more sensitive for detetion of MSI in endometrial cancers and perhaps other extra-
colonic tumors. 
 
ST48. Frequency of EGFR Mutation in a Series of Brazilian Patients with Non-
Small Cell Lung Carcinomas 
P.M. Peresi Roldan, M.P. Macedo, B.C. Lisboa, F.M. Melo, L.d. Andrade, C.A. Pinto, 
C.A. Osório, F.A. Soares, D.M. Carraro, I.W. Cunha 
Hospital A.C.Camargo, São Paulo, Brazil. 
Introduction: Epidermal growth factor receptor (EGFR) mutation is usually a positive 
predictor of response to tyrosine kinase inhibitors in non small cell lung cancer 
(NSCLC), mainly in adenocarcinomas. More recently it has been show that the type of 
mutation can lead to better response or even resistence for some drugs. The frequency 
of mutation is more prevalent in women, asian ethnicity and in patients that have never 
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smoked. In this study we show the frequency of EGFR mutations in NSCLC analysed  
in a single Brazilian institution in the last 12 months. Methods: DNA sample was 
obtained either by scrape or by laser microdissection of tumoral cells from paraffin 
embedded tissue. Exons 18, 19, 20 and 21 of EGFR gene were tested for mutation by 
direct sequencing using standard protocols. Results: 91 patients been 51 males and 40 
females, with mean age of 65,46 yrs (39-99 yrs) were included in this study. The 
material obtained were from 71 (78%) primary tumor and 20 (22%) from metastatic 
lesions, all adenocarcinomas. Mutation was observed in 26% of the cases. The most 
frequent type of mutation was L858R in exon 21 (46%) and deletions in exon 19 (37%). 
No difference in mutation rate was seen between females (30%) and males (23%) 
patients (p=0,487) nor between age groups. Additionally no difference in mutation 
frequency or type were observed between the primary tumor group (24%) and 
metastatic (35%) group (p=0,322). Conclusions: These data showed a slightly higher 
EGFR mutation rate in NSCLC when compared to previous studies reported by 
American and European groups. Most of the mutations observed were in exons 21 and 
19, as already showed by others groups. In this brazilian patients studied, there were 
no association between presence of mutation with: age, sex or tissue origin (primary or 
metastatic), although it were little higher in metastatic tissue. This higher prevalence of 
EGFR mutation in Brazilian patients should be compared with other Latin American 
populations in other to clarified the real frequency of EGFR mutation in lung 
adenocarcinomas. 
 
ST49. Analysis of Biomarkers for Colon Cancer Progression and 
Chemoprevention Using RT-qPCR in Formalin Fixed Paraffin Embedded Colon 
Tissues 
I.J. Stijleman1, K. Swaner2, D. Nilson2, T. Jensen2, R.A. Lubet3, M.H. Cessna2, C.A. 
Davis1, P.S. Bernard1 
1University of Utah/Huntsman Cancer Institute, Salt Lake City, UT; 2Intermountain 
Health Care, Salt Lake City, UT; 3National Cancer Institute, Bethesda, MD. 
Introduction: Colon cancer is the second and third leading cause of death for men and 
women, respectively, accounting for over 320,000 annual deaths in developed 
countries. It is estimated that screening programs, such as colonoscopy, can reduce 
colon cancer deaths by 30-50% by removal of pre-invasive lesions (eg, adenomas). In 
addition, it has been shown that treating at risk individuals with non-steroidal anti-
inflammatory drugs (NSAIDs), such as aspirin or Coxibs, can substantially decrease 
formation of colonic lesions. However, the chemoprevention field in colon cancer has 
been hampered by having limited biological material for molecular analyses, particularly 
with regards to early and advanced adenomas compared to grossly uninvolved (ie, 
normal) tissues and invasive colon cancer. Methods: Total RNA was extracted (Roche 
High Pure miRNA Isolation Kit) from 150 colon samples archived as formalin-fixed, 
paraffin-embedded tissue blocks for greater than 10 years. Samples included 60 unique 
colon cancer cases with matched “normal” colon samples, and paired early adenomas 
and/or paired advanced adenomas. Gene expression profiles were generated by RT-
qPCR on the Roche LC480 and using the Roche SYBR Green Master Mix. The relative 
expression of 51 biomarkers was compared across the tissues. Results: The gene 
expression profiles showed that the histological classifications correlate with distinct 
gene expression profiles. Hierarchical clustering revealed 4 distinct groups, including 1) 
invasive colon cancer, 2) adenomas, 3) “normal” colon, and 4) “transitional” samples (all 
tissue types represented). There were 25 significant (p<0.05) genes for distinguishing 
grossly uninvolved “normal” colon from invasive tumor, the largest fold changes were 
seen in TACSTD2 (up in tumor; p=2.85E-07), LGR5 (up in tumor; p=0.00044), and 
CEACAM1 (down in tumor; p=3.74E-07). Notably, COX-2 expression was not 
significantly changed in “normal” versus invasive tumor, whereas 15-PGDH was lower 
in the invasive cancers (p=1.06E-19). COX-2 expression was significantly lower in early 
polyps compared to more advanced polyps (p=0.03) with a reciprocal change in 15-
PGDH, which was higher in early polyps (p=0.005). Conclusions: Our study showed 
that “normal” colon epithelium, adenomas, and carcinomas have distinct expression 
profiles and that adenomas from different individuals are more similar in biology than 
matching adenomas and adjacent adenocarcinomas from the same individual. In 
addition, COX-2 and 15-PGDH are inversely related in expression by RT-qPCR and the 
ratio of these biomarkers correlates with progression from early to advanced 
adenomas. These findings are important to understanding the progression of colon 
cancer and provide new assays for retrospective analyses of chemoprevention studies. 
 
 
 
 
 
 
ST50. A Pilot Study Comparing the Sensitivity of Detecting Prostate Associated 
Transcripts by AdnaTest Prostate Assay to CellSearch in Whole Blood from 
Patients with Castration Resistant Prostate Cancer 
A. Samoila, M. Wan, A. Anand, T. Chuang, H.I. Scher, M. Fleisher, D.C. Danila 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Veridex CellSearch is a FDA approved method used to capture and 
enumerate circulating tumor cells (CTC) in a clinical setting for patients with metastatic 
breast, prostate and colon cancer. There is an unmet need for improved sensitive of the 
CTC assay in patients with low cell count (<5 CTC/7.5 ml WB). In this pilot study we 
examined the efficiency of a CTC enrichment assay based on micro bead technology 
(AdnaTest Prostate assay) to detect prostate associated transcripts PSA, PSMA and 
EGFR in whole blood from patients with castration resistant prostate cancer (CRPC). 
Methods: Whole blood was collected under an IRB approved protocol from 20 patients 
with CRPC treated at Memorial Sloan-Kettering Cancer Center in EDTA (10 ml) and 
CellSave tubes (7.5 ml). CellSave tubes were used to enrich and detect CTCs by 
immunomagnetic bead procedure (CellSearch) in a CLIA certified laboratory. The EDTA 
preserved blood was placed on ice and processed within 4 hours of collection from the 
patient. Each sample was processed in duplicate. CTC enrichment was performed by 1-
hour long incubation of 5 ml whole blood with immuno-magnetic beads coated with a 
cocktail of EpCam and Her2 antibodies (AdnaTest ProstateCancer Select kit). The end 
product lysate was further used with AdnaTest ProstateCancer Detect kit to isolate 
mRNA utilizing oligo (dT)25-coated beads, followed by reverse transcription into cDNA. 
Multiplex end-product PCR for 42 cycles was performed with PrimerMix ProstateDetect, 
followed by analsysis with Bioanalyzer Agilent 2100 for amplification of 3 prostate 
associated transcripts (PSMA – 449 base pairs, PSA – 357 bp, EGFR – 163 bp), in 
parallel with actin (111 bp) as a house-keeping gene. Each test was considered positive 
if at least one prostate associated transcript measured above 0.1ng/μl, provided the 
controls performed as expected. Results: Overall CTC detection rate in the 20 patients 
tested by CellSearch was 7 patients and using AdnaTest 9 patients, respectively. All 
duplicate runs for each patient showed robust concordance. All 7 patients with 
detectable CTC by CellSearch were positive by the AdnaTest (PSA or PSA+PSMA 
present). Out of 13 patients with no CTC detected by CellSearch, 2 patients were 
positive by the AdnaTest. Conclusions: AdnaTest Prostate assay was highly 
concordant with the CellSearch methodology for the detection of CTC. The AdnaTest 
Prostate assay demonstrated incremental sensitivity in patients with no CTC detected 
by CellSearch, which will be further studied before the clinical utility in monitoring 
treatment response can be tested. 
 
ST51. Validation of a Multiplex Assay for the Detection of BRAF Mutations in 
Colorectal and Thyroid Tissues 
D.L. Smith, W. Laosinchai-Wolf, L. Friar, R. Shinde, L. Langfield, S. Beaudenon-
Huibregtse, E. Labourier 
Asuragen, Austin, TX. 
Introduction: BRAF encodes a RAS-regulated serine/threonine kinase, a member of 
the epidermal growth factor receptor (EGFR) signaling pathway that controls cell 
proliferation, differentiation and apoptosis. Mutations in the BRAF oncogene are 
frequently found in human cancers, such as metastatic colorectal cancer (mCRC), non-
small cell lung carcinoma, melanoma or papillary thyroid cancer (PTC). We previously 
reported the development of a multiplex assay for the sensitive detection of BRAF 
c.1799T>A (p.V600E) in formalin-fixed paraffin-embedded (FFPE) colorectal tissue. 
Here we present a complete analytical validation of the assay and its evaluation with 
different sample types. Methods: The Signature BRAF Mutation Kit (Research Use 
Only) was evaluated with plasmid DNA, genomic DNA from cultured cell lines and de-
identified residual clinical specimens. Fine needle aspirates (FNA) from thyroid tissue 
were collected in RNARetain, a single-use vial containing a non-toxic solution for the 
preservation and stabilization of intracellular nucleic acids. BRAF codon 600 and an 
endogenous internal control sequence were amplified by multiplex PCR using target-
specific, biotin-modified primers. The PCR products were then hybridized on a liquid 
bead array containing oligonucleotide probes specific for each target and detected 
using the Luminex 100 or 200 System. Results: Analytical characterization 
experiments showed robust and reproducible detection of V600E at 0.5% mutant allele 
(100 pg mutant genomic DNA in 19.9 ng of wild-type DNA). Other double mutants 
carrying the same activating T to A substitution at position 1799 were also co-detected 
(V600E2, V600D and V600K). No cross-reactivity was observed with V600A or K601E. 
Within-run, between-run and total precision were evaluated in 32 independent runs with 
multiple operators and instruments. There was 100% qualitative agreement between 
the 178 replicates. The assay was further compared against independent reference 
molecular methods using a total of 416 FFPE mCRC specimens and 1,133 thyroid FNA 
specimens. The overall agreement between methods was 99.2% (95% confidence 
intervals: 98.6-99.5%) with 100% positive agreement. Conclusions: The assay is 
compatible with representative genomic DNA samples extracted from colorectal or 
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thyroid tissues. It can be performed in less than 5 hours in a multiplex format 
compatible with the laboratory workflow. After additional validation, this research tool 
may aid in the identification of colorectal or thyroid specimens positive for BRAF V600E, 
a mutation that has been shown to correlate with poor prognosis and compromised 
clinicopathological outcome in mCRC and PTC patients. 
ST52. Use of Targeted Next-Generation Sequencing to Assess Potential 
Alterations In HPV Associated Squamous Cell Carcinoma 
P. Zhang, A. Seth, H. Fernandes 
University of Medicine and Dentistry of New Jersey/New Jersey Medical School, 
Newark, NJ. 
Introduction: Human papillomavirus (HPV) infection in squamous cell carcinoma(SCC) 
of the oropharynx is a powerful predictive and prognostic biomarker. Several studies 
have demonstrated associations between the presence of HPV 16/18 in these tumors 
and progression of the cancer. In this study we have assessed potential risk factors and 
cancer markers that may be associated with the HPV status of SCC. We have 
genotyped polymorphisms in the promoter region of a pro-inflammatory cytokine 
associated with SCC. In addition we evaluated the potential of the AmpliSeq Cancer 
Panel on the IonTorrent (IT) Personal Genome Machine (PGM) to identify specific 
cancer-related mutations. Methods: DNA was extracted from 50 FFPE specimens from 
patients with SCC of the oropharynx. The presence of HPV 16 and/or HPV 18 was 
detected using allele specific PCR in a LDT on the ABI 7500. Tissue sections were 
immunostained with a commercial antibody to p16INK4a. Polymorphisms in the TNF-a 
promoter were assessed using melt curve analysis on the Lightcycler. DNA from twelve 
specimens (10 HPV positive and 2 HPV negative) were analyzed using next generation 
sequencing (NGS) with the Ampliseq Cancer panel (Life technologies). This panel 
interrogates 739 common mutations in 46 cancer genes in a multiplex PCR reaction 
concomitantly, from four individual specimens. The barcoded amplicons are enriched to 
select viable nanospheres for sequencing on a 316 chip. Results: HPV 16 was 
detected 27% of patients with oropharyngeal SCC and HPV 18 in 2% of specimens. 
One specimen was positive for both HPV 16/18. The rates of HPV positivity were 
comparable for males and females. Immunohistochemistry results showed 89% of the 
HPV positive specimens were also positive for p16. Of the 50 specimens genotyped for 
TNF-a polymorphisms, 22.2 % of HPV positive specimens were shown to have a 
proinflammatory genotype, and 31.6% of HPV negative specimens were shown to have 
this genotype. All 11 specimens finally analyzed for cancer-associated mutations by 
NGS had somatic mutations. The average number of genes that were mutated in HPV 
negative specimens was 4.5 whereas the average number of genes with mutations in 
HPV positive specimens was 18.4. Three HPV positive specimens were observed to 
have >100 of the SNP’s as analyzed by the panel. Conclusions: Comprehensive NGS 
profiling in squamous cell carcinoma of the oropharynx showed an increased number of 
genomic alterations when associated with HPV infection. The predictive value of these 
mutations along with other associated risk factors needs to be further investigated. 
 
ST53. MicroRNA-148a as a Diagnostic Marker for Pancreatic Ductal 
Adenocarcinoma 
Y. Xue, A.N. Abou Tayoun, K.M. Abo, J. Pipas, S.R. Gordon, T.B. Gardner, R.J. Barth, 
A.A. Suriawinata, G.J. Tsongalis 
Geisel School of Medicine at Dartmouth, Lebanon, NH. 
Introduction: Pancreatic cancer is the fourth leading cause of cancer-related death in 
the United States. Although surgical resection represents the best hope for cure, most 
patients present with tumors of advanced stage that are inoperable and associated with 
a poor prognosis. The preoperative evaluation of pancreatic tumors includes 
radiographic imaging to determine potential resectability and diagnostic biopsy, which is 
essential to guiding appropriate surgical and chemotherapeutic management. However, 
biopsy interpretation may be hindered by limited sampling and inflammatory changes 
that mask, or mimic, neoplasms. For this reason, many investigators have tried to 
identify biomarkers that reliably distinguish pancreatic neoplasm from benign 
conditions. In this study, we tested different types of pancreatic disease to determine if 
microRNAs expression could aid the diagnosis of pancreatic ductal adenocarcinoma in 
pancreatic resection specimens. Methods: Resection specimens containing 
adenocarcinoma (n=16), paired pancreatic tissue with negative margins in each case 
(n=16), chronic pancreatitis (n= 4), normal pancreatic parenchyma (n=5), and 
pancreatic intraepithelial neoplasia (n=5), were selected from the archives of the 
Department of Pathology between 2004 and 2011. Unstained FFPE tissue sections 
(5μm) underwent macrodissection and then RNA extraction (Qiagen RNeasy FFPE 
Kit). Reverse transcriptase reactions were performed using the TaqMan MicroRNA 
Reverse Transcription Kit (Applied Biosystems) with primers specific for the following 
miRNAs: RNU6B (internal control), miR-10b, miR-21, miR-148a, miR-196a, or miR-217. 
Real time PCR reactions were subsequently performed (TaqMan MicroRNA Assays, 
Applied Biosystems). Each PCR reaction was run in duplicate and the average cycle 
threshold (CT) value was calculated. Expression levels of each miRNA was calculated 
using the log2 (2-ǻCT) and relative expression between different groups using the log2 
(2-ǻǻCT). Results: Our data show that miR-148a levels were reduced in all benign and 
malignant pancreatic lesions compared to normal parenchyma. This reduction was 
exacerbated in neoplastic samples. Comparison of miR-148a levels between the 
different neoplastic lesions and chronic pancreatitis shows levels that were much lower 
in PDAC (~3 CT difference, P < 0.05), and in PanIN (~2.5 CT difference, P < 0.05) 
compared to chronic pancreatitis. We confirmed that miR-148a levels were significantly 
reduced in PDAC (~4.5 CT difference, P < 0.0001) relative to its paired control 
containing chronic pancreatitis. Conclusions: Our data demonstrate that miR-148a 
expression level appears to be down-regulated in pancreatic ductal adenocarcinoma, 
even in the early stage of pancreatic intraepithelial neoplasm and thus more likely to be 
useful as a diagnostic marker to distinguish pancreatic ductal adenocarcinoma from 
benign lesions. 
 
ST54. Clinical Next-Generation Sequencing for the Identification of Somatic 
Mutations in Cancer  
H. Al-Kateb, C.E. Cottrell, E.J. Duncavage, T.T. Nguyen, C. Lockwood, D. Spenser, A. 
Bredemeyer, R.D. Head, R. Nagarajan, J. Pfeifer, K. Seibert, R. Govindan , S. Kulkarni 
Washington University School of Medicine, St. Louis, MO. 
Introduction: The clinical utility of targeted mutation analysis of oncology-related genes 
associated with specific clinical outcomes has been well documented. However, an 
increasing number of clinically actionable variants has made it resource-intensive and 
technically challenging to analyze the full spectrum of somatic gene mutations by 
current methods. Herein we report our clinical experience at the Washington University 
School of Medicine Genomics and Pathology Services (GPS@WUSTL) on our first 30 
cases using a multiplexed Next Generation Sequencing (NGS) platform to analyze a 
panel of twenty-five genes relevant to multiple cancer types. Methods: DNA was 
extracted from three to six 1 mm punches of formalin-fixed tissue blocks from areas of 
viable tumor identified by histopathologic review. One microgram of the resulting DNA 
was subjected to multiplexed library preparation and capture-enrichment using liquid 
phase cRNA capture probes targeting a ~300kb region. The enriched library was then 
sequenced to obtain 101bp paired end reads. Data were then aligned to the NCBI-
build37 genome, and variants were called, prioritized, and interpreted using the Clinical 
Genomicist Workstation, developed by GPS@WUSTL. Results: Of the 30 consecutive 
clinical cases requested for analysis, twenty-six (86.6%) samples were derived from 
lung cancer, three (10%) were from thymic cancer and one was from breast cancer 
(3.3%). Ten of the samples (33%) either did not have sufficient tissue quantity or quality 
to attempt DNA extraction, or sufficient DNA quantity post-extraction. Of the 20 samples 
that passed QC, coverages of 50x, 400x and 1000x were achieved for 98.4%, 93.1% 
and 83.2% of targeted positions, respectively. Abnormal results were defined as the 
presence of any variant that was either associated with prognosis, resistance/sensitivity 
to certain drugs or was predicted to result in a protein loss-of-function were observed in 
8/20 (40%) cases. A total of ten such mutations were identified in eight cases, including 
four non-synonymous changes, three nonsense mutations, two in-frame deletions and 
one frame-shift mutation caused by a complex insertion-deletion variant. Of the 
mutations identified three mutations in KRAS, one in each of EGFR, KIT, PTEN, and 
TP53 genes were actionable. Conclusions: These results demonstrate that NGS-
based diagnostics can be performed in the molecular oncology laboratory to provide 
clinically relevant information. Forty percent of sequenced cases exhibited variants that 
were predicted to be clinically actionable or to result in loss of protein function. Targeted 
inhibitors for several of these mutations including KIT and EGFR exist, suggesting that 
such data could alter patient treatment and/or prognosis.  
 
ST55. TaqMan Mutation Detection Assays Powered by castPCR Technology for 
Detection of EGFR Mutations in Routine Clinical Diagnostic Samples 
C. Roma, R. Pasquale, A. Rachiglio, C. Esposito, F. Fenizia, M. La Porta, F. 
Bergantino, S. Costantini, N. Normanno 
Centro di Ricerche Oncologiche di Mercogliano (CROM), Mercogliano, Italy. 
Introduction: Assessment of EGFR mutations has become mandatory to chose the 
most appropriate first line therapy for non-small-cell lung cancer (NSCLC) patients. 
Detection of EGFR mutations is often limited by the low percentage of tumor cells in 
clinical specimens leading to a low concentration of mutant alleles in wild type (WT) 
copies of the gene. Competitive Allele-Specific TaqMan PCR (CAST PCR, Life 
Technologies) has an higher sensitivity as compared with routine diagnostic techniques. 
We assessed the sensitivity and specificity of CAST PCR to detect EGFR mutations in 
formalin fixed, paraffin embedded (FFPE) tumour samples. Methods: EGFR mutations 
were assessed by CAST PCR in 40 FFPE tumour samples including 34 NSCLC and 6 
colorectal carcinoma (CRC). The sensitivity and specificity of this method was 
compared with routine diagnostic techniques including fragment analysis, Real-Time 
PCR (allelic discrimination) and the EGFR Therascreen RGQ kit. Results: By using 
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routine diagnostic techniques, EGFR mutations were detected in 12/34 NSCLC 
patients, including 6 samples with deletions in exon 19; 4 samples with a L858R point 
mutations in exon 21; 2 samples with respectively a G719S and a G719A point 
mutation in exon 18. No EGFR mutations were detected in 6 CRC specimens. We next 
analyzed the 28 EGFR mutation negative samples with CAST PCR to identify cutoffs 
that ensure high specificity of the assay in FFPE samples. We found that 27/28 
samples were also negative by CAST PCR when excluding samples with a Ct>37 or 
with a deltaCt>7. A NSCLC sample from a former smoker patient with adenocarcinoma 
was found to carry a L858R point mutation that was not detected by using routine 
diagnostic methods. The presence of this mutation was confirmed by using a PNA 
(Peptide Nucleic Acid ) clamping-based Real-Time PCR technique. CAST PCR was 
also able to identify the same 12 mutations detected by routine diagnostic methods. 
Conclusions: Our preliminary data suggest that CAST PCR is highly specific to detect 
EGFR mutations in NSCLC FFPE samples. In addition, CAST PCR might reveal EGFR 
mutations that are not detectable by routine diagnostic methods, and this might have 
important clinical implications. These findings are being confirmed in a larger cohort of 
patients in which CAST PCR will be also compared with Next Generation Based-
methods using an AmpliSeq Custom Panel specific for colon and lung cancer on the Ion 
Torrent PGM. 
 
ST56. The Prevalence of FGFR1 Amplification in Lung Squamous Cell 
Carcinoma as Revealed by FISH Analysis 
L. Wang, K. Wang, N. Islamdoust, A. Hasanovic, M. Ladanyi, S.C. Jhanwar 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Frequent and focal amplification of FGFR1 has recently been identified in 
lung squamous cell carcinoma (LUSC) and is associated with cellular dependency on 
FGFR1 and sensitivity to FGFR inhibitors. A clinical trial is ongoing to investigate 
whether patients with FGFR1-amplified LUSC benefit from targeted FGFR1 kinase 
inhibitor therapy. We present here our data on the frequency of FGFR1 amplification or 
increase in copy number (CN) in a series of 68 patients with LUSC. Methods: 
Fluorescence-labeled FGFR1 (green) /CEN 8 (red) probes were used. FISH was 
successful in 68 LUSC FFPE tissue samples. A minimum of 100 nuclei were examined 
per tissue section from 4-6 distinct tumor areas. FGFR1 CN changes were classified 
into four categories: I) high-level focal amplification (FGFR19 or presence of clusters 
of signals, and FGFR1/CEP82); II) high-level CN gain (FGFR19, but 
FGFR1/CEP8<2, including high-level polysomy); III) low-level focal amplification 
(FGFR1=5-8 and FGFR1/CEP82); IV) low-level CN gain (FGFR1=3-8 and 
FGFR1/CEP8<2, including low-level polysomy). A signal pattern with category I and/or 
III detected in 10% of tumor cells was considered to represent FGFR1 amplification. 
Results: FGFR1 amplification was identified in 13 samples, including 4 with category I 
signal pattern only, 1 with both high- and low- level amplification in the same tissue; and 
the rest displayed some heterogeneity in FGFR1 CN change across the tissue section 
examined, indicative of a spectrum of different levels of FGFR1 CN gains as well as 
focal amplification. Nine samples showed no FGFR1 CN change. The remaining 46 
samples showed high- and/or low-level CN gain of FGFR1. It is worth noting that high-
level CN gain of FGFR1 was seen in three samples, two of which also had cells with 
focal amplification. Conclusions: This study confirmed that FGFR1 amplification is a 
common genetic event occurring at a frequency of 19% in the present LUSC cohort. 
The heterogeneity in both CN change of FGFR1 and the ratio to CEP8 detected in a 
number of samples underscores the significance of examining cells from different 
tumor-cell rich areas across the tissue sections to minimize sampling bias. The 
spectrum of different levels of FGFR1 CN change observed in some samples may be 
indicative of clonal evolution reflecting tumor progression. We suggest that follow-up 
FISH analyses on subsequent samples may be indicated if above medium-level CN 
gain of FGFR1 or a small proportion of tumor cells (<10%) with focal amplification is 
detected in one biopsy sample.  
 
ST57. Liquid Biopsy: the Application of Allele-Specific PCR (AS-PCR) and 
Mutation-Directed SNaPshot Assay to Detect BRAF and NRAS Mutant DNA in 
Peripheral Blood from Metastatic Melanoma Patients  
J.S. Tadepalli1, S.M. Hafner2, J. Kristof2, C.D. Galderisi2, C.S. Spittle2, E.E. Bruening2, 
S. Wong2, D. Polsky1 
1New York University Langone Medical Center, New York, NY; 2MolecularMD Corp., 
Portland, OR. 
Introduction: Liquid biopsy provides a non-invasive method to identify tumor 
signatures in peripheral blood. Clinical assays that can detect tumor-derived cells or 
circulating DNA in patients with metastatic melanoma may provide a valuable tool for 
diagnosis of disease, monitoring of response to therapy, and detection of relapse. The 
optimal assay will encompass high sensitivity and specificity with the greatest dynamic 
range of quantification. Malignant melanoma signatures in circulating nucleic acids have 
been documented in the form of primary BRAF and NRAS mutations. Recent data 
suggests secondary NRAS mutations in relapse of patients receiving RAF inhibitor 
therapy. This work focuses on the development of a combinatorial platform approach 
for analysis of the BRAF and NRAS activating mutations in peripheral blood. Methods: 
Allele-specific PCR (Taqman) and SNaPshot mutant identification assays were 
designed and evaluated for BRAF V600 and NRAS Q61 for tissue and plasma based 
testing. Platform comparisons were conducted to validate assay performance using 
simulated patient samples created by spiking dilutions of mutant BRAF V600E positive 
cells (SKMel29) and synthetic DNA into blood and plasma. Assay performance criteria 
were further validated using patient samples to establish the clinical performance 
specifications of each assay. Results: The AS-PCR panel for BRAF and NRAS 
demonstrates sensitivities to <0.5% mutant diluted into wild-type. SNaPshot provided 
similar results in the low input range down to ~8 mutant cells; however pre-amplification 
of the target and the narrow dynamic range of capillary electrophoresis limits the ability 
to quantify the result. The study includes assay performance and platform concordance 
with a cohort of metastatic melanoma patient plasma and matching FFPE tissue 
samples. Preliminary results from a randomly selected set showed concordance 
between the platforms. Results were substantiated in both plasma and FFPE by AS-
PCR and concordance with the BRAF V600E/K multiplex SNaPshot assay. 
Conclusions: AS-PCR provides a high sensitivity screening method for the 
identification and quantification of BRAF V600 and NRAS Q61 in blood. The data 
revealed that AS-PCR was able to quantify mutant to wild-type allele ratios over a larger 
dynamic range compared to SNaPshot, which exhibited signal saturation at high copy 
target or wild-type levels. Combining the AS-PCR test with a SNaPshot assay for 
concordance can increase the overall confidence of the call for low template specimens 
by pre-amplifying the template. These preliminary results are being confirmed with an 
expanded set of blood and FFPE samples from metastatic melanoma patients. 
 
ST58. An Evaluation of Next-Generation Sequencing for Diagnostic Use in 
Cancer Care 
K. Wang1, R. Yelensky1, S. Dogan2, L. Borsu2, G.M. Frampton1, D. Lipson1, B. Bastian3, 
D. Klimstra2, M. Ladanyi2, P. Stephens1, M. Cronin1, M. Berger2 
1Foundation Medicine, Inc, Cambridge, MA; 2Memorial Sloan-Kettering Cancer Center, 
New York, NY; 3University of California San Francisco, San Francisco, CA. 
Introduction: Characterization of genomic changes driving an individual patient’s 
cancer is now critical to inform treatment planning for rationally targeted therapies. 
Next-generation sequencing (NGS) technology can expand on current clinical assays 
because it can detect genomic alterations across the entire coding sequence of a gene, 
including copy changes and gene fusions, and can interrogate hundreds of genes in a 
single test. However, for NGS to be considered viable clinically, it must be made 
compatible with formalin-fixed, paraffin embedded (FFPE) tissue across a range of 
tumor types, sizes, and cellularities. It is also necessary to examine the correlation 
between mutation profiles derived using NGS versus best available diagnostic methods. 
Methods: To evaluate the diagnostic potential of NGS, we selected 118 FFPE 
resection specimens (67 lung cancers, 31 colorectal cancers, 20 melanoma) previously 
tested for 91 mutations in 8 oncogenes by Sequenom and a gel-sizing approach. DNA 
was extracted from new 4x10ȝm unstained sections from the original FFPE block, 
followed by sequencing of 3230 exons of 182 cancer-related genes and 37 introns of 14 
common targets of gene fusion. Protocols and reagents optimized for FFPE specimens 
yielded an average coverage of >900X per sample. NGS data were analyzed for all 
classes of genomic alterations using customized algorithms, including local sequence 
assembly for indels and a “CGH”-like approach for copy number changes. Mutation 
calls were compared to prior results and assessed for additional potentially clinically 
actionable findings. All assays were performed in CLIA-compliant laboratories. Results: 
High concordance was noted across platforms: Of the 101 mutations identified by 
Sequenom and gel-sizing, 97 were also called by NGS, whereas NGS found an 
additional 7 mutations at mutually tested sites. Importantly, over 25% of concordant 
calls had mutant allele frequency 10%, demonstrating high sensitivity by both 
approaches. Furthermore, NGS revealed a total of 55 additional alterations in 45 
specimens at sites not tested by Sequenom that may confer sensitivity or resistance to 
approved or experimental targeted therapies and thus may plausibly influence 
treatment decisions. These included 38 (69%) copy changes or novel tumor suppressor 
gene truncations and an EML4-ALK fusion, highlighting the versatility of the approach. 
Conclusions: Our results demonstrate the accuracy and potential benefits of 
comprehensive cancer gene profiling through NGS of clinical FFPE specimens. As 
NGS can accurately detect all classes of somatic alterations in hundreds of genes 
simultaneously, we suggest that this type of testing will become an essential component 
of patient care.  
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ST59. Vysis PathVysion HER-2 Assay Performance on Gastric Cancer 
Specimens 
G. Li, B. Blondin, K. Jacobson, P. Matushek, C. Herman, C. Slenk, E. Pestova 
Abbott Laboratories, Des Plaines, IL. 
Introduction: PathVysion HER-2 DNA Probe Kit has been developed to detect 
amplification of the HER-2/neu gene via FISH in FFPE human breast cancer tissue 
specimens for over a decade. The kit is utilized for assessment of breast cancer 
patients for whom HERCEPTIN (Trastuzumab) treatment is being considered. In recent 
years, amplification of the HER-2/neu gene has been shown in ~22% of patients with 
advanced gastric cancer. We developed and optimized manual and automated 
PathVysion HER-2 assay protocols on FFPE gastric tissue specimens. In this study, the 
success rate, reproducibility and cutoff of the gastric PathVysion assay were evaluated. 
Additionally, HER-2 FISH status across FFPE gastric tissue sections was evaluated to 
assess whether heterogeneity is observed. Methods: The success rate of PathVysion 
HER-2 assay on primary gastric cancer was tested with 19 FFPE tumor resection 
specimens, 6 section slides each, with both manual and VP2000 automated method. 
Assay reproducibility on HER-2 amplification status was assessed with 2 HER-2 
positive and 2 HER-2 negative gastric cancer specimens, 4 replicates for 5 days and 
evaluated by 3 readers. The cutoff verification was performed with 20 HER-2 negative 
and 5 HER-2 positive gastric cancer specimens. HER-2 FISH status across FFPE 
gastric tissue sections was evaluated with 2 HER-2 positive, 2 HER-2 negative and 1 
near-cutoff specimens. For each specimen, 60 to 100 serial sections were made, and 
approximately every 20th serial section was tested with PathVysion HER-2 assay. 
Results: The success rate of PathVysion HER-2 assay on FFPE gastric cancer 
specimens was 100 % (96.1%, lower bound 95% CI) with manual method and 100% 
(92.4, lower bound 95% CI) with the automated method. The PathVysion gastric assay 
further demonstrated 100% overall agreement for both reader-to-reader and day-to-day 
reproducibility analyses. The cutoff for HER-2 amplification status was verified to be 2.0 
for HER-2/neu to CEP17 ratio, identical to that for breast cancer assay, with all 20 IHC-
negative samples tested as FISH negative and 5 IHC-positive samples as FISH positive 
by PathVysion HER-2 assay. Finally, the HER-2 FISH results showed consistent HER-2 
amplification status across ~60 to 100 serial sections for all HER-2 positive, negative 
and near-cutoff gastric cancer specimens. Conclusions: The PathVysion HER-2 
gastric assay demonstrated robust assay performance on success rate and 
reproducibility. The cutoff of HER-2 amplifications status was verified to be 2.0 for HER-
2/neu to CEP17 ratio on gastric cancer specimens. Furthermore, we did not observe 
heterogeneity on HER-2 amplification status across sections with PathVysion HER-2 
gastric assay.  
 
ST60. Epstein-Barr Virus Infected Gastric Adenocarcinoma Expresses Latent 
and Lytic Viral Transcripts and Harbors Potential Druggable Targets 
W. Tang1, D.R. Morgan1, R.L. Dominguez2, P. Kuan1, M.L. Gulley1 
1University of North Carolina at Chapel Hill, Chapel Hill, NC; 2Western Regional 
Hospital, Santa Rosa de Copan, Honduras. 
Introduction: Epstein-Barr virus (EBV) DNA is found within malignant cells of 10% of 
gastric cancers. Modern molecular tools permit us exploit virus-related biochemical 
pathways to facilitate early diagnosis and to predict therapeutic response to targeted 
agents. Methods: Nanostring nCounter-based RNA expression profiling was done on 
319 macrodissected paraffin-embedded tissues including cancers and, when available, 
adjacent non-malignant mucosa. Following total nucleic acid extraction using a Roche 
HighPure miR Isolation kit, probes targeted 96 RNAs (20 viral, 69 human, 4 
housekeeping, and 3 spiked RNAs), and statistical analysis was done on tissues with 
adequate housekeeping RNAs. Results: Unsupervised clustering revealed distinct 
profiles in infected versus uninfected cancers, and in malignant versus benign mucosa. 
EBV-infected gastric cancers expressed all 18 EBV RNAs and one of two 
cytomegalovirus RNAs in the test panel. Levels of EBER1 and EBER2 non-coding RNA 
(as measured by the Nanostring panel) were proportional to EBV DNA viral load (as 
measured by Q-PCR). RNA profiles appeared to be more sensitive and specific than 
were EBV DNA levels for identifying cancer-related viral infection. Human mRNAs most 
closely associated with EBV infection were downstream of NFKB signaling (FCER2, 
TRAF1) and immune response elements (TNFSF9, CXCL11, IFITM1, FCRL3), with 
PPARG expression implicating potentially targetable alteration in glucose metabolism 
and microtubule networks. Compared to adjacent non-malignant mucosa, gastric 
cancers overexpressed INHBA, SPP1, THY1, SERPINH1, CXCL1, COL1A1, and 
FSCN1, whereas they underexpressed CDH1 (e-cadherin), CLDN18, and CHGA 
(chromogranin). Compared with lymphoepithelioma-like cervical carcinoma, gastric 
cancers overexpressed CLDN18, EPCAM, REG4, BBC3, OLFM4, PPARG, and CDH17 
whereas they underexpressed IFITM1 and HIF1A. Pharmacogenetic targets identified 
in subsets of gastric cancer specimens included EBV infection itself, ERBB2, MET, 
TYMS, SPARC, and FCGR2B. Conclusions: This study shows how modern molecular 
technology applied to RNA from archival fixed tissues yields novel insights into gastric 
and cervical oncogenesis that could be useful in managing affected patients.  
 
ST61. EML4-ALK Fusion Transcript Detection by a Multiplex Reverse-
Transcriptase PCR, Real-Time Capillary Electrophoresis Assay in FFPE Lung 
Adenocarcinoma Samples 
J.A. Lefferts, M.C. Schwab, H.B. Steinmetz, G.J. Tsongalis, L.J. Tafe 
Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: Approximately 2-5% of lung adenocarcinomas harbor a novel EML4-ALK 
gene rearrangement that is mutually exclusive from EGFR and KRAS mutations. 
Tumors with ALK rearrangement are eligible for treatment with the FDA approved ALK 
inhibitor, crizotinib, therefore, it is important to identify these patients for targeted 
therapy. The EML4-ALK rearrangement may occur at various breakpoints resulting in 
multiple possible fusion transcripts. Currently, most laboratories detect ALK 
rearrangements with a break-apart FISH assay. In this study we designed a reverse-
transcriptase PCR (RT-PCR) based assay to detect eight of the most common EML4-
ALK fusions transcripts in a multiplexed assay that was then compared to FISH results. 
Methods: A RT-PCR assay using real-time capillary electrophoresis for use on the 
ICEPlex platform (PrimeraDx) was developed to detect wild type (wt) EML4, ALK and 
eight different EML4-ALK fusion transcripts (variants 1, 2, 3a, 3b, 4a, 4b, 5a and 5b) in 
FFPE tissue samples. Plasmid DNA representing the eight EML4-ALK fusion transcripts 
served as positive controls. RNA samples extracted from 76 FFPE lung 
adenocarcinoma cases that were previously found to be negative for EGFR and KRAS 
mutations were subjected to EML4-ALK analysis. Confirmation of ALK rearrangement in 
select samples was performed by FISH. Results: RNA extraction followed by RT-PCR 
was successful (EML4 wt RNA amplified with Ct<34) in 71 (93.4%) of the FFPE tissue 
sections. Variant transcripts were detected in four samples (two with variant 1 and two 
with variant 3a). High levels of ALK transcript were detected in these four samples as 
well as in one other sample in which none of the eight variants were detected. This 
suggests that this sample may harbor a variant other than the eight in our assay. FISH 
showed ALK rearrangement in all four samples in which variant transcripts were 
detected. Conclusions: We developed a RT-PCR, real-time capillary electrophoresis 
assay for multiplex detection of eight common EML4-ALK fusion transcripts utilizing 
FFPE samples. Our assay detected variant transcripts in 4 cases (6%) that were 
confirmed to have ALK rearrangement by FISH. This multiplex assay has the flexibility 
to add additional fusion transcripts to expand the detection coverage and include other 
ALK rearrangement partner genes besides EML4. In addition, the high levels of ALK 
transcript expression may correlate with ALK rearrangement and therefore, this assay 
may simultaneously be used to detect ALK rearrangements not specifically covered in 
this assay with an improved throughput and turn-around-time in comparison to FISH 
analysis.  
 
ST62. Usefulness of Detecting KRAS Mutation for the Diagnosis of Pancreatic 
Cancer in Specimens from Endoscopic Ultrasound-Guided Fine-Needle 
Aspiration 
C.F. Li, S.J. Bauer, O. Pangan, G. May, H. Ghaffar, S. Jothy 
St. Michael's Hospital, Toronto, Canada. 
Introduction: Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-
FNAB) is a useful tool in the diagnosis of pancreatic masses. The majority of pancreatic 
carcinomas harbor somatic mutation of the KRAS gene. Methods: We studied the 
usefulness of detecting KRAS mutation for the diagnosis of pancreatic cancer in liquid 
based ThinPrep samples obtained via EUS-FNAB. EUS-FNABs were performed on 29 
patients with pancreatic masses. The aspirates were cytopathologically evaluated and 
classified as malignant, atypical /indeterminate and benign according to the morphology 
of the cells analyzed. DxS KRAS mutation kit, which combines ARMS (allele specific 
PCR) with the Scorpions real-time PCR technology and can detect 1% of mutant in a 
background of wild type genomic DNA, was used to detect seven KRAS mutations in 
codons 12 and 13. Results: KRAS mutation was found in 13 of 22 malignant cases 
(59%), one of 4 atypical /indeterminate cases (25%) and zero of 3 benign cases (0%). 
Surgical pathology reports were available in 4 cytopathologically malignant cases (3 
cases with KRAS mutation, 1 case with wild-type KRAS) and 1 cytopathologically 
atypical /indeterminate case with KRAS mutation. Adenocarcinoma was diagnosed 
histopathologically in all cases with KRAS mutation (3 cytologically malignant cases and 
1 cytologically atypical /indeterminate case), whereas duodenal villous adenoma with 
low and focal high grade dysplasia was found in the cytopathologically malignant case 
with wild-type KRAS. In addition, neuroendocrine tumour was diagnosed 
cytopathologically in a cytopathologically malignant case with wild-type KRAS. 
Autoimmune pancreatitis and benign cyst were reported as final clinical diagnosis in two 
cytopathologically atypical /indeterminate cases with wild-type KRAS. Conclusions: 
This preliminary result indicates that detection of KRAS mutation may be useful to 
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supplement cytopathologic evaluations for pancreatic cancer in specimens from 
endoscopic ultrasound-guided fine-needle aspiration. 
 
ST63. CIMP, BRAF Mutations, and MLH1 Methylation Status of Large Polyps of 
the Proximal Colon 
L.V. Furtado1, C.P. Vaughn2, C.L. Baker2, D.G. Luba3, J.A. DiSario3, W.S. Samowitz1 
1University of Utah Health Science Center, Salt Lake City, UT; 2ARUP Institute for 
Clinical and Experimental Pathology, Salt Lake City, UT; 3Monterey Bay 
Gastrointestinal Consultants Medical Group, Monterey, CA. 
Introduction: CpG island methylator phenotype (CIMP), MLH1 promoter methylation 
and BRAF mutations are commonly found in microsatellite unstable cancers. These 
cancers are predominantly located in the proximal colon and thought to arise from 
proximal hyperplastic polyps through the “serrated neoplastic pathway”. Our group had 
previously identified CIMP and BRAF mutations in small (<1cm) proximally located 
hyperplastic polyps, but not MLH1 methylation. The goal of this study was to evaluate if 
large serrated polyps of the proximal colon showed clinically relevant molecular 
features indicative of serrated pathway precursors. Methods: We retrospectively 
collected 58 proximally located colorectal polyps 1cm from the University of Utah and 
Monterey Bay Gastrointestinal Consultants Medical Group & Research Institute surgical 
pathology files. Cases with hyperplastic polyposis were excluded. The specimens 
consisted of 23 serrated polyps and 35 adenomas of conventional histology (30 tubular 
adenomas and 5 tubulovillous adenomas). Of those, 4 serrated lesions exhibited areas 
of low grade dysplasia and 1 tubular adenoma had focal areas of high grade dysplasia. 
DNA was extracted from microdissected polyps selected by histologic examination of 
an H&E stained section. Unpurified DNA lysates were sodium bisulfate treated and the 
methylation status of the promoter region of COL2A1, CACNA1G, IGF2, MLH1, 
NEUROG1, RUNX3, and SOCS1 were determined by quantitative real time PCR 
(MethyLight). Positive methylation was defined as the percentage of methylated 
reference (PMR>10). The designation of CIMP was applied to all samples with 
methylation at 3 or more loci. All polyp samples that showed MLH1 promoter 
methylation (PMR>10) were subsequently analyzed for MLH1 protein expression. 
BRAF V600E mutation analysis was performed in all DNA samples by pyrosequencing. 
Results: Eight of 23 (35%) serrated lesions showed CIMP, whereas only 2 of 35 (6%) 
adenomas showed CIMP. One CIMP-negative serrated lesion and one tubular 
adenoma showed positive MLH1 promoter methylation. However, MLH1 protein 
expression of both of these polyps was normal by immunohistochemistry. The BRAF 
V600E mutation was detected in 21 of 23 (91%) serrated lesions, including 6 of 8 (75%) 
CIMP-positive serrated lesions. None of the adenomas harbored the BRAF V600E 
mutation.Conclusions: Like microsatellite unstable cancers, large proximally located 
serrated lesions exhibit high level CIMP and BRAF mutations; however these polyps do 
not show significant MLH1 promoter methylation. These findings support the role of 
serrated polyps as precursors of sporadic unstable cancers, and suggest that MLH1 
methylation is a later event in carcinogenesis, unrelated to polyp size.  
 
ST64. Quantitative MGMT Promoter Methylation Analysis Using Bisulfite 
Pyrosequencing for Molecular Diagnostic Testing in Glioblastoma Multiforme 
L. Xi, W. Navarro, M.M. Quezado, C.J. Oberholtzer, H.A. Fine, M. Raffeld 
National Cancer Institute, National Institutes of Health, Bethesda, MD. 
Introduction: The drug temozolomide results in the formation of O6-methylguanine 
(O6-MeG) adducts in DNA to trigger apoptosis, and has been shown to be efficacious in 
glioblastoma. Its activity, however, is counteracted by the DNA repair enzyme O6-
Metylguanine DNA methyltransferase (MGMT), whose expression in tumors is 
correlated with promoter methylation. The predictive significance of MGMT promoter 
methylation to temozolomide in glioblastoma, and its value as an independent 
prognostic factor, is underscored in two clinical trials; first in a phase II study testing 
concomitant and adjuvant temozolomide and radiation (Hegi et al, 2004) and 
subsequently in EORTC 26981/22981 & NCIC CE.3 (Hegi et al, 2005). Although MGMT 
promoter methylation assays in these studies were based on the qualitative 
(methylation-specific PCR) MSP technique, more recently quantitative methods for 
determining promoter methylation have been developed that show promise in refining 
the value of the assay (Dunn et al, 2009). To assess whether the degree of promoter 
methylation has added predictive or prognostic value in NCI glioblastoma protocols, we 
have adapted and modified the quantitative assay used by Dunn et al. Methods: The 
assay is based on bisulfite pyrosequencing and can be performed from as little as 
200ng of FFPE DNA. In brief, following bisulfite conversion, DNA is subjected to PCR 
using primers encompassing the MGMT promoter, and sequenced on a Qiagen 
Pyromark Q24. The average percentage C>T conversion among the 12 CpG sites in 
the amplicon is calculated. A positive cutoff of 10% C>T was established by assessing 
the average promoter methylation from normal brain tissues, plus 3 standard 
deviations. Results: Between December 2010 and March 2012, 87 glioblastoma cases 
from the Neuro-Oncology Branch of NCI were evaluated. 40 of 87 (46%) cases were 
unmethylated, 19 (21.8%) were methylated at levels between 10-35%, and 28 (32.2%) 
were methylated at levels greater than 35%. In methylated glioblastoma cases, a 
consistent variation pattern among the 12 CpG sites was observed, in which CpGs 4, 8, 
and 11 showed the highest methylation and CpGs 1, 2, and 7 showed the lowest levels. 
Conclusions: These data indicate that analysis of MGMT promoter methylation by 
bisulfite pyrosequencing is a robust and reliable method and can be easily incorporated 
into routine clinical testing. Clinical correlations are ongoing to determine the predictive 
ability of the assay for response to temozolomide in NCI GBM protocols, and the 
prognostic value of MGMT promoter methylation in these patients. 
 
ST65. Agreement Study of BRAF V600E Testing with SYBR Green Allele 
Specific PCR and TaqMan Allelic Discrimination Assays  
R.A. Levy1, C.L. Bissaillon1, K.A. Lebel1, M.C. Schwab2, S.M. Pflueger1, L.J. Tafe2, J.A. 
Lefferts2, G.J. Tsongalis2, F. Moore1 
1Baystate Health, Springfield, MA; 2Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: Serine/threonine-protein kinase B-Raf (BRAF) is a part of the 
RAS/RAF/MAP1 pathway, involving the regulation of cell proliferation, division, and 
apoptosis. Mutated BRAF functions as an oncogene and is associated with multiple 
different tumor types including metastatic melanoma, papillary thyroid carcinoma and 
sporadic microsatellite unstable colon cancer. 90% of known activating mutations occur 
when thymine is substituted for adenine at nucleotide 1799 (V600E). This study 
compares the SYBR Green allele specific PCR and TaqMan allelic discrimination 
assays as a tool for diagnostic testing for the BRAF V600E mutation. Methods: DNA 
was extracted from 80 paraffin embedded tissue samples. All DNA samples were then 
diluted to a concentration of 5ng/Pl with Tris EDTA (pH8.0). Real-time PCR was 
performed utilizing the ABI 7500 for both the SYBR Green and TaqMan protocols. 
However, the extraction methods, primer sequences and PCR conditions differed 
between the two assays. Agreement studies were performed using a total of 80 DNA 
samples that were tested by both methods. Results: Twenty specimens were initially 
tested by the TaqMan assay and subsequently tested by the SYBR Green assay. Sixty 
additional specimens were initially tested by the SYBR Green assay followed by the 
TaqMan assay. Of the 80 specimens tested, 72 or 90% were concordant between the 
two assays. Four samples were positive with the TaqMan assay only and four were 
positive with the SYBR Green assay only. The sensitivity and specificity of the TaqMan 
assay compared with the SYBR Green assay was 89% and 91%, respectively. The 
TaqMan assay had an analytic sensitivity of 5% (from paraffin embedded tissue), and 
the SYBR Green assay had an analytic sensitivity of 1% (from diluted cell line). 
Conclusions: Both the TaqMan assay and the SYBR Green assay have been shown 
to detect the V600E BRAF mutation in multiple tissue types. Possible reasons for 
discrepancies in test results include the different methodologies and potential 
differences in sensitivity and specificity between the two assays. The differing limits of 
detection could be due to the alternate means of generating low positive controls 
(paraffin embedded tissue vs. cell line). Both assays are applicable for targeted therapy 
testing for melanoma and can be used for diagnostic testing for papillary thyroid 
carcinoma and sporadic colon carcinoma.  
 
ST66. NSCLC Patients with an Isolated 5' Green Signal Pattern in ALK FISH 
Testing may be Positive for Complex EML4-ALK Rearrangement with 3' Deletion 
and May Benefit from Crizotinib Targeted Therapy 
G. Sun, L. Montella, S. Woo, L. Kozon 
Labcorp, New York, NY. 
Introduction: Accurately identifying patients with NSCLC and positive for ALK gene 
rearrangement is essential for selecting crizotinib targeted therapy. Currently the result 
reporting guide in the FDA approved companion diagnostic FISH test considers the 
separation of the 3' red and 5' green segment or a deletion of the 5' segment of the ALK 
probe as positive. However, we have periodically observed the isolated 5' green pattern 
in 3-4% of cases with structural ALK abnormalities. The 3' flanking red probe of the 
Vysis ALK probe set does not cover the tyrosine kinase domain of the gene, and thus 
its deletion may not necessarily affect the rearranged EML4-ALK with upregulated 
tyrosine kinase activity. Methods: FISH was tested on FFPE tumor tissues using the 
Vysis ALK break apart (ba) probe. A confirmative EML4-ALK inversion/translocation 
FISH testing was performed using a probe set by Kreatech with a 360kb 3'ALK red 
probe and a 350kb 5'EML4 green probe. Ten cases with isolated 5' green signals were 
included in this study. Attempts were made to obtain available information on clinical, 
pathologic and other lab findings such as EGFR and KRAS mutations. Results: All 10 
cases with isolated 5' green signals along with fusion signals, present in 48-100% of 
interphase cells (median 70.5%) by the Vysis ALK ba probe, were positive for the 
EML4-ALK rearrangement by the Kreatech EML4-ALK probe with one to multiple 
copies of fusion signals (20-92%; median 36%). Six patients had EGFR and 4 had 
KRAS mutations performed; two of them were positive for the L858R in exon 21 and the 
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L747_P753del7insS in exon 19 respectively for the EGFR gene. This is significant 
compared to 2 of 83 ALK ba probe positive cases during the same testing period 
(p=0.02). One of the 4 patients with KRAS mutation detection showed a p.G12C 
(c.34G>T) mutation in codon 12. Conclusions: NSCLC is biologically and genomically 
heterogeneous. The less commonly observed isolated 5' green signal FISH pattern 
reflects the EML4-ALK gene rearrangement with a concomitant 3' red probe deletion 
confirmed by an inversion/translocation FISH testing in our study. The complex 
chromosomal alterations may represent a regional chromothripsis event in NSCLC, and 
the likely high dual mutation rate with EGFR/KRAS suggests clonal selection and 
coexisting multi-driver mutatons. Further studies using RT-PCR and sequencing in 
those patients with a 3' ALK probe deletion may lead to the addition of more patients 
with NSCLC to crizotinib targeted therapy.  
ST67. Detection of Known Copy Number Variation in Formalin-Fixed, Paraffin-
Embedded Tissue by Single Nucleotide Polymorphism Arrays 
A. Oultache, C.V. Hedvat 
Memorial Sloan-Kettering Cancer Center, Brooklyn , NY. 
Introduction: SNP array technology is a powerful tool that has revolutionized molecular 
cytogenetics by allowing the detection of allelic imbalances and submicroscopic copy 
number variations. Formalin-fixed, paraffin-embedded (FFPE) tissue represents a 
valuable source for testing; however, the DNA degradation induced by formaldehyde 
fixation makes the use of SNP arrays challenging. We evaluated the ability of the 
Illumina HumanOmniExpress-FFPE BeadChip with the Infinium FFPE DNA restoration 
protocol to detect known clinically significant copy number alterations. Methods: 
Genomic DNA was extracted from 8 FFPE samples representing 4 glioblastomas with 
known cytogenetic aberrations and 4 lung adenocarcinomas with EGFR exon 19 
amplification by fragment analysis. The samples were run on the Illumina 
HumanOmniExpress Beadchip microarray that contains 730,525 probes with a 4 kb 
mean spacing. The B-Allele Frequency and Log2R ratio were analyzed using both 
Illumina GenomeStudio analysis and Nexus Copy Number software. Results: All the 
samples passed Illumina FFPE QC (Delta Cq < 5). The mean call rate was 91.45%. We 
observed an overall concordance of 87%. Of all the tumor samples tested, only one 
case was discordant; with FISH indicating no EGFR gene amplification with polysomy 7 
whereas SNP array identified gene amplification and polysomy. All the EGFR exon 19 
amplifications were confirmed (100% concordance). Conclusions: Assessment of 
specific clinically significant genomic changes in routine FFPE specimens using SNP 
arrays is feasible and has great potential for application in routine clinical testing of solid 
tumor specimens. 
 
ST68. Beyond the Cobas 4800 V600 Mutation Test: Targeted Next-Generation 
Sequencing of BRAF, NRAS, and c-KIT in Formalin-Fixed, Paraffin-Embedded 
Specimens of Metastatic Melanoma 
B. Kwok1, W. Shi1, C. Burgess2, R. Loper1, E. Guillen1, T. Holscher1, J. Diver1, W. Kroll2, 
M. McGinniss1, B. Dabbas1 
1Genoptix Medical Laboratory, Carlsbad, CA; 2Novartis, Cambridge, MA. 
Introduction: The selective BRAF inhibitor vemurafenib has demonstrated impressive 
clinical activity in patients with metastatic melanoma harboring BRAF V600E mutations. 
Recent studies and National Comprehensive Cancer Network (NCCN) guidelines have 
suggested that patients harboring BRAF V600K mutations may also benefit from 
vemurafenib. The cobas 4800 V600 Mutation Test (Roche Molecular Systems) is a 
Food and Drug Adminstration (FDA)-approved test intended to be used as an aid in 
selecting melanoma patients whose tumors carry BRAF V600E mutations for treatment 
with vemurafenib. The cobas, however, is reported to have limited cross-reactivity with 
non-V600E BRAF mutations, and patients who are negative by cobas currently have 
few effective treatment options. Several studies have shown that NRAS and c-KIT 
mutations may also be of clinical relevance in patients with metastatic melanoma. 
Methods: Formalin-fixed, paraffin-embedded specimens of 63 consecutive patients 
with metastatic melanoma were analyzed by a validated and sensitive (5% limit of 
detection) next-generation sequencing (NGS) assay (Ion Personal Genome Machine, 
Life Technologies) targeting BRAF, NRAS, and c-KIT. 46 of these specimens were also 
retrospectively analyzed by cobas, and 16 by Sanger sequencing. 7 of the 63 patients 
reportedly tested negative for BRAF V600E mutations elsewhere prior to NGS analysis. 
Results: NGS detected BRAF, NRAS, and c-KIT mutations in 20 (32%), 17 (27%), and 
1 (2%) of the specimens, respectively. Among BRAF mutations, 8 (40%) were V600E, 7 
(35%) V600K, 1 (5%) V600E2, and 4 (20%) non-V600. Among NRAS mutations, 7 
(41%) were Q61K, 3 (18%) Q61R, 3 (18%) Q61L, 2 (12%) Q61H, and 2 (12%) non-
Q61. The only c-KIT mutation detected was a novel G827R mutation. All 8 specimens 
with BRAF V600E mutations (mean mutant allele of 33%) were positive by cobas, 
whereas all 7 specimens with BRAF V600K mutations (mean mutant allele of 19%) 
were negative. Sanger confirmed BRAF V600K mutations in 6 specimens, whereas 1 
failed due to insufficient amplification. The 1 specimen with BRAF V600E2 mutation 
(mutant allele of 5%) was negative by both cobas and Sanger. NGS detected additional 
BRAF, NRAS, or c-KIT mutations in 19 (50%) of the 38 specimens that were negative 
by cobas. Conclusions: The cobas 4800 V600 Mutation Test is an unreliable detector 
of non-V600E BRAF mutations, including V600K. A validated and sensitive NGS assay 
targeting BRAF, NRAS, and c-KIT provides additional clinically relevant information in 
half of the specimens that are negative by cobas. 
ST69. Identification of BRAF and RAS Mutations in 13 Atypical Thyroid Nodules 
Using the qBiomarker Thyroid Cancer Mutation Array  
L.J. Tafe, J.D. Marotti, M.C. Schwab, V. Padmanabhan, G.J. Tsongalis 
Dartmouth-Hitchcock Medical Center, Lebanon, NH. 
Introduction: The diagnosis of classical papillary thyroid carcinoma (PTC) is based on 
characteristic nuclear features and is typically straightforward. Some follicular lesions 
with borderline nuclear features of PTC create diagnostic difficulty and clinical 
uncertainty. The role of molecular analysis in evaluation of these atypical lesions 
remains unclear. BRAF and RAS mutations are seen in well and poorly-differentiated 
carcinomas, likely representing an early event in tumor progression. The frequency of 
BRAF V600E mutations ranges from 12% in follicular variants, to 60% in classical 
PTCs. RAS mutations are present in 10-20% of PTC, 40-50% of follicular carcinomas 
and 20-40% of follicular adenomas. In this study, we evaluated atypical thyroid nodules 
(ATN) and PTC using an expanded panel of somatic mutations focused on the MAPK 
and PI3K-AKT pathways using real-time PCR multiplexed arrays. Methods: Thirteen 
ATN were selected as well at two PTC cases for control. DNA was extracted from FFPE 
sections; PCR using the Qiagen qBiomarkerTM Thyroid Cancer Mutation Array was run 
on the AB 7500 Fast Real-time PCR System. The average Ct analysis method with a 
deltaCT cutoff of 4 was used to determine the mutation status of each case for 81 
somatic mutations across 13 genes. BRAF p.V600E mutation testing was previously 
performed by an allele-specific PCR assay and all ATN were non-mutated and the 2 
PTC were p.V600E mutated. Results: Twelve of the ATN had valid results as did 2/2 
PTCs. Six mutations were identified in the ATN (46%) consisting of 2 mutations in 
NRAS (both p.Q61R), 2 in HRAS (p.Q61K and p.Q61R), 1 in BRAF (p. K601E) and 1 in 
KRAS (p.Q61R). However, in neither PTC case was the BRAF p.V600E mutation 
confirmed by the qBiomarkerTM Array. Conclusions: Overall, the qBiomarkerTM 
Thyroid Cancer Mutation Array worked well in the FFPE thyroid tissue with only one 
failure. However, the qBiomarkerTM Array did not confirm two known BRAF p.V600E 
mutation in a PTC suggesting that this array may require further optimization for FFPE 
and further characterization of the assay sensitivity. Additional studies such as 
sequencing will be performed to confirm the mutations found. However, mutations that 
may play a role in the pathogenesis of PTC were identified in 46% of the ATN. Based 
on the mutations identified, it is plausible that these ATN might represent precursor 
lesions of thyroid cancer. Further studies are warranted to examine the role of 
molecular analysis in evaluation of atypical /borderline thyroid nodules on surgical 
specimens. 
 
ST70. Evaluation of a Genomic Classifier for Improved Risk Stratification in 
Prostate Cancer Patients with Adverse Pathology  
D. Dolginow1, A. Crisan2, M. Ghadessi2, C. Buerki2, N. Erho2, I.A. Vergara2, Z. Haddad2, 
T. Sierocinski2, E. Davicioni2, T.T. Triche3 
1University of California San Francisco, San Francisco, CA; 2GenomeDx Biosciences 
Inc., Vancouver, British Columiba; 3University of Southern California, Los Angeles, CA. 
Introduction: In radical prostatectomy (RP) specimens, the presence of one or more 
adverse pathological features (APF) is considered a risk factor for metastatic disease 
progression. However, the majority of patients with APF will never develop metastatic 
disease and will die with prostate cancer, not from it. In this study, we evaluated the 
performance of a previously validated genomic classifier in seminal vesicle invasion, 
extracapsular extension, node and margin positive APF subsets for predicting 
metastatic disease progression post-RP. Methods: A genomic classifier (GC), 
developed by transcriptome-wide expression analysis of FFPE-surgical specimens, was 
developed to predict metastatic disease (as evidenced by positive bone or CT scans). 
Subsets of APF tumors were selected from 219 prostate cancer patients from the Mayo 
Clinic tumor registry. The GC scores range from 0 (low metastatic potential) to 1 (high 
metastatic potential), in unit increments of 0.1. 5-year survival ROC c-index, 
multivariable proportional hazard regression model and Kaplan Meier (KM) curves were 
used to assess GC predictions for metastatic disease in subsets of patients with: 
seminal vesicle invasion (SVI+, n=81), lymph node involvement (N+, n=32), 
extracapsular extension (ECE+, n=98), and positive surgical margins (SM+, n=123). 
Results: The c-index of GC in the APF subset analysis for SVI+, N+, ECE+, and SM+ 
subsets was 0.81, 0.82, 0.76 and 0.82, respectively. In all patients, the c-index of GC 
was 0.77 and significantly higher than any individual APF (range 0.49-0.65) for 
predicting metastatic disease post-RP. Multivariable analysis revealed that in all 
comparisons, GC was the most significant predictor of metastatic disease progression 
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in all APF subsets with HR (for a unit increase in score on a ten point scale) of 1.70, 
1.90, 1.42 and 1.70 in SVI+, N+, ECE+ and SM+, respectively (p<0.001, except for N+ 
p=0.03). KM curves showed that overall those patients with high GC scores had worse 
outcomes independent of individual APF status. Conclusions: This subset analysis 
suggests that a genomic classifier approach provides additional prognostic information 
to pathological variables and maintains consistent performance for predicting metastatic 
disease even among subsets of patients with specific APF. Further validation studies 
are required to support these findings in diagnostic biopsy specimens and may provide 
a useful adjunct to pathological analysis in efforts to improve risk stratification and 
treatment decision-making in men with high-risk prostate cancer.  
 
ST71. Use of a Novel FISH Assay as an Adjunct to Diagnosis of Lipoblastoma 
J.A. Bridge1, Y. Zhang1, H. Correa2, M. Cajaiba2, P. Dickman3, A. Saad4, C. Fletcher5, 
D. Perry4 
1University of Nebraska Medical Center, Omaha, NE; 2Vanderbilt Children's Hospital, 
Nashville, TN; 3Phoenix Children's Hospital, Phoenix, AZ; 4Arkansas Children's 
Hospital, Little Rock, AR; 5Brigham and Women's Hospital, Boston, MA. 
Introduction: Lipoblastoma is characterized by chromosomal aberrations involving 
8q11~13. PLAG1, a developmentally regulated zinc finger transcription factor localized 
to 8q12.1, is the target of the 8q rearrangements. PLAG1 aberrations can be 
cytogenetically cryptic. Identification of the characteristic PLAG1 rearrangement may be 
diagnostically useful when confronted with lipoblastomas arising in an uncommon site 
or age, deviating from the classic histopathologic appearance, or exhibiting prominent 
myxoid change concerning for a myxoid liposarcoma. As a diagnostic aid, we 
constructed a FISH probe set that can: 1) be performed on formalin-fixed, paraffin-
embedded tissue; and, 2) identify potential cryptic rearrangements. Methods: Probe 
cocktails of selected BAC clones were developed to assess the PLAG1 locus as a 
break-apart rearrangement. After establishing the specificity of the probes (on normal 
peripheral blood lymphocytes and 8q11~13 rearranged lipoblastoma metaphase cells), 
we evaluated metaphase cells, touch preparations or paraffin-embedded tissue 
sections of 15 specimens (5 lipomas, 4 pediatric myxoid liposarcomas, and 6 
lipoblastomas including an unusual case arising in the retroperitoneum) using a two-
color FISH assay. Results: PLAG1 abnormalities were detected by FISH in all six 
lipoblastomas. Detection of equivalent split red and green signals in 5 cases indicated a 
balanced translocation event involving PLAG1. Low level amplification (5-10 copies) of 
only the proximal PLAG1 probe signal was seen in one lipoblastoma suggesting the 
presence of an unbalanced structural rearrangement. The FISH findings with this novel 
PLAG1 FISH probe set were concordant in all but one of the four lipoblastomas that 
also had informative results by conventional karyotyping; the discordant case was 
karyotypically normal suggesting a failure to culture the lesional cells. PLAG1 
abnormalities were absent in the other adipocytic neoplasms analyzed. Conclusions: 
FISH analysis with this newly designed probe set is a reliable and specific method of 
detecting abnormalities of the PLAG1 locus (rearrangement and/or gain) in routinely 
processed tissue (including formalin-fixed, paraffin-embedded tissue) and it may serve 
as a useful aid in distinguishing lipoblastoma from histopathologically similar lesions or 
in establishing the diagnosis in patients with unusual clinical presentations.  
 
ST72. Analytical Performance of the Vysis ALK Companion Diagnostics Assay 
K. Pestova1, F. Siebert1, G. Li1, P.L. Swatkowski1, K.L. Sachs1, C. Herman1, S. 
Vanmany1, Y. Zhang1, B.A. Blondin1, K.B. Jacobson1, J.H. Tepperberg2, K. Dickinson3, 
S.B. Fox4, K.B. Abravaya1 
1Abbott Molecular, Inc., Des Plaines, IL; 2LabCorp, Triangle Park, NC; 3US Labs, Irvine, 
CA; 4Peter McCallum Cancer Centre and University of Melbourne, Melbourne, VIC, 
Australia. 
Introduction: Rearrangements of the ALK gene with the known fusion partners result 
in a chimeric, constitutively-activated tyrosine kinase implicated in the development of 
the Non-Small Cell Lung Cancer (NSCLC). The Vysis ALK Break Apart (BAP) FISH 
Probe Kit was developed to detect chromosome 2p23 rearrangements in FFPE NSCLC 
tissue by fluorescence in situ hybridization, as an aid in identifying patients eligible for 
treatment with the tyrosine kinase inhibitor crizotinib. Studies were conducted to verify 
the assay cutoff, and to assess analytical performance and reproducibility of the assay. 
Methods: The assay cutoff was verified using 33 FFPE NSCLC specimens without ALK 
translocation. Analytical sensitivity and specificity of the 3’- and 5’-ALK probes against 
the target chromosomal locus were tested on metaphase spreads from blood samples 
of 5 normal donors. Analytical reproducibility of the ALK signal enumeration, including 
reproducibility between reviewers and between serial sections from the same 
specimen, was ascertained by 3 reviewers on 5-μm serial sections from 6 ALK-positive 
and 14 ALK-negative specimens. Clinical reproducibility of the assay was evaluated on 
a panel of 4 ALK-positive and 2 ALK negative NSCLC specimens at 3 laboratories. 60 
serial section slides per specimen were randomized; 2 technicians at each laboratory 
tested 2 kit lots (1 slide per specimen per lot) for 5 days to a total of 120 slides per site, 
each slide enumerated by 2 reviewers. Results: The negative cutoff of 15% ALK 
positive cells was verified using enumeration rules with 2-diameter separation between 
3’- and 5’-ALK probe signals. The study results demonstrated analytical sensitivity and 
specificity of the 3’-ALK and 5’-ALK probes to be 100.0% (95% CI 98.5-100.0) and 
100% (95% CI 97.0-100.0), respectively. Analytical reproducibility assessed by the 
Fisher-Freeman-Halton test on the FISH classification based on 15% cutoff showed no 
significant difference between reviewers and between tissue sections (p-values of 1.0). 
In the clinical reproducibility, out of the 60 slides per specimen, the agreement with the 
expected result was 100% for the 2 ALK-negative specimens, and 93.3% to 100% for 
the 4 ALK-positive specimens. The overall percent agreement was 97.64% (95% CI 
96.25 – 98.52). Conclusions: The analytical accuracy, and reproducibility between 
reviewers, between tissue sections, and between laboratories was demonstrated for the 
Vysis ALK BAP FISH Probe assay. The assay was shown to reproducibly classify ALK 
status on multiple consecutive sections through the FFPE NSCLC tissue specimens. 
 
ST73. Prognostic Morphologic Correlations of Kras gene Mutations in a Series 
of Unselected Colorectal Carcinoma Patients of a Single Brazilian Institution 
M.P. Macedo, B.C. Lisboa, M. Begnami, F.M. Melo, L.d. Andrade, S.A. Junior, F.A. 
Soares, D.M. Carraro, I.W. Cunha 
A.C.Camargo Hospital, Sao Paulo, Brazil. 
Introduction: Kras mutation is a negative predictor of response to treatment with 
Epidermal Growth Factor receptor inhibitors and present in approximately 35% of 
Colorectal Carcinomas (CRC). Codon 12 is involved in 75% of the cases and 13 in 
25%. Great attempt has been made to understand its prognostic value. Depth of 
invasion (pT) and lymph node (LN) status (pN) are major prognostic evaluated 
parameters in CRC specimens. The presence of angiolymphatic (VLI), neural (NI) 
invasions and more recently LN ratio (positive LN divided by total) > 0,6, are also 
factors of poor outcome. In this study we show the frequency of Kras mutation in a 
series of CRC patients and correlate the findings with morphological findings related to 
prognosis. Methods: Kras mutation in codons 12 or 13 was tested by pyro sequencing 
improved by nested PCR (Q96 qiagen) in samples of patients operated for primary or 
metastatic CRC in a single institution. DNA sample was obtained from paraffin 
embedded tissue. Results: The population consists of 421 patients (221 males and 200 
females), with mean age of 60 yrs (20-93 yrs). Mutation was observed in 33% of the 
cases, codon 12 involved in 76% and 13 in 24% of total cases. 358 cases were from 
the primary tumor and 63 were from metastasis. No difference of mutation was found 
comparing men and women or between age groups. Right colon cancer showed a 
higher frequency of mutation (45%) than left side CRC (26%) (p=0,005). There was no 
statistical difference between mutation according to tumor pT status, VLI, LN 
metastasis, or LN ratio. Cases harboring perineural invasion showed an association 
with Kras mutation (41% versus 28% without NI) (p= 0,043). The frequency of Kras 
mutation in tissue from primary tumors was similar to the metastatic ones (33.8% 
versus 31.75%), but the codon 13 was affected more frequently in metastatic lesions 
(45%) than in primary tumors (21%). Conclusions: The data show concordance with 
the literature regarding the frequency of Kras mutation in a CRC population, its 
distribution between codons 12 and 13 and the higher frequency of mutation in right 
sided tumors. It was shown that perineural invasion have an association with the 
presence of Kras mutation. Additionally metastatic tissue showed a higher frequency of 
codon 13 mutation than primary tumor. The data adds information about the possible 
role of Kras mutation in tumor aggressiveness and also about the association of codon 
13 mutation in metastatic tumors.  
 
ST74. BRAF Mutation Testing in Thyroid Carcinoma: Experience of 929 Cases at 
a Single Tertiary Care Medical Center 
J. Ziai, A. Kamath, P. Hui 
Yale New Haven Hospital/Yale University School of Medicine, New Haven, CT. 
Introduction: BRAF V600E is the single most prevalent mutation in classic papillary 
thyroid cancer (PTC) with an estimated prevalence of 40-68% and is strongly 
associated with adverse clinical parameters. Because BRAF mutation status bears 
important clinical and prognostic implications, sensitive and specific detection of BRAF 
mutation(s), especially in cytologic specimens, is paramount to appropriate clinical 
management. We report our experience of BRAF mutation testing using single strand 
conformation polymorphism (SSCP) and Sanger sequencing analyses at a single 
tertiary care center in a 30-month period. Methods: DNA samples were extracted from 
formalin-fixed paraffin embedded tissue or FNA cytological samples. The BRAF gene 
was amplified by PCR using primers flanking exon 15. PCR products were then 
resolved by single strand conformation polymorphism (SSCP) gel electrophoresis and, 
when necessary, by direct Sanger sequencing of the PCR products. Results: A total of 
929 thyroid specimens were tested for the presence of BRAF V600E mutation . There 
were 642 thyroid cytology cases, of which 356 cases had follow-up surgical specimens. 
287 cases had only surgical specimens without a corresponding prior FNA specimen. 
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Of 642 cases with an FNA specimen, BRAF mutation testing was successful in 95% 
(612/642) with an overall mutation detection rate of 35% (225/642). Of cases with a 
‘positive’ cytologic diagnosis, 69% (182/265) were BRAF mutation positive, 25% 
(67/265) were wild type, 1.5% (4/265) had a suspicious band, and 4.5% (12/265) had 
insufficient material. All surgical cases (100%) corresponding to cytologies positive for 
BRAF mutation showed PTC irrespective of morphologic diagnosis. In cytology cases 
diagnosed as ‘suspicious’ or ‘indeterminate,’ 11% (43/370) were BRAF mutation 
positive, 82% (307/370) were WT, 3% (11/370) had insufficient material, 2% (7/370) 
had no product and 0.5% (2/370) had a suspicious band. Cytology cases with ‘other’ 
diagnoses (e.g., Hurthle cell adenoma, follicular neoplasm) never harbored a BRAF 
mutation (0/7). 45% of cytology cases with a diagnosis of ‘suspicious’ or ‘indeterminate’ 
and WT BRAF status had corresponding surgical resections. Of these, 68% were 
positive for PTC. Fifteen percent of PTCs were BRAF negative by SSCP and Sanger 
sequencing of the surgical tumor tissue, 9% were BRAF-positive and the remainder had 
no further molecular testing ordered. Conclusions: Our study demonstrates SSCP 
combined with Sanger sequencing is a highly sensitive and near-perfectly specifc 
method for detection of PTC in comparison to published data. As such, SSCP is a 
powerful tool in the diagnosis, management and prognostication of patients with or 
suspected of having PTC. 
 
ST75. Cancer of Uncertain Origin: Comparative Effectiveness of 
Immunohistochemistry and Gene Expression Profiling in Diagnosing the Primary 
Site in Metastatic Cancer 
C.R. Handorf1, A. Kulkarni1, A.M. Ezekiel1, J.P. Grenert2, O.S. Kim3, W.M. Rogers4, L.M. 
Weiss5, C.I. Dumur6, M.O. Idowu6, G.E. Sandusky7, F.A. Monzon8, R. Panos9, M. Halks-
Miller9, A. Pingitore9, E. Fuentes9, J. Shi9, M. Walker9, R. Pillai9, W. Henner9 
1University of Tennessee Health Science Center, Memphis, TN; 2University of 
California, San Francisco, San Francisco, CA; 3Advocate Good Shepherd Hospital, 
Barrington, IL; 4El Camino Hospital, Mountain View, CA; 5Clarient, Inc., Aliso Viejo, CA; 
6Virginia Commonwealth University, Richmond, VA; 7Indiana Univeristy School of 
Medicine, Indianapolis, IN; 8Baylor College of Medicine , Houston, TX; 9Pathwork 
Diagnostics, Redwood City, CA. 
Introduction: Determining the origin of metastatic cancer with confidence can be 
challenging. Pathologists commonly use a battery of immunohistochemical (IHC) stains 
to determine the primary site. Gene expression profiling (GEP – Pathwork Tissue of 
Origin Test), which relies on mRNA expression of 2000 genes to predict the primary site 
from a panel of 15 tumor tissue types, is an alternative method for evaluating these 
cases. We directly compared the accuracy of IHC and GEP in identifying the origin of 
160 blinded metastatic specimens. Methods: Sample eligibility criteria included 1) 
formalin-fixed paraffin-embedded surgical biopsy specimens from the 15 tumor tissue 
types on the GEP test panel, containing 60% tumor and adequate size to provide at 
least 25 sections, 2) an identifiable primary site based on clinical records, eg, imaging 
and surgical reports. Samples where the primary site diagnosis relied on IHC were 
excluded. The four evaluating pathologists (EPs) and the team performing GEP were 
given patient sex and gross sample description and were blinded to the primary site. 
Study design allowed the EP to diagnose a primary site in a maximum of 3 steps: after 
evaluation of H&E images (initial diagnosis), first batch of stains (intermediate 
diagnosis) and second batch of stains (final diagnosis). A panel of 84 IHC and 
histochemical stains were available to the EPs. Slides were digitized for EP analysis. 
Conditional logistic regression was used to compare the results from the two methods. 
Results: 157 samples were evaluated by both IHC and GEP. The GEP test results 
were more accurate at identifying the primary site for metastatic tumors (89%) than IHC 
(83%) (p=0.013). Histology and IHC-based diagnoses increased from 64% accuracy 
(average) following H&E alone to 81% after one IHC round and to 83% after two 
rounds. For GEP, the average number of sections used per case was 3.8 (median 4, 
range 1-8) vs. 8.4 stains (median 8.0, range 0-20) per EP per case. In poorly 
differentiated and undifferentiated cases, GEP was 94% accurate compared to 79% for 
IHC (p=0.016). Conclusions: In this study of comparative effectiveness of IHC and 
GEP, the accuracy of primary site diagnosis using GEP was superior to accuracy 
achieved with IHC-based diagnosis. These results suggest that GEP can be a useful 
tool for determining the site of origin for metastatic tumors.  
 
ST76. Methylation Profiling in Morphologically Normal Appearing Tissues and 
Cancerous Tissues from Korean Breast Cancer Patients  
I. Kim1, E. Jung2 
1Pusan National University Hospital, Republic of Busan, Korea; 2Gyeongsang National 
University Hospital, Republic of Jinju, Korea. 
Introduction: Hypermethylation of CpG islands of gene promoters is associated with 
breast carcinogenesis. This study was designed to evaluate gene hypermethylation 
profiles of both the normal appearing tissues adjacent to breast tumors and the 
corresponding primary breast tumors. Methods: A single reaction using methylation-
specific multiplex ligation-dependent probe amplification was employed to analyze the 
DNA methylation status of 24 tumor suppressor genes in 60 paired cancerous and 
normal tissue samples from breast cancer patients. Results: In the cancerous breast 
tissues, 21 of 24 genes displayed promoter methylation in one or more of the breast 
samples. The most frequently methylated genes were RASSF1 (43.3%), APC (31.7%), 
CDKN2B (25.0%), CDH13 (23.3%), GSTP1 (16.7%) and BRCA1 (10%). RASSF1 was 
associated with the tumor type such as invasive ductal carcinoma, APC was associated 
with lymph node metastasis and BRCA1 was associated with negative ER and PR 
expressions. In the morphological normal breast tissues, 8 of 24 tumor suppressor 
genes displayed promoter hypermethylation, and CDKN2B (28.3%) and RASSF1 
(8.3%) hypermethylation were mostly frequently noted. Conclusions: Our data 
indicates that the methylation of specific genes is a frequent event in the morphological 
normal breast tissues adjacent to breast tumors as well as in the corresponding primary 
breast tumors. These methylation changes may play a role in the earliest stages of the 
development of breast carcinogenesis in breast cancer patients. This study also 
suggests that gene methylation may be linked to various pathological features of breast 
cancer, yet this requires confirmation in larger studies. 
 
ST77. Targeted Next-Generation Sequencing Offers Added Value in the 
Assessment of Cancer Related Mutations in Molecular Diagnostics 
A. Seth, P. Zhang, H. Fernandes 
University of Medicine and Dentistry of New Jersey/New Jersey Medical School, 
Newark, NJ. 
Introduction: The advent of targeted next-generation sequencing (NGS) technologies 
in clinical diagnostics promises to enhance the identification of a comprehensive panel 
of cancer-related mutations. However, for NGS to be incorporated into a clinical 
diagnostic laboratory, it must be applicable to the utilization of small amounts of FFPE 
tissue and sensitive enough to detect minimal amount of the somatic variant. We have 
evaluated the potential of the AmpliSeq Cancer Panel on the IonTorrent (IT) Personal 
Genome Machine (PGM) to detect mutations in varied FFPE specimens that were 
validated using alternate sequencing technologies. Methods: DNA from previously 
sequenced FFPE specimens and controls were analyzed for cancer-related mutations 
using the Ampliseq panel 2.0 (Life Technologies). The fourteen tissues included in the 
analyses came from colon cancer specimens with varying KRAS and BRAF mutations, 
lung adenocarcinoma with EGFR mutations including deletions and gliomas with IDH 1 
mutations. In addition cell lines with documented mutations and genomic DNA from 
apparently healthy individuals were used as controls. The specimens used in the 
evaluation had varying amounts of somatic mutations, from 10% to 50% as determined 
by Pyrosequencing. The primer mix from the cancer AmpliSeq panel 2.0 was used to 
generate a library in a multiplex PCR reaction concomitantly, from four individually 
barcoded specimens. The parameters for amplification were modified for maximal yield 
and efficiency. The assay interrogates 739 common mutations in 46 cancer genes 
using 190 primer pairs. The amplicons are subsequently enriched to select viable 
nanospheres for sequencing on a 316 chip. Results: An overall concordance of 94.7% 
was obtained for the point mutations and deletions tested previously by Pyrosequencing 
or melt curve analysis. One mutation in the IDH gene of a glioma specimen that was 
identified by melt curve analysis was not detected by NGS. There was an average of 
1890 reads per amplicon with a range of 5 to 15 additional clinically-actionable variant 
calls in each specimen analyzed. The mutations of interest associated with the 
specimens included APC, RET, TP53, FBXW7and PDGFRA. Conclusions: Next- 
generation sequencing has advantages for the comprehensive evaluation of multiple 
clinically-actionable mutations, particularly in heterogenous diseases like cancer. The 
specimen barcoding and multiplexing capabilities afford a reasonably high throughput 
with acceptable turn-around-time and inbuilt quality control. The IonTorrent Personal 
Genome Machine can be adopted for use in a routine molecular diagnostic laboratory. 
 
ST78. A Methods Comparison Analysis of the Roche cobas 4800 BRAF V600 
Mutation Test and the Qiagen BRAF RGQ PCR Kit on Melanoma Specimens with 
Challenging Attributes 
J.W. Longshore1, S. Banawan2, H. Amidon2, H.N. Todd2, J. Fu3, M. Christensen3, J. 
Tsai3, G. Hillman3, H. Halait3, F. Shieh3, J. Lawrence3, E. Lipford1 
1Carolinas Pathology Group, Charlotte, NC; 2Carolinas Medical Center, Charlotte, NC; 
3Roche Molecular Systems, Pleasanton, CA. 
Introduction: Activating BRAF mutations occur in many human tumors, predominantly 
at codon 600. These mutations occur in ~50% of malignant melanomas. The most 
common nucleotide change is a T>A transversion that results in a V600E mutation and 
constitutive activation of the BRAF kinase. A variety of techniques have been used to 
test for the V600E mutation yet few direct comparisons exist between these 
methodologies. Given the increased emphasis on BRAF analysis with the approval of 
the BRAF inhibitor vemurafenib in 2011, two commercially available V600E detection 
methodologies were compared, the Qiagen BRAF RGQ PCR kit (RUO) and the FDA-
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approved companion diagnostic cobas 4800 BRAF V600 Mutation Test. Methods: To 
evaluate test performance, comprehensive histological assessments were conducted 
on 126 FFPET melanoma samples with challenging attributes. Specimens were 
selected based upon small tissue size (<60mm²), >10% pigmentation, >50% necrosis, 
core needle biopsy, or unusual metastatic sites. For each method, a single 5 μm 
unstained slide was tested as recommended in the package insert. Discrepant results 
between the two methods were resolved by next generation sequencing. Results: Of 
the 126 specimens, 15 specimens (11.9%) had insufficient DNA content for the RGQ 
assay, yet all samples yielded a mutation call. By the cobas test, 8 specimens (6.3%) 
had insufficient DNA and 121/126 (96%) of all specimens gave a valid result. There 
were 18 discordant results. Using the cobas test as the reference method, the RGQ test 
had a false positive rate of 10.4% and a false negative rate of 20.4%. Following 
resolution analysis with next generation sequencing, 15/18 (83%) results obtained by 
the cobas test agreed with sequencing, yielding a final PPA of 100% and NPA of 
95.5%. Additional testing is pending on specimens with inconclusive results from next 
generation sequencing. Total time to result for a batch size of 24 samples was 5.65 
hours for the cobas test and 9.75 hours for the RGQ assay. Conclusions: Two 
commercial real-time, probe-based BRAF mutation detection assays differ in their ability 
to detect V600 mutations in melanoma samples with challenging attributes. Based upon 
this analysis, the cobas BRAF Test displayed a higher degree of mutation detection 
accuracy than the BRAF RGQ kit. In addition, the total time to result, assay hands on 
time, and diagnostic interpretation were more efficient and rapid with the cobas BRAF 
Test. 
 
ST79. Moving Towards a Standard IHC Algorithm Along With Gene-Expression 
Profiling for Diagnositically Challenging Metastatic Cancer  
M.L. Nordberg1, M. Pollen2, K. Albee2 
1Delta MDx, Shreveport, LA; 2Delta Pathology, Shreveport, LA. 
Introduction: Cancer of unknown primary origin (CUP) represents 2-6% of all cancers 
diagnosed in the United States. Since the development of personalized cancer 
treatments, the primary site of cancer may dictate the choice of therapeutic agent as 
well as affect prognosis. Determining site of origin becomes an imperative. Gene-
expression profiling has provided insight into the heterogeneity of these lesions and has 
driven development of predictive molecular signatures to aid in clinical decision-making. 
It remains to be determined how much refinement prognostic genomic models provide 
over standard clinicopathologic features and whether this will translate into 
improvement in clinical outcomes. Studies of primary and metastatic lesions of poorly 
differentiated malignancies find approximately 80% of lesions are identified with routine 
stains and immunohistochemistry (IHC). When examining only metastatic carcinomas 
of unknown primary, less than 65% of these lesions are classifiable in regard to origin. 
Limited clinical information further decreases the likelihood of a reliable assessment. 
There are no standard algorithms for IHC panels, although key antibodies for 
undifferentiated malignancies have been outlined (NCCN Guidelines, Occult Primary, 
v1.2012). Information from these stains Methods: This is a retrospective study of cases 
referred for TOO from April I, 2009 through present. Cases included: are considered 
difficult-to-diagnose carcinomas, have histopathology reports, have three or more 
possible sites of origin. Original diagnosis, TOO results, differences, if any, between 
working and final diagnoses, and treatments are compared. TOO relies on mRNA 
expression in 15 organs. Over 2,000 mRNA sequences compile the expression profiles. 
Tumors are given a similarity score, ranging from 0-100, to a particular tissue based on 
mRNA sequences. The scores sum to 100 across tissue types. A high score confidently 
assesses origin. Scores under 20 are non-contributory. Results: Thirty-four cases of 
difficult-to-diagnose carcinomas were examined for original working diagnoses, gene-
expression profiling and differences in final opinion based on gene-expression results. 
The number of IHC stains per case ranged from 3 to 19. Of the thirty-four cases, 15 
(44%) revealed a different site of origin from the pathologist-favored site. Similarity 
scores were insufficient to change the position of the pathologist in a subset of cases. In 
one striking case, a lesion originally labeled a pancreatic carcinoma, resulted in a high 
similarity score with a breast primary. Conclusions: The Pathwork Diagnostic Tissue-
of-Origin test is a valuable adjunct to immunohistochemistry in determining site of origin 
for lesions.  
ST80. Results of an International Pilot External Quality Assurance Scheme for 
Somatic EGFR Mutation Testing in Non-Small-Cell Lung Cancer (NSCLC) 
S. Patton1, N. Normano2, F. Blackhall3, S. Murray4, K. Kerr5, M. Dietel6, M. Filipits7, S. 
Benlloch8, R. Stahel9, E. Thunnissen10 
1European Molecular Genetics Quality Network (EMQN), Manchester, United Kingdom 
(Great Britain); 2INT-Fondazione Pascale, Naples, Italy; 3Christie Hospital, Manchester, 
United Kingdom; 4GeneKOR, Athens, Greece; 5Aberdeen Royal Infirmary, Aberdeen, 
United Kingdom; 6Humboldt-Universität zu Berlin, Berlin, Germany; 7Medical University 
of Vienna, Vienna, Austria; 8Pangaea Biotech, Barcelona, Spain; 9University Hospital 
Zürich, Zürich, Switzerland; 10VU University Medical Center, Amsterdam, The 
Netherlands. 
Introduction: The External Quality Assurance (EQA) / Proficiency testing (PT) process 
aims at establishing performance levels and may identify systematic errors in 
methodology that may not be revealed by internal QA processes. The European 
Molecular Genetics Quality Network (EMQN), the European Society for Pathology 
(ESP), the European Thoracic Oncology Platform (ETOP) and the European Society of 
Medical Oncology (ESMO) with other leading European groups collaborated in a pilot 
EQA scheme for somatic EGFR gene mutational analysis in NSCLC. Methods: 
Samples generated from cell lines mimicking clinical fractions of neoplastic cell content 
were validated by 5 laboratories and then provided to participating laboratories. Each 
sample was supplied with a mock clinical case. Participating laboratories registered with 
the EMQN, performed the analysis using their usual method(s), and submitted their 
results within a 6 week timeframe. Anonymous results were assessed and made 
available to all participants. Results: Of a total of 117 labs from 30 countries registered, 
91 labs returned results. Sequencing and the DxS Therascreen kit were the main 
methodologies used by the participants. The standard of genotyping was worrying, with 
a significant number of genotyping errors made. Only 42 (46.1%) participants reported 
the correct result for all 10 samples. The majority of errors were false-negative results 
(82.2%); however, 15.1% of errors were due to false-positive results and 2.7% to a 
combination of both errors. There were 42 (4.8%) analytical failures of which 88.1% 
were distributed across 6 laboratories. The performance of 18 (19.8%) labs fell below 
the criteria for acceptable performance (score <18 points). The standard of report 
formats was acceptable, a large proportion were clear, concise and easy to read. 
However, some participants reported the genotyping result in absence of any 
interpretation. Conclusions: The technical performance of genotyping in EGFR 
mutation testing for NSCLC has room for improvement, evident from a high level of 
“true” diagnostic errors. Overall the standard of reporting was acceptable. Robust EQA 
can contribute to global optimization of EGFR testing.  
 
ST81. Multiplex Genotyping Technology for Assessment of Mutations in 
Paraffin-Embedded Tissue 
T. Zhang, C. Wei, B. Nwachukwu, N. Boruvka, J. De Souza, S. Kamel-Reid 
Molecular Diagnostics, The University Health Network, Toronto, Ontario, Canada. 
Introduction: Studies indicate that genetic biomarkers can be predictive and/or 
prognostic of patient outcome and response to therapy. We designed a genotyping 
panel specific for solid tumors that can interrogate 280 mutations in 24 oncogenes 
using the Sequenom MassARRAY system. In this study, we assessed the analytical 
sensitivity and specificity of this high-throughput approach for potential use in a clinical 
lab setting. Methods: DNA extracted from 562 FFPE samples representing different 
solid tumor types as well as 4 normal bloods and 11 cell lines was used in this study. 
Macrodissection was performed on all FFPE tissues, and tumor cellularity was noted. 
For mutation detection, this panel was tested on the MassARRAY platform using the 
Sequenom iPLEX Pro complete reagent set. Data analysis was performed both 
manually and using Typer Analyzer software. Genotyping results from 183 samples 
were compared to independent data derived using either different technologies or the 
commercially available Sequenom OncoCarta panel v1.0. Results: In this study, 56 
different mutations in 11 oncogenes BRAF, CTNNB1, EGFR, ERBB2, HRAS, KIT, 
KRAS, NRAS, PIK3CA, RET and STK11 were detected using a lab developed solid 
tumor panel. Of the 562 FFPE samples profiled, there were 272 mutations detected in 
239 samples (42.5%). To test its analytical sensitivity, 144 known positive specimens 
(133 FFPE +11 diluted cell lines) with differing mutation levels (as identified by 
sequencing, RFLP or Sequenom OncoCarta panel) were tested using the lab 
developed panel. Using this panel, 143 out of 144 positive samples (99.3%) showed 
concordant results. Only 1 cell line bearing a BRAF mutant allele at ~10% allelic burden 
was negative using the MassARRAY technology. To test for analytical specificity, 39 
samples (35 FFPE + 4 normal bloods) that had previously tested negative using the 
OncoCarta panel were retested using the new panel. Results from 37 out of 39 negative 
samples were concordant, with 2 additional mutations identified by the solid tumor 
panel. One mutation, PIK3CA E545K, was missed in the original analysis. The 2nd 
mutation, STK11 F354L was not on the OncoCarta panel. Therefore, 97.4% 
concordance was achieved in the 38 “true” negative samples. Conclusions: Current 
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genotyping technology allows comprehensive mutation analysis in paraffin embedded 
tissues with excellent sensitivity and specificity. The ability to design solid tumor specific 
mutation panels makes it an ideal choice in the clinical setting, where data interpretation 
and reporting can be challenging. 
 
ST82. Clinical Validation of a Novel, Same Day OligoFISH Chromosome Panel 
for Bladder Carcinoma Detection in Urine 
R. Tinawi-Aljundi, M.D., R.H. Frontera, M.D., R. Diloreto, M.D., E. Schervish, M.D., K. 
Kernen, M.D. 
Michigan Institute of Urology, St. Clair Shores, MI. 
Introduction: Whole chromosome gains are the most common type of aberration in 
cancer cells. Bladder cancer is commonly detected by cystoscopy; however voided 
urine cytology and FISH are currently performed prior to cystoscopy. Although many 
molecular methods have provided great insights into the pathology of this cancer, 
classical cytogenetics gives the most detail of specific chromosome involvement by 
analyzing each cell individually. Utilizing the publicly available Mitelman Database, we 
sought to determine the frequency of aneuploidy for every human chromosome within 
the deposited clinical cases of bladder carcinoma with the goal of designing a 
diagnostic panel with improved clinical sensitivity. This probe panel went through a 
comprehensive clinical validation study to determine that it can be used as a diagnostic 
tool for bladder carcinoma detection, equivalent to the UroVysion test. Methods: We 
present an informatics model easily obtained from the Mitelman Database. Once we 
determined the most clinically sensitive chromosome panel, a cohort of known negative 
and positive patient samples, as determined by UroVysion FISH analysis, was collected 
for this study. Results: We identified a Same Day OligoFISH panel containing probes 
for chromosomes 3, 6, 7, and 20 as the most clinically sensitive four-color panel for the 
detection of bladder carcinoma. The analytical sensitivity for this probe panel was 
100%. Because of the high quality of the OligoFISH probes, a single chromosome gain 
could be considered abnormal. The cut-off values of the test were determined by the 
maximum number of abnormal cells in the negative samples. we concluded the finding 
of 4 positive cells, in 100 cells scored, is considered a positive diagnosis. The reference 
range of abnormal cells observed in these patient samples was 2.97% - 50.24%. We 
also found 100% concordance with the UroVysion results indicating that this test has at 
least the same clinical sensitivity and specificity as claimed by the UroVysion kit. 
Conclusions: Using the Mitelman database, We successfully confirmed the probe 
panel we designed as a clinically relevant test to be used for detecting bladder 
carcinoma in urine.  
 
ST83. Comparison of Digene Hybrid Capture 2 and Roche cobas 4800 Human 
Papilloma Virus Assays 
J. Mendiola1, D. Ikier1, B. Roushar1, J. Schrauth1, J. Reinartz2, P. Grutkoski1 
1Allina Health, Minneapolis, MN; 2Hospital Pathology Associates , Minneapolis, MN. 
Introduction: HPV molecular testing has become the standard for triage of ASCUS 
cervical cytology specimens and for screening together with cytology for women over 
30 years old. We compared the performance of the Qiagen Hybrid Capture 2 (hc2) HPV 
assay with the recently FDA approved Roche cobas 4800 HPV assay Methods: 348 
residual, deidentified Cytec ThinPrep specimens were retained and used in this study. 
Specimens were run on the Roche cobas 4800 HPV assay. Results were compared to 
routine testing by the hc2 HPV. Discrepant results were evaluated using a linear array 
assay that identifies both high risk and low risk HPV infections. Results: 348 
specimens previously analyzed by hc2 were run on the cobas 4800 HPV test system. 
162 samples were negative on both assays and 154 samples were positive on both 
assays. 2 specimens were negative by the hc2 HPV assay but positive on the Roche 
4800 HPV assay. However, the hc2 ratios on these specimens were elevated but below 
the positive cutoff. The cobas HPV test generated CT values of 36 indicating weak 
signals. These data suggest that both samples were low level HPV infections that were 
just below the cutoff for the hc2 assay but above the cutoff for the 4800 assay. 30 
specimens tested positive by hc2 but negative on the 4800 assay. These discrepant 
cases represented 16.3% of all hc2 positive samples in the study. 11 of these 
discrepant samples were further analyzed by linear array, which identifies high risk and 
low risk HPV infections. One sample showed no HPV by linear array, 9 specimens 
showed only low risk HPV infections and one specimen showed a co-infection with a 
low risk HPV infection (type 53) and a high risk HPV infection (type 58). These results 
suggest that discrepant results seen in our patient population between the hc2 assay 
and the 4800 assay are a result of cross reactivity with low risk HPV types with the hc2 
assay. Review of 1850 hc2 results in our lab indicated a repeat rate for gray zone 
results of 2.6%. Through the first 1500 samples run clinically on the 4800 system, we 
have seen a repeat rate of 1.8% for pipetting/clot detection errors. Conclusions: In our 
patient population, the cobas HPV test shows a higher level of specificity for high risk 
HPV infections compared to the Qiagen hc2 HPV assay. 
 
ST84. Optimized Protocol for Solid Tumor Samples Yields Maximal Microarray 
Results, Including Evidence of an Acquired MAF Gene Deletion in Largerhans 
Cell Histiocytosis in a Patient with TAR Syndrome 
R.A. Schultz1, B.C. Ballif1, V. Cawich1, C. Johnson1, N. Neill1, J.W. Ellison1, L.G. 
Shaffer1, A.D. Florea2, E. Gitelson2 
1Signature Genomics Laboratories, PerkinElmer Inc, Spokane, WA; 2Thomas Jefferson 
University, Philadfelphia, PA. 
Introduction: Array comparative genomic hybridization (aCGH) testing is an accurate 
and reliable method providing increased sensitivity compared with traditional 
cytogenetic techniques. Evaluation of formalin fixed paraffin embedded (FFPE) solid 
tumor specimens by aCGH is often challenged by limits to DNA quality. We developed 
an optimized aCGH protocol for FFPE samples that yields low standard deviations, 
permitting high resolution analysis. The technology has been applied across a variety of 
tumor types including breast cancer, lymphoma, osteosarcoma, and others. Detection 
of a small, tumor-specific deletion within the MAF gene in a patient with Langerhans 
Cell Histiocytosis is presented as an illustration of the high quality results obtainable. 
Methods: Six commercial DNA extraction kits and a previously described proteinase K 
digestion/phenol extraction procedure were compared, along with three commercial 
labeling kits (Agilent, ULS, Roche) and two DNA repair reagents (PreCR Repair Mix, 
Restorase). Multiplexed PCR was used to identify specimens amenable to long PCR 
(1kb). Microarray analysis was performed using a specially designed Roche 
NimbleGen array [OncoChip v2)] with oligonucleotide coverage biased to >2400 cancer 
features and backbone SNP coverage. Results: The optimized FFPE microarray 
protocol is comprised of a non-commercial 3-day proteinase K digestion with phenol 
extraction, and labeling with the Roche kit. DNA repair kits failed to improve results. 
Multiplexed PCR with isolated DNA yields 1-kb products and microarrays yield low 
standard deviations (median=0.1379) and high-resolution results. The protocol was 
applied successfully across a variety of tumor types including breast cancer, lymphoma, 
osteosarcoma, and others. High quality of results obtained is illustrated by detection of 
a 1.8-kb deletion within the MAF gene, the sole acquired abnormality (from matched 
tumor and normal tissue) in a patient with Langerhans Cell Histiocytosis (LCH) and 
thrombocytopenia-absent radius (TAR) syndrome (1q21.1 deletion identified in both 
tissues). Conclusions: We have established an optimized procedure for performing 
microarray analysis for FFPE tumor samples. The protocol achieves quality results 
across tumor types with detection of relatively small abnormalities of clinical relevance. 
A deletion within the MAF gene was identified in the tumor of a patient with LCH and 
TAR syndrome. This constitutes the second report of LCH in a patient with TAR 
syndrome, suggesting an association between these disorders. Furthermore, this study 
offers the first description of a tumor-specific molecular alteration in LCH, a result 
afforded by the superior quality of the microarray data obtained. Potential relationships 
between TAR, LCH, and MAF will be presented. 
 
ST85. A Comparison of Different Dissection Methods for FFPE Tissue Sections 
in a Clinical Laboratory Setting 
C.N. Paxton1, M. Herrmann1, K. Geiersbach2 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 2University 
of Utah, Salt Lake City, UT. 
Introduction: Most genetic testing on solid tumors is performed on tissue dissected 
from formalin-fixed, paraffin embedded (FFPE) sections. The majority of dissections are 
performed manually due to the high cost and inefficient workflow of microdissection 
technologies such as laser capture microdissection (LCM). Manual dissection involves 
aligning the dissection slide with an H&E stained slide marked by a pathologist to locate 
the area of interest (AOI) containing tumor. The AOI is scraped with a scalpel or other 
cutting tool from the dissection slide and transferred to microfuge tube for DNA 
extraction. To semi-automate this process AvanSci Bio (Salt Lake City, UT) recently 
developed a mesodissection tool (Meso-1). We compared this new technology to the 
manual dissection method and LCM in a clinical laboratory setting. Methods: KRAS or 
BRAF positive FFPE tumor samples (n = 20) were sectioned and mounted on paired 
slides. The AOI was identified on an H&E stained slide and transferred to dissection 
slides, either by manually aligning and marking the dissection slide, or by digitally 
aligning the slides using the MESO-1 packaged software. The dissection methods were 
compared for the following criteria: 1) Percent mutant allele for KRAS or BRAF by 
pyrosequencing; 2) DNA concentration by PicoGreen measurements; 3) amount of 
“amplifiable” DNA by quantitative PCR for a housekeeping gene (B2M); 4) time to 
perform the dissection; and 5) precision of the dissection by visual inspection of the pre- 
and post-dissection slides. Results: Percent mutation detected by pyrosequencing was 
comparable for all dissection methods using the same designated AOI. The 
concentration of DNA recovered by the different methods did not correlate as well 
between the different methods. However, the amount of amplifiable DNA corresponded 
well to DNA concentration measured by PicoGreen. The time and precision of the 
MESO-1 dissections were intermediate between manual methods (faster but less 
718  AMP Abstracts
JMD November 2012, Vol. 14, No. 6
precise) and LCM (slower but more precise). Conclusions: MESO-1 dissection of 
FFPE sections from slides is comparable to manual dissection methods presently being 
performed in a clinical laboratory setting. Although LCM is the most precise method, 
this increased precision is not necessary for most specimens. The MESO-1 dissection 
tool is designed to semi-automate the dissection process and has the advantage of 
digitally marking and aligning the AOI to assist in the dissection process.  
 
ST86. Comparison Study of the Performance of the QIAGEN EGFR RGQ and 
EGFR Pyro Assays for Mutation Analysis in Non-Small Cell Lung Cancer 
A.M. Cushman-Vokoun, A.M. Crowley, S.A. Rapp, T.C. Greiner 
University of Nebraska Medical Center, Omaha, NE. 
Introduction: EGFR mutations occur in 10% of non-small cell lung cancers (NSCLC), 
commonly in non-smokers. Since most EGFR-mutated tumors demonstrate sensitivity 
to EGFR inhibitor therapy, EGFR mutation analysis is recommended in all advanced 
NSCLC. Methods: 53 formalin-fixed paraffin embedded NSCLC specimens from 52 
patients (enriched for non-smokers) were selected. Extracted DNA was analyzed using 
the EGFR RGQ ARMS Scorpions probe-based real-time PCR assay and the EGFR 
Pyro pyrosequencing assay. The systems were compared with regard to mutation 
frequency and distribution, sensitivity and precision. Observations were made on 
clinical performance, technical requirements and ease of data analysis in the laboratory 
workflow. Results: Fourteen EGFR mutations were identified in 13 specimens using at 
least one system with a concordance rate of 92.9% between the RGQ and Pyro 
systems.  Performance observations included: 1) The RGQ system required higher 
DNA input; 2) The RGQ system is a single-step procedure with multiple tubes, whereas 
the Pyro EGFR assay is a two-step procedure with fewer tubes; 3) Only the RGQ 
system can identify exon 20 insertions; 4) The RGQ system is more clinically sensitive 
than the Pyro system (87.5% vs 81.3%) 5) The RGQ system is more analytically 
sensitive than the Pyro system when testing two mutated cell lines 6) The Pyro system 
can specify exact mutations for all interrogated sites 7) The ease of data analysis is 
similar between assays. Conclusions: Both the RGQ and the Pyro assays have 
specific advantages and disadvantages to consider when adopting an EGFR mutation 
assay into a laboratory workflow. Overall, the RGQ system demonstrated better clinical 
and analytical sensitivity than the Pyro assay.  
 
ST87. p53 Mutation Status and Functional Test in p53 Mutation Human Cancer 
Cell Line Panels 
A. Sohrabi, A. Brewer, J. Foulke, M. Jackson, L. Chen, A. Bal, C. White, K. 
Langenbach, F. Tian 
American Type Culture Collection, Manassas, VA. 
Introduction: Transcription factor p53 is a major tumor suppressor. It controls the 
cellular response to stress signals through the induction of cell-cycle arrest, apoptosis 
and senescence. In addition, p53 regulates key stages of metabolism, tumor metastasis 
and invasion. As such, p53 has been described as "the guardian of the genome.” At 
least 50 percent of human tumors contain mutations or deletions of TP53, which is the 
gene code p53 protein. In another 50 percent, p53 itself is not mutated but the pathway 
is partially abrogated. Approximately 95% of p53 mutations lie in the core DNA-binding 
domain, and 40% of these involve several “hotspot” mutations that severely restrain p53 
function. Although considerable energy has been focused on the p53 pathway and the 
p53 mutation in the past, the reactivation of mutant p53 is becoming to a new focus. 
Cell line panel containing wide type p53 cell lines and various p53 hot spot mutation cell 
lines could be an essential tool for studying molecular pathology of cancer and the 
novel drug discovery. Methods: Forty-seven common used human cancer cell lines 
derived from breast, lung, colon, pancreas as well as haematopoietic and lymphoid 
tissue were selected and sequenced. p53 hotspots mutations at codon 175, 220, 245, 
248, 249, 255, 265, 273, 275, and 282 that lie in exons 5 - 8 of the p53 gene reference 
sequence were analyzed. Moreover, the selected cells lines were composed to p53 
mutation panels. The p21 mRNA expression level and protein level in cells treated with 
or without etoposide were also evaluated. Results: In this study, we tested p53 hot spot 
mutations in about 47 selected ATCC distributed cell lines, and confirmed most of the 
published studies on p53 mutations. We have discovered that a few tumor cell lines that 
yielded different p53 genotypes than had previously been reported. Further, the p53 
function between WT and mutant p53 cell lines were compared by determining the p53 
downstream target p21 expression under DNA damage condition. Conclusions: To 
obtain valid and reproducible experiment data, it is essential for common used cell lines 
to be clearly characterized at the molecular level. Although numerous studies on p53 
mutations have been published, the information in literature is a mixture of confirmed 
and controversial p53 status. Our study clearly showed the sequencing and functional 
testing of p53 mutation cell line panels, which provide reliable tools for p53 research in 
cancer biology and therapy filed. 
 
ST88. Loss of Cyclin D1 or p53 in Non-Dysplastic Surveillance Biopsies 
Predicts Pouch Neoplasia: A Pilot Study 
B.L. Shadrach1, W. Jiang1, M.P. Bronner2, M.L. Settle3, X. Liu3 
1Cleveland Clinic, Cleveland, OH; 2ARUP, Salt Lake City, UT; 3Cleveland Clinic 
Foundation, Cleveland, OH. 
Introduction: The occurrence of adenocarcinoma following ileal pouch-anal 
anastomosis (IPAA) for ulcerative colitis (UC) is an infrequent but potentially lethal 
complication. Endoscopic surveillance with biopsy has been used empirically to detect 
early pouch neoplasia in patients with IPAA; however, this approach is imperfect. 
Hypothesis: Pouch cancers arise from dysplasia developing within a much broader 
genetically abnormal mucosal field that can be detected even in non-dysplastic biopsies 
by fluorescent in situ hybridization analysis (FISH). Methods: Cyclin D1 and p53 loci 
were analyzed by FISH in fixed, paraffin-embedded non-dysplastic pouch, afferent 
ileum, or anal transitional zone biopsies from patients with pouch neoplasia (pouch 
progressors, n=12: 2 with high grade dysplasia, 10 with adenocarcinoma) and those 
without it (pouch non-progressors, n=10: mean pouch duration of 21.4 years). A total of 
16 non-dysplastic fixed biopsies from the pouch progressor group and 18 non-
dysplastic fixed biopsies from the pouch non-progressors were examined in this study. 
Results: Loss of cyclin D1 alone was noted in 81.3% of non-dysplastic biopsies in 
pouch progressors and 33.3% of non-dysplastic biopsies from pouch non-progressors 
(p=0.001). Loss of p53 alone was noted in 77.7% and 50% non-dysplastic biopsies 
from the pouch progressors and nonprogressors, respectively (p=0.33). The presence 
of either cyclin D1 loss or p53 loss is noted in 100% and 25% of non-dysplastic biopsies 
in pouch progressors and non-progressors (p= 0.002). Using the presence of either 
cyclin D1 loss or p53 loss, a sensitivity of 100% and specificity of 75% was achieved for 
the diagnosis of progression to pouch neoplasia. The results are summarized in Table 
1. Conclusions: The data from this pilot study support the concept that genomic 
biomarkers can distinguish pouch progressors from non-progressors and improve 
cancer surveillance in patients with IPAA. Longitudinal studies are needed to further 
assess the utility of the current findings. Table 1: Loss of CCND1 or p53 detected by 
FISH in non-dysplastic biopsies predicts pouch neoplasia in patients with IPAA. Loss of 
cyclin D1: Sensitivity=81.3%, Specificity=66.7%, PPV=0.68, NPV=0.8. Loss of p53: 
Sensitivity=77.8%, Specificity=50%, PPV=0.64, NPV=0.67. Either cyclin D1 loss or p53 
loss: Sensitivity=100%, Specificity=75%, PPV=0.82, NPV=1. Loss of cyclin D1 and p53: 
Sensitivity=77.8%, Specificity=62.5%, PPV=0.7, NPV=0.71. 
 
ST89. Chromosomal Instability Predicts the Progression of Premalignant Head 
and Neck Lesions 
E.M. Speel1, E. Bergshoeff2, T. Siebers3, S. Fleskens3, J. van der Laak3, T. Merkx3, R. 
Takes3, P. Slootweg3, B. Kremer1 
1Maastricht UMC, Maastricht, Netherlands; 2Atrium MC, Heerlen, Netherlands; 
3Radboud UMC, Nijmegen, Netherlands. 
Introduction: A major dilemma in the management of patients with precursor lesions of 
the head and neck mucosa lies in deciding which lesions will progress into carcinoma. 
Currently used treatments are guided by histopathological examination, which, 
however, is troubled by inter-observer variability. The aim of this study was to evaluate 
the value of chromosomal instability (CIN) detected by fluorescence in situ hybridization 
(FISH) for the identification of head and neck premalignant lesions at risk for 
progression. Methods: We examined a series of premalignant oral mucosa lesions 
(n=106 patients) and laryngeal precursor lesions (n=75 patients) by means of FISH on 
paraffin-embedded tissue sections using chromosome 1 and 7-specific centromere 
probes. Cell nuclei were analyzed for CIN in the fluorescence microscope, indicated by 
the presence of chromosome imbalances and/or polyploidization. Results were 
correlated with histopathological data as well as with collected clinical follow-up data. 
Results: In both oral and laryngeal precursor lesions, the 5-year progression-free 
survival rate was ~90%. Outcome of routine histopathology did only predict malignant 
progression when comparing severe dysplasia with lower stage precursor lesions 
(hyperplasia, mild en moderate dysplasia) (p0.038). CIN was detected in all different 
subgroups of histopathological differentiation. Moreover, the percentage of precursor 
lesions harboring CIN increased with progressing histopathological stage. CIN was 
significantly associated with a lower progression-free survival as compared with lesions 
without CIN (p<0.001). Conclusions: The tumorigenesis of the head and neck mucosa 
is associated with the development of CIN, which can reliably identify lesions at risk for 
malignant progression. Therefore, intensive follow-up and/or a more aggressive 
treatment of lesions with CIN should be considered, and for example examined in 
prospective studies.  
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ST90. Gains of 2p23/ALK Locus are Common in Non-Small Cell Lung 
Carcinoma: Clinical and Molecular Correlations 
S. Pandey, W. Bellamy, K. Arnaoutakis, Z. Singh 
University of Arkansas for Medical Sciences, Little Rock, AR. 
Introduction: Three to seven percent of Non-Small Cell Lung Carcinoma (NSCLC) 
have molecular alterations of the anaplastic lymphoma kinase (ALK) gene resulting 
from an intrachromosomal rearrangement between echinoderm microtubule-associated 
protein-like 4 (EML4) (2p21) and ALK (2p23). The chimeric EML4-ALK protein has 
constitutive tyrosine kinase activity, which is the basis of targeted drug therapy in 
NSCLC using tyrosine kinase inhibitors. Increases in copy numbers and amplification of 
ALK gene have also been reported in NSCLC, but the significance of these 
observations has not been fully characterized. The objective of this study was to 
determine the prevalence of ALK gene copy number changes and / or amplification in 
patients with NSCLC and correlate with clinical/ morphological findings and treatment 
outcomes. Methods: Interphase FISH analysis was performed using a dual color ALK 
break apart probe set (Abbott Molecular) to detect ALK gene rearrangements in 
patients diagnosed with NSCLC at UAMS within the past two years. EGFR mutational 
analysis was also performed in many of these patients. A retrospective review of 
medical charts and pathology features was done and correlations made with clinical 
and morphological findings and treatment outcomes. Results: The mean age of the 
patients was 61 years (range 43-87 years). No significant differences were apparent 
with respect to age, sex, race, or smoking status. The predominant histological pattern 
observed was adenocarcinoma/poorly differentiated adenocarcinoma. The most 
common ALK abnormality observed was a gain of 3 to 4 copies of 2p23 locus 
(approximately 58% of patients). Other abnormalities included t(2p23) (approximately 
19%), and deletion of 2p23 locus (approximately 14%). Approximately 9% of the 
patients showed no cytogenetic abnormalities involving the 2p23 locus were observed 
by interphase FISH. None of the patients examined had an EGFR mutation. Most of the 
tumors (66%) with gain of 2p23 appeared to be central in origin. Interestingly, 41% of 
the patients with gain of 2p23 were found to have brain metastases whereas none of 
the patients with ALK translocation or ALK wild type had brain metastasis. 
Approximately 56% of the patients received chemotherapy and radiation therapy 
whereas 38% of them received chemotherapy alone. Only 6% of the patients 
underwent surgical resection. Conclusions: Conclusion: A gain of 2p23 is a common 
abnormality observed in our series of patients. An interesting relationship with brain 
metastases was identified in these patients that warrants further investigation. Large 
multicenter studies will help to elucidate if gains in 2p23 contribute to carcinogenesis, 
and whether these patients could benefit from crizotinib. 
 
ST91. MET Pathway Activation in Lung Cancer with and without MET Genomic 
Amplification 
M. Sanidad, J. Windham, Q. Pan, K. Arvai, J. Kelly, R. Hilferty, Y. Wang, D. Jones 
Nichols Institute, Chantilly, VA. 
Introduction: Non-small cell lung cancer (NSCLC) shows activation of several distinct 
growth factor pathways that provide opportunities for targeted therapy. The MET gene 
has been shown to be mutated, amplified, and overexpressed in NSCLC. This has led 
to the development of MET inhibitors for therapy. We investigated the correlation of 
MET pathway activation with MET amplification and related mutations. Methods: MET 
activation was assessed in an unselected group of advanced stage NSCLC cases. 
Immunohistochemistry (IHC) on formalin-fixed paraffin-embedded (FFPE) tissue 
sections was performed using an activation-specific phosphoantibody (pMET, 
Try1234/1235, Cell Signaling, 3077). Specificity of this antibody for MET activation was 
shown by IHC on FFPE cell blocks of lung cancer cell lines that had been treated with 
increasing doses of MET inhibitors SU11274 (Sigma) and PHA665752 (Tocris). With 
both compounds, the MET-amplified line NCI-H1993 showed dose-dependent inhibition 
of pMET staining with an IC50 of 0.5 uM; no staining was seen in 2 non-amplified lines. 
The MET locus was assessed using 2 different FISH probes (Abbott LSI MET 
SpectrumRed, and Cytocell c-MET), with amplification assessed in relation to 
chromosome 7 alpha satellite region probes. DNA sequencing for mutations in EGFR 
(exons 18-21), KRAS (exons 1/2), and BRAF (exons 11/12/15) and ALK 
rearrangements by FISH were assessed in pMET+ cases. Results: MET pathway 
activation, as evidenced by strong uniform membrane immunoreactivity for pMET, was 
found in 10 of 83 advanced stage NSCLC specimens (12%, 8/45 
adenocarcinoma/ACA, 2/2 mixed adenosquamous) and absent in pure squamous cell 
carcinoma (n = 36, p = .007). Focal pMET staining was seen in one additional ACA 
case. Definitive MET locus amplification (extra signals in >10% of cells) was found in 5 
of the pMET-positive cases. Polysomy for chromosome 7 was frequent in NSLC (22/41, 
54%) and was not correlated with pMET. Mutations in KRAS codon 12 were found in 4 
pMET+ cases, EGFR in 2 (L858R, E709G) and BRAF in 1 (V600E). Conclusions: 
MET pathway activation, as evidenced by uniform pMET staining, occurs in ACA and 
mixed histologies, often without unequivocal MET genomic amplification and is 
correlated with coexisting mutations in other growth factor pathway genes. 
Understanding other mechanisms underlying MET activation, including crosstalk with 
EGFR pathway dysregulation, will be critical in identifying candidate tumors for MET 
inhibitor therapy. 
 
ST92. Genomic Microarray Analysis of Formalin-Fixed Paraffin-Embedded 
(FFPET) and Frozen (FZT) Uveal Melanoma Detects Clinically Relevant 
Abnormalities and Provides Valuable Biologic Insights 
E.C. Minca1, R.R. Tubbs1, B.P. Portier1, Z. Wang1, C. Lanigan1, C.V. Biscotti1, M.E. 
Aronow1, P.L. Triozzi1, A. Singh1, J.R. Cook1, Y. Saunthararajah1, L. Schoenfield1, B.C. 
Ballif2, R.A. Schultz2 
1Cleveland Clinic Foundation, Cleveland, OH; 2Perkin Elmer, Spokane, WA. 
Introduction: Molecular cytogenetic alterations, especially monosomy of chromosome 
3, are strongly correlated with metastases and death in uveal melanoma (UVM). For 
prognostic stratification, monosomy 3 is frequently assessed by fluorescence in situ 
hybridization (FISH). A subset of UVM exhibit only regional chromosome 3 loss or loss 
of heterozygosity (LOH) that are undetectable by chromosome enumeration probes. 
Furthermore, routine fine needle aspiration samples afford little material for additional 
FISH analysis. CGH/SNP microarray is a potential alternative method that can generate 
high resolution multi-chromosome data, especially if it could be applied to lower quality 
DNA from FFPET. Here we compare microarray and FISH performance for the 
detection of genomic changes in DNA from FFPET and FZT UVM samples. Methods: 
Enucleations performed for 36/119 patients on clinical trial NCT00952939 yielded 
sufficient DNA for genomic analysis from FZT (n=25) and/or FFPET (n=22) samples 
representing 30 patients with CEP3 FISH results obtained as described (Invest Opthal 
Vis Sci 2012 Apr 17 Epub PMID 22511634). DNA was fluorescently labeled (Roche) 
and microarray analysis was performed using a custom designed Roche NimbleGen 
array (OncoChipv2) with oligonucleotide coverage biased to >2400 cancer features and 
backbone SNP coverage affording combined oligo and SNP analysis (CGH/SNP). 
Results: CGH/SNP results were technically successful in 43/47 samples representing 
28 patients. Although DNA from FFPET accounted for all 4 failed aCGH samples and 
appeared to yield suboptimal results relative to DNA from FZT (average standard 
deviations: 0.293 for FFPET, 0.150 for FZT), analyses on FFPET DNA readily identified 
large whole-arm gains and losses. Of 15 paired FFPET and FZT samples, 10 revealed 
equivalent results, whereas 4 FFPET samples identified additional abnormalities not 
seen in FZT. CGH/SNP was concordant with FISH in 15/20 monosomy 3 cases (3/5 
discordants were FZT) and in 5/6 eusomy 3 cases (monosomy 3 in 1 FZT case). Two 
cases FISH-positive for MYC amplification exhibited near-whole-arm gains of 8q. Large 
terminal 6p gains were seen in all cases with chromosome 3 eusomy. TERT and 
NEDD9 amplifications, deletions involving CDKN2A/B, and LUM gene, and whole 
chromosome LOH were also identified. Conclusions: CGH/SNP genotyping of DNA 
from FFPET and FZT of UVM were highly concordant with each other and with results 
by FISH. CHG/SNP appears more informative and sensitive than FISH, identifying 
complex genomic signatures including LOH. Genome-wide coverage provides 
additional data having potential relevance to UVM biology, diagnosis and prognosis. 
 
ST93. Optimized Sample and Library Preparation of FFPE Tumor Samples for 
Targeted Next-Generation Sequencing 
U. Nitin, R. Haigis, E.B. Jaeger 
Illumina, San Diego, CA. 
Introduction: The use of formalin-fixed paraffin-embedded (FFPE) tissues for DNA-
based assays is limited by the quality of the DNA that can be obtained from these 
samples. In addition to introducing chemical contaminants that can inhibit molecular 
reactions, the fixation process leads to crosslinking, DNA fragmentation, and other 
damage to individual nucleotides. The extent of this damage can vary widely from 
sample to sample, but the end result is generally reduced performance of the DNA 
template. We have optimized performance by selecting an optimal DNA extraction 
process, ascertaining the amplifiability of the extracted material, maximizing the amount 
of assay template input, and modifying reagent formulation. This permitted the 
generation of high-quality data with 90% of FFPE samples screened to date. Methods: 
Four different solvents for the deparaffinization of FFPE samples were tested in 
combination with eight different FFPE DNA extraction kits from six different 
manufacturers on a variety of FFPE samples from multiple cancer tissue types. 
Extracted DNA was used as input for a quantitative PCR reaction, and the delta Cq for 
each sample was calculated relative to the Cq of the standard non-FFPE human 
reference gDNA from the Illumina FFPE QC Kit. To maximize the volume of template 
added to the library prep assay, the hybridization buffer was modified to remove all 
dead volume, and reagents were added as powders rather than solutions where 
possible. Results: Deparaffinization with the Qiagen DPS solution followed by DNA 
extraction with the Qiagen All-Prep DNA/RNA FFPE Kit yielded the most consistent 
high-quality sample preps for the TSCA assay. The amplifiability of these sample preps 
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according to our qPCR measurements was completely concordant with sample 
performance in the library prep assay. Sample input volumes for the library prep assay 
were increased four-fold, and the sample success rate correspondingly improved from 
75% to 90%, or 45 of 50 samples. Conclusions: We have optimized the performance 
of our library prep assay for use with FFPE tumor samples. We have also developed a 
qPCR assay that correctly identifies all samples that will provide interpretable sequence 
data. These samples yielded high quality data that enabled the identification of mutant 
alleles at frequencies as low as 1%, which were subsequently confirmed by allele-
specific PCR. Given the large numbers of tissues preserved as FFPE material, the 
added robustness of the assay only increases its value as a research tool for genetic 
analysis. 
 
ST94. Validation of a Laboratory Developed Test (LDT) for the Detection of 
BRAF V600 Mutations for Therapeutic Decision Making in Melanoma Patients 
C.I. Dumur, M.O. Idowu, J.A. Almenara, D.S. Wilkinson, A. Ferreira-Gonzalez, C.N. 
Powers 
Virginia Commonwealth University, Richmond, VA. 
Introduction: Somatic mutations in codon V600 of the BRAF gene have been identified 
in 40 to 60% of melanomas, as well as in other cancer types. Treatment for metastatic 
melanoma has recently advanced by the FDA’s approval of the BRAF inhibitor 
vemurafenib for patients with tumors that carry the BRAF-activating V600E mutation. 
Moreover, patients with tumors harboring the V600K mutation have also shown 
response to vemurafenib. However, treatment with BRAF inhibitors could have 
deleterious effects in patients with melanoma harboring the normal BRAF gene, 
therefore, BRAF mutation analysis prior to treatment is crucial, not only to predict 
response to this targeted therapy, but also to avoid significant and unwarranted side 
effects. Methods: We designed an LDT that consists of two allelic-specific multiplex 
PCR reactions, one to detect the BRAF V600E mutation, and another to detect the 
BRAF V600K mutation, that co-amplify the mutant sequence and an upstream 
conserved sequence. The 141 bp mutant and the 241 bp conserved PCR products are 
resolved on capillary electrophoresis using Lab-on-a-Chip technology. The SK-MEL-28 
cell line, homozygous for the V600E mutation, was used as a source of mutant DNA 
and normal placenta DNA as a source of normal DNA for the analytical validation. Ten 
metastatic melanoma DNA samples with BRAF mutation status previously assessed by 
independent methods (a post-PCR melting curve analysis-based LDT and the cobas 
4800 BRAF V600 Mutation Test, a real-time PCR IVD designed to only detect the 
V600E mutation) were blindly processed for clinical correlation. Results: The sensitivity 
of our LDT was found to be 1% of mutant DNA in a background of normal DNA. The 
inter-run coefficients of variation for the concentration of the 141 bp mutant peak for 
samples containing 100% and 1% mutant DNA were 7% and 12%, respectively. For the 
ten patient samples, a 100% agreement with the previous mutational status results was 
obtained. Interestingly, one sample showed a V600K mutation by our LDT, but was 
reported as V600E by the cobas 4800 BRAF V600 Mutation Test. However, that IVD 
test has shown varying degrees of cross-reactivity with V600D, V600K, and V600E2, 
and is unable to discriminate between them. Conclusions: The use of allelic-specific 
multiplex PCR reactions and capillary electrophoresis provides a robust, highly 
sensitive and specific method for detecting low-level BRAF mutations occurring in 
codon V600 and is able to discriminate between V600E and V600K mutations, in 
metastatic melanoma specimens. 
 
ST95. Detection of ROS Fusion Transcripts in Glioblastoma Multiforme (GBM) 
T. Tran, N. Jun, P. Choppa, K. Bloom, K. Gutekunst 
Clarient, Aliso Viejo, CA. 
Introduction: Receptor tyrosine kinases (RTKs) are a major component of the signal 
transduction pathway that behave as cell surface receptors for growth factors. 
Overexpression of these growth factors caused by gene translocations can result in 
kinase fusions that drive the initiation and advancement of various cancers. With the 
development of various drug therapies that target the inhibition of tyrosine kinase 
activity, the clinical significance of identifying patients who will respond to the 
treatments becomes a growing concern. Recently, a number of gene alterations have 
been identified and characterized in the ROS gene that can potentially lead to the 
development of new drug therapies. Large-scale studies of ROS translocations have 
been conducted in non-small cell lung cancer (NSCLC) and the outcome of the studies 
are playing a pivotal role in generating traction for drug therapy development. The 
expression of ROS has also been identified in a number of glioblastomas (GBM), which 
makes it a strong candidate for further observation. This study was conducted to show 
the mutational frequencies of ROS fusion transcripts in a population of GBM samples. 
Methods: RNA was extracted from 77 formalin fixed paraffin embedded GBM tissue 
samples and tested for 5 ROS fusion transcripts using allele-specific real-time RT-PCR. 
Results: The results showed that out of the 77 GBM samples tested; only 2 samples 
were positive for ROS fusions, which yielded a 2.60% (2/77) rate of detection. 
Conclusions: The data suggests that the presence of ROS fusion transcripts may not 
be limited to NSCLC and should be further evaluated in other cancer types. Further 
research needs to be conducted to evaluate the utility of developing targeted drug 
therapies in numerous cancers based on the mutational status of a gene.  
 
ST96. Immunohistochemistry (IHC) vs a 92-Gene Cancer Classifier in the 
Diagnosis of Primary Site in Metastatic Tumors: A Blinded Comparator Study 
L.M. Weiss1, P. Chu2, B.E. Schroeder3, V. Singh3, Y. Zhang3, M.G. Erlander3, C.A. 
Schnabel3 
1Clarient, Inc., Aliso Viejo, CA; 2City of Hope, Duarte, CA; 3bioTheranostics, Inc., San 
Diego, CA. 
Introduction: Metastatic tumors often pose diagnostic challenges; in particular, poorly- 
or undifferentiated tumors, those with atypical clinical presentation, or samples with 
limited tissue for immunophenotypic analysis may be difficult-to-diagnose. Standard of 
care employs IHC analysis for tumor classification. More recently, gene expression-
based tests have been proposed as diagnostic aids in difficult-to-diagnose cases. This 
study directly compared the diagnostic accuracy of IHC vs molecular classification with 
a 92-gene RT-PCR assay (CancerTYPE ID) for determination of primary tumor site. 
Methods: In this prospectively-defined, blinded study, 131 diagnostically challenging, 
high-grade, primarily metastatic cases were selected by City of Hope (COH) Pathology. 
Cases were reviewed and reference diagnoses established through clinical correlation 
by COH investigators. Blinded FFPE sections were sent to two study sites and 
independently evaluated by either IHC + morphology (H&E) or the 92-gene RT PCR 
assay. Results were scored within a clinically-relevant categorization system 
designated by COH for main tumor type and subtype. The primary endpoint was 
concordance with the reference diagnosis. Study unblinding and data analysis were 
conducted by an independent third party. Results: Final analysis included 122 cases 
(mean age±SD: 61.0±14.3y, 52% female; grades 3/4; 90% metastatic); 9 cases were 
excluded (8: RNA quality; 1: insufficient tumor tissue). The 92-gene assay 
demonstrated an overall accuracy of 79% for tumor classification vs 69% for 
IHC/morphology (P=0.019). Mean IHC use was 7.9 stains per case (median: 8, range: 
2-15). A subset analysis evaluated the accuracy of IHC/morphology stratified by 
number of IHC stains used. When 1-6 (n=42) or 7-9 (n=41) IHC stains were used, the 
primary site was correctly identified by IHC/morphology in 79% and 80% of cases, 
respectively. In cases requiring >9 IHC stains (n=39), IHC/morphology accuracy was 
46%. In the same subsets, correct predictions were made by the 92-gene classifier in 
81%, 85%, and 69% of cases, respectively. Conclusions: This is the first study to 
directly compare the diagnostic accuracy of IHC vs molecular classification. Results 
from this blinded series of high grade metastatic cases demonstrate superior accuracy 
with the 92-gene assay vs standard of care IHC, and strongly support the diagnostic 
utility of molecular classification in difficult to diagnose metastatic cancer. Furthermore, 
the results suggest referral to a molecular diagnostic approach should be considered in 
cases requiring more than 7 to 9 IHC stains to establish the organ of origin, as 
IHC/morphology had the lowest yield in this setting. 
 
ST97. Design and Development of a Next-Generation Sequencing Assay for 
Multiplex Detection of Somatic Mutations in FFPE Tissues  
E.B. Jaeger, R. Haigis, M. Bauer, J. Betley, J. Yeakley, N. Udar 
Illumina, San Diego, CA. 
Introduction: Current methods for detecting somatic mutations are limited by the 
sensitivity with which they detect low-frequency mutations often present in highly 
heterogeneous tumors, or by the number of loci that can be queried in a single assay. 
Next-generation sequencing provides an opportunity to overcome these challenges. We 
have developed an assay to survey over 17,500 nucleotides in cancer-associated 
genes that are commonly mutated in a variety of solid tumor types. When paired with 
ultra-deep next-generation sequencing, this assay is capable of detecting mutant alleles 
at frequencies below 5%. Methods: DNA was extracted from 50 FFPE samples from 
multiple tissue types using the Qiagen AllPrep kit and the QiaCube automated 
extraction system. Genes of interest were targeted using an extension and ligation 
based amplicon library prep assay, and the resulting sequencing libraries were run on 
the Illumina HiSeq system. Average depth of coverage was 6000X, and 89% of assays 
had at least 1000X coverage. Sequencing reads were aligned to a pseudogenome 
constructed from targeted sequences in hg19. Background noise relative to the hg19 
reference genome was calculated in 30bp windows across each amplicon. The highest 
noise measurement from each amplicon was set as the baseline background for that 
target, and base changes exceeding 5 standard deviations of that background were 
considered variant nucleotides. Key variants were confirmed by Sanger sequencing, the 
Qiagen KRAS PCR Kit where possible, and by complementary targeted library 
preparation assays. Results: A total of 50 samples were extracted and processed for 
sequencing. Forty-five samples yielded sufficient product for sequence analysis. Seven 
of twenty-two colorectal samples showed mutations in KRAS, as did three of twenty 
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lung samples. Mutant allele frequencies ranged from 1% to 56%, all of which were 
verified using the KRAS PCR Kit. A subset of these mutations, as well as others 
identified in BRAF and TP53, could only be confirmed consistently by Sanger 
sequencing when the mutant allele frequency exceeded approximately 30%. 
Conclusions: We have developed a targeted extension and ligation based library prep 
assay for detection of somatic mutations that was applied successfully to 90% of FFPE 
samples tested. The depth of coverage achieved with this assay permits detection of 
mutant alleles at frequencies as low at 1%. A subset of the mutations could be 
confirmed by alternate methods, including highly sensitive allele-specific PCR. With the 
continued development of this assay, we expect it to be capable of similar performance 
at the >17,500 other nucleotides it surveys. 
 
ST98. Routine Brush Cytology and FISH for Diagnosis of Pancreatic and Biliary 
Duct Carcinoma: Validation and Testing of Consecutive Cases in a Rural 
Regional Center 
R. Sasi1, J. Weiss1, H. Frayer2, S. Paternoster2, J. Conklin2, K.C. Halling3, S. Kenn1 
1Marquette General Health System, Marquette, MI; 2Marquette General Hospital, 
Marquette, MI; 3Mayo Clinic, Rochester , Rochester, MN. 
Introduction: Conventional cytology of pancreaticobiliary brushings (PBB) has a high 
specificity for carcinoma but low sensitivity. Fluorescent in situ Hybridization (FISH) 
increases the sensitivity of PBB studies. Previous studies have revealed that a high 
proportion of malignant PBB strictures exhibit polysomy that can be detected with FISH. 
Methods: A FISH validation was performed using Vysis UroVysion probes designed for 
detecting centromeres of chromosomes 3, 7, 17 and 9p21 locus. The FISH validation 
consisted of: 1) parallel split sample testing with Mayo Clinic, Rochester, MN, 2) 
technologist’s competency assessments and 3) review of the corresponding cytology 
results by a pathologist (JW). For the validation, 16 PBB were collected in PreservCyt 
(Hologic). ThinPrep slides were prepared for cytology and FISH studies. Blinded FISH 
scoring was performed by two technologists board certified in cytogenetics and 
cytology. An abnormal FISH result was defined as 5 or more cells exhibiting polysomy 
or 10 or more cells exhibiting trisomy 3 or 7. Results were reviewed by a pathologist 
(JW). Six hybridized slides were sent to Mayo Clinic for parallel testing. An additional 5 
non-hybridized slides were received from Mayo Clinic for staining, preparation and 
competency assessments. Results: 100% concordance was observed between the 
technologist results from the two sites. In addition, all slides meeting the minimum 
cellularity achieved a 100% concordance with Mayo Clinic results in both trials of 
parallel testing. FISH testing was clinically implemented by the Marquette General 
Cytogenetics and Molecular Pathology lab in February 2010 after completion of the 
PBB FISH validation. By April 2012 we had completed FISH analysis of 41 PBB. 
Abnormal FISH results were observed in 48.6% of the cases comprising polysomy 
(32.4%), trisomy 7 (10.8%), trisomy 3 (2.7%), tetrasomy 7 (2.7%). Conclusions: FISH 
for PBB testing was successfully validated utilizing split sample testing. The FISH 
results were correlated with clinical parameters and routine PBB cytology diagnosis 
confirming that nuclei prepared from PBB provide diagnostic material for detecting the 
chromosome abnormalities of carcinoma. The addition of FISH testing to routine 
cytologic interpretation has considerably improved the diagnostic sensitivity for PBB 
specimens without compromising specificity.  
 
ST99. Mutational Frequencies of NRAS and BRAF in 119 Metastatic Melanoma 
Samples 
T. Tran, R. White, P. Choppa, K. Bloom, K. Gutekunst 
Clarient, Aliso Viejo, CA. 
Introduction: Melanoma is a form of skin cancer with 9,180 deaths and 76,250 new 
cases reported in the United States each year. Recent data suggests that subsets of 
melanomas can be assessed at the molecular level by driver mutations that exist in 
certain oncogenes. The constitutive activation of signaling pathways caused by driver 
mutations can result in a number of adverse effects, such as decreased apoptosis and 
increased tumorigenesis. The recent approval of Zelboraf for BRAF V600E positive 
melanoma patients has led to an increased interest in identifying additional gene 
alterations that may serve as a target for therapy development. In addition to BRAF, 
there have been a number of studies identifying NRAS gene mutations in metastatic 
melanoma cases. This study was conducted to show mutational frequencies of well-
known mitogen-activated protein kinase (MAPK) genes, BRAF and NRAS, in a cohort 
of metastatic melanoma cases. Methods: DNA was extracted from 119 metastatic 
melanoma tissue samples and tested for BRAF V600 mutations utilizing the Cobas 
4800 real-time PCR system. Following the BRAF test, each sample was tested for 11 of 
the most common mutations in the NRAS gene by allele-specific real-time PCR. 
Results: Results for mutation frequency were as follows; BRAF = 59/119 (49.6%) and 
NRAS = 20/119 (16.8%). Out of the 20 samples that were positive for NRAS mutations, 
only 1 sample tested positive for both NRAS and BRAF mutations. Conclusions: In 
addition to confirming the high frequency of BRAF V600 mutations in metastatic 
melanoma samples, the data also suggests that there is a high occurrence of NRAS 
mutations in metastatic melanoma. Further research needs to be conducted to identify 
the clinical significance of mutations outside of BRAF V600 mutations on drug efficacy.  
 
ST100. Protein Predictive Signatures for Lymph Node Metastasis of Gastric 
Cancer 
W. Li1, F. Ye2, D. Wang1, X. Sun1, G. Lian1, J. Jiang1, J. Suo1, D. Zhang2 
1The First Hospital of Jilin University, Changchun, Jilin; 2Mount Sinai School of 
Medicine, New York, NY. 
Introduction: Lymph node status remains one of most crucial indicators for gastric 
cancer prognosis and treatment planning. Current image methods have limited 
accuracy in predicting lymph node metastasis. We sought to identify protein markers in 
primary gastric cancer and to define a risk model to predict lymph node metastasis. 
Methods: The Protein Pathway Array was used to assess the expression of 193 
proteins in 130 fresh frozen gastric cancer samples. The protein expression levels were 
compared between samples with lymph node metastasis (n=73) and those without 
lymph node metastasis (n=57). Results: There were 27 proteins differentially 
expressed between lymph node positive samples and lymph node negative samples. 
Five proteins (Factor XIII B, TFIIH p89, ADAM8, Cox-2 and CUL-1) were identified as 
independent predictors for lymph node metastasis. Together with vascular/lymphatic 
invasion status, a risk score model was established to determine the risk of lymph node 
metastasis for each individual gastric cancer patient. Finally, the risk scores can also be 
used as prognostic indicator for gastric cancer patients and are independent from tumor 
staging. Conclusions: Some proteins identified in gastric cancer can be selected as 
clinical useful biomarkers. The risk score model is useful for determining patients' risk of 
presence of lymph node metastasis and predicting prognosis. 
 
ST101. Single Copy RNA in situ Approach for Detecting ALK Activating Fusions 
G. Bien, T. Ha, P. Choppa, K. Bloom, K. Gutekunst 
Clarient, Aliso Viejo, CA. 
Introduction: Anaplastic lymphoma kinase (ALK) translocations have been observed in 
different types of cancers and can result in oncogenic fusion proteins. Fluorescent in-
situ hybridization (FISH) has been the gold standard in detecting ALK gene 
rearrangements, but it lacks the ability to detect expression levels and markers used to 
detect specific fusion partners requires additional specimen. PCR assays can be 
designed to detect exact ALK fusion partners such as EML4 but are limited in being 
able to determine localization of expression. We developed a single copy RNA insitu 
methodology that could give translocation information whereas detecting ALK 
expression and localization. Methods: Two probes were designed (Affymetrix, Santa 
Clara CA) to sit on either side of the break region on the ALK mRNA sequence. One 
“upstream” of the break toward the 5’end and the other “downstream” of the break 
towards the 3’ end. Different Sections of formalin fixed paraffin embedded samples with 
known ALK break apart FISH status were stained with both the upstream and 
downstream probes according to manufacturer’s protocol and results were analyzed 
using a bright field microscope. Results: We detected an increased expression in the 
downstream probe in 4 out of 9 of the samples that were positive for ALK by FISH. All 
of the samples that were negative by FISH had little to no expression for both the 
upstream and downstream probes. Conclusions: FISH is the gold standard approach 
for detecting translocations in the ALK gene, but it is limited because it cannot provide 
information about ALK expression levels. Having probes on both sides of the break on 
the mRNA sequence allows us to determine ALK expression levels for both a fully intact 
ALK sequence and a translocated ALK kinase domain. Four out of nine of our FISH 
positive samples showed an increased ALK expression for the probe that sits 
downstream of the break on the mRNA sequence. The increased expression of the 
downstream probe over the upstream probe infers ALK translocation and fusion to an 
alternative gene, causing increased expression compared to normal.  
 
ST102. Necessity of Micro-Dissecting Morphologically Different Tumor 
Components in Solid Tumor Pyrosequencing 
D. Qin, Z. Zheng, S. Shen 
Moffitt Cancer Center, Tampa, FL. 
Introduction: Micro-dissection has been used to obtain tumor tissue from paraffin 
embedded micro-sections. It is usually aiming at separating tumor from normal tissue. 
However, in some tumors, the tumor cells are not monotonous. For example, it is not 
uncommon to see an adenocarcinoma with neuroendocrine differentiation. Therefore, a 
solid tumor may have morphologically different components. Is it necessary to micro-
dissect each tumor components and test each component separately? In this study, we 
report a KRAS mutation test on a pulmonary tumor, which has adenocarcinoma and 
neuroendocrine carcinoma components. The results indicate that, in some cases, 
micro-dissection of morphologically different components of a solid tumor is necessary. 
Methods: The reported case is a 3 cm pulmonary subpleural tumor at left lower lobe. 
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Pathology diagnosis is poorly differentiated adenocarcinoma with focal neuroendocrine 
differentiation. After specimen de-identification, the paraffin embedded tumor tissue 
sections were micro-dissected in two methods. One was that whole tumor, which 
included adenocarcinoma and neuroendocrine carcinoma components, was micro-
dissected together. The other method was micro-dissecting the adenocarcinoma and 
the neuroendocrine components separately. Pyrosequencing was performed on each 
micro-dissected tissue sample, targeting KRAS mutation at codon 12 and 13. The 
targeted sequence was NNTGRCGTAGGC. The dispensing order was 
ACTGTACGTGATCGTAGCAAGAG. Results: The morphology of the tumor is shown 
in Figure 1. The tumor consists of adenocarcinoma and neuroendocrine components. 
The pyrogram from whole tumor DNA is shown in Figure 2. This pyrogram shows a 
sequence peak pattern different from that of wild type. However, it cannot be interpreted 
with any mutation in the targeted DNA sequence. The pyrogram from the 
adenocarcinoma component is shown in Figure 3, which indicates KRAS G12C 
mutation. The pyrogram from the neuroendocrine component is shown in Figure 4, 
which indicates KRAS G12D mutation. Conclusions: When the DNA from whole tumor 
was pyrosequenced, the pyrogram from the sample did not fit any possible KRAS 
mutations. A diagnosis could not be established from such a result. Only after micro-
dissecting each component of the tumor and testing each component separately, it was 
realized that the two tumor components harbor different KRAS mutations. 
Retrospectively, the pyrogram from the whole tumor DNA actually represents the 
overlapping pyrograms of G12C and G12D KRAS mutations. The results indicate that it 
is necessary, in some cases, to micro-dissect morphologically different components and 
test each component separately. 
 
ST103. Process Improvement: Impact of a Reflex Testing Policy for EGFR and 
ALK Mutations on Newly Diagnosed Lung Carcinomas 
O. Raetskaya-Solntseva, J. Laudadio 
Wake Forest Baptist Medical Center, Winston-Salem, NC. 
Introduction: EGFR mutations and ALK rearrangements are known to occur in a 
subset of non-small cell lung carcinoma (NSCLC). With the emergence of therapeutics 
targeting EGFR and ALK mutations, molecular testing is becoming standard of care but 
challenges remain regarding how best to incorporate testing into patient care and the 
work-flow of a busy anatomic pathology service. The purpose of this study was to 
determine the utility of a reflex testing policy for the mutations. Methods: A policy was 
proposed for testing all newly diagnosed lung adenocarcinomas and NSCLC-NOS for 
EGFR mutations and all newly diagnosed NSCLC for ALK rearrangements. The policy 
was approved in October 2011. A retrospective search of the pathology information 
system was performed to determine the adherence to and impact of the new policy. In 
the six months since the initiation of the reflex testing policy, 123 cases of newly 
diagnosed adenocarcinomas and NSCLC-NOS were identified. Six months in the year 
prior to the initiation of the reflex testing policy yielded 63 such cases. EGFR testing is 
currently a send-out and ALK testing is performed in the FISH laboratory. Results: 
Prior to the policy, 11.1% and 9.5% of cases were tested for EGFR and ALK mutations, 
respectively, versus 36.6% and 48.8% after the policy was introduced. No EGFR or 
ALK mutations were detected prior to the initiation of the policy but six EGFR and two 
ALK mutations were detected after the policy began. The policy also resulted in 
additional cases having unstained recuts prepared at the time of initial processing 
versus after diagnosis (39.0% versus 11.1%). The average time from collection of the 
sample to the molecular testing result has decreased from 38 to 21 days for EGFR 
mutation analysis (45% decrease), and from 61 to 23 days for ALK rearrangement 
analysis (62%). Conclusions: Prior to the reflex policy, oncologists were required to 
contact pathologists, and request testing. The process of obtaining molecular testing 
required many steps including retrieval of the archived material. Creation of a molecular 
reflex testing policy in anatomic pathology provided ease of access to testing for 
clinicians and significantly improved the turnaround time. Considerable increase in 
testing was observed among pathologists with adoption of the reflex policy. The 
institution of a reflex testing policy was successful in detecting EGFR and ALK 
mutations and thereby identifying patients eligible for therapy. Additional follow up will 
be necessary to determine how reflex testing impacts patient outcomes. 
 
ST104. Evaluation of IGF-1 and IGF-1R in Triple Negative Breast Cancer 
S. Desai1, A. Vora1, H. Kurani1, N. Nair1, M. Sable1, T. Shet2, S. Gupta1, V. Parmar1, R. 
Badwe1 
1Tata Memorial Centre, Mumbai, India; 2Tata Memorial Hospital, Mumbai, India. 
Introduction: Insulin-like growth factors (IGF) system plays an active role in 
tumorigenesis, inhibition of apoptosis, transformation and could be a target for 
therapeutic intervention in cancer. There is a suggestion that a proportion of triple 
negative breast cancer (TNBC) cases overexpress IGF-1R. Metformin, a known 
antidiabetic drug, is being investigated as an anticancer drug by reducing IGF, insulin 
and HER2-mediated signaling, inhibition of mTOR signaling, inhibition of angiogenesis, 
induction of cell cycle arrest and apoptosis. The present study aims at assessing 
expression of IGF-1 and IGF-1R in pre and post neoadjuvant chemotherapy (NACT 
with or without Metformin) breast biopsies of TNBC patients. Methods: A total of 72 
fresh frozen breast core biopsies, 36 paired pre and post NACT +/- Metformin, breast 
biopsies in patients detected with TNBC were procured from the ICMR National Tumour 
Tissue Repository, Tata Memorial Centre. RNA was extracted using QIAGEN RNeasy 
MINI kit. Multiplex real-time quantitative reverse transcription-polymerase chain reaction 
was employed to study expression of IGF-1 and IGF-1R genes with respect to 
endogenous control Beta actin. Predesigned FAM/MGB TaqMan primer-probes for IGF-
1 and IGF-1R and VIC/MGB primer- probe for Beta actin (Applied Biosystems, USA) 
and ABI 7900 HT Real Time PCR Instrument were used. The CT values obtained for 
IGF-1, IGF-1R and Beta actin from MCA-MB-453 breast carcinoma total RNA (Ambion, 
USA) were used to validate the CT values from the pre-treatment biopsies samples. 
The raw data was obtained using the ABI SDS 2.1 software. The relative quantification 
was done using 2-ǻǻCT analysis. IHC was performed on paraffin sections to determine 
the IGF-1R expression using IGF-1R mouse monoclonal antibody (clone BC10, 
BIOCARE Medical, USA). Results: All 72 samples of TNBC core biopsies had 
detectable expression levels of IGF-1 and IGF-1R genes, pre and post treatment. A 
trend in change of IGF-1 and IGF-1R gene expression was not observed between 
NACT with and without Metformin (p=0.8 for IGF-1, 0.2 for IGF-1R). Pre and post NACT 
biopsies showed similar IGF-1R cytoplasmic expression in 29 (80.5%) cases, whereas 
7 cases (19.5%) showed discordant expression. Conclusions: There was no 
correlation observed between gene and protein expression of IGF-1 and IGF-1R and 
Metformin treatment in TNBC. Evaluation of phosphorylated/activated IGF-1R, 
identification of synergistic effects of Metformin with other chemotherapeutic drug and 
crosstalk between components of IGF system and other signaling pathways would 
further elucidate anticancer properties of Meformin. 
 
ST105. GNAS Mutation Analysis in Fibrous Dysplasia and Low Grade 
Osteosarcomas  
A. Oultache, T.N. Mitchell, J. Healey, M. Hameed, K. Nafa 
Memorial Sloan-Kettering Cancer Center, New York, NY. 
Introduction: Mutations involving GNAS codons 201 or 227 constitutively activate the 
alpha subunit of the signal transducing G protein (GSĮ) leading to permanent cAMP 
signaling and have been implicated in the development of the multiple endocrinopathies 
of the McCune Albright syndrome and fibrous dysplasia. Fibrous dysplasia, a benign 
medullary osteofibrous lesion and fibrous dysplasia like low grade osteosarcoma shares 
substantial histological and radiological similarities. Because these two entities have 
different therapeutic and prognostic outcome, we investigated the occurrence of GNAS 
exon 8 mutations in both fibrous dysplasia and low grade osteosarcoma. Methods: We 
tested 22 cases of fibrous dysplasia and 13 cases of low grade osteosarcoma using 
formalin-fixed paraffin-embedded tissue by direct DNA sequencing. All the samples had 
confirmed histologic diagnosis and were macro-dissected to enrich for tumor content. 
Results: GNAS exon 8 mutation was seen in 9 fibrous dysplasia cases (9/22= 41%), 
and none in the low grade osteosarcoma cases. We found the frequently described 
p.R201H (c.602CGT>CAT) mutation in 67% (6/9) of the cases, p.R201C 
(c.601CGT>TGT) in 22% (2/9), and one p.R201S (c.601CGT>AGT). Conclusions: Our 
results confirm the presence of GNAS R201 mutation in fibrous dysplasia and its 
absence in low grade osteosarcoma. Therefore, GNAS mutation testing will help in the 
pathological differential diagnosis in difficult cases of fibrous dysplasia and low grade 
osteosarcoma. 
 
ST106. Efficiency of Fluorescence in Situ Hybridization (FISH) in Combination 
with Clinicopathology and Immunohistochemistry Increases Accuracy in the 
Diagnosis of Bone and Soft Tissue Sarcomas  
P. Kadam Amare, N. Jambhekar, C. Baisane, A. Pais, D. Gawde, A. Puri, M. Ararwal 
Tata Memorial Hospital, Mumbai, Maharastra, India. 
Introduction: The diagnosis of each subset of heterogeneous bone & soft tissue 
sarcomas remains a challenge due to overlapping histopathological features and limited 
application of  immunohistochemistry (IHC) markers. The accurate diagnosis of these 
tumors is highly essential because of their differential biological and clinical behavior. 
With this background, it was proposed to establish molecular cytogenetic–FISH 
parameter for identification of distinct translocations in combination with IHC profile 
alongwith histopathology with an approach to generate data in our Indian group of bone 
& soft tissue sarcoma patients that can be utilized to design reliable classification of this 
heterogeneous disease for differential diagnosis and better management of disease. 
Methods: For this study, total 230 tumor specimens (Fresh tumors 110 and archival 
paraffin-embedded tissues 120) were received with successful results obtained in 203 
tumors. These tumors were classified as Ewing sarcoma (EWS) (n= 95), extraskeletal 
myxoid chondrosarcoma (EMC) (n=16), desmoplastic small round cell tumors (DSRCT) 
(n=5), alveolar rhabdomyosarcoma (ARMS) (n= 31) and synovial sarcoma (SS)(n= 56). 
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Fresh tumor and archival tissues were subjected to metaphase and interphase-FISH 
using EWSR1, FKHR, SYT break apart probes and home brew loci-specific probes viz, 
EWSR1, FLI1, ERG, ETV1 , TEC(NR4A3) ,PAX3, PAX7 and SYT. Results: Of total 
203 tumors, 22% of EWS , 30% of EMC, 25% of RMS and 30% of SS showed absence 
of translocation/s involving EWSR1, EWSR1 & TEC, FKHR and SYT gene respectively. 
Besides recurrent translocations, variants like t(21;21): EWSR1-ERG, EWSR1-ETV1 in 
EWS, t(1;13): PAX7-FKHR, in ERMS, t(2;18)( q33;q11.2): ?-SYT in SS were detected 
using home brew probes on metaphase and interphase cells. We could also detect 
genomic deletions in translocation positive cases, viz, 5’ EWSR1 deletion, 3’ EWSR1 
deletion, 11q deletion; 5’ SYT deletion and 3’ FKHR deletion in EWS, SS and ERMS 
respectively. Aberrant clone size was in the range of 10-100%. Conclusions: In 
conclusion, FISH was found to be reliable, efficient diagnostic tool in combination with 
IHC and histopathology, helped identification of distinct translocations and 
reclassification of bone and soft tissue tumors and hence increased diagnostic 
accuracy.  
 
ST107. Identification and Quantification of Somatic Mutations with the Ion 
AmpliSeq Cancer Panel 
M. Andersen1, S. Roman1, K. Rhodes1, C. VanLoy1, A. Broomer1, D. Topacio1, G. 
Roma1, R. Bennett1, T. Neff2, C. Beadling2, C. Corless2 
1Life Technologies, Carlsbad, CA; 2 Oregon Health & Science University, Portland, OR. 
Introduction: Advancing clinical cancer research requires rapid approaches compatible 
with small input amounts of challenging samples such as archived FFPE tissue. Ion 
AmpliSeq technology is a useful tool for enriching tens to thousands of genomic targets 
in a single tube from 10ng of input DNA. The purpose of this study was to validate the 
performance of the Ion AmpliSeq Cancer panel in identifying and quantifying somatic 
mutations in archived FFPE tumor tissue. Methods: Genomic DNA was extracted from 
45 archived FFPE tumor samples and quantified with the Qubit Fluorometer. Ten ng of 
DNA was amplified with Ion AmpliSeq Cancer Panel primers, then digested and ligated 
with barcodes according to the Ion AmpliSeq Library Preparation User Guide. After 
template preparation the amplicon libraries were loaded on Ion 316 sequencing chips (4 
samples per chip) and sequenced on the Ion PGM sequencer. The Torrent Suite 
Software was used for variant calling. Results: The Ion AmpliSeq Cancer Panel 
consists of a pool of 190 primer pairs that are designed to amplify mutation hotspot 
regions (including 739 known somatic mutations) across 46 genes. Forty-five FFPE-
derived samples of tumor DNA that were previously genotyped on a Sequenom 
MassARRAY platform were amplified and sequenced using this panel. The average 
read depth was 2000; more than 95% of the amplicons had a read depth >400. All 53 
known point mutations were correctly identified by the Ion Torrent variant caller 
software, including mutations in two DNA samples prepared from tumor cells dissected 
by laser-capture microscopy (Arcturus XT, Life Technologies). The range of somatic 
mutation frequencies was 8% to 96% and correlated well with results from the 
MassARRAY (R2= 0.84). There were 19 in/dels represented in the tumor samples, of 
which all were visible in the final sequence but only a subset were identified by the 
variant caller software. In addition to the known sequence variants, 27 new non-
synonymous mutations were detected. These included 24 single nucleotide 
substitutions and 3 deletions of 2 bp. All 27 were confirmed by Sanger sequence 
analysis, including one variant detected in both a tumor sample and a laser 
microdissected specimen prepared from the same tumor. Conclusions: The Ion 
AmpliSeq Cancer Panel represents a fast and easy approach to generating target 
sequence for next-generation sequencing. It requires very little input DNA, and high 
read depths can be generated to support good sensitivity. Custom panels based on this 
technology are now being tested.  
 
ST108. Comparison of 2 Methodologies for the BRAF V600E and Other Protein 
Variants in Melanoma: Pyrosequencing and the Roche Cobas 4800 Mutation Test 
N. Dimov, J. Talwar, D. Pritchett , M. Dave, R. Zoino, J. Weisberger 
BioReference Laboratories, Inc. , Elmwood Park, NJ. 
Introduction: For patients with metastatic melanoma, testing for the protein variant 
V600E is indicated for consideration of therapy with verumafenib (Zelboraf); the FDA-
cleared Roche cobas 4800 BRAF test is the designated companion diagnostic test. 
Verumafenib is an inhibitor of some mutated forms of BRAF, including V600E. Two 
methodologies for assessing BRAF V600E (GTG>GAG) and other V600 protein 
variants were compared: a laboratory developed pyrosequencing assay and the Roche 
cobas test. An initial accuracy study in our laboratory had a 97.6% correlation in 36 
melanoma specimens - 17 negative and 18 positive samples were in agreement, and 1 
invalid result in cobas was negative by pyrosequencing. The results of 62 consecutively 
positive pyrosequencing cases were then compared to cobas results. Methods: DNA 
from metastatic melanoma cases was extracted from formalin-fixed, paraffin-embedded 
tissue after macrodissection following pathology review. Pyrosequencing was 
performed using PSQ HS96 Gold SNP reagents on a PSQ HS 96A pyrosequencer 
(Biotage, QIAGEN). The cobas BRAF mutation test was performed according to 
specifications using 125 ng DNA in 25 uL (Roche Diagnostics, Indianapolis, IN). The 
analytic sensitivity (Limit of Detection, LOD) for the pyrosequencing assay is 3% 
mosaicism, whereas the LOD of the cobas test is stated in the package insert as ">5% 
using 125 ng of DNA/25 uL, and a 10% blend correctly called all replicates at a 31 
ng/uL dilution. The cobas 4800 assay has limited cross reactivity with V600K 
(GTG>AAG), V600D (GTG>GAT), and V600E2 (GTG>GAA) but not V600R 
(GTG>AGG)." The following protein variants can be detected by pyrosequencing: 
V600E, V600E2, V600D, V600K, V600R, V600A (GTG>GAA), V600G (GTG>GGG), 
and V600M (GTG>ATG). The reagent cost per test for pyrosequencing is less than half 
that of the cobas test. Results: Analysis of 62 pyrosequencing-positive melanoma 
cases by cobas demonstrated 51 positive and 11 negative cases (82% concordance). 
Of the 11 discrepant (cobas negative) cases, 6 showed low levels of V600E mosaicism 
by pyrosequencing (5%, 6%, 8%, 8%, 8%, 10%), 3 cases had the V600R protein 
variant, and 1 case had the V600E2 variant. The remaining case was V600E with 35% 
mosaicism; however, the DNA was of poor quality and had a high background signal by 
pyrosequencing, but was interpretable. Conclusions: Compared to the Roche cobas 
test, the laboratory-developed pyrosequencing test appears to be a more sensitive, 
specific, and cost-effective methodology for low level V600E mosaicism, in detection of 
other V600 protein variants, and possibly in samples of poor DNA quality.  
 
ST109. mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals 
Recapitulation of Gene Expression and Pathways Found in Prostate Cancer 
G. Cann1, Z. Gulzar2, S. Cooper1, M. Tat1, R. Li1, S. Stuart1, S. Luo1, M. Ronaghi1, J. 
Brooks2, A. Talasaz1 
1Illumina, San Diego, CA; 2Stanford Medical School, San Francisco, CA. 
Introduction: Circulating tumor cells (CTC) mediate metastatic spread of many solid 
tumors types, and enumeration of CTCs is used as a prognostic indicator of survival for 
metastatic prostate cancer patients. Some evidence suggests that additional 
information about primary tumors can be derived from expression analysis of CTCs, but 
the technical difficulty of isolating and analyzing individual CTCs has limited progress in 
this area. Methods: We assessed the ability of a new generation of MagSweeper to 
isolate CTCs suitable for mRNA-Seq. Using LNCaP cells spiked into normal blood, cell 
recovery, purity and viability were measured post-isolation with antibody staining 
against EpCAM, CD45 and staining of membrane-compromised cells with the nuclear 
dye DAPI. For enumeration comparisons with CellSearch, duplicate patient blood 
samples were collected with one sample processed by the MagSweeper and the other 
collected in a CellSave tube and processed by Quest Diagnostics. mRNA-Seq libraries 
were constructed with the SMARTer Ultra Low Input RNA Kit for Illumina Sequencing 
(Clontech) followed by single-read 50bp sequencing on an Illumina Genome Analyzer 
IIx. mRNA-Seq data was analyzed using CASAVA 1.8, and aligned to human genome 
build 19 using Tophat v1.3.3. Counts per transcript were calculated in iGenomes using 
cufflinks v1.1. Gene-by-gene raw counts and FPKM (fragments per kilobase of exon per 
million fragments mapped) were generated from the cufflinks isoform.fpkm tracking file 
by identifying all the transcripts with the same gene name and taking the sum of 
coverage transcript length / read length for each transcript and the sum of the FPKM for 
each transcript. Results: The MagSweeper isolated CTCs with a capture efficiency 
matching the CellSearch platform. Unlike CellSearch, the MagSweeper allowed final 
isolation of live CTCs without contaminating leukocytes. MagSweeper isolation did not 
have discernable impacts on transcriptional signatures of LNCaP cells isolated from 
spiked human blood as measured by mRNA-Seq. RNA from patient CTCs showed 
signs of significant degradation, consistent with reports of short half-lives and apoptosis 
amongst CTCs. Transcriptional signatures of prostate tissue such as androgen receptor 
and KLK3 (PSA) expression were detectable in prostate CTC using mRNA-Seq. A gene 
list of 182 genes up-regulated in prostate CTCs compared to normal prostate was 
derived. Conclusions: The MagSweeper allows gentle isolation of patient CTCs 
suitable for mRNAseq. Expression analysis of prostate CTCs confirms expression of 
prostate specific genes and allowed new gene discovery. These results indicate that 
MagSweeper isolation coupled with CTC mRNA-Seq has the potential of supplying 
clinically relevant information. 
 
ST110. Characterization of Cell Line Mutations to Assess the Performance of the 
Ion AmpliSeq Cancer Panel Assay on the Ion Torrent Personal Genome Machine  
T.C. Greiner, S.A. Rapp, D.M. Lytle, A.M. Cushman-Vokoun 
University of Nebraska Medical Center, Omaha, NE. 
Introduction: In 2011 Ion Torrent introduced the Ion AmpliSeq Cancer Panel for testing 
739 mutations in 46 genes. However, there have been no publications addressing the 
performance characteristics of this assay in cell lines or tumors with known mutations. 
Methods: We identified 17 cell lines with 20 known mutations in EGFR, BRAF, KRAS, 
TP53, NPM1, FLT3 or JAK2. The mutation percentage had been previously 
characterized by pyrosequencing in our lab (n=14) or the expected percentage was 
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determined by review of the COSMIC database or other sources (n=6). 50 ng of DNA, 
composed of a mixture of 4-5 cell lines per chip, were amplified with the Ion AmpliSeq 
Cancer Panel primers, and 16 pmoles of products were processed on the One Touch 
system for emulsion amplification and enrichment of Ion Sphere Particles. Sequencing 
was performed using the 314 chip on the Ion Torrent Personal Genome Machine. The 
resulting data were analyzed with the Variant Caller software plug-in v2.0.1.1. Results: 
For assays with at least 10 megabases of data, the coverage of the genes with 
expected mutations ranged from 82 to 5462 reads (average=1978 ±SD 1730). 
Mutations in KRAS, EGFR, BRAF, TP53, and JAK2 were observed with a range of 9.7-
80.0 percent mutant allele. The difference from the expected to the observed percent 
mutation ranged from 0.65 to 18.7% with a mean of 6% (±SD 5.4). Mutations were also 
identified in five other genes including APC, CTNNB1, NRAS, MET, and STK11. 
Neither a NPM1 4 base pair insertion nor a FLT3 internal tandem duplication could be 
detected in a five cell line mixture at the expected level (10 or 20% respectively) using 
the Variant Caller software. Conclusions: The Ion AmpliSeq Cancer Panel 
demonstrated accurate detection of 90% of known mutations with a high correlation to 
the expected percentages of mutant alleles in cell line mixtures.  
 
ST111. Comparison of Two Methods for hMLH1 Promoter Methylation Status 
M. Cuaresma1, L. Mazur1, M. Mihalov2 
1ACL Central Laboratory, Rosemont, IL; 2Lutheran General Hospital/ACL Laboratories, 
Park Ridge, IL. 
Introduction: Epigenetic mechanisms, such as human mutL homolog (hMLH1) 
promoter hypermethylation silencing, play an important role in human oncogenesis. 
Their detection have become routine in clinical oncology today and are imperative for 
proper diagnosis and therapy. Numerous methods are available for estimation of 
methylation status, each with inherent analytic and clinical performance characteristics. 
In this study, we compare two methods combining bisulfite conversion with methylation 
quantification. Methods: Sixty-six, FFPE, clinical samples and two cell lines (SW48 and 
HCT116) were evaluated. Briefly, tumor content was quantified; tissue was extracted 
and bisulfite treated (Pin Point Slide DNA Isolation system and EZ DNA Methylation-
Gold Kit; Zymo Research; Irvine, CA). Methylation status was evaluated with two 
quantitative methods: 1) a laboratory-developed assay utilizing MethyLight (ML) 
technology; and, 2) PCR amplification and pyrosequencing (PS). The ML assay is 
based on real time qPCR, normalized with COL2A1 using custom-designed 
primers/probes (QuantiFast Probe PCR kit; Qiagen, Inc; Valencia, CA) run on 
LightCycler 480. Percent methylated DNA was calculated as hMLH1/COL2A1 X 100. 
The PS assay detects and averages five CpG sites with PyroMark CpG Assay and Pyro 
Q-CpG software (Qiagen, Inc; Valencia, CA). Methylation status was expressed as fully 
methylated (>75%), partially methylated (10-74%) and unmethylated (<10%). Analytic 
sensitivity, specificity and reproducibility of both methods were calculated. Results: All 
samples were successfully analyzed, as follows: fully methylated (n=2); partially 
methylated (n=11); unmethylated (n=53). Concordance of the two methods was 100%. 
Variability in tumor content was well tolerated by both methods (80%-30%). Analytical 
sensitivity, specificity and reproducibility for both methods were 100% (within range 5%-
100% methylation) with coefficient of variation (CV) (8-20%) for ML and (0.5-13%) for 
PS. The limit of detection for both assays was 5%. Conclusions: Our study 
demonstrates that MethyLight and Pyrosequencing are both sensitive and reproducible 
methods for quantitation of methylation in the hMLH1 promoter from FFPE samples. 
We selected Pyrosequencing for implementation in our Lynch syndrome screening 
algorithm in colorectal and endometrial carcinoma cases because it is less complex to 
perform and had a lower coefficient of variation.  
ST112. Specialized Specimen Handling for Molecular Testing of Solid Tumors: 
The 'Molecular Only' Approach Results in a High Success Rate for Molecular 
Testing 
M.D. Rumery, D.R. Camidge, K. Kondo, D. Linderman, R.C. Doebele, N.J. Thomas, M. 
Varella-Garcia, Q. Ren, W.A. Franklin, D.L. Aisner 
University of Colorado, Aurora, CO. 
Introduction: The use of minimally invasive techniques has led to small diagnostic 
specimens, which are often consumed by routine immunohistochemistry (IHC) and 
aggressive facing. Often, subsequent molecular testing (MT) is impeded, even when a 
repeat biopsy has been sought, because minimal to no tissue remains following routine 
diagnostic work-up. We developed a specialized ‘molecular only’ approach designed to 
maximize tissue for MT from repeat biopsies in patients in whom the diagnosis was 
already known or in initial biopsies where the diagnosis was strongly suspected and MT 
thought to be of high importance assuming the diagnosis was confirmed. Methods: We 
established standardized protocols defining the number/preparation of cores, FNA and 
other biopsy techniques, contact details for direct transport to the molecular lab and 
standardized placing of the tissue in multiple blocks, shallow block facing, and 
confirmation/ establishment of histologic diagnoses with minimal IHC. 'Molecular only' 
specimens collected between September 2010 and March 2012 were evaluated for 
tumor presence and whether MT was successful (defined as any positive or negative 
molecular result with adequate controls for mutational and/or FISH analyses). Results: 
During the analysis period, 75 tissue specimens were submitted for 'molecular only' 
handling: NSCLC (70), melanoma (3), colonic adenocarcinoma (1) and GIST (1). 21 
biopsies were performed for initial MT (prior diagnostic specimen insufficient) and 54 
were performed to evaluate mechanisms of resistance following progression on 
therapy. 67 cases were procured by interventional radiology;  6 by bronchoscopy and 2 
by surgery. 61/75 (81%) specimens had successful MT. Of the 14 specimens in which 
MT was unsuccessful, 8 had no tumor present, 2 had MT attempted despite extremely 
limited tumor identified on histology, but were ultimately insufficient, and 4 were found 
to be quantitatively inadequate based on histologic assessment. Thus, of 67 cases 
showing any tumor present in the biopsy, the success rate for MT was 91%. 
Conclusions: Our novel 'molecular only' methodology appears highly successful in 
maximizing the chances of MT success in a) tumors likely to require routine MT at 
diagnosis, or b) repeat biopsies taken exclusively for MT (after depletion of the initial 
specimen or to evaluate mechanisms of resistance on therapy). We found that all cases 
that were not successful were due to a paucity or absence of tumor cells in the 
submitted specimen, not to the ‘molecular only’ process or the MT itself. Details of 
specialized handling will be discussed.  
 
ST113. Clinical Validation of a 46 Cancer Gene Mutation Panel using Semi-
Conductor Based Next-Generation Sequencing Technology 
R.R. Singh, N.G. Reddy, B. Barkoh, B. Handal, K.P. Patel, M. Routbort, K.D. Aldape, 
J.L. Medeiros, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Detailed mutation profiling of tumors is warranted to better understand 
the genetic basis of cancer and to identify actionable targets for patient care. Next 
generation sequencing (NGS) methods enable mutational analysis of large genomic 
regions using nanograms of DNA. Transfer of these technologies to a CLIA-certified 
clinical setting has been slow due to the requirement of extensive validation and a lack 
of consensus guidelines. We describe validation and implementation of a 
semiconductor-based NGS platform to interrogate 740 mutational hotspots in 46 
cancer-related genes for routine clinical testing using a large number of solid tumor 
samples. Methods: DNA from 58 formalin-fixed, paraffin-embedded (FFPE) tumors 
was isolated following manual microdissection. 10ng of genomic DNA was used to 
prepare a library of 190 amplicons using Ion AmpliSeq 2.0 Beta kit (Life Technologies, 
CA). Barcoded adaptors were ligated using the Ion Express Barcode Adaptor kit and 
clonally amplified on to IonSpheres using either Ion Express Template or One Touch 
Template kit and sequenced on Ion Torrent Personal Genome Machine (PGM) using 
316 or 318 Ion chips. 16 samples were sequenced independently, at least twice, to test 
reproducibility. Assay sensitivity was determined by sequencing sequential dilutions of 
DNA from the H2122 cell line with HL60 cell line DNA. Mutations detected were 
confirmed either by Sequenom Massarray or Sanger sequencing. Results: 58 solid 
tumors tested were sequenced successfully with a minimum of 500,000 Aq20 reads per 
sample. A total of 130 mutations were detected with a minimum coverage of 500X. 
Each of 31 expected mutations were detected by Ion Torrent in the 15 retrospective 
cases. 64 of 99 mutations were confirmed by Sequenom or Sanger sequencing. 
Mutations were detected in BRAF (n=14), KRAS (n=17), NRAS (n=10), TP53 (n=22), 
MET (n=7) and PIK3CA (n=5). Sensitivity studies performed by two different technicians 
showed a lower limit of detection of 5% heterozygous and 2.5% homozygous mutations 
in the background of wild type sequence. No discordance in mutation detection was 
found in the 16 samples sequenced more than once for reproducibility. Conclusions: 
Mutational screening using Ion Ampliseq Cancer Panel library preparation method 
coupled with sequencing on Ion Torrent PGM was validated in a CLIA-certified setting 
to be a sensitive, FFPE DNA compatible and efficient mutation detection assay, 
enabling simultaneous high-throughput screening of hotspots in 46 cancer-related 
genes using as little as 10 ng tumor DNA.  
 
ST114. Multiplex RNA/miRNA in Situ Detection in Cancer Tumor Cells Captured 
by an Innovative Circulating Tumor Cell (CTC) Filter- Based Device 
A. Lin1, M. Yanagita 2, S. Levinson1, J. Pache 1, Y. Nguyen1, A. Chueh 1, B. Lu1, M. 
Nguyen1, B. Maqsodi1, Y.E. Cayre 3, J.J. Miret4, R.J. Distel5, P.A. Jänne2, G. 
McMaster1, G. Bers1, S. Lai1, Q. Nguyen1 
1Affymetrix Inc., Santa Clara, CA; 2Belfer Institute for Applied Cancer Science, Dana-
Farber Cancer Institute, Boston, MA; 3ScreenCell, Paris, Île-de-France; 4Dana-Farber 
Cancer Institute, Boston, MA; 5Center For Clinical &Translational Research, Dana-
Farber Cancer Institute, Boston, MA. 
Introduction: Circulating Tumor Cells (CTCs) are pivotal to understanding the biology 
of metastasis and promise potential as a biomarker to noninvasively evaluate tumor 
progression and response to treatment. Several methods have been developed to 
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detect and isolate the minute number of CTCs in the peripheral blood, primarily based 
on antibody capturing methods limited to availability of antibodies and potential bias for 
the expressing epitopes. Most recently, an innovative filter-based device has been 
developed to enable efficient capture of CTCs by size. Here we describe a branched 
DNA (bDNA)-based multiplex RNA FISH assay in cancer cells captured by this device. 
The bDNA-based multiplex RNA FISH assay enables single molecule detection of up to 
4 targets in captured cancer cells. Methods: Cancer cell lines (PC-9, SK-BR-3 and 
HeLa) were spiked in human whole blood of normal donors, including in some 
experiments, cells pre-labeled using Cell Tracker Green. The samples were processed 
with the CTC filter device to capture the cancer cells. After capturing, filters were 
subjected to the RNA FISH assay using oligo-based target probes to mRNAs for 
cytokeratins (KRTs), ERBB2 (Her2), PPIB, ACTB and miRNA Let7a. After target probe 
hybridization, signals were amplified using bDNA technology. The filter was sequentially 
hybridized with PreAmplifier, Amplifer and finally, fluorescent dye-conjugated Label 
Probe for detection. Imaging and cancer cell detection were performed with an 
automated epifluorescent microscope including enumeration using both manual and 
automated imaging methods. Results: The CTC filter device was effective in capturing 
all three cancer cell lines from whole blood. Cancer cell retention for the entire process 
including filter capture and the RNA FISH assay was 50%, 70% and 90% when cells 
were spiked at about 10, 20 and 40 cells into 3 mL of blood, respectively. KRT mRNA 
expression was detected in the captured cancer cells by the RNA FISH assay. SK-BR-3 
cells known for ERBB2 gene amplification, demonstrated co-localized expression of 
ERBB2 and KRT mRNAs. Using pre-labeled PC-9 cells, 97% of KRT positive cells were 
also stained positive with Cell Tracker Green. Besides mRNA detection, the RNA FISH 
assay was able to detect miRNA Let7a and KRT mRNA simultaneously in captured 
HeLa. Conclusions: The CTC filter device is effective for capturing cancer cells from 
whole blood by size. The bDNA-based RNA FISH assay is a highly sensitive method for 
multiplex RNA/miRNA detection in cancer cells providing an invaluable tool in 
combination with the filter device for CTC enumeration and biomarker characterization. 
 
ST115. Analysis of Two Next Generation Sequencing Cancer Panels 
R.R. Bastien1, C.P. Vaughn1, M.L. Wallander1, D.K. Crockett1, L.J. Layfield2, W.S. 
Samowitz2, P.S. Bernard2 
1ARUP Laboratories, Salt Lake City, UT; 2University of Utah Health Sciences Center, 
Salt Lake City, UT. 
Introduction: Next generation sequencing (NGS) technologies are increasingly being 
utilized in clinical diagnostics. Recently, both Life Technologies and Illumina have 
released commercial NGS panels targeting genes important in the treatment of solid 
tumors. Methods: To assess the utility of these two systems for use in a clinical 
laboratory setting, we analyzed five formalin-fixed, paraffin-embedded (FFPE) tumor 
samples of various origins. Each sample was enriched using both the Ion AmpliSeq 
Cancer Panel (Life Technologies) and the TruSeq Amplicon Cancer Panel (Illumina) 
and sequenced on the Ion Torrent PGM (318 chip) and MiSeq (2Gb flow cell), 
respectively. Data analysis was performed using the software packages supplied with 
the instrumentation. Results: After alignment to a reference sequence, each AmpliSeq 
run produced an average of 5.07 million reads, as compared to an average 4.51 million 
reads for the TruSeq panel. The AmpliSeq panel coverage ranged from 7,140 to 7,489 
reads (mean = 7304) with greater than 95% of the targets having more than 0.2X of the 
average. The TruSeq panel coverage ranged from 2,628 to 17,904 (mean = 11,499). 
Conclusions: Both systems offer adequate read depth of detection of somatic 
mutations in FFPE samples. Per run costs are comparable between the systems; 
however, the increased reads per base using the TruSeq panel offers increased 
multiplexing capabilities. The time to results is approximately two days for the AmpliSeq 
panel and three days for the TruSeq panel, including sample preparation, sequencing, 
and data analysis. Platform selection for clinical purposes will depend on depth of reads 
needed and desired turnaround time. 
ST116. Detection of BRAF V600E Mutation Using Pyrosequencing: Comparison 
with PNA Clamping PCR and Real-Time PCR 
S. Kang1, J. Pyo2, S. Hong3 
1Chosun University Medical School, Republic of Gwangju, Gwangju, Korea; 2Hanyang 
University Guri Hospital, Republic of Guri, Korea; 3GangNam Severance Hospital, 
Yonsei University, Republic of Seoul, Korea. 
Introduction: Various methods such as direct sequencing, allele specific PCR, real-
time PCR, and pyrosequencing are used to detect of BRAF V600E mutation.In the 
present study, we used PNA clamping PCR, real-time PCR and pyrosequencing to 
investigate the characteristics of BRAF mutation in tissue sample and the prognostic 
impact of BRAF V600E mutation. The present study was also aimed to compare PNA 
clamping PCR and real-time PCR with pyrosequencing. Methods: One hundred 
patients diagnosed as papillary thyroid cancer (PTC) were enrolled. DNA was extracted 
from paraffin block using QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany). 
PNA clamping PCR was performed using PNAClamp BRAF Mutation Detection kit 
(PANAGENE, INC. Daejeon, Korea). Real-time PCR was performed using Anyplex 
BRAF V600E real-time detection system (Seegene, Seoul, Korea). Pyrosequencing 
reaction was done on a Pyromark Q24 (QIAGEN, Hilden, Germany). Results: PNA 
clamping PCR detected BRAF V600E mutation in 66 patients out of 100 patients (66%). 
Anyplex real-time PCR detected BRAF V600E mutation in 70 patients out of 100 
patients (70%). Pyrosequencing detected BRAF V600E mutation in 68 patients out of 
100 patients (68%). BRAF V600E mutation was detected in 77 patients by one or more 
of three methods (77%). Kappa value of clamping PCR compared with pyrosequencing 
was 0.729 and that of Anyplex real-time PCR compared with pyrosequencing was 
0.626. Accuracy of clamping PCR was 88% and that of Anyplex real-time PCR was 
84%. Discrepant results between PNA clamping PCR and pyrosequencing range 2.46% 
to 5.41% of pyrosequencing peak and discrepant results between Anyplex real-time 
PCR and pyrosequencing range 1.76% to 6.41% of pyrosequencing peak. In the 
patients with BRAF V600E mutation (68 patients), mean peak was 8.8% and standard 
deviation was 5.9% (range 3.35-37.1%). 20 patients (20/68, 29.4%) were between 3.2% 
(cutoff) and 6% of peak for pyrosequencing. Mean age, multifocality, lymph node 
metastasis and stage were not significantly different between BRAF V600E positive 
group and negative group. Mean tumor size was significantly different between two 
groups (P=0.031). Conclusions: Quantification of BRAF V600E mutation using 
pyrosequencing in the present study demonstrated that about 30% of patients with 
BRAF V600E mutation are below 6% of pyrosequencing peak. A sensitive detection 
method should be employed to detect BRAF V600E mutation in tissue with PTC. The 
present study also showed that PNA clamping PCR is a sensitive method to detect 
BRAF V600E mutation.  
 
ST117. Novel complex BRAF Mutation Detected in Colorectal Carcinoma 
M. Mihalov1, B. Baltadjieva2, L. Ma2, L. Mazur2 
1Lutheran General Hospital/ACL Laboratories, Park Ridge, IL; 2ACL Central Laboratory, 
Rosemont, IL. 
Introduction: BRAF is a member of RAF kinase family and part of the ERK/MAPK 
signal pathway. Oncogenic BRAF mutations play an essential role in the development 
of numerous cancers such as melanoma, colon and thyroid cancers. It is also a 
potential target for treatment. More than 40 BRAF mutations associated with human 
cancers have been identified. These mutations increase kinase activity resulting in cell 
proliferation and survival that further cause tumor progression. In the present study a 
novel complex BRAF mutation has been identified in a patient with colon 
adenocarcinoma. Methods: Percentage of tumor tissue was evaluated (<30%); FFPE 
sample was manually dissected and extracted by using PinPoint extraction kit (Zymo 
Research). Three different techniques were used for detection: 1) BRAF V600E real 
time PCR assay with melting curve analysis - run on Light Cycler 2.0 (Roche), 2) BRAF 
V600E Pyrosequencing - run on PyroMark Q24 (Qiagen) and 3) Sanger sequencing 
with restriction enzyme enrichment modifications run on ABI 3130 Genetic Analyzer 
(Life Technologies). All three methods were applied for V600E mutation screen, 
confirmation and verification. Results: Result of initial mutation screen (1) showed low 
positive atypical meting peak consistent with V600E variant or complex mutation 
present. Confirmation by Pyrosequencing showed a negative result for V600E or other 
complex mutation. The discrepancy was resolved by using enzyme RspRI to enrich 
tumor mutant cells and increase detection sensitivity of Sanger sequencing. 
Sequencing data revealed a new complex BRAF mutation of V600D (Val>Asp) plus 
K601 (Lys) deletion. The novel mutation was present in the phosphorylation activation 
loop (A-loop), between the two phosphorylation sites Thr599 and Ser602. 
Conclusions: The function of this new complex BRAF mutation is still unclear and 
needs further study; however, the mutation is associated with structural basis of the 
activation site that is a potential target for oncology therapies. Finally, choosing the 
appropriate screening technique is crucial for detection of new mutations.  
 
ST118. Testing for HER2 by Fluorescent insitu Hybridization (FISH) in 
Comparison with Immunohistochemistry (IHC) in Gastric and Gastro-Esophageal 
Adenocarcinoma  
M.R. Ramadwar1, S. Ahmed1, K. Deodhar1, M. Menon1, S. Desai1, J. Bodake2, R. 
Bagal2, S. Dhanavade2, N. Jambhekar1 
1Tata Memorial Hospital, Mumbai, India; 2Tata Memorial Centre, Mumbai, India. 
Introduction: HER2 status in advanced gastric and (GE) gastro-oesophageal junction 
adenocarcinoma is a prognostic and predictive marker. ToGA trial published in 2010 
has showed that HER2 amplified status is associated with response to treatment with 
Cetuximab in advanced gastric and GE junction adenocarcinoma. Algorithm for testing 
Her2 status in gastric and GE junction adenocarcinoma has also been formulated 
similar to breast carcinoma wherein immunohistochemistry (IHC) is done first to select 
patients to be tested further by FISH technique. Our study aims to validate results of 
FISH testing against IHC and attempts to support the proposed algorithm. Methods: 28 
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biopsy specimens of gastric and GE junction adenocarcinoma were studied. 
Immunohistochemistry and FISH was performed on all cases. Abbott-Vysis Path Vysion 
DNA dual colour probe kit was used for FISH. Ratio of Her2 and CEP-17 signals was 
derived upon counting of 40 cell nuclei. Amplification of the HER2 gene was defined 
when the ratio of HER2:17CEP was more than or equal to 2. IHC was performed using 
a monoclonal antibody c-erbB-2/HER2/neu from Biocare, clone EP 10454 at dilution 
1:300. Interpretation of IHC was done according to scoring criteria proposed by 
Hoffman. Results were scored as 0-1+ (negative), 2+ (equivocal) and 3+ (positive). 
Results of FISH and IHC were compared. Results: On immunohistohistochemistry, 21 
cases were negative (score 0 and 1), 2 were equivocal (score2) and 5 were positive 
(score3). FISH testing revealed 21 cases to be negative, 4 non-interpretable and 3 
amplified for Her2. All three FISH positive cases were also score 3 by IHC. However, 
two cases positive for IHC did not show amplification on FISH. Both cases equivocal by 
IHC were non-amplified. Four cases remained non-interpretable by FISH that were 
negative by IHC. Conclusions: Concordance between IHC and FISH results was 100 
% when IHC results were negative (score 0 and 1). Concordance between IHC and 
FISH results was 60% when IHC was positive (score 3). Thus our validation study 
proves a good correlation between IHC and FISH for Her2 testing. The results support 
the use of IHC before selecting a case for FISH test that is an expensive test; hence 
important in cost constrained setting in India.However, this validation study also puts 
forth problems associated with interpretation of IHC, eg, differentiation between score 1 
and 2 pattern using Hoffman’s criteria. Tumour heterogeniety and technical issues 
affect both IHC and FISH results.  
 
ST119. Development of a Highly Informative Clinical Applicable Serum miRNAs 
371-3 and 302/367 Test for (Germ Cell) Cancer Patients  
L.H. Looijenga, A. Gillis, M. Rijlaarsdam, R. Eini, L. Dorssers 
Erasmus MC-University Medical Center Rotterdam, Netherlands. 
Introduction: microRNAs (miR) expression patterns can be different between normal 
and malignant cells. Human germ cell cancers (GCC), i.e., seminomas (SE) and 
nonseminomas (NS), the most frequent malignancy in Cauucasian young males, show 
high expression of the miRNA 371-3 and 302/367 clusters, related to presence of the 
stem cell component. Current clinically used serum markers for GCC are AFP and hCG 
(and LDH1), which are informative in a selection of patients (yolk sac tumor and/or 
choriocarcinoma), not linked to the stem cell cancer component. Use of the fore-
mentioned miRNAs has been suggested as serum markers for GCC, although no 
robust protocol including proper calibration, normalization, and quantification is 
available so far. Methods: A novel, sensitive and specific pipeline for miRNA profiling in 
body fluids is developed based on a magnetic anti-probe bead purification step. This 
method shows stable recovery based on multiple synthetic non-human spike-ins, 
allowing calibration. Out of a set of 9 potential serum-specific controls, two were 
identified by Normfinder and geNorm as most stable (miR-20a and 93), therefore used 
for normalization. This protocol was applied to a series of independent serum samples 
of 12 controls (no cancer), 16 SE and 16 NS patients, taken at time of primary 
diagnosis. Undetermined values were replaced by Ct maximum per assay +2. 
Histology, stage of the disease, as well as serum marker measurements, of each 
patient was known. Results: Patients with a GCC showed significantly higher serum 
levels of miR-302a/367/371/372/373 (p<0.006, Mann-Whitney test, two sided, 
Bonferroni corrected (MWB)). Pooled analysis, irrespective of histology, showed that 
miR-302a/367/373 were significantly higher in patients with metastatic – compared to 
localized disease (p<0.006, MWB). Histology specific analysis (SE or EC), 
demonstrated that miR-367 was significantly higher in patients with metastasized – 
versus localized SE (p=0.003, MWB). Conclusions: The findings indicate that serum 
miRNA profiling based on a limited set of embryonic miRNAs is informative to diagnose 
patients with a GCC, better than known serum markers. The method is suitable to 
define patients with a stage I and higher (metastasized) disease. Defined steps within 
the protocol for calibration, normalization, and quantification result in a robust method, 
suitable for clinical implementation. The protocol can be applied to diagnosis and follow 
up of patients with different types of cancer, or diseases in general, for which specific 
miRNA profiles are reported, to be detected in various body fluids.  
ST120. Implementation of a Pan-Tumor Next Generation Sequencing (NGS)-
Based High Throughput Diagnostic Service for Actionable Mutations in the 
Clinical Cancer Setting 
A. Fellowes1, T. Bosma1, C. Meldrum2, A. Bell1, S. Fox1 
1Peter MacCallum Cancer Centre, Melbourne, Australia; 2Hunter Area Pathology 
Services, Newcastle, Australia. 
Introduction: As the decade unfolds, the paradigm in cancer treatment is shifting to 
one informed by the specific molecular genetic characteristics of an individual’s tumor, 
as opposed to the broad tissue origin, type and stage of malignancy. Thus molecular 
pathology is likely to become the critical diagnostic modality, arguably supplanting 
anatomical pathology and diagnostic radiography in the treatment decision algorithm for 
many common cancers. To date only a few targeted cancer therapies have been 
approved for clinical practice, whereas a large number of molecular biomarkers, 
primarily consisting of activating mutations in genes involved in known cancer 
pathways, are now known. Unfortunately, clinical trials establishing the efficacy of 
targeted therapies generally lag behind the discovery phase such that today, the 
inclusion of many potentially actionable targets in a cancer panel is not likely to improve 
the clinical utility of the assay. Nonetheless, multiplex panels promise to maximise 
efficiency within the lab. A staged approach to cancer panel development is therefore 
required, allowing addition of more targets as clinical utility is established. Methods: 
We utilised the Fluidigm AccessArray and Illumina MiSeq next generation sequencing 
to implement a cancer panel for clinical use. Proof of principle was established by deep 
sequencing 48 amplicons covering 93% of the EGFR CDS. This led to the development 
of an initial panel targeting the hot spots of just six oncogenes that encompass today’s 
actionable targets in Australia (BRAF, EGFR, KIT, KRAS, NRAS and PDGFRA). 
Results: In EGFR experiments we observed 100% concordance with variant calls 
obtained by Sanger sequencing, and established a limit of detection of 3% minor allele 
frequency using cell line dilutions. Our cancer panel design i) allows expansion to meet 
growing clinical need by the incremental addition of amplicons without the need for 
comprehensive assay redesign, ii) readily accommodates typical input DNA amounts 
derived from FFPE material, and iii) facilitates continuous quality assurance by the 
incorporation of synthetic quality controls. Conclusions: Microfluidics and next 
generation sequencing permits the operation of a scalable multiplexed panel supporting 
a single assay workflow. This introduces efficiencies into laboratory practice that are 
needed to deliver tumor profile results in a clinically relevant timeframe. 
 
TECHNICAL TOPICS 
 
TT01. Mutational Analysis Using Allele Specific One-Step Real-Time RT-PCR 
P. Choppa, G. Bien, K. Bloom, K. Gutekunst 
Clarient, A GE Healthcare Company, Aliso Viejo, CA. 
Introduction: Bidirectional Sanger sequencing has long been the gold standard for 
mutational analysis. Although Sanger sequencing is the method of choice in many 
testing applications, it suffers from limited sensitivity when applied to samples with 
mixed DNA populations. It is generally accepted that traditional sequencing 
methodologies are capable of identifying mutations when between 10-20% of the alleles 
carry the alteration. Allele specific PCR (AS-PCR) provides an increased sensitivity 
over traditional sequencing by selectively amplifying the mutant allele out of the 
background wild-type DNA. This approach is generally capable of detecting a mutation 
to an analytical sensitivity of approximately 1% to 5%. Depending on the specific 
alteration, some AS-PCRs may suffer from non-specific amplification in late 
amplification cycles due to mispriming of the wild-type genes present in the sample. 
Although this background amplification may not be significant it may complicate 
analysis of low level mutations. We have developed an alternative approach to standard 
AS-PCR that uses reverse transcriptase to selective convert only mutated transcripts 
into cDNA. The enrichment of the mutated targets into usable substrate for downstream 
PCR amplification provided an increased sensitivity and specificity over traditional AS-
PCR. Methods: DNA and RNA were extracted from cell line and FFPE tissue using a 
modified version of AllPrep DNA/RNA FFPE kit. An allele specific primer/probe set was 
designed to target the T>A transversion at nucleotide 1799 of the BRAF gene. The 3’ 
position of the reverse primer was designed to hybridize to the mutated nucleotide. A 
single primer set was optimized for the DNA and RNA based assays. Genotyper master 
mix was used for the DNA based reactions and the EZ One-step core reagents were 
used for the RNA based approach. Results: BRAF V600E positive cell line RNA 
demonstrated a 20-fold increase in sensitivity over the DNA based approach from the 
same number of cells. All FFPE tissue samples tested generated a lower Ct value from 
the RNA based reaction when compared to results generated from the same number of 
cells using traditional AS-PCR. Additionally, no background signal was observed in any 
of the RNA based reactions whereas all DNA based reactions showed late cycle 
amplification. Conclusions: Using mRNA as a target for allele specific mutational 
analysis provided an increased sensitivity and specificity over traditional AS-PCR as 
well as a means to perform quantitative mutant gene expression. This methodology 
could be used as an alternative approach in situations where standard AS-PCR 
performance is less than optimal. 
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TT02. Clinical Performance of Roche Cobas 4800 HPV Test 
M. Cui, M. Liu, K. Thai, J. Malaczynska, D. Zhang, F. Ye 
Mount Sinai Medical Center, New York, NY. 
Introduction: The human papilloma virus (HPV) is one of the most common sexually 
transmitted agents in the worldwide and the primary cause of cervical cancer. The 
Cobas 4800 HPV test, recently approved by FDA, is an automatic, real-time PCR-
based assay that detects 14 high-risk HPV (hrHPV) genotypes as well as HPV 16 and 
18. The aim of the current study was to evaluate the sensitivity and specificity of Cobas 
4800 HPV test by comparing their result with those obtained from the hc2 High-Risk 
HPV DNA Test. Methods: One hundred eighty cervical samples collected PreservCyt 
were included in this study. The samples were tested for HPV by hc2 High-Risk HPV 
DNA test (QIAGEN, CA) and Cobas 4800 HPV test (Roche, CA). The discrepant results 
between these two methods were resolved using linear array (LA) HPV Genotyping test 
(Roche, CA). Results: There was a significant difference in the number of positive and 
negative samples identified between HC2 HPV Test and the Cobas HPV Test based on 
the McNemar test (P = 0.0218). However, concordance between the two HPV tests was 
88.33%. The discrepant samples were further tested by LA HPVmethod, and the hrHPV 
genotypes were found in none of HC2-positive/Cobas -negative samples (0/4) but in 
80% (12/15) of HC2-negative/Cobas -positive samples. In addition, the reproducibility of 
Cobas was determined using 68 samples. The concordance between results of the first 
run and the second run was 93.55% (95% CI: 0.744-0.993). Furthermore, pre-aliquot 
(before cytology test) and post-aliquot (after cytology test) of 187 samples were tested 
using Cobas. Only 7 samples were mismatched with a rate of 3.74%. Finally, we 
compared 2 sample mixing methods (vortexing versus swirling) before performing 
Cobas HPV test on 5621 samples. Our results showed that the failure rates for 
vortexing and swirling were 4.78% and 1.16% respectively (F2 59.983, P<0.0001), 
suggesting gentle swirling had a much less effect on assay. Conclusions: This study 
demonstrates that the Cobas 4800 HPV test had a better sensitivity and accuracy and 
reproducibility than hc2 HPV test and is an effective method to detect different HPV 
genotypes (HPV16/18 and other 12 types). In addition, less cross-reactivity was 
observed for Cobas 4800 HPV test than HC2 test.  
 
TT03. Validation of Droplet Digital PCR using gDNA, FFPE and Xenograft 
Reference Standards 
J. Goodall, V. Spivey, C. Thorne, S. Dixon, J. Frampton, P. Morrill 
Horizon Discovery, Cambridge, Cambridgeshire, United Kingdom (Great Britain). 
Introduction: DNA used in molecular diagnostics assays is typically extracted from 
formalin fixed paraffin embedded (FFPE) material and mutation detection can be 
complicated if the mutation of interest is only present at very low levels. Horizon 
Discovery’s patented gene editing technology (GENESIS) has enabled the manufacture 
of genetically defined reference material. Here, we use this material to test the 
sensitivity and sample tolerance of the QX100 Droplet Digital PCR (ddPCR) platform 
(Bio-Rad). Methods: B-Raf V600E X-Man (gene-X, mutant and normal) cell lines were 
developed using GENESIS, and used to generate FFPE cell and xenograft blocks 
containing V600E allelic frequencies of between 33% - 1%. Sections were cut and DNA 
extracted from these using the Promega Maxwell platform. Droplet Digital PCR was 
performed on the QX100 using TaqMan copy number variance (CNV) and custom 
single nucleotide polymorphism (SNP) assays. Results: The allelic frequency of B-Raf 
V600E was measured in a panel of X-Man cell lines using ddPCR, and was found to be 
consistent with the of B-Raf ploidy in these cells. Sensitivity of the system was tested 
using serial dilutions prepared with wild type and mutant genomic DNA. A high degree 
of correlation between predicted and ddPCR-measured allelic frequencies was 
observed, with mutant frequency down to 0.05% detected. To determine whether assay 
performance was compromised when using DNA extracted from FFPE material, DNA 
isolated from a range of FFPE cell line and xenograft blocks containing defined B-Raf 
V600E allelic frequencies was measured. Again, a high degree of correlation between 
predicted and ddPCR-measured allelic frequencies was observed in all samples tested. 
Conclusions: Our results show that the Droplet Digital PCR is a highly sensitive and 
robust platform for measuring allelic frequency as well as measuring copy number in 
DNA extracted from a range of formats including cells, FFPE cell blocks and FFPE 
xenografts, and highlights the molecular diagnostic potential of ddPCR technology. 
 
 
 
 
 
 
 
 
TT04. Temperature-Tolerant Cold-PCR, a Temperature Flexible Approach that 
Yields Reproducible Mutation Enrichment  
E. Castellanos-Rizaldos1, P. Liu1, C.A. Milbury1, M. Guha1, A. Brisci2, L. Cremonesi2, M. 
Ferrari2, H. Mamon3, G.M. Makrigiorgos3 
1Dana Farber-Cancer Institute, Harvard Medical School, Boston, MA; 2San Raffaele 
Scientific Institute , Milan, Italy; 3Dana-Farber Cancer Institute, Brigham and Women's 
Hospital, Boston, MA. 
Introduction: Identification of low-level mutations in cancer is of crucial importance for 
the diagnosis, prognosis and treatment of the disease. Often, these low abundance 
alleles appear with a frequency below the limit of detection of current molecular 
methods. COLD-PCR is a technology that magnifies unknown mutations during PCR 
prior to other downstream applications and is able to identify 0.04% mutant alleles into 
wild type DNA if combined with next generation sequencing technologies (Milbury et al, 
Clin Chem 2012; 58:580-9). Nevertheless, COLD-PCR requires a stringent denaturation 
temperature control for any given amplicon, which hinders amplification and enrichment 
of diverse amplicons in different wells of a single thermocycler. We describe a 
temperature-tolerant (TT-COLD-PCR) approach that circumvents this issue. Methods: 
There is a gradual increase in the denaturation temperature during TT-COLD-PCR that 
enables preferential amplification of mutant DNA. When the correct denaturation 
temperature is attained for a given amplicon, amplification and mutation enrichment are 
both initiated for this amplicon. TT-COLD-PCR is validated for KRAS and TP53 exons 
6-9 using dilutions of mutated DNA, clinical cancer samples and plasma-circulating 
DNA. Results: Different DNA targets with various Tm values were enriched 
simultaneously using a single thermocycling program that spanned a denaturation-
temperature window of 2.5-3.0ºC. Mutation enrichments observed were between 6-9-
fold using a TT-full-COLD-PCR approach, whereas higher values were attained with 
other forms of COLD-PCR (fast-COLD-PCR and ice-COLD-PCR). Conclusions: TT-
COLD-PCR enriches low-level mutations in amplicons with diverse Tms within a 
denaturation temperature window spanning several degrees. This approach enables 
simultaneous enrichment of mutations in different amplicons, and increases significantly 
the versatility of COLD-PCR. 
 
TT05. Cross-Platform, Targeted Cancer Gene Panels for the Rapid and 
Sensitive Detection and Confirmation of Clinically Actionable Mutations in FFPE 
and FNA Tumor Biopsies 
G.J. Latham, A. Hadd, E. Mambo, L. Chen, S. Sah, J.F. Houghton, K. Buddavarapu, T. 
Sanford, L. Garmire, D. Wylie, A. Marko, A. Choudhary, A. Adai 
Asuragen, Inc., Austin, TX. 
Introduction: The goal of individualized cancer treatment is to improve patient 
outcomes through targeted therapeutics. A critical first step in this process is to 
accurately interrogate key genes in tumor-specific molecular pathways and identify 
mutations that are clinically relevant. Next Generation Sequencing (NGS) has emerged 
as an enabling technology to provide high throughput cancer gene assessments from 
tumor biopsies. Methods: We developed a set of cross-platform, high sensitivity, low 
input, and FFPE-compatible multiplex PCR enrichment and analysis methods that 
provide rapid and reliable NGS of clinically actionable mutations in both oncogenes and 
tumor suppressor genes. PCR panels that targeted 5 to 52 cancer genes were 
compared and contrasted across Illumina GAIIx and MiSeq, and Ion Torrent PGM 
instruments. Variant calling was accomplished using novel methods that 
accommodated the challenging sample characteristics of FFPE DNA. Results: Using 
informed combinations of reference materials and incremental quality control assays 
and metrics, we established the detection of low-level mutations from dozens to 
hundreds of FFPE and fine needle aspiration (FNA) samples per NGS run sequenced 
at high depth (>1000x coverage). Bioinformatic algorithms were optimized to balance 
PPV and sensitivity, resulting in the detection of variants represented in as few as 2% of 
reads. These algorithms were successfully refined following extensive empirical testing 
that categorized and quantified the inherent “noise” in FFPE samples. In addition, we 
developed an on-demand mutation confirmation strategy that allowed variants called on 
one NGS instrument (Illumina) to be validated by evaluation using a distinct NGS 
chemistry (Ion Torrent), and demonstrated the value of this approach in detecting low 
abundance mutations compared to Sanger sequencing. Last, results from evaluations 
of >100 residual clinical specimens are summarized, including both FFPE and FNA 
samples from multiple cancer types and across different NGS platforms, including the 
MiSeq and PGM. Conclusions: The development of robust, high sensitivity NGS of 
clinically actionable mutations in FFPE and FNA tumor biopsy DNA requires 
quantitative reference materials, incremental QC metrics and bioinformatic algorithms 
tuned to accommodate the elevated sequence-specific background observed in fixed 
and embedded samples. In addition, the method can be leveraged to enable rapid 
confirmation of a primary NGS result, enhancing the accuracy of the final call, 
particularly for low abundance mutations. Consequently, our research outlines an 
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optimized approach for broad mutation detection that is suitable for routine sample 
assessments within the timeframes needed for clinical decision-making.  
 
TT06. PIK3CA Mutation Analysis in Breast Lesions using LNA-PCR Sequencing  
D.C. Ang, C. Corless, M. Troxell 
Oregon Health and Science University , Portland, OR. 
Introduction: Somatic mutations in PIK3CA are commonly seen in invasive breast 
cancer, as well as gastric, colon, endometrial, and other carcinomas, occurring in 3 
hotspots: codons 542 and 545 of exon 9 (helical domain) and in codon 1047 of exon 20 
(kinase domain). PIK3CA mutations and activation of the downstream AKT pathway 
have prognostic and therapeutic implications, but mutation detection is challenging in 
samples with low tumor content. We designed a locked nucleic acid (LNA)-PCR 
sequencing assay to detect low levels of mutant PIK3CA DNA with attention to avoiding 
amplification of a pseudogene on chromosome 22 that has >95% homology to exon 9 
of PIK3CA. Methods: We tested 60 breast DNA samples with PIK3CA exon 9 and exon 
20 mutation status that were previously screened using a PCR-mass spectrometry 
assay (PCR-MS). PIK3CA exons 9 and 20 were amplified in the presence or absence 
of LNA-oligonucleotides designed to bind to the wild-type sequences for codons 542, 
545 and 1047. Multiple concentrations of LNA-oligonucleotide were tested to optimize 
conditions that allowed the LNA-PCR sequencing to preferentially amplify mutant allele 
without completely suppressing wild-type allele. Results: LNA oligonucleotide 
concentrations of 0.075uM and 0.03uM for PIK3CA exon 9 and exon 20, respectively, 
were found to be optimum for mutation detection, yielding technical sensitivities of 
between 0.6-2.5% mutant allele. The 60 cases evaluated included preneoplastic breast 
lesions (31), breast carcinoma (21 including in situ, invasive and metastatic), and 
normal breast samples (8). Based on prior PCR-MS screening, 48 cases had 1 or more 
PIK3CA mutations (15 E545K, 1 E545G, 4 E542K, 25 H1047R, 1 case with both E545K 
and E542K, 1 case with both E542K and H1047R, and 1 case with both E545K and 
H1047R), and 12 were wild type. LNA-PCR sequencing confirmed all 51 of these 
PIK3CA mutations, whereas the mutation detection rate by standard Sanger 
sequencing was only 69% (35/51). Of the 12 PIK3CA wild type cases, LNA-PCR 
sequencing detected 3 additional H1047R mutations in “normal” breast tissue and 1 
E545K in usual ductal hyperplasia. Histopathologic review of these 3 “normal” breast 
specimens showed contaminating columnar cell change in 2 (both with known H1047R 
mutations), and apocrine metaplasia in the third. Conclusions: LNA-PCR shows higher 
sensitivity than both standard Sanger sequencing and PCR-MS assay. Our PIK3CA 
exon 9 LNA-PCR assay had excellent sensitivity and did not amplify the known 
pseudogene.  
 
TT07. Polymerase Chain Reaction in Less Than 30 Seconds 
J.S. Farrar, C.T. Wittwer 
University of Utah School of Medicine, Salt Lake City, UT. 
Introduction: The polymerase chain reaction (PCR) is a fundamental technique in 
molecular biology and diagnostics. Initially taking hours to perform, PCR amplification 
has been reduced to 10-30 minutes on commercial instruments. Published research 
efforts have attempted to reduce PCR amplification below 5 minutes. However, these 
investigations have generally focused on less complex targets (plasmids, PCR 
products, viruses, bacteria) at high initial template concentrations and have shown 
decreased PCR efficiency or failure as PCR cycle times are reduced. Methods: A 
custom instrument was built to study the PCR reaction conditions for < 2 second PCR 
cycles. Accurate temperature measurement was achieved with a micro-thermocouple 
inside a dedicated reaction tube. Fast thermal transfer was achieved by using high 
surface area-to-volume glass capillary tubes or stainless steel tubing as reaction 
containers. Temperature cycling was achieved by a stepper motor rotating samples 
between two stirred water baths held at a constant temperature (eg, 95°C and 40°C). 
The required concentrations of primers and polymerase were studied for specific 
product lengths and cycle times. PCR products were verified by high resolution melting 
analysis and gel electrophoresis. Results: Successful PCR with <2 second cycles was 
achieved with optimized concentrations of polymerase and primers. Amplification of a 
45 bp fragment of KCNE1 and 49 bp fragment of IRL10RB from human genomic DNA 
was completed in less than 30 seconds (0.8 sec/cycle). A 102 bp fragment of NQO1 
was amplified in less than 1 minute (1.93 sec/cycle). When stainless steel tubes were 
used as reaction containers, amplification was reduced to less than 16 seconds (0.45 
sec/cycle) for short products. Genotyping by high resolution melting analysis was 
demonstrated for <2 second cycle PCR amplification. Conclusions: Specific, efficient 
PCR amplification from human genomic DNA can be performed in less than 30 
seconds. Requirements for sub-30 second PCR include optimized concentrations of 
polymerase and primers and high surface area-to-volume reaction containers with high 
thermal conductivities. Such extreme PCR amplification has obvious advantages for 
point of care, “while you wait” diagnostics. 
 
TT08. Design, Development, and Validation Planning for a Clinical Next 
Generation Sequencing Panel 
L.M. Peterson, M.L. Butz, L.K. Courteau, E.W. Klee, M.J. Ferber 
Mayo Clinic, Rochester, MN. 
Introduction: Next-generation sequencing (NGS) is moving quickly from the research 
environment into the clinical laboratory. As with any new methodology, a thorough 
examination of test performance characteristics must be performed prior to clinical 
laboratory implementation. Understanding how variation in both chemistry and 
bioinformatics affect accuracy, precision, sensitivity, and specificity is a challenging 
subject matter given the complexities of NGS based assays. In light of ever increasing 
oversight of LDTs, our laboratory has adapted existing guidance to assist us in 
preparing a new NGS assay for clinical use, including creating a design and 
development plan and a thorough end-to-end validation strategy. Methods: A design 
and development plan (DDP) was drafted to provide documentation on instrumentation, 
software, reagent specifications, user requirements, regulatory risk assessment, and 
design verification. All of this effort culminated with a locked analytical method that 
provided the basis for a comprehensive end-to-end validation plan. The validation plan 
follows current guidance documents on molecular assay validation and includes 80 
previously genotyped specimens to help us assess experimental accuracy, precision 
(inter and intra assay), sensitivity, specificity, and limit of detection (LOD). We have 
designed our LOD experiments to test different amounts of input gDNA (analytical 
measurement range) and diluting mixing studies with a known variant carrier to test the 
analytical range. By blindly running previously genotyped samples, we are able to test 
our method from library preparation through final data analysis in a single validation 
process. Results: The drafting of the DDP provides one document to track all aspects 
of design and development planning and a means to ensure all regulatory requirements 
are being met. The result of the DDP is a locked analytical method from which the 
validation plan was drafted. The validation plan provides detailed information on 
validation studies to test the performance characteristics of the assay. The validation 
plan results in a final analytical method that will be carried into the subsequent assay 
implementation phase. Conclusions: The DDP provides clear and thorough 
documentation for every component of the test development process including 
preliminary test concept, user requirements, instrument, software and reagent 
specifications, regulatory review, and pilot study plan to verify and document test 
design. The DDP results in a locked analytical method that provides the basis for 
validation planning. The validation plan outlines a thorough end-to-end system 
evaluating the performance characteristics of the assay ensuring safe and accurate 
results for patients. 
 
TT09. Identification of Copy Number Variation in Target Capture Next 
Generation Sequencing Data 
H.J. Abel, C. Cottrell, H. AlKateb, S. Kulkarni, E.J. Duncavage 
Washington University School of Medicine, St Louis, MO. 
Introduction: Copy number variation (CNV) including gains and losses of DNA 
sequence is common in many solid tumors. In non-small cell lung cancer, for example, 
gain of EGFR is associated with adverse outcome and response to targeted 
pharmacologic inhibitors. Current methods to detect CNV generally involve 
fluorescence in situ hybridization (FISH) or array-based technologies that are incapable 
of detecting the full range of DNA alterations such as single nucleotide variation and 
small insertions/deletions present in cancer. We demonstrate that CNV can be 
detected, without paired normal samples, in gene panel-based, targeted next 
generation sequencing (NGS) data using specialized software. Methods: We identified 
a set of 18 solid tumors that were sequenced using the WU-CaMP 26 high coverage 
NGS cancer panel. Briefly, DNA was extracted from formalin-fixed paraffin-embedded 
tissue, indexed libraries created, then captured using liquid-phase cRNA probes, and 
finally sequenced in multiplex with an average sequencing depth of 1000-2000x. Nine 
of these cases (3 glioblastomas and 6 lung carcinomas) had known EGFR amplification 
detected by FISH using the Colorado scoring criteria; the remaining 9 were negative for 
EGFR amplification. NGS data were analyzed using publicly available software 
packages including CONTRA, the University of Washington CNV analysis pipeline 
(UW-CNV), and the laboratory-derived Copy Change Assessment Tool (CopyCAT). All 
three of these tools rely on analysis of normalized sequencing depth to determine CNV; 
CopyCAT also provides secondary verification by calculating allele frequencies for 
single nucleotide variants present in each gene. Results: CopyCAT correctly identified 
8/9 (89%) EGFR amplified cases and made one false positive call 1/9 (11%); CONTRA 
correctly identified 5/9 (56%) EGFR amplified cases and made 2/9 (22%) false positive 
calls; UW-CNV correctly identified 6/9 (67%) cases and made no false positive calls. 
Conclusions: We demonstrate that CNV can be detected in high coverage targeted 
NGS data. Although currently none of the tested methods produces perfect 
concordance with FISH, NGS-based CNV detection methods allow for the detection of 
CNV in single exons as opposed to large (>100kb) FISH regions. The ability to quantify 
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CNV occurring in much smaller regions may account for some of the discrepancies. 
These data suggest that NGS has the ability to replace numerous ancillary tests 
currently performed in the molecular diagnostic laboratory, greatly increasing the 
efficiency of molecular oncology testing.  
 
TT10. Using a “Loop-Out” Primer for Identification and Prevention of MEN1
Genotyping Errors Caused by G-Quadruplex- and I-Motif-Like Sequences 
K.L. Sumner, J. Swensen, M. Jama, B. Brulotte, R. Godfrey, G. Pont-Kingdon, D. Best 
ARUP Laboratories, Salt Lake City, UT. 
Introduction: A common polymorphism in intron 1 of the MEN1 gene, c.-23-16C>G 
(rs509606), alters the stability of G-quadruplex- and i-motif-like DNA secondary 
structures such that they interfere with PCR amplification. In heterozygous carriers of 
rs509606, the variant allele is preferentially amplified by PCR, and mutations in exon 2 
of MEN1 can either be missed or appear homozygous due to allele dropout. Although 
varying the PCR enzyme and buffer conditions has been reported as one solution to 
this problem, we sought a methodology that would allow us to maintain consistent PCR 
conditions between different amplicons. Methods: A forward PCR primer for MEN1 
exon 2 was designed to “loop-out” a 10 nucleotide region from the template that 
included the rs509606 polymorphism. Primers were validated for accuracy with 19 
samples that were also characterized with an alternative primer set (external primers) 
that would amplify through the problematic region. Inter-run and intra-run variation was 
also assessed. Results: Eight of the 19 samples characterized had the rs509606 
polymorphism, one of which also had a known pathogenic mutation, 
c.249_252delGTCT in exon 2. Of the remaining samples, 10 had normal wild-type 
sequence, and one had a polymorphism, c.435C>T. When using the external primer 
set, the sample with both rs509606 and c.249_252delGTCT clearly showed preferential 
amplification of the allele containing the polymorphism; the deletion on the opposite 
allele was undetectable. When amplifying the same sample with the noncontiguous 
primer, c.249_252delGTCT was clearly discernible. The sample containing the 
c.435C>T polymorphism was clearly heterozygous when amplified by either primer set, 
because it did not contain the rs509606 polymorphism. Conclusions: Allele dropout 
resulting from the common MEN1 gene polymorphism, rs509606, can be prevented by 
using a noncontiguous primer that loops out the polymorphism. Additionally, the use of 
this design principle for primers may simplify the analysis of other exons that are 
flanked by sequences that complicate amplification or sequencing. 
 
TT11. Cepheid’s Xpert HemosIL Factor II & Factor V Combo Assay and 
ViennaLab’s FV-PTH-MTHFR Strip Assay: Rapid, Reliable and Complementary 
Tests with Increasing Role in Molecular Thrombophilia Profiling 
S. Hassanieh, R. Abdel Khalek, R.A. Mahfouz 
American University of Beirut Medical Center, Beirut, TN. 
Introduction: The association of factor II (G20210A), factor V Leiden (G1691A) and 
methylenetetrahydrofolate reductase (MTHFR) gene mutations with an increased risk 
for venous thrombosis has been well documented. Molecular diagnostics has markedly 
improved the diagnosis and work-up of different clinical conditions including 
hypercoagulable state or thrombophilia where different genes are involved. In this 
study, we compared Cepheid’s Xpert HemosIL Factor II & Factor V Combo Assay and 
ViennaLab’s FV-PTH-MTHFR Strip Assay on a sample of referred cases for workup. 
Methods: Study Samples and DNA Extraction: we compared 18 cases referred for 
thrombophilia workup at the American University of Beirut Medical Center. For the 
ViennaLab’s Strip Assay, DNA was extracted and stored at -80°C for later use. PCR 
and reverse hybridization: To test for the various genotypic profiles of the Factor V, 
Prothrombin, and Methylenetetrahydrofolate genes, the FV-PTH-MTHFR StripAssay 
(ViennaLab, Austria) was used and the manufacturer’s protocol was followed as 
recommended. This assay screens for the G1691A, G20210A, and C677T mutations of 
the factor V, prothrombin, and MTHFR genes, respectively, whereby in vitro, the 
different gene sequences are simultaneously amplified and biotin-labeled in a single 
amplification reaction (multiplexing). Real-time PCR: The Xpert HemosIL Factor II & 
Factor V Combo Assay includes reagents for the detection of Factor II and Factor V 
normal and mutant alleles from sodium citrate or EDTA anticoagulated whole blood. 
The primers and probes in the Xpert HemosIL Factor II & Factor V Assay determine the 
genotype of the factor II gene (at position 20210) and/or the factor V gene (at position 
1691). Results: The 18 samples that were run simultaneously using the two assays 
were 100% concordant. The turnaround time for the GeneXpert assay is 37 minutes 
whereas that of the ViennaLab assay is 6 hours. Conclusions: Both ViennaLab and 
Cepheid thrombophilia assays are reliable and technically easy to use and implement in 
molecular diagnostic laboratories. Although the FV-FII-MTHFR assay by ViennaLab 
provides additional information in terms of assessing MTHFR gene mutations, the Xpert 
HemosIL has a shorter turnaround time with minimal technical involvement. 
 
TT12. Filter Paper-Based Nucleic Acid Storage In High-Throughput Solid Tumor 
Genotyping 
M. Stachler1, J. Wade1, N. Sharaf1, J. Longtine2, E. Garcia1, L. Sholl1 
1Harvard Medical School, Brigham and Women's Hospital, East Boston, MA; 2The 
Mount Sinai Medical Center, New York, NY. 
Introduction: Molecular testing of solid tumors from formalin-fixed paraffin embedded 
(FFPE) tissue blocks is central to clinical diagnostics practice; however it requires 
histology support and introduces additional costs and delays, particularly in high-volume 
testing centers. Filter paper-based collection of tumor DNA reduces the need for 
histology support and requires little storage space. We investigated the performance of 
fresh tumor smears on filter paper in solid tumor genotyping, as compared to standard 
FFPE tissue protocols. Methods: Tumor smears on Whatman FTA cards (FTA preps) 
were prepared from 21 fresh samples including 16 carcinomas (seven lung, four colon, 
two pancreas and four renal), one carcinoid tumor, one mesothelioma, one lipoma, and 
two desmoid tumors. A cytology smear was prepared in each case to assess tumor 
cellularity and necrosis. DNA was isolated from 10 x 1 mm punches and cores from 
filter cards and corresponding FFPE blocks, respectively, using a Qiasymphony 
automated DNA extractor. DNA was quantified using SYBR-green based dsDNA 
detection. Samples containing >250 ng of DNA were genotyped on a Sequenom 
platform testing >400 mutations. Results: Tumor cellularity of the FTA preps, inferred 
from cytology smears, ranged from ~10 to >90%. This correlated well with the cellularity 
of corresponding tissue slides for pre-treatment carcinomas but less well with post-
treatment carcinomas and mesenchymal tumors (Spearman’s ı=0.37, p=0.1). Of the 21 
paired samples tested, 15 (71.4%) of the FTA preps gave sufficient quantity of DNA for 
genotyping compared to 16 (76.2%) for FFPE samples. DNA concentrations from the 
two sources correlated (Spearman’s ı=0.61, p = 0.004), but on average was lower from 
FTA preps (13.8ng/ul) as compared to FFPE (30.6ng/ul). Mesenchymal tumors and 
post-treatment carcinomas were more likely to have insufficient DNA from both sources. 
Of the 15 paired DNA samples that were genotyped, 14 (93.3%) gave concordant 
results. These included five KRAS, one P53, one CDKN2A, and one PIK3CA mutations. 
The remaining paired cases were wild type. A single discordant case was a squamous 
cell carcinoma of the lung with a PIK3CA mutation detected using DNA from the FFPE 
block but not from FTA punches. PIK3CA mutations are frequently heterogeneous in 
lung adenocarcinomas and this may account for the discrepancy. Conclusions: Filter 
paper-based nucleic acid collection and storage is a viable alternative to FFPE, 
particularly for cellular carcinoma specimens. Solid tumor DNA isolated from FTA preps 
performs well on sensitive, high-throughput genotyping platforms, and can be 
introduced into an automated workflow starting at the extraction step. 
 
TT13. H&E, Immunochemistry and Fluorescence in Situ Hybridization (FISH) in 
the Diagnosis of BK Viral Nephropathy in Renal Allograft Biopsies 
Z. Wang, B.P. Portier, J.C. Myles, A. Chiesa-Vottero, G.W. Procop, R.R. Tubbs 
Cleveland Clinic, Cleveland, OH. 
Introduction: BK viral nephropathy is a potential complication of post renal transplant 
immunosuppression. Graft loss will occur if the nephropathy is not managed 
appropriately. Early recognition of BK viral nephropathy is essential to successful 
management. Although patients are typically followed clinically by real time PCR 
performed on blood or urine, certain patients receive renal biopsy for tissue diagnosis. 
Our aim in this study is to compare the detection of inclusions by hematoxylin and eosin 
(H&E), positive immunohistochemistry (IHC) for SV40 and the technique of 
fluorescence in situ hybridization (FISH) for detection of BK virus in renal transplant 
biopsies. Methods: Data was retrieved from the Cleveland Clinic electronic medical 
record database from 1/2005 to 12/2011 wherein patients were included if they had a 
history of renal transplantation, subsequent renal biopsy preformed at the Cleveland 
Clinic, and documented blood or urine BK virus PCR performed concurrently at time of 
biopsy. In this study, 108 renal allograft biopsies were analyzed via H&E for inclusions, 
(IHC) for SV40 and FISH for BK virus. Results: Presence of BK virus was detected in 
16 (14.8%) cases by H&E, 13 (12%) cases by IHC, 18 (16.6%) cases by FISH and 19 
(17.6%) cases by real time PCR. Of the 108 cases tested, 24 showed a discrepancy in 
one or more of the testing modalities. A direct comparison between each tissue based 
(H&E, IHC and FISH) showed no statistical difference in detection of BK virus. 
However, performing comparisons between the different tissue based assays in the 
context of plasma or urine real time PCR results revealed significant improvement in 
detection of BK by FISH over that of H&E (P= 0.02) but not IHC (P= 0.07). Detection of 
positive SV40 by IHC is also showed no statistical difference over that of H&E (P= 0.62) 
in the context of plasma or urine real time PCR results. 
Conclusions: Utilization of FISH based approach for BK virus identification in renal 
allograft biopsy tissue closely mirrored real time PCR results and showed superior 
performance to detection of inclusions by H&E. FISH are straightforward, offer a short 
turn around time, and require no variation from standard IHC protocol, thus making 
them viable options for BK virus identification.  
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TT14. Use of MassARRAY Technology for Determination of Mutation Status in 
Multiple Clinically Relevant Genes in Malignant Melanoma 
K.C. Behling, R.J. Letrero, J.R. Gonzalez, V.G. Bhoj, K.L. Nathanson, V.M. Van Deerlin, 
C.D. Watt 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: Patients with advanced melanoma generally have a poor prognosis and 
poor response to conventional chemotherapy. Recent identification of targeted 
therapies for driver mutations in melanoma has led to improvement in survival for a 
portion of these patients. Early data has shown, however, that targeting a single 
mutation can lead to rapid development of treatment resistance, suggesting that future 
therapy will likely involve multiple targeted inhibitors simultaneously aimed at several 
pathways, thereby necessitating rapid and efficient testing for multiple mutations using 
limited patient sample material. Methods: Paraffin embedded tissue (PET) samples 
containing >25% lesional tissue (n=26) from patients with malignant melanoma at the 
Hospital of the University of Pennsylvania were obtained, and DNA was extracted using 
chaotropic salt-silica column extraction. Specimens were evaluated using a BRAF V600 
pyrosequencing assay, KIT high resolution melt curve analysis (HRM), and a laboratory 
developed mutation panel (MelaMAP) for the Sequenom MassARRAY platform 
(Sequenom, San Diego, CA) to assess mutation status of 12 genes: AKT1, AKT3, 
BRAF, CDK4, CTNNB1, GNAQ, GNA11, KIT, MAP2K1, MAP2K2, MET, and NRAS. 
DNA from melanoma cell lines (n = 20) was also obtained and evaluated using the 
MelaMAP assay. Results: BRAF V600 mutations were detected in 16/26 (62%) of the 
PET specimens examined by both MelaMAP and BRAF pyrosequencing with 100% 
concordance between methods. These mutations consisted of V600E (n= 10, 63%), 
V600K (n= 4, 25%), and V600R (n=2, 8%). NRAS mutations were identified in 4/10 
(40%) specimens using the MelaMAP assay. These mutations in NRAS were: Q61R, 
Q61K, G12S, and G12C. No KIT mutations were found in these specimens using either 
MelaMAP or HRM (performed at a reference laboratory). Mutations in BRAF, CDK4, 
KIT, MAP2K2, and NRAS were confirmed in previously characterized melanoma cell 
lines using MelaMAP. Analytical sensitivity data for selected mutations in MelaMAP as 
well as a comparison of specimen requirements (including DNA input), assay workflow, 
and data analysis of the MelaMAP assay to other common platforms for mutation 
analysis will be presented. Conclusions: The MassARRAY platform offers an efficient 
approach for multiplex analysis of multiple somatic gene mutations in melanoma with 
relatively low input DNA, making it suitable for small biopsy specimens. Although data 
analysis can be complex, with customized software, ease of interpretation approaches 
that of comparable assays. 
 
TT15. FFPE FISH in 3½ Hours Achieved Through Development of a New 
Ethylene Carbonate Based, Non-Toxic Hybridization Buffer 
A. Schønau, S.H. Matthiesen, S. Müller, L. Andresen, K.V. Nielsen 
Dako Denmark A/S, Glostrup, Denmark. 
Introduction: Fluorescence in situ hybridization (FISH) is a robust and reliable 
technique for direct visualization and quantitative determination of gene amplifications, 
deletions and translocations in human cancer cells. FISH assays are often relied upon 
for determining the patient status and making treatment decisions (e.g., HER2 and 
ALK). But FISH protocols are also known to be time-consuming and involve toxic 
reagents. This study demonstrates how a number of the disadvantages of formamide 
based hybridization buffers can be overcome by use of a newly developed ethylene 
carbonate based hybridization buffer. By using solvents that interact with the stacking 
bonds of DNA as opposed to the Hydrogen bonds, hybridization time is reduced, 
specificity increased and denaturation can be omitted. Methods: Specimens: Formalin 
fixed and paraffin embedded (FFPE) breast carcinomas, tonsil and colon tissue. FISH 
probes: Nick translated BAC and cosmid clones for gene specific sequences used in 
combination with peptide nucleic acid (PNA) oligos for repetitive targets. FISH protocol: 
Standard FISH protocol according to Histology FISH Accessory kit. Quantification of 
signals: Images were captured using a monochrome CCD camera mounted on a 
fluorescence microscope. Signal intensities were measured and corrected for 
background using ImageJ software. Results: The ethylene carbonate based buffer 
demonstrated a number of new characteristics compared to the formamide based 
buffer.1) Significantly shorter hybridization times required to generate same signal 
intensity (1 hour hybridization versus overnight) 2) Blocking for repetitive sequences is 
no longer required 3) Hybridization to FFPE specimens can be achieved without 
denaturation (hybridization at 50°C for two hours) 4) High concordance to traditional 
FISH when testing 79 representative gastric cancer samples for HER2 FISH ratio. 
Overall agreement: 98.7%. Trend line: y = 1.0208x - 0.0005. R-squared = 0.9948. 
Conclusions: The newly developed ethylene carbonate based hybridization buffer 
offers a new set of intriguing and attractive hybridization characteristics, including short 
hybridization time, no need for blocking and no need for denaturation, whereas 
presenting improved signal to noise ratio and maintaining high level of concordance to 
traditional FISH. In addition the replacement of the teratogenic formamide offers 
improved laboratory safety and reduces the need for use of fume hoods. Reduction of 
the overall assay time from a two-day procedure to 3.5 hours for FFPE FISH, offers 
more flexible laboratory routines and same day reporting for all working days of the 
week, resulting in faster answers and improved patient care. The 30-year-old tradition 
of formamide based hybridization may be up for change. 
 
TT16. An Algorithm to Improve Identification of BRAF V600 Wild Type,V600E, 
V600K and V600R Mutations Tested by Pyrosequencing 
S. Shen, Z. Zhong, D. Qin 
Moffitt Cancer Center, Tampa, FL. 
Introduction: Pyrosequencing is a DNA sequencing technique that sequences a single 
strand of DNA by synthesizing the complementary strand along it, one base pair at one 
dispensation. The amount of pyrophosphate released on nucleotide incorporation is 
proportional to the amount of nucleotide incorporated at each dispensation. The 
detection of V600E, V600K and V600R mutation of BRAF gene can be made by 
appearance of abnormal peaks and/or changes of peak height. These changes are 
subtle when the ratio of cancer cell is low. It makes identification of these mutations 
difficult. In wild type BRAF pyrograms, signal of C7 is always stronger than C2 and A11 
is always stronger than A5, which makes distinguishing these mutations even more 
difficult. We have developed an algorithm to improve accuracy and efficiency of 
pyrosequencing data analysis. Methods: Pyrosequencing data of 242 wild types is 
analyzed. Averages of background, single nucleotida extensions are calculated. The 
ratios of C7/C2 and A11/A5 are also calculated. V600E, V600K and V600R mutation 
sequences are aligned with wild type and dispensation order. Algorithms for recognition 
these mutations are developed. Based on the algorithms, we developed a software to 
help identifying BRAF V600 wild type and mutations, and calculate the percentage of 
mutation. Results: The average background peak height is lower that 1% of average 
signal of single non-dAMP extensions. Average and standard deviation (std) of peak 
height of single non-dAMP extensions are different from case to case, but the 
coefficient of variation (CV) are stable and about 10%. Average ratio and standard 
deviation of C7 to C2 are similar to that of A11 to A5 (1.22 vs. 1.16, 1.18 vs. 1.19). The 
ratio of C7 to C2 is highly correlated to the ratio of A11 to A5 for all cases (RSQ = 
0.894808). A software is developed to help distinguishing wild type and mutations, ajd 
calculate the percentage of mutation. 637 cases of BRAF V600 test results have been 
re-examined by the software. Among these tests, 408 are wild type, 164 are V600E 
mutation (including 56 positive controls), 24 V600K, 5 V600R and 36 no-template 
controls are recognized correctly. Conclusions: Conclusion: We have developed an 
algorithm that utilizes all these variations to be the parameters to distinguish BRAF 
V600 wild type, V600E, V600K and V600R mutations. A Microsoft Excel worksheet 
utilizes this algorithm is also developed. The result suggests that the software can 
recognize the mutations and speed up the test data analysis procedure.  
 
TT17. Formalin-Free Tissue Fixation for Multimodal Biomarker Analysis  
D. Groelz1, C. Viertler2, S. Gündisch3, K. Becker3, K. Zatloukal2, R. Wyrich1, L. Rainen1 
1PreAnalytiX GmbH, Hombrechtikon, Switzerland; 2Medical University of Graz, Austria; 
3Technische Universität München, Munich, Germany. 
Introduction: Although tissue fixation with formalin preserves morphology, it leads to 
crosslinking and chemical modification of biomolecules. Since chemical modifications 
cannot be completely reversed, biomolecules isolated from FFPE are of limited use for 
molecular analyses. The PAXgene Tissue System (PAXgene) is a non-crosslinking 
fixation technology for fixation and stabilization of tissue specimens. PAXgene-fixed, 
paraffin-embedded (PFPE) tissue sections are suitable for conventional histochemical 
and immunohistochemical staining as well as for extraction of unmodified biomolecules 
such as nucleic acids, proteins, and phosphoproteins. Methods: Human non-malignant 
(cystadenoma, liver) and malignant (ovarian, prostate and breast cancer) tissue 
specimens were divided and fixed in formalin, PAXgene, or cryo-preserved in liquid 
nitrogen. Morphology of FFPE and PFPE tissue was analyzed by H&E and 
immunohistochemistry (IHC) staining. HER2 gene amplification was determined by 
chromogenic in situ hybridization (CISH) using the SPoT-Light HER2 CISH kit (Life 
Technologies). RNA was analyzed with the Agilent Bioanalyzer and in RT-qPCR using 
PCR arrays from Applied Biosystems (TaqMan Array Gene Signature 96-well plates) 
and SABiosciences (RT² ProfilerTM PCR Arrays). DNA was analyzed by agarose gel 
electrophoresis and long-range and multiplex PCR. Proteins, including 
phosphoproteins, were analyzed by western blotting. Results: Morphology was 
preserved in PFPE tissue similarly to FFPE. The staining intensity of IHC for estrogen 
and progesterone receptors in breast cancer, as well as the number and size of dots in 
the HER2 CISH assay were comparable between PFPE and FFPE samples. High 
correlation of gene signatures between PFPE and cryo-preserved liver and breast 
cancer samples was found in two different predefined TaqMan arrays (R²=0.97 and 
0.92). In contrast, FFPE samples showed a decreased correlation to the cryo-preserved 
reference (R²=0.79 and 0.65) and major gene-to-gene variations. DNA from cryo-
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preserved and PFPE tissue was of high molecular weight and performed well in PCR, 
whereas DNA from FFPE was highly degraded and failed in most PCR assays. Signal 
intensities analyzed by western blotting were similar between PFPE and cryo-preserved 
tissue for the phosphoproteins p-PTEN, p-Akt, p-GSK3ȕ, p-PRAS40, p-p44/42 MAPK, 
p-p38 but signals from FFPE tissue were weaker than signals from the cryo-preserved 
reference material. Conclusions: Morphology and antigenicity is preserved in PFPE 
tissues, and chemically unmodified DNA, RNA and proteins can be isolated. Therefore, 
multimodal biomarker testing can be performed on the same sample used for 
morphological analysis. For research use only. Not for use in diagnostic procedures. No 
claim or representation is intended to provide information for the diagnosis, prevention, 
or treatment of a disease. 
 
TT18. Sensitivity and Limit of Detection of Next-Generation Sequencing for 
Detecting Somatic Mutations in Heterogeneous Samples 
D. Spencer1, F. Vallania1, J.K. Sehn2, R.D. Mitra1, E.J. Duncavage1 
1Washington University, St. Louis, MO; 2Massachusetts General Hospital, Boston, MA. 
Introduction: Hybridization-capture enrichment and next-generation sequencing (NGS) 
are currently being used to identify somatic mutations in cancer specimens. Although 
the accuracy of this approach for inherited variants has been described, it is less clear 
how well these methods can discover somatic variants in clinical cancer specimens that 
may be present at low frequency due to dilution by intervening stroma, inflammatory 
cells, and tumor heterogeneity. In this study we performed capture-enrichment and 
sequencing of five DNA samples both individually and in a range of mixtures to simulate 
sequencing of a heterogeneous specimen. We used this dataset to test four NGS 
analysis programs to determine the sensitivity and limit of detection affored by these 
tools. Methods: DNA from five distinct Hapmap samples was sequenced individually 
and in mixtures to simulate samples with variant allele fractions (VAF) ranging from 
25% to 1.25%. High coverage sequencing was performed for 26 genes spanning ~300 
kbp with a clinical NGS assay using Agilent SureSelect enrichment and Illumina 
multiplex sequencing. Sequence data from all samples were mapped to the NCBI-b37 
reference sequence with Novoalign and analyzed with the general-purpose tools 
Genome Analysis Toolkit (GATK) and Samtools and rare-variant detection programs 
Varscan2, and SPLINTER. Sensitivity and limit of detection were determined by 
comparing basecalls from the mixed datasets with manually reviewed basecalls from 
the corresponding pure samples. Results: Targeted sequencing resulted in 
approximately 1500-fold coverage for each pure and mixed sample. Inspection of 
observed allele fractions at known variants in the mixed datasets showed the expected 
VAF distributions, which demonstrates that capture-enrichment and sequencing 
faithfully reflects underlying sample heterogeneity. Analysis of the mixed datasets with 
GATK, Samtools, Varscan2, and SPLINTER revealed substantial differences in 
sensitivity. Samtools detected only 40% of variants at a VAF of 25% and no variants at 
lower VAFs, whereas SPLINTER, GATK, and Varscan2 detected >95% of variants at a 
VAF of 12.5%. The sensitivity of GATK decreased at lower VAFs, but SPLINTER and 
Varscan2 detected >90% of variants at VAFs as low as 2.5%. Conclusions: 
Substantial variation exists in the sensitivity of common NGS analysis tools for 
detecting low frequency variants in heterogeneous specimens. Popular programs 
Samtools and GATK will likely miss variants present at low frequencies, whereas 
Varscan2 and SPLINTER have significantly better sensitivity for these variants. These 
results have important implications for laboratories attempting to use targeted NGS for 
testing of somatic mutations in heterogeneous cancer specimens. 
 
TT19. Microarray for Detection of Balanced Reciprocal Translocations in 
Oncology 
S. Shetty1, K. Mallempati2, T. Lewis2, R. Mao2 
1Cleveland Clinic Foundation, Cleveland, OH; 2ARUP, Salt Lake City, UT. 
Introduction: We propose to develop a high density tiling microarray chip-based test 
(BCRONC/RS array) for the detection of balanced reciprocal translocations in oncology. 
This array will detect variable breakpoints associated with the reciprocal translocations 
commonly described in neoplasia especially in hematological malignancies and solid 
tumors. Methods: To prove the concept, a 50 gene panel has been selected for 
targeting by this microarray. The genes were selected based on our current knowledge 
of cancer cytogenetics. The oligonucleotide probes have been densely spotted onto a 
small chip surface at a 5-7 bp spacing resolution and will be used to cover the 
promoter, introns and exons of each targeted gene. In addition, approximately 500 bp 
upstream and downstream of the targeted genes will be included in the design. 
Results: 20 samples with gene rearrangement previously detected by either 
karyotyping or FISH have been tested with BCRONC/RS array. All the translocations 
can be detected as the “U” shape from probe drop-offs. Conclusions: Our approach 
supplements the standard microarray analysis platform, which cannot detect balanced 
rearrangements, and will replace costly FISH analysis with multiple probes. The tiling 
array also has the potential to detect the signal ratio for copy number changes (i.e, 
deletions or duplications in the targeted regions). Our one-step chip (BCRONC/RS chip) 
is expected to provide significant cost savings and facilitate broader implementation of 
microarray analysis in diagnostic laboratories worldwide for detection of balanced 
reciprocal translocations in oncology, thereby realizing substantial commercial potential. 
We plan to increase the value of this technology by using the BCRONC/RS array in 
patients with hematological malignancies and solid tumors to derive better 
understanding of the variations in the breakpoint regions. In addition, we will determine 
the sensitivity of this assay to detect mosaicism or heterogeneity that is common in 
cancers. This test will result in rapid diagnosis of specific subtypes of cancers, provide 
important prognostic information and thereby aid in the choice of therapy and 
management of patients. 
 
TT20. Utility of Electronic Synoptic Reporting for Retrieval of Molecular Results 
B.H. Hinrichs1, A.B. Carter1, C.E. Hill1, Y. Liu2, J. Switchenko2, K.P. Mann1 
1Emory University, Atlanta, GA; 2Emory Winship Cancer Institute, Atlanta, GA. 
Introduction: Although many clinical laboratories report molecular testing results using 
free text formats, the use of standard data formats such as electronic synoptic reporting 
offers distinct advantages. Entry of data as discrete elements greatly facilitates the 
accuracy and ease of data retrieval for retrospective quality assurance monitoring, data 
analysis, and identification of specimens for research and validation studies. Using a 
commercial electronic synoptic reporting system, results of the TRG@, IGH@, and 
IGK@ gene rearrangement assays at Emory Medical Laboratory were interrogated to 
evaluate patterns of primer set positivity and overall testing efficiency. Methods: 
Custom synoptics were created for IGH@ (later altered to include IGK@) and TRG@ 
gene rearrangement analyses using the CoPathPlus 3.2 electronic synoptic reporting 
module. They have been in routine clinical use for over one year. Queries were 
executed using the CoPathPlus synoptic search tool (synoptic method) to identify the 
total tests performed, the number with clonal rearrangements, and the frequency that 
specific primer sets detected clonal rearrangements in isolation or in the context of 
other positive primer sets. The accuracy and speed of data retrieval was compared to 
manual data extraction by reviewing final reports (manual method), and the patterns of 
primer set positivity were analyzed. Results: A total of 434 reports (325 TRG@, 161 
IGH@ including 41 IGK@) were identified. Clonal rearrangements were identified in 
126/325 of the TRG@, 36/120 of the IGH@ (without IGK@), and 20/41 of the combined 
IGH@ IGK@ assays. The data collected using the synoptic method and manual 
method were in complete concordance. However, the time required to retrieve the data 
using the synoptic method was six times less than the manual method (30 min vs. 3 h). 
Data analysis revealed that the IGHV@-FR2 primer set and combinations involving 
TRGV11 were never positive in isolation. Eliminating these would not result in 
statistically significant decreases in rates of clonality detection as determined by the 
one-sided Fisher's Exact Test (p = 0.549 and p = 0.532, respectively). Patterns of 
positivity were skewed and will be displayed. Conclusions: Synoptic reporting allows 
for efficient and accurate data retrieval in a fraction of the time it takes to extract data 
using the manual method. Review of the data demonstrated that not all patterns of 
rearrangement were represented, and some patterns were more frequent than others. 
Of note, some primer sets were positive only in the context of other primer sets, 
indicating they may be removed without compromising patient care. 
 
TT21. Ion AmpliSeqTM Technology Enables Highly Multiplexed Amplicon 
Preparation for Rapid and Efficient Targeted Re-Sequencing of Sample-Limited 
Specimens Using PGMTM Semiconductor Sequencing 
D. Ruff, M. Shannon, M. Andersen, D. Joun, B. Kong, A. Li, S. Chen, I. Casuga, R. 
Bennett 
Life Technologies, South San Francisco, CA. 
Introduction: Whole genome and exome sequencing studies have provided a broad 
sampling of the somatic and germ-line genetic variation that occurs in individuals and 
populations. These types of studies provide the framework for deeper exploration of the 
genome and identification of de novo mutations associated with cancer and inherited 
genetic disorders in humans. Such exploration relies on efficient and economical 
strategies for interrogating the most relevant regions of the genome across well-
annotated and uncharacterized specimens. Targeted isolation of coding regions of 
genomic DNA has been proven to be a cost-effective way of detecting genetic variation. 
However, hybridization-based exon enrichment strategies have extensive sample 
preparation time and are not well-suited to applications that require the analysis of 
scarce and/or highly degraded DNA materials from sources such as fine needle 
biopsies or archival FFPE samples. In contrast, Ion AmpliseqTM technology combines 
the specificity, sensitivity, and efficiency of PCR technology to enrich tens to thousands 
of genomic targets from less than 10ng of FFPE or gDNA in a single reaction for next 
generation sequencing (NGS). Methods: The workflow consists of target amplification 
from a DNA sample using primer pools designed by Ion AmpliSeqTM Designer followed 
by enzymatic polishing of the amplicon ends for library preparation and subsequent 
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sequencing. The unique amplicon preparation workflow sharply reduces side-products 
in multiplexed PCR and thereby enables this technology to venture into extremely high 
levels of PCR multiplexing for NGS. The Ion AmpliSeqTM workflow, from sample to 
library, can be completed in 3.5 hours with just 30 minutes of hands-on-time. We 
recently developed the Ion AmpliSeqTM Inherited Disease and Comprehensive Cancer 
Panels, which have primer designs of about 10,000 or 16,000 amplicons distributed 
across only 3 or 4 tubes and target the coding regions of hundreds of genes associated 
with a broad spectrum of inherited diseases or cancers, respectively. Results: 
Sequencing results from both panels consistently achieve >98% of all reads on target 
and uniform coverage of >94% of bases covered 20X when normalized to 100X 
average coverage. We also demonstrate the ability to detect mutations in DNA from cell 
lines, fresh tissue, and archived FFPE samples with these panels. Conclusions: An 
early demonstration of a 18,500-plex, single-tube reaction suggests that the multiplex 
limit of Ion AmpliSeqTM has yet to be reached. This level of scalability opens up the 
possibility of rapid targeted re-sequencing of exons from 25,000 genes in a few 
reactions with only sub-microgram quantities of DNA.  
 
TT22. ChimerAnalyzer: An Automated Approach to Standardize and Streamline 
Engraftment Quantification 
J. Young1, K. Beierl2, M. Harris2, M. Lin2, C.D. Gocke2 
1University of Maryland, Baltimore, MD; 2Johns Hopkins University School of Medicine, 
Baltimore, MD. 
Introduction: Hematopoietic stem cell transplantation is a common therapy for 
hematologic/lymphoid malignancies and bone marrow failure syndromes. Measuring 
donor engraftment by analyzing STR polymorphisms is the current clinical standard of 
care. Many laboratories perform this analysis manually by comparing the relative 
amounts of donor-derived alleles to patient-derived alleles as determined by multiplex 
PCR and capillary electrophoresis. This analysis is detailed, time-consuming, and lacks 
standardization. We created a computer program named ChimerAnalyzer to assist with 
engraftment chimerism analysis. Methods: DNA was extracted from clinical specimens. 
Multiplex PCR was performed using a commercial multiplexed STR kit. Capillary 
electrophoresis was on the ABI 3130. ChimerAnalyzer was written in the Python 
programming language (version 2.7), and incorporated the same manual engraftment 
analysis rules that are currently used in the clinical laboratory at Johns Hopkins 
University. Text files of the electrophoresis data were created using Genemapper 
software and uploaded into ChimerAnalyzer. Validation of 113 specimens was 
performed and compared to the existing manual analysis. Results: On average, 
approximately 30 minutes were needed to analyze a single complete case including a 
pre-transplant analysis of donor and patient alleles and 3 post-transplant follow-up 
samples. Using ChimerAnalyzer, this analysis took approximately 2 to 2.5 minutes. This 
represented an estimated time savings of 27.5 minutes (92%). Of the 113 validation 
samples, 11 were not analyzed by ChimerAnalyzer (no call rate of 9.7%) due to one of 
many error catching algorithms in the program. Seven of the no calls were attributed to 
long capillary injection times, which lead to markedly off-scale peaks and an inordinate 
number of false peaks. Three of the no calls were due to low amplification of DNA or 
too short injection times. The final no call was due to a sample with multiple donors. Of 
the 102 samples that were analyzed by ChimerAnalyzer, we observed approximately 
98% concordance with our current manual methods. The 2% discordance was 
attributable to minor calculation errors during the manual evaluation caught by 
ChimerAnalyzer. A user-determined locus exclusion tool prevented errors attributed to 
low amplification from being included in the final engraftment percentage in 
approximately 1% of the validation samples. Conclusions: Using ChimerAnalyzer to 
assist with engraftment quantification results in significant time savings, improved 
accuracy, and the potential to standardize. Reinjecting for shorter or longer intervals will 
significantly reduce the no call rate and the chance for computing errors. This program 
will be made freely available for public use. 
TT23. Fully Automated Dual Color in situ Hybridization (Dual ISH) Detection of 
PIK3CA, PTEN, TOP2A and MET Genotypes in Neoadjuvant Trastuzumab Treated 
Breast Carcinomas via ASR Class Repeat Depleted Probes 
Z. Wang, B.P. Portier, E. Minca, C. Lanigan, G.T. Budd, R.R. Tubbs 
Cleveland Clinic, Cleveland, OH. 
Introduction: Common prognostic/predictive markers utilized in breast cancer testing 
include ER, PR, Ki67, and HER2. Currently, positivity for HER2 by IHC or FISH serves 
as eligibility for anti-HER2 based Trastuzumab (Genentech, USA) therapy. However, 
response to Trastuzumab in HER2 positive patients is variable, suggesting that 
additional markers could add predictive value. In this study, we retrospectively 
examined the feasibility of detecting amplification and deletion status ofPIK3CA, PTEN, 
TOP2A and MET genotypes using repeat depleted probes for a cohort of invasive 
breast carcinomas treated in the neoadjuvant setting with trastuzumab-based therapy. 
Methods: All patients that received trastuzumab at the Cleveland Clinic from 1/2008 to 
12/2010 were reviewed for study inclusion (234 patients); 47 patients met inclusion 
criteria that included a diagnosis of primary invasive breast cancer, neoadjuvant 
trastuzumab therapy, and a pre-treatment biopsy performed at the Cleveland Clinic. 
The paraffin embedded formalin fixed biopsy specimens were evaluated by fully 
automated dual color in situ hybridization (dual ISH) for PIK3CA (chromosome 3), 
PTEN (chromosome 10), TOP2A (chromosome 17), MET (chromosome 7) using 
repeat-depleted ASR class probes. Dual ISH staining was performed using Dual Color 
Open Probe software on a Ventana Benchmark XT. DNP labeled/repeat depleted 
probes and Digoxigenin labeled paired alpha centromeric control probes were utilized. 
Denaturation was at 80°C for 12 minutes; hybridization at 44°C for 6 hours;followed by 
stringency washes (3 at 72°C, 8 minutes). DNP probe was detected with ultraView 
silver ISH (SISH) DNP Detection Kit: silver anti-hapten antibody (20 minutes), and SISH 
detection (8 minutes). CHR DIG probe was detected with ultraView Red ISH DIG 
Detection Kit: anti-hapten antibody incubated (20 minutes) and Red detection (8 
minutes). Genotypes were assigned via qualitative and semi-quantitative enumeration 
of metallic black silver and reference CHR red signals and the gene/reference ratio 
calculated. Results: Loss of PTEN and PIK3CA (ratio <0.7) and gain of TOP2A and 
MET (ratio >2.0) were readily assessed by conventional light microscopy. 
Conclusions: Fully automated Dual ISH is a robust tool for PIK3CA, PTEN, TOP2A 
and MET in situ genotyping as predictive markers for trastuzumab based therapy in 
breast cancer. 
 
TT24. Standardizing BCR-ABL MBr Monitoring without External Standards 
T.B. Morrison1, B. Austermiller1, W. Chen2, A. Vaidya2, D. Henley3, J. Lefferts4, N. 
Quigley3, N. Lazaridis1, N. Marella2, G. Tsongalis4 
1AccuGenomics, Inc., Wilmington, NC; 2Cancer Genetics, Inc., Rutherford, NJ; 
3Geneuity Clinical Research Services, Maryville, TN; 4Dartmouth-Hitchcock Medical 
Center, Lebanon, NH. 
Introduction: BCR-ABL blood transcript abundance is a key marker for monitoring 
tyrosine kinase inhibitor treatment of chronic myelogenous leukemia (CML). 
Standardization of BCR-ABL qPCR measurements suffer from variability introduced by 
sample purity, and preparation, reagents and instrument. International standardization 
efforts have made modest improvements but rely on cumbersome external reference 
material and lab calibration. This article describes beta testing of a novel qPCR method 
that controls for the majority of real-time qPCR variation. Methods: The BCR-ABL MBr 
qPCR reagents use Standardized Nucleic Acid Quantification (SNAQ), a method 
combining competitive template (CT) mixtures and melting curve analysis that is 
compatible with existing real-time qPCR instrumentation. cDNA synthesized from blood 
sample RNA were divided into three CT mixtures of 6, 100 and 10,000 copies BCR-ABL 
CT in a background of 20,000 GusB CT and mastermix containing amplification 
primers, duel labeled hybridization probes (FAM for BCR-ABL & AP525 for GusB). 
Following amplification, melting curve analysis characterized the relative native 
template (NT) & CT products from which transcript abundance and BCR-ABL/GusB 
ratio were calculated. BCR-ABL/GusB interday, interlaboratory imprecision and linearity 
were measured using cDNA mixtures of KCL22 (b2a2) or K562 (b3a2) cell lines diluted 
in HL60 (no BCR-ABL) as test samples (100,000, 10,000, 1,000, 100, 10 BCR-ABL 
copies in background of 55,000 GusB copies). LOD was estimated by limiting dilution 
(n=48) of KCL22 or K562 in a background of 20,000 GusB and 1 μg RNA. 23 CML 
patient samples were used to test concordance with the Cepheid BCR-ABL 
measurements. Results: Ten cDNA samples spanning 4 logs of BCR-ABL transcript 
abundance had a median interday total variation of 11% CV (range 4-27%) and a 
median interlaboratory variation of 18% (range 3- 27%). The log measured vs. log 
expected response slope/intercept was 1.01x + 0.02 (R2=1.00). Cell line cDNA diluted 
to one copy per PCR yielded 0.9±0.1 copies by limiting dilution analysis. RNA yield 
from frozen CML cell pellets was 10-fold below optimum (median GusB of 7747, range 
600-18,000 copies, n=22) and would not support <0.1% BCR-ABL/GusB 
measurements; Cepheid concordance (range 0.3 to 30% BCR-ABL/GusB) had a 
slope/intercept of 1.05x + 0.089 (R2=0.995, n=6). Conclusions: SNAQ BCR-ABL MBr 
reagent beta test demonstrated an excellent interday, interlaboratory reproducibility 
sufficient for 2-fold interlaboratory accuracy claims without reliance on external 
reference material. Follow up studies will gauge impact of sample collection & RNA 
isolation. 
 
TT25. Validation and Quality Control Utilizing a One Step qPCR Assay for Pre-
Array Comparative Genomic Hybridization DNA Assessment 
Z. Wang, B.P. Portier, E. Minca, C. Lanigan, R.R. Tubbs 
Cleveland Clinic, Cleveland, OH. 
Introduction: Array based comparative genomic hybridization (aCGH) is a routinely 
utilized technique in constitutional genetic studies. However, this methodology has not 
been fully exploited for use in solid tumor applications. One complication in adapting 
this technology to a solid tumor application, is working with formalin fixed paraffin 
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embedded (FFPE) tissue as starting material. To utilize DNA from FFPE tissue, we 
generated a reproducible method for rapid DNA quality screening that reproducibly 
predicts DNA’s suitability for downstream aCGH. In this study, we detail a simple 
laboratory developed test for single step qPCR based pre-aCGH sample quality control. 
Methods: DNA was extracted from fresh and formalin fixed paraffin embedded 
(Qiagen, Valencia, CA) cell lines and invasive breast carcinomas following macro-
dissection. Utilizing a laboratory developed multiplexed format, allowed utilization of a 
single qPCR assay to determine fragment size of isolated DNA (range 100 to 500bp 
fragments). Following extraction and qPCR, DNA was then applied to a custom 720k 
oligo-array CGH (Roche Nimblegen, Madison, WI) with high probe density (100bp to 
7,500bp in multiple exons of interest). Analysis of aCGH was performed using DEVA 
software suite (Roche-Nimblegen, Madison, WI). Results: qPCR reproducibly showed 
preservation of larger DNA fragments in fresh compared to FFPE cell line DNA (300-
500bp vs. 100-300bp in FFPE). This difference in amplification size did not show a 
significant difference in aCGH quality control metrics or generation of software based 
consensus segment calls. Utilizing DNA isolated from invasive breast carcinomas, 
qPCR showed larger DNA fragments isolated from frozen vs. FFPE samples (100-
500bp vs. 100bp in FFPE). In FFPE samples with at least 100bp amplified signal, 
there was no significant difference in aCGH quality control metrics or generation of 
software based consensus segment calls. However, in FFPE samples with sub-100bp 
amplified fragments, aCGH failed array quality control and software based consensus 
segment calls were irregular and not sufficient for evaluation. Conclusions: In this 
study, we report the utility of a novel multiplexed qPCR assay for pre aCGH DNA 
quality control. This assay is straightforward and can be completed in less than three 
hours. Results from the assay allow pre-selection of cases for aCGH and can serve a 
solitary assay for pre-aCGH specimen selection. In addition to pre-array DNA quality 
control, this assay also provides a cost effective means to screen DNA and can 
eliminate unnecessary sample runs and downstream analysis time.  
 
TT26. A Comparative Study of Methods for Extracting Genomic DNA from FFPE 
Tissue Samples 
C. Gentile, J.P. Segal, V. Van Deerlin, C. Watt 
Hospital of the University of Pennsylvania, Philadelphia, PA. 
Introduction: Purification of genomic DNA from formalin fixed paraffin-embedded 
tissue (FFPE) is a critically important process in the genetic profiling of solid tumors. 
The overall demand for solid tumor testing is increasing, as is the need to evaluate 
small samples, such as fine needle aspirates. These changes are the driving force for 
laboratories to find an extraction method that can produce both high yield and high 
purity genomic DNA whereas maximizing efficiency. Methods: FFPE samples (some 
requiring macrodissection) were split between two Qiagen column based extraction 
methods, QIAamp DNA Blood Mini Kit (Blood kit) and QIAamp DSP DNA FFPE Tissue 
Kit (FFPE kit) using two different deparaffinization methods, Deparaffinization Solution 
(Qiagen) and xylenes (Sigma-Aldrich). Genomic DNA quantity was determined by 
measuring absorbance at 260 nm and statistical analysis was performed using 
GraphPad InStat software (v3.1). Purity was calculated as the ratio of absorbance at 
260 nm and 280 nm wavelengths and samples were tested on a variety of platforms to 
evaluate downstream assay performance. Deparaffinization method comparison 
included evaluation of additional metrics such as cost, ease of use, processing time 
required and reagent hazard classification. Results: Regardless of deparaffinization 
method all macrodissected samples extracted with the FFPE kit had higher yields than 
samples extracted with the Blood kit. More than half of the macrodissected FFPE 
samples processed with Deparaffinization Solution using the FFPE kit resulted in DNA 
with higher yields as compared to DNA from samples processed with xylenes using the 
FFPE kit (p=0.059, n=20). Purity of extracted DNA, as determined by 260/280 ratio, 
was comparable across all extraction methods. No appreciable difference was seen in 
assay performance when comparing column extraction method or deparaffinization 
method. Deparaffinization Solution is more cost-effective, less hazardous, and requires 
less processing time to get FFPE samples to the lysis step as compared to xylenes. 
Conclusions: Although use of the QIAamp DSP DNA FFPE Tissue Kit improved DNA 
yield, it does not appear that assay performance in our laboratory was greatly improved 
through the use of an extraction kit optimized for FFPE tissue samples. It is possible 
that platforms such as next generation sequencing, which have stringent requirements 
for DNA quantity and purity, might benefit from DNA extracted using the FFPE kit. The 
use of Deparaffinization Solution was more beneficial to the laboratory as it decreased 
processing time and increased yield, ensuring that sufficient DNA can be extracted from 
small samples to perform multiple assays. 
 
 
 
 
TT27. Evaluation of the Promega Maxwell 16 for the Extraction of DNA from 
Formalin Fixed Paraffin Embedded Tissue and RNA from Whole Blood 
S.M. Mitchell1, B. Conrad2, D. Anderson2, T.W. Kelley2 
1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 2ARUP 
Laboratories, Salt Lake City, UT. 
Introduction: A diversity of sample types are submitted for molecular oncology testing. 
The most common, formalin fixed paraffin embedded (FFPE) tissues and blood/bone 
marrow, each present unique challenges especially to high volume clinical laboratories. 
Automated nucleic acid extraction methods have made RNA and DNA extraction 
procedures more efficient but tend to yield somewhat inferior results compared to 
manual methods and may still require substantial amounts of ‘hands-on’ time. With 
these issues in mind, we evaluated the Promega Maxwell 16 platform (Promega, 
Madison, WI) for the extraction of DNA from FFPE samples and for the extraction RNA 
from whole blood leukocytes. Methods: Twenty-two FFPE samples were extracted on 
the Maxwell instrument using the FFPE Plus LEV DNA kit, according to standard 
protocol. Samples were evaluated for quantity and purity using spectrophotometry. PCR 
amplification of extracted DNA was evaluated using primers to the housekeeping gene 
IF2. Similarly, RNA from thirty two whole blood samples was isolated using the LEV 
Simply RNA Blood Kit. The volume of whole blood extracted ranged from 600μL to 2.5 
mL. The quantity, purity and RT-PCR performance of RNA extracted by the Maxwell 
system was compared to RNA extracted from the same samples by the Qiagen 
Qiacube system (Qiagen, Valencia, CA). Results: The quantity of DNA extracted from 
the FFPE tissue ranged from 1.9 μg to 48μg. Purity (A260/280 ratio) averaged 1.8. 
Amplification of the IF2 gene was successful in all of the extracted DNA samples. For 
RNA extraction from whole blood leukocytes, the pre-processing time required for 
leukocyte isolation was similar (approximately 60 min for 16 samples for the Maxwell 
and approximately 50 min for 12 samples for the Qiacube). For most samples RNA 
yield was slightly higher using the Maxwell system (Avg Maxwell = 0.9 ng/million cells) 
than with the Qiacube (Avg Qiacube= 0.2 ng/million cells) using the same number of 
leukocytes. Purity (A260/280) was similar (Avg Maxwell = 2.1; avg Qiacube = 2.0). 
Amplification of the reference gene ABL failed in 4 of 32 samples (12.5%) extracted 
using the Maxwell and in 3/32 (9.4%) samples using the QIAcube. Conclusions: DNA 
extracted from FFPE samples and RNA extracted from whole blood leukocytes using 
the Promega Maxwell system provides acceptable quantity and quality for downstream 
PCR assays. 
 
TT28. A Comparison of Indel Detection Software Tools in Targeted Clinical Next 
Generation Sequencing Data 
J. Sehn1, D. Spencer2, R. Mitra2, E. Duncavage2 
1Massachusetts General Hospital, Boston, MA; 2Washington University School of 
Medicine, St. Louis, MO. 
Introduction: Next generation sequencing (NGS) is a useful tool for identifying 
clinically significant somatic mutations in multiple cancer-associated genes. Although 
identification of single nucleotide variants is relatively straightforward, detection of 
insertions/deletions (INDELs) is challenging, with inconsistent results obtained from 
commonly used variant calling packages. Clinically, reliable detection of recurring 
INDELs (eg, FLT3, EGFR, KIT, NPM1) is required for diagnosis and treatment with 
targeted therapeutics. We compared publically available INDEL-calling programs to 
determine their sensitivities and limitations. Methods: DNA was extracted from 5 
HapMap cell lines and enriched using liquid-phase capture probes targeting exons of 27 
genes frequently mutated in cancer, covering approximately 480 kb (WU-CaMP27 
panel). The resulting enriched DNA was sequenced in multiplex using 2x101 bp paired-
end reads. To avoid the possibility of inadequate detection due to low coverage, high-
depth sequencing was performed. Sequence data was aligned to hg19/GRch37 using 
Novoalign. Indels were called using the Genome Analysis Toolkit (GATK), SamTools, 
VarScan, and Pindel, using default parameters. Only INDELs occurring in targeted 
exons (114 kb) were analyzed. INDEL calls were validated by Sanger sequencing. 
Results: Coverage of the targeted region averaged 3714x/case. Pindel called the most 
INDELs, averaging 43 INDELs/case (1.9-bp average INDEL length). SamTools found 
27 INDELs/case (average 3.2-bp length). VarScan called 20 INDELs/case (average 
1.9-bp length). GATK identified 17 INDELs/case (average 2.9-bp length). Most calls 
occurred in areas of low sequence complexity (72% in homopolymer runs). Only an 
average of 2 calls/case occurred in regions without simple multimeric repeats. Overall, 
44% of NGS INDEL calls agreed with Sanger sequencing in both location and actual 
inserted/deleted sequence. VarScan showed the highest accuracy, with 50% of calls 
identifying the correct mutation in the correct location. GATK had an accuracy of 49%; 
SamTools, 45%; Pindel, 38%. An average of 2 calls/case were identified by Sanger 
sequencing but not by NGS callers. An average of 6.6 (15%) NGS calls/case showed 
no INDEL on Sanger sequencing. Conclusions: INDELs can be detected in NGS data 
using publically available software. Compared to Sanger sequencing, NGS INDEL 
detection software shows a high sensitivity, reasonably low false-positive rate (15%), 
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and decreased accuracy. In most cases, NGS calls point to areas of true INDELs as 
identified by Sanger sequencing, though the exact number and location of bases 
mutated is often discrepant. With currently available NGS software packages, detection 
of INDELs in clinical samples requires a combination of variant-calling programs, with 
subsequent confirmation by Sanger sequencing for accuracy. 
 
TT29. Feasibility of Using Microbeads with Holographic Barcodes to Track DNA 
Specimens in the Molecular Pathology Laboratory 
I. Schrijver1, L. Gojenola1, J.D. Merker1, N. O’Grady2, M.H. Dao1, R. Lenta2, J.M. 
Yeakley2 
1Stanford University School of Medicine, Stanford, CA; 2Illumina, Inc., San Diego, CA. 
Introduction: Although rare, errors can occur in all phases of testing (pre-analytical, 
analytical, and post-analytical), with the majority occurring in the pre-analytical phase. 
This emphasizes the importance quality assurance in all phases of testing. Methods: 
We demonstrate the feasibility of using glass microbeads with a holographic barcode 
identifier to track DNA specimens in the molecular pathology laboratory. These beads 
can be added to peripheral blood specimens and are carried through automated DNA 
extraction protocols that use magnetic glass particles. Results: We found that an 
adequate number of microbeads are consistently carried over during genomic DNA 
extraction to allow specimen identification, that the beads do not interfere with the 
performance of several different molecular assays, and that the beads and genomic 
DNA remain stable when stored together under regular storage conditions in the 
molecular pathology laboratory. The beads function as an internal, easily readable 
specimen barcode. This approach may provide an additional approach to identifying 
DNA specimens and reducing errors associated with molecular laboratory testing. 
Conclusions: Incorporation of this microbead system directly into the blood draw tubes 
could be used to immediately barcode the specimen very early in the pre-analytical 
phase of testing. Presently, this approach could be used to recheck the identity of DNA 
specimens that give unexpected results or to check specimens at a set interval as part 
of the laboratory quality assurance program. This would be a novel way to monitor for 
possible specimen mix-ups. The present microbeads are too large to co-elute with DNA 
using column-based extraction methods, and consequently this microbead tracking 
system cannot be used with many DNA and RNA extraction methods. Likewise, the 
relatively large size of the microbeads makes it difficult to consistently transfer a 
sufficient number of beads from the DNA eluate to downstream assay steps due to the 
microliter volumes typically used during molecular testing. As an example, we found 
that addition of DNA from the tube containing the DNA eluate with microbeads to a 
standard PCR reaction did not reliably result in the transfer of a sufficient number of 
beads to be detected by the barcode reader. However, further manipulation of the 
beads or extraction process may allow for these limitations to be overcome and for this 
application to become even more broadly applied. 
 
TT30. Allele Specific Loop Mediated Amplification (AS-LAMP) is More Sensitive 
and Rapid than AS-PCR in Detection of Single Point Mutation  
G. Minnucci1, G. Amicarelli1, E. D'Agostini1, R. Mesturini1, S. Salmoiraghi2, O. Spinelli2, 
F. Bonelli1, F. Colotta1, A. Rambaldi2 
1DiaSorin SpA, Gerenzano, Italy; 2Ospedali Riuniti di Bergamo, Bergamo, Italy. 
Introduction: The single nucleotide substitution is one of the most common DNA 
mutation found in cancer cells. The molecular detection of the point mutation is 
technically challenging since the wild type and mutated sequence are identical except 
for one single base. Allele specific PCR (AS-PCR) is the most used method for 
molecular detection of this genetic alteration and is the gold standard for detection of 
the Guanine to Thymine substitution in position 1849 of the JAK2 gene, marker of 
Myeloproliferative Neoplasms. Methods: we have developed a novel assay, called 
Allele Specific (AS)-LAMP, to maximize the level of selectivity of the standard Loop 
Mediated Amplification reaction first described by Notomi (NAR, 2000). AS-LAMP assay 
consists in a fluorescent non-PCR reaction able to selectively amplify low amount of 
mutated DNA in a single step. The assay amplifies and distinguishes both the JAK2 
G1849T point mutation and the internal control (ABL endogenous gene), being the two 
amplified products characterized by two distinct melting temperatures. Results: The 
performance of the duplex JAK2V617F/ABL AS-LAMP have been established and 
compared with the ones of AS-PCR. AS-LAMP demonstrated 100% specificity on DNA 
from cell lines proved JAK2 wild type by AS-PCR (315 replicates). The level of 
sensitivity, established on serial dilution of mutant JAK2V617F DNA (from UKE-1 cell 
line) into wild type DNA (form B-JAB cell line) was 2% for AS-PCR and reaches 0.05% 
for AS-LAMP. These limits of detection are obtained within 2.5 hours by AS-PCR and 
within 20 minutes by AS-LAMP. On DNA extracted from granulocytes of patients 
affected by PV (n=9), ET (n=12) and IMF (n=2) bearing the JAK2 mutation AS-LAMP 
and AS-PCR demonstrating 100% concordance. Interestingly, 17 DNA positive samples 
extracted directly from whole blood, avoiding the step of granulocytes enrichment, have 
been correctly detected by AS-LAMP, whereas AS-PCR failed. Finally, all the negative 
controls from healthy donors (n=10) and hematologic patients wild type for JAK2 (n=26) 
resulted negative for both AS-PCR and AS-LAMP, that produced an optimal ABL gene 
amplification. Conclusions: The AS-LAMP assay, compared with conventional AS-
PCR, demonstrated comparable specificity and superior sensitivity. The time to result is 
extremely fast thanks to the higher efficiency and the single step format that does not 
require gel-separation. The higher sensitivity allows detecting the G1849T mutation in 
whole blood cells, avoiding granulocytes isolation needed by AS-PCR. For all these 
reasons AS-LAMP is more convenient than AS-PCR for detection of single point 
mutations. 
 
TT31. Comprehensive Evaluation of Cell Stabilizing Blood Collection Tubes 
(Streck BCT) in Real Life Conditions 
D. Wong, R. Mueller, S. Moturi, V. Ankachatchai, D. van den Boom, M. Ehrich 
Sequenom, San Diego, CA. 
Introduction: Fetal mutations and chromosomal abnormalities can be detected non-
invasively by molecular analysis of cell-free circulating DNA derived from maternal 
plasma. Previous small studies have reported that a new blood cell preservation 
collection tube (Streck Cell-free DNA BCT, Streck, Omaha, NE) can be used to enable 
shipment at ambient temperatures and storage for up to 14 days, whereas preventing 
maternal cell degradation. This study is the first comprehensive evaluation to 
investigate the impact of shipping and storage on the integrity of the cellular 
compartment and the stability of the cell-free DNA. Methods: Peripheral blood was 
collected into Streck BCTs to investigate four main aspects of processing conditions. 1) 
Time from blood draw to plasma processing: A spray-coated K2 EDTA tube was used 
as a control to investigate the impact of prolonged storage times on the cell stabilizing 
properties. 2) Storage temperature: After blood collection the tubes were stored at 4 
different temperatures ranging from 4°C to 40°C. 3) Mechanical Stress: Following blood 
collection the tubes were exposed to mechanical stress testing according to ATSM 
standards. 4) Lot-to-Lot comparison: Blood from each donor was collected into tubes 
from three different BCT production lots to investigate the variation between lots. 
Results: Maternal blood stored for 7 days in cell-free DNA BCTs at ambient 
temperature delivers stable levels of fetal and total DNA. The amount of fetal DNA did 
not change with storage temperature; however the total amount of cell-free DNA 
increased in samples stored at 23°C and greater temperatures, indicating some 
maternal cell degradation. Shipping maternal blood in cell-free BCTs, followed by 
mechanical stress of the shipping container, did not result in a significant difference in 
fetal or total copies. No differences were observed between the results obtained from 
the three BCT production lots. Conclusions: Maternal plasma DNA, stabilized for up to 
7 days, in cell-free DNA BCT can be used for noninvasive prenatal molecular 
applications, if excessive temperatures are avoided. In summary, Using the cell-free 
DNA BCT for blood collection is a significant advantage in preventing maternal cell 
degradation over non cell-stabilizing K2 EDTA blood collection tubes.  
 
TT32. Low Level Virus Load Detection Confidence of Abbott Real-Time HIV-1, 
Roche TaqMan HIV-1 and Versant HIV-1 RNA (bDNA) Technologies for 
Quantification of Plasma HIV-1 RNA in HIV-1 Infected Individuals 
M. Toth1, L. Davila1, R. Valiathan1, K. Deeb1, T.P. Young2, G. Cloherty2, M. Fischl1, D. 
Asthana1, H. Bolivar1 
1University of Miami, Miami, FL; 2Abbott Molecular , San Rafael, CA. 
Introduction: Accurate and reproducible viral load is important in effective clinical and 
therapeutic management of HIV-1 infected individuals. Various in-vitro assays are 
available for measurement of HIV-1 RNA levels with sensitivity limits ranging from 40 to 
75 copies/ml. In this study, we compared 3 currently used methods of HIV-1 RNA 
quantitation, Abbott Real-Time HIV-1 assay (v2.0, Abbott), Roche TaqMan HIV-1 (1.0, 
Roche) and Versant HIV-1 RNA bDNA assay (v3.0, Siemens) in parallel from plasma 
specimens of 187 HIV-1 infected individuals to compare systems and assess 
robustness of the assays when low level of virus copies were measured. Methods: 
Whole blood EDTA specimens obtained from 187 HIV-1 infected individuals were used 
for this analysis. These samples were received at the Laboratory for Clinical and 
Biological Studies, University of Miami, FL for plasma HIV-1 RNA as part of an ongoing 
study. Quantitation of plasma HIV-1 RNA was performed in parallel using three 
platforms according to approved quantification protocols provided by the manufacturers. 
All the statistical evaluations were performed using the Prism software (v 5.0). Results: 
Among 187 plasma specimens, HIV-1 RNA levels detected above the manufacturer’s 
detection limit was 153 by Abbott (sensitivity, 82%), 159 by Roche (sensitivity, 85%) 
and 150 by bDNA (sensitivity, 80%). As expected, HIV-1 RNA levels obtained from all 
the three methods positively correlated with each other (Pearson Correlation, 
P<0.0001) indicating specificity of detection between each method. On comparing the 
technologies on one to one basis we observed that HIV-1 RNA levels obtained with 
Abbott and Siemens had higher linear association (r = 0.95) versus Abbott and Roche (r 
= 0.79) or Roche and Siemens (r = 0.85). However, when samples with <100 copies/ml 
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was compared the three methods showed varying levels of detection and the detection 
levels were not correlated each other. Although comparing the 95% confidence level for 
Abbott and Roche assay; it was 44 copies/ml (CI:39.5-48.5 copies/ml) for Abbott and 
52.34 copies/ml and (CI:48.03-56.65 copies/ml) for Roche. Conclusions: Our results 
show that when virus levels are higher three technologies produce concordant results in 
terms of accurate readout. However, when the detection is limited to lower copy 
numbers, each assay varies significantly. These findings might influence the 
interpretation of the outcome of treatment based on virus suppression when a single 
assay is considered for evaluation. Results indicate that lower detection threshold of 
assays might be influenced by factors associated with inherent variability of the assay 
technologies. 
 
TT33. Characterization of K562 Cell Line, Using Cytogenetic, FISH, SNP Array 
and RT-PCR Techniques 
C.A. Curtis1, M. Kochera1, L. Christ1, S. Vahabi1, B. Sundman1, S. Gurusiddappa2, Y. 
Zhao2, X. Lu3, S. Zhang1 
1University Hospitals - Case Medical Center, Cleveland, OH; 2Texas Children's 
Hospital, Houston, TX; 3Baylor College of Medicine, Houston, TX. 
Introduction: The K562 cell line, derived in 1970 from a pleural effusion of a patient 
with chronic myelogenous leukemia (CML) in blast crisis, is widely used as a positive 
and test sensitivity control cell line for the quantitative measurement of BCR/ABL fusion 
transcripts. It has been genetically characterized by multiple researchers, recently by 
Naumann et al (2001) and Rush et al (2002) using cytogenetic, FISH and CGH 
techniques. From a quality control perspective, it is important to understand genetic 
changes occurring during cell-line passage and the implications of using an 
immortalized cell line as a control for quantitative assays. We report on our 
characterization of the K562 cell line using cytogenetics and FISH, SNP array and 
quantitative RT-PCR. Methods: The K562 cell line was purchased from ATCC, 
Manassas, VA. Cytogenetic analyses and metaphase FISH (using commercial and 
RP11 BAC probes) were performed according to standard protocols. SNP array 
analysis utilized Illumina Cyto12 SNP microarray, and the array data was analyzed 
using Genome Studio (Illumina) and Nexus (Biodiscovery), respectively. Quantitative 
BCR-ABL was performed using Ipsogen BCR-ABL FusionQuant kit. Results: 
Cytogenetic analysis revealed a near-triploid cell line with numerical and structural 
abnormalities. There was cell-to-cell variation in both the number of chromosomes and 
the structural abnormalities. Our karyotype was similar to those of Naumann et al 
(2001) and Rush et al (2002) but contained additional changes. The SNP array results 
revealed genome wide copy number aberrations involving almost every chromosome, 
with most chromosomes present in 3 or 4 copies. High level amplifications of 3p14.2, 
9q34.12->q34.13, 13q31.1-13q33.3, and 22q11.1-22q11.22 were identified. There were 
two regions of copy neutral LOH in 3q22.3-qter, 9q22.31-qter. For the level of BCR-ABL 
fusion transcripts, among 57 runs in 2011, the average normalized copy number (NCN, 
BCR-ABL/ABL) was 82.3±16.2%. Conclusions: This work reveals that the K562 cell 
line continues to evolve. The SNP array was generally in agreement with the 
cytogenetic and FISH studies but allowed refinement of breakpoints and the 
identification of specific genes included in the regions of gain and loss. Amplification of 
BCR/ABL rearrangement was identified by FISH and SNP array. However, the 
implication of fusion gene amplification on the quantitative BCR-ABL assay may be 
minimal due to the wide use of ABL or BCR genes as internal controls. This study aims 
to show the utility of comprehensive characterization of control cell lines. 
 
TT34. Development of a Quantitative Assay for the Assessment of T-Cell 
Receptor Excision Circles (TRECs) 
M.C. Schwab, R.A. Zuckerman, M.C. Chobanian, G.J. Tsongalis 
Geisel School of Medicine at Dartmouth, Lebanon, NH. 
Introduction: In the immune compromised patient, recovery of the adaptive immune 
system may take longer than 1 year. This reconstitution may occur by the expansion of 
the peripheral T-cell pool or by thymopoiesis. During differentiation, thymically derived 
T-cells undergo rearrangement of the Įȕ T-cell receptor that excises stable, circular 
fragments of DNA known as the small joint T-cell receptor excision circle (sjTREC). T-
cell proliferation will increase the number of T-cells without increasing the amount of 
sjTREC in the peripheral blood. Quantification of sjTREC in peripheral blood may be 
used as a clinical indication of immune recovery via thymopoiesis. We describe a 
method for reliable quantification of sjTREC in peripheral blood. Methods: A standard 
curve was created using a plasmid containing the human sjTREC sequentially diluted to 
yield standards ranging from 1.0E10 to 10 molecules/5 mL. The standard curve was 
created with 5 replicates of each dilution and precision determined over several days. 
The average Ct for each concentration was plotted against the log of the number of 
sjTREC molecules/reaction. The y-intercept equation for the standard curve was then 
used to calculate sjTREC concentrations in human samples. T-cell populations were 
positively selected from peripheral blood using CD3, CD4 or CD8 magnetically labeled 
beads. Quantitative PCR for sjTREC was run in triplicate on the cell lysates using real-
time PCR. In a second series of CD4 selected T-cells, the lysate was spun and 
separated into a pellet and a supernatant. Quantitative PCR for the sjTREC molecule 
was run in triplicate for three input volumes of each sample fraction. Results: The 
standard curve showed linearity with concentrations ranging from 1.0E10 to 10 
molecules/5 mL and 1.0E9 to 1.0E2 molecules/5 mL yielding coefficients of 
determination of 0.9901 and 0.995, respectively. The y-intercept equation for the “short” 
standard curve was then used to calculate the percentage of sjTREC per T-cells in the 
reaction. In healthy individuals the percentage of sjTREC ranged from 20.7-0.01% over 
a range of ages. In the dilution series of CD4 selected T-cells, the percentage of 
sjTREC ranged from 3.0-0% and 21.0-0% in the cleaned pellet and supernatant 
samples, respectively. Conclusions: The quantification of sjTREC in peripheral blood 
may be a prognostic indicator of adaptive immune recovery. The percentage of 
thymically derived T-cells in peripheral blood can be calculated. The quantification of 
sjTREC in CD8, CD4 and CD3 positive T-cells in healthy individuals correlates with 
published reports of thymic drop off with age.  
 
TT35. Ambient Temperature Stabilization of Nucleic Acids in Human Blood and 
Saliva 
V. Liberal, S. Wilkinson, S. Whitney, S. Ghirmai, A. Stassinopoulos, W. Huang, L. 
Shireen, R. Muller, J. Muller Cohn 
Biomatrica, San Diego, CA. 
Introduction: Biospecimen stabilization during collection and transport is of critical 
importance in the fields of biomedical research and molecular diagnostics. The 
emergence of personalized medicine has placed an even greater emphasis on the 
significance of protecting the quality and reliability of clinical samples. The current 
methods for blood and saliva collection depend heavily on cold-chain logistics and are 
fraught with potential complications to specimen integrity that can result inconsistencies 
in sample analysis. Nucleic acids in biological specimens are threatened by nucleolytic 
attack, oxidative damage and hydrolysis. Such agents can severely disrupt sequencing, 
genotyping and expression profile analyses. Methods: In this report we describe the 
development of chemical stabilization formulations that address the problem of 
sampling induced inconsistencies in human blood and saliva. The formulations 
described preserve nucleic acids in these biospecimens even under extreme 
environmental shipping conditions and remove the need for cold-chain logistics during 
sample collection, transport or storage. Results: Here we show that the genomic DNA 
in blood collected in DNAgard Blood Tubes is stabilized during extreme temperature 
fluctuations ranging from -20°C to +45°C. Samples remain stable for up to 14 months 
at room temperature. The analogous DNA stabilization technology for saliva specimens, 
DNAgard Saliva, preserves sample integrity for over 12 months at ambient temperature. 
We also compare freezer storage with the room temperature stabilization formulation 
RNAgard Blood and other technologies for ambient temperature blood RNA 
stabilization. Conclusions: Our results demonstrate that RNAgard Blood is a valuable 
alternative to cold-storage for preserving RNA expression profiles for over 7 days at 
ambient temperature. 
 
TT36. Comparison of HRMCA and Primer Extension to Detect KRAS Mutations 
C. Chen1, M. Cui2, M. Lee2, J. Malaczynska 2, J. Longtine2, D. Zhang2, F. Ye2 
1Mount Sinai Hospital, New York City, NY; 2Mount Sinai Medical Center, New York City, 
NY. 
Introduction: Detection of KRAS mutations at codons 12/13 in non-small-cell lung and 
colon adenocarcinoma is important in guiding anti-EGFR therapy. The detection of 
these mutations in formalin-fixed, paraffin-embedded tissue (FFPE) and cytology 
samples is technically challenging due to the heterogeneity of the tumor, contamination 
of normal cells, and small sample size. It will be cost-effective to have a complementary 
screening method with high sensitivity and a conformational test with high specificity. 
The goal of this study is to determine the feasibility of using high resolution melting 
curve analysis (HRMCA) for initial mutation screening and Trimgen’s primer 
extension/capillary electrophoresis method for confirmation. Methods: Two cell lines 
(SW620 cells with codon 12 mutations and HCT116 cells with codon 13 mutations) 
were used to determine analytical sensitivity. One hundred ninety FFPE and cytology 
samples from patients with non-small cell lung cancer and colorectal adenocarcinoma 
from 2011-2012 were analyzed using HRMCA. The results were compared those from 
Trimgen’s Mutector II KRAS assay. Results: The assay sensitivity was 2% for both 
cells (codon 12 and 13 mutations) that is compatible with the Trimgen assay. The 
overall sensitivity and specificity for HRMCA were 96.4% and 96.8% respectively, when 
compared to Trimgen. Mutations in KRAS were detected in 46 cases of 
adenocarcinoma (24.1%) by HRMCA and 55 cases (28.8%) by Trimgen. Five types of 
mutations were observed for Codon 12 (38.2% GGT>TGT, 18.2% GGT>GAT, 3.6% 
GGT>GCT, 16.4% GGT>GTT, and 7.3% GGT>AGT) and three types of mutation were 
seen for Codon 13 (9.1% GGC>TGC, 5.5% GGC>GAC, and 1.8% GGC>CGC). 
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Discordance between HRMCA and Trimgen results were found in 10 cases (5.3%). 
There were 2 cases (1.0%) in which HRMCA reported no mutation (WT) whereas 
Trimgen reported to have mutation (MUT), all of which were the GGT>TGT mutation. 
Ten cases (5.2%) did not have sufficient samples (QNS) for both HRMCA and Trimgen. 
Additionally, 7 cases (3.7%) were reported as “unknown” by HRMCA, of which 4 were 
reported as WT by Trimgen and 3 as MUT (1 GGT>TGT, 1 GGT>GAT, and 1 
GGT>GCT). Conclusions: Our results showed that the sensitivity and specificity of 
HRMCA is compatible with Trimgen assay. However, HRMCA is fast and cost-efficient 
and is most suitable for KRAS mutation screening.  
 
TT37. Design and Verification of Cystic Fibrosis Transmembrane Regulator 
Gene Scanning Assays Using High-Resolution DNA Melting Analysis  
L. Jiang, S.O. Sundberg, L. Xu, J. Huuskonen, R.M. Howell 
Canon US Life Sciences, Rockville, MD. 
Introduction: The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) 
gene is highly mutated with over 1900 mutations currently identified, most of which 
occur at frequencies less than 0.1%. Additionally, mutations occur with differing 
prevalence based on race and ethnicity. Exon scanning using high-resolution DNA 
melting analysis (HRMA) of PCR products has previously been shown to capture 
sequence differences rapidly. Methods: We have developed an HRMA assay that 
scans all of the 27 CFTR exons using 42 separate PCR reactions. A set of small 
amplicon genotyping assays was also developed to target the 23 specific mutations 
recommended by the American Congress of Obstetricians and Gynecologists (ACOG). 
The small amplicon assays can be used either to routinely test for the most common 
variants or used reflexively to confirm differences to normal sequence that are detected 
by scanning. To confirm assay design, we designed and produced 207 synthetic 
constructs containing 178 homozygote variants and 29 normal sequences that cover all 
27 exons and 1 intron region. Each of the normal constructs include one exon and 
adjacent intron regions except exon13, which was split into 2 constructs due to its large 
size. The 178 mutations included all of the 23 ACOG recommended mutations and 
other clinically significant CFTR mutations. The homozygote constructs were designed 
by changing the DNA sequence composition with a single mutation for each plasmid 
construct. We challenged the assay design by testing constructed heterozygous 
samples where homozygote construct DNAs were spiked into a normal genomic DNA 
background. Results: We verified CFTR scanning assay on 167 constructed 
heterozygous samples with 100% detection rate. We are investigating the 11 remaining 
construct samples. Additionally we have demonstrated that homozygous variants can 
be detected in a scanning assay in the presence of synthetic DNA with normal 
sequence content. We are currently testing a set of clinical samples to verify the results 
obtained with the synthetic constructs. Conclusions: In summary, we have developed 
robust high-resolution melting scanning assays for the CFTR gene. This assay, 
complemented by the targeted genotyping assays and addition of wild-type construct 
DNA, can rapidly scan the large CFTR gene and reduce sequencing loads to focus on 
clinically relevant changes. The use of synthetic constructs has allowed us to rapidly 
verify the assays despite lack of patient material for rare clinically relevant variants. 
 
TT38. Direct-from-FFPE Molecular Assay that Is Rapid, Simple, and Sensitive 
for Scarce Samples and Correlates Highly with Data from Matching Fresh-Frozen 
Tissue 
C. Kim, A. Gerstner, J.R. Childers, A.R. Jacobs, R. Terbrueggen 
DxTerity Diagnostics, Rancho Dominguez, CA. 
Introduction: Molecular analysis of Formalin-Fixed Paraffin Embedded (FFPE) tissue 
samples is difficult because DNA or RNA extraction from these samples is laborious 
and complicated. Moreover, the current sample preparation methods require large 
amounts of FFPE (up to 10 slices of 20mm x 20 mm x 10 Pm). We have developed a 
multiplex (up to ~100 genes) gene expression assay for FFPE called DxDirect FFPE 
that works directly on FFPE samples and requires only a single 2 mm x 5mm x 5 
microns FFPE slice scraped from a pathology slide. The assay is completed 4 hours, 
and has a simple workflow that requires only 30 minutes of total hands-on time. 
Methods: 3 normal breast tissue FFPE and 3 matching, mirrored FF (fresh, frozen) 
normal breast samples from commercial sources were analyzed for gene expression 
using a 63-gene set assay panel containing probes to genes expressed in breast or 
prostate. 3 normal prostate tissue FFPE and 3 matching, mirrored FF normal prostate 
were analyzed for gene expression using the same 63-gene set assay. The gene 
expression data from FFPE and matching FF were compared. The gene expression 
data from FFPE was also compared to data obtained using Affymetrix Genechip 
microarrays as an independent technology validation. Results: The correlation of gene 
expression data between FFPE and the matching mirrored FF samples ranged between 
0.8 to 0.88. The correlation of the Log FC (prostate/breast) obtained from DxDirect 
FFPE assay to microarray data was 0.8. When gene expression data using the 
DxDirect FFPE assay was compared to gene expression on RNA extracted from the 
same FFPE sample, the correlation was 0.99. Conclusions: DxDirect FFPE Assay is 
fast, simple, sensitive and correlates highly with data from matching Fresh Frozen 
tissue. Sample preparation is not required since the data obtained directly on the FFPE 
sample correlates very highly to the data acquired on RNA extracted from the same 
FFPE sample. The assay can be developed for detection using Luminex, Capillary 
Electrophoresis (Caliper GX or ABI 3500, ABI 3730) or Real-Time PCR instrument. 
 
TT39. Proficiency Testing for Chromosomal Microarray Analysis: Lessons from 
an International Program 
D.E. Barton1, H. Gabriel2, O. Kämäräinen3, S. Patton3, J.R. Vermeesch4, R.J. Hastings5 
1National Centre for Medical Genetics, Dublin, Ireland; 2Diagnos, Osnabrueck, 
Germany; 3EMQN, Manchester, United Kingdom; 4Katholieke Universiteit Leuven, 
Leuven, Belgium; 5Women’s Centre, Oxford University Hospitals NHS Trust, Oxford, 
United Kingdom. 
Introduction: Array-based technologies to determine genomic copy number 
(chromosomal microarray analysis, CMA) have rapidly entered the clinical arena in 
recent years. Programs to assess the quality of such testing are urgently required. The 
Cytogenetics European Quality Assessment scheme (CEQA) and the European 
Molecular Genetics Quality Network (EMQN) provide external quality 
assessment/proficiency testing (EQA/PT) for cytogenetics and molecular genetics 
laboratories in Europe and world-wide. Methods: A joint pilot PT program for CMA was 
successfully completed in 2008/2009 and this was followed by a second pilot in 2010. 
Each program involved the distribution of a single genomic DNA sample to all 
participants along with a mock clinical referral. Participants were asked to report in their 
usual format. Information was gathered at the time of registration on the analysis 
platforms and software used. The purpose of the pilot programs was to determine the 
feasibility of establishing a routine PT program for CMA. A full open program was run in 
2011. Results: Thirty labs participated in the first program in 2009. All participants were 
sent genomic DNA from a patient with a 1.7Mb subtelomeric deletion at 20p and a 
9.1Mb interstitial duplication at 18p11.32p11.22. All major array platforms and software 
packages were represented. In the 2009 program 23% of participants made significant 
genotyping errors. 83% of participants failed to provide an adequate interpretation. In 
summary, only 3 participants (10%) fulfilled all required criteria. In the 2010 program, 
only 1 participant failed to detect a 1.3Mb interstitial deletion of 4p16.3. Three 
participants detected second abnormalities, giving 4 genotyping errors in 54 returns 
(7%). All labs provided a satisfactory clinical interpretation. Thus, 50/54 (93%) of 
participants fulfilled the required criteria. The open 2011 program presented a sample 
from a normal individual. 7 of 90 (7%) participants made errors, the most common error 
being over-interpretation of a benign variant. Conclusions: We present an account of 
early rounds of PT for a complex new diagnostic technology. These pilot studies have 
established that it is feasible to run a large-scale international EQA program for CMA 
that is independent of the analysis platform used. It is striking to observe that all errors 
in years 2 and 3 were made by new entrants to the program. This preliminary evidence 
indicates that regular participation in PT helps to improve performance. This is likely to 
be especially true for new and complex technologies. 
 
TT40. Comparison of EGFR L858R and EGFR E746-A750 Del Mutation-Specific 
Immunohistochemistry to EGFR Exon 19 and 21 Mutational Analysis by PCR in 
Primary and Metastatic Lung Adenocarcinomas 
D. Chabot-Richards1, K. Buehler2, M.A. Vasef3 
1University of New Mexico, Albuquerque, NM; 2TriCore Ref Laboratories, Albuquerque, 
NM; 3University of New Mexico Health Science, Albuquerque, NM. 
Introduction: Activating mutations in the epidermal growth factor receptor (EGFR) 
gene leading to tumor growth and progression are well described in non-small cell lung 
carcinoma. The most common mutations are exon 19 deletions and L858R mutation in 
exon 21. These can be heterogeneously distributed within a tumor. Identification of 
these mutations is clinically significant due to their susceptibility to treatment with EGFR 
tyrosine kinase inhibitors. Testing is typically done via PCR amplification and melting 
curve analysis and/or sequencing. Recently developed mutation specific 
immunohistochemical stains for L858R and E746-A750 may offer a fast, cost effective 
alternative to molecular testing and allow for morphologic correlation. Methods: Our 
database was searched for cases with positive molecular testing for EGFR exon 19 
deletions or exon 21 L858R mutations, as well as cases negative for both mutations for 
controls. The cases included 15 with exon 19 deletions, 5 with exon 21 L858R mutation, 
and 11 cases negative for both exon 19 and 21 mutations. Paraffin 
immunohistochemical stains were performed using EGFR, EGFR-E746-A750 del, and 
EGFR-L585R antibodies (Ventana). The immunohistochemical stains were blindly 
reviewed by two pathologists and scored for intensity in staining (0 to 4+) in positive 
cases. Results: Five out of 15 cases (33%) with exon 19 deletions by PCR were 
positive with EGFR-E746-A750 del specific antibody with cytoplasmic and membrane 
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patterns. The staining intensity was variable, ranging from 1+ to 4+ with some cases 
showing negative areas. 4 out of 5 (80%) cases with exon 21 L858R mutations by PCR 
were positive with the EGFR-L585R specific antibody with intensity ranging from 1+ to 
4+. One out of 11 (1%) cases with negative exons 19 and 21 mutations by PCR 
showed bright (3 to 4+) cytoplasmic and membranous staining with the EGFR-E746-
A750 del specific antibody in a subset of neoplastic cells. 28 out of 29 cases with 
available tissue for EGFR immunostaining were positive indicating no correlation 
between this immunostain and the mutational status. Conclusions: Although the 
EGFR-E746-A750 del specific antibody shows good specificity, the low sensitivity of 
33% is insufficient for use in the clinical setting at this time. Interestingly, the single 
positive case by immunohistochemistry but negative by molecular testing showed focal 
positive staining in only a subset of tumor cells that could have fallen below the 5% 
sensitivity of the molecular assay. This finding suggests that immunohistochemistry 
may be useful in identifying minor subsets of tumor cells carrying the mutation. 
 
TT41. The Assay Design Suite: A Versatile Tool to Develop Panels for High 
Throughput Mutation Profiling Using MALDI-TOF Mass Spectrometry 
A. Nakorchevsky, M. Swaisgood, Y. Chen, D. van den Boom, M. Ehrich, A.O. Nygren 
Sequenom Inc., San Diego, CA. 
Introduction: In the genomic era cancer research has made great strides in dissecting 
the molecular basis of heterologous tumors where multiple mutations contribute to 
create a number of genetic subtypes. To obtain an accurate molecular classification 
that may impact therapy selection of large sample sets, a flexible solution is required 
that can rapidly include newly discovered mutations as well as accurately detect small 
amounts of mutated DNA. Therefore, research groups and laboratories require 
customized panels that contain specific genes or mutations to validate new genomic 
findings over many samples in high-throughput fashion. MALDI-TOF mass 
spectrometry is a widely used tool for high-throughput analysis of genetic lesions. 
Individual assays are designed to interrogate different genomic regions simultaneously, 
enabling high sample throughput, rapid turnaround times and reduced sample 
consumption. Multiplexed assay design poses significant challenges: proximal SNPs, 
hairpin and primer dimer formation must be considered. Additionally, for somatic 
mutation detection assay design is further complicated because many mutations appear 
in close proximity and often involve overlapping regions. Methods: We have 
implemented a new version of the Assay Design Suite (ADS) software, for rapid and 
user-friendly design of somatic mutation detection assays. The ADS streamlines all 
design steps in one package that combines importing, retrieving and formatting 
sequences, finding proximal SNPs, identifying optimal areas for PCR primers, and 
assay multiplexing. We demonstrate the functionality of the ADS on a set of 26 known 
oncogenes and tumor-suppressor genes by designing a somatic mutation panel for 
confirmation of 279 mutations in non-small cell lung cancer. Results: For the 26 input 
genes we have successfully designed 266 assays that cover 247 somatic mutations 
with the overall design success rate of 89% (see methods). Subsequently, we present 
the “wet lab” validation of the panel using human DNA and NCI60 cancer cell line 
samples where we achieved an overall success rate from design to the functional assay 
of 96%. Conclusions: We present the ADS-based methodology and principles of 
assay design for somatic mutation detection. We propose a unified rational approach to 
designing targeted assays for overlapping and co-localized somatic mutations. We also 
describe performance of the designed panel in terms of the individual assay quality and 
highlight the exceptional high-throughput and sensitivity of the MALDI-TOF mass 
spectrometry for somatic mutation detection. 
 
TT42. Does Formalin-Fixation and Paraffin-Embedding Affect Genotyping by 
Next Generation Sequencing?  
N.G. Reddy, R. Singh, K.P. Patel, F. Grant, H. Rahimi, M.A. Harmon, B. Handal, B.A. 
Barkoh, M. Routbort, K.D. Aldape, J.L. Medeiros, R. Luthra 
The University of Texas M.D. Anderson Cancer Center, Houston, TX. 
Introduction: Formalin-fixed, paraffin-embedded (FFPE) represents the majority of the 
specimen type for solid tumors. Next Generation Sequencing (NGS) technology has 
showed potential for multi-gene mutational profiling from archival FFPE tissue 
specimens; however, effect of potential artifacts resulting from formalin fixation on 
genotyping using NGS has not been studied extensively. Here, we investigated the 
effect of FFPE on a MiSeq NGS platform (Ilumina, San Diego, CA) using a paired fresh 
and FFPE cell pellets of 5 cancer cell lines. Methods: DNA from fresh and FFPE cell 
pellets from five cancer cell lines (H2122, H69, HEL, OCI-AML3 and HL60) carrying a 
total of 11 mutations were extracted and quantitated using the Qubit fluorometer (Life 
technologies Inc, San Francisco, CA). Library preparation and multiplexing of the 
samples was performed from 250 ng DNA using a 48-gene TruSeq Amplicon-Cancer 
Panel (Illumina). The amplicons were subjected to paired-end sequencing (2 x150 bp) 
on MiSeq. Variant calling was performed by MiSeq Reporter software (Illumina). 
Sensitivity of the assay for mutation detection for FFPE and fresh DNA was established 
using sequential dilution of HL60 DNA in HEL DNA. Results: The sequencing efficiency 
of the FFPE DNA samples was highly comparable to the fresh DNA samples for the five 
cell lines tested. Average AQ30 reads (error rate of 0.1%) for FFPE and fresh samples 
were 358843 (range: 305121-401837, median: 361739) and 356095 (range: 289220 - 
417399, median: 336964), respectively. All 11 known mutations, ie, TP53, p.C176F, 
STK11, p.P281fs*6, KRAS, p.G12C (H2122), RB1, p.E748*, PIK3CA, p.G106_R108del, 
TP53, p.E171* (H69), TP53, p.M133K, JAK2, p.V617F (HEL), NPM1, p288_ins4 (OCI-
AML3), NRAS, p.Q61L and PDGFRA, p.V824V (HL60) were detected in both fresh and 
FFPE cell line DNA. Presence of these mutations was confirmed by an independent 
method. Importantly, no erroneous mutations were detected in FFPE samples. 
Sensitivity studies using serial dilution of HL60 DNA in HEL DNA exhibited comparable 
lower limit of detection of 5% heterozygous mutation in the background of wild type for 
both fresh and FFPE samples. Conclusions: Data from this pilot study suggests that 
MiSeq NGS can be successfully applied for mutational profiling of DNA from FFPE 
tissue. Matched analysis of fresh and FFPE cell line pellets show results with 
comparable quality scores and without detection of any artifactual mutations in FFPE 
tissue by NGS.  
 
TT43. Analytical Validation of Ion Amplicon Seq Cancer Panel 2.0 
W. Liu, Z. Yan, P. Fang, A. Darwanto, S. Wong, C. Galderisi, J. Li 
MolecularMD Corp., Portland, OR. 
Introduction: The Ion AmpliSeq Cancer Panel 2.0 designed for Ion Torrent PGM 
allows for targeted sequencing of 46 cancer-related genes. Since it is impractical to 
validate the panel with all 793 hotspot mutations, here we select clinically actionable 
mutations to cover all mutation classes including single base substitutions and 1-30bp 
indels. We perform validation studies using DNA from wild type cell lines (NA12878 and 
NA19240) that have been fully sequenced via multiple NextGen platforms. In addition, 
we compare three data analysis methodologies. Methods: DNA from cancer cell lines 
harboring representative mutations is serially diluted into NA12878 to determine 
analytical sensitivity. Specificity is validated with sequencing of NA12878 and NA19240. 
Forty FFPE tumor samples are analyzed with PGM and validated with alternative 
methodologies (NGS/Sanger sequencing/AS-PCR/Sequenom genotyping panel). Data 
analysis is performed with BWA-GATK, NextGene and Torrent Suite 2.2. Results: Our 
initial validation demonstrates that average coverage ranges from 1300-3500X (10 of 
12 >2000X) in a run of one library per 314 chip or 4 libraries per 316 chip, and greater 
than 95% of nt in ROI are covered at more than 0.2x mean coverage. In contrast to the 
commonly-observed GC bias in many target capture methods, there is no clear bias 
observed with the Ion AmpliSeq approach. Among the mutations tested, single base 
substitutions KRAS G12S, BRAF V600E, and EGFR L858R and importantly, the 15bp 
deletion EGFR E746_A750del, are reproducibly reported with analytical sensitivities of 
4-5% mutant allele. EGFR T790M is a challenging spot for the variant caller, possibly 
due to its proximity to the end of ROI (1bp away). No false positives in the hotspot 
regions are observed; false positives are observed outside of the hotspot regions, 
usually near the end of the amplicon and with strand bias. In addition to expected errors 
in homopolymer regions, we find that target enrichment, alignment, and variant calling 
are impeded by pseudogenes or high homology regions, eg, PIK3CA exon 14 versus a 
pseudogene on chr22, PTEN versus PTENP1, and CDKN2A versus CDKN2B. 
Preliminary data indicate that Torrent Suite 2.2 is the superior analysis method. 
Conclusions: Our study demonstrates that the Ion AmpliSeq Cancer Panel 2.0 allows 
for high-throughput and sensitive detection of hotspot mutations. Since this is still early 
in the deployment of the technique, independent confirmation tests, especially for the 
challenging positions including EGFR T790M, are still needed. The design of the Panel 
should also be refined to avoid interference from pseudogenes. 
 
TT44. A Simple Assay for DNA Polymerase Activity 
J.L. Montgomery, N. Rejali, C. Wittwer 
University of Utah, Salt Lake City, UT. 
Introduction: DNA polymerase activity is expressed in terms of Units. Activity assays 
measure the incorporation of dNTPs into acid-precipatable material within a given time 
period. This does not have direct relevance to the kinetics of PCR. In addition, assay 
variables such as time, temperature and molar quantity of dNTPs are not standardized, 
making a comparison of enzymes difficult. A simple assay has been developed to 
define the activity of DNA polymerase in terms relevant to PCR. Methods: An assay 
has been developed for DNA polymerase extension rates in units of nucleotides per 
molecule of polymerase per second (nt/s). Extension rates were measured at 72°C and 
monitored with EvaGreen. The data was normalized so that the magnitude of the signal 
corresponded to the total number of extended nucleotides per molecule of polymerase. 
The initial slope of the data then corresponds to the extension rate in units of 
nucleotides per molecule of polymerase per second. This has been demonstrated on a 
stopped flow instrument as well as with a benchtop fluorimeter to demonstrate general 
laboratory utility. This assay has been applied to eight commercial polymerases: 
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FastStart (Roche), Amplitaq Gold (Applied Biosystems), Standard Taq (New England 
Biolabs), GoTaq (Promega), Platinum Taq (Invitrogen), KOD (Novagen), Kapa2G (Kapa 
Biosystems), and Klentaq (Ab Peptides). Polymerases were initially quantified and rates 
were determined at equimolar concentrations to gain a direct comparison of enzyme 
activity. Results: Extension rates ranged from 6 nt/s (KOD) to 141 nt/s with an average 
of 54 nt/s. Increasing the template concentration extends reaction time and allowed 
measurements to be performed with a benchtop fluorimeter. Conclusions: The activity 
of commercial polymerases vary widely. This assay will aid in the selection of the 
appropriate enzyme for a given application. Calculating activity in units of nt/s allows 
measurements to be applied directly to PCR.  
 
TT45. An Optimized Workflow Integrating High-Throughput DNA Extraction 
from FFPE Samples and Whole Genome Sequencing 
T. Guettouche, J. Rantus, D. Hedges, K. Slosek, L. Navarro, Y. Pasco, R. Tursi, E. 
Lalanne, N. Leyva, I. Konidari, A. Andersen, A. Diaz, R. Gentry, W. Hulme, M. Pericak-
Vance, J. Gilbert 
University of Miami, School of Medicine, Miami, FL. 
Introduction: Millions of formalin-fixed, paraffin embedded samples (FFPEs) are stored 
in Biorepositories around the world. These samples contain a vast compendium of 
phenotypic, histological and pathological data. However, nucleic acid extraction of 
FFPEs can be challenging as the quantity of the extracted material is often limited and 
the quality usually poor. DNA extractions from FFPE samples are commonly performed 
manually and involve laborious protocols that are not amenable to high throughput 
processing. There are also no standard quality control methods for downstream 
applications such as second generation sequencing. Furthermore protocols for whole 
genome sequencing are usually not optimized for FFPEs, require large amounts of 
starting material and yield poor sequencing results. Methods: In this study, we present 
an optimized workflow for whole genome sequencing of FFPEs. Using FFPEs created 
from breast cancer cell lines we set out to improve three important steps of a FFPEs 
whole genome sequencing workflow: 1) extraction of high molecular weight DNA from 
FFPEs; 2) quality control to screen out samples that will likely fail downstream 
analyses; 3) improvement of second generation sequencing library preparation to allow 
whole genome sequencing of FFPEs with low input amounts (<100ng) without 
amplification methods other than the PCR steps included in library creation. Results: 
We successfully extracted high molecular weight DNA without significant fragmentation 
from FFPE samples. The quality control methods used were able to discriminate FFPEs 
with poor quality that will likely fail downstream analysis. The optimized shearing and 
sequencing library preparation protocol produced significantly more ligated fragments 
and more final product for second generation sequencing allowing the use of 
significantly less starting material than is commonly recommended in whole genome 
sequencing protocols. Conclusions: Our integrated optimized workflow should 
significantly simplify utilization of FFPE samples for downstream genomic analyses, 
improve second generation sequencing results and as a consequence unlock a largely 
untapped source of information.  
 
TT46. Validation of an Oligonucleotide-Based Chromosomal Microarray Assay 
for the Detection of Genomic Copy Number Variations  
G. Murugesan, K.M. McDonnell, R.R. Tubbs, M. Natowicz, T.M. Daly 
Cleveland Clinic, Cleveland, OH. 
Introduction: Oligonucleotide-based chromosomal microarrays have enabled whole 
genome analysis at a resolution of ~100 kb. We validated a NimbleGen microarray 
system for copy number variations (CNVs) and illustrate the strengths, limitations and 
challenges related to the use of this powerful diagnostic method. Methods: Validation 
of the microarray system with CGX 3-plex array format and pooled reference DNA 
included the following metrics: diagnostic accuracy, method comparison, intra- and 
inter-assay precision, sensitivity to detect mosaicism, limit of detection, methods of DNA 
extraction, and effects of dye-swap and gender-matched single individual versus pooled 
reference DNA. Results: For eleven specimens tested for accuracy, the assay correctly 
identified known cytogenetic abnormalities involving whole chromosomes, 
isochromosomes, interstitial duplications and deletions (100%). Method comparison 
with a reference laboratory that used a CGX 12-plex array format and gender-matched 
single reference DNA revealed 100% concordant results for identifying six clinically 
relevant CNVs and 75% (61/81) concordance for all CNVs in twenty-nine specimens 
analyzed. The discordant 25% (20 CNVs), mostly weak log2ratio copy losses, were 
identified only at the reference laboratory whereas 15 CNVs, mostly weak log2ratio 
copy gains, were identified with our assay. The discordant CNVs were largely smaller 
(<100kb) and flagged by fewer than 10 probes. This variability was likely related to 
differences in the reference DNA used, DNA extraction methods, array format and DNA 
labeling and hybridization efficiencies. The sensitivity of the NimbleGen assay to detect 
mosaicism was ~30% with Genoglyphix default settings and ~20% by visual 
examination of whole genome plot or individual chromosome plots. The precision of the 
assay determined as the coefficient of variation of log2ratio ranged from 0.4-7% for five 
specific CNVs evaluated in seven replicates. Manually extracted DNA yielded data with 
improved signal and reduced noise level compared to DNA from automated extraction. 
Use of 500 ng DNA and labeling test DNA with Cy3 and reference DNA with Cy5 
yielded consistent results. Conclusions: Our data indicate excellent diagnostic 
sensitivity for whole chromosome aneuploidy and clinically relevant CNVs. The analytic 
sensitivity and intra- and inter-assay precision are within accepted norms. The method 
is sensitive to differences in the quality of genomic DNA applied. Inter-laboratory 
standardization is desirable to limit the differences attributable to microarray platforms. 
 
TT47. Advanced Microdissection Technologies with Potential Clinical 
Applications 
M.A. Tangrea1, J.D. Hipp2, M.D. Armani1, J.C. Hanson1, J. Rodriguez-Canales1, A.R. 
Blackler1, S. Roy Chowdhuri3, L. Xi1, M. Raffeld1, N. O'Flaherty1, S.P. Markey4, A.C. 
Filie1, J. Cheng2, N.Y. Morgan5, T.J. Pohida6, R.F. Bonner7, U. Balis2, M.R. Emmert-
Buck1 
1National Cancer Institute, Bethesda, MD; 2University of Michigan, Ann Arbor, MI; 
3Memorial Sloan-Kettering Cancer Center, New York, NY; 4National Institute of Mental 
Health, Bethesda, MD; 5National Institute of Biomedical Imaging and Bioengineering, 
Bethesda, MD; 6National Institutes of Health, Bethesda, MD; 7National Institute of Child 
Health and Human Development, Bethesda, MD. 
Introduction: Since the mid-1990s, laser microdissection has evolved into a powerful 
technology for the isolation of specific cell populations from heterogeneous tissue 
sections. Today’s commercial devices allow for precise procurement of targets; 
however, they still require a pathologist or trained investigator to perform the dissection, 
which may be time consuming especially in large scale studies. To mitigate this 
difficulty our group has worked on developing two novel technologies; Expression 
Microdissection (xMD) and Spatially Invariant Vector Quantization-Laser Capture 
Microdissection (SIVQ-LCM). These technologies facilitate semi-automated 
microdissection with minimal input by the user. xMD is a rapid immuno-based 
dissection method in which an optically absorbing stain is used in conjunction with 
immunohistochemistry (IHC) to guide cell procurement. SIVQ-LCM relies on a pattern 
recognition algorithm to detect and dissect histological features of interest. Methods: 
xMD and SIVQ-LCM were used to dissect target cells from a wide variety of frozen and 
fixed/embedded tissues and cell blocks from three sources (mouse, rat, human) and six 
organs (prostate, brain, kidney, breast, lung, esophagus). Results: Cells (epithelium, 
endothelium, stroma) and subcellular targets (nuclei) were successfully isolated with 
xMD and SIVQ-LCM. A variety of molecular downstream analyses were then 
completed, including DNA methylation studies, KRAS and EGFR gene mutational tests, 
cDNA microarrays, and proteomic mass spectrometry analysis. Conclusions: The 
microdissection field is continuing to evolve toward user-independent methodologies 
that complement established instrumentation. xMD and SIVQ-LCM are steps in that 
direction. Future efforts will be geared toward assessing the potential of these 
developing microdissection technologies for improving molecular diagnostics in the 
clinical workflow. 
 
TT48. Heterozygote PCR Product Melting Curve Prediction 
Z.L. Dwight1, R. Palais2, C.T. Wittwer1 
1University of Utah, Salt Lake City, UT; 2Utah Valley University, Orem, UT. 
Introduction: Melting curve prediction of PCR products has been previously limited to 
perfectly complementary strands. Multiple domain melting curves are predicted using 
recursive nearest-neighbor thermodynamic calculations. A heterozygote product, 
however, is the composite of four PCR products: the two matched homoduplex 
products and the two mismatched heteroduplex products. Our goal was to weight the 
contribution of heteroduplex melting curves of different SNP types to minimize the 
difference between composite predicted and experimental heterozygous melting 
curves. Prediction of PCR products is useful in validation of molecular diagnostic 
assays, primer design, and to study the effects of reaction conditions on both melting 
curve shape and melting temperature. Methods: PCR product contribution parameters 
were derived from brute force in silico computations of 52 forensic SNPs with a 
modified version of uMelt software (http://www.dna.utah.edu/umelt/umelt.html). The in 
silico predictions were quantitatively compared to experimental curves using the area 
between the two curves. Minimizing the area by incrementing the contribution of 
heteroduplex products to the heterozygous product determined the ‘best fit’. The 
average heteroduplex contributions were determined for each variation type: (A/G), 
(G/C), (C/A), (A/T), (T/G), (C/T). Results: By minimizing the error between 
experimental data and thermodynamic predictions, a set of variation specific 
parameters was identified, revealing heteroduplex predictions and contribution to the 
final composite heterozygote melting curve. Contribution to the final composite product 
for a heterozygote was on average 72.6% (+/- 5.7) homoduplex and 27.4% (+/- 5.7) 
heteroduplex. Further analysis revealed the highest total heteroduplex contribution was 
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seen with A/T SNPs (35%) followed by A/C (31%), G/T (30%), G/A (27%), C/T (25%), 
and C/G (19%), though statistical significance was only found between A/T and C/T 
(p=0.036) and A/T and C/G (p=0.044) using an unpaired t-test. A strong trend was also 
observed between A/T and A/G (p=0.10). Conclusions: Accounting for the contribution 
of heteroduplex products better matches the shape of experimental melting curves that 
result from the amplification of heterozygotes. The homoduplex contribution is 
approximately 3 times the heteroduplex contribution for the composite experimental 
melting curve. Factors other than SNP type such as sequence content and PCR 
conditions may contribute to variation in the heteroduplex contribution. The prediction 
model is freely available in software form, uMelt HETS (http://www.dna.utah.edu/hets). 
 
TT49. Web Software for Design of Snapback Genotyping Assays 
A.A. Barnes, Z.L. Dwight, A. Millington, C. Wittwer 
Wittwer Lab for DNA Analysis, Salt Lake City, UT. 
Introduction: Snapback primer genotyping is a simple method that requires only 2 
primers in a closed-tube system. One primer includes a 5’-tail that is complementary to 
its extension product. After asymmetric amplification, both hairpin melting at lower 
temperatures and full-length amplicon melting at higher temperatures are observed. 
The melting curves of the hairpins are sensitive to sequence variations and allow 
genotyping by Tm differences. However, hairpin thermodynamics are unique and 
designing snapback primers can be confusing. Methods: A list of potential hairpin 
stems surrounding the variant are first cataloged. Starting with the position of the 
variant to be genotyped, the design algorithm adds single bases to alternate ends, 
keeping the variant central to the stem. Valid hairpin loops must be mismatched at the 
first internal pair of bases. Furthermore, two hairpin structures are produced after 
asymmetric amplification for snapback genotyping. The major product has an annealed 
5’-end and provides the melting signal for genotyping. To prevent the minor product 
(with an annealed 3’-end) from extending and inhibiting PCR, a mismatched base is 
added as a cap to the primer extension that satisfies the following conditions: 1) neither 
mismatched base in the minor product is a T, and 2) mismatched pairs in the minor 
product are either C:C, A:G or G:A. A single base mismatch is adequate to prevent 
extension if the above rules are followed. If the probe element (the 5’-extension of the 
snapback primer) passes all conditions, the calculated Tm is stored with its sequence in 
a data table. Results: The user inputs an existing single-stranded amplicon, a target 
snapback Tm and the position and identity of the single nucleotide variation. The 
program selects the primer closest to the variation as the snapback primer, and builds 
its 5'-extension so that it hybridizes around the known variant. Mismatched bases are 
added to prevent extension from the 3’-end of the minor product. The hairpin structure 
closest in Tm to the user’s target is displayed along with the sequence of the snapback 
primer. Graphics highlight the required mismatches at the first internal pair of loop 
bases of the major product, along with the complementary structure of the minor 
product and the mismatched bases at its 3’-end. Conclusions: We introduce web-
accessible and user-friendly software that provides rapid design of snapback 
genotyping primers for existing amplicons that bracket known variants. The design tool 
is freely available in software form, uSnapback 
(http://www.dna.utah.edu/usb/snap.php). 
 
TT50. Clinical Sanger Sequencing Made Efficient by Aide of Automated Liquid 
Handling and Laboratory Developed Software 
M. Dina, L.M. Holtegaard, D. Van Cuyk, M. Ferber 
Mayo Clinic, Rochester, MN. 
Introduction: With ever expanding clinical test catalogues and growing demands for 
DNA sequencing comes the opportunity to develop efficient sample processing 
methodologies. Laboratory developed software and use of robotic liquid handlers are 
two key components in efficient sample processing. Reagent standardization allows for 
processing samples in batches, further aiding efficient processing practices. The 
combination of these practices is central in creating a process with minimal wasted 
space in an easy to manage workflow. Methods: After DNA extraction, customized 
laboratory developed software applications can help facilitate an automated PCR 
workflow. The Universal Primer Sequencing Process Manager (UPSPM) software 
application generates paperwork, liquid handler files for the JANUS (Perkin-Elmer, 
Waltham, MA) robotic workstation, and data tracking forms from detailed user input. 
Barcoded sample positioning and ordered service selection are key components within 
the UPSPM. Assay specific definitions for each ordered service are programmed into 
the UPSPM providing a centralized location to build batched sample runs. A custom 
report is generated in Mutation Surveyor (SoftGenetics, State College, PA), and used to 
populate results for each patient in the Sequencing Result Compiler (SRC). Sequence 
that does not meet lab derived quality standards is flagged in the SRC and rework 
specifics are exported to a centralized network location. The rework details can then be 
accessed via the UPSPM for follow-up processing. Results: The use of automated 
liquid handlers efficiently utilizes plate real estate, saves processing time during post-
PCR clean up, and provides consistent inter and intra run quality control. The UPSPM 
facilitates process workflow by generating liquid handler files for automated PCR setup, 
plate maps for sequencing plate submissions, and reagent mix worksheets for accurate 
master mix generation. The UPSPM also provides a central location for rework sample 
information and allows for easy tracking and batched processing of samples requiring 
additional analysis. The SRC makes management of clinical runs easy to organize, 
allows for clear display of alterations identified, and seamlessly queues samples not 
meeting quality standards into a repeat list that is accessed by the UPSPM and added 
to batched runs. Conclusions: Many factors come into play when creating an efficient 
sample processing system in the clinical laboratory. Robotics and laboratory developed 
software can be leveraged in creating such systems. To accommodate increasing 
sample volumes, tools that allow for data management and minimal laboratory waste 
are invaluable. 
 
TT51. Pyrosequencing Improved by Nested PCR for KRAS Detection in Routine 
Practice  
M.P. Macedo, B.C. Lisboa, F.M. Melo, L.d. Andrade, F.A. Soares, I.W. Cunha, D.M. 
Carraro 
A.C.Camargo Hospital, Sao Paulo, Brazil. 
Introduction: Kras mutation testing is mandatory before treatment with EGFR inhibitors 
in colorectal cancer (CRC) patients. Pyrosequencing is one of the best techniques 
available due to its high sensibility and possibility of mutated allele quantification. DNA 
amplification from paraffin embedded (FFPE) tissue results in good quality DNA when 
all the histological pre-analytical processing has been controlled. In cases not properly 
processed, DNA results can be poor with low amplicon quality using conventional PCR 
and low peak pyrosequencing results. We designed a forward and reverse primer to be 
used in a nested PCR method to minimize this problem before making the 
pyrosequencing and tested it in a series of 421 CRC. Methods: DNA (30-150ng) 
obtained from FFPE tissue was first amplified by PCR using two primers designed by 
our laboratory based on the human genome bank, creating an amplicon with 250 base 
pairs of size. The PCR reactions contained 0.4 μM of each primer, 0.2 mM of each 
dNTPs, 1.5 mM of MgSO4 and 0.5 U Platinum Taq DNA Polymerase High Fidelity 
(Invitrogen) in a final reaction volume of 20 μl. The nested PCR was performed with 5 
μl of amplicon from the pre-amplification PCR, 1,5 μl of forward and reverse biotinilated 
primers (KRAS PyroMarkTM Q96 V2.0 kit Qiagen) for the regions containing codons 12 
and 13, and 25μl of Hot StartTaq Master Mix (Qiagen) in a total volume of 50 μl. PCR 
cycling conditions were 95° for 15 mim, 38 cycles of (95° for 20 seconds, 53° for 30 
sec, 72° for 20 seconds) and 72° for 5 min. The pyrosequencing reaction was 
performed according to manufacturer’s instructions. 30ul of biotinylated PCR product 
was attached to streptavidin-sepharose bead (GE Healthcare) according to a standard 
protocol for single strand preparation. PyrosequencingTM was performed using 
PyroMarkTM Gold Q96 reagent kit (Qiagen). A cut off of 10% of mtated cell was used to 
consider a case as mutated. Results: Mutation was observed in 33% of the cases. 
Codon 12 was mutated in 76% and codon 13 in 24%. The most common nucleotide 
substitution in codon 12 was GAT>GGT (61%), followed by GTT>GGT (33%). All 
mutations in codon 13 were GAC>GGC. No inconclusive results were achieved using 
this method. Conclusions: The data show concordance with the literature regarding 
the frequency of Kras mutation, its distribution between codons 12 and 13 and type of 
nucleotide substitution. It corroborates the reproducibility of the findings using the 
nested PCR. 
TT52. A Simple Method for Improving the Limit of Detection for Capillary 
Electrophoresis DNA Sequencing – A Comparison of Methodologies for KRAS
Variant Detection 
C. Davidson1, E. Zeringer1, K. Champion2, M. Gauthier3, F. Wang3, J. 
Boonyaratanakornkit1, J.R. Jones2, E. Schreiber1 
1Life Technologies, Foster City, CA; 2Greenwood Genetic Center, Greenwood, SC; 
3Applied Biosystems, Foster City, CA. 
Introduction: Fluorescent dye terminator Sanger sequencing (FTSS), with detection by 
automated capillary electrophoresis (CE), has long been regarded as the gold standard 
for variant detection. However, software analysis and base-calling algorithms used to 
detect mutations were largely optimized for resequencing applications in which different 
alleles were expected at heterozygous mixtures of 50%. Increasingly, the requirements 
for variant detection are an analytic sensitivity for minor alleles of <20%, in particular, 
when assessing the mutational status of heterogeneous tumor samples. Methods: 
Here we describe a simple modification to the FTSS workflow that improves the limit of 
detection of cell-line gDNA mixtures. Results: The limit of detection of cell-line gDNA 
mixtures was improved from 50-20% to 5% for G>A transitions and from 50-5% to 5% 
for G>C and G>T transversions. Conclusions: In addition, we use two different sample 
types to compare the limit of detection of sequence variants in codons 12 and 13 of the 
KRAS gene between Sanger sequencing and other methodologies including shifted 
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termination assay (STA) detection, single-base extension (SBE), pyrosequencing (PS), 
high resolution melt (HRM), and real-time PCR (qPCR). 
 
TT53. Improving FFPE DNA Extraction: A Study of Three Methodologies 
O.S. Chajewski, S.A. Marconi, K.A. Lebel, F. Moore 
Baystate Health, Springfield, MA. 
Introduction: In the current era of personalized medicine, more information is sought 
from smaller samples, which is a significant challenge in molecular pathology. In our 
study, we compared two commonly used extraction methodologies and one 
experimental hybrid method in the extraction of DNA from small specimens. The results 
were then tested for DNA content and purity, and eventually submitted for the 
downstream application of KRAS mutation testing. Methods: A three-year retrospective 
computer search identified fluid preparations and small samplings of colonic and 
pulmonary adenocarcinoma. Each case was examined for remaining tissue and percent 
tumor present. Unstained recuts were scraped and DNA was extracted from the 
formalin fixed paraffin embedded tissue by three methods: Qiagen EZ1 XL per protocol, 
Qiagen QIAamp DSP DNA FFPE Tissue Kit and a hybrid method involving Xylene and 
Ethanol steps from the manual method combined with the automated EZ1 extraction. 
DNA content and purity were assessed by the NanoDrop 2000 and selected cases 
were tested for two of seven KRAS mutations performed in our laboratory. Results: 
Our search yielded 28 cases suitable for extraction. All cases were extracted by two 
methods; our currently used Qiagen EZ1 XL method and Qiagen QIAamp DSP DNA 
FFPE Tissue Kit (manual spin column) method. The results showed that the EZ1 
method yielded higher DNA content (approximately double the amount) and the spin 
column method yielded better purity. Five of these 28 cases were then run with our 
KRAS TaqMan assay (lab developed) and 2 of 5 cases extracted by EZ1 failed 
amplification. All 5 cases extracted by spin column demonstrated cycle thresholds 
(CTs) of 1-2 cycles lower compared to cases extracted by EZ1. Next, 5 additional cases 
from the original 28 were extracted by the hybrid method. NanoDrop results for these 5 
cases showed both decreased DNA yield and purity compared to the other two 
extraction methods. Three of these 5 cases proceeded to KRAS mutation analysis. One 
case failed to amplify and 2 cases demonstrated CTs comparable to the other two 
methods. Conclusions: Although the manual spin column method yielded slightly 
better results (improved purity and lower CTs), the difference compared to the 
automated EZ1 extraction method was not significant. The hybrid method showed 
decreased extraction results overall. In conclusion, the currently used Qiagen EZ1 XL 
method remains the method of choice as it provides adequate DNA and requires fewer 
manual steps and less technologist time. 
 
TT54. Comparison of BRAF V600E Mutation Detection Between Sanger 
Sequencing and Companion Diagnostic Methods 
R. Bender, K. Arnold, A. Ghazalpour, M. McGinniss, Z. Gatalica 
Caris Life Sciences, Phoenix, AZ. 
Introduction: A high percentage of melanomas harbor activating mutations of BRAF, 
which also renders them susceptible to the use of a small molecule inhibitor (eg, 
vemurafenib). Crucial to this therapeutic approach is a reliable detection of an activating 
BRAF mutation. Methods: We compared analytic performance of the cobas 4800 
BRAF V600 Mutation Test, a recently FDA approved companion diagnostic test, to 
Sanger sequencing in select 40 melanoma samples. The group consisted of 20 wild 
type (w.t.) and 20 mutated genotypes (11 cases of c.1799T>A, p.V600E; 1 case of 
c.1799_1780TG>AA, p.V600E; 1case of c.1799_1803delinsAT, p.V600_K601delinsD; 3 
cases of c.1798_1799GT>AG, pV600R; 3 cases of c.1798_1799GT>AA, pV600K; 1 
c1405G>A, p.G469R) Results: Companion diagnostics detected all 1799T>A point 
mutations in this codon (V600E; positive). In addition all three V600K mutations 
(c.1798_1799GT>AA) and one deletion insertion mutation (c.1799_1803delinsAT, 
p.V600_K601delinsD) were called positive (V600E). None of the three V600R 
sequence positive cases, a V600E mutation resulting from c.1799_1780TG>AA nor 
c.1405G>A, p.G469R were called positive in the companion diagnostic test. 
Conclusions: Although the companion diagnostic test detects all of the c.1799T>A 
mutations, it does not detect all mutations in the BRAF 600 codon that may result in the 
same amino acid change (V600E). Additionally, this test does not detect other 
activating missense mutations (eg, V600R), all of which may be significant for the 
therapeutic drug associations (vemurafenib, dabrafenib). 
 
TT55. Successful Long-Range PCR from Saliva DNA after Removal of PCR 
Inhibitors 
D.L. Pierce, B. Ramey-Hartung, M.P. Borgman, K.K. Reynolds, M.W. Linder 
PGXL Laboratories, Louisville, KY. 
Introduction: Saliva is an easily collected, non-invasive sample type that appeals to 
patients, physicians, and clinical laboratories. This sample source can pose new 
challenges to the clinical lab. Compared to blood, saliva often yields less DNA, DNA of 
lesser quality, and introduces potential PCR inhibitors. Long-range PCR, such as that 
performed using the Luminex CYP2D6 mutation detection kit, can be particularly 
vulnerable to these problems. Our objective was to maximize success of long-range 
PCR with less than optimal samples, in the presence of suspected inhibitors. Methods: 
We noted inhibition of long PCR products with DNA from saliva. PCR inhibition was 
relieved by diluting the DNA more than 1:2 in water. For samples that could not be 
diluted, pelleting the DNA, removing the supernatant, and resuspending in fresh water 
removed the inhibitor. Sixty-six saliva samples were collected using the Oragene OG-
510 kit (DNA Genotek) for CYP2D6 genotype analysis in our CLIA lab. DNA was 
extracted using the Qiagen EZ1 robot and Qiagen Tissue kits. Saliva was incubated 
overnight at 50°C, vortexed briefly, then 200 ȝl was digested with proteinase K, and 
placed in the EZ1. Elution volume was 50 ȝl. DNA was quantified using a NanoDrop100 
instrument. To precipitate DNA, 1/25th volume of 5M NaCl and 2 volumes 100% 
Ethanol were added. DNA was pelleted at maximum speed in a microcentrifuge for 10 
minutes. Supernatant was removed and the pellet air-dried for several minutes. DNA 
was resuspended in nuclease-free water. Results: In a set of 66 samples, 18 failed 
PCR. After precipitating the DNA, 15 of the 18 samples yielded successful PCR. The 
CYP2D6 PCR products range in size from 2.6 to 3.8 kb, and require DNA of high quality 
to successfully amplify. The 3.8-kb product has proven the most difficult and most 
sensitive to the presence of the inhibitor in saliva DNA. The samples that continued to 
fail were analyzed by agarose gel electrophoresis, which revealed significant DNA 
degradation. The cause of degradation in these samples is unknown. Prior to 
precipitation, the absorbance peak for each sample was centered at 230nm. This peak 
shifted after precipitation to the expected 260nm DNA absorption peak. Conclusions: 
Saliva DNA samples intended for use in long-range PCR may be pre-treated with EtOH 
precipitation to improve the likelihood of PCR success. This is especially important in a 
CLIA laboratory, when patient comfort may dictate that less than optimal sample types 
are received. 
 
TT56. Deterministic Design and Implementation of Single Nucleotide Variant 
Genotyping by High Resolution Melting 
J. Kent1, A.L. Millington2, C.T. Wittwer2 
1University of Utah, Salt Lake City, UT; 2University of Utah Pathology, Salt Lake City, 
UT. 
Introduction: Genotyping by PCR and high resolution melting is potentially the 
simplest and fastest method for genotyping single nucleotide variants (SNVs). However, 
a confusing amalgamation of software, web-based services, and intuition are utilized in 
design. The list of concerns from primer placement to dimerization is daunting and 
generally inconsistent. Even with strict considerations, PCR products are not always 
successfully amplified, and complete redesign is often necessary. We propose a simple 
method for assay design that includes both primer design and optimal PCR conditions 
to make the process work well the first time. Methods: The 52 forensic SNVs 
developed by the SNPforID consortium were selected as the target for study. PCR 
primers were designed by software that places the 3’ end of both the reverse and 
forward primers next to the SNV with a 1-nucleotide buffer. Subsequent nucleotides 
were then added to the 5’ end of the primer until the nearest-neighbor predicted Tm 
reached 60ÛC. Universal PCR protocol for simultaneous amplification of each SNV was 
developed, consisting of a two-step touch down protocol. After initial denaturation at 
95ÛC for 15 seconds, cycling consisted of denaturation at 85ÛC and annealing/extension 
at temperatures decreasing from 73ÛC to 63ÛC in 10 cycles, followed by 30 cycles of 
amplification at 63ÛC. Choice of denaturation temperature was determined by the 
maximum melting temperature of the 52 amplicons to prevent the amplification of high 
Tm products. The annealing/extension temperature was based on the primer Tms that 
varied between 58.42ÛC and 61.14ÛC. Results: Using the simplified primer design and 
universal protocol, we successfully amplified and produced clear melting curves for all 
52 SNVs. In 7 out of 52 cases, the melting curve of the wild-type and mutant 
homozygote SNVs were indistinguishable due to sequence thermodynamics. All 7 
cases were correctly predicted by uMELT (http://dna.utah.edu/umelt/umelt.html). The 
reliability of this prediction should allow us to incorporate automatically designed 
snapback genotyping probes on the 5’ end of one of the PCR primers to type 100% of 
wild-type and mutant homozygotes. Conclusions: A simplified primer design algorithm 
provided clear PCR results in 100% of the targets tested when amplified according to 
the universally optimized PCR protocol. The algorithm did not discriminate against 
primers with sequence runs or repeat, or sequences proven to produce primer dimers. 
This method reduces the complicated task of assay design to a user-friendly and 
effective algorithm requiring only knowledge of the target sequence and a basic 
thermodynamic calculation. 
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TT57. College of American Pathologists’ Laboratory Standards for Next 
Generation Sequence Clinical Testing 
N. Aziz1, B. Lynn2, D. Driscoll1, J. Gibson3, W. Grody4, M. Hegde5, G. Hoeltge6, J.A. 
Kant7, D. Leonard8, J.D. Merker9, L. Palicki1, R. Robetorye10, I. Schrijver11, K. Weck12, 
K.V. Voelkerding13 
1College of American Pathologists, Lexington, MA; 2Brigham&Women's Hospital 
Partners Center Personalized Genetic Medicine, Boston, MA; 3University of Central 
Florida College of Medicine, Orlando, FL; 4University of California, Los Angeles, CA; 
5Emory University, Atlanta, GA; 6Cleveland Clinic , Cleveland, OH; 7University of 
Pittsburgh Medical Center, Pittsburgh, PA; 8Weill Cornell Medical College , New York, 
NY; 9Stanford University School of Medicine, Stanford, CA; 10Mayo Clinic, Scottsdale, 
AZ; 11Stanford University Medical Center, Stanford, CA; 12University of North Carolina 
at Chapel Hill, Chapel Hill, NC; 13University of Utah, ARUP Laboratories, Salt Lake City, 
UT. 
Introduction: The rapid evolution of next generation sequencing (NGS) technologies 
presents significant opportunities and challenges for researchers and clinicians for 
improving health outcomes, particularly with respect to the increased emphasis on 
personalized/precision medicine. Currently, a growing number of laboratories offer 
clinical tests using NGS for gene panels, exomes, and genomes in the absence of any 
NGS specific CLIA or other regulatory agency standards for this highly complex 
technology. The large volumes of data produced by NGS platforms put substantial 
demands on laboratories in terms of the requirements for documentation, validation, 
quality control and assurance, and data storage, as well as assessment and 
implementation of new technology and software releases. Adoption of NGS in the 
clinical laboratory setting requires implementation of laboratory standards for both 
analytical wet bench and bioinformatics components of analysis. Methods: The College 
of American Pathologists (CAP) formed a NGS Work Group (WG) whose task was to 
develop the first set of clinical testing standards for NGS. The WG was mindful that the 
field is undergoing rapid evolution in throughput, costs, and quality with frequent 
updates in instrumentation, sequencing chemistries and technologies, and 
bioinformatics analysis algorithms. Therefore, the WG attempted to construct standards 
without being overly prescriptive to find the right balance in standards development that 
would not inhibit adoption of this technology in diagnostic medicine, and yet provide the 
necessary regulatory framework for quality clinical testing. NGS incorporates two 
processes: (1) the analytical process of sample and library preparation and sequence 
generation and (2) the bioinformatics process of sequence alignment, annotation and 
variant calling. The WG approached the analytical and bioinformatics processes to be 
two discrete processes requiring separate considerations for standards, since some 
laboratories may outsource either the analytical process or bioinformatics analysis of 
NGS-based testing. Results: A total of 18 checklist items for the analytical and 
bioinformatics processes were developed and have been included for the NGS 
laboratory standards section within CAP’s 2012 molecular pathology checklist. The 
NGS checklist items include new standards for documentation, validation, quality 
assurance, confirmatory testing, patient reports, exception logs, monitoring of upgrades, 
variant interpretation and reporting, incidental findings, input storage, version 
traceability, and data transfer confidentiality. Conclusions: This report summarizes 
new CAP standards for the clinical laboratory to promote high-quality NGS-based 
testing for informed clinical decision making.  
TT58. Evaluation of RNA Purification Protocols for Targeted Deep Sequencing 
of RNA from FFPE Tumors 
G. Otto1, K. Brennan1, J. He1, D. Horejsh2, D. Lipson1, J. Ross3, A. Parker1 
1Foundation Medicine, Cambridge, MA; 2Promega Corporation, Madison, WI; 3Albany 
Medical College, Albany, NY. 
Introduction: A single assay capable of characterizing both the genome and the 
transcriptome of diverse tumor types using targeted, deep sequencing will improve the 
application of personalized medicine to cancer. Integrating RNA-seq into our clinical 
FFPE DNA-seq test, which is highly sensitive to many types of genomic alterations in 
over 200 cancer related genes, will enable a comparison of changes in gene copy 
number with digital gene expression levels, facilitate validation of both recurrent and 
novel gene rearrangements and reveal changes exclusive to the transcriptome such as 
alternative splicing. Tumor samples are commonly stored as formalin fixed paraffin 
embedded (FFPE) blocks that degrades nucleic acids and requires careful processing 
to extract sufficient quantity and quality of DNA and RNA to enable comprehensive 
molecular profiling. Quantitative recovery of high purity RNA from FFPE tissues is 
essential to implementation of a targeted RNA-seq cancer assay. Methods: Five FFPE 
RNA extraction kits were evaluated for RNA yield, quality and laboratory workflow using 
sets of 8 tumor:normal pairs from four different tumor types. FFPE tissue digestion and 
RNA purification was performed using a prototype kit for the Promega Maxwell and 
commercially available kits from Roche, Agencourt, Qiagen and Omega Biotek. RNA 
yield and purity were assessed by Ribogreen and nanodrop before measuring double-
stranded cDNA conversion efficiency. The two best performing kits were further 
compared using targeted, deep sequencing with 2x49 paired-end reads on an Ilumina 
HiSeq 2000 to monitor relative transcript abundance and concordance with DNA-seq 
results. Results: RNA was successfully purified from FFPE tissues using all five kits, 
but across all tumor types, RNA yield and quality was higher with the prototype 
Promega Maxwell (PM) and Roche High Pure Paraffin (RHP) kits. The PM kit is semi-
automated and required <2 hours to process all 16 samples as compared to >6 hours 
for the RHP kit. Sequencing results from five matched PM and RHP RNA samples had 
comparable library quality and highly correlated gene expression profiles (r>0.98). Both 
kits also enabled detection of a recurrent SLC45A3-ERG gene fusion in a prostate 
tumor, and had good concordance with variants detected by DNA-seq. Sequencing of 
additional samples is in progress and results will be presented. Conclusions: Both the 
RHP and PM kits are compatible with targeted RNA-seq from FFPE tissues, but facile 
workflow and reduced turnaround time make the semi-automated workflow of the PM kit 
the preferred choice for clinical RNA sample preparation. 
 
TT59. Predicting the Melting Temperature of Snapback Primer Genotyping 
Assays 
A.L. Millington, R. Errigo, R. Palais, C.T. Wittwer 
Wittwer Lab, University of Utah Pathology, Salt Lake City, UT. 
Introduction: If a 5’-tail is added to one PCR primer that is complementary to its own 
extension product, DNA hairpins form after asymmetric PCR, because the tail ‘snaps 
back’ and hybridizes to its own strand. If a single nucleotide variant is within the stem, 
melting analysis enables simple genotyping. The implementation of such methods 
however, requires the ability to accurately predict the melting temperature of the hairpin 
stem. Standard nearest-neighbor thermodynamics do not adequately account for the 
stabilizing effect of the hairpin loop. Prior work has shown that snapback Tms are 
linearly related to the number of base pairs in the stem and inversely related to the log 
of the loop size. Our goal was to use multi-dimensional regression to analyze these 
trends and determine a simple equation that accurately predicts the Tm of single-
stranded products. Methods: We propose a model equation of the form 
Tm=A*ln(loopsize)+B*(StemTm)+C, where loopsize is the number of base pairs within 
the loop, Stem Tm is the nearest-neighbor predicted Tm of the stem, and A,B,C are 
coefficients of ‘best-fit.’ Further adjustment to the concentration term of the calculated 
StemTm was required as the loopsize increased and the two ends of the single strand 
behaved more like individual products. Sequences and experimental Tm data from 52 
snapback genotyping assays were used as a training set. The values of coefficients 
were allowed to float until the linear fit algorithm implemented in LabVIEW 2011 
returned the least residue. Results: Our computational model produced ‘best-fit’ values 
of A=-1.31, B=0.77, and C=11.45. The difference between predicted and experimental 
Tms had an absolute mean deviation of 1.13ÛC and a standard deviation of 1.61ÛC. The 
tightness of this fit suggests that the equation can be used to predict the Tm of other 
similarly designed snapback genotyping assays to within 3ÛC. Conclusions: The 
simple equation presented in this work predicts the Tm of snapback PCR products 
within 3ÛC. This estimate facilitates the design and interpretation of experimental 
melting curve data of snapback genotyping assays. 
 
TT60. Sanger Confirmation Assay to Support Clinical Next Generation 
Sequencing: Efficient Workflow, High Throughput Primer Design, and On-Going 
Validation 
S. Lagerstedt, L. Train, L. Baudhuin 
Mayo Clinic, Rochester, MN. 
Introduction: Although Next Generation Sequencing (NGS) is a powerful technology, it 
is not set to completely replace traditional Sanger sequencing, at least for the near 
term. Required to confirm NGS variants, to provide complementary analysis in NGS low 
coverage areas, and to perform analyses on known familial variants, traditional Sanger 
sequencing reactions will remain in the clinical laboratory to supplement NGS. We 
present a rapid primer design technique and an efficient workflow to merge a large 
collection of Sanger reactions. We expect the collection to expand over time, requiring 
on-going validation. Methods: We used a rapid primer design process including a 
number of specialized software tools to design over one thousand sequencing primer 
sets in just a few weeks. Custom oligonucleotides were ordered in plate format to 
accommodate multichannel and robotic pipetting. Singleplex PCR amplification was 
performed using a standardized master mix and a touch down thermal cycling program. 
Universally tagged oligonucleotides along with the use of a clinical sequencing core 
facility expedited and simplified sequencing analysis. Specialized DNA variant analysis 
software allowed for easy visual inspection of each trace. Custom Excel VBA Tools 
created for full gene analysis were easily adapted to quickly process reactions, assess 
quality, and consolidate reports. Additional Excel tools were created to identify reactions 
and display primer well positions and potential control samples, given the genomic 
locations of specific variants. Samples possessing heterozygous variants, needed for 
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controls and validation, were identified by Whole Exome Sequencing. Results: We 
observed acceptable bi-directional sequencing quality in over seventy-five percent of 
the first pass designs. Ninety percent showed acceptable quality in at least one 
direction. Primers were re-designed and re-tested as needed. Confirmation of a subset 
of these reactions was performed by sequencing a minimum of 5 samples, including 
heterozygous variants when available, and repeating this two times on a 25ng/μL 
concentration of genomic DNA, proving concordance with NGS, reproducibility, and 
analytical sensitivity to 25ng/μL for each reaction. Confirmation of reactions is 
prioritized based on expected mutation frequency and observations in our NGS 
samples. Conclusions: In summary, we have successfully designed over one 
thousand sequencing reactions for the purpose of confirming NGS data and performing 
known mutation analysis. We have created an efficient workflow, and have successfully 
confirmed a subset of this group of reactions. We will continue to expand our range of 
validated genomic intervals with on-going development and validation. 
 
TT61. Next Generation Sequencing-Based Multiplex Detection of High Risk HPV 
Strains 
T. Clarke, Y. Adesokan 
Pathogenica, Boston, MA. 
Introduction: Pathogenica’s DxSeq technology uses next-generation sequencing to 
provide rapid and sensitive detection of infectious diseases. The DxSeq technology, 
composed of reagent kits and analysis software, is sequencer-agnostic; DxSeq probes 
can be used in conjunction with all commercially available sequencing platforms. 
Methods: DNA extracted from clinical samples was assayed using DxSeq probes for 
human papillomavirus and sequenced on an IonTorrent PGM. Results: The DxSeq 
system was applied to enable identification of HPV strains present within clinical 
samples, correctly identifying single or multiple high risk HPV infections. The technology 
was able to accurately distinguish strains present in DNA extracted from both FFPE and 
ThinPrep samples with high sensitivity. DxSeq can be highly multiplexed, allowing for 
simultaneous detection of high risk strains as well as low risk strains in a single tube in 
under twelve hours. In addition, the Pathogenica HPV DxSeq assay is able to co-detect 
relevant human biomarkers present in the background of the samples as well as other 
common viral or bacterial infections. Conclusions: Pathogenica’s DxSeq technology 
enables the sensitive sequencing of a broad range of HPV strains from a patient 
sample with a single-tube assay. This low cost technology will enable the broader 
application of new sequencing platforms to clinical genotyping. 
 
TT62. Monitoring Temperature by Fluorescence During PCR and Melting 
Analysis 
L. Sanford, C. Wittwer 
University of Utah, Salt Lake City, UT. 
Introduction: Successful polymerase chain reaction (PCR) depends on accurately 
controlling the solution temperature during temperature cycling. Typically, temperature 
measurements are made externally to the sample. This compromises solution 
temperature accuracy, particularly during rapid temperature transitions, where the 
solution temperature will lag behind instrument readings. Practically, this results in the 
solution temperature being lower at denaturation and higher at annealing than desired. 
This can lead to reduced PCR product yield, low efficiency, and the amplification of 
non-specific products. To address solution-instrument temperature discrepancies, 
alternative methods of accurately tracking the solution temperature are required. The 
use of fluorescence, already an integral part of real-time PCR and melting analysis, 
may be extended to serve as a monitor of solution temperature. Methods: Nine real-
time PCR instruments were examined during PCR and melting. A temperature-sensitive 
passive reference dye was added to the PCR reaction, so that the solution temperature 
could be non-invasively monitored in real-time. Fluorescence-temperature calibration 
curves were generated that allowed for solution temperatures to be determined by 
fluorescence. Instrument readings, fluorescence-based solution temperatures, and 
thermocouple temperatures were compared during PCR cycling and melting. 
Temperature differences and the time delay required for the sample temperature (an 
average of the solution and thermocouple temperatures) to reach instrument readings 
were quantitatively examined during temperature transitions. Solution-target 
temperature differences were examined at different holding times during PCR cycling. 
Lambda DNA melting curves were also compared using either the instrument reading or 
the fluorescence-based solution temperature. Results: Solution and thermocouple 
temperature traces were aligned more closely than instrument readings during cycling 
and melting. Sample temperatures lagged behind instrument readings by an average of 
0.5 - 6.4 s during cycling, depending on the instrument, rate and sample volume. The 
maximum time delay was 8.3 s on the approach to denaturation. Average sample-
instrument temperature differences were 0.5°C to 4.3°C, reaching a maximum of 5.1°C 
on the approach to annealing. Solution-instrument temperature hysteresis during 
heating and cooling reached a maximum of 8.1°C. Lambda DNA melting curves were 
displaced 0.4°C to 1.3°C, depending on the ramping rate used. Conclusions: The use 
of a passive reference dye to monitor solution temperatures on real-time instruments 
during both PCR cycling and melting analysis was demonstrated. Appreciable 
differences between solution and instrument temperatures were presented and 
quantified. The ability to accurately monitor solution temperatures during PCR and 
melting analysis has the potential to further impact high-resolution melting, instrument 
temperature validation, and the design of future real-time instrumentation.  
 
TT63. Evaluation of the Ion Torrent AmpliSeq 1.0 Cancer Panel for Molecular 
Profiling in Thoracic Malignancies 
L. Xi, M.O. Evbuomwan, M. Raffeld 
National Cancer Institute, National Institutes of Health, Bethesda, MD. 
Introduction: Next-generation sequencing technologies offer new approaches for the 
detection of clinically relevant mutations in human cancers, allowing detection of rare 
mutations at low frequency. The AmpliSeq 1.0 Cancer Panel is a tool designed to 
prepare targeted gene regions for subsequent NGS sequencing on the Ion Personal 
Genome Machine (PGM), using 10-50ng of FFPE tissue DNA in a single multiplex PCR 
reaction. The amplicon panel includes 190 primer sets covering 790 mutation hotspots 
in 47 genes. Using conventional pyrosequencing and fragment analysis, our current 
mutation panel, designed for the requirements of NCI Thoracic Oncology protocols, 
includes 80 hotspots in 7 genes. The AmpliSeq 1.0 Cancer Panel potentially expands 
our current panel to 11 targetable genes, and extends hotspot coverage to 300. In this 
preliminary investigation, we report the performance of the AmpliSeq 1.0 Cancer Panel 
in detecting mutations previously identified by standard methods. Methods: 30 DNA 
samples isolated from FFPE tissues containing 29 mutations in BRAF, ERBB2, EGFR, 
KRAS, KIT, PDGFRA, PIK3CA, and NRAS were studied. The multiplexed PCR 
reactions were performed with 30ng of DNA. NGS sequencing templates were prepared 
from individual libraries using the OneTouch System and sequencing was performed 
with the 100bp Sequencing Kit for the PGM. Mutation analysis was performed with Ion 
variantCaller. Results: The mean number of reads for the 30 samples was 363,000 
(range 167,000-550,000). The average base coverage depth for all hotspot regions 
ranged from 580-2,800, the uniformity of coverage ranged from 61-83% and the 100x 
coverage for the hotspot regions ranged from 74-98%. 41 of 45 amplicons targeting the 
11 genes of our clinical interest had consistent coverage of greater than 200 reads. 
Among the 29 mutations present, 21 were detected with the AmpliSeq analysis. Seven 
mutations, including 5 indels and two point mutations went undetected. Examination of 
the raw sequence data revealed that all of the undetected indels were present in the 
sequence files, but were not identified by the variantCaller software. Four of the 
undetected mutations were in EGFR exon 20 due to poor representation of this 
amplicon. Conclusions: The AmpliSeq Cancer Panel shows promise for facilitating 
mutation detection from clinical FFPE samples. However, some critical amplicons will 
require redesign because of low coverage, and the current software release at the time 
of this writing is inadequate to identify indels consistently. Continued rapid 
improvements of the amplicon pool and software will undoubtedly make this approach 
an attractive alternative for mutation detection. 
 
TT64. A Method Comparison between Invader and Autogenomics Infiniti in 
Factor V Leiden and Prothrombin Gene Mutation Testing 
J. Newell, F. Benko, K. Donaldson 
Penn State Hershey Medical Center, Hershey, PA. 
Introduction: Factor V Leiden (FVL ) and Prothromin gene mutation (PGM) are 
responsible for the majority of inherited thrombophilic states in Caucasians. Testing for 
these abnormalities has become standard of care when inherited thrombophilia is 
suspected. Genotyping of both FVL and PGM is critical as these results will risk stratify 
patients and aid determination of appropriate anti-coagulation therapy. According to the 
College of American Pathologists, 65% of laboratories employ PCR-based testing 
methodologies for FVL and PGM. Approximately 20% utilize an Invader assay, whereas 
microarray testing represented only approximately 3% of testing. The objective of this 
study was to establish concordance between current Invader assays and Autogenomics 
Infiniti microarray assays in FVL and PGM testing and to subsequently investigate the 
viability of the Infiniti platform to expand the molecular laboratory’s test menu. The 
Invader technology is a non-PCR-dependent methodology that is established in the 
literature and has been used for a variety of tests including FVL and PGM. The Infiniti 
platform is a PCR-based microarray chip capable of FVL and PGM testing, but it is 
more versatile in that multiple assays can be performed on the same platform at the 
same time. Methods: To establish concordance between the two tests, forty-four FVL 
and thirty PGM previously run samples and their results were identified from the Invader 
assay database. These samples were then run on the Infiniti platform, and FVL and 
PGM results were compared. Results: 100% concordance was established in both FVL 
(44/44) and PGM (30/30) testing. Conclusions: These results indicate that the Infiniti 
AMP Abstracts  743
JMD November 2012, Vol. 14, No. 6
platform can reliably genotype FVL and PGM, and that it is a versatile platform that is a 
viable option for small laboratories to expand their test menu. 
 
TT65. Validation and Clinical Performance of Competitive Allele Specific 
TaqMan PCR Assay for EGFR Mutation Detection in Formalin Fixed Paraffin 
Embedded Samples 
K. Edwards, L. Eskildsen, L. Thomas, A.R. Smith, J. Sizemore, K. Horton, A. Martin, S. 
Talwalkar 
CPA Lab, Louisville, KY. 
Introduction: EGFR alterations are by far the most commonly tested in non-small cell 
lung carcinomas (NSCLC). However screening for all potential alterations can be time 
consuming and technically challenging especially due to DNA fragmentation seen in 
formalin fixed paraffin embedded (FFPE) samples. Specimen inadequacy especially 
with needle biopsies further precludes obtaining sensitive yet accurate results. We 
validated the utility and tested the clinical performance of competitive allele specific 
TaqMan (CAST) PCR technology. Methods: Validation set consisted of 20 samples (7 
needle-core biopsies, 9 wedge-resections and 4 metastatic). 29 EGFR alterations were 
evaluated, including 19 individual deletions in exon 19. Slides were reviewed by 
pathologist prior to extraction to confirm atleast 50% non-necrotic tumor. DNA quality 
and quantity were assessed post extraction and all samples were diluted to 10 ng/ul to 
achieve final input concentration of 20ng. Reference gene assay and spiked internal 
positive control (IPC) were run for each sample. Cut-off cycle-threshold (Ct) for IPC and 
mutant probe was <30. PCR performed on ABI 7500 Fast and data was analyzed using 
comparative Ct (ǻǻCt) method. Results for validation set were compared to a reference 
lab that tested the same samples. Following validation blinded clinical testing was 
performed on 14 samples. Results: Average DNA concentration, 260/280 ratio and IPC 
Ct range were 93.25ng/ul, 2.34 and 22.0-29.25 respectively. Average hands-on time 30 
mintues and average run-time 120 minutes. Validation set showed 9 positive and 11 
negative samples with a 100% concordance with reference laboratory results. All calls 
for the individual deletions in exon 19 were accurate. Average Ct for positive samples 
was 24.58 (range = 22.1-34.45). Presence of MGB blocker for the wild-type allele 
resulted in preferential amplification of only the mutant allele thereby resulting in 100% 
specificity. This assay could accurately detect <1% mutant allele with a lower limit of 
detection of 0.1% in a background of wild-type allele upon dilution studies. There was 
no cross-reactivity between the individual probes except for T790M. No interferences 
were noted. 14 samples have been tested for clinical performance with cross-reactivity 
seen in the T790M probe only. Conclusions: CAST PCR technology is rapid with a 
shorter turn-around time and requires less stringent precautions to prevent cross-over 
of PCR products. It is very sensitivity compared to other target-amplification based 
assays and has good specificity due to preferential amplification of mutant allele. It also 
allows quantitation of percent mutation and therefore can be useful for monitoring 
treatment response. 
TT66. The Access Array System: A High-Throughput Target Enrichment System 
for Targeted Resequencing, Suitable for Both FFPE and Genomic DNA Samples 
C. Friedlander, X. Wang, A. May, R. Ramakrishnan 
Fluidigm Corp, South San Francisco, CA. 
Introduction: An efficient method for library preparation is essential to match the 
increased throughput and decreased turnaround time associated with next-generation 
sequencing (NGS) platforms. The Access Array System is capable of generating 
amplified material from up to 480 genomic regions across 48 unique samples per IFC. 
The unique design of the Access Array IFC permits efficient DNA amplification in 
multiplex reactions and enables successful amplification of challenging DNA samples, 
such as those from FFPE tissues. In this work, we demonstrate the flexibility and 
performance of the Access Array System in producing libraries, from both fresh-frozen 
and matched FFPE tissue, with consistent results on 454 and multiple Illumina NGS 
platforms. Methods: 100 DNA copies from matched FFPE and fresh-frozen human liver 
tissue were preamplified and specific target enriched using an Access Array IFC along 
with positive control samples in 10-plex reactions (assays grouped by using Fluidigm’s 
proprietary multiplex algorithm). These assays present a common sequence tag that is 
used as target on a subsequent PCR reaction for addition of sample specific barcode 
sequences and sequencer specific tags. Results: Two sets of 480 assays were tested 
on the following platforms: 454 Junior; Illumina GA2, MiSeq and HiSeq. About 80-98% 
of all assays tested produced a number of reads within five-fold from the average on all 
platforms. Around 90% of the reads produced mapped to the genome and of these, 
over 99% mapped to the target regions. Libraries prepared using DNA from FFPE 
samples were sequenced on the HiSeq and MiSeq. About 70% of all 960 assays tested 
produced reads within five-fold from the average on HiSeq compared to 22% on MiSeq. 
Approximately 50% of all reads produced on HiSeq mapped to the genome compared 
to 18% on MiSeq. Conclusions: The consistent detection of 80-98% of the 960 
genomic targets amplified with the Access Array System demonstrates the flexibility 
and reliability of this tool in producing libraries for NGS using different platforms. The 
Access Array System has also proven to be a powerful tool to interrogate DNA from 
FFPE samples, allowing detection of 70% of the target regions on the genome from as 
little as 100 DNA copies adding extra value to the system in the molecular diagnostics 
field. This compares favorably with published reports, which show maximum mean exon 
coverage of 35-40% for FFPE and fresh-frozen DNA (BMC Med Genomics. 2011; 4: 
68). 
 
TT67. Research Instrumentation for Improved Resolution of Fluorescent DNA 
Melting 
K.R. Carney, C.T. Wittwer 
University of Utah, Salt Lake City, UT. 
Introduction: Melting analysis in the presence of fluorescent dsDNA has become a 
standard genetic tool for rapid DNA genotyping and mutation scanning. The HR-1 
(Idaho Technology) is a melting instrument that currently has the best temperature 
resolution of available melting instruments. The HR-1 melts DNA samples at a rate of 
0.1-0.3 degrees/second. Using a low mass DNA ladder of 2,000, 1,200, 800, 400, 200 
and 100 bps, the HR-1 resolves 8 peaks in the derivative melt curve, including 2 DNA 
molecules that melt in two domains. Our goal was to further improve melting resolution 
by very fine temperature control and slower heating rates. Improved melting resolution 
is attempted by reducing the standard melting rate to 0.003-0.01 deg/sec, and creating 
an environment of extremely uniform heating with accurate temperature measurement. 
Methods: A new prototype instrument for DNA melting was constructed to obtain 
extremely uniform heating at melting rates of 0.003-0.01 deg/sec. The 10 μl sample 
was contained in a standard glass LightCycler capillary tube and overlaid with 60 μl of 
mineral oil. The sample was positioned inside a custom-built black Delrin cylindrical 
housing filled with mineral oil. The oil bath was mixed vigorously and heated using 
immersion heaters. Fiber optics pierce the housing to provide excitation light to the 
bottom of the capillary and collect emitted fluorescence from the side. Excitation was 
provided by a 448 nm laser, and the emission was filtered through a 475-525 nm band-
pass. A thermocouple was placed inside the capillary to measure temperature of the 
sample, and a thermistor in the oil bath controlled heating rates via a custom LabVIEW 
software. Data analysis was done by custom MATLAB software. Results: Using the 
HR-1 as a comparison instrument, our custom instrumentation was able to discern 
additional melting transitions in the DNA melting curve as well as sharper peaks in the 
derivative plot of the fluorescence melting data. Conclusions: Slower heating rates and 
better temperature control produce derivative melting curves with more peaks and 
better resolution. We have not yet reached the limit of melting resolution on commercial 
instruments. “High-resolution” melting analysis is a relative term, and as instruments 
improve, better genotype resolution and scanning sensitivity can be expected for longer 
and longer PCR products. 
 
TT68. Detection of Immunoglobulin Light Chain Restriction via Two-Color 
Duplexed Ultrasensitive mRNA in situ Hybridization 
Z. Wang1, H. Wang2, B.P. Portier1, A.M. Gruver1, E. Minca1, X. Ma2, Y. Luo2, J.R. 
Cook1, R.R. Tubbs1 
1Cleveland Clinic, Cleveland, OH; 2Advanced Cell Diagnostics, Hayward, CA. 
Introduction: Detection of immunoglobulin (Ig) light chain restriction (LCR) by flow 
cytometry (FCM) is a useful ancillary tool in the differential diagnosis between lymphoid 
hyperplasia and B-cell non-Hodgkin lymphoma (NHL) if fresh tissue is available. 
Current methods for identification of LCR in formalin fixed paraffin embedded (FFPE) 
tissue include immunohistochemistry (IHC) and conventional chromogenic in situ 
hybridization (CISH), but both methods lack sufficient sensitivity to detect the low levels 
of Ig kappa and lambda expressed in most NHL. We assessed the feasibility of using a 
novel ultrasensitive RNA ISH (RISH) method (RNAscope, Advanced Cell Diagnostics, 
Hayward, CA} capable of detecting single copy mRNA to evaluate light chain mRNA 
expression in situ in B-cell NHL. Methods: We developed a two-color duplexed 
RNAscope assay for simultaneous detection of Ig kappa and lambda mRNA to 
determine the feasibility of sensitive and accurate LCR detection in: 1) 4 B cell lines 
expressing restricted Ig light chain undetectable by conventional IHC and CISH; and 2) 
27 FFPE plasma cell neoplasms. Thereafter, 32 clinical cases evaluated for lymphoma 
were assessed via RISH. Kappa and lambda mRNA RISH scores based on single-cell 
quantification were correlated with the light chain immunophenotype by FCM (n=30) or 
the clonality status determined by BIOMED2 B-cell PCR (n=2) .Cases included: benign 
lymphoid hyperplasia (n=2), classical Hodgkin lymphoma (n=2), follicular lymphoma 
(n=9), diffuse large B cell lymphoma (n=9), CLL/SLL (n=2), "Gray Zone" lymphoma 
(n=2), Mantle cell lymphoma (n=2), B Cell NHL not otherwise specified (n=1), EBV LPD 
of elderly (n=1), and extranodal marginal zone lymphoma of MALT type (n=2). Results: 
Evaluable kappa and lambda mRNA ISH results were obtained for all 4 cell lines, 27 
FFPE plasma cell neoplasms and 32 clinical cases evaluated for lymphoma. The kappa 
and lambda mRNA expressions of 4 cell lines and 27 FFPE plasma cell neoplasms 
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detected by RISH were concordant with the established light chain immunophenotype. 
In each of the 32 clinical cases LCR results by RISH were concordant with FCM or 
BIOMED B PCR. Conclusions: RNAscope analysis of Ig kappa and lambda mRNA 
expression is a sensitive tool for establishing in situ LCR in B-cell NHL when FCM 
results are not available, and is potentially a valuable diagnostic tool in the evaluation of 
NHL in FFPE tissue for which LCR cannot be established by CISH or IHC. 
 
TT69. A Novel Retrospective Medical Record Review Instrument for the 
Genomic Era 
A.M. Issa, N. Atehortua 
University of the Sciences, Philadelphia, PA. 
Introduction: Personalized genomic diagnostics often in combination with targeted 
therapeutics have become an important component of clinical oncologic practice over 
the last decade. However, there is a dearth of studies examining utilization of specific 
genomic diagnostics and their influence on clinical practice patterns in health systems. 
Methods: To begin to explore and understand the clinical utility of particular genomic 
diagnostics in current use, we developed an instrument to collect data on utilization and 
clinical practice patterns in health systems. We focused our efforts on gene expression 
profiling (GEP) assays, and particularly on a commonly used GEP in breast cancer: 
Oncotype DX (Genomic Health Inc., Redwoods, CA). We used the literature and our 
own knowledge of electronic medical records and designed a retrospective cohort 
study. Results: We developed a medical records abstraction instrument applied to the 
utilization of Oncotype DX (Genomic Health, Inc., Redwoods, CA) in clinical settings. To 
address the identified gaps in the literature regarding utilization and practice patterns of 
GEP, we sought to develop a methodology for conducting retrospective research on 
utilization of genomic diagnostics and how it influences practice patterns in clinical 
settings. We constructed specific guidelines for the collection of accurate genomic data, 
which we discuss and illustrate. Conclusions: The guidelines we developed enable us 
to collect high quality data on genomic utilization. It is important to ensure properly 
designed case record forms, a manual to train data collectors for standardized data 
collection. It is also critical to pilot test the new medical records abstraction instrument 
to ensure accurate data collection, and correct interpretation of clinical outcomes. 
 
TT70. Selecting a Platform for Chromosomal Microarray Testing in a Clinical 
Setting 
K.A. Lebel1, S.M. Pflueger1, J.A. Lefferts2, L.J. Tafe2, H.B. Steinmetz2, G.J. Tsongalis2 
1Baystate Health Center, Springfield, MA; 2Geisel School of Medicine at Dartmouth, 
Lebanon, NH. 
Introduction: Recently, guidelines have recommended the use of chromosomal 
microarray analysis (CMA) as an initial screening assay for children with 
neurodevelopmental delays. Traditionally these patients have been evaluated with 
conventional cytogenetic karyotyping and FISH based assays. However, these 
techniques lack the needed resolution to provide adequate diagnostic detection of small 
copy number variants that might be identified using CMA. There are several vendors 
who provide CMA platforms and microarray chips. Here we describe the selection 
process followed by two institutions seeking to bring CMA testing in house. Methods: 
We began a four phase process by organizing a selection committee representative of 
both institutions at the technical and professional levels. Members of the committee had 
been following CMA developments for the past several years and a thorough literature 
review was performed. Next, each of four vendors (Affymetrix, Agilent, Illumina and 
Nimblegen) was invited to present the advantages and disadvantages of their platforms, 
chips and software. Each vendor was given 90 minutes and all presentations were on 
the same day. Several committee members then called current users, identified by each 
vendor, with predetermined questions to ask. Committee members began attending 
microarray meetings and site visits were made to various laboratories to observe 
testing. There was a final debriefing and deliberation meeting before a unanimous 
decision was made. Results: Microarray applications for CMA testing have evolved 
rather quickly with constant upgrades to systems but the changes have finally resulted 
in products that appear suitable for clinical applications. Because of this, both 
institutions made the decision to bring this testing in house. Vendor presentations on 
the same day allowed the committee to learn about the different platforms directly from 
the industry representatives and to compare and contrast the presented information in 
real time. Speaking directly to end users provided insight into perceived advantages 
and disadvantages of their chosen platforms. Site visits allowed members of the 
committee to better grasp workflow issues and space requirements. Significant 
communication avenues between committee members for sharing thoughts, concerns 
and information were critical to this process. Conclusions: Although many types of 
molecular diagnostic tests are becoming routine with the use of turnkey systems, there 
are still a significant number of clinical applications that require evaluation of advanced 
and highly complex technologies and platforms. We describe our process that allowed 
us to make a very informed and responsible selection of a CMA platform.  
TT71. Mesodissection of Paraffin Embedded Slide Mounted Tissue Sections 
N. Adey, D. Bosh, D. Emery, L. Birch, R. Parry 
AvanSci Bio, LLC, Salt Lake City, UT. 
Introduction: When properly fixed and prepared, biomolecules can remain stable for 
years when embedded in paraffin. To avoid the potential for degradation of these 
biomolecules during the retrieval process, many laboratories prefer not to deparaffinize 
slide mounted tissue sections prior to dissection, particularly when assaying RNA. 
However, the paraffin can obscure the tissue sections making manual dissections 
difficult and not possible using Laser Capture Microdissection. Here we demonstrate it 
is possible to dissect still paraffinized slide mounted tissue sections using a non-toxic 
biocompatible organic solvent and the MESO-1  dissection system. Methods: Slide 
mounted tissue sections were either dissected directly from paraffinized tissue sections 
using the subsequently extracted organic solvent, or the slides were first deparaffinzed 
with a xylene substitute then dissected using and aqueous buffer. The resulting tissue 
fragments were digested with a Proteinase K based solution and the yield of DNA 
quantitated using Pico Green. The samples were then subject to PCR analysis to 
compare the biocompatibility of each process. Results: Comparable areas of interest 
(AOIs) were digitally indicated on 20 pairs of slide mounted tissue sections, one 
deparaffinized and one still embedded in paraffin, then used to guide for the dissection 
process. The digital AOIs greatly facilitated the dissection of the somewhat obscure 
paraffinized tissue. The DNA yield from the deparaffinized and still paraffin embedded 
samples was equivalent, and no difference in the ability to act as a PCR template was 
observed. Conclusions: Dissection directly from still paraffin embedded tissue sections 
is a viable alternative to the need for prior deparaffinization of the tissue section, a 
process that may help reduce the degradation of biomolecules. Studies are currently 
underway to evaluate this process for RNA based assays. 
 
TT72. A Clinical Specimen Management and Productivity Application Designed 
for a Molecular Anatomic Pathology Laboratory 
G.S. Mantha, J. Murphy, A. Priddy, T. Fennel, D. Brown, D. Maglicco, G. Shullo, J. 
Cunningham, M. Miller, N. Parish, M. Durso, C. Trusky, R. King, M. Nikiforova 
University of Pittsburgh Medical Center, Pittsburgh, PA. 
Introduction: As the need and complexity of molecular testing within anatomic 
pathology increases, the organization, management and timely analysis of patient 
specimens becomes vital for laboratory success. The University of Pittsburgh Medical 
Center (UPMC) consists of more than 20 hospitals and has more than 64,000 annual 
admissions. The Molecular Anatomic Pathology (MAP) laboratory performed over 6000 
molecular tests in 2011 and anticipates a conservative 25% growth for 2012. With such 
demands, the need for a specimen management system became critical. Our team 
created such a module that interfaces directly with the department of pathology’s 
reporting system. Here we present this module and its clinical productivity applications 
during each molecular testing time point. Methods: The UPMC MAP and Specialty Lab 
Informatics (SLT) teams designed the web based application written in Cold Fusion. 
HIPAA compliance and security was ensured. Dates and technologist initials were 
collected for the following time points: microdissection, extraction, PCR, real time, 
sequencing, and/or fragment analysis, technical sign out, MAP faculty sign out. Patient 
name/demographics, test name and order date were directly imported from the 
pathology informatics reporting software (COPATH). Management report modules for 
case volume and turn-around-time (total and by test) were programmed. Extensive 
validations were performed prior to clinical implementation. Results: The clinical 
specimen management/tracking module was launched November 2011 and can be 
accessed by multiple users simultaneously. Each day technologists, assigned to 
specific lab workstations, enter the dates for the work completed for each case. 
Specimen issues (scant specimen, poor quality, etc) can be documented in the 
“comment” field. The status of any case can easily be accessed by entering the patient 
identifier into the search criteria. Case volume (weekly, monthly, yearly or by test) and 
associated turn-around-time productivity reports can be generated and exported into 
EXCEL for further analysis. Conclusions: Due to increasing test volume and technical 
complexity, knowing the status of a molecular test at any one time point can be 
challenging; however with this application, the test status can be accessed in seconds. 
Specimen workflow for three molecular platforms (sequencing, real-time and fragment 
analysis) is systematically organized electronically. Productivity reports have assisted in 
volume/budget projections and trending for quality improvement. 
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TT73. Concurrent Validation of Chromosome Microarray Testing in Separate 
Molecular Pathology Laboratories 
C.L. Bissaillon1, A.M. Tyropolis1, K.A. Lebel1, F. Moore1, S.M. Pflueger1, J.A. Lefferts2, 
L.J. Tafe2, H.B. Steinmetz2, G.J. Tsongalis2 
1Baystate Health, Springfield, MA; 2Dartmouth Hitchcock Medical Center, Lebanon, NH. 
Introduction: The ACMG Practice Guidelines state Cytogenetic Microarray (CMA) 
testing for copy number variation should be a first-line test in postnatal evaluation of 
individuals with multiple anomalies not otherwise specified to well-delineated genetic 
syndromes; as well as other developmental, growth and speech delays. This 
recommendation results in a pressing need for a commercially available assay. Here 
we report on the validation of the Affymetrix CytoScan HD Array in two clinical 
molecular pathology laboratories. Methods: DNA from 37 patients previously submitted 
to two external reference laboratories for CMA testing was collected at the two sites. 
These included 13 samples with normal CMA reports and 24 with abnormal reports. All 
samples were exchanged and tested at each molecular laboratory using the Affymetrix 
CytoScan HD array according to the manufacturer’s protocol and analyzed using 
Chromosome Analysis Suite (ChAS) software (Affymetrix). Copy number changes were 
initially analyzed using standard settings, and subsequently analyzed with higher 
resolution settings as well as for Loss of Heterozygosity (LOH). The gains and losses 
detected by the two molecular laboratories were compared and verified against the 
results reported by the reference laboratories. Results: The molecular laboratories 
identified the same gains and losses in all 37 samples tested. One laboratory failed to 
identify significant LOH across the genome in one sample. Analyzed sample results 
were then compared with reference laboratory reports. Small gains and losses reported 
by the reference laboratories varied slightly from the molecular laboratory results. All 
sample results were concordant in reporting genomic changes of clinical significance as 
well as those of unclear clinical significance and likely benign variants. Conclusions: 
Analysis of data showed overall concordance of results between all testing laboratories. 
Although small differences in detected gains and losses were seen, these variations did 
not result in a change in final reporting. Differences seen may be attributed to the 
marker density of the reference laboratory microarrays compared to the CytoScan HD 
arrays. Consistency was seen between the two molecular laboratories utilizing the 
same Affymetrix array platform. This collaborative study demonstrates a commercially 
available assay can yield reproducible results between assays. This helps address the 
increasing need for microarray analysis as a clinical tool for first line assessment of 
individuals with multiple anomalies or varied developmental delays. 
 
TT74. High-Throughput Gene Expression Analysis of Samples Derived from 
FFPE Tissue Using a Microfluidic System 
S.L. Spurgeon, R. Ramakrishnan 
Fluidigm Corporation, South San Francisco, CA. 
Introduction: Pathology tissues are frequently archived as FFPE samples. The 
purpose of this work was to evaluate the research use of a microfluidic system for gene 
expression analysis of samples derived from FFPE tissue. The advantage of this 
system is that a large number of genes can be tested on a relatively small amount of 
material. Methods: The FFPE tissues used for this study were obtained from 
commercial sources. After deparaffinization, the RNA was extracted and converted to 
cDNA with a mixture of oligo-dT and random primers. The cDNA was then preamplified 
with the genes of interest followed by gene expression analysis on a microfluidic 
system. Results: RNA was successfully extracted from sections cut from a one-and-a-
half-year-old tissue block and from five-micron sections on slides. The bulk of the RNA 
was less than 500 bases in length. For some assays, a positive signal was seen with 
preamplified no reverse transcriptase controls, and data from these assays were not 
included in further analysis. All but one of the assays used gave amplification curves 
with control cDNA samples. With the microfluidic system, 96 gene expression assays 
could be tested with as many as 48 samples and controls in a single chip run. The 
number of assays that gave positive amplification curves ranged from 30% to 80% 
depending on the samples tested. CENPF and GTF21 each showed increased 
expression in both samples of tissue from lobular carcinoma of the breast relative to 
normal breast tissue. Other genes showed smaller increases or were increased in only 
one of the two samples analyzed. ARHGD1A, CTNNB1 and RPLP0 showed decreased 
expression in both cancer tissue samples. Conclusions: RNA that is suitable for gene 
expression analysis using a microfluidic system can be extracted from FFPE samples. 
Preamplification was used to increase the number of copies for further analysis. The 
use of a microfluidic system for gene expression analysis results in a significant 
decrease in the cost and labor associated with analyzing large numbers of samples. 
 
 
 
 
TT75. Identification of Recurrent Somatic Translocations from Multiplexed 
Capture-Enriched Next Generation Sequencing of Genomic DNA 
H. Abel, C. Cottrell, H. AlKateb, S. Kulkarni, E.J. Duncavage 
Washington University School of Medicine, St Louis, MO. 
Introduction: Recurrent somatic translocations are common in many types of 
malignancies including leukemias and solid tumors. Identification of these 
translocations is of both diagnostic and prognostic significance, and in some cases, 
such as an ALK rearrangements, directs specific treatment. In most molecular 
diagnostic labs translocations are detected by fluorescence in situ hybridization (FISH). 
However, FISH requires expert interpretation, and may not identify the translocation 
partner as is the case with break-apart probes. In this study we demonstrate that 
translocations can be identified from capture-enriched, next generation sequencing 
(NGS) data using publicly available software tools. Methods: A set of 10 cases 
including 5 acute leukemias and 5 lung cancers with MLL and ALK rearrangements, 
respectively, detected using commercially available interphase break-apart FISH 
probes were identified. DNA was extracted from bone marrow leukocytes (leukemias) 
or formalin-fixed tissue (lung cancers), capture-enriched for ALK (exons/intron 14-29) 
and MLL (all introns/exons), and sequenced in multiplex on an NGS instrument using 
2x101bp reads; fusion partner genes were not directly targeted. Median coverage of 
ALK and MLL was 3440x and 3832x, respectively. Data were then aligned using BWA, 
and translocations identified with multiple publicly-available software packages, 
including BREAKDANCER, CREST, and SLOPE. Results: Using a battery of software 
tools, ALK translocations were identified in 3 of 5 cases (60%) and MLL translocations 
in 4 of 5 cases (80%). All identified ALK translocations were ALK-EML4 fusions; MLL 
translocations included a t(4;11), t(6;11), t(11;17), and a t(11;19). The two ALK 
rearranged cases not detected by NGS had a lower number of FISH positive nuclei 
(22% non-detected vs 50% detected). All translocations were identified with single 
basepair resolution. Conclusions: Clinically significant translocations can be detected 
at the DNA-level using panel-based, capture-enriched NGS. This method has several 
advantages over FISH, including the ability to detect novel fusion partners, to pinpoint 
exact DNA breakpoints, and to detect a full spectrum of DNA alterations from single 
nucleotide variants to translocations. Not all FISH rearranged cases were detected by 
NGS. Inability to detect translocations in these cases may be due to low abundance 
translocations, translocations occurring in low complexity regions, and translocations 
occurring outside of the targeted area. Given the rapid pace of NGS methodologies; 
however, these problems will likely be mitigated by longer read lengths and increased 
coverage.  
 
TT76. Development of a Platform-Specific Validation Plan for Sanger 
Sequencing Assays Using Current Recommendations from ACMG, CAP, CDC, 
and AMP 
A. McDonald, M. Butz, D. Gavrilov, D. Oglesbee, M. Ferber, K. Halling 
Mayo Clinic, Rochester, MN. 
Introduction: Validation of laboratory developed tests (LDT) is a critical element of 
molecular diagnostics and required by CLIA ('88). DNA-based LDTs are also 
increasingly under scrutiny by the FDA. Current guidance documents focusing on 
molecular methods do not readily address the particulars of Sanger-based assays, the 
gold standard for DNA mutation detection. In this study, we compared guidelines 
published by ACMG, CAP, CDC, and AMP and established a plan that applies to 
Sanger sequencing as a diagnostic platform and satisfies regulatory requirements of 
CLIA ('88) as well as regulations from New York State (NYS). This plan has been 
applied to the validation of 549 amplicons covering 46 genes for germline mutation 
analysis. Methods: A thorough assessment of the definitions of accuracy, precision, 
reference range, reportable range, analytical sensitivity, and analytical specificity was 
obtained from published guidelines and standardized for our LDT validation process. 
Accuracy was assessed via 3 separate methods: either by confirming alterations found 
in reference material, comparison with another laboratory's results, or analyzed by 
another validated method for 174 samples encompassing 46 genes of interest. 
Precision was demonstrated by confirming concordance of results intra- and inter-runs 
on 3 different reference samples. Reference range was defined as the range of bases 
on the chromosomal reference sequence (published on NCBI) covering the target gene. 
Reportable range was defined as the range of bases on a reference sequence from 
which variants could be reproducibly assayed. To demonstrate analytical specificity, 
primers were processed by SNP search and BLAT analysis with UCSC. Analytical 
sensitivity was assessed by demonstrating the ability to detect variant sequences in 
DNA admixtures. Published studies on the clinical sensitivity and specificity of gene-
specific DNA analysis were referenced for every LDT. Quality metrics (signal intensity, 
trace quality score) were monitored for assessing robustness. Results: 174 of 174 
samples were 100% concordant for accuracy. Inter-assay and intra-assay precision 
was satisfactory from 32,940 sequencing reactions. Analytical sensitivity was 30% 
variant in 70% wild type background with a requirement of at least 5 ng of DNA. The 
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average sequence trace quality failure was 3.7%. Conclusions: Our validation strategy 
encompasses recommendations from several guidance documents and allows for a 
thorough and efficient assessment of the performance characteristics of laboratory 
developed Sanger sequencing tests. Our results show that these LDTs are safe and 
reliable for clinical use to detect germline mutations in the human genome.  
 
TT77. SPIA cDNA Targets Provide Higher Sensitivity and Specificity in 
Microarray Analysis Compared to senseRNA Targets Derived by IVT  
L. Turner1, W. Keilholtz1, Q. Wang2, M. Moreau2, A. Brooks2 
1NuGEN Technologies Inc., San Carlos, CA; 2Rutgers University, New Brunswick, NJ. 
Introduction: Analysis of clinical samples in the study or diagnosis of disease 
continues to be a significant challenge to researchers and clinicians. Limitations in the 
amount and integrity of samples are most significant for the formalin-fixed, paraffin-
embedded (FFPE) samples widely used in cancer research. NuGEN Technologies’ 
newest version of its whole transcriptome based approach for the analysis of FFPE 
samples (Ovation FFPE WTA System) enables amplification and target preparation 
from these samples through a simple, robust and easily automatable process. 
Methods: In the current study, performance of the cDNA produced by the NuGEN kit 
was compared to the performance of the senseRNA produced by the Sensation RNA 
Amplification kit (Genisphere). Four distinct FFPE tissue samples (Spleen, Lung, Liver 
and Lymph) with RIN scores of 2-3 were amplified at two input levels (50 and 100 ng) in 
triplicate using either the NuGEN kit or the Genisphere kit. Results: Amplified products 
were fragmented, labeled and hybridized to Affymetrix HG-U219 plate arrays, according 
to manufacturer’s protocol. Principal Component Analysis revealed that the cDNA 
targets (NuGEN) were better able to discriminate between tissues. Significantly 
changed genes were identified by 1-way ANOVA of individual FFPE tissues versus the 
pool of the other three, to distinguish tissue-specific gene sets and assess the relative 
sensitivity of cDNA vs senseRNA. Although there was significant overlap in genes 
identified by both methods, the NuGEN targets identified more significantly changed 
genes with greater dynamic range and tissue-specificity than the senseRNA targets. 
Conclusions: The Ovation FFPE WTA System provides many advantages including 
existing automation protocols, significantly shorter and simpler workflow (from RNA to 
arrays in one day), compatibility with multiple array platforms (including both sense and 
antisense probe based arrays), and higher specificity and sensitivity that leads to the 
acquisition of richer biological information. The combined advances in processivity, 
specificity and sensitivity for compromised samples make diagnostic applications an 
achievement that can be attained in the near future. 
 
TT78. Choosing Specimen Between Plasma and Serum for Quantifying 
Circulating microRNAs  
S. Kim, K. Shin, H. Kim 
Pusna National University School of Medicine, Republic of Busan, Korea. 
Introduction: Circulating microRNAs (miRNAs) are emerging cancer and disease 
biomarker. But the quantity of miRNAs from plasma and serum were showed significant 
difference. Which blood specimen would be more suitable for stable and reliable result 
of quantifying circulating miRNAs in environment of clinical laboratories? Methods: We 
evaluated the effect of several conditions (cell contamination, additives of tubes, 
centrifugation force, coagulation process) for variation in quantifying of miRNAs with 
serum and plasma. Blood from 3 healthy volunteers were collected in vacutainer tube 
containing EDTA, sodium citrate, serum separator (SST) and plain tube and one 
platelet rich plasma (PRP) also was obtained by platelet pheresis. Two kinds of 
centrifugation protocols were applied for every tubes, at 795 x g and at 15000 x g at 
4°C for 10 min. We also made serially diluted MNCs and PRP with serum and plasma 
for cell contamination test. Serum samples were made from plasma in EDTA and citrate 
tube by evoking artificial coagulation process. RBC, WBC and platelet counts were 
measured in each sample before and after each process. Then we extracted total RNA 
using mirVana PARIS Kit (Ambion, Austin, TX) from all samples. RNA extracts was 
used for quantifying miR-27a, miR-106b and miR-223 by real-time quantitative PCR 
(qPCR). We compared the results of quantified miRNA from every tube of each 
specimen. Results: As cells or platelets were more contaminated in serum and plasma, 
miRNAs were also increased. With 795 x g centrifugation that was routinely used in 
clinical laboratory, there were much remnant of the platelets in plasma samples and the 
numbers of platelet remnants were largely varied, but in serum samples, there was no 
significant platelet contamination. With 15,000 x g centrifugation, no platelet remnants 
were found in serum and plasma. miRNAs expression in plasma were also significantly 
varied by the kinds of addictive of sampling tube and centrifugation protocols. But 
miRNAs in serum were much less affected by centrifugation protocols or tube type. 
During forced coagulation process, a small amount of miRNAs were increased in 
plasma samples but it was less than the difference of miRNAs between plasma and 
serum. Conclusions: The serum sample would be more free from the contamination of 
platelet and cellular component that can affect the amount of miRNAs than plasma 
sample in the clinical environment where the centrifugation were performed at 795 x g. 
 
TT79. OncoSeek - A Versatile Annotation and Reporting System for Next 
Generation Sequencing-Based Clinical Mutation Analysis of Cancer Specimens 
M. Routbort, B. Handal, K.P. Patel, R. Singh, K. Aldape, N. Reddy, B. Barkoh, M. 
Riben, J. Medeiros, R. Luthra 
University of Texas MD Anderson Cancer Center, Houston, TX. 
Introduction: Efforts to translate next-generation sequencing (NGS) data into 
meaningful clinical reports are hampered by lack of clinically validated software tools 
intermediating between the raw variant output of NGS pipelines and laboratory 
information systems. Based on analytic issues discovered during our recent clinical 
implementation of a 46-gene cancer mutation panel using the Ion Torrent 
semiconductor sequencing platform (Life Technologies, Carlsbad, CA), we describe 
software developed to bridge the gap between existing NGS data pipelines and clinical 
reporting needs. Methods: We performed a gap-analysis of functionality required for 
effective reporting of clinically significant genome variants based on iterative feedback 
from a consensus panel of pathologists and clinical laboratory scientists. Based on this 
analysis, we implemented a client/server application - OncoSeek - that was written in 
C# using a backend SQL Server relational database (Microsoft, Seattle, WA). Software 
optimization and validation was performed using data from an initial validation set, using 
both functional testing and formal software validation plans. Results: The in-house 
developed OncoSeek software platform, comprising approximately 50000 lines of code, 
was used to parse Ion Torrent output files to create a comprehensive database of 
variants over the initial validation set of 77 samples. In this sample set, 1555 total 
variants (282 unique) were initially called (mean 20.2 per sample, sd 8.1). Our gap 
analysis established the functional goals of OncoSeek, and clinical signout was 
facilitated using this software via: 1. The ability to annotate samples with patient 
identifiers, 2. Identification of amplicons with suboptimal coverage for clinical reporting, 
3. Mapping of variants directly to knowledge bases including COSMIC and dbSNP, 4. 
Automatic translation of variants and their genomic position to Human Genome 
Variation Society compliant nomenclature, 5. A viewer for intersample comparison for 
germline/somatic comparison, 6. Integration with the Integrative Genomics Viewer 
(Broad Institute) for alignment viewing and documentation, and 6. Self-updating 
population analysis available within the software, which readily identified a group of 
disregardable common variants present at high frequency, attributable to reference 
genome polymorphisms or sequencing artifacts. Conclusions: The development of 
middleware application frameworks supporting rich functional annotation and 
knowledge base incorporation may represent an effective strategy for bridging gaps 
between commercially available NGS platforms and clinical reporting, and allow the 
integration of multiple vendor platforms into a common pathologist annotation and 
signout environment. 
 
TT80. Use of Plasma from Pregnant Women as a Biologic Positive Control for 
Septin 9 Methylated DNA Detection by Real-Time PCR 
J.D. Warren, W. Xiong, A.M. Bunker, K.A. Heichman 
Associated Regional and University Pathologists, Salt Lake City, UT. 
Introduction: The detection of Septin-9 (SEPT9) methylated DNA by real-time PCR 
has been previously described as a sensitive and specific screening test for colorectal 
cancer. The current positive workflow control is a technical sample with methylated 
DNA spiked into either buffer or pooled normal human plasma. SEPT9 methylated DNA 
has been found to be present in high amounts in the plasma of pregnant women. 
Plasma from pregnant women would serve as a more biologically relevant control 
sample compared to purified DNA in buffer or plasma. Methods: Twenty-five pregnant 
women in their third trimester had two 10mL EDTA tubes of whole blood drawn. Plasma 
was prepared from both tubes from each woman, pooled and two 4mL aliquots were 
frozen at -20°C. DNA extraction, bisulfite conversion, purification and triplicate PCR 
were completed for one aliquot of each individual woman (warren). The remaining 
aliquot for each woman was thawed and pooled with the rest of the samples. Twenty-
five 4mL aliquots were created from the pooled plasma. DNA extraction, bisulfite 
conversion, purification and triplicate PCR were completed for six aliquots of undiluted 
pooled plasma and six aliquots pooled plasma diluted 1:1 with PBS. Results: SEPT9 
methylated DNA was reproducibly detected in all three PCRs for each individual 
woman, pooled plasma and 1:1 dilution. Conclusions: Although the current positive 
control for the SEPT9 test is satisfactory, the notion of a biologically relevant positive 
control is appealing. The ability to dilute the pooled plasma with buffer provides a way 
to increase the number of controls from a pool of plasma from pregnant women. The 
plasma from pregnant women may also be useful as a positive control substrate for 
other blood-based DNA methylation assays like SEPT9. 
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TT81. Enzymatic Enrichment of BRAF V600E Mutations: A Method to Improve 
Assay Sensitivity 
L. Ma1, A. Maj1, B. Baltadjieva1, L. Mazur1, M. Mihalov2 
1ACL Central Laboratory, Rosemont, IL; 2Lutheran General Hospital/ACL Laboratories, 
Park Ridge, IL. 
Introduction: BRAF mutation detection is now a common component in the diagnosis 
and treatment of numerous conditions, including metastatic melanoma, colorectal 
carcinoma and Lynch syndrome. Tissue samples, particularly needle aspirates, are 
often small, may at times be extensively necrotic, or may contain mostly non-tumor 
cells. In these settings, when the percentage of target tumor cells is very low, it is of 
utmost clinical importance to utilize an assay with maximum analytical sensitivity. 
Numerous detection methods have been employed to increase sensitivity, including 
PCR with melt curve analysis, Sanger sequencing and pyrosequencing as well as 
complex and expensive cloning techniques. To date, few methods have achieved allele 
detection levels to 1%. This report describes a novel method of BRAF V600E mutation 
detection utilizing simple, readily available components and techniques. Methods: Cell 
line HTB 38 (BRAF V600E heterozygous mutation) was diluted with a known wild-type 
sample in a serial dilution of 10%, 5%, 1%, 0.5%, 0.1% and 0.05% mutant. Our 
enhanced mutation melt curve assay involves wild-type-target restriction endonuclease 
digestion and run by BRAF V600E PCR melt-curve analysis with sequencing 
confirmation. One restriction enzyme was utilized: RspRI (recognition sequence 
NNCASTGNN), New England Biolabs, Inc, Ipswich, MA. The PCR product was 
digested with RspRI at 65°C for 60 minutes. Each dilution was analyzed in triplicate. 
Results: BRAF V600E mutations were detected in 3 out of 3 replicates for the 10%, 
5%, 1%, and 0.1% dilutions; and 0 out of 3 replicates of the 0.05%. Analytic sensitivity 
is 100% (at 0.1%). Reproducibility was 100% for all dilutions to 0.1%. Limit of detection 
is 0.1%, which is equivalent to 10 tumor cells in 10,000 wild-type cells. Conclusions: 
This enzymatic-enrichment method of BRAF V600E mutations detection is sensitive 
and reproducible. It may be useful in specimens with low tumor cellularity, particularly 
aspiration samples.  
 
TT82. Multiplex Viral PCR Testing Using the FilmArray Shows Improved 
Operational Simplicity and Less Hands-On Time Compared to Direct 
Fluorescence Antibody Testing 
J. Wang1, B.B. Rogers2, D.B. Simons2, J.L. Adams2, R.C. Jerris2 
1Emory University School of Medicine, Atlanta, GA; 2Children's Healthcare of Atlanta, 
Atlanta, GA. 
Introduction: Laboratory testing for upper respiratory infections commonly includes 
identification of pathogens using rapid antigen testing, direct fluorescence antibody 
testing (DFA), and polymerase chain reaction (PCR) systems. Testing complexity is 
variable, but nearly all methods are identified as high complexity. The FilmArray 
Respiratory Panel (RP), certified by CLIA as moderate complexity, is the first PCR-
based assay for respiratory pathogens to combine ease of use with multiplex PCR 
testing for 15 FDA-cleared respiratory viral pathogens. We compare a detailed workflow 
analysis of the FilmArray RP with DFA for the detection of respiratory viruses. 
Methods: The process workflow was evaluated by measuring product "movement" 
through the tasks, steps, and operator touches. Operator analysis for the FilmArray RP 
involved videotaping three naïve medical technologists who were trained with one-on-
one instruction and each tested three specimens. Videos were reviewed to document 
the number of steps, touches, and hands-on time to achieve a result. Operator analysis 
for the DFA test involved one experienced operator performing the DFA test using 3 
samples, run individually to mimic single piece flow. The technologist was videotaped 
and the steps, touches, and hands-on time were recorded. Results: The number of 
operator steps using the FilmArray RP was standard at 32. On each technologist's first 
run, the total number of touches was 117, 100, and 91, with a hands-on time of 8m, 
12m41s, and 5m31s, respectively. There was no improvement with repeated runs, 
indicating that minimal training was sufficient to perform at the optimal level. The turn-
around time (TAT) ranged from 1h8m31s to 1h15m41s. The total cost of the FilmArray 
RP at our institution is $134.31. The DFA had fewer steps (23), but the average number 
of touches was 302, indicating greater number of touches per step. Average hands-on 
time was 12m, TAT was 2h40m, and total cost at our institution is $38.03. 
Conclusions: This study assessed the operational simplicity of the FilmArray RP and 
DFA. We showed that the FilmArray is less complex, has less hands-on time (4m52s vs 
12m), has shorter TAT (as little as 1h6m52s vs 2h40m), identifies more pathogens (15 
vs 7), but is pricier ($134.41 vs $38.03) than DFA. The FilmArray instrument further 
simplifies respiratory viral testing by making it possible to move previously highly 
complex testing into the routine clinical laboratory, or even at the point of care. The 
FilmArray opens the door for sensitive, specific, and rapid detection of 15 respiratory 
pathogens 24 hours a day, 7 days a week. 
 
TT83. Comparison Studies for the Detection of PTEN Loss in Formalin-Fixed, 
Paraffin-Embedded Prostate Tissues Using Fluorescence in Situ Hybridization 
Technique with 2-, 3- and 4- Color Probes 
A. LeBlanc, C. Steele, J. Siler, R. Aryeequaye, J. Benson 
CBLPath, Inc, Rye Brook, NY. 
Introduction: Detection of PTEN genomic loss by fluorescence in situ hybridization 
(FISH) is a clinically applicable tumor marker for Prostate Cancer (PCa). FISH testing 
performed on routine formalin-fixed, paraffin-embedded (FFPE) tissue samples can 
present a high level of truncation artifact with an increase in false-positive and false-
negative results. The addition of adjacent loci to the PTEN gene in a typical 2-color 
FISH probe will increase the diagnostic accuracy of PTEN loss in FFPE sections. In this 
study, 2-, 3- and 4-color FISH probes were evaluated on FFPE PCa samples to 
determine the efficiency of each in detecting PTEN genomic loss. Methods: 
Commercially available PTEN FISH probes in 2-colors [CEP10 (green) and PTEN 
(orange) (Abbott/Vysis)] and 4-colors [10cen (red), WAPAL (green), PTEN (orange) and 
FAS (aqua) (Cymogen)] as wells as a custom 3-color probe [10cen (red), WAPAL 
(green), and PTEN (gold) (Cytocell)] were obtained. FFPE tissue sections were 
processed on a VP2000 processor with overnight hybridization on a Thermobrite. 
Normal cut-off percentages with 95% Confidence Interval (CI) (Excel BETAINV) were 
established from ten normal prostate samples for aberrations involving heterozygous, 
homozygous, and chromosome losses. Ten PCa samples with suspicious PTEN activity 
by immunohistochemistry were tested for PTEN loss. Results: The sensitivity of the 3- 
and 4-color probes for heterozygous loss of the PTEN gene surpassed the 2-color 
probe (9% and 9% versus 16%) whereas the sensitivity of homozygous loss (3-6%) and 
chromosome loss (19-24%) was similar for all three probes. PTEN analysis identified 
the following among the PCa samples: heterozygous PTEN loss in three samples (all 
probes), heterozygous and homozygous PTEN loss in in two samples (3- and 4-color), 
chromosome loss in one sample (all probes), and homozygous PTEN loss with either 
heterozygous or chromosomal loss in one sample (3- and 4-color). Three samples 
remained within normal parameters. Conclusions: In this study, the 3- and 4-color 
PTEN probes revealed an increased sensitivity for heterozygous loss due to the 
additional loci labeled to rule out truncation artifact. Heterozygous loss was not detected 
by the 2-color probe in two samples. Homozygous loss was not identified with the 2-
color probe in any sample tested. Concordance between the 3- and 4-color probes was 
observed with a slight variance in one sample and attributed to tissue sample 
preparation. In conclusion, this study showed the addition of at least one locus to a 
standard 2-color enumeration probe increased the accuracy of the PTEN FISH assay.  
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